<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006625.pub2" GROUP_ID="SCHIZ" ID="290006090713180986" MERGED_FROM="" MODIFIED="2013-11-18 10:44:13 +0000" MODIFIED_BY="Claire Irving" REVIEW_NO="" REVMAN_SUB_VERSION="5.2.7 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.2">
<COVER_SHEET MODIFIED="2013-11-18 10:44:13 +0000" MODIFIED_BY="Claire Irving">
<TITLE MODIFIED="2009-11-02 12:58:35 +0000" MODIFIED_BY="[Empty name]">Quetiapine versus other atypical antipsychotics for schizophrenia</TITLE>
<CONTACT MODIFIED="2013-11-18 10:44:13 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="19456777972203192729091006122844" ROLE="AUTHOR"><FIRST_NAME>Laila</FIRST_NAME><LAST_NAME>Asmal</LAST_NAME><POSITION>Research Fellow</POSITION><EMAIL_1>laila@sun.ac.za</EMAIL_1><ADDRESS><DEPARTMENT>Department of Psychiatry</DEPARTMENT><ORGANISATION>University of Stellenbosch</ORGANISATION><ADDRESS_1>Faculty of Medicine and Health Sciences</ADDRESS_1><ADDRESS_2>PO Box 19063</ADDRESS_2><CITY>Tygerberg</CITY><ZIP>7505</ZIP><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 219 3892 27/9116</PHONE_1><FAX_1>+27 219 389738</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-11-18 10:44:13 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="19456777972203192729091006122844" ROLE="AUTHOR"><FIRST_NAME>Laila</FIRST_NAME><LAST_NAME>Asmal</LAST_NAME><POSITION>Research Fellow</POSITION><EMAIL_1>laila@sun.ac.za</EMAIL_1><ADDRESS><DEPARTMENT>Department of Psychiatry</DEPARTMENT><ORGANISATION>University of Stellenbosch</ORGANISATION><ADDRESS_1>Faculty of Medicine and Health Sciences</ADDRESS_1><ADDRESS_2>PO Box 19063</ADDRESS_2><CITY>Tygerberg</CITY><ZIP>7505</ZIP><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 219 3892 27/9116</PHONE_1><FAX_1>+27 219 389738</FAX_1></ADDRESS></PERSON><PERSON ID="48883014667133728293100302143502" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Srnka</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Flegar</LAST_NAME><POSITION>Medical Specialist (Psychiatrist)</POSITION><EMAIL_1>flegarsj@gmail.com</EMAIL_1><MOBILE_PHONE>079 560 5815</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Psychiatry</DEPARTMENT><ORGANISATION>University of Stellenbosch</ORGANISATION><ADDRESS_1>Tygerberg Hospital</ADDRESS_1><ADDRESS_2>PO Box 19063</ADDRESS_2><CITY>Tygerberg</CITY><ZIP>7505</ZIP><REGION>Western Cape</REGION><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 (0)21 940 4400</PHONE_1><FAX_1>+27 21 940 4543</FAX_1></ADDRESS></PERSON><PERSON ID="63826458798700673883101109115350" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jikun</FIRST_NAME><LAST_NAME>Wang</LAST_NAME><POSITION>Attending Doctor</POSITION><EMAIL_1>liwangjk@gmail.com</EMAIL_1><MOBILE_PHONE>86 134 8234 1637</MOBILE_PHONE><ADDRESS><DEPARTMENT>School of Psychology and Cognitive Science</DEPARTMENT><ORGANISATION>East China Normal University</ORGANISATION><ADDRESS_1>3663 North Zhongshan Road</ADDRESS_1><CITY>Shanghai</CITY><ZIP>200062</ZIP><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>86 (0)21 659 88874</PHONE_1></ADDRESS></PERSON><PERSON ID="11852B3682E26AA201DC7B3E1C938991" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Christine</FIRST_NAME><LAST_NAME>Rummel-Kluge</LAST_NAME><POSITION>Research Fellow</POSITION><EMAIL_1>Christine.rummel-kluge@medizin.uni-leipzig.de</EMAIL_1><ADDRESS><DEPARTMENT>Clinic and Outpatient Clinic of Psychiatry and Psychotherapy</DEPARTMENT><ORGANISATION>University of Leipzig</ORGANISATION><ADDRESS_1>Semmelweisstrasse 10</ADDRESS_1><CITY>Leipzig</CITY><ZIP>04103</ZIP><REGION>Saxony</REGION><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-34-1972-4493</PHONE_1><FAX_1>+49-34-1972-4599</FAX_1></ADDRESS></PERSON><PERSON ID="87F1AFC682E26AA20078D4E6A8FF088C" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Katja</FIRST_NAME><LAST_NAME>Komossa</LAST_NAME><POSITION>Psychiatric Consultant</POSITION><EMAIL_1>Katja.Komossa@usz.ch</EMAIL_1><ADDRESS><DEPARTMENT>Department of Psychiatry and Psychotherapy</DEPARTMENT><ORGANISATION>University Hospital of Zurich</ORGANISATION><ADDRESS_1>Culmannstrasse 8</ADDRESS_1><CITY>Zurich</CITY><ZIP>CH-8091</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>0041 (0) 44 255 5280</PHONE_1><FAX_1>0041 (0) 44 255 4408</FAX_1></ADDRESS></PERSON><PERSON ID="D3501EE082E26AA20080535F42019853" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Stefan</FIRST_NAME><LAST_NAME>Leucht</LAST_NAME><POSITION>Oberarzt</POSITION><EMAIL_1>Stefan.Leucht@lrz.tu-muenchen.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Ismaningerstrasse 22</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140 ext: 4249</PHONE_1><FAX_1>+49-89-4140-4888</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-05-21 10:06:11 +0100" MODIFIED_BY="Laila Asmal">
<UP_TO_DATE>
<DATE DAY="7" MONTH="5" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="6" MONTH="5" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="4" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2013-10-22 13:01:37 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-10-22 13:01:37 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="10" YEAR="2013"/>
<DESCRIPTION>
<P>Substantial update with no overall change to conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-10-16 12:14:00 +0100" MODIFIED_BY="Laila Asmal">
<DATE DAY="2" MONTH="4" YEAR="2012"/>
<DESCRIPTION>
<P>New search performed May 2010, 14 studies added.<BR/>Summary of findings tables added.<BR/>Findings of two additional comparator drugs (paliperidone, aripiprazole) added. Overall findings unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-07-22 11:22:19 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-07-22 11:22:10 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2013-07-08 08:59:42 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Psychiatrische Klinik, Klinikum rechts der Isar, Tu München, Freistaat Bayern</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2013-04-25 10:03:37 +0100" MODIFIED_BY="Laila Asmal">
<SOURCE>
<NAME>Bundesministerium für Bildung und Forschung, Nr FKZ: 01 KG 0606, GZ:GF-GFKG01100506</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2013-04-25 10:03:37 +0100" MODIFIED_BY="Laila Asmal">
<NAME>Foundation of the Ministry of National Science and Technology (2009BAI77B05)</NAME>
<COUNTRY CODE="CN">China</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-11-18 10:42:15 +0000" MODIFIED_BY="Laila Asmal">
<SUMMARY MODIFIED="2013-10-16 12:15:49 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-11-03 10:12:02 +0000" MODIFIED_BY="[Empty name]">Quetiapine versus other atypical antipsychotic drugs for schizophrenia</TITLE>
<SUMMARY_BODY MODIFIED="2013-10-16 12:15:49 +0100" MODIFIED_BY="[Empty name]">
<P>Quetiapine is a second-generation antipsychotic. Second-generation or atypical antipsychotic drugs have become the mainstay of treatment in many countries for people with schizophrenia. They are called <I>second-generation drugs</I> because they are newer than the older drugs, known as <I>typical antipsychotics</I>. Second-generation drugs are thought to be better than the older drugs in reducing the symptoms of schizophrenia, such as hearing voices and seeing things, and are suggested to produce fewer side effects, such as sleepiness, weight gain, tremors and shaking. However, it is not clear how the various second- generation antipsychotic drugs differ from one other. The aim of this review therefore was to evaluate the effects of quetiapine compared with other second-generation antipsychotic drugs for people with schizophrenia. The review included a total of 35 studies with 5971 people, which provided information on six comparisons (quetiapine vs the following: clozapine, olanzapine, risperidone, ziprasidone, paliperidone and aripiprazole). Comparisons with amisulpride, sertindole and zotepine do not exist, so more research is needed. A major limitation of all findings was the large number of people leaving studies and stopping quetiapine treatment (50.2% of people). The most important finding to note is that if a group is started on quetiapine, most will be off this drug within a few weeks (although the reasons for stopping quetiapine treatment are not covered by the review and so remain uncertain). Quetiapine may be slightly less effective than risperidone and olanzapine in reducing symptoms, and it may cause less weight gain and fewer side effects and associated problems (such as heart problems and diabetes) than olanzapine and paliperidone, but more than are seen with risperidone and ziprasidone. The limited information tends to suggest that people taking quetiapine may need to be hospitalised more frequently than those taking risperidone or olanzapine. This may lead to higher costs in some settings, but the information is not robust enough to guide managers.</P>
<P>This summary has been written by a consumer, Ben Gray (Benjamin Gray, Service User and Service User Expert, Rethink Mental Illness).</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-10-16 13:44:51 +0100" MODIFIED_BY="Laila Asmal">
<ABS_BACKGROUND MODIFIED="2013-10-16 13:44:51 +0100" MODIFIED_BY="[Empty name]">
<P>In many countries, second-generation ('atypical') antipsychotic drugs have become the first-line drug treatment for people with schizophrenia. It is not clear how the effects of the various second-generation antipsychotic drugs differ.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-10-16 12:14:09 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the effects of quetiapine compared with other second-generation (atypical) antipsychotic drugs in the treatment of people with schizophrenia and schizophrenia-like psychoses.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-02-21 09:50:54 +0000" MODIFIED_BY="Laila Asmal">
<P>We searched the Cochrane Schizophrenia Group Trials Register (May 2010), inspected references of all identified studies, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-10-16 12:14:19 +0100" MODIFIED_BY="Laila Asmal">
<P>We included all randomised controlled trials (RCTs) comparing oral quetiapine with other oral forms of atypical antipsychotic medication in people with schizophrenia or schizophrenia-like psychoses.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-10-16 12:14:26 +0100" MODIFIED_BY="Laila Asmal">
<P>We extracted data independently. For dichotomous data, we calculated risk ratios (RRs) and their 95% confidence intervals (CIs) on an intention-to-treat basis based on a random-effects model. We calculated number needed to treat for an additional beneficial outcome (NNTB) where appropriate. For continuous data, we calculated mean differences (MDs), again based on a random-effects model.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-10-16 12:14:58 +0100" MODIFIED_BY="Laila Asmal">
<P>Efficacy data tended to favour the control drugs over quetiapine (Positive and Negative Syndrome Scale (PANSS) total score vs olanzapine: 11 RCTs, n = 1486, mean quetiapine endpoint score 3.67 higher, CI 1.95 to 5.39, <I>low quality</I>; vs risperidone: 13 RCTs, n = 2155, mean quetiapine endpoint score 1.74 higher, CI 0.19 to 3.29, <I>moderate quality</I>; vs paliperidone: 1 RCT, n = 319, mean quetiapine endpoint score 6.30 higher, CI 2.77 to 9.83, <I>moderate quality</I>), but the clinical meaning of these data is unclear. No clear mental state differences were noted when quetiapine was compared with clozapine, aripiprazole or ziprasidone. Compared with olanzapine, quetiapine produced slightly fewer movement disorders (7 RCTs, n = 1127, RR use of antiparkinson medication 0.51, CI 0.32 to 0.81, <I>moderate quality</I>) and less weight gain (8 RCTs, n = 1667, RR 0.68, CI 0.51 to 0.92, <I>moderate quality</I>) and glucose elevation, but increased QTc prolongation (3 RCTs, n = 643, MD 4.81, CI 0.34 to 9.28). Compared with risperidone, quetiapine induced slightly fewer movement disorders (8 RCTs, n = 2163, RR use of antiparkinson medication 0.5, CI 0.36 to 0.69, <I>moderate quality</I>), less prolactin increase (7 RCTs, n = 1733, MD -35.25, CI -43.59 to -26.91) and some related adverse effects but greater cholesterol increase (6 RCTs, n = 1473, MD 8.57, CI 4.85 to 12.29). On the basis of limited data, compared with paliperidone, quetiapine induced fewer parkinsonian side effects (1 RCT, n = 319, RR use of antiparkinson medication 0.64, CI 0.45 to 0.91, <I>moderate quality</I>) and less prolactin increase (1 RCT, n = 319, MD -49.30, CI -57.80 to -40.80) and weight gain (1 RCT, n = 319, RR weight gain of 7% or more of total body weight 2.52, CI 0.5 to 12.78, <I>moderate quality</I>). Compared with ziprasidone, quetiapine induced slightly fewer extrapyramidal adverse effects (1 RCT, n = 522, RR use of antiparkinson medication 0.43, CI 0.2 to 0.93, <I>moderate quality</I>) and less prolactin increase. On the other hand, quetiapine was more sedating and led to greater weight gain (2 RCTs, n = 754, RR 2.22, CI 1.35 to 3.63, <I>moderate quality</I>) and cholesterol increase when compared with ziprasidone.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-10-16 12:15:11 +0100" MODIFIED_BY="Laila Asmal">
<P>Available evidence from trials suggests that most people who start quetiapine stop taking it within a few weeks (around 60%). Comparisons with amisulpride, sertindole and zotepine do not exist. Although efficacy data favour olanzapine and risperidone compared with quetiapine, the clinical meaning of these data remains unclear. Quetiapine may produce fewer parkinsonian effects than paliperidone, aripiprazole, ziprasidone, risperidone and olanzapine. Quetiapine appears to have a similar weight gain profile to risperidone, as well as clozapine and aripiprazole (although data are very limited for the latter two comparators). Quetiapine may produce greater weight gain than ziprasidone and less weight gain than olanzapine and paliperidone. Most data that have been reported within existing comparisons are of very limited value because of assumptions and biases within them. Much scope is available for further research into the effects of this widely used drug.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-11-04 17:27:29 +0000" MODIFIED_BY="Laila Asmal">
<BACKGROUND MODIFIED="2013-10-23 14:00:15 +0100" MODIFIED_BY="Laila Asmal">
<P> </P>
<CONDITION MODIFIED="2013-10-16 12:16:03 +0100" MODIFIED_BY="Laila Asmal">
<P>Schizophrenia is a serious psychiatric disorder that affects almost 1% of the population at some point in their lives (<LINK REF="REF-Andreasen-1991" TYPE="REFERENCE">Andreasen 1991</LINK>). Its typical manifestations are positive symptoms such as fixed, false beliefs (delusions) and perceptions without cause (hallucinations), negative symptoms such as apathy and lack of drive and disorganisation of behaviour and thought and catatonic symptoms such as mannerisms and bizarre posturing, as well as cognitive impairment (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>; <LINK REF="REF-Mueser-and-McGurk-2004" TYPE="REFERENCE">Mueser and McGurk 2004</LINK>). The degree of suffering and disability is considerable, with 80% to 90% not working (<LINK REF="REF-Marvaha-2004" TYPE="REFERENCE">Marvaha 2004</LINK>) and a two-fold increase in mortality (<LINK REF="REF-Allebeck-1986" TYPE="REFERENCE">Allebeck 1986</LINK>). Conventional antipsychotic drugs, such as chlorpromazine and haloperidol, have traditionally been used as first-line antipsychotic drugs for people with schizophrenia (<LINK REF="REF-Kane-1993" TYPE="REFERENCE">Kane 1993</LINK>). The re-introduction of clozapine in the United States and findings indicating that clozapine seemed more effective than other drugs, as well as its association with fewer movement disorders than chlorpromazine (<LINK REF="REF-Kane-1988" TYPE="REFERENCE">Kane 1988</LINK>), have boosted the development of new/second-generation/atypical antipsychotic drugs (SGAs).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-10-16 12:16:13 +0100" MODIFIED_BY="Laila Asmal">
<P>No good definition has been put forth for what an 'atypical' antipsychotic is, but these agents were initially said to differ from typical antipsychotic drugs in that they do not cause movement disorders (catalepsy) in rats at clinically effective doses (<LINK REF="REF-Arnt-1998" TYPE="REFERENCE">Arnt 1998</LINK>). The terms 'new' and 'second-generation' antipsychotic drugs are not much better because clozapine is now a very old drug. According to treatment guidelines (<LINK REF="REF-APA-2004" TYPE="REFERENCE">APA 2004</LINK>; <LINK REF="REF-Gaebel-2006" TYPE="REFERENCE">Gaebel 2006</LINK>), second-generation antipsychotic drugs include agents such as amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone, zotepine and paliperidone. It remains unclear whether some older compounds such as sulpiride or perazine have atypical properties (<LINK REF="REF-Moller-2000" TYPE="REFERENCE">Moller 2000</LINK>); therefore, they have been excluded from this review. The second-generation antipsychotic drugs have raised hopes for superior effects in several areas, such as compliance, cognitive functioning, negative symptoms, movement disorders, quality of life and the treatment of people whose illness had formerly been resistant to treatment.</P>
</INTERVENTION>
<THEORY MODIFIED="2013-10-23 14:00:15 +0100" MODIFIED_BY="[Empty name]">
<P>Experimental laboratory studies have suggested that quetiapine is a clozapine-like atypical antipsychotic (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="REF-Goldstein-1993" TYPE="REFERENCE">Goldstein 1993</LINK>; <LINK REF="REF-Migler-1993" TYPE="REFERENCE">Migler 1993</LINK>; <LINK REF="REF-Saller-1993" TYPE="REFERENCE">Saller 1993</LINK>). In contrast to olanzapine, risperidone, sertindole and ziprasidone, which have high affinities (&lt;50 nM) for both dopamine-2 (D2) and serotonin-2A (5-HT2A) receptors, quetiapine is similar to clozapine in having only moderate affinities (&lt;500 nM) for these sites (<LINK REF="REF-Goldstein-1995" TYPE="REFERENCE">Goldstein 1995</LINK>). Quetiapine has a high affinity for histamine receptors (&lt;50 nM) (<LINK REF="REF-Arnt-1998" TYPE="REFERENCE">Arnt 1998</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-10-16 12:16:50 +0100" MODIFIED_BY="[Empty name]">
<P>The debate continues as to how much the second-generation antipsychotic drugs improve these outcomes compared with conventional antipsychotic drugs (<LINK REF="REF-Duggan-2005" TYPE="REFERENCE">Duggan 2005</LINK>; <LINK REF="REF-El_x002d_Sayeh-2006" TYPE="REFERENCE">El-Sayeh 2006</LINK>), and the results of recent studies are sobering (<LINK REF="REF-Jones-2006" TYPE="REFERENCE">Jones 2006</LINK>; <LINK REF="REF-Liebermann-2005" TYPE="REFERENCE">Liebermann 2005</LINK>). Nevertheless, in some parts of the world, especially in the highly industrialised countries, second-generation antipsychotic drugs have become the mainstay of treatment. They also differ in terms of their costs: although amisulpride and risperidone are already available in generic formulations in many countries, quetiapine for example still is not. Therefore, the question as to whether these agents differ from each other in terms of their clinical effects becomes increasingly important. In this review, we aim to summarise evidence from randomised controlled trials (RCTs) that compared quetiapine with other second-generation antipsychotic drugs.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-10-16 12:17:02 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the effects of quetiapine compared with other second-generation (atypical) antipsychotic drugs in the treatment of people with schizophrenia and schizophrenia-like psychoses.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-11-04 17:27:11 +0000" MODIFIED_BY="Laila Asmal">
<SELECTION_CRITERIA MODIFIED="2013-11-04 17:27:11 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-10-16 12:17:13 +0100" MODIFIED_BY="[Empty name]">
<P>We included relevant RCTs that were at least single-blind (blind raters). When a trial was described as double-blind but it was only implied that the study was randomised, we included it in a sensitivity analysis. If no substantive difference within primary outcomes was noted (see <LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>) when these implied randomisation studies were added, we included them in the final analysis. If a substantive difference within primary outcomes was described, we used only clearly randomised trials and described the results of the sensitivity analysis in the text. We excluded quasi-randomised studies, such as those that allocated by using alternate days of the week. We included randomised cross-over studies but only data up to the point of first cross-over because of the instability of the problem behaviours and the likely carry-over effects of all treatments.</P>
<P>
<I>Please note:</I> This update adopted the same criteria for considering the types of studies for inclusion as were applied in the previous version of this review, wherein only RCTs that were at least single-blind (blind raters) were included. We therefore did not include open-label studies in this update. However, open-label trials provide valuable information, particularly for objective outcomes, and will be included in the next update.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-10-16 12:17:20 +0100" MODIFIED_BY="Dolores Matthews">
<P>We included people with schizophrenia and other types of schizophrenia-like psychosis (e.g. schizophreniform and schizoaffective disorders), irrespective of the diagnostic criteria used. No clear evidence suggests that the schizophrenia-like psychoses are caused by fundamentally different disease processes or require different treatment approaches (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-10-16 12:17:31 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Quetiapine</HEADING>
<P>Any oral form of application, any dose.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Other 'atypical' antipsychotic drugs</HEADING>
<P>Amisulpride, aripiprazole, clozapine, olanzapine, risperidone, sertindole, ziprasidone, zotepine: any oral form of application, any dose.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-11-04 17:27:11 +0000" MODIFIED_BY="[Empty name]">
<P>We grouped outcomes into short term (up to 12 weeks), medium term (13 to 26 weeks) and long term (over 26 weeks).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-10-22 13:09:02 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Global state</HEADING>
<P>No clinically important response as defined by the individual studies (e.g. clinical global impression (CGI) less than much improved or less than 50% reduction on a rating scale)</P>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-11-04 17:27:11 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Leaving the study early (any reason, adverse events, inefficacy of treatment)</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Global state</HEADING>
<P>2.1 No clinically important change in global state (as defined by individual studies)<BR/>2.2 Relapse (as defined by the individual studies)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Mental state (with particular reference to the positive and negative symptoms of schizophrenia)</HEADING>
<P>3.1 No clinically important change in general mental state score<BR/>3.2 Average endpoint general mental state score<BR/>3.3 Average change in general mental state score<BR/>3.4 No clinically important change in specific symptoms (positive symptoms of schizophrenia, negative symptoms of schizophrenia)<BR/>3.5 Average endpoint specific symptom score<BR/>3.6 Average change in specific symptom score</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. General functioning</HEADING>
<P>4.1 No clinically important change in general functioning<BR/>4.2 Average endpoint general functioning score<BR/>4.3 Average change in general functioning score</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Quality of life/satisfaction with treatment</HEADING>
<P>5.1 No clinically important change in general quality of life<BR/>5.2 Average endpoint general quality of life score<BR/>5.3 Average change in general quality of life score</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6. Cognitive functioning</HEADING>
<P>6.1 No clinically important change in overall cognitive functioning<BR/>6.2 Average endpoint overall cognitive functioning score<BR/>6.3 Average change in overall cognitive functioning score</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7. Service use</HEADING>
<P>7.1 Admitted</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8. Adverse effects</HEADING>
<P>8.1 Number of people with at least one adverse effect<BR/>8.2 Clinically important specific adverse effects (cardiac effects, death, movement disorders, prolactin increase and associated effects, sedation, seizures, weight gain, effects on white blood cell count)<BR/>8.3 Average endpoint specific adverse effects<BR/>8.4 Average change in specific adverse effects</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">9. Summary of findings table</HEADING>
<P>We used the GRADE approach to interpret findings (<LINK REF="REF-Sch_x00fc_nemann-2008" TYPE="REFERENCE">Schünemann 2008</LINK>) and used the <A HREF="http://www.ims.cochrane.org/revman/gradepro">GRADEPRO</A> profiler to import data from Review Manager 5 (<A HREF="http://www.ims.cochrane.org/revman">RevMan</A>) to create 'Summary of findings' tables. These tables provide outcome-specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined and the sum of available data on all outcomes that we rated as important to patient care and decision making. We selected the following main outcomes for inclusion in the 'Summary of findings' table.</P>
<P>1. Mental state: general average endpoint score (Positive and Negative Syndrome Scale (PANSS) total, high = poor).</P>
<P>2. Mental state: positive symptoms average endpoint score (PANSS positive subscore, high = poor).</P>
<P>3. Mental state: negative symptoms average endpoint score (PANSS negative subscore, high = poor)</P>
<P>4. Quality of life: general average endpoint score (quality of life total score (QLS), low = poor).</P>
<P>5. Adverse effects: central nervous system sedation.</P>
<P>6. Adverse effects: extrapyramidal effects use of antiparkinson medication.</P>
<P>7. Adverse effects: metabolic weight gain of 7% or more of total body weight.</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-10-16 16:03:49 +0100" MODIFIED_BY="Laila Asmal">
<P>No language restriction was applied within the limitations of the search tools.</P>
<ELECTRONIC_SEARCHES MODIFIED="2013-10-16 16:03:49 +0100" MODIFIED_BY="Laila Asmal">
<SUBSECTION>
<HEADING LEVEL="4">1. Cochrane Schizophrenia Group Trials Register (update May 2010)</HEADING>
<P>We searched the Specialised Register of the Cochrane Schizophrenia Group (May 2010) using the phrase:</P>
<P>[(quetiapine* or seroquel* or ICI-204636* or (ICI and 204636) or ICI204636* in title or *quetiapine* or *seroquel* or *ICI-204636* or (ICI and 204636) or *ICI204636* in title, abstract or index terms of REFERENCE) or (quetiapine in interventions of STUDY)</P>
<P>This register is compiled by systematic searches of major databases, handsearches and searches of conference proceedings (see <A HREF="http://www.mrw.interscience.wiley.com/cochrane/cochrane_clsysrev_crglist_fs.html">Group Module</A>). The Cochrane Schizophrenia Group Trials Register is maintained on Meerkat 1.5. This version of Meerkat stores references as studies. When an individual reference is selected through a search, all references that have been identified as the same study are also selected.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Previous searches from earlier versions of this review</HEADING>
<P>Please see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-10-16 13:49:45 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Reference searching</HEADING>
<P>We inspected the references of all identified studies for more trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Personal contact</HEADING>
<P>We contacted the first author of each included study to request missing information.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Drug companies</HEADING>
<P>We contacted the manufacturers of all included atypical antipsychotic drugs to ask for additional data.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-11-04 17:17:28 +0000" MODIFIED_BY="Laila Asmal">
<P> For previous data collection methods, see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<STUDY_SELECTION MODIFIED="2013-11-04 17:17:28 +0000" MODIFIED_BY="Laila Asmal">
<P>Two review authors (LA and SJF for the 2010 update, KK and CRK for the 2007 review, JW in discussion with LA for Chinese language studies) independently inspected all reports. We resolved any disagreement by discussion, and when there was still doubt, we acquired the full article for further inspection. Once the full articles were obtained, we independently decided whether the studies met the review criteria. If disagreement could not be resolved by discussion, we sought further information and added these trials to the list of those awaiting assessment.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-10-16 16:03:49 +0100" MODIFIED_BY="Laila Asmal">
<SUBSECTION>
<HEADING LEVEL="4">1. Extraction</HEADING>
<P>Review authors LA, SJF and JW extracted data from included studies for the 2010 update; review authors KK and CRK extracted data for the 2007 review. We extracted only data presented in graphs and figures whenever possible. When further information was necessary, we contacted authors of studies to obtain missing data or to ask for clarification. If studies were multi-centre, where possible, we separately extracted data relevant to each component centre.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Management</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Forms</HEADING>
<P>We extracted data onto standard, simple forms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Scale-derived data</HEADING>
<P>We included continuous data from rating scales only if:</P>
<P>a. the psychometric properties of the measuring instrument have been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>); and</P>
<P>b. the measuring instrument has not been written or modified by one of the trialists for that particular trial.</P>
<P>Ideally the measuring instrument should be a self-report or should be completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly; we have noted whether or not this is the case in <LINK TAG="STUDY_DESCRIPTION" TYPE="SECTION">Description of studies</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3 Endpoint versus change data</HEADING>
<P>Both endpoint and change data provide advantages. Change data can remove a component of between-person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint), which can be challenging to perform in unstable and difficult to measure conditions such as schizophrenia. We decided to primarily use endpoint data and to use change data only if the former were not available. We combined endpoint and change data in the analysis by using mean differences (MDs) rather than standardised mean differences throughout (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>, Chapter 9.4.5.2).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4 Skewed data</HEADING>
<P>Continuous data on clinical and social outcomes often are not normally distributed. To avoid the pitfalls of applying parametric tests to non-parametric data, we aimed to apply the following standards to all data before inclusion: (1) standard deviations (SDs) and means are reported in the paper or are obtainable from the authors; (2) when a scale starts from the finite number zero, the SD, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>)); and (3) if a scale started from a positive value (such as PANSS, which can have values ranging from 30 to 210), we modified the calculation described above to take the scale starting point into account. In these cases, skew is present if 2 SDs &gt; (S S min), where S is the mean score and S min is the minimum score. Endpoint scores on scales often have finite starting and ending points, and these rules can be applied. We entered skewed endpoint data from studies of fewer than 200 participants into other tables within the data analyses section rather than into a statistical analysis. Skewed data pose less of a problem when the mean is examined if the sample size is large; we entered such endpoint data into syntheses. When continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether or not data are skewed. If we found skewed change data according to the above rules, we entered these into statistical analyses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5 Common measure</HEADING>
<P>To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month), to a common metric (e.g. mean days per month).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6 Conversion of continuous to binary</HEADING>
<P>Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' and 'not clinically improved' subgroups. It is generally assumed that if a 50% reduction is noted in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS; <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or the PANSS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>), this could be considered a clinically significant response (<LINK REF="REF-Leucht-2005" TYPE="REFERENCE">Leucht 2005</LINK>; <LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>). If data based on these thresholds were not available, we used the primary cut-off presented by the original authors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.7 Direction of graphs</HEADING>
<P>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for quetiapine.</P>
</SUBSECTION>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-10-16 13:52:47 +0100" MODIFIED_BY="Laila Asmal">
<P>Review authors worked independently by using criteria described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) to assess trial quality. This new set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article, such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting.</P>
<P>Where inadequate details of randomisation and other characteristics of trials were provided, we contacted authors of the studies to request additional information.</P>
<P>We have noted the level of risk of bias both in the text of the review and in the 'Summary of findings' tables.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-10-16 13:55:08 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Binary data</HEADING>
<P>For binary outcomes, we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that the RR is more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) than the odds ratio and that odds ratios tend to be interpreted by clinicians as RRs (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). The number needed to treat for an additional beneficial outcome (NNTB)/number needed to treat for an additional harmful outcome (NNTH) statistic with its CIs is intuitively attractive to clinicians but is problematic in its inaccuracy of calculations in meta-analyses and in interpretation (<LINK REF="REF-Hutton-2009" TYPE="REFERENCE">Hutton 2009</LINK>). For binary data presented in the 'Summary of findings' table/s, where possible, we calculated illustrative comparative risks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Continuous data</HEADING>
<P>For continuous outcomes, we used estimated mean differences (MDs) between groups. We prefer not to calculate effect size measures (standardised mean differences (SMDs)). However, if scales of considerable similarity were used, we presumed that a small difference in measurement would be noted, and we calculated effect size and transformed the effect back to the units of one or more of the specific instruments.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-10-16 14:09:02 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Cluster trials</HEADING>
<P>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice), but analysis and pooling of clustered data pose problems. Authors often fail to account for intraclass correlation in clustered studies, leading toward a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>), whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>; <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>If we had found studies in which clustering was not accounted for in primary studies, we would have presented data in a table, with an (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review, we will seek to contact first authors of studies to obtain intraclass correlation coefficients for their clustered data and to adjust for this by using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). If we had found studies for which clustering had been incorporated into the analysis of primary studies, we would have presented these data as if from a non cluster randomised study but would have adjusted for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intraclass correlation coefficient (ICC) [Design effect = 1 + (m 1) * ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported, it was assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>If cluster studies had been appropriately analysed by taking ICCs into account, and if relevant data had been documented in the report, synthesis with other studies using the generic inverse variance technique would have been possible.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Cross-over trials</HEADING>
<P>A major concern associated with cross-over trials is the carry-over effect. This occurs if an effect (e.g. pharmacological, physiological, psychological) of treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase, participants can differ systematically from their initial state despite a wash-out phase. For the same reason, cross-over trials are not appropriate if the condition of interest is unstable (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). Both effects are very likely in severe mental illness; therefore we used data only from the first phase of cross-over studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Studies with multiple treatment groups</HEADING>
<P>When a study involves more than two treatment arms, we presented the additional treatment arms in comparisons if they were relevant. If data were binary, we simply added these and combined them within the two-by-two table. If data were continuous, we combined them in accordance with the formula in Section 7.7.3.8 (Combining groups) of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). When the additional treatment arms were not relevant, we did not reproduce these data.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-10-16 14:09:12 +0100" MODIFIED_BY="[Empty name]">
<P>At some degree of loss of follow-up, data must lose credibility (<LINK REF="REF-Xia-2007" TYPE="REFERENCE">Xia 2007</LINK>). Although high rates of premature discontinuation are a major problem in this field, we believe that it is unclear which degree of attrition leads to a high degree of bias. Therefore, we did not exclude trials on the basis of the percentage of participants completing them. However, we addressed the attrition problem in all parts of the review, including the abstract. For this purpose, we calculated, presented and commented on frequency statistics (overall rates of leaving the studies early among all studies and comparators pooled).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-10-16 14:09:50 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Clinical heterogeneity</HEADING>
<P>We considered all included studies initially to judge clinical heterogeneity without seeing comparison data. We simply inspected all studies for clearly outlying people or situations that we had not predicted would arise. When such situations or participant groups arose, we fully discussed these.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Methodological heterogeneity</HEADING>
<P>We considered all included studies initially to judge methodological heterogeneity without seeing comparison data. We simply inspected all studies for clearly outlying methods that we had not predicted would arise. When such methodological outliers arose, we fully discussed these.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Statistical heterogeneity</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Visual inspection</HEADING>
<P>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Employing the I<SUP>2</SUP> statistic</HEADING>
<P>We investigated heterogeneity between studies by considering the I<SUP>2 </SUP>method alongside the Chi<SUP>2</SUP> P value. The I<SUP>2 </SUP>statistic provides an estimate of the percentage of inconsistency thought to be due to chance (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). The importance of the observed value of I<SUP>2 </SUP>depends on magnitude and direction of effects and strength of evidence for heterogeneity (e.g. P value from Chi<SUP>2</SUP> test, or a confidence interval for I<SUP>2</SUP>). An I<SUP>2 </SUP>estimate greater than or equal to around 50% accompanied by a statistically significant Chi<SUP>2</SUP> statistic was interpreted as evidence of substantial levels of heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). When substantial levels of heterogeneity were found in the primary outcome, we explored reasons for heterogeneity (<LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-10-16 14:09:56 +0100" MODIFIED_BY="[Empty name]">
<P>Reporting biases arise when dissemination of research findings is influenced by the nature and direction of results (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). These are described in Section 10 of the <I>Cochrane</I> <I>Handbook</I> <I>for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We are aware that funnel plots may be useful in investigating reporting biases, but they have limited power to detect small-study effects. We did not use funnel plots for outcomes when 10 or fewer studies were included, or when all studies were of similar size. In other cases, for which funnel plots were possible, we sought statistical advice in their interpretation.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-10-16 14:10:04 +0100" MODIFIED_BY="[Empty name]">
<P>We understand that there is no closed argument regarding preference for use of fixed-effect or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us, and the random-effects model takes into account differences between studies even if no statistically significant heterogeneity is noted. However, use of the random-effects model creates a disadvantage: It puts added weight onto small studies, which often are the most biased ones. Depending on the direction of effect, these studies can inflate or deflate the effect size. We chose the random-effects model for all analyses. However, the reader is able to choose to inspect the data using the fixed-effect model, if preferred.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-10-16 14:10:14 +0100" MODIFIED_BY="[Empty name]">
<P>If data were clearly heterogeneous, we checked that data were correctly extracted and entered and that we had made no unit of analysis errors. If inconsistency was high and clear reasons explaining the heterogeneity were found, we presented the data separately. If not, we commented on the heterogeneity of the data.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-10-16 14:10:19 +0100" MODIFIED_BY="[Empty name]">
<P>We planned sensitivity analyses to examine the change in robustness of sensitivity to include studies with potentially skewed data. A recent report showed that some of the comparisons of atypical antipsychotic drugs may have been biased by the use of inappropriate comparator doses (<LINK REF="REF-Heres-2006" TYPE="REFERENCE">Heres 2006</LINK>). Therefore, we also analysed whether exclusion of studies with inappropriate comparator doses changed the results of the primary outcome and the general mental state.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-11-04 17:26:42 +0000" MODIFIED_BY="Laila Asmal">
<STUDY_DESCRIPTION MODIFIED="2013-11-04 17:26:42 +0000" MODIFIED_BY="Laila Asmal">
<P>For substantive descriptions of studies, please see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> tables.</P>
<SEARCH_RESULTS MODIFIED="2013-10-16 14:10:26 +0100" MODIFIED_BY="Laila Asmal">
<P>Results of the search are presented in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> (study flow diagram). We found 537 references, of which 134 were closely inspected during the May 2010 search. The original April 2007 search strategy yielded 3620 references, of which 104 were closely inspected.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-11-04 17:26:42 +0000" MODIFIED_BY="Laila Asmal">
<P>We were able to include 35 studies in total; this includes 14 added in the 2010-2011 update. Seven studies were sponsored by pharmaceutical companies producing quetiapine, six were sponsored by the manufacturer of the comparator antipsychotic and ten had a neutral sponsor. For the remaining twelve studies, the sponsor was unclear.</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Length of trials</HEADING>
<P>Twenty-six studies were short term with a duration of 2 to 12 weeks. Six studies were medium term, and two trials fell into the long-term category.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Setting</HEADING>
<P>Seven trials were conducted in an inpatient or outpatient setting, sixteen studies were conducted exclusively in an inpatient setting and two studies were conducted exclusively in an outpatient setting. Ten studies did not report the setting.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Participants</HEADING>
<P>Twenty-three studies included participants with diagnoses derived from the <I>Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)</I>. <LINK REF="STD-Riedel-2005" TYPE="STUDY">Riedel 2005</LINK> and <LINK REF="STD-Hatta-2009" TYPE="STUDY">Hatta 2009</LINK> additionally used the <I>International Classification of Diseases, Tenth Revision (ICD-10).</I> Ten studies diagnosed participants according to the <I>Chinese Classification of Mental Disorders Version 3 (CCMD-3).</I> <LINK REF="STD-Li-2003b" TYPE="STUDY">Li 2003b</LINK> used <I>CCMD-2.</I> Five studies included only acutely ill people (<LINK REF="STD-Canuso-2008" TYPE="STUDY">Canuso 2008</LINK>; <LINK REF="STD-Riedel-2007" TYPE="STUDY">Riedel 2007</LINK>; <LINK REF="STD-Svestka-2003b" TYPE="STUDY">Svestka 2003b</LINK>; <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>; <LINK REF="STD-Wei-2006b" TYPE="STUDY">Wei 2006b</LINK>), and four included only people with a first episode of schizophrenia (<LINK REF="STD-Hu-2008" TYPE="STUDY">Hu 2008</LINK>; <LINK REF="STD-Luo-Xin-2008" TYPE="STUDY">Luo Xin 2008</LINK>; <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK>; <LINK REF="STD-Wei-2006a" TYPE="STUDY">Wei 2006a</LINK>). Two studies included people with chronic schizophrenia or people with more than one schizophrenic episode (<LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>, <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK>). Only one study focused on treatment-resistant participants (<LINK REF="STD-Conley-2005" TYPE="STUDY">Conley 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Study size</HEADING>
<P>
<LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK> was the largest study, with 1453 participants; <LINK REF="STD-Ozguven-2004" TYPE="STUDY">Ozguven 2004</LINK> was the smallest, randomly assigning only 22 people. Six studies had fewer than 50 participants, and three randomly assigned more than 400 people.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Interventions</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">5.1 Quetiapine: All included studies used flexible dosing</HEADING>
<P>Overall, quetiapine was given in a dose range from 50 mg/d to 800 mg/d. <LINK REF="STD-Conley-2005" TYPE="STUDY">Conley 2005</LINK> limited the upper dose range to 500 mg/d, <LINK REF="STD-Wei-2006b" TYPE="STUDY">Wei 2006b</LINK> used a dose range of 100 mg/d to 400 mg/d and <LINK REF="STD-Ozguven-2004" TYPE="STUDY">Ozguven 2004</LINK> had a mean dose that was higher than the upper dose range of 800 mg/d (827 mg/d).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.2 Comparators</HEADING>
<P>The comparator drugs were aripiprazole, clozapine, olanzapine, paliperidone, risperidone and ziprasidone, again given in flexible doses. Some studies also included treatment arms with fluphenazine, perphenazine and perospirone, but because these are not second-generation antipsychotic drugs, we did not report these results.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">6.1 Leaving the study early</HEADING>
<P>The number of participants leaving the studies early was reported for the categories &#8216;any reason&#8217;, &#8216;adverse events&#8217; and &#8216;lack of efficacy&#8217;.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.2 No clinically significant response</HEADING>
<P>We pre-specified at least 50% PANSS/BPRS reduction from baseline as a clinical relevant cut-off to define, but only <LINK REF="STD-Svestka-2003b" TYPE="STUDY">Svestka 2003b</LINK> reported this outcome. Instead, <LINK REF="STD-Liu-2004" TYPE="STUDY">Liu 2004</LINK> indicated at least 50% SANS reduction from baseline, <LINK REF="STD-Potkin-2006" TYPE="STUDY">Potkin 2006</LINK> and <LINK REF="STD-Zhong-2006a" TYPE="STUDY">Zhong 2006a</LINK> at least 30 % PANSS total score reduction from baseline, <LINK REF="STD-Ozguven-2004" TYPE="STUDY">Ozguven 2004</LINK> at least 20% SANS total score reduction from baseline, <LINK REF="STD-Conley-2005" TYPE="STUDY">Conley 2005</LINK> a CGI (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>) of mild or better combined with at least 20% BPRS total reduction from baseline and <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK> all PANSS items mild or better plus a CGI of mild or better.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.3 Outcome scales</HEADING>
<P>Details of scales that provided usable data are shown below. Reasons for exclusion of data from other instruments are given under 'Outcomes' in the '<LINK TAG="INCLUDED_STUDIES_DESCR" TYPE="SECTION">Included studies</LINK>' section.</P>
<SUBSECTION>
<HEADING LEVEL="6">6.3.1 Global state scales</HEADING>
<P>6.3.1.1 <U>Clinical Global Impression Scale - CGI</U> (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>This is used to assess both severity of illness and clinical improvement by comparing the conditions of the standardised person against other people with the same diagnosis. A seven-point scoring system is usually used, and low scores show decreased severity and/or overall improvement.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">6.3.2 Mental state scales</HEADING>
<P>6.3.2.1 <U>Positive and Negative Syndrome Scale - PANSS</U> (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>)<BR/>This schizophrenia scale consists of 30 items, each of which can be defined on a seven-point scoring system ranging from 1 (absent) to 7 (extreme). It can be divided into three subscales that can be used to measure the severity of general psychopathology, positive symptoms (PANSS-P) and negative symptoms (PANSS-N). A low score indicates lesser severity.</P>
<P>6.3.2.2 <U>Brief Psychiatric Rating Scale - BPRS</U> (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>)<BR/>This scale is used to assess the severity of the abnormal mental state. The original scale consists of 16 items, but a revised 18-item scale is commonly used. Each item is defined on a seven-point scale ranging from 'not present' to 'extremely severe', and scoring ranges from 0 to 6 or from 1 to 7. Scores can range from 0 to 126, and high scores indicate more severe symptoms.</P>
<P>6.3.2.3 <U>Scale for the Assessment of Negative Symptoms - SANS</U> (<LINK REF="REF-Andreasen-1989" TYPE="REFERENCE">Andreasen 1989</LINK>)<BR/>This six-point scale gives a global rating of the following negative symptoms: alogia, affective blunting, avolition-apathy, anhedonia-associality and attention impairment. Higher scores indicate more severe symptoms.</P>
<P>6.3.2.4 <U>Scale for the Assessment of Positive Symptoms - SAPS</U> (<LINK REF="REF-Andreasen-1984" TYPE="REFERENCE">Andreasen 1984</LINK>)<BR/>This four-point scale gives a global rating for the following positive symptoms: hallucination, delusion, bizarre attitudes and positive formal thought disorder.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">
<I>6.3.3 Global Assessment of Functioning</I> - <I>GAF (DSM IV, 1994)</I>
</HEADING>
<P>A rating scale for patients´ overall capacity of psychosocial functioning, with scores ranging from 1 to 100. Higher scores indicate a higher level of functioning.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">6.3.4. Quality of Life Scales</HEADING>
<P>6.3.4.1 <U>Quality of Life Scale - QLS</U> (<LINK REF="REF-Carpenter-1984" TYPE="REFERENCE">Carpenter 1984</LINK>)<BR/>This semi-structured interview is administered and rated by trained clinicians. It contains 21 items, rated on a seven-point scale on the basis of interviewers' judgement of patient functioning. A total QLS and four subscale scores are calculated, with higher scores indicating less impairment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">6.3.5 Adverse effects scales</HEADING>
<P>6.3.5.1 <U>Abnormal Involuntary Movement Scale - AIMS</U> (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>This scale has been used to assess tardive dyskinesia, a long-term, drug-induced movement disorder, and short-term movement disorders such as tremor.</P>
<P>6.3.5.2 <U>Barnes Akathisia Scale - BAS</U> (<LINK REF="REF-Barnes-1989" TYPE="REFERENCE">Barnes 1989</LINK>)<BR/>This scale comprises items rating the observable, restless movements that characterise akathisia, a subjective awareness of restlessness and any distress associated with the condition. These items are rated from 0 (normal) to 3 (severe). In addition, an item for rating global severity is included (ranging from 0 (absent) to 5 (severe)). A low score indicates low levels of akathisia.</P>
<P>6.3.5.3 <U>Extrapyramidal Symptom Rating Scale - ESRS</U> (<LINK REF="REF-Chouinard-1980" TYPE="REFERENCE">Chouinard 1980</LINK>)<BR/>This is a questionnaire that pertains to parkinsonian symptoms (nine items), a physician's examination for parkinsonism and dyskinetic movements (eight items) and a CGI of tardive dyskinesia. High scores indicate severe levels of movement disorder.</P>
<P>6.3.5.4 <U>Simpson Angus Scale - SAS</U> (<LINK REF="REF-Simpson-1970" TYPE="REFERENCE">Simpson 1970</LINK>)<BR/>This ten-item scale, which includes a scoring system of 0 to 4 for each item, measures drug-induced parkinsonism, a short-term drug-induced movement disorder. A low score indicates low levels of parkinsonism.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.4 Other adverse effects</HEADING>
<P>Other adverse effects were reported as continuous variables for QTc prolongation (ms), cholesterol level (mg/dL), glucose level (mg/dL), prolactin level (ng/mL) and weight (kg). Still other adverse events were reported in a dichotomous manner in terms of the number of people with a given effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.5 Service use</HEADING>
<P>Service use was described as the number of participants re-hospitalised during the trial.</P>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-10-16 14:16:24 +0100" MODIFIED_BY="Laila Asmal">
<P>We excluded 196 studies for the following reasons: 51 (26%) were not randomised, 113 (58%) were open label, 22 (11%) employed inappropriate interventions, 9 (5%) reported no usable data, 1 included participants with mood disorders and 1 was a pooled analysis rather than a trial.</P>
<SUBSECTION>
<HEADING LEVEL="4">Awaiting assessment</HEADING>
<P>One trial (<LINK REF="STD-Gafoor-2005" TYPE="STUDY">Gafoor 2005</LINK>) is awaiting assessment until further information can be obtained.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ongoing studies</HEADING>
<P>Four randomised trials comparing quetiapine with other antipsychotic drugs seem to be ongoing (<LINK REF="STD-Eli-Lilly-2004b" TYPE="STUDY">Eli Lilly 2004b</LINK>; <LINK REF="STD-Li-2009b" TYPE="STUDY">Li 2009b</LINK>; <LINK REF="STD-Ratna-2003" TYPE="STUDY">Ratna 2003</LINK>; <LINK REF="STD-Reynolds-2001" TYPE="STUDY">Reynolds 2001</LINK>). For further details, see '<LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>'.</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-10-16 14:16:53 +0100" MODIFIED_BY="Laila Asmal">
<P>For details, please refer to the risk of bias tables (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>, <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
<ALLOCATION MODIFIED="2013-10-16 14:16:40 +0100" MODIFIED_BY="Laila Asmal">
<P>All of the included studies were described as randomised; however, only five studies from the total of 37 described the method of randomisation (<LINK REF="STD-Canuso-2008" TYPE="STUDY">Canuso 2008</LINK>; <LINK REF="STD-Eerdekens-2007" TYPE="STUDY">Eerdekens 2007</LINK>; <LINK REF="STD-Kinon-2006b" TYPE="STUDY">Kinon 2006b</LINK>; <LINK REF="STD-Lu-2006" TYPE="STUDY">Lu 2006</LINK>; <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>). Only four were explicit about the method of allocation concealment used (<LINK REF="STD-Canuso-2008" TYPE="STUDY">Canuso 2008</LINK>; <LINK REF="STD-Eerdekens-2007" TYPE="STUDY">Eerdekens 2007</LINK>; <LINK REF="STD-Hatta-2009" TYPE="STUDY">Hatta 2009</LINK>; <LINK REF="STD-Potkin-2006" TYPE="STUDY">Potkin 2006</LINK>). For all other studies, it was unclear whether the allocation strategies were appropriate.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-10-16 14:16:53 +0100" MODIFIED_BY="Laila Asmal">
<P>Thirteen of the included studies were 'single-blind' (blind raters); all other included studies were 'double-blind'. Nine studies used identical capsules for blinding (<LINK REF="STD-Canuso-2008" TYPE="STUDY">Canuso 2008</LINK>; <LINK REF="STD-Eerdekens-2007" TYPE="STUDY">Eerdekens 2007</LINK>; <LINK REF="STD-Kinon-2006b" TYPE="STUDY">Kinon 2006b</LINK>; <LINK REF="STD-Li-2002" TYPE="STUDY">Li 2002</LINK>; <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>; <LINK REF="STD-McEvoy-2006" TYPE="STUDY">McEvoy 2006</LINK>; <LINK REF="STD-Potkin-2006" TYPE="STUDY">Potkin 2006</LINK>; <LINK REF="STD-Riedel-2005" TYPE="STUDY">Riedel 2005</LINK>; <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK>). The other trials did not provide any information on the blinding procedure. No study examined whether blinding was effective. We found that the adverse effect profiles of some of the compounds are quite different, and we believe that this may have made blinding difficult. We therefore conclude that the risk of bias for objective outcomes (e.g. death, laboratory values) was less than that for subjective outcomes, and for the latter, risk was considerable as a result of poor blinding.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-10-16 14:16:53 +0100" MODIFIED_BY="Laila Asmal">
<P>Nineteen studies displayed attrition bias. Other than poorly described reasons for premature study discontinuation, a major problem was the very high attrition, which in thirteen studies was higher than 30% (50.2% overall, <LINK REF="STD-Astrazeneca-1998" TYPE="STUDY">Astrazeneca 1998</LINK>; <LINK REF="STD-Canuso-2008" TYPE="STUDY">Canuso 2008</LINK>; <LINK REF="STD-Conley-2005" TYPE="STUDY">Conley 2005</LINK>; <LINK REF="STD-Deberdt-2008" TYPE="STUDY">Deberdt 2008</LINK>; <LINK REF="STD-Hatta-2009" TYPE="STUDY">Hatta 2009</LINK>; <LINK REF="STD-Kinon-2006b" TYPE="STUDY">Kinon 2006b</LINK>; <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>; <LINK REF="STD-McEvoy-2006" TYPE="STUDY">McEvoy 2006</LINK>; <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK>; <LINK REF="STD-Riedel-2005" TYPE="STUDY">Riedel 2005</LINK>; <LINK REF="STD-Riedel-2007" TYPE="STUDY">Riedel 2007</LINK>; <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK>; <LINK REF="STD-Zhong-2006" TYPE="STUDY">Zhong 2006</LINK>). In most studies, the last-observation-carried-forward method was used to account for attrition. This is an imperfect method, which assumes that a participant's outcome would not have changed if he/she had remained in the study; this is often wrong. However, it is questionable whether other methods (e.g. imputation strategies, mixed-effects models) could have coped better with such dramatically high rates of attrition. The high loss to follow-up is a clear threat to the validity of findings.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-10-16 14:16:53 +0100" MODIFIED_BY="Laila Asmal">
<P>Only five studies were judged to be free of selective reporting (<LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK>; <LINK REF="STD-Byerly-2008" TYPE="STUDY">Byerly 2008</LINK>; <LINK REF="STD-Li-2002" TYPE="STUDY">Li 2002</LINK>; <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>; <LINK REF="STD-Hatta-2009" TYPE="STUDY">Hatta 2009</LINK>). For most of the other trials, risk of bias was high, mainly because of incomplete reporting of pre-defined outcomes (<LINK REF="STD-Conley-2005" TYPE="STUDY">Conley 2005</LINK>; <LINK REF="STD-Kinon-2006b" TYPE="STUDY">Kinon 2006b</LINK>; <LINK REF="STD-Li-2003" TYPE="STUDY">Li 2003</LINK>; <LINK REF="STD-Li-2005b" TYPE="STUDY">Li 2005b</LINK>; <LINK REF="STD-Liu-2004" TYPE="STUDY">Liu 2004</LINK>; <LINK REF="STD-McEvoy-2006" TYPE="STUDY">McEvoy 2006</LINK>; <LINK REF="STD-Mori-2004" TYPE="STUDY">Mori 2004</LINK>; <LINK REF="STD-Ozguven-2004" TYPE="STUDY">Ozguven 2004</LINK>; <LINK REF="STD-Riedel-2005" TYPE="STUDY">Riedel 2005</LINK>; <LINK REF="STD-Riedel-2007" TYPE="STUDY">Riedel 2007</LINK>; <LINK REF="STD-Sacchetti-2004" TYPE="STUDY">Sacchetti 2004</LINK>, <LINK REF="STD-Sirota-2006" TYPE="STUDY">Sirota 2006</LINK>; <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK>; <LINK REF="STD-Svestka-2003b" TYPE="STUDY">Svestka 2003b</LINK>; <LINK REF="STD-Voruganti-2007" TYPE="STUDY">Voruganti 2007</LINK>). In other studies, only adverse events that occurred in at least 5% or 10% of participants, or that were moderately severe, have been reported (<LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK>; <LINK REF="STD-Potkin-2006" TYPE="STUDY">Potkin 2006</LINK>; <LINK REF="STD-Zhong-2006" TYPE="STUDY">Zhong 2006</LINK>). The former method is problematic because rare but important adverse effects may have been missed. In <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>, all data from one site were excluded before analysis because of concerns about their integrity.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-10-16 14:16:53 +0100" MODIFIED_BY="Laila Asmal">
<P>No study was clearly free of other potential sources of bias. In six studies, the risk of &#8216;other bias&#8217; was, however, unclear. Nine studies were industry sponsored (<LINK REF="STD-Kinon-2006b" TYPE="STUDY">Kinon 2006b</LINK>; <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK>; <LINK REF="STD-Potkin-2006" TYPE="STUDY">Potkin 2006</LINK>; <LINK REF="STD-Riedel-2005" TYPE="STUDY">Riedel 2005</LINK>; <LINK REF="STD-Riedel-2007" TYPE="STUDY">Riedel 2007</LINK>; <LINK REF="STD-Sacchetti-2004" TYPE="STUDY">Sacchetti 2004</LINK>; <LINK REF="STD-Sirota-2006" TYPE="STUDY">Sirota 2006</LINK>; <LINK REF="STD-Voruganti-2007" TYPE="STUDY">Voruganti 2007</LINK>; <LINK REF="STD-Zhong-2006" TYPE="STUDY">Zhong 2006</LINK>). Evidence suggests that pharmaceutical companies sometimes highlight the benefits of their compounds and tend to suppress their disadvantages (<LINK REF="REF-Heres-2006" TYPE="REFERENCE">Heres 2006</LINK>). Other reasons for potential bias included heterogeneity of pre-study treatment (<LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK>; <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK>), lack of or only short wash-out phases (<LINK REF="STD-Li-2005b" TYPE="STUDY">Li 2005b</LINK>; <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>; <LINK REF="STD-McEvoy-2006" TYPE="STUDY">McEvoy 2006</LINK>; <LINK REF="STD-Mori-2004" TYPE="STUDY">Mori 2004</LINK>; <LINK REF="STD-Voruganti-2007" TYPE="STUDY">Voruganti 2007</LINK>), baseline imbalance in terms of numbers of previous hospitalisations (<LINK REF="STD-Conley-2005" TYPE="STUDY">Conley 2005</LINK>), no information on the allowed dose range (<LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK>; <LINK REF="STD-Li-2003" TYPE="STUDY">Li 2003</LINK>; <LINK REF="STD-Voruganti-2007" TYPE="STUDY">Voruganti 2007</LINK>) and too-fast titration of clozapine, which may be associated with a greater number of adverse events (<LINK REF="STD-Liu-2004" TYPE="STUDY">Liu 2004</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-10-23 08:47:51 +0100" MODIFIED_BY="Laila Asmal">
<SUBSECTION>
<HEADING LEVEL="3">1. Comparison 1. QUETIAPINE versus ARIPIPRAZOLE</HEADING>
<P>Four studies met the inclusion criteria for the comparison of quetiapine with aripiprazole.</P>
<SUBSECTION>
<HEADING LEVEL="4">1.1 Leaving the study early</HEADING>
<P>On the basis of two studies, no significant difference was noted in the numbers of participants leaving the studies early for any reason (2 RCTs, n = 149, RR 1.00, CI 0.59 to 1.70; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.2 Mental state: 1. General - average endpoint score (PANSS total)</HEADING>
<P>No significant difference was noted in the average endpoint total PANSS score between quetiapine and aripiprazole (4 RCTs, n = 297, MD 1.62, CI -0.89 to 4.14; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). Exclusion of potentially skewed data (<LINK REF="STD-Luo-Xin-2008" TYPE="STUDY">Luo Xin 2008</LINK>; <LINK REF="STD-Peng-2007" TYPE="STUDY">Peng 2007</LINK>) did not significantly change the results (2 RCTs, n = 142, MD 1.24, CI -1.91 to 4.39; <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.3 Mental state: 2. Positive symptoms - average endpoint score (PANSS positive subscore)</HEADING>
<P>No significant difference was noted in the average endpoint PANSS positive subscore (4 RCTs, n = 297, MD 0.62, CI -1.13 to 2.38; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). However, data from all studies for this outcome were potentially skewed, and a sensitivity analysis could not be performed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.4 Mental state: 3. Negative symptoms - average endpoint score (PANSS negative subscore)</HEADING>
<P>No significant difference was noted in the average endpoint PANSS negative subscore (4 RCTs, n = 297, MD 1.00, CI -0.25 to 2.25; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). Again, data from all studies for this outcome were potentially skewed, and a sensitivity analysis could not be performed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.5 General functioning</HEADING>
<P>No significant difference was noted in the general average endpoint score (GAF total score, 1 RCT, n = 41, MD -1.20, CI -14.43 to 12.03; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.6 Adverse effects: 1. Numbers of participants with at least one adverse effect</HEADING>
<P>No significant difference was noted (3 RCTs, n = 215, RR 0.91, CI 0.71 to 1.17; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.7 Adverse effects: 2a. Cardiac effects - QTc prolongation</HEADING>
<P>No significant difference in QTc prolongation was noted (1 RCT, n = 85, RR 3.21, CI 0.13 to 76.74; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.8 Adverse effects: 2b. Cardiac effects - tachycardia</HEADING>
<P>A trend towards quetiapine producing fewer tachycardia events was noted on the basis of one trial (1 RCT, n = 85, RR 7.50, CI 0.40 to 140.91; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.9 Adverse effects: 3. Extrapyramidal effects</HEADING>
<P>No significant difference was noted in akathisia (3 RCTs, n = 196, RR 0.57, CI 0.08 to 4.02), tremor (2 RCTs, n = 155, RR 1.68, CI 0.08 to 35.92), dystonia (2 RCTs, n = 126, RR 1.42, CI 0.10 to 20.77), dyskinesia (1 RCT, n = 41, RR 3.14, CI 0.14 to 72.92), parkinsonism (1 RCT, n = 41, RR 0.75, CI 0.28 to 1.98) or use of antiparkinson medication (1 RCT, n = 40, RR 0.67, CI 0.12 to 3.57; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.10 Adverse effects: 4. Prolactin - associated side effects</HEADING>
<P>Quetiapine was associated with increased risk of galactorrhea on the basis of one trial (n = 85, RR 3.21, CI 0.13 to 76.74; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.11 Adverse effects: 5a. Metabolic - weight gain of 7% or more of total body weight</HEADING>
<P>On the basis of limited data, no significant difference was noted in the number of participants with significant weight gain (2 RCTs, n = 155, RR 0.52, CI 0.10 to 2.74; <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.12 Adverse effects: 5b. Metabolic - weight gain (change from baseline in kilograms</HEADING>
<P>No difference or significant change in weight was noted from baseline (1 RCT, n = 41, MD 1.70, CI -0.14 to 3.54; <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.13 Adverse effects: 5c. Metabolic - cholesterol (change from baseline in mg/dL)</HEADING>
<P>No significant difference was noted on the basis of one study (1 RCT, n = 41, MD 8.20, CI -12.24 to 28.64; <LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>). </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.14 Adverse effects: 5d. Metabolic - glucose (change from baseline in mg/dL)</HEADING>
<P>One small study showed an advantage of quetiapine (1 RCT, n = 41, MD -9.40, CI -17.90 to -0.90; <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.15 Adverse effects: 6. Death</HEADING>
<P>One study recorded no deaths from suicide or natural causes in the quetiapine and aripiprazole groups (1 RCT, n = 37, RR not estimable; <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.16 Publication bias</HEADING>
<P>We did not perform a funnel plot analysis because so few studies were identified.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Comparison 2. QUETIAPINE versus CLOZAPINE</HEADING>
<P>Five studies met the inclusion criteria for the comparison of quetiapine with clozapine. All data were short term</P>
<SUBSECTION>
<HEADING LEVEL="4">2.1 Leaving the study early</HEADING>
<P>No significant difference was noted in the number of participants leaving the studies early for any reason (2 RCTs, n = 95, RR 0.67, CI 0.18 to 2.43), because of adverse events (1 RCT, n = 72, RR 0.14, CI 0.01 to 2.6) or as the result of inefficacy of treatment (1 RCT, n = 72, RR not estimable; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2 Global state: 1a. No clinically significant response (as defined by original studies)</HEADING>
<P>No significant difference was noted in clinical response as defined by the original studies (1 RCT, n = 72, RR 0.94, CI 0.78 to 1.13; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.3 Global state: 1b. No clinically important change - short term (CGI)</HEADING>
<P>No significant difference was noted in clinical change using the CGI (1 RCT, n = 72, RR 0.94, CI 0.74 to 1.18; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.4 Mental state: 1a. General - no clinically important change (&lt; 50% PANSS total score reduction from baseline)</HEADING>
<P>No clear difference was found (1 RCT, n = 63, RR 1.07, CI 0.53 to 2.14; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.5 Mental state: 1b. General - average endpoint score (PANSS total)</HEADING>
<P>Four short-term studies did not indicate a significant difference (4 RCTs, n = 232, MD -0.5, CI -2.85 to 1.86; <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.6 Mental state: 1c. General - average endpoint score (BPRS total)</HEADING>
<P>No significant difference was found at short term (1 RCT, n = 67, MD -0.89, CI -3.20 to 1.42; <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.7 Mental state: 2. Positive symptoms - average endpoint score (PANSS positive subscore)</HEADING>
<P>No significant difference was found (2 RCTs, n = 142, MD -0.7, CI -2.07 to 0.68; <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.8 Mental state: 3a. Negative symptom - average endpoint score (PANSS negative subscore)</HEADING>
<P>Two small Chinese studies showed significant superiority of quetiapine (2 RCTs, n = 142, MD -2.23, CI -3.48 to -0.99; <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.9 Mental state: 3b. Negative symptoms - no clinically important change (&lt; 50% SANS total score reduction from baseline)</HEADING>
<P>No significant difference was found (1 RCT, n = 72, RR 0.94, CI 0.78 to 1.13; <LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.10 Mental state: 3c. Negative symptoms - average endpoint score (SANS total)</HEADING>
<P>No significant difference was found (1 RCT, n = 67, MD -1.64, CI -8.17 to 4.89; <LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.11 Adverse effects: 1. General - numbers of participants with at least one adverse effect</HEADING>
<P>A significant difference noted on the basis of data from <LINK REF="STD-Li-2002" TYPE="STUDY">Li 2002</LINK>, favoured the treatment group (1 RCT, n = 63, RR 0.42, CI 0.26 to 0.66, NNTH 2, CI 1 to 3; <LINK REF="CMP-002.11" TYPE="ANALYSIS">Analysis 2.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.12 Adverse effects: 2. Cardiac effects - ECG abnormalities</HEADING>
<P>A significant difference favoured quetiapine (1 RCT, n = 72, RR 0.13, CI 0.02 to 0.95; <LINK REF="CMP-002.12" TYPE="ANALYSIS">Analysis 2.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.13 Adverse effects: 3. Central nervous system -sedation</HEADING>
<P>Fewer participants in the quetiapine group reported this outcome (2 RCTs, n = 135, RR 0.22, CI 0.11 to 0.47; <LINK REF="CMP-002.13" TYPE="ANALYSIS">Analysis 2.13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.14 Adverse effects: 4. Extrapyramidal effects</HEADING>
<P>No significant difference was noted in akathisia (2 RCTs, n = 135, RR 0.4, CI 0.08 to 1.99), rigour (1 RCT, n = 63, RR 1.94, CI 0.18 to 20.3), tremor (2 RCTs, n = 135, RR 0.99, CI 0.29 to 3.34) or use of antiparkinson medication (1 RCT, n = 28, RR not estimable; <LINK REF="CMP-002.14" TYPE="ANALYSIS">Analysis 2.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.15 Adverse effects: 5 Haematological - important decline in white blood cells</HEADING>
<P>No significant difference was noted (1 RCT, n = 33, RR 0.19, CI 0.01 to 3.88; <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.16 Adverse effects: 6a Metabolic - weight gain (number of participants with significant weight gain)</HEADING>
<P>No significant difference was noted (2 RCTs, n = 135, RR 0.53, CI 0.25 to 1.11; <LINK REF="CMP-002.16" TYPE="ANALYSIS">Analysis 2.16</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.17 Adverse effects: 6b. Metabolic - weight gain (change from baseline in kilograms)</HEADING>
<P>One small study reported a trend in favour of quetiapine (1 RCT, n = 27, MD -2.11, CI -4.3 to 0.08; <LINK REF="CMP-002.17" TYPE="ANALYSIS">Analysis 2.17</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.18 Publication bias</HEADING>
<P>We did not perform a funnel plot analysis because so few studies were identified.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.19 Investigation for heterogeneity and sensitivity analysis</HEADING>
<P>The exclusion of <LINK REF="STD-Li-2002" TYPE="STUDY">Li 2002</LINK>; <LINK REF="STD-Li-2003b" TYPE="STUDY">Li 2003b</LINK> and <LINK REF="STD-Li-2005b" TYPE="STUDY">Li 2005b</LINK> from analysis of the PANSS total score because of possibly skewed data did not change the results to a marked extent (<LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Comparison 3. QUETIAPINE versus OLANZAPINE</HEADING>
<P>Fourteen studies met the inclusion criteria for this comparison.</P>
<SUBSECTION>
<HEADING LEVEL="4">3.1 Leaving the study early</HEADING>
<P>Fewer participants in the olanzapine group (54%) compared with the quetiapine group (69%) left the studies early for &#8216;any reason&#8217; (12 RCTs, n = 1821, RR 1.26, CI 1.12 to 1.42) or because of &#8216;inefficacy&#8217; (14% vs 25%, 9 RCTs, n = 1600, RR 1.83, CI 1.42 to 2.36) but not as the result of adverse events (12% vs 11%, 9 RCTs, n = 1610, RR 0.90, CI 0.69 to 1.18; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.2 Global state: 1a. No clinically significant response - as defined by the original studies</HEADING>
<P>No significant difference was noted (3 RCTs, n = 339, RR 1.11, CI 0.86 to 1.43; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.3 Global state: 1b. No clinically important change - as defined by the original studies</HEADING>
<P>No significant difference was noted (2 RCTs, n = 309, RR 1.18, CI 0.89 to 1.57; <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.4 Mental state: 1a. General mental state - no clinically important change - short term (&lt; 50% PANSS total score reduction)</HEADING>
<P>No significant difference was noted (1 RCT, n = 42, RR 0.91, CI 0.54 to 1.53; <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.5 Mental state: 1b. General mental state - average endpoint score (PANSS total)</HEADING>
<P>A significant difference favoured olanzapine overall (11 RCTs, n = 1486, MD 3.67, CI 1.95 to 5.39), medium term (3 RCTs, n = 482, MD 5.57, CI 1.97 to 9.17) and long term (3 RCTs, n = 825, MD 3.40, CI 0.91 to 5.88). A difference was not seen in the short term (5 RCTs, n = 179, MD 2.29, CI -1.30 to 5.87; <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>). Exclusion of <LINK REF="STD-Voruganti-2007" TYPE="STUDY">Voruganti 2007</LINK>, which potentially contributed skewed data to the long-term studies, favoured olanzapine further (2 RCTs, n = 740, MD 4.31, CI 1.60 to 7.01; <LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.6 Mental state: 2a. Positive symptoms - no clinically important change - short term (&lt; 20% SAPS total score reduction)</HEADING>
<P>No difference was identified with confidence (1 RCT, n = 30, RR 15.0, CI 0.93 to 241.2; <LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.7 Mental state: 2b. Positive symptoms - average endpoint (PANSS positive subscore)</HEADING>
<P>Overall data on PANSS positive average endpoint score did not show a statistically significant difference between groups (9 RCTs, n = 801, MD 1.02, CI -0.81 to 2.85), short term (4 RCTs, n = 152, MD 1.24, CI -0.48 to 2.96), medium term (3 RCTs, n = 483, MD 2.21, CI 0.90 to 3.52) or long term (2 RCT, n = 166, MD 3.70, CI -0.48 to 7.88; <LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>). However, exclusion of potentially skewed data (<LINK REF="STD-Mori-2004" TYPE="STUDY">Mori 2004</LINK>; <LINK REF="STD-Voruganti-2007" TYPE="STUDY">Voruganti 2007</LINK>) revealed an overall significant difference in favour of olanzapine (7 RCTs, n = 676, MD 1.84, CI 1.02 to 2.67; <LINK REF="CMP-009.02" TYPE="ANALYSIS">Analysis 9.2</LINK>). </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.8 Mental state: 2c. Positive symptoms - average change in score - short term (SAPS total score - percentage change from baseline)</HEADING>
<P>A significant difference favoured olanzapine (1 RCT, n = 30, MD 40.84, CI 23.97 to 57.71; <LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.9 Mental state: 3a. Negative symptoms - no clinically important change - short term (&lt; 20% SANS total score reduction from baseline)</HEADING>
<P>No significant difference was noted (1 RCT, n = 30, RR 1.5, CI 0.53 to 4.26; <LINK REF="CMP-003.09" TYPE="ANALYSIS">Analysis 3.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.10 Mental state: 3b. Negative symptoms - average endpoint score (PANSS negative subscore)</HEADING>
<P>No significant difference was noted between groups (9 RCTs, n = 801, MD 0.86, CI -0.32 to 2.03), short term (4 RCTs, n = 152, MD -0.07, CI -1.70 to 1.56), medium term (3 RCTs, n = 483, MD 0.40, CI -0.67 to 1.47) or long term (2 RCTs, n = 166, MD 2.64, CI -1.29 to 6.56; <LINK REF="CMP-003.10" TYPE="ANALYSIS">Analysis 3.10</LINK>). Exclusion of potentially skewed data (<LINK REF="STD-Voruganti-2007" TYPE="STUDY">Voruganti 2007</LINK>) yielded no significant difference in the results of long-term data studies (1 RCT, n = 81, MD 0.7, CI 0.73 to 2.13; <LINK REF="CMP-009.03" TYPE="ANALYSIS">Analysis 9.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.11 Mental state: 3c. Negative symptoms - average endpoint score (SANS total)</HEADING>
<P>No significant difference was noted (1 RCT, n = 335, MD 3.7, CI -0.48 to 7.88; <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.12 Mental state: 3d. Negative symptoms - average change in endpoint score (SANS total - percent change from baseline)</HEADING>
<P>No significant difference was noted (1 RCT, n = 30, MD 2.46, CI -31.9 to 36.82; <LINK REF="CMP-003.12" TYPE="ANALYSIS">Analysis 3.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.13 General functioning - average endpoint score - medium term (GAF total)</HEADING>
<P>A significant difference favoured olanzapine (3 RCT, n = 400, MD 2.55, CI 0.33 to 4.76; <LINK REF="CMP-003.13" TYPE="ANALYSIS">Analysis 3.13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.14 Quality of life - average endpoint score - medium term (QLS total)</HEADING>
<P>No significant difference was noted (1 RCT, n = 286, MD 1.8, CI -2.42 to 6.02; <LINK REF="CMP-003.14" TYPE="ANALYSIS">Analysis 3.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.15 Service use - number of participants re-hospitalised</HEADING>
<P>A significant difference favoured olanzapine (3 RCTs, n = 1009, RR 1.83, CI 1.33 to 2.52; <LINK REF="CMP-003.15" TYPE="ANALYSIS">Analysis 3.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.16 Adverse effects: 1. General - at least one adverse effect</HEADING>
<P>No significant difference was noted in the number of participants experiencing at least one adverse effect (7 RCTs, n = 1306, RR 0.96, CI 0.88 to 1.05; <LINK REF="CMP-003.16" TYPE="ANALYSIS">Analysis 3.16</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.17 Adverse effects: 2. Death</HEADING>
<P>No significant difference was noted (4 RCTs, n = 1450, RR 0.74, CI 0.13 to 4.23; <LINK REF="CMP-003.17" TYPE="ANALYSIS">Analysis 3.17</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.18 Adverse effects: 3a. Cardiac effects - number of participants with QTc prolongation</HEADING>
<P>No significant difference was noted (1 RCT, n = 673, RR 12.96, CI 0.73 to 229.17; <LINK REF="CMP-003.18" TYPE="ANALYSIS">Analysis 3.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.19 Adverse effects: 3b. Cardiac effects - mean change of QTc interval from baseline in ms</HEADING>
<P>A significant difference favoured olanzapine (3 RCTs, n = 643, MD 4.81, CI 0.34 to 9.28; <LINK REF="CMP-003.19" TYPE="ANALYSIS">Analysis 3.19</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.20 Adverse effects: 4a. Central nervous system - sedation</HEADING>
<P>No significant difference was noted (7 RCTs, n = 1615, RR 0.97, CI 0.78 to 1.2; <LINK REF="CMP-003.20" TYPE="ANALYSIS">Analysis 3.20</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.21 Adverse effects: 4b. Central nervous system - seizures</HEADING>
<P>No significant difference was noted (1 RCT, n = 40, RR 3.3, CI 0.14 to 76.46; <LINK REF="CMP-003.21" TYPE="ANALYSIS">Analysis 3.21</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.22 Adverse effects: 5a. Extrapyramidal effects</HEADING>
<P>Fewer participants in the quetiapine group used antiparkinson medication at least once (7 RCTs, n = 1127, RR 0.51, CI 0.32 to 0.81). Apart from this, no significant differences in extrapyramidal symptoms (EPS) were found for akathisia (7 RCTs, n = 1314, RR 0.97, CI 0.68 to 1.38), akinesia (1 RCT, n = 267, RR 1.02, CI 0.67 to 1.56), dystonia (3 RCTs, n = 752 RR 1.13, CI 0.21 to 6.23), any EPS (2 RCTs, n = 245, RR 1.62, CI 0.72 to 3.67), parkinsonism (2 RCTs, n = 77, RR 0.77, CI 0.34 to 1.74) or tremor (1 RCT, n = 42, RR 0.39, CI 0.12 to 1.31; <LINK REF="CMP-003.22" TYPE="ANALYSIS">Analysis 3.22</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.23 Adverse effects: 5b. Scale measured</HEADING>
<P>Extrapyramidal adverse effects were evaluated with the Barnes Akathisia Scale, the Extrapyramidal Side Effects Rating Scale and the Simpson-Angus Scale. None of these indicated a significant difference between groups (<LINK REF="CMP-003.23" TYPE="ANALYSIS">Analysis 3.23</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.24 Adverse effects: 6a. Prolactin-associated side effects</HEADING>
<P>Fewer participants in the quetiapine group suffered from sexual dysfunction (4 RCTs, n = 1177, RR 0.8, CI 0.64 to 0.99). No significant difference was noted in abnormally high prolactin (1 RCT, n = 42, RR 0.10, CI 0.01 to 1.77), amenorrhoea (3 RCTs, n = 252, RR 0.66, CI 0.36 to 1.21), galactorrhoea (4 RCTs, n = 1025, RR 0.66, CI 0.25 to 1.73) and gynaecomastia (1 RCT, n = 267, RR 0.33, CI 0.09 to 1.20; <LINK REF="CMP-003.24" TYPE="ANALYSIS">Analysis 3.24</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.25 Adverse effects: 6b. Prolactin - change from baseline in ng/mL</HEADING>
<P>Quetiapine was associated with less prolactin increase than olanzapine (5 RCTs, n = 1021, RR -5.89, CI -11.62 to -0.16), but the data were heterogeneous (<LINK REF="CMP-003.25" TYPE="ANALYSIS">Analysis 3.25</LINK>). Nevertheless, the single studies reported a consistent effect in favour of quetiapine (<LINK REF="STD-Svestka-2003b" TYPE="STUDY">Svestka 2003b</LINK>: n = 35, MD -40.07, CI -64.10 to -16.04; <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>: n = 673, MD -3.20, CI - 6.81 to 0.41; <LINK REF="STD-McEvoy-2006" TYPE="STUDY">McEvoy 2006</LINK>: n = 29, MD -9.10, CI -19.88 to 1.68; <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK>: n = 203, MD -3.20, CI -11.17 to 4.77 and <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK>: n = 81, MD -2.80, CI -10.03 to 4.43). Heterogeneity seems more likely to be due to differences in degree of prolactin increase rather than to direction of effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.26 Adverse effects: 7a. Metabolic - cholesterol - significant cholesterol increase</HEADING>
<P>No significant difference was noted in the number of participants with an abnormally high cholesterol increase (1 RCT, n = 267, RR 0.99, CI 0.59 to 1.68; <LINK REF="CMP-003.26" TYPE="ANALYSIS">Analysis 3.26</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.27 Adverse effects: 7b. Metabolic - cholesterol - mean change from baseline in mg/dL</HEADING>
<P>Overall data on cholesterol change from baseline did not show a statistically significant difference between groups (6 RCTs, n = 1156, MD -2.73, CI -8.05 to 2.59; <LINK REF="CMP-003.27" TYPE="ANALYSIS">Analysis 3.27</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.28 Adverse effects: 7c. Metabolic - glucose - number of participants with abnormally high fasting glucose</HEADING>
<P>No significant difference was noted (3 RCTs, n = 1025, RR 0.47, CI 0.21 to 1.02; <LINK REF="CMP-003.28" TYPE="ANALYSIS">Analysis 3.28</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.29 Adverse effects: 7d. Metabolic - glucose - change from baseline in mg/dL</HEADING>
<P>The mean increase in glucose from baseline was lower in the quetiapine group than in the olanzapine group (6 RCTs, n = 1156, MD -4.67, CI -9.41.to 0.07; <LINK REF="CMP-003.29" TYPE="ANALYSIS">Analysis 3.29</LINK>). Although significant heterogeneity was noted between the studies, all favoured quetiapine.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.30 Adverse effects: 7e. Metabolic - weight gain</HEADING>
<P>Fewer participants in the quetiapine group had a significant weight gain (8 RCTs, n = 1667, RR 0.68, CI 0.51 to 0.92; <LINK REF="CMP-003.30" TYPE="ANALYSIS">Analysis 3.30</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.31 Adverse effects: 7f. Metabolic - weight change from baseline in kilograms</HEADING>
<P>Overall, participants in the quetiapine group gained less weight than those in the olanzapine group (10 RCTs, n = 1428, MD -2.54, CI -3.82 to -1.26; <LINK REF="CMP-003.31" TYPE="ANALYSIS">Analysis 3.31</LINK>). Again, significant heterogeneity was noted, but the results of the single studies consistently favoured quetiapine (<LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK>: n = 27, MD -4.51, CI -6.57 to -2.45; <LINK REF="STD-Deberdt-2008" TYPE="STUDY">Deberdt 2008</LINK>: n = 133, MD -1.81, CI -3.70 to 0.08; <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>: n = 612, MD -3.8, CI -4.91 to -2.69; <LINK REF="STD-Kinon-2006b" TYPE="STUDY">Kinon 2006b</LINK>: n = 346, MD -0.64, CI -1.76 to 0.48); <LINK REF="STD-McEvoy-2006" TYPE="STUDY">McEvoy 2006</LINK>: n = 34, MD -2.3, CI -10.18 to 5.58; <LINK REF="STD-Sirota-2006" TYPE="STUDY">Sirota 2006</LINK>: n = 40, MD -3.2, CI -5.51 to -0.89; <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK>: n = 81, MD -5.18, CI -10.00 to -0.36; <LINK REF="STD-Riedel-2007" TYPE="STUDY">Riedel 2007</LINK>: n = 33, MD -0.48, CI -2.52 to 1.56; <LINK REF="STD-Hatta-2009" TYPE="STUDY">Hatta 2009</LINK>: n = 37, MD 0.1, CI -2.19 to 2.39 and <LINK REF="STD-Voruganti-2007" TYPE="STUDY">Voruganti 2007</LINK>: n = 85, MD -4.40, CI -5.30 to -3.50).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.32 Publication bias</HEADING>
<P>Funnel plots did not suggest a possible publication bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.33 Investigation for heterogeneity and sensitivity analysis</HEADING>
<P>When <LINK REF="STD-Mori-2004" TYPE="STUDY">Mori 2004</LINK> was excluded from the evaluation of the PANSS positive score because of possibly skewed data, olanzapine remained more effective.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Comparison 4. QUETIAPINE versus PALIPERIDONE</HEADING>
<P>Only two short-term studies with limited outcome measures met the inclusion criteria for the comparison of quetiapine with paliperidone.</P>
<SUBSECTION>
<HEADING LEVEL="4">4.1 Leaving the study early</HEADING>
<P>No significant difference was noted in the number of participants who left the study early in the paliperidone group compared with the quetiapine group for &#8216;any reason&#8217; (2 RCTs, n = 406, RR 1.03, CI 0.61 to 1.73), because of &#8216;inefficacy&#8217; (1 RCT, n = 319, RR 4.97, CI 0.59 to 42.05) or as the result of adverse events (2 RCTs, n = 406, RR 0.90, CI 0.37 to 2.17; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.2 Mental state: 1. General - average endpoint score (PANSS total)</HEADING>
<P>A significant difference favoured paliperidone on the basis of one RCT (n = 319, MD 6.30, CI 2.77 to 9.83; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.3 Mental state: 2. Positive symptoms - average endpoint score (PANSS positive subscore)</HEADING>
<P>A significant difference favoured paliperidone (1 RCT, n = 319, MD 1.60, CI 0.42 to 2.78; <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.4 Mental state: 3. Negative symptoms - average endpoint score (PANSS negative subscore)</HEADING>
<P>A significant difference favoured paliperidone (1 RCT, n = 319, MD 1.30, CI 0.52 to 2.08; <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.5 Adverse effects: 1. Numbers of participants with at least one adverse effect</HEADING>
<P>A significant difference favoured paliperidone (1 RCT, n = 87, RR 1.27, CI 1.06 to 1.53; <LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.6 Adverse effects: 2a. Cardiac effects - QTc prolongation</HEADING>
<P>Only one study examined for this side effect, and the risk ratio was not estimable because of a low event rate (<LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.7 Adverse effects: 2b. Cardiac effects - QTc abnormalities (change from baseline in ms)</HEADING>
<P>No significant difference was noted (1 RCT, n = 87, RR 2.30, CI -2.50 to 7.10; <LINK REF="CMP-004.07" TYPE="ANALYSIS">Analysis 4.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.8 Adverse effects: 3a. Extrapyramidal effects</HEADING>
<P>More participants in the paliperidone group used antiparkinson medication at least once (1 RCT, n = 319, RR 0.64, CI 0.45 to 0.91). The paliperidone group was significantly more likely to experience rigidity (2 RCTs, n = 406, RR 0.34, CI 0.12 to 0.92) and tremor (1 RCT, n = 319, RR 0.37, CI 0.17 to 0.80). No difference was noted in dystonia (1 RCT, n = 87 RR 1.02, CI 0.15 to 6.94) or akathisia (2 RCTs, n = 406, RR 1.35, CI 0.55 to 3.34; <LINK REF="CMP-004.08" TYPE="ANALYSIS">Analysis 4.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.9 Adverse effects: 3b. Extrapyramidal effects - scale measured</HEADING>
<P>Extrapyramidal adverse effects were evaluated in one RCT with the Barnes Akathisia Scale, the Extrapyramidal Side Effects Rating Scale and the Simpson-Angus Scale. None of these scales reported a significant difference between groups (<LINK REF="CMP-004.09" TYPE="ANALYSIS">Analysis 4.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.10 Adverse effects: 4a. Prolactin - associated effects - sexual dysfunction</HEADING>
<P>No difference was noted in the number of participants who suffered from sexual dysfunction (1 RCT, n = 317, RR 0.02, CI 0.01 to 4.16; <LINK REF="CMP-004.10" TYPE="ANALYSIS">Analysis 4.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.11 Adverse effects: 4b. Prolactin - change from baseline (ng/mL)</HEADING>
<P>On the basis of one study, quetiapine was associated with significantly less prolactin increase than paliperidone (1 RCT, n = 317, MD -49.30, CI -57.80 to -40.80; <LINK REF="CMP-004.11" TYPE="ANALYSIS">Analysis 4.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.12 Adverse effects: 5a. Metabolic - weight gain - number of participants with weight gain of 7% or more of total body weight</HEADING>
<P>Participants in the paliperidone group were not more likely to experience significant weight gain as defined by the study investigators (1 RCT, n = 319, RR 2.52, CI 0.50 to 12.78; <LINK REF="CMP-004.12" TYPE="ANALYSIS">Analysis 4.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.13 Adverse effects: 5b. Metabolicweight gain - mean change from baseline in kilograms</HEADING>
<P>Paliperidone did cause a significantly greater weight gain in terms of change from baseline in kilograms (1 RCT, n = 319, MD 0.40, CI 0.20 to 0.60; <LINK REF="CMP-004.13" TYPE="ANALYSIS">Analysis 4.13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.13 Publication bias</HEADING>
<P>Funnel plots were not performed because of the paucity of studies.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. Comparison 5. QUETIAPINE versus RISPERIDONE</HEADING>
<P>Nineteen studies met the inclusion criteria for the comparison of quetiapine with risperidone.</P>
<SUBSECTION>
<HEADING LEVEL="4">5.1 Leaving the study early</HEADING>
<P>Leaving the studies early for any reason showed an almost significant superiority of risperidone (quetiapine 54%, risperidone 49%; 13 RCTs, n = 2784, RR 1.09, CI 1.00 to 1.19). Leaving early because of inefficacy showed a small significant advantage of risperidone over quetiapine (25% vs 19%; 8 RCTs, n = 1891, RR 1.32, CI 1.02 to 1.71). No significant difference was noted in the number of participants leaving early as the result of adverse events (10% vs 9%; 9 RCTs, n = 2299, RR 1.12, CI 0.80 to 1.57; <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.2 Global state: 1a. No clinically significant response - as defined by the original studies</HEADING>
<P>Overall, no significant difference was evident when all studies were considered (4 RCTs, n = 1264, RR 1.07, CI 0.95 to 1.22; <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>). The first three studies reported short-term data, and only <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK> reported long-term data. Heterogeneity was moderate (I<SUP>2</SUP> = 57%<I>); </I>however, on exclusion of potentially skewed data from <LINK REF="STD-Potkin-2006" TYPE="STUDY">Potkin 2006</LINK>, there remained no significant difference between groups (3 RCTs, n = 965, RR 1.01, CI 0.93 to 1.09; <LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.3 Global state: 1b. No clinically important change - as defined by the original studies</HEADING>
<P>A small superiority of risperidone was noted, but it did not reach statistical significance (5 RCTs, n = 1342, RR 1.10, CI 0.98 to 1.25; <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.4 Mental state: 1a. General - no clinically important change - short term (&lt; 30% PANSS total score reduction from baseline)</HEADING>
<P>No significant difference was noted (2 RCTs, n = 982, RR 1.11, CI 0.87 to 1.42), but the results were heterogeneous (<LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>). We therefore present the single studies separately: <LINK REF="STD-Potkin-2006" TYPE="STUDY">Potkin 2006</LINK> (n = 177, RR 1.27, CI 1.05 to 1.55) and <LINK REF="STD-Zhong-2006a" TYPE="STUDY">Zhong 2006a</LINK> (n = 495, RR 1.0, CI 0.91 to 1.09).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.5 Mental state: 1b. General: no clinically important change - short term (&lt; 20% BPRS total score reduction)</HEADING>
<P>No significant difference was noted (1 RCT, n = 25, RR 0.98, CI 0.63 to 1.52; <LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.6 Mental state: 1c. General: average endpoint score (PANSS total)</HEADING>
<P>A significant difference favoured risperidone: overall (14 RCTs, n = 2302, MD 1.67, CI 0.39 to 2.96), short term (8 RCTs, n = 1232, MD 1.37, CI -0.28 to 3.01) and long term (2 RCTs, n = 743, MD 3.11, CI 0.40 to 5.82; <LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK>).  Medium-term studies displayed considerable heterogeneity; the results are therefore presented separately. <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK> reported a significant difference in favour of risperidone (n = 132, MD 10, CI 2.38 to 17.62); <LINK REF="STD-McEvoy-2006" TYPE="STUDY">McEvoy 2006</LINK> (n = 14, MD -1.0, CI -15.41 to 13.41), <LINK REF="STD-Wei-2006a" TYPE="STUDY">Wei 2006a</LINK> (n = 51, MD 1.60, CI -5.69 to 2.49) and <LINK REF="STD-Lu-2006" TYPE="STUDY">Lu 2006</LINK> (n = 64, MD 3.82, CI -2.51 to 10.15) found no significant difference between groups. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.7 Mental state: 1d. General mental state: average endpoint score - short term (BPRS total)</HEADING>
<P>No significant difference was noted (1 RCT, n = 25, MD 1.68, CI -8.33 to 11.69; <LINK REF="CMP-005.07" TYPE="ANALYSIS">Analysis 5.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.8 Mental state: 2a. Positive symptoms - no clinically important change in PANSS positive subscore</HEADING>
<P>No significant difference was noted in the number of people with no clinically important change in PANSS score in the short term, as measured by &lt; 40% PANSS positive score reduction from baseline (1 RCT, n = 673, RR 1.00, CI 0.9 to 1.12; <LINK REF="CMP-005.08" TYPE="ANALYSIS">Analysis 5.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.9 Mental state: 2b. Positive symptoms - average endpoint score (PANSS positive subscore)</HEADING>
<P>A significant difference favoured risperidone overall (11 RCTs, n = 1639, MD 1.22, CI 0.51 to 1.94), medium term (5 RCTs, n = 327, MD 1.21, CI -0.21 to 2.63) and long term (1 RCT, n = 81, MD 1.30, CI -0.13 to 2.73; <LINK REF="CMP-005.09" TYPE="ANALYSIS">Analysis 5.9</LINK>). Despite considerable heterogeneity, short-term studies tended to favour risperidone: <LINK REF="STD-Mori-2004" TYPE="STUDY">Mori 2004</LINK> (n = 39, MD 2.5, CI 0.37 to 4.63), <LINK REF="STD-Potkin-2006" TYPE="STUDY">Potkin 2006</LINK> (n = 308, MD 2.80, CI 1.42 to 4.18), <LINK REF="STD-Riedel-2005" TYPE="STUDY">Riedel 2005</LINK> (n = 44, MD 3.80, CI -0.51 to 8.11), <LINK REF="STD-Song-2008" TYPE="STUDY">Song 2008</LINK> (n = 66, MD 0.16, CI -1.12 to 1.44) and <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK> (n = 60, MD 0.1, CI -1.87 to 2.07). <LINK REF="STD-Hu-2008" TYPE="STUDY">Hu 2008</LINK> favoured quetiapine but had a wide CI (n = 68, MD-0.50, CI -3.81 to 2.81). Excluding data from potentially skewed short-term (<LINK REF="STD-Hu-2008" TYPE="STUDY">Hu 2008</LINK>; <LINK REF="STD-Mori-2004" TYPE="STUDY">Mori 2004</LINK>; <LINK REF="STD-Song-2008" TYPE="STUDY">Song 2008</LINK>; <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>) and medium-term (<LINK REF="STD-Lu-2006" TYPE="STUDY">Lu 2006</LINK>; <LINK REF="STD-Song-2008" TYPE="STUDY">Song 2008</LINK>; <LINK REF="STD-Wei-2006a" TYPE="STUDY">Wei 2006a</LINK>) studies in a sensitivity analysis maintained a significant difference in favour of risperidone (6 RCTs, n = 1225, MD 1.76, CI 1.04 to 2.48).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.10 Mental state: 2c. Positive symptoms - average change endpoint score - short term (BPRS positive subscore)</HEADING>
<P>A significant difference favoured risperidone (1 RCT, n = 25, MD 1.1, CI 0.18 to 2.02; <LINK REF="CMP-005.10" TYPE="ANALYSIS">Analysis 5.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.11 Mental state: 3a. Negative symptoms - no clinically important change - PANSS negative subscore short term (&lt; 40% PANSS negative score reduction from baseline)</HEADING>
<P>No significant difference was noted in the number of people with no clinically important change in the PANSS negative subscore in the short term, as measured by &lt; 40% PANSS negative score reduction from baseline (1 RCT, n = 673, RR 0.98, CI 0.93 to 1.04; <LINK REF="CMP-005.11" TYPE="ANALYSIS">Analysis 5.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.12 Mental state: 3b. Negative symptoms - average endpoint score (PANSS negative subscore)</HEADING>
<P>No significant difference was noted in short-term studies (6 RCTs, n = 1106, MD 0.55, CI -0.25 to 1.34), medium-term studies (5 RCTs, n = 327, MD 1.05, CI -0.24 to 2.34) and long-term studies (1 RCT, n = 81, MD 0.8, CI -0.64 to 2.24; <LINK REF="CMP-005.12" TYPE="ANALYSIS">Analysis 5.12</LINK>). Exclusion of potentially skewed data in a sensitivity analysis for short-term and medium-term studies yielded no significant difference in results (<LINK REF="CMP-010.04" TYPE="ANALYSIS">Analysis 10.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.13 Mental state: 3c. Negative symptoms - average change endpoint score - short term (BPRS negative subscore)</HEADING>
<P>A significant difference favoured risperidone (1 RCT, n = 25, MD 0.57, CI 0.17 to 0.97; <LINK REF="CMP-005.13" TYPE="ANALYSIS">Analysis 5.13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.14 Quality of life - average endpoint score (QLS total score)</HEADING>
<P>A significant difference favoured quetiapine (3 RCTs, n = 152, MD -3.44, CI -4.46 to -2.43; <LINK REF="CMP-005.14" TYPE="ANALYSIS">Analysis 5.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.15 Service use: 1. Number of participants re-hospitalised</HEADING>
<P>The difference almost reached statistical significance, with a slight benefit for the risperidone group (2 RCTs, n = 877, RR 1.34, CI 1.0 to 1.79; <LINK REF="CMP-005.15" TYPE="ANALYSIS">Analysis 5.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.16 Adverse effects: 1. General - at least one adverse effect</HEADING>
<P>No significant difference was noted (13 RCTs, n = 2868, RR 1.01, CI 0.91 to 1.13; <LINK REF="CMP-005.16" TYPE="ANALYSIS">Analysis 5.16</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.17 Adverse effects: 2. Death</HEADING>
<P>No significant difference was noted (6 RCTs, n = 3146, RR 0.73, CI 0.17 to 3.09; <LINK REF="CMP-005.17" TYPE="ANALYSIS">Analysis 5.17</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.18 Adverse effects: 3a. Cardiac effects - number of participants with QTc prolongation</HEADING>
<P>No significant difference was noted (3 RCTs, n = 1419, RR 1.34, CI 0.36 to 5.04; <LINK REF="CMP-005.18" TYPE="ANALYSIS">Analysis 5.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.19 Adverse effects: 3b. Mean change in QTc interval from baseline in ms</HEADING>
<P>Overall, no significant difference was noted (3 RCTs, n = 940, MD 2.21, CI -5.05 to 9.48). The data were heterogeneous. In the individual studies, <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK> found a significant difference in favour of risperidone (n = 432, MD 5.7, CI 0.57 to 10.83), but <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK> (n = 166, MD 6.3, CI -3.41 to 16.01) and <LINK REF="STD-Zhong-2006a" TYPE="STUDY">Zhong 2006a</LINK> (n = 342, MD -3.6, CI -7.55 to 0.35) found no significant difference between groups (<LINK REF="CMP-005.19" TYPE="ANALYSIS">Analysis 5.19</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.20 Adverse effect: 4. Central nervous system - sedation</HEADING>
<P>A significant difference favoured risperidone (8 RCTs, n = 2226, RR 1.21, CI 1.06 to 1.38; <LINK REF="CMP-005.20" TYPE="ANALYSIS">Analysis 5.20</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.21 Adverse effects: 5a. Extrapyramidal effects</HEADING>
<P>Quetiapine produced fewer movement disorders than risperidone in terms of 'extrapyramidal symptoms' (2 RCTs, n = 872, RR 0.59, CI 0.43 to 0.81), dystonia (4 RCTs, n = 1451, RR 0.13, CI 0.04 to 0.43), use of antiparkinson medication at least once (8 RCTs, n = 2163, RR 0.50, CI 0.36 to 0.69), akathisia (8 RCTs, n = 2270, RR 0.55, CI 0.32 to 0.95), akinesia (1 RCT, n = 267, RR 0.91, CI 0.61 to 1.37) and lesser parkinsonism (4 RCTs, n = 825, RR 0.39, CI 0.19 to 0.78; <LINK REF="CMP-005.21" TYPE="ANALYSIS">Analysis 5.21</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.22 Adverse effects: 5c. Extrapyramidal effects as measured by scales</HEADING>
<P>Quetiapine produced fewer extrapyramidal side effects than risperidone according to the Simpson-Angus Scale (5 RCTs, n = 1077, MD -0.59, CI -1.16 to -0.02). No significant difference was noted in dyskinesia (AIMS, 2 RCTs, n = 958, MD -0.34, CI -0.76 to 0.08) and akathisia (BAS, 2 RCTs, n = 700, MD -0.73, CI -2.0 to 0.54; <LINK REF="CMP-005.22" TYPE="ANALYSIS">Analysis 5.22</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.23 Adverse effects: 6. Haematological - important decline in white blood cells</HEADING>
<P>No significant difference was noted (1 RCT, n = 673, RR 2.97, CI 0.12 to 72.73; <LINK REF="CMP-005.23" TYPE="ANALYSIS">Analysis 5.23</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.24 Adverse effects: 7a. Prolactin associated adverse effects</HEADING>
<P>Quetiapine produced significantly fewer cases of amenorrhoea (5 RCTs, n = 427, RR 0.55, CI 0.32 to 0.96), galactorrhoea (5 RCTs, n = 1188, RR 0.37, CI 0.16 to 0.85) and gynaecomastia (1 RCT, n = 78, RR 0.23, CI 0.07 to 0.75) but not dysmenorrhoea (1 RCT, n = 163, RR 0.45, CI 0.08 to 2.38). Data on sexual dysfunction showed an almost significant superiority of quetiapine (6 RCTs, n = 2157, RR 0.70, CI 0.48 to 1.01; <LINK REF="CMP-005.24" TYPE="ANALYSIS">Analysis 5.24</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.25 Adverse effects: 7b. Prolactin - change from baseline in ng/mL</HEADING>
<P>A significant and consistent difference favoured quetiapine, although the extent of the difference varied, leading to statistical heterogeneity (7 RCTs, n = 1773, MD -35.25, CI -43.59 to -26.91; the results of the single studies were as follows: <LINK REF="STD-Byerly-2008" TYPE="STUDY">Byerly 2008</LINK>: n = 44, MD -35.10, CI -50.68 to -19.52; <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>: n = 678, MD -24.70, CI -28.72 to -20.68; <LINK REF="STD-McEvoy-2006" TYPE="STUDY">McEvoy 2006</LINK>: n = 24, MD -28.6, CI -43.02 to -14.18; <LINK REF="STD-Potkin-2006" TYPE="STUDY">Potkin 2006</LINK>: n = 309, MD -50.4, CI -60.24 to -40.56; <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK>: n = 199, MD -30.3, CI -37.1 to -23.5; <LINK REF="STD-Zhong-2006a" TYPE="STUDY">Zhong 2006a</LINK>: n = 440, MD -47.0, CI -52.97 to -41.03and <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK>: n = 81, MD -30.8, CI -38.1 to -23.5; <LINK REF="CMP-005.25" TYPE="ANALYSIS">Analysis 5.25</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.26 Adverse effects: 8a. Metabolic - cholesterol - number of participants with a significant cholesterol increase</HEADING>
<P>No significant difference was noted (2 RCTs, n = 940, RR 1.27, CI 0.72 to 2.24; <LINK REF="CMP-005.26" TYPE="ANALYSIS">Analysis 5.26</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.27 Adverse effects: 8b. Metabolic - cholesterol - mean change from baseline in mg/dL</HEADING>
<P>A significant difference favoured risperidone (6 RCTs, n = 1473, MD 8.57, CI 4.85 to 12.29; <LINK REF="CMP-005.27" TYPE="ANALYSIS">Analysis 5.27</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.28 Adverse effects: 8c. Metabolic - glucose - number of participants with abnormally high fasting glucose</HEADING>
<P>No significant difference was noted (3 RCTs, n = 1618, RR 0.89, CI 0.47 to 1.69; <LINK REF="CMP-005.28" TYPE="ANALYSIS">Analysis 5.28</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.29 Adverse effects: 8d. Metabolic - glucose - mean change from baseline in mg/dL</HEADING>
<P>No significant difference was noted (6 RCTs, n = 1476, MD 0.30, CI -2.45 to 3.05; <LINK REF="CMP-005.29" TYPE="ANALYSIS">Analysis 5.29</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.30 Adverse effects: 8e. Metabolic - weight gain - number of participants with weight gain of 7% or more of total body weight</HEADING>
<P>No significant difference was noted (9 RCTs, n = 2070, RR 0.96, CI 0.82 to 1.14; <LINK REF="CMP-005.30" TYPE="ANALYSIS">Analysis 5.30</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.31 Adverse effects: 8f. Metabolic - weight gain - mean change from baseline in kilograms</HEADING>
<P>Overall, no significant difference was noted, but the data were highly heterogeneous, presumably because of one small outlier study (<LINK REF="STD-Atmaca-2003" TYPE="STUDY">Atmaca 2003</LINK>) that showed a dramatic advantage of risperidone (8 RCTs, n = 1486, MD 0.94, CI -0.59 to 2.46; <LINK REF="CMP-005.31" TYPE="ANALYSIS">Analysis 5.31</LINK>). Nevertheless, excluding this study did not change the overall result.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.32 Publication bias</HEADING>
<P>A reasonable funnel plot analysis was possible only for the PANSS total score (&gt; 10 included studies). It did not suggest a possible publication bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5.33 Investigation for heterogeneity and sensitivity analysis</HEADING>
<P>Exclusion of <LINK REF="STD-Mori-2004" TYPE="STUDY">Mori 2004</LINK> from the evaluation of the PANSS positive subscore as the result of possibly skewed data did not reveal markedly different results. The data on akathisia (Barnes Akathisia Scale) indicated considerable heterogeneity, but clear reasons to explain this could not be found.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">6. Comparison 6. QUETIAPINE versus ZIPRASIDONE</HEADING>
<P>Two studies met the inclusion criteria for the comparison of quetiapine versus ziprasidone.</P>
<SUBSECTION>
<HEADING LEVEL="4">6.1 Leaving the study early</HEADING>
<P>No significant difference was noted in the number of participants leaving the studies early for any reason (2 RCTs, n = 722, RR 1.05, CI 0.97 to 1.13), because of adverse events (2 RCTs, n = 722, RR 1.04, CI 0.72 to 1.49) or as the result of inefficacy of treatment (2 RCTs, n = 722, RR 1.14, CI 0.89 to 1.47).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.2 Mental state: 1. General mental state - average endpoint score (PANSS total)</HEADING>
<P>No significant difference was noted, but the data from two studies were heterogeneous and therefore are presented separately. Neither <LINK REF="STD-Stroup-2006" TYPE="STUDY">Stroup 2006</LINK> (medium-term data, n = 198, MD 3.7, CI -2.97 to 10.37) nor <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK> (long-term data, n = 512, MD -2.78, CI -6.81 to 1.25) found a significant difference between groups (<LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.3 Mental state: 2. Positive symptoms - average endpoint score - medium term (PANSS positive subscore)</HEADING>
<P>No significant difference was noted (1 RCT, n = 198, MD 0.0, CI -2.18 to 2.18; <LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.4 Mental state: 3. Negative symptoms: average endpoint score - medium term (PANSS negative subscore)</HEADING>
<P>No significant difference was noted (1 RCT, n = 198, MD 1.6, CI -0.34 to 3.54; <LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.5 Service use: 1. Number of participants re-hospitalised</HEADING>
<P>No significant differencewas noted in the overall analysis (2 RCTs, n = 754, RR 1.17, CI 0.85 to 1.59) or in the analysis of medium-term data (1 RCT, n = 232, RR 1.25, CI 0.71 to 2.17) or long-term data (1 RCT, n = 522, RR 1.13, CI 0.78 to 1.65; <LINK REF="CMP-006.05" TYPE="ANALYSIS">Analysis 6.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.6 Adverse effects: 1. General - at least one adverse effect</HEADING>
<P>No significant difference was noted (2 RCTs, n = 754, RR 1.03, CI 0.91 to 1.17; <LINK REF="CMP-006.06" TYPE="ANALYSIS">Analysis 6.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.7 Adverse effects: 2. Death</HEADING>
<P>No significant difference was noted (2 RCTs, n = 754, RR 0.41, CI 0.05 to 3.15; <LINK REF="CMP-006.07" TYPE="ANALYSIS">Analysis 6.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.8 Adverse effects: 3a. Cardiac effects - QTc prolongation</HEADING>
<P>No significant difference was noted in the number of participants with QTc prolongation (1 RCT, n = 522, RR 1.65, CI 0.34 to 8.08; <LINK REF="CMP-006.08" TYPE="ANALYSIS">Analysis 6.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.9 Adverse effects: 3b. Cardiac effects - mean change in QTc interval in ms</HEADING>
<P>No significant difference was noted (2 RCTs, n = 549, MD 3.41, CI -1.37 to 8.18; <LINK REF="CMP-006.09" TYPE="ANALYSIS">Analysis 6.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.10 Adverse effects: 4. Central nervous system - sedation</HEADING>
<P>Significantly fewer participants in the ziprasidone group than in the quetiapine group felt sedated (2 RCTs, n = 754, RR 1.36, CI 1.04 to 1.77, NNH 14, CI 7 to 100; <LINK REF="CMP-006.10" TYPE="ANALYSIS">Analysis 6.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.11 Adverse effects: 5. Extrapyramidal effects</HEADING>
<P>Significantly fewer people in the quetiapine group used antiparkinson medication at least once (1 RCT, n = 522, RR 0.43, CI 0.2 to 0.93), but no clear differences were noted in akathisia (2 RCTs, n = 754, RR 0.78, CI 0.42 to 1.45) or in 'any extrapyramidal symptoms' (1 RCT, n = 232, RR 2.02, CI 0.66 to 6.17; <LINK REF="CMP-006.11" TYPE="ANALYSIS">Analysis 6.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.12 Adverse effects: 6a. Prolactin - associated effects</HEADING>
<P>No significant difference was noted in amenorrhoea (1 RCT, n = 138, RR 0.43, CI 0.15 to 1.24), galactorrhoea (2 RCTs, n = 202, RR 0.68, CI 0.23 to 2.01) or sexual dysfunction (2 RCTs, n = 754, RR 0.96, CI 0.64 to 1.42; <LINK REF="CMP-006.12" TYPE="ANALYSIS">Analysis 6.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.13 Adverse effects: 6b. Prolactin - change from baseline in ng/mL</HEADING>
<P>A significant difference favoured quetiapine (2 RCTs, n = 754, MD -4.77, CI -8.16 to -1.37; <LINK REF="CMP-006.13" TYPE="ANALYSIS">Analysis 6.13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.14 Adverse effects: 7a. Metabolic - cholesterol - mean change from baseline in mg/dL</HEADING>
<P>Ziprasidone was associated with significantly less cholesterol increase than quetiapine (2 RCTs, n = 754, MD 16.01, CI 8.57 to 23.46; <LINK REF="CMP-006.14" TYPE="ANALYSIS">Analysis 6.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.15 Adverse effects: 7b. Metabolic - glucose - mean change from baseline in mg/dL</HEADING>
<P>No significant difference was noted (2 RCTs, n = 754, MD 3.1, CI -3.99 to 10.19; <LINK REF="CMP-006.15" TYPE="ANALYSIS">Analysis 6.15</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.16 Adverse effects: 7c. Metabolic - glucose - abnormally high fasting glucose value</HEADING>
<P>No significant difference was noted (1 RCT, n = 522, RR 0.64, CI 0.3 to 1.36; <LINK REF="CMP-006.16" TYPE="ANALYSIS">Analysis 6.16</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.17 Adverse effects: 7d. Metabolic - weight gain - number of participants with weight gain of 7% or more of total body weight</HEADING>
<P>Significantly more participants in the quetiapine group than in the ziprasidone group gained weight (2 RCTs, n = 754, RR 2.22, CI 1.35 to 3.63; <LINK REF="CMP-006.17" TYPE="ANALYSIS">Analysis 6.17</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.18 Adverse effects: 7e. Metabolic - weight gain - change from baseline in kilograms</HEADING>
<P>A superiority of ziprasidone almost reached statistical significance (1 RCT, n = 466, MD 1.2, CI -0.05 to 2.45; <LINK REF="CMP-006.18" TYPE="ANALYSIS">Analysis 6.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.19 Publication bias</HEADING>
<P>Because of the small number of included studies, we did not perform a funnel plot analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6.20 Investigation for heterogeneity and sensitivity analysis</HEADING>
<P>The reasons for the preplanned sensitivity analysis did not apply; therefore it was not performed.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-11-04 17:27:29 +0000" MODIFIED_BY="Laila Asmal">
<SUMMARY_OF_RESULTS MODIFIED="2013-11-04 17:27:29 +0000" MODIFIED_BY="Laila Asmal">
<SUBSECTION>
<HEADING LEVEL="4">General</HEADING>
<P>This analysis of the effects of quetiapine compared with other second-generation antipsychotic drugs in the treatment of schizophrenia currently includes 37 studies reporting data on only six of nine possible comparisons. High discontinuation rates (overall 50.2%) limit the value of findings. In addition, 26 of the 37 included studies randomly assigned fewer than 100 people. The duration of the trials was usually short, and we identified only two long-term studies. Short-term trials are not ideal for judging the efficacy and tolerability of treatments for a chronic disease. Eighteen of the 37 studies were sponsored by a pharmaceutical industry with a clear pecuniary interest in the result. This is likely to be a further problem.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1. Comparison 1. QUETIAPINE versus ARIPIPRIZOLE</HEADING>
<P>Four small short-term studies with a total of 293 participants fell into this comparison. Data were available for only one study for a number of outcomes. Please see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">1.1 Leaving the studies early</HEADING>
<P>The overall rate of participants leaving studies early was 19.5%, with no clear difference between groups. However, this finding was based on only two small, short-term trials, limiting interpretation (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2 Efficacy outcomes (overall and specific mental state)</HEADING>
<P>Four studies of low-quality evidence found no significant difference in general mental state, positive symptoms or negative symptoms. Data from all studies measuring efficacy were potentially skewed and should be interpreted with caution (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3 Adverse effects</HEADING>
<P>We found limited data on &#8216;at least one adverse effect&#8217; (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>), cardiac effects (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>), extrapyramidal symptoms (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>) and weight gain (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>;<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>), showing no significant difference between quetiapine and aripiprazole.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.4 Quality of life</HEADING>
<P>Quality of life was not measured and was not reported in these studies.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Comparison 2. QUETIAPINE versus CLOZAPINE</HEADING>
<P>Five studies with a total of 334 participants fell into this comparison. Please see <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Leaving the studies early</HEADING>
<P>The overall rate of participants leaving studies early was remarkably low (8.4%) and showed no clear difference between groups. Nevertheless, this finding was based on only two small (n = 135), short-term trials, limiting any interpretation (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Efficacy outcomes (global state, overall and specific mental state)</HEADING>
<P>No significant difference was noted in global state, general mental state or positive symptoms on the basis of studies of low-quality evidence (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>; <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>; <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>; <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>; <LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>; <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>; <LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>). A small reduction in negative symptoms was noted in those taking quetiapine, but this result must be interpreted with caution, as it was based on two small trials with low-quality evidence (<LINK REF="STD-Li-2003b" TYPE="STUDY">Li 2003b</LINK>; <LINK REF="STD-Li-2005b" TYPE="STUDY">Li 2005b</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3 Adverse effects</HEADING>
<P>We found limited data on &#8216;at least one adverse effect&#8217; (<LINK REF="CMP-002.11" TYPE="ANALYSIS">Analysis 2.11</LINK>), cardiac effects (<LINK REF="CMP-002.12" TYPE="ANALYSIS">Analysis 2.12</LINK>), sedation (<LINK REF="CMP-002.13" TYPE="ANALYSIS">Analysis 2.13</LINK>), extrapyramidal symptoms (<LINK REF="CMP-002.14" TYPE="ANALYSIS">Analysis 2.14</LINK>), white blood cell count (<LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>) and weight gain (<LINK REF="CMP-002.16" TYPE="ANALYSIS">Analysis 2.16</LINK>; <LINK REF="CMP-002.17" TYPE="ANALYSIS">Analysis 2.17</LINK>). Results on &#8216;at least one adverse effect&#8217;, cardiac effects and sedation indicated an advantage for quetiapine. These findings were based on only one or two studies; therefore, they cannot be considered to be robust.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4 Quality of life</HEADING>
<P>Quality of life was not measured and was not reported in these studies.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Comparison 3. QUETIAPINE versus OLANZAPINE</HEADING>
<P>Most of the studies included in the review contributed data to this comparison (14 studies, n = 1953) (<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Leaving the studies early</HEADING>
<P>Fewer people in the olanzapine group compared with the quetiapine group left studies early for &#8216;any reason&#8217; or because of &#8216;inefficacy of treatment&#8217;. This finding suggests that olanzapine is a more acceptable treatment than quetiapine, at least in the confines of clinical trials. Nevertheless, the overall rate of premature study discontinuations was high (61.7%), limiting the validity of all other results (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Efficacy outcomes (global state, overall and specific mental state)</HEADING>
<P>Quetiapine is probably slightly less effective than olanzapine in reducing general mental state symptoms according to studies of moderate-quality evidence (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>; <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>). No significant difference was noted in the reduction of negative symptoms or positive symptoms (<LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>; <LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>; <LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>; <LINK REF="CMP-003.09" TYPE="ANALYSIS">Analysis 3.9</LINK>; <LINK REF="CMP-003.10" TYPE="ANALYSIS">Analysis 3.10</LINK>; <LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>; <LINK REF="CMP-003.12" TYPE="ANALYSIS">Analysis 3.12</LINK>). The latter findings should be interpreted with caution; studies measuring negative and positive symptoms were of low and very low quality, respectively.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3 Service use: number of participants re-hospitalised</HEADING>
<P>The number of participants re-hospitalised was significantly higher in the quetiapine group (<LINK REF="CMP-003.15" TYPE="ANALYSIS">Analysis 3.15</LINK>). This may reflect a certain efficacy advantage of olanzapine.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.4 Adverse effects</HEADING>
<P>Adverse effects were reported as at least one adverse effect, cardiac effects, QTc abnormalities and an increase in serum cholesterol, serum glucose and serum prolactin, as well as associated side effects, death, extrapyramidal symptoms, the occurrence of sedation, seizures and weight gain. Among these adverse effects, a benefit for quetiapine was found for the use of antiparkinson medication (a proxy measure for extrapyramidal adverse effects; <LINK REF="CMP-003.22" TYPE="ANALYSIS">Analysis 3.22</LINK>), weight gain (<LINK REF="CMP-003.30" TYPE="ANALYSIS">Analysis 3.30</LINK>; <LINK REF="CMP-003.31" TYPE="ANALYSIS">Analysis 3.31</LINK>), glucose elevation (<LINK REF="CMP-003.28" TYPE="ANALYSIS">Analysis 3.28</LINK>; <LINK REF="CMP-003.29" TYPE="ANALYSIS">Analysis 3.29</LINK>), prolactin increase (<LINK REF="CMP-003.25" TYPE="ANALYSIS">Analysis 3.25</LINK>) and some prolactin-associated adverse effects. On the other hand, a certain superiority of olanzapine was noted in terms of QTc prolongation (<LINK REF="CMP-003.18" TYPE="ANALYSIS">Analysis 3.18</LINK>). Overall, it seems that quetiapine may be more tolerable than olanzapine, but this is weighed against slightly less efficacy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.5 General functioning and quality of life</HEADING>
<P>Very limited data on these important outcomes are available. Olanzapine may improve general functioning (GAF total score) to a greater extent than quetiapine (<LINK REF="CMP-003.13" TYPE="ANALYSIS">Analysis 3.13</LINK>). One study of moderate quality reported no difference in quality of life measures between olanzapine and quetiapine (<LINK REF="CMP-003.14" TYPE="ANALYSIS">Analysis 3.14</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Comparison 4. QUETIAPINE versus PALIPERIDONE</HEADING>
<P>Only two studies (<LINK REF="STD-Canuso-2008" TYPE="STUDY">Canuso 2008</LINK>; <LINK REF="STD-Eerdekens-2007" TYPE="STUDY">Eerdekens 2007</LINK>) with 406 participants provided data on this comparison. Eerdekens contributed only to adverse effects outcomes. Both studies were short term and were sponsored by the manufacturers of paliperidone. Please see <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">4.1 Leaving the studies early</HEADING>
<P>The overall number of participants leaving the studies early was relatively low compared with other comparisons (14.0%). No significant difference was reported between groups or for reasons why participants left the studies (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>). </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.2 Efficacy outcomes (global state, overall and specific mental state)</HEADING>
<P>Paliperidone showed better efficacy than quetiapine in improving the overall mental state score and in reducing positive and negative symptoms (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>; <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>; <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>). However, this finding was based on only one small, short-term trial, thus limiting interpretation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.3 Adverse effects</HEADING>
<P>In one small study, more participants reported at least one side effect while taking quetiapine compared with paliperidone (<LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>). However, the <LINK REF="STD-Canuso-2008" TYPE="STUDY">Canuso 2008</LINK> study showed an advantage of quetiapine in terms of parkinsonian side effects, prolactin levels, sexual side effects and weight gain. Further studies are required to clarify the differences in adverse effect profiles between these two medications. </P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Comparison 5. QUETIAPINE versus RISPERIDONE</HEADING>
<P>Nineteen studies including 3123 participants met the inclusion criteria for this comparison. Please see <LINK REF="SOF-05" TYPE="SOF">Summary of findings table 5</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">5.1 Leaving the studies early</HEADING>
<P>No clear difference was evident in the number of participants leaving the studies early, suggesting a similar overall acceptability of quetiapine and risperidone (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>). Nevertheless, the overall discontinuation rate was high (51.8%), thus limiting the interpretation of all other results.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.2 Efficacy outcomes (global state, overall and specific mental state)</HEADING>
<P>Differences in efficacy were found for the general mental state, positive symptoms and, on exclusion of an outlier, negative symptoms (<LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>; <LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>; <LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK>; <LINK REF="CMP-005.07" TYPE="ANALYSIS">Analysis 5.7</LINK>; <LINK REF="CMP-005.08" TYPE="ANALYSIS">Analysis 5.8</LINK>; <LINK REF="CMP-005.09" TYPE="ANALYSIS">Analysis 5.9</LINK>; <LINK REF="CMP-005.10" TYPE="ANALYSIS">Analysis 5.10</LINK>; <LINK REF="CMP-005.11" TYPE="ANALYSIS">Analysis 5.11</LINK>; <LINK REF="CMP-005.12" TYPE="ANALYSIS">Analysis 5.12</LINK>; <LINK REF="CMP-005.13" TYPE="ANALYSIS">Analysis 5.13</LINK>). Quetiapine was less effective than risperidone in these aspects of psychopathology. Nevertheless, the differences were small (e.g. only three points on the PANSS total score).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.3 Adverse effects</HEADING>
<P>Adverse effects were reported as at least one adverse effect, cardiac effects, cholesterol increase, changes in serum glucose, increase in prolactin level and associated side effects, death, extrapyramidal adverse effects, sedation, weight gain and white blood cell count. Among these, quetiapine was better than risperidone in various measures of extrapyramidal adverse effects (<LINK REF="CMP-005.21" TYPE="ANALYSIS">Analysis 5.21</LINK>; <LINK REF="CMP-005.22" TYPE="ANALYSIS">Analysis 5.22</LINK>) and prolactin-associated effects (<LINK REF="CMP-005.24" TYPE="ANALYSIS">Analysis 5.24</LINK>; <LINK REF="CMP-005.25" TYPE="ANALYSIS">Analysis 5.25</LINK>). On the other hand, quetiapine was associated with increased sedation (<LINK REF="CMP-005.20" TYPE="ANALYSIS">Analysis 5.20</LINK>) and cholesterol (<LINK REF="CMP-005.26" TYPE="ANALYSIS">Analysis 5.26</LINK>; <LINK REF="CMP-005.27" TYPE="ANALYSIS">Analysis 5.27</LINK>) compared with risperidone. These differences in the adverse effect profile and the slightly lower efficacy of quetiapine may be weighed in drug selection.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5.4 Quality of life</HEADING>
<P>Three studies of moderate quality assessed quality of life (<LINK REF="CMP-005.14" TYPE="ANALYSIS">Analysis 5.14</LINK>). Participants treated with quetiapine reported significantly higher quality of life scores than those treated with risperidone.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Comparison 6. QUETIAPINE versus ZIPRASIDONE</HEADING>
<P>Only two studies with 722 participants provided data on this comparison. Please see <LINK REF="SOF-06" TYPE="SOF">Summary of findings table 6</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">6.1 Leaving the studies early</HEADING>
<P>The overall number of participants leaving the studies early was very high (80.7%), clearly limiting the interpretation of any findings beyond the outcome of &#8216;leaving the study early&#8217;. No significant difference was noted between groups, but the acceptability of both compounds seems to be poor (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.2 Efficacy outcomes (global state, overall and specific mental state)</HEADING>
<P>No significant difference in global state, general mental state or positive symptoms was noted in studies with evidence of very low (general state) or low (positive and negative symptoms) quality (<LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>; <LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>; <LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.3 Adverse effects</HEADING>
<P>Adverse effects were reported as at least one adverse effect; cardiac effects; death; extrapyramidal side effects; changes in cholesterol, glucose and prolactin; the occurrence of sedation and weight gain. Quetiapine was advantageous in the use of antiparkinson medication (one study, low-quality evidence; <LINK REF="CMP-006.11" TYPE="ANALYSIS">Analysis 6.11</LINK>) and for prolactin levels (two studies, moderate-quality evidence; <LINK REF="CMP-006.12" TYPE="ANALYSIS">Analysis 6.12</LINK>; <LINK REF="CMP-006.13" TYPE="ANALYSIS">Analysis 6.13</LINK>), and two studies with moderate-quality evidence favoured ziprasidone for weight gain (<LINK REF="CMP-006.17" TYPE="ANALYSIS">Analysis 6.17</LINK>; <LINK REF="CMP-006.18" TYPE="ANALYSIS">Analysis 6.18</LINK>) and sedation (<LINK REF="CMP-006.10" TYPE="ANALYSIS">Analysis 6.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6.4 Quality of life</HEADING>
<P>Quality of life was not measured in these studies.</P>
</SUBSECTION>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-10-16 16:03:49 +0100" MODIFIED_BY="[Empty name]">
<P>We did not identify a single study for almost half of the possible comparisons of quetiapine with other second-generation antipsychotic drugs. Evidence, therefore, is incomplete. Only two studies were long term, limiting applicability of the evidence, as, after all, schizophrenia is a chronic, often lifelong, disorder. Furthermore, most of the included studies were efficacy studies; therefore external validity is limited, and further effectiveness (pragmatic/real-world) studies are needed.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-10-16 16:03:49 +0100" MODIFIED_BY="Laila Asmal">
<P>All studies were randomised and at least single-blind, but details were rarely presented. Therefore it is unclear in almost all studies whether randomisation and blinding were really done appropriately. Furthermore, the high numbers of participants leaving the studies early (overall 50.2%) and the small number of long-term studies (<LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>; <LINK REF="STD-McEvoy-2007" TYPE="STUDY">McEvoy 2007</LINK>; <LINK REF="STD-Voruganti-2007" TYPE="STUDY">Voruganti 2007</LINK>) call the validity of the findings into question. Selective reporting was evident in all but five studies, and thirteen studies were sponsored by an industry with considerable pecuniary interest in the results. All these factors limit the quality of the evidence.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-10-31 08:24:20 +0000" MODIFIED_BY="[Empty name]">
<P>We are aware of flaws in our review process. We are unclear whether or not these have add biases to the review.</P>
<UL>
<LI>First: The search took place some time ago. This review has been a considerable undertaking, and its expansion and upgrading have taken time. We are aware that more trials are likely to be available, and we do hope to update swiftly.</LI>
<LI>Second: We have excluded studies that are not fully blinded. This excludes many trials. On one hand, by doing this we have attempted to find trials that have taken some precautions against performance bias and detection bias. On the other hand, however, we have not made judgements to suggest that this has really been successful (and from the profile of adverse effects, this seems unlikely). In addition, quetiapine or the control drugs are not given blindly in the real world. The intervention in everyday care is not solely prescription of the drug, it is open giving of the drug with potential biases surrounding that open giving. This review, therefore, attempts to summarise the more explanatory studies (<LINK REF="REF-Thorpe-2009" TYPE="REFERENCE">Thorpe 2009</LINK>) by providing their advantages, drawbacks and potential biases.</LI>
</UL>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-11-04 17:20:27 +0000" MODIFIED_BY="Laila Asmal">
<P>This update substantially expands the earlier version (<LINK REF="REF-Komossa-2009" TYPE="REFERENCE">Komossa 2009</LINK>). However, generally its findings are consistent with findings from previous versions.</P>
<P>A previous Cochrane review compared the effects of quetiapine with those of placebo, first-generation antipsychotic drugs and second-generation antipsychotic drugs for schizophrenia (<LINK REF="REF-Srisurasapont-2004" TYPE="REFERENCE">Srisurasapont 2004</LINK>). A single study fell into the last category and compared quetiapine with risperidone. This update with reformatting of the review has identified many new studies, and the data included are far more comprehensive than those provided previously.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-11-04 17:21:44 +0000" MODIFIED_BY="Laila Asmal">
<IMPLICATIONS_PRACTICE MODIFIED="2013-10-16 16:03:50 +0100" MODIFIED_BY="Laila Asmal">
<SUBSECTION>
<HEADING LEVEL="4">1. For people with schizophrenia</HEADING>
<P>For people with schizophrenia, it may be important to know that most people who start the drug within short trials choose to stop taking it within a few weeks. Quetiapine may be slightly less effective than risperidone and olanzapine. However, quetiapine may have low risk for extrapyramidal adverse effects and prolactin increase, and its use may lead to less weight gain and fewer associated problems than are seen with olanzapine and paliperidone but more than with risperidone and ziprasidone.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. For clinicians</HEADING>
<P>Clinicians should know that for only six of nine possible comparisons of quetiapine with other second-generation antipsychotic drugs, relevant studies were identified, and that the evidence is limited because very high numbers of participants leave the studies early. Our most robust finding is that most people who are started on quetiapine will be off this drug within a few weeks. Certainly, more studies comparing quetiapine with other second-generation antipsychotic drugs are needed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. For managers/policy makers</HEADING>
<P>Little information on service use (such as time in hospital) or functioning is available, but the limited data suggest that people taking quetiapine may need to be hospitalised more frequently than those receiving risperidone or olanzapine. This may be accompanied by higher overall costs in some settings. Furthermore, a single study suggested better general functioning of participants treated with olanzapine. We believe that these findings are not sufficiently robust to guide managers.</P>
</SUBSECTION>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-11-04 17:21:44 +0000" MODIFIED_BY="Laila Asmal">
<SUBSECTION>
<HEADING LEVEL="4">1. General</HEADING>
<P>Adherence to the <A HREF="http://www.consortstatement.org">CONSORT</A> statement (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>) probably would have resulted in a more conclusive review. Clear descriptions of randomisation would have reassured users of these trials that selection bias had been minimised, and well-described and tested blinding could have encouraged greater confidence in the control of performance and detection bias. The use of binary outcomes should take preference over continuous results because they are easier to interpret, and the use of validated rating scales would have provided more usable data. Reporting of outcomes with their means and standard deviations again would have provided more usable data and would have facilitated synthesis of findings. When data are presented in a graph, the exact numbers and standard deviations should be reported. We were able to use only published reports, and even these many trials report at least some of their data in a way as to make them unusable for those wishing to undertake reviews (<LINK REF="STD-Astrazeneca-1998" TYPE="STUDY">Astrazeneca 1998</LINK>; <LINK REF="STD-Conley-2005" TYPE="STUDY">Conley 2005</LINK>; <LINK REF="STD-Deberdt-2008" TYPE="STUDY">Deberdt 2008</LINK>; <LINK REF="STD-Hu-2008" TYPE="STUDY">Hu 2008</LINK>; <LINK REF="STD-Kinon-2006b" TYPE="STUDY">Kinon 2006b</LINK>; <LINK REF="STD-Li--2005" TYPE="STUDY">Li 2005</LINK>; <LINK REF="STD-Li-2002" TYPE="STUDY">Li 2002</LINK>; <LINK REF="STD-Li-2003" TYPE="STUDY">Li 2003</LINK>; <LINK REF="STD-Lieberman-2005" TYPE="STUDY">Lieberman 2005</LINK>; <LINK REF="STD-Liu-2004" TYPE="STUDY">Liu 2004</LINK>; <LINK REF="STD-Lu-2006" TYPE="STUDY">Lu 2006</LINK>; <LINK REF="STD-Luo-Xin-2008" TYPE="STUDY">Luo Xin 2008</LINK>; <LINK REF="STD-McEvoy-2006" TYPE="STUDY">McEvoy 2006</LINK>; <LINK REF="STD-Mori-2004" TYPE="STUDY">Mori 2004</LINK>; <LINK REF="STD-Peng-2007" TYPE="STUDY">Peng 2007</LINK>; <LINK REF="STD-Potkin-2006" TYPE="STUDY">Potkin 2006</LINK>; <LINK REF="STD-Riedel-2005" TYPE="STUDY">Riedel 2005</LINK>; <LINK REF="STD-Riedel-2007" TYPE="STUDY">Riedel 2007</LINK>; <LINK REF="STD-Sacchetti-2004" TYPE="STUDY">Sacchetti 2004</LINK>; <LINK REF="STD-Sirota-2006" TYPE="STUDY">Sirota 2006</LINK>; <LINK REF="STD-Song-2008" TYPE="STUDY">Song 2008</LINK>; <LINK REF="STD-Svestka-2003b" TYPE="STUDY">Svestka 2003b</LINK>; <LINK REF="STD-Voruganti-2007" TYPE="STUDY">Voruganti 2007</LINK>; <LINK REF="STD-Wei-2006b" TYPE="STUDY">Wei 2006b</LINK>). More data may have never reached publication. Several trials had to be excluded solely because all numerical data were impossible to use (<LINK REF="STD-Antonova-2005" TYPE="STUDY">Antonova 2005</LINK>; <LINK REF="STD-Byerly-1999" TYPE="STUDY">Byerly 1999</LINK>; <LINK REF="STD-Byerly-2006" TYPE="STUDY">Byerly 2006</LINK>; <LINK REF="STD-Sarma-2008a" TYPE="STUDY">Sarma 2008a</LINK>; <LINK REF="STD-Davies-2007" TYPE="STUDY">Davies 2007</LINK>). When trials do not make all data available, this must give cause for concern (<A HREF="http://alltrials.net">ALLTRIALS</A>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Specific</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Reviews</HEADING>
<P>This review should be updated both with a relevant search and with data from more open studies. However, this will have to wait until we gather energy after the marathon of producing this review (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>)</P>
<P>Excluded studies, as is common, suggest that other reviews that should be added to the quetiapine suite (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Trials</HEADING>
<P>Comparisons with amisulpride, sertindole and zotepine do not exist. Studies comparing quetiapine with aripiprazole and with paliperidone are few and comprise small sample sizes. Most data that have been reported within existing comparisons are almost without value because of the assumptions and biases contained within them. Therefore, there is plenty of room for further research into the effects of this widely used drug. We realize that planning for such studies needs meticulous attention to detail, but we suggest some pointers that have come from our reading and understanding of the existing trials (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-10-16 16:03:50 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to thank Franziska Schmid, Heike Hunger, Sandra Schwarz, Manit Srisurapanont and Werner Kissling for their contributions as co-review authors in the previous version of this review. We would like to express our gratitude to the South African Cochrane Centre and to the editorial base of the Cochrane Schizophrenia Group for their assistance. We would also like to thank the following authors for providing additional information on their studies: R Conley, Y Liu, H Ozguven, M Riedel, J Svestka and K Zhong.</P>
<P>We would like to thank Ben Gray for completing the Plain Language Summary for this update.</P>
<P>The Cochrane Schizophrenia Group produces and maintains a template for the methods sections of their reviews. We have used this and adapted it for our requirements.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-11-18 10:42:15 +0000" MODIFIED_BY="Laila Asmal">
<P>Laila Asmal: none known.</P>
<P>Srnka J Flegar: has received a travel grant from Reckitt Benckiser to attend a scientific meeting.</P>
<P>Jikun Wang: none known</P>
<P>Katja Komossa: none known.</P>
<P>Stefan Leucht: Stefan Leucht - has received honoraria for lectures from Abbvie, Astra Zeneca, BristolMyersSquibb, ICON, EliLilly, Janssen, Johnson &amp; Johnson, Roche, SanofiAventis, Lundbeck and Pfizer; honoraria for consulting/advisory boards from Roche, EliLilly, Medavante, BristolMyersSquibb, Alkermes, Janssen, Johnson &amp; Johnson and Lundbeck. EliLilly has provided medication for a study with Stefan Leucht as primary investigator.<BR/>
<BR/>Christine Rummel-Kluge: has received lecture honoraria and travel grants to attend scientific meetings from AstraZeneca, Janssen-Cilag, Eli Lilly and Pfizer.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-10-16 16:03:50 +0100" MODIFIED_BY="Laila Asmal">
<P>Laila Asmal: protocol review, searching, study selection, data extraction, report writing.</P>
<P>Srnka J Flegar: protocol review, searching, study selection, data extraction.</P>
<P>Jikun Wang: study selection, data extraction from Chinese language studies.</P>
<P>Katja Komossa: protocol development, searching, study selection, data extraction, report writing.</P>
<P>Christine Rummel-Kluge: protocol development, searching, study selection, data extraction.</P>
<P>
<BR/>Stefan Leucht: protocol development, searching, study selection, data extraction, report writing.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-10-16 16:03:50 +0100" MODIFIED_BY="[Empty name]">
<P>This review was adapted to new formatting and functions available in Review Manager 5, notably the inclusion of 'Summary of findings' and 'Risk of bias' tables. We have updated our data collection and analysis section with the new text template of the Cochrane Schizophrenia Group. Previous methods can be found in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-10-23 13:21:21 +0100" MODIFIED_BY="Laila Asmal">
<STUDIES MODIFIED="2013-10-23 13:17:07 +0100" MODIFIED_BY="Laila Asmal">
<INCLUDED_STUDIES MODIFIED="2013-10-23 12:44:38 +0100" MODIFIED_BY="Laila Asmal">
<STUDY DATA_SOURCE="PUB" ID="STD-Astrazeneca-1998" MODIFIED="2012-04-27 11:25:06 +0100" MODIFIED_BY="Laila Asmal" NAME="Astrazeneca 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-04-27 11:25:06 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Astrazeneca 1998</AU>
<TI>A multicentre, double-blind randomised comparison of seroquel (TM) and risperidone in the treatment of schizophrenic patients with acute exacerbation</TI>
<SO>Astrazeneca trial data</SO>
<IDENTIFIERS MODIFIED="2011-07-07 08:26:34 +0100" MODIFIED_BY="Laila Asmal"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Atmaca-2003" MODIFIED="2009-01-05 15:39:15 +0000" MODIFIED_BY="[Empty name]" NAME="Atmaca 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-01-05 15:39:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Atmaca M, Kuloglu M, Tezcan E, Ustundag B</AU>
<TI>Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>64</VL>
<NO>5</NO>
<PG>598-604</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:39:15 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Byerly-2008" MODIFIED="2013-10-23 12:31:48 +0100" MODIFIED_BY="Laila Asmal" NAME="Byerly 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 12:31:48 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Byerly MJ, Nakonezny PA, Rush AJ</AU>
<TI>Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial</TI>
<SO>Psychiatry Research</SO>
<YR>2008</YR>
<VL>159</VL>
<PG>115-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Canuso-2008" MODIFIED="2013-10-23 12:32:49 +0100" MODIFIED_BY="Laila Asmal" NAME="Canuso 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 12:31:56 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Canuso C, Carothers J, Dirks B, Zhu Y, Kosik-Gonzalez C</AU>
<TI>A double-blind, placebo-controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia</TI>
<SO>Proceedings of the American Psychiatric Association 161st Annual Meeting, Washington, DC, May 3-6, 2008</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:32:28 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Canuso C, Dirks B, Carothers J, Zhu Y, Kosik-Gonzalez C</AU>
<TI>A comparative analysis of paliperidone ER and quetiapine in patients with a recent, acute exacerbation of schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2008</YR>
<VL>98</VL>
<PG>158-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:32:41 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Canuso C, Dirks B, Carothers J, Zhu Y, Kosik-Gonzalez C</AU>
<TI>A double-blind, placebo controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia</TI>
<SO>Proceedings of the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders, Montreux, Switzerland, February 3-7, 2007</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:32:19 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Canuso C, Dirks B, Carothers J, Zhu Y, Kosik-Gonzalez C</AU>
<TI>A double-blind, placebo-controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia</TI>
<SO>Proceedings of the 20th Annual U.S. Psychiatric &amp; Mental Health Congress, Orlando, FL, October 11-14, 2007</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:32:49 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Canuso CM, Dirks B, Carothers ScD, Kosik-Gonzalez C, Bossie CA, Zhu Y, et al</AU>
<TI>Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2009</YR>
<VL>AiA</VL>
<PG>1-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Conley-2005" MODIFIED="2013-10-23 12:33:38 +0100" MODIFIED_BY="[Empty name]" NAME="Conley 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-10-23 12:33:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Conley RR, Kelly DL, Nelson MW, Richardson CM, Feldman S, Benham R, et al</AU>
<TI>Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>2005</YR>
<VL>28</VL>
<NO>4</NO>
<PG>163-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-05 13:56:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kelly DL, Conley RR</AU>
<TI>A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia</TI>
<SO>Psychoneuroendocrinology</SO>
<YR>2006</YR>
<VL>31</VL>
<NO>3</NO>
<PG>340-6</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2009-01-05 15:39:32 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:33:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kelly DL, Conley RR</AU>
<TI>Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2005</YR>
<VL>66</VL>
<PG>80-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:33:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richardson CM, Kelly DL, Gold JM, McMahon R, Yu Y, Conley RR</AU>
<TI>Risperidone vs quetiapine vs fluphenazine in treatment-resistant schizophrenia: neuropsychological outcome</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>501-2</PG>
<IDENTIFIERS MODIFIED="2009-02-05 13:56:18 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deberdt-2008" MODIFIED="2013-10-23 12:33:47 +0100" MODIFIED_BY="Laila Asmal" NAME="Deberdt 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 12:33:47 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Deberdt W, Lipkovich I, Heinloth AN, Liu L, Kollack-Walker S, Edwards SE, et al</AU>
<TI>Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder</TI>
<SO>Therapeutics and Clinical Risk Management</SO>
<YR>2008</YR>
<VL>4</VL>
<NO>4</NO>
<PG>713&#8211;20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eerdekens-2007" MODIFIED="2013-10-23 12:33:57 +0100" MODIFIED_BY="Laila Asmal" NAME="Eerdekens 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 12:33:57 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Eerdekens M, Kramer M, Cleton A, Vanderbosch A, Natarajan J, Earnest J, et al</AU>
<SO>Proceedings of the 20th European College of Neuropsychopharmacology, Vienna, Austria, October 13-17, 2007</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-07-11 09:22:55 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hough DW, Natarajan J, Vandebosch A, Rossenu S, Kramer M, Eerdekens M</AU>
<TI>Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2010</YR>
<VL>0</VL>
<NO>0</NO>
<PG>1-10. </PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hatta-2009" MODIFIED="2013-10-23 12:34:07 +0100" MODIFIED_BY="Laila Asmal" NAME="Hatta 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-10-23 12:34:07 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hatta K, Sato K, Hamakawa H, Takebayashi H, Kimura N, Ochi S, et al</AU>
<TI>Effectiveness of second-generation antipsychotics with acute-phase schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>113</VL>
<PG>49-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hu-2008" MODIFIED="2013-10-23 12:34:34 +0100" MODIFIED_BY="Laila Asmal" NAME="Hu 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 12:34:34 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hu GH, Wu YJ, Li QX</AU>
<TI>A comparative study between quetiapine and risperidone in the treatment of first-episode schizophrenia</TI>
<SO>Chinese Medical Journal of Metallurgical Industry</SO>
<YR>2008</YR>
<VL>25</VL>
<NO>1</NO>
<PG>16-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinon-2006b" MODIFIED="2013-10-23 12:34:17 +0100" MODIFIED_BY="Laila Asmal" NAME="Kinon 2006b" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 12:34:17 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kinon BJ, Liu-Siefert H, Hill AL, Roychowdhury S, Edwards SB</AU>
<TI>Superiority of olanzapine versus quetiapine in improving overall functioning in patients with schizophrenia</TI>
<SO>Proceedings of the 16th European College of Neuropsychopharmacology Congress, September 20-24, 2003</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-11 08:31:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kinon BJ, Noordsy DL, Liu-Seifert H, Gulliver AH, Ascher-Svanum H, Kollack-Walker S</AU>
<TI>Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>5</NO>
<PG>453-61</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-01-05 15:39:50 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2002" MODIFIED="2013-10-23 12:34:45 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-10-23 12:34:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Li Y, Wang CH, Zhang DH, Wang LH, Zhao Z</AU>
<TI>A study of quetiapine and clozapine in treatment of first-episode schizophrenia</TI>
<SO>Chinese Journal of Nervous and Mental Diseases</SO>
<YR>2002</YR>
<VL>28</VL>
<PG>219-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2003" MODIFIED="2013-10-23 12:34:52 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-10-23 12:34:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Li CH</AU>
<TI>A study of quetiapine and clozapine in treatment of schizophrenia</TI>
<SO>Chinese Journal of Nervous and Mental Diseases</SO>
<YR>2003</YR>
<VL>29</VL>
<PG>306-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li--2005" MODIFIED="2013-10-23 12:35:04 +0100" MODIFIED_BY="[Empty name]" NAME="Li  2005" YEAR="2005">
<REFERENCE MODIFIED="2013-10-23 12:35:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Li Y, Feng YG</AU>
<TI>A double blind comparing study between the effects of quetiapine and clozapine on the life quality of the patients with schizophrenia</TI>
<SO>Medical Journal of Chinese Peoples Health</SO>
<YR>2005</YR>
<VL>17</VL>
<PG>262-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lieberman-2005" MODIFIED="2013-10-23 12:39:03 +0100" MODIFIED_BY="Laila Asmal" NAME="Lieberman 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-10-23 12:35:14 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>* Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al</AU>
<TI>Effectiveness of antipsychotic drugs in patients with chronic schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<NO>12</NO>
<PG>1209-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:35:21 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chwastiak LA, Rosenheck RA, McEvoy JP, Stroup TS, Swartz MS, Davis SM, et al</AU>
<TI>The impact of obesity on health care costs among persons with schizophrenia</TI>
<SO>General Hospital Psychiatry</SO>
<YR>2009</YR>
<VL>31</VL>
<PG>1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:35:30 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, et al</AU>
<TI>Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study</TI>
<SO>Schizophrenia Research</SO>
<YR>2008</YR>
<VL>105</VL>
<PG>178-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:35:37 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al</AU>
<TI>Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2007</YR>
<VL>64</VL>
<PG>633-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:35:55 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keefe RSE, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, et al</AU>
<TI>Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2007</YR>
<VL>164</VL>
<PG>1061-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:36:04 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyer JM, Davis VG, McEvoy JP, Goff DC, Nasrallah HA, Davis SM, et al</AU>
<TI>Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE schizophrenia trial phase 1</TI>
<SO>Schizophrenia Research</SO>
<YR>2008</YR>
<VL>103</VL>
<PG>104-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:36:16 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, et al</AU>
<TI>Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study</TI>
<SO>Biological Psychiatry</SO>
<YR>2006</YR>
<VL>66</VL>
<PG>1013-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:36:29 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, et al</AU>
<TI>The clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>80</VL>
<PG>9-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:36:42 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, et al</AU>
<TI>Extrapyramidal side-effects of antipsychotics in a randomised trial</TI>
<SO>The British Journal of Psychiatry</SO>
<YR>2008</YR>
<VL>193</VL>
<PG>279-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:36:51 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller DD, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH, et al</AU>
<TI>Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>80</VL>
<PG>33-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-07-14 09:32:28 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA</AU>
<TI>Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2009</YR>
<VL>35</VL>
<NO>2</NO>
<PG>336-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-07-14 09:32:28 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman JA, Keefe RSE</AU>
<TI>Relationship of cognition and psychopathology to functional impairment in schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2008</YR>
<VL>165</VL>
<PG>978-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-07-14 09:32:28 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nasrallah HA</AU>
<TI>Metabolic findings from the CATIE trial and their relation to tolerability</TI>
<SO>CNS Spectrum</SO>
<YR>2006</YR>
<VL>11</VL>
<NO>7 Suppl 7</NO>
<PG>32-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:37:02 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patel JK, Buckley PF, Woolson S, Hamer RM, McEvoy JP, Perkins DO, et al</AU>
<TI>Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>111</VL>
<PG>9-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:37:13 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Penn DL, Keefe RSE, Davis SM, Meyer PS, Perkins DO, Losardo D, et al</AU>
<TI>The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>115</VL>
<PG>17-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-07-14 10:06:38 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perkins DO, Gu H, Weiden PJ, McEVoy JP, Hamer RM, Lieberman JA</AU>
<TI>Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double-blind, flexible-dose, multicenter study</TI>
<SO>J Clin Psychiatry</SO>
<YR>2008</YR>
<VL>69</VL>
<NO>1</NO>
<PG>106-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:37:24 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perlick DA, Rosenheck RA, Kaczynski R, Swartz MS, Canive JM, Lieberman JA</AU>
<TI>Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2010</YR>
<VL>116</VL>
<PG>118-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:37:36 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Resnick SG, Rosenheck RA, Canive JM, Souza CD, Stroup TS, McEvoy J, et al</AU>
<TI>Employment outcomes in a randomised trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia</TI>
<SO>Journal of Behavioral Health Services and Research</SO>
<YR>2008</YR>
<VL>35</VL>
<NO>2</NO>
<PG>215-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:37:44 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S, et al</AU>
<TI>Data from the CATIE Trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>107</VL>
<PG>22-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:38:00 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenheck RA, Davis VG, Davis SM, Stroup S, McEvoy J, Swartz M, et al</AU>
<TI>The CATIE schizophrenia trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>113</VL>
<PG>12-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:38:09 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stroup S, Appelbaum P, Swartz M, Patel M, Davis S, Jeste D, et al</AU>
<TI>Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>80</VL>
<PG>1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:38:21 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RSE, et al</AU>
<TI>Results of phase 3 of the CATIE schizophrenia trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>107</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:38:31 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swanson JW, Swartz MS, van Dorn RA, Volavka J, Monahan J, Stroup TS, et al</AU>
<TI>Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia</TI>
<SO>The British Journal of Psychiatry</SO>
<YR>2008</YR>
<VL>193</VL>
<PG>37-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:38:47 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, et al</AU>
<TI>Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2007</YR>
<VL>164</VL>
<PG>428-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:38:55 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RSE, et al</AU>
<TI>What CATIE found: results from the schizophrenia trial</TI>
<SO>Psychiatric Services</SO>
<YR>2008</YR>
<VL>59</VL>
<NO>5</NO>
<PG>500-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:39:03 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Reimherr F, et al</AU>
<TI>The effectiveness of antipsychotic medications in patients who use of avoid illicit substances: results from the CATIE study</TI>
<SO>Schizophrenia Research</SO>
<YR>2008</YR>
<VL>100</VL>
<PG>39-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2004" MODIFIED="2009-01-05 15:40:04 +0000" MODIFIED_BY="[Empty name]" NAME="Liu 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-01-05 15:40:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Liu Y, Xu M, Chen X</AU>
<TI>A controlled study of quetiapine and clozapine in the treatment of schizophrenia with predominantly negative symptoms</TI>
<SO>Shandong Archires of Psychiatry</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>1</NO>
<PG>6-8</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:40:04 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-2006" MODIFIED="2013-10-23 12:39:27 +0100" MODIFIED_BY="Laila Asmal" NAME="Lu 2006" YEAR="2004">
<REFERENCE MODIFIED="2013-10-23 12:39:27 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lu X, Cheng H, Song S, Sun L, Zhang Y, Fan Y</AU>
<TI>A study of quetiapine and risperidone and clozapine in the treatment of schizophrenia</TI>
<SO>China and Foreign Medical Journal</SO>
<YR>2006</YR>
<VL>4</VL>
<NO>6</NO>
<PG>62-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luo-Xin-2008" MODIFIED="2013-10-23 12:39:42 +0100" MODIFIED_BY="Laila Asmal" NAME="Luo Xin 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 12:39:42 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luo X, An BF</AU>
<TI>Comperison of quetiapine and aripiprazole in the treatment of first episode schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2008</YR>
<VL>18</VL>
<NO>3</NO>
<PG>191-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McEvoy-2006" MODIFIED="2013-10-23 12:39:54 +0100" MODIFIED_BY="[Empty name]" NAME="McEvoy 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 12:39:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al</AU>
<TI>Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<NO>4</NO>
<PG>600-10</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-01-05 15:40:37 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McEvoy-2007" MODIFIED="2013-10-23 12:41:10 +0100" MODIFIED_BY="Laila Asmal" NAME="McEvoy 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 12:40:09 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Keefe R, Gu H, Sweeney J, Perkins D, McEvoy J, Hamer R, Lieberman J</AU>
<TI>A comparison of the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in first-episode psychosis</TI>
<SO>Proceedings of the 44th Annual Meeting of the American College of Neuropsychopharmacology, Waikoloa, Hawaii, December 11-15, 2005</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:40:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Keefe RSE, Gu H, Sweeney JA, Perkins DO, McEvoy JP, Hamer RM, Lieberman JA</AU>
<TI>The effects of olanzapine, quetiapine and risperidone on neurocognitive function in first-episode psychosis: a double-blind 52-week comparison</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 20-25, 2006</SO>
<IDENTIFIERS MODIFIED="2009-01-05 15:40:44 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:40:26 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keefe RSE, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, et al</AU>
<TI>Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2007</YR>
<VL>164</VL>
<PG>1061-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-03 18:40:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman J, McEvoy JP, Perkins D, Hamer RH</AU>
<TI>Comparison of atypicals in first-episode psychosis: a randomized, 52-week comparison of olanzapine, quetiapine, and risperidone</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>Suppl 3</NO>
<PG>S525</PG>
<IDENTIFIERS MODIFIED="2009-11-03 18:40:23 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:40:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, et al</AU>
<TI>Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2007</YR>
<VL>164</VL>
<PG>1050-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McEvoy JP, Perkins DO, Gu H, Hamer RM, Lieberman JA</AU>
<TI>Clinical effectiveness and predictors of treatment non-adherence: comparison of olanzapine, quetiapine, and risperidone in first-episode psychosis</TI>
<SO>Schizophrenia Research</SO>
<YR>2006</YR>
<VL>86</VL>
<NO>Suppl 1</NO>
<PG>S130</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:40:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>McEvoy JP</AU>
<TI>Comparison of clozapine versus other atypical drugs in prospectively defined, unresponsive patients</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association, May 20-25, 2006, Toronto, Canada</SO>
<IDENTIFIERS MODIFIED="2009-02-05 13:55:58 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:40:59 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patel JK, Buckley PF, Woolson S, Hamer RM, McEvoy JP, Perkins DO, et al</AU>
<TI>Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>111</VL>
<PG>9-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:41:10 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perkins DO, Gu H, Weiden PJ, McEVoy JP, Hamer RM, Lieberman JA</AU>
<TI>Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomised, double-blind, flexible-dose, multicenter study</TI>
<SO>J Clin Psychiatry</SO>
<YR>2008</YR>
<VL>69(1)</VL>
<PG>106-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mori-2004" MODIFIED="2009-01-05 15:40:57 +0000" MODIFIED_BY="[Empty name]" NAME="Mori 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-01-05 15:40:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mori K, Nagao M, Yamashita H, Morinobu S, Yamawaki S</AU>
<TI>Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia</TI>
<SO>Progress in Neuro-Psychopharmacology and Biological Psychiatry</SO>
<YR>2004</YR>
<VL>28</VL>
<NO>4</NO>
<PG>659-65</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:40:57 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ozguven-2004" MODIFIED="2013-10-23 12:41:23 +0100" MODIFIED_BY="[Empty name]" NAME="Ozguven 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-10-23 12:41:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ozguven Hd, Oner O, Baskak B, Oner P, Atbasoglu EC</AU>
<TI>The metabolic and clinical effects of olanzapine and quetiapine: preliminary findings from a randomized single-blind trial in patients with schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2004</YR>
<VL>67</VL>
<NO>1</NO>
<PG>190-1</PG>
<CY>Po Box 211, 1000 Ae Amsterdam, Netherlands</CY>
<IDENTIFIERS MODIFIED="2009-01-05 15:41:04 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peng-2007" MODIFIED="2013-10-23 12:41:31 +0100" MODIFIED_BY="Laila Asmal" NAME="Peng 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 12:41:31 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peng X, Huang Y, Liu XY</AU>
<TI>A clinical analysis of aripiprazole and quetiapine in treatment of first episode schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2007</YR>
<VL>17</VL>
<NO>5</NO>
<PG>329-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Potkin-2006" MODIFIED="2013-10-23 12:42:06 +0100" MODIFIED_BY="[Empty name]" NAME="Potkin 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 12:41:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gharabawi GM, Greenspan A, Rupnow MFT, Kosik-Gonzalez C, Bossie CA, Zhu Y, et al</AU>
<TI>Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial</TI>
<SO>BMC Psychiatry</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>45</NO>
<PG>1-7</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2009-01-05 15:41:13 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-03 18:43:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenspan A, Kosik-Gonzalez C, Moreau-Mallet V, Bossie CA, Rupnow MFT, Zhu Y, Gharabawi GM</AU>
<TI>Risperidone vs quetiapine in inpatients with schizophrenia: a double-blind placebo-controlled study</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>Suppl 3</NO>
<PG>S503</PG>
<IDENTIFIERS MODIFIED="2009-02-05 13:55:40 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:41:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Potkin SG, Gharabawi GM, Greenspan AJ, Mahmoud R, Kosik-Gonzalez C, Rupnow MFT, et al</AU>
<TI>A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization</TI>
<SO>Schizophrenia Research</SO>
<YR>2006</YR>
<VL>85</VL>
<NO>1-3</NO>
<PG>254-65</PG>
<CY>Netherlands</CY>
<IDENTIFIERS MODIFIED="2009-02-05 13:55:28 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:42:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Potkin SG, Greenspan A, Kosik-Gonzalez C, Bossie C, Rupnow M, Zhu Y, et al</AU>
<TI>A placebo-controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>501</PG>
<IDENTIFIERS MODIFIED="2009-02-05 13:55:11 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riedel-2005" MODIFIED="2013-10-23 12:42:42 +0100" MODIFIED_BY="Laila Asmal" NAME="Riedel 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-10-23 12:42:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riedel M, Muller N, Strassnig M, Spellmann I, Engel RR, Musil R, et al</AU>
<TI>Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms</TI>
<SO>European Archives of Psychiatry and Clinical Neuroscience</SO>
<YR>2005</YR>
<VL>255</VL>
<NO>6</NO>
<PG>432-7</PG>
<CY>Germany</CY>
<IDENTIFIERS MODIFIED="2009-01-05 15:41:23 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:42:33 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Riedel M, Spellmann I, Muller N, Strassnig M, Muller-Arends A, Dehning S, Moller HJ</AU>
<TI>Cognitive benefits of quetiapine versus risperidone in schizophrenia</TI>
<SO>Proceedings of the 158th Annual Meeting of the American Psychiatric Association, Atlanta GA, USA, May 21-26, 2005</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:42:42 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riedel M, Spellmann I, Strassnig M, Douhet A, Dehning S, Opgen-Rhein M, et al</AU>
<TI>Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms</TI>
<SO>European Archives of Psychiatry and Clinical Neuroscience</SO>
<YR>2007</YR>
<VL>257</VL>
<PG>360-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riedel-2007" MODIFIED="2013-10-23 12:43:02 +0100" MODIFIED_BY="Laila Asmal" NAME="Riedel 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 12:43:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Riedel M, Müller N, Spellmann I, Engel RR, Musil R, Valdevit R, et al</AU>
<TI>Efficacy of olanzapine versus quetiapine on cognitive dysfunctions with an acute episode of schizophrenia</TI>
<SO>European Archieves of Psychiatry and Clinical Neuroscience</SO>
<YR>2007</YR>
<VL>257</VL>
<NO>7</NO>
<PG>402-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sacchetti-2004" MODIFIED="2013-10-23 12:43:29 +0100" MODIFIED_BY="[Empty name]" NAME="Sacchetti 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-01-05 15:41:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sacchetti E, Valsecchi P, Regini C, Galluzo a, Cacciani P, Agrimi E, Mencacci C</AU>
<TI>Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: interim results of a randomised, rater-blinded study</TI>
<SO>Schizophrenia Research</SO>
<YR>2004</YR>
<VL>67</VL>
<NO>1</NO>
<PG>150</PG>
<CY>Po Box 211, 1000 Ae Amsterdam, Netherlands</CY>
<IDENTIFIERS MODIFIED="2009-01-05 15:41:47 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-01-06 14:39:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sacchetti E, Valsecchi P, Regini C, Galluzzo A, Cacciani P, Agrimi E, Mencacci C</AU>
<TI>Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: interim results of a randomised, rater-blinded study</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>4</NO>
<PG>S350</PG>
<IDENTIFIERS MODIFIED="2009-01-06 14:39:18 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-03 18:44:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sacchetti E, Valsecchi P, Regini C, Galluzzo A, Cacciani P, Agrimi E, Mencacci C</AU>
<TI>Comparison of quetiapine, olanzapine, and risperidone in schizophrenia</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>Suppl 3</NO>
<PG>S286</PG>
<IDENTIFIERS MODIFIED="2009-01-06 14:39:26 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:43:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sacchetti E, Valsecchi P, Regini C, Galluzzo A, Cacciani P, Agrimi E, et al</AU>
<TI>Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: interim results of a randomised, rater-blinded study</TI>
<SO>Proceedings of the 16th European College of Neuropsychopharmacology Congress, Prague, Czech Republic, September 20-24, 2003</SO>
<IDENTIFIERS MODIFIED="2009-01-06 14:38:58 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:43:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sacchetti E, Valsecchi P, Regini C, Galluzzo A, Cacciani P</AU>
<TI>Comparison of quetiapine, olanzapine and risperidone in a randomized study in patients with schizophrenia</TI>
<SO>Proceedings of the Thematic Conference of the World Psychiatric Association on "Treatments in Psychiatry: An Update", Florence, Italy, November 10-13, 2004</SO>
<IDENTIFIERS MODIFIED="2009-01-06 14:39:39 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sirota-2006" MODIFIED="2009-11-03 15:37:07 +0000" MODIFIED_BY="[Empty name]" NAME="Sirota 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-01-05 15:42:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sirota P, Pannet I, Koren A, Tchernichovsky E</AU>
<TI>Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia</TI>
<SO>Human Psychopharmacology</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>4</NO>
<PG>227-34</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2009-01-05 15:42:01 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-03 15:37:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sirota P, Tchernichowsky E, Panet I, Koren A</AU>
<TI>The effectiveness of quetiapine versus olanzapine in improving negative symptoms of patients with schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2004</YR>
<VL>67</VL>
<NO>1</NO>
<PG>170</PG>
<CY>Po Box 211, 1000 Ae Amsterdam, Netherlands</CY>
<IDENTIFIERS MODIFIED="2009-01-05 15:42:31 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Song-2008" MODIFIED="2013-10-23 12:43:40 +0100" MODIFIED_BY="Laila Asmal" NAME="Song 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 12:43:40 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Song GM, Li JH, Zhong H, Lu SL</AU>
<TI>Control study of risperidone oral solution and quetiapine on schizophrenia</TI>
<SO>Modern Journal of Integrated Traditional Chinese and Western Medicine</SO>
<YR>2008</YR>
<VL>17</VL>
<NO>32</NO>
<PG>4961-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stroup-2006" MODIFIED="2013-10-23 12:43:53 +0100" MODIFIED_BY="[Empty name]" NAME="Stroup 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 12:43:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, et al</AU>
<TI>Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<NO>4</NO>
<PG>611-22</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-01-05 15:42:14 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-2003b" MODIFIED="2009-01-06 14:39:48 +0000" MODIFIED_BY="[Empty name]" NAME="Svestka 2003b" YEAR="2003">
<REFERENCE MODIFIED="2009-01-06 14:39:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svestka J, Synek O, Zourkova A</AU>
<TI>A double-blind comparison of olanzapine and quetiapine in treatment of acute exacerbations of schizophrenic or schizoaffective disorders</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>4</NO>
<PG>S291</PG>
<IDENTIFIERS MODIFIED="2009-01-06 14:39:48 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Voruganti-2007" MODIFIED="2013-10-23 12:44:05 +0100" MODIFIED_BY="[Empty name]" NAME="Voruganti 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 12:44:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Voruganti LP, Awad AG, Parker G, Forrest C, Usmani Y, Fernando MLD, et al</AU>
<TI>Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine</TI>
<SO>Schizophrenia Research</SO>
<YR>2007</YR>
<VL>96</VL>
<NO>1</NO>
<PG>146-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2006" MODIFIED="2013-10-23 12:44:16 +0100" MODIFIED_BY="Laila Asmal" NAME="Wang 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 12:44:16 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang DF, Wang XR</AU>
<TI>A control study of quetiapine and risperidone in the treatment of schizophrenia</TI>
<SO>Medical Journal of Chinese People's Health</SO>
<YR>2006</YR>
<VL>35</VL>
<NO>18</NO>
<PG>1697-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wei-2006a" MODIFIED="2013-10-23 12:44:26 +0100" MODIFIED_BY="Laila Asmal" NAME="Wei 2006a" YEAR="">
<REFERENCE MODIFIED="2013-10-23 12:44:26 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wei QW, Fang YR, Shen XL, Tian T, Liao JG, Fang XG</AU>
<TI>A comparative study of social function in first-episode schizophrenic patients treated with quetiapine and risperidone</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2006</YR>
<VL>19</VL>
<NO>1</NO>
<PG>34-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wei-2006b" MODIFIED="2013-10-23 12:44:38 +0100" MODIFIED_BY="Laila Asmal" NAME="Wei 2006b" YEAR="">
<REFERENCE MODIFIED="2013-10-23 12:44:38 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wei SZ, Tang QS, Xu ZN, Rang XJ, Lu B</AU>
<TI>Dummy parallel controlled study in the female first-episode schizophrenia treated with aripiprazole and quetiapine</TI>
<SO>Chinese Journal of Nervous and Mental Disorders</SO>
<YR>2006</YR>
<VL>32</VL>
<NO>6</NO>
<PG>511-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhong-2006" MODIFIED="2009-01-05 15:43:01 +0000" MODIFIED_BY="[Empty name]" NAME="Zhong 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-01-05 15:42:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Patterson TL, Potter LS, Zhong K, Brecher M</AU>
<TI>Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<NO>11</NO>
<PG>1918-25</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-01-05 15:42:49 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2009-01-05 15:43:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA</AU>
<TI>Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2006</YR>
<VL>67</VL>
<NO>7</NO>
<PG>1093-103</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-01-05 15:43:01 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-10-23 13:16:57 +0100" MODIFIED_BY="Laila Asmal">
<STUDY DATA_SOURCE="PUB" ID="STD-An-2003" MODIFIED="2009-01-05 15:49:11 +0000" MODIFIED_BY="[Empty name]" NAME="An 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-01-05 15:49:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>An BF, Liu XQ, Chen JX</AU>
<TI>A comparative study between quetiapine and clozapine in the treatment of schizophrenia and the relation with the plasman levels of IL-2, SIL-2R</TI>
<SO>Schuan Mental Health</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>3</NO>
<PG>152-4</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:49:11 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-An-2006" MODIFIED="2013-10-23 12:44:51 +0100" MODIFIED_BY="Laila Asmal" NAME="An 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 12:44:51 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>An BF, Zhang ML, Qi SG</AU>
<TI>Comparitive study between the effect olanzapine and quetiapine in first-episode schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>2</NO>
<PG>84-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-An-2006a" MODIFIED="2013-10-23 12:44:57 +0100" MODIFIED_BY="Laila Asmal" NAME="An 2006a" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 12:44:57 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>An BF, Li Y, Wang CH</AU>
<TI>A study on the executive function of first episode paranoid schizophrenia</TI>
<SO>Chinese Journal of Behavioral Medical Science</SO>
<YR>2006</YR>
<VL>15</VL>
<NO>4</NO>
<PG>340-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Antonova-2005" MODIFIED="2013-10-23 12:45:11 +0100" MODIFIED_BY="[Empty name]" NAME="Antonova 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-10-23 12:45:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Antonova E, Kumari V, Halari R, Zachariah E, Mehrotra R, Kumar A, et al</AU>
<TI>Superior cognitive efficacy of atypical antipsychotics olanzapine, risperidone, and quetiapine, as a group, relative to low doses of conventional antipsychotics</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>474</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:49:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arango-2009" MODIFIED="2013-10-23 12:48:52 +0100" MODIFIED_BY="Laila Asmal" NAME="Arango 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-10-23 12:48:52 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arango C, Robles O, Parellada M, Fraguas D, Sancho-Ruiz A, Medina O, et al</AU>
<TI>Olanzapine compared to quetiapine in adolescents with a first psychotic episode</TI>
<SO>Eur Child Adolesc Psychiatry</SO>
<YR>2009</YR>
<VL>18</VL>
<PG>418-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ascher_x002d_Svanum-2006" MODIFIED="2009-07-27 11:28:03 +0100" MODIFIED_BY="[Empty name]" NAME="Ascher-Svanum 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-27 11:28:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J</AU>
<TI>Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia</TI>
<SO>BMC Psychiatry</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>8</NO>
<PG>1-16</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2009-01-05 15:49:25 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baloescu-2006" MODIFIED="2013-10-23 12:49:03 +0100" MODIFIED_BY="[Empty name]" NAME="Baloescu 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 12:49:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baloescu A, Vasile D, Gheorghe MD, Grigorescu G</AU>
<TI>Side effects of atypical antipsychoticsprediction factor for compliance</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S403</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:49:34 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ban-2008" MODIFIED="2013-10-23 12:49:10 +0100" MODIFIED_BY="Laila Asmal" NAME="Ban 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 12:49:10 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ban N, Cui JB</AU>
<TI>Analysis of the efficacy of aripiprazole and quetiapine in the treatment of schizophrenia</TI>
<SO>Occupation and Health</SO>
<YR>2008</YR>
<VL>24</VL>
<NO>3</NO>
<PG>292-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beuzen-2005" MODIFIED="2013-10-23 12:49:24 +0100" MODIFIED_BY="[Empty name]" NAME="Beuzen 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-10-23 12:49:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Beuzen J-N, Pans M, Modell S, Hagens P, McQuade R, Iwamoto T, et al</AU>
<TI>Naturalistic study of aripiprazole treatment</TI>
<SO>Proceedings of the XIII World Congress of Psychiatry, Cairo, Egypt, September 10-15, 2005</SO>
<IDENTIFIERS MODIFIED="2009-01-05 15:49:40 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boter-2005" MODIFIED="2013-10-23 12:50:01 +0100" MODIFIED_BY="Laila Asmal" NAME="Boter 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-10-23 12:49:33 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boter H, Peuskens J, Libiger J, Fleischhacker WW, Davidson M, Galderisi S, Kahn RS</AU>
<TI>Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST)</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>115</VL>
<PG>97-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:49:51 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galderisi S, Davidson M, Kahn RS, Mucci A, Boter H, Gheorghe MD, et al</AU>
<TI>Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>115</VL>
<PG>104-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-10-23 12:50:01 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IPM, et al</AU>
<TI>Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>371</VL>
<PG>1085&#8211;97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brecher-2007" MODIFIED="2013-10-23 12:50:15 +0100" MODIFIED_BY="Laila Asmal" NAME="Brecher 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 12:50:15 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Brecher M, Newcomer JW, Ratner RE, Eriksson JW, Emsley R, Meulien D, et al</AU>
<TI>Differential effects of quetiapine, olanzapine and risperidone on glucose metabolism: a 24-week study in schizophrenia</TI>
<SO>International Congress on Schizophrenia Research</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Byerly-1999" NAME="Byerly 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Byerly M, Weber M</AU>
<TI>Clozapine versus quetiapine for schizophrenia</TI>
<SO>Stanley Foundation Research Programs</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Byerly-2006" MODIFIED="2013-10-23 12:50:27 +0100" MODIFIED_BY="[Empty name]" NAME="Byerly 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 12:50:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Byerly MJ, Nakonezny P, Bugno R, Boles J</AU>
<TI>A randomized, double-blind pilot trial of switching to quetiapine vs. risperidone continuation in outpatients with risperidone-associated sexual dysfunction</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 20-25, 2006</SO>
<IDENTIFIERS MODIFIED="2009-01-05 15:49:49 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cai-2005" MODIFIED="2013-10-23 12:50:34 +0100" MODIFIED_BY="Laila Asmal" NAME="Cai 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-10-23 12:50:34 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cai QQ, Wang ZW, Lin YC, Wang XY</AU>
<TI>A control study of quetiapine and clozapine in the treatment of schizophrenia</TI>
<SO>The Medicine Magazine of China</SO>
<YR>2005</YR>
<VL>3</VL>
<NO>8</NO>
<PG>465-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Canas-2006" MODIFIED="2013-10-23 12:50:45 +0100" MODIFIED_BY="[Empty name]" NAME="Canas 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 12:50:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Canas F, Perez V, Tafalla M</AU>
<TI>Quetiapine and risperidone in the treatment of schizophrenia: a short- and long-term, non-randomized study</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 20-25, 2006</SO>
<IDENTIFIERS MODIFIED="2009-01-05 15:49:54 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cao-2005" MODIFIED="2009-01-05 15:49:59 +0000" MODIFIED_BY="[Empty name]" NAME="Cao 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-05 15:49:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cao D, Xie S-P, Chen Q-B, Yuan Y-G, Fang Q</AU>
<TI>Characteristics of the sexual disturbance caused by chlorpromazine, risperidone, quetiapine and olanzapine and their associations with the changes of blood glucose and blood lipids in male patients with schizophrenia</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2005</YR>
<VL>9</VL>
<NO>36</NO>
<PG>63-8</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:49:59 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cao-2005-a" MODIFIED="2009-01-12 11:50:41 +0000" MODIFIED_BY="[Empty name]" NAME="Cao 2005 a" YEAR="2005">
<REFERENCE MODIFIED="2009-01-05 16:02:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cao D, Xie S-P, Chen Q-B, Yuan Y-G, Fang Q</AU>
<TI>Comparison of the effects of chlorpromazine, risperidone and quetiapine on hypothalamic-pituitary-gonadal axis and sexual function in male patients with schizophrenia</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2005</YR>
<VL>9</VL>
<NO>20</NO>
<PG>148-51</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:50:04 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cao-2006a" MODIFIED="2013-10-23 12:50:57 +0100" MODIFIED_BY="Laila Asmal" NAME="Cao 2006a" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 12:50:57 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cao D, Xie SP, Chen QB, Yuan YG, Fang Q</AU>
<TI>Effects of antipsychotic on pituitary-gonadal axis in male patients with schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>4</NO>
<PG>209-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cao-2006d" MODIFIED="2013-10-23 12:51:06 +0100" MODIFIED_BY="Laila Asmal" NAME="Cao 2006d" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 12:51:06 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cao CA, Guo JH, Gao H</AU>
<TI>Comparison of curative effect and safety of quetiapine and risperidone in the treatment of female schizophrenia</TI>
<SO>Medical Journal of Chinese People's Health</SO>
<YR>2006</YR>
<VL>18</VL>
<NO>6</NO>
<PG>433-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chang-2007" MODIFIED="2013-10-23 12:51:15 +0100" MODIFIED_BY="Laila Asmal" NAME="Chang 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 12:51:15 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chang GS, Li J</AU>
<TI>A control study of quetiapine and risperidone in the treatment of schizophrenia</TI>
<SO>China Practice Medicine</SO>
<YR>2007</YR>
<VL>2</VL>
<NO>34</NO>
<PG>52-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chang-2008" MODIFIED="2013-10-23 12:51:27 +0100" MODIFIED_BY="Laila Asmal" NAME="Chang 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 12:51:27 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chang YS, Gu YS</AU>
<TI>A control study of quetiapine and risperidone in the treatment of schizophrenia</TI>
<SO>Medical Journal of Chinese People's Health</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>17</NO>
<PG>2010-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chaudhry-2006" MODIFIED="2009-01-05 15:50:14 +0000" MODIFIED_BY="[Empty name]" NAME="Chaudhry 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-01-05 15:50:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chaudhry HR, Niaz S, Arshad N, Peracha F, Ayub A, Mufti KA</AU>
<TI>Comparison of risperidone, olanzapine and quetiapine in relation to body weight, serum blood glucose and prolactin levels</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S241</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:50:14 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2006a" MODIFIED="2013-10-23 12:51:40 +0100" MODIFIED_BY="Laila Asmal" NAME="Chen 2006a" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 12:51:40 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen ZE, Liu HR, Wu SQ</AU>
<TI>A control study of quetiapine and risperidone in the treatment of female schizophrenia</TI>
<SO>Herald of Medicine</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>6</NO>
<PG>548-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2006k" MODIFIED="2013-10-23 12:51:50 +0100" MODIFIED_BY="Laila Asmal" NAME="Chen 2006k" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 12:51:50 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen RY, Luo RQ, Wang AQ, Mei HB</AU>
<TI>A study of quetiapine on the quality of life of elderly schizophrenia</TI>
<SO>Medical Journal of Chinese People's Health</SO>
<YR>2006</YR>
<VL>18</VL>
<NO>6</NO>
<PG>447-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2007a" MODIFIED="2013-10-23 12:53:55 +0100" MODIFIED_BY="Laila Asmal" NAME="Chen 2007a" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 12:53:55 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen JG</AU>
<TI>Control study on management of first-episode schizophrenia with risperidone and quetiapine</TI>
<SO>China Pharmaceuticals</SO>
<YR>2007</YR>
<VL>16</VL>
<NO>9</NO>
<PG>43-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2007b" MODIFIED="2013-10-23 12:55:31 +0100" MODIFIED_BY="Laila Asmal" NAME="Chen 2007b" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 12:55:31 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen FX</AU>
<TI>A control study of quetiapine vs risperidone in first-episode schizophrenia</TI>
<SO>Jiangxi Medicine</SO>
<YR>2007</YR>
<VL>42</VL>
<NO>10</NO>
<PG>917-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2007c" MODIFIED="2013-10-23 12:55:45 +0100" MODIFIED_BY="Laila Asmal" NAME="Chen 2007c" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 12:55:45 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen F, Wang HY, Li DY, Zhou BW, Chen FY</AU>
<TI>A control study of quetiapine and aripiprazole in the treatment of female first-episode schizophrenia</TI>
<SO>Journal of Psychiatry</SO>
<YR>2007</YR>
<VL>20</VL>
<NO>6</NO>
<PG>381-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2008" MODIFIED="2013-10-23 12:55:54 +0100" MODIFIED_BY="Laila Asmal" NAME="Chen 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 12:55:54 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen HB, Fu F, Yang QJ</AU>
<TI>A control study of quetiapine and risperidone in the treatment of schizophrenia</TI>
<SO>Medical Information</SO>
<YR>2008</YR>
<VL>21</VL>
<NO>3</NO>
<PG>389-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chu-2006" MODIFIED="2013-10-23 12:56:05 +0100" MODIFIED_BY="Laila Asmal" NAME="Chu 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 12:56:05 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chu JP</AU>
<TI>Comparative study of quetiapine and risperidone in the treatment of late onset schizophrenias</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>1</NO>
<PG>34-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cortese-2008" MODIFIED="2011-08-20 14:35:51 +0100" MODIFIED_BY="Laila Asmal" NAME="Cortese 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-08-20 14:35:47 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cortese L, Caligiuri MP, Williams R, Schieldrop P, Manchanda R, Malla A, Harricharan R</AU>
<TI>Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia</TI>
<SO>J Clin Psychopharmacol</SO>
<YR>2008</YR>
<VL>28</VL>
<PG>69-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dai-2004" MODIFIED="2013-10-23 12:56:18 +0100" MODIFIED_BY="[Empty name]" NAME="Dai 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-10-23 12:56:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dai J-P, Zhao Z-H, Mai G-Y</AU>
<TI>Comparative study on the effect of olanzapine and seroquel of schizophrenia</TI>
<SO>Chinese Journal of Behavioral Medical Science</SO>
<YR>2004</YR>
<VL>13</VL>
<NO>3</NO>
<PG>291-3</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:50:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dai-2005" MODIFIED="2009-11-03 19:16:08 +0000" MODIFIED_BY="[Empty name]" NAME="Dai 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-11-03 19:16:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dai J-P, Zhao Z-H, Liu G-X</AU>
<TI>Comparison of efficacy and safety of aripiprazole and quetiapine in the treatment of schizophrenia</TI>
<SO>Chinese Journal of Behavioral Medical Sience</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>8</NO>
<PG>712-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dai-2008" MODIFIED="2013-10-23 12:56:30 +0100" MODIFIED_BY="Laila Asmal" NAME="Dai 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 12:56:30 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dai XG, Xia XL, Ye XR</AU>
<TI>The effects of seroquel and risperidone on serum prolactin levels of female schizophrenia</TI>
<SO>Chinese Journal of Modern Drug Application</SO>
<YR>2008</YR>
<VL>2</VL>
<NO>3</NO>
<PG>10-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davies-2007" MODIFIED="2013-10-23 12:56:37 +0100" MODIFIED_BY="Laila Asmal" NAME="Davies 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 12:56:37 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davies LM, Lewis S, Jones PB, Barnes TRE, Gaughran F, Hayhurst D, et al</AU>
<TI>Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy</TI>
<SO>Value in Health</SO>
<YR>2008</YR>
<VL>11</VL>
<NO>4</NO>
<PG>549-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ding-2004" MODIFIED="2013-10-23 12:56:53 +0100" MODIFIED_BY="[Empty name]" NAME="Ding 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-10-23 12:56:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ding Y, An B, Li G, Li Y</AU>
<TI>A comparative study of risperidone and quetiapine in the treatment of schizophrenia and relationship between efficacy and the serum levels of il-2?sil-2r</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>2</NO>
<PG>76-8</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:50:30 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dong-2008" MODIFIED="2013-10-23 12:57:17 +0100" MODIFIED_BY="Laila Asmal" NAME="Dong 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 12:57:17 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dong W, Yang X</AU>
<TI>A control study of quetiapine and ziprasidone in the treatment of first-episode schizophrenia</TI>
<SO>Medical Journal of Chinese People's Health</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>12</NO>
<PG>1275-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dossenbach-2005" MODIFIED="2013-10-23 12:57:30 +0100" MODIFIED_BY="[Empty name]" NAME="Dossenbach 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-10-23 12:57:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dossenbach M, Arango-Davila C, Silva Ibarra H, Landa E, Aguilar J, Caro O, et al</AU>
<TI>Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the intercontinental schizophrenia outpatient health outcomes (IC-SOHO) study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2005</YR>
<VL>66</VL>
<PG>1021-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Du-2003" MODIFIED="2009-11-03 19:21:46 +0000" MODIFIED_BY="[Empty name]" NAME="Du 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-11-03 19:21:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feng D-J, Zhou T, Xiong L-H, Thian D-F</AU>
<TI>A study of quetiapine and clozapine in treatment of chronic schizophrenia</TI>
<SO>Journal of Luzhou Medical College</SO>
<YR>2003</YR>
<VL>26</VL>
<NO>6</NO>
<PG>511-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Emsley-2005" MODIFIED="2009-12-08 11:04:15 +0000" MODIFIED_BY="[Empty name]" NAME="Emsley 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-12-08 11:04:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP</AU>
<TI>Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>8</VL>
<NO>2</NO>
<PG>175-82</PG>
<CY>Cape Town</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fan-2005" MODIFIED="2009-12-08 11:20:15 +0000" MODIFIED_BY="[Empty name]" NAME="Fan 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-12-08 11:20:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fan J-H, Li W-J</AU>
<TI>A study of quetiapine in treatment of negative symptoms dominant schizophrenia</TI>
<SO>Sichuan Mental Health</SO>
<YR>2005</YR>
<VL>18</VL>
<PG>178</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fan-2008" MODIFIED="2013-10-23 12:57:51 +0100" MODIFIED_BY="Laila Asmal" NAME="Fan 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 12:57:51 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fan BF, Chen CF, Xu Y, Cao PL, Gao P</AU>
<TI>The effects of quetiapine, risperidone and clozapine for schizophrenia on serum prolactin level</TI>
<SO>Chinese Medical Journal of Metallurgical Industry</SO>
<YR>2008</YR>
<VL>25</VL>
<NO>1</NO>
<PG>14-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fleischhacker-2005" MODIFIED="2009-01-05 15:51:07 +0000" MODIFIED_BY="[Empty name]" NAME="Fleischhacker 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-05 15:51:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fleischhacker WW, Keet IPM, Kahn RS</AU>
<TI>The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>78</VL>
<NO>2-3</NO>
<PG>147-56</PG>
<CY>Netherlands</CY>
<IDENTIFIERS MODIFIED="2009-01-05 15:51:07 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fu-2005" MODIFIED="2009-01-05 15:51:27 +0000" MODIFIED_BY="[Empty name]" NAME="Fu 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-05 15:51:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fu H, Yu H , Huo J</AU>
<TI>A comparative study of quetiapine vs clozapine in the treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>4</NO>
<PG>313-4</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:51:27 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fu-2005a" MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" NAME="Fu 2005a" YEAR="2005">
<REFERENCE MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fu H, Yu H , Huo J</AU>
<TI>A comparative study of quetiapine vs clozapine in the treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>4</NO>
<PG>313-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gao-2003" MODIFIED="2009-01-05 15:51:35 +0000" MODIFIED_BY="[Empty name]" NAME="Gao 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-01-05 15:51:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gao CZ, Gao Z</AU>
<TI>A study of quetiapine in the treatment of first-onset schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>4</NO>
<PG>221-2</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:51:35 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garc_x00ed_a-2006" MODIFIED="2011-08-20 08:49:30 +0100" MODIFIED_BY="Laila Asmal" NAME="García 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-08-20 08:49:30 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>García MC, Vidal M, Ramos R</AU>
<TI>Sexual side effects of antipsychotics and treatment adherence</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S378</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:51:42 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guo-2008" MODIFIED="2013-10-23 12:58:05 +0100" MODIFIED_BY="Laila Asmal" NAME="Guo 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 12:58:05 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guo ZY, Liu JM, Yang JZ, Guo H, Wang AQ</AU>
<TI>Efficacy quetiapine in the treatment of schizophrenic patients and effect on the quality of life</TI>
<SO>China Journal of Health Psychology</SO>
<YR>2008</YR>
<VL>16</VL>
<NO>5</NO>
<PG>544-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hao-2007" MODIFIED="2013-10-23 12:58:12 +0100" MODIFIED_BY="Laila Asmal" NAME="Hao 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 12:58:12 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hao H</AU>
<TI>A control study of quetiapine and seroquel in the treatment of schizophrenia</TI>
<SO>Journal of Medical Forum</SO>
<YR>2007</YR>
<VL>28</VL>
<NO>15</NO>
<PG>60-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harrigan-2004" MODIFIED="2013-10-23 12:58:21 +0100" MODIFIED_BY="[Empty name]" NAME="Harrigan 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-10-23 12:58:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, et al</AU>
<TI>A randomized evaluation of the effects of six antipsychotic agents on QTC, in the absence and presence of metabolic inhibition</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>1</NO>
<PG>62-9</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-01-05 15:51:51 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-He-2003" MODIFIED="2009-01-05 15:52:08 +0000" MODIFIED_BY="[Empty name]" NAME="He 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-01-05 15:52:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>He J, Chen YX</AU>
<TI>A controlled study on quetiapine and clozapine in the treatment of schizophrenic patients</TI>
<SO>Medical Journal of Chinese Civil Administration</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>6</NO>
<PG>335-6</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:52:08 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horacek-2004" MODIFIED="2013-10-23 12:58:32 +0100" MODIFIED_BY="Laila Asmal" NAME="Horacek 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-10-23 12:58:32 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Horacek J, Seifertova D, Janu L, Petranova T</AU>
<TI>The effect of quetiapine on different domains of cognition and negative symptoms in schizophrenia</TI>
<SO>Proceedings of the Biennial Winter Workshop on Schizophrenia, February 7-13, 2004</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2003" MODIFIED="2011-08-20 08:49:15 +0100" MODIFIED_BY="Laila Asmal" NAME="Huang 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-08-20 08:49:15 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang S-P, Ma Z-W, Guo B-Y</AU>
<TI>Effectiveness of quetiapine vs clozapine in the treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>4</NO>
<PG>206-7</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:52:21 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2006" MODIFIED="2013-10-23 12:58:39 +0100" MODIFIED_BY="Laila Asmal" NAME="Huang 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 12:58:39 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang X, Liu JY</AU>
<TI>Effects of clozapine and seroquel on the glucose metabolism in schizophrenic patients</TI>
<SO>Jiangxi Medicine</SO>
<YR>2006</YR>
<VL>41</VL>
<NO>5</NO>
<PG>264-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huber-2004" MODIFIED="2013-10-23 12:59:00 +0100" MODIFIED_BY="[Empty name]" NAME="Huber 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-10-23 12:59:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huber TJ, Borsutzky M, Schneider U, Emrich HM</AU>
<TI>Psychotic disorders and gonadal function: evidence supporting the oestrogen hypothesis</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>2004</YR>
<VL>109</VL>
<NO>4</NO>
<PG>269-74</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2009-01-05 15:52:27 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jiang-2006" MODIFIED="2013-10-23 12:59:07 +0100" MODIFIED_BY="Laila Asmal" NAME="Jiang 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 12:59:07 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jiang ZX, He XY, He XC, Li LW, Peng ZE</AU>
<TI>A control study of quetiapine and aripiprozole in the treatment of schizophrenia</TI>
<SO>Journal of Clinical Research</SO>
<YR>2006</YR>
<VL>23</VL>
<NO>8</NO>
<PG>1327-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karow-2002" MODIFIED="2013-10-23 12:59:14 +0100" MODIFIED_BY="Dolores Matthews" NAME="Karow 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-10-23 12:59:14 +0100" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karow A, Naber D</AU>
<TI>Subjective well-being and quality of life under atypical antipsychotic treatment</TI>
<SO>Psychopharmacology</SO>
<YR>2002</YR>
<VL>162</VL>
<PG>3-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keks-2006" MODIFIED="2013-10-23 12:59:24 +0100" MODIFIED_BY="[Empty name]" NAME="Keks 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 12:59:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keks NA, Tonso M, Tabone K, McHugh M, Thomas R, Tune P, Gelman M</AU>
<TI>Clinical experience with atypical antipsychotics in acute inpatient unit: focus on quetiapine</TI>
<SO>International Journal of Psychiatry in Clinical Practice</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>2</NO>
<PG>1-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kelemen-2006" MODIFIED="2009-01-05 15:52:38 +0000" MODIFIED_BY="[Empty name]" NAME="Kelemen 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-01-05 15:52:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kelemen O, Nagy O, Máttyássy A, Kiss I, Janka Z, Kéri S</AU>
<TI>Do second-generation antipsychotics disrupt decision-making abilities in schizophrenia?</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S430</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:52:38 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2004" MODIFIED="2013-10-23 12:59:38 +0100" MODIFIED_BY="[Empty name]" NAME="Kim 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-10-23 12:59:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim JG, Cho DH, Choi HK, Kim HJ, Cho JH, Kang SH, et al</AU>
<TI>The comparison of risperidone, olanzapine and quetiapine in the treatment of chronic schizophrenia and schizoaffective disorder</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>Suppl 3</NO>
<PG>S245</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:52:44 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knegtering-2004" MODIFIED="2013-10-23 12:59:46 +0100" MODIFIED_BY="[Empty name]" NAME="Knegtering 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-10-23 12:59:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knegtering R, Castelein S, Bous H, Van Der Linde J, Bruggeman R, Kluiter H, et al</AU>
<TI>A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>1</NO>
<PG>56-61</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-01-05 15:52:51 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kolotkin-2008" MODIFIED="2013-10-23 12:59:54 +0100" MODIFIED_BY="Laila Asmal" NAME="Kolotkin 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 12:59:54 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kolotkin RL, Corey-Lisle PK, Crosby RD, Kan HJ, McQuade RD</AU>
<TI>Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care</TI>
<SO>European Psychiatry</SO>
<YR>2008</YR>
<VL>23</VL>
<PG>561-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koponen-2008" MODIFIED="2011-08-20 15:19:04 +0100" MODIFIED_BY="Laila Asmal" NAME="Koponen 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-08-20 15:19:02 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Koponen</AU>
<TI>Study in Schizophrenic In-Patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose</TI>
<SO>Clinical Trial Registration Data</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuang-2007" MODIFIED="2013-10-23 13:00:05 +0100" MODIFIED_BY="Laila Asmal" NAME="Kuang 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 13:00:05 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuang YH, Zhao L</AU>
<TI>A comparative study on the efficacy and weight gain between quetiapine and clozapine in the treatment of schizophrenia</TI>
<SO>Journal of Psychiatry</SO>
<YR>2007</YR>
<VL>20</VL>
<NO>4</NO>
<PG>217-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-L_x0027_Italien-2007" MODIFIED="2013-10-23 13:00:13 +0100" MODIFIED_BY="Laila Asmal" NAME="L'Italien 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 13:00:13 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>L&#8217;Italien G, Hanssens L, Kan HJ, Baker RA, Marcus RN, McQuade RD, et al</AU>
<TI>Metabolic effects of aripiprazole versus olanzapine, quetiapine, or risperidone (the Star trial)</TI>
<SO>Proceedings of the 11th International Congress on Schizophrenia Research, Colorado Springs, Colorado, USA, March 28-April 1, 2007</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lan-2006" MODIFIED="2013-10-23 13:00:21 +0100" MODIFIED_BY="Laila Asmal" NAME="Lan 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 13:00:21 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lan GX, Li ZC, Liu R, Deng G, Wu YM, Xie GP</AU>
<TI>A control study of quetiapine and clozapine in the treatment of schizophrenia</TI>
<SO>Journal of Ganna Medical University</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>6</NO>
<PG>850-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2001" MODIFIED="2009-01-05 15:52:59 +0000" MODIFIED_BY="[Empty name]" NAME="Li 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-01-05 15:52:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li HF, Gu NF, Xie B, Li M, Zhang L, Cheng Y, Wang MJ</AU>
<TI>Quetiapine in treatment of schizophrenia: a randomized, controlled, multicentre study</TI>
<SO>Chinese Journal of New Drugs and Clinical Remedies</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>4</NO>
<PG>260-3</PG>
<CY>China</CY>
<IDENTIFIERS MODIFIED="2009-01-05 15:52:59 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2002a" MODIFIED="2013-10-23 13:00:54 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2002a" YEAR="2002">
<REFERENCE MODIFIED="2013-10-23 13:00:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li DG, Zheng MX, Zheng JJ</AU>
<TI>A comparative study between quetiapine and clozapine in the treatment of schizophrenia</TI>
<SO>Jiuheyuan Hospital of Shishou</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>5</NO>
<PG>267-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2003a" MODIFIED="2013-10-23 13:01:17 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2003a" YEAR="2003">
<REFERENCE MODIFIED="2013-10-23 13:01:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li CM</AU>
<TI>A comparison of cognitive function in the first-onset schizophrenia treated with quetiapine and clozapine</TI>
<SO>Medical Journal of Chinese People Health</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>12</NO>
<PG>718-21</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:53:35 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2003b" MODIFIED="2009-02-05 16:49:56 +0000" MODIFIED_BY="[Empty name]" NAME="Li 2003b" YEAR="2003">
<REFERENCE MODIFIED="2009-02-05 16:49:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li X, Lao G, Cao L</AU>
<TI>Comparison of efficacy and safety of seroquel and resperidone in the treatment of schizophrenia</TI>
<SO>Chinese Journal of Behavioral Medical Science</SO>
<YR>2003</YR>
<VL>12</VL>
<NO>1</NO>
<PG>45-6</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:53:10 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2005a" MODIFIED="2013-10-23 13:01:33 +0100" MODIFIED_BY="Laila Asmal" NAME="Li 2005a" YEAR="2005">
<REFERENCE MODIFIED="2013-10-23 13:01:33 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li H</AU>
<TI>A controlled study of schizophrenia treated with quetiapine and clozapine</TI>
<SO>Chinese Modern Medical and Clinical</SO>
<YR>2005</YR>
<VL>3</VL>
<NO>7</NO>
<PG>33-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2005b" MODIFIED="2013-10-23 13:01:44 +0100" MODIFIED_BY="Laila Asmal" NAME="Li 2005b" YEAR="2005">
<REFERENCE MODIFIED="2013-10-23 13:01:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li G, Chen Q-G, Zhang Q-H</AU>
<TI>A comparison analysis on the efficacy of quetiapine and risperidone in cognitive function of schizophrenia</TI>
<SO>Chinese Journal of Behavioral Medical Science</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>11</NO>
<PG>1007-8, 1036</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:53:17 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2007a" MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" NAME="Li 2007a" YEAR="2007">
<REFERENCE MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li M, Lv W, Xing X</AU>
<TI>A control study of quetiapine and aripiprazole in the treatment of schizophrenia</TI>
<SO>Chinese Journal of Postgraduate Medicine</SO>
<YR>2007</YR>
<VL>30</VL>
<NO>11</NO>
<PG>49-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2007h" MODIFIED="2013-10-23 13:02:14 +0100" MODIFIED_BY="Laila Asmal" NAME="Li 2007h" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 13:02:14 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li Q, Wang W, Chen C, Li YM</AU>
<TI>Comparison of efficacy and safety of seroquel and risperidone in the treatment of schizophrenia</TI>
<SO>Huaxi Pharmacy</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>3</NO>
<PG>354-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2008a" MODIFIED="2013-10-23 13:02:21 +0100" MODIFIED_BY="Laila Asmal" NAME="Li 2008a" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 13:02:21 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li G, Zuo J, Chen Q, Zhou H</AU>
<TI>A comparison analysis on the efficacy of quetiapine and risperidone in the treatment of schizophrenia</TI>
<SO>Tianjin Pharmacy</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>1</NO>
<PG>42-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2008b" MODIFIED="2013-10-23 13:02:27 +0100" MODIFIED_BY="Laila Asmal" NAME="Li 2008b" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 13:02:27 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li S</AU>
<TI>A control study of quetiapine and olanzapine in the treatment of schizophrenia</TI>
<SO>Journal of Nongken Medicine</SO>
<YR>2008</YR>
<VL>30</VL>
<NO>1</NO>
<PG>31-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2008c" MODIFIED="2013-10-23 13:02:34 +0100" MODIFIED_BY="Laila Asmal" NAME="Li 2008c" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 13:02:34 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li W</AU>
<TI>Influence on the psychopathology and the quality of life of schizophrenia treated with risperidone, clozapine and quetiapine</TI>
<SO>Medical Information</SO>
<YR>2008</YR>
<VL>21</VL>
<NO>12</NO>
<PG>2253-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2008d" MODIFIED="2013-10-23 13:02:46 +0100" MODIFIED_BY="Laila Asmal" NAME="Li 2008d" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 13:02:46 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li DM</AU>
<TI>The cross-check analysis of risperdal and quetiapine alleviating negative symptoms of schizophrenia</TI>
<SO>Laboratory Medicine and Clinic</SO>
<YR>2008</YR>
<VL>5</VL>
<NO>19</NO>
<PG>1162-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liang-2008" MODIFIED="2013-10-23 13:02:53 +0100" MODIFIED_BY="Laila Asmal" NAME="Liang 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 13:02:53 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liang L, Wang D, Shen Y</AU>
<TI>Influence of quetiapine and clozapine on fasting blood glucose of first-episode schizophrenia</TI>
<SO>Practical Pharmacy and Clinical Remedies</SO>
<YR>2008</YR>
<VL>11</VL>
<NO>5</NO>
<PG>296-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2005" MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" NAME="Lin 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin Z</AU>
<TI>Analysis of therapeutic effect of quetiapine on schizophrenia patient</TI>
<SO>China Tropical Medicine</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>6</NO>
<PG>1299</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2007" MODIFIED="2013-10-23 13:03:08 +0100" MODIFIED_BY="Laila Asmal" NAME="Lin 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 13:03:08 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin H, Wang J</AU>
<TI>A study of quetiapine in the treatment of elderly schizophrenia</TI>
<SO>Qinghai Pharmacy</SO>
<YR>2007</YR>
<VL>37</VL>
<NO>4</NO>
<PG>67-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2003" MODIFIED="2013-10-23 13:03:16 +0100" MODIFIED_BY="Laila Asmal" NAME="Liu 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-10-23 13:03:16 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu X, Lin L, Fan Y, Dong X</AU>
<TI>A comparative study of new anti-psychopathic drugs lead to gain weight</TI>
<SO>Medical Journal of Chinese People's Health</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>4</NO>
<PG>230-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2003a" MODIFIED="2013-10-23 13:03:25 +0100" MODIFIED_BY="Laila Asmal" NAME="Liu 2003a" YEAR="2003">
<REFERENCE MODIFIED="2013-10-23 13:03:25 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu K, Wang X, Jiang L, Geng H, Cng X, Shi L, Zhao H</AU>
<TI>A control study of quetiapine and risperidone in the treatment of schizophrenia</TI>
<SO>Journal of Hebei Mental Health</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>1</NO>
<PG>37-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2004a" MODIFIED="2009-01-12 12:09:12 +0000" MODIFIED_BY="[Empty name]" NAME="Liu 2004a" YEAR="2004">
<REFERENCE MODIFIED="2009-01-05 16:04:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu Y, Xu M, Chen X</AU>
<TI>A controlled study of quetiapine and clozapine in the treatment of schizophrenia with predominantly negative symptoms</TI>
<SO>Shandong Archires of Psychiatry</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>1</NO>
<PG>6-8</PG>
<IDENTIFIERS MODIFIED="2009-01-05 16:04:52 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2004b" MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" NAME="Liu 2004b" YEAR="2004">
<REFERENCE MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu Y, Xu M, Chen X</AU>
<TI>A controlled study of quetiapine and clozapine in the treatment of schizophrenia with predominantly negative symptoms</TI>
<SO>Shandong Archires of Psychiatry</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>1</NO>
<PG>6-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2005" MODIFIED="2013-10-23 13:03:45 +0100" MODIFIED_BY="[Empty name]" NAME="Liu 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-10-23 13:03:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu CX, Liu SH, Tu ZM, Liu B</AU>
<TI>A study of quetiapine with small doze of clozapine in treatment of resistant schizophrenia</TI>
<SO>Medical Journal of Chinese People´s Health</SO>
<YR>2005</YR>
<VL>17</VL>
<PG>748-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2005a" MODIFIED="2013-10-23 13:03:56 +0100" MODIFIED_BY="Laila Asmal" NAME="Liu 2005a" YEAR="2005">
<REFERENCE MODIFIED="2013-10-23 13:03:56 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu H, Shi Y, Liu Z</AU>
<TI>A comparative study between quetiapine and risperidone in the treatment of schizophrenia</TI>
<SO>Journal of Heze Medical College</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>1</NO>
<PG>15-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2006" MODIFIED="2013-10-23 13:04:07 +0100" MODIFIED_BY="Laila Asmal" NAME="Liu 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 13:04:07 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu Z, Han J, Cheng Y, Yan M, Zhou H</AU>
<TI>Study on quetiapine fumarate and risperidone in the treatment of schizophrenia</TI>
<SO>Journal of Hebei Medical College for Continuing Education</SO>
<YR>2006</YR>
<VL>23</VL>
<NO>2</NO>
<PG>14-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2007" MODIFIED="2013-10-23 13:04:14 +0100" MODIFIED_BY="Laila Asmal" NAME="Liu 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 13:04:14 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu B</AU>
<TI>Clinical study on quetiapine in treatment of refractory schizophrenia</TI>
<SO>China Modern Doctor</SO>
<YR>2007</YR>
<VL>45</VL>
<NO>18</NO>
<PG>24-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2008" MODIFIED="2013-10-23 13:04:23 +0100" MODIFIED_BY="Laila Asmal" NAME="Liu 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 13:04:23 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu L, Hou Z, Guo Y</AU>
<TI>A control study of quetiapine and risperidone in the treatment of elderly schizophrenia</TI>
<SO>Medical Journal of Chinese People's Health</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>7</NO>
<PG>639-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-2005" MODIFIED="2009-11-03 19:30:27 +0000" MODIFIED_BY="[Empty name]" NAME="Lu 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-11-03 19:30:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lu S, Zhang S-A, Ren Y</AU>
<TI>Comparative study on the psychopathology and the quality of life of schizophrenia treated with risperidone, clozapine and quetiapine</TI>
<SO>Journal of Nursing Science</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>3</NO>
<PG>57-9</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:53:57 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luo-2005" MODIFIED="2009-02-05 13:58:37 +0000" MODIFIED_BY="[Empty name]" NAME="Luo 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-02-05 13:58:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luo Y, Zhang S-W, Wang A-Q</AU>
<TI>The comparative study of quetiapine and clozapine in the treatment of female schizophrene</TI>
<SO>Medical Journal of Chinese People Health</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>6</NO>
<PG>269-70</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:54:06 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lv-2008" MODIFIED="2013-10-23 13:04:41 +0100" MODIFIED_BY="Laila Asmal" NAME="Lv 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 13:04:41 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lv B, Wang J, Lin Y</AU>
<TI>A control study of quetiapine and risperidone in the treatment of eldly schizophrenia</TI>
<SO>Shandong Pharmacy</SO>
<YR>2008</YR>
<VL>48</VL>
<NO>16</NO>
<PG>91-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mei-2006" MODIFIED="2013-10-23 13:04:49 +0100" MODIFIED_BY="Laila Asmal" NAME="Mei 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 13:04:49 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mei Y, Pan J, Ma P, Pan G</AU>
<TI>Clinical observation on acute excitation of schizophrenia treated with quetiapine</TI>
<SO>Chinese Nursing Research</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>5</NO>
<PG>1176-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mintzer-2004" MODIFIED="2009-01-05 15:54:14 +0000" MODIFIED_BY="[Empty name]" NAME="Mintzer 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-01-05 15:54:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mintzer JE, Mullen JA, Sweitzer DE</AU>
<TI>A comparison of extrapyramidal symptoms in older outpatients treated with quetiapine or risperidone</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>9</NO>
<PG>1483-91</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2009-01-05 15:54:14 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mullen-2001" MODIFIED="2009-11-03 19:30:55 +0000" MODIFIED_BY="[Empty name]" NAME="Mullen 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-11-03 19:30:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mullen J, Jibson MD, Sweitzer D</AU>
<TI>A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study</TI>
<SO>Clinical Therapeutics</SO>
<YR>2001</YR>
<VL>23</VL>
<NO>11</NO>
<PG>1839-54</PG>
<CY>USA</CY>
<IDENTIFIERS MODIFIED="2009-01-05 15:54:27 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Musil-2006" MODIFIED="2013-10-23 13:04:58 +0100" MODIFIED_BY="[Empty name]" NAME="Musil 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 13:04:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Musil RL, Spellmann I, Riedel M, Douhet A, Dehning S, Maino K, et al</AU>
<TI>SNAP-25 gene polymorphisms and weight gain in schizophrenic patients treated with atypical antipsychotics</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S415</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:54:35 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nai-2007" MODIFIED="2013-10-23 13:05:15 +0100" MODIFIED_BY="Laila Asmal" NAME="Nai 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 13:05:15 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nai X, Hu X, Qiu W, Liu N, Wei H</AU>
<TI>Effect of quetiapine on cognitive function of patients with first episode schizophrenia</TI>
<SO>Journal of Medical Forum</SO>
<YR>2007</YR>
<VL>28</VL>
<NO>2</NO>
<PG>38-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pan-2004" MODIFIED="2013-10-23 13:05:24 +0100" MODIFIED_BY="[Empty name]" NAME="Pan 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-10-23 13:05:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pan M, Wang H, Zhang S</AU>
<TI>A controlled study of domestic quetiapine and risperidone in the treatment of first-episode schizophrenia</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>4</NO>
<PG>244-6</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:54:44 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pan-2004a" MODIFIED="2013-10-23 13:05:36 +0100" MODIFIED_BY="[Empty name]" NAME="Pan 2004a" YEAR="2004">
<REFERENCE MODIFIED="2013-10-23 13:05:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pan M, Zhang S-Q, Zhao Z</AU>
<TI>A comparative study of domestic quetiapine and risperidone in the treatment of schizophrenia</TI>
<SO>Medical Journal of Chinese Peoples Health</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>10</NO>
<PG>597-8, 637</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:55:14 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pan-2004b" MODIFIED="2013-10-23 13:05:45 +0100" MODIFIED_BY="[Empty name]" NAME="Pan 2004b" YEAR="2004">
<REFERENCE MODIFIED="2013-10-23 13:05:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pan M, Zhang S, Zhao Z</AU>
<TI>Influence of three antipsychotic drugs on electrocardiogram in patients with schizophrenia</TI>
<SO>Journal of XinXiang Medical College</SO>
<YR>2004</YR>
<VL>21</VL>
<PG>403-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pan-2008" MODIFIED="2013-10-23 13:06:01 +0100" MODIFIED_BY="Laila Asmal" NAME="Pan 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 13:06:01 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pan W, Lin Z, Cheng B</AU>
<TI>A study of ziprasidone in the treatment of schizophrenia</TI>
<SO>Guide of China Medicine</SO>
<YR>2008</YR>
<VL>6</VL>
<NO>13</NO>
<PG>22-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pang-2002" MODIFIED="2009-01-05 15:55:22 +0000" MODIFIED_BY="[Empty name]" NAME="Pang 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-01-05 15:55:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pang D, Wang C, Cui A</AU>
<TI>Effect of quetiapine fumarate and clozapine on clinical rehabilitation of schizophrenia:a controlled study</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2002</YR>
<VL>6</VL>
<NO>7</NO>
<PG>1007</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:55:22 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peng-2004" MODIFIED="2013-10-23 13:06:25 +0100" MODIFIED_BY="[Empty name]" NAME="Peng 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-10-23 13:06:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peng XX, Huang X</AU>
<TI>Control study of quetiapine on schizophrenia mainly with negative symptoms</TI>
<SO>Modern Journal of Integrated Traditional Chinese and Western Medicine</SO>
<YR>2004</YR>
<VL>13</VL>
<NO>12</NO>
<PG>1557-8</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:55:30 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petty-2005" MODIFIED="2011-08-20 15:36:11 +0100" MODIFIED_BY="Laila Asmal" NAME="Petty 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-08-20 15:36:08 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="OTHER">
<AU>Petty F</AU>
<TI>Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia</TI>
<SO>Clinical Trial Registration Data</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pfizer-2005" MODIFIED="2013-10-23 13:06:32 +0100" MODIFIED_BY="Laila Asmal" NAME="Pfizer 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-10-23 13:06:32 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="OTHER">
<AU>Pfizer</AU>
<TI>Effect and Safety of Ziprasidone Compared to Other Atypical Antipsychotic Drug in Schizophrenic Patients</TI>
<SO>Clinical Trial Registration Data</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qi-2004" MODIFIED="2013-10-23 13:06:41 +0100" MODIFIED_BY="[Empty name]" NAME="Qi 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-10-23 13:06:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qi F, Wang L, Zhen Y</AU>
<TI>Comparison of efficacy and safety of quetiapine and risperidone in the treatment of schizophrenia</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>2</NO>
<PG>78-9, 119</PG>
<IDENTIFIERS MODIFIED="2009-11-03 20:37:13 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qian-2004" MODIFIED="2013-10-23 13:07:10 +0100" MODIFIED_BY="[Empty name]" NAME="Qian 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-10-23 13:07:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qian D, Pan B, Yang G</AU>
<TI>Cost-effectiveness analysis of 3 kinds of therapeutic schemes for schizophrenia</TI>
<SO>Evaluation and Analysis of Drug Use in Hospital of China</SO>
<YR>2004</YR>
<VL>4</VL>
<NO>2</NO>
<PG>110-1</PG>
<IDENTIFIERS MODIFIED="2009-11-03 20:37:32 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reznik-2004" MODIFIED="2013-10-23 13:07:22 +0100" MODIFIED_BY="[Empty name]" NAME="Reznik 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-10-23 13:07:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Reznik I, Slavkin L, Shabash E, Shaked G, Kertzman S, Spivak B, et al</AU>
<TI>Quetiapine ("Seroquel") and olanzapine for acute treatment of patients with schizophrenia: an open-label, comparative study</TI>
<SO>Proceedings of the XXIV Collegium Internationale Neuro-Psychopharmacologicum; Paris, France, June 20-24, 2004</SO>
<PG>1-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riera-2004" MODIFIED="2013-10-23 13:07:43 +0100" MODIFIED_BY="Laila Asmal" NAME="Riera 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-10-23 13:07:43 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Riera L, Tandon R, Stock EG, Kujawa MJ, Torbeyns AF, Borian FE</AU>
<TI>Broad effectiveness trial with aripiprazole</TI>
<SO>Proceedings of the Twelfth Biennial Winter Workshop on Schizophrenia, Davos, Switzerland, February 7-13, 2004</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruan-2005" MODIFIED="2013-10-23 13:08:00 +0100" MODIFIED_BY="Laila Asmal" NAME="Ruan 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-10-23 13:08:00 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruan J, Huang G</AU>
<TI>A control study of quetiapine and clozapine in the treatment of difficult-to-treat schizophrenia</TI>
<SO>Medical Journal of Chinese People's Health</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>12</NO>
<PG>747-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ryu-2006" MODIFIED="2009-01-05 15:56:09 +0000" MODIFIED_BY="[Empty name]" NAME="Ryu 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-01-05 15:56:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ryu SH, Jang WS, Cho EY, Kim SK, Lee DS, Hong KS</AU>
<TI>Association of leptin gene polymorphism with antipsychotic drug-induced weight gain</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S419</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:56:09 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sajatovic-2002" MODIFIED="2013-10-23 13:08:06 +0100" MODIFIED_BY="[Empty name]" NAME="Sajatovic 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-10-23 13:08:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sajatovic M, Mullen JA, Sweitzer D</AU>
<TI>Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychotic disorders</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association, Philadelphia, Pennsylvania, USA, May 18-23, 2002</SO>
<IDENTIFIERS MODIFIED="2009-01-05 15:56:16 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sarma-2008a" MODIFIED="2012-04-27 11:22:41 +0100" MODIFIED_BY="Laila Asmal" NAME="Sarma 2008a" YEAR="">
<REFERENCE MODIFIED="2012-04-27 11:22:41 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Sarma K</AU>
<TI>Lurasidone HCl - A Long Term Phase 3 Study ofPatients With Chronic Schizophrenia (PEARL 3Ext)</TI>
<SO>Clinical Trial Registration Data</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheng-2006" MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" NAME="Sheng 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sheng D, Yang Y</AU>
<TI>A study of cognitive function about quetiapine and clozapine in the treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>5</NO>
<PG>304</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Song-2006" MODIFIED="2012-04-27 11:35:29 +0100" MODIFIED_BY="Laila Asmal" NAME="Song 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-04-27 11:35:29 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Song F</AU>
<TI>A control study of quetiapine and clozapine in the treatment of schizophrenia</TI>
<SO>Health Horizon·Medical Science Fascicule</SO>
<YR>2006</YR>
<VL>(7)</VL>
<PG>91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Song-2008a" MODIFIED="2013-10-23 13:08:20 +0100" MODIFIED_BY="Laila Asmal" NAME="Song 2008a" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 13:08:20 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Song C, Wang H, Sun X</AU>
<TI>A control study of quetiapine and clozapine in the treatment of schizophrenia of quality of life</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2008</YR>
<VL>18</VL>
<NO>2</NO>
<PG>133-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Song-2008b" MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" NAME="Song 2008b" YEAR="2008">
<REFERENCE MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Song G, Li Y</AU>
<TI>A control study of quetiapine and clozapine in the treatment of chronic schizophrenia</TI>
<SO>Medical Journal of Chinese People's Health</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>23</NO>
<PG>2790</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2006a" MODIFIED="2013-10-23 13:08:29 +0100" MODIFIED_BY="Laila Asmal" NAME="Sun 2006a" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 13:08:29 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun T, Liu H</AU>
<TI>A control study of quetiapine and clozapine in the treatment of children's first-episode schizophrenia</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2006</YR>
<VL>19</VL>
<NO>2</NO>
<PG>141-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2006e" MODIFIED="2013-10-23 13:08:41 +0100" MODIFIED_BY="Laila Asmal" NAME="Sun 2006e" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 13:08:41 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun X, Zou S, Li Z, Han Z</AU>
<TI>Effect of cognitive function in first-episode schizophrenia treated with quetiapine</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>2</NO>
<PG>94-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2007a" MODIFIED="2013-10-23 13:08:51 +0100" MODIFIED_BY="Laila Asmal" NAME="Sun 2007a" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 13:08:51 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun Q, Zeng D, Chen K</AU>
<TI>Clinical comparative study of ziprasidone in the treatment of schizophrenia</TI>
<SO>Journal of Psychiatry</SO>
<YR>2007</YR>
<VL>20</VL>
<NO>3</NO>
<PG>150-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2007b" MODIFIED="2013-10-23 13:08:59 +0100" MODIFIED_BY="Laila Asmal" NAME="Sun 2007b" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 13:08:59 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun M, Liang F, Meng Y</AU>
<TI>A control study on quetiapine in gerontic first-episode schizophrenia</TI>
<SO>Journal of Chinese Psychosomatic Disorders</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>5</NO>
<PG>407-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2007c" MODIFIED="2011-08-20 12:39:33 +0100" MODIFIED_BY="Laila Asmal" NAME="Sun 2007c" YEAR="2007">
<REFERENCE MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun L, Wang Y</AU>
<TI>A control study of quetiapine and clozapine in the treatment of schizophrenia</TI>
<SO>China Practical Medicine</SO>
<YR>2007</YR>
<VL>2</VL>
<NO>21</NO>
<PG>97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2008" MODIFIED="2013-10-23 13:09:11 +0100" MODIFIED_BY="Laila Asmal" NAME="Sun 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 13:09:11 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun H, Jiao Y, Li J</AU>
<TI>A comparative study of quetiapine and risperidone in the treatment of old men with schizophrenia</TI>
<SO>Medical Journal of Chinese People's Health</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>1</NO>
<PG>14-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swadi-2010" MODIFIED="2012-04-27 11:36:29 +0100" MODIFIED_BY="Laila Asmal" NAME="Swadi 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-04-27 11:36:29 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swadi HS, Craig BJ, Pirwani NZ, Black VC, Buchan JC, Bobier CM</AU>
<TI>A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2010</YR>
<VL>25</VL>
<NO>1</NO>
<PG>1-6</PG>
<IDENTIFIERS MODIFIED="2011-08-20 16:02:58 +0100" MODIFIED_BY="Laila Asmal"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swanson-2006" MODIFIED="2013-10-23 13:09:23 +0100" MODIFIED_BY="[Empty name]" NAME="Swanson 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 13:09:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Swanson JW, Swartz MS, Van Dorn RA</AU>
<TI>Effectiveness of atypical antipsychotics for substance abuse in schizophrenia patients</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 20-25, 2006</SO>
<IDENTIFIERS MODIFIED="2009-01-05 15:57:11 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tang-2003" MODIFIED="2009-01-05 15:57:18 +0000" MODIFIED_BY="[Empty name]" NAME="Tang 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-01-05 15:57:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tang Y</AU>
<TI>A controlled study of schizophrenia treated with quetiapine and clozapine</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>1</NO>
<PG>27-9</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:57:18 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tang-2005" MODIFIED="2009-02-05 16:51:35 +0000" MODIFIED_BY="[Empty name]" NAME="Tang 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-02-05 16:51:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tang Z-K, Xu C-M, Chen D</AU>
<TI>A comparative study of quetiapine and clozapine in the treatment of recurrent schizophrenia</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>3</NO>
<PG>167-8</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:57:24 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tao-2008" MODIFIED="2013-10-23 13:09:48 +0100" MODIFIED_BY="Laila Asmal" NAME="Tao 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 13:09:48 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tao S, Chen Q, Yang C, Pan R, Pan T, Li L, Zhou W</AU>
<TI>A comparison of the effects on lipid metabolic among four different atypical antipsychotic agents</TI>
<SO>Journal of Youjiang Medical College</SO>
<YR>2008</YR>
<NO>6</NO>
<PG>7-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tian-2006" MODIFIED="2013-10-23 13:09:55 +0100" MODIFIED_BY="Laila Asmal" NAME="Tian 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 13:09:55 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tian B, Li J, Jing H, Zhang W, Liu Y</AU>
<TI>A comparative study between seroquel and risperidone in the treatment of schizophrenia</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2006</YR>
<VL>19</VL>
<NO>1</NO>
<PG>25-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tian-2007" MODIFIED="2013-10-23 13:10:04 +0100" MODIFIED_BY="Laila Asmal" NAME="Tian 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 13:10:04 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tian C, Li Z</AU>
<TI>Control studies on the curative effect and influence of quetiapine and clozapine on quality of life of schizophrenics</TI>
<SO>J Clin Psychosom Disease</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>2</NO>
<PG>133-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tian-2008" MODIFIED="2013-10-23 13:10:19 +0100" MODIFIED_BY="Laila Asmal" NAME="Tian 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 13:10:19 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tian H, Zhu Q</AU>
<TI>A comparative study of new antipsychopathic drugs lead to gain weight</TI>
<SO>Medical Journal of Chinese People's Health</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>18</NO>
<PG>2119-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2000" MODIFIED="2009-01-05 15:57:37 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-01-05 15:57:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang M, Liu M, Lu L</AU>
<TI>A controlled study on seroquel and risperidone in the treatment of schizophrenic patients</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2000</YR>
<VL>10</VL>
<NO>4</NO>
<PG>200-1</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:57:37 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2004" MODIFIED="2013-10-23 13:10:49 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-10-23 13:10:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang X</AU>
<TI>Comparative study of effects of quetiapine and clozapine on quality of life of schizophrenics</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>3</NO>
<PG>167-8</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:58:16 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2004a" MODIFIED="2013-10-23 13:10:59 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2004a" YEAR="2004">
<REFERENCE MODIFIED="2013-10-23 13:10:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang M, Han F, Ma H</AU>
<TI>Comparation of quetiapine and clozapine in treatment of patients with first-onset schizophrenia</TI>
<SO>Chinese Journal of Clinical Pharmacology and Therapeutics</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>5</NO>
<PG>551-4</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:57:57 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2005" MODIFIED="2009-02-05 16:51:54 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-02-05 16:51:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang C-H, Li Y, Liu X</AU>
<TI>Cognitive function and p300 potentials in first-episode schizophrenia treated with quetiapine and risperidone</TI>
<SO>Chinese Mental Health Journal</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>5</NO>
<PG>333-6</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:57:42 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2005a" MODIFIED="2009-01-12 12:10:01 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2005a" YEAR="2005">
<REFERENCE MODIFIED="2009-01-05 16:06:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang C-H, Li Y, Wang L-H, Pan M, ZHao Z, Mu J-L</AU>
<TI>Comparison of cognitive function and event related potentials in first episode schizophrenic treated with antipsychotic drugs</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>3</NO>
<PG>168-70</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:57:48 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2005b" MODIFIED="2009-01-12 12:10:28 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2005b" YEAR="2005">
<REFERENCE MODIFIED="2009-01-05 15:58:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang X, Yang J, Guo H</AU>
<TI>Clinical study of quetiapine and risperidone in the treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>2</NO>
<PG>118-9</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:58:08 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2005c" MODIFIED="2013-10-23 13:11:16 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2005c" YEAR="2005">
<REFERENCE MODIFIED="2013-10-23 13:11:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang X-F, Wang W-H, Wang J-C</AU>
<TI>Analysis of quetiapine in treatment of first-episode schizophrenia</TI>
<SO>Sichuan Mental Health</SO>
<YR>2005</YR>
<VL>18</VL>
<PG>235-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2005d" MODIFIED="2009-01-12 12:11:56 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2005d" YEAR="2005">
<REFERENCE MODIFIED="2009-01-05 16:11:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang Y, Sun M, Shao X</AU>
<TI>A comparative study between quetiapine and clozapine in the treatment of schizophrenia</TI>
<SO>Heath Psychology Journal</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>4</NO>
<PG>271-2</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:58:24 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2006a" MODIFIED="2013-10-23 13:11:25 +0100" MODIFIED_BY="Laila Asmal" NAME="Wang 2006a" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 13:11:25 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang D, Wang X</AU>
<TI>Comparative study of guetiapine and risperidone in the treatment of schizophrenia</TI>
<SO>Modern Medicine Health</SO>
<YR>2006</YR>
<VL>22</VL>
<NO>6</NO>
<PG>815-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2006b" MODIFIED="2013-10-23 13:11:39 +0100" MODIFIED_BY="Laila Asmal" NAME="Wang 2006b" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 13:11:39 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang J, Ran R</AU>
<TI>Effects of quetiapine vs clozapine on the quality of life in first-episode schizophrenics</TI>
<SO>Journal of Clinical Psychosomatic Disorders</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>6</NO>
<PG>416-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2007" MODIFIED="2013-10-23 13:11:47 +0100" MODIFIED_BY="Laila Asmal" NAME="Wang 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 13:11:47 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang C, Xu X, Huo X</AU>
<TI>A study of quetiapine and risperidone in treatment of chronic schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2007</YR>
<VL>17</VL>
<NO>4</NO>
<PG>165-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2007a" MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" NAME="Wang 2007a" YEAR="2007">
<REFERENCE MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang H, Sun D, Zhang Z, Gao C</AU>
<TI>A control study of quetiapine and risperidone in the treatment of children's schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2007</YR>
<VL>17</VL>
<NO>3</NO>
<PG>199-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2007b" MODIFIED="2013-10-23 13:12:02 +0100" MODIFIED_BY="Laila Asmal" NAME="Wang 2007b" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 13:12:02 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang Y, Chen T</AU>
<TI>Non-classical antipsychotic drugs for schizophrenia :cost minimization analysis on 3 schemes</TI>
<SO>China Pharmacy</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>32</NO>
<PG>2487-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2008" MODIFIED="2013-10-23 13:12:14 +0100" MODIFIED_BY="Laila Asmal" NAME="Wang 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 13:12:14 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang J, Wu H</AU>
<TI>A comparative study of social function in schizophrenia patients treated with seroquel or clozapine</TI>
<SO>Medical Journal of Chinese People's Health</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>11</NO>
<PG>1137-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2008a" MODIFIED="2013-10-23 13:12:25 +0100" MODIFIED_BY="Laila Asmal" NAME="Wang 2008a" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 13:12:25 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang X, Song C</AU>
<TI>Comparative study of efficacy and safety of quetiapine and risperidone in the treatment of elderly schizophrenia</TI>
<SO>China Journal of Health Psychology</SO>
<YR>2008</YR>
<VL>16</VL>
<NO>12</NO>
<PG>1394-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2008b" MODIFIED="2013-10-23 13:12:33 +0100" MODIFIED_BY="Laila Asmal" NAME="Wang 2008b" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 13:12:33 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang Y, Li G, Li T</AU>
<TI>Comparison on the efficacy of quetiapine and risperidone in the treatment of the depressive symptom of schizophrenia</TI>
<SO>Tianjin Pharmacy</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>2</NO>
<PG>33-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2008c" MODIFIED="2013-10-23 13:12:48 +0100" MODIFIED_BY="Laila Asmal" NAME="Wang 2008c" YEAR="2008">
<REFERENCE MODIFIED="2013-10-23 13:12:48 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang Y, Wang J</AU>
<TI>Effects of quetiapine on cognitive function in schizophrenia patients</TI>
<SO>China Practical Medicine</SO>
<YR>2008</YR>
<VL>3</VL>
<NO>18</NO>
<PG>61-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wei-2006" MODIFIED="2013-10-23 13:12:54 +0100" MODIFIED_BY="Laila Asmal" NAME="Wei 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 13:12:54 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wei S</AU>
<TI>A randomized, double blind double dummy parallel controlled study in the female first-onset schizophrenia treated with aripiprazole and quetiapine</TI>
<SO>Nervous Diseases and Mental Health</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>3</NO>
<PG>194-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wei-2006c" MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" NAME="Wei 2006c" YEAR="2006">
<REFERENCE MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wei S</AU>
<TI>A control study of quetiapine and clozapine in the treatment of eldly schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>1</NO>
<PG>43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weickert-2003" MODIFIED="2009-01-05 15:58:31 +0000" MODIFIED_BY="[Empty name]" NAME="Weickert 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-01-05 15:58:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weickert TW, Goldberg TE, Marenco S, Bigelow LB, Egan MF, Weinberger DR</AU>
<TI>Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds</TI>
<SO>Neuropyschopharmacology</SO>
<YR>2003</YR>
<VL>28</VL>
<NO>8</NO>
<PG>1491-500</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2009-01-05 15:58:31 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wen-2005" MODIFIED="2013-10-23 13:13:06 +0100" MODIFIED_BY="Laila Asmal" NAME="Wen 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-10-23 13:13:06 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wen S, Chen F</AU>
<TI>A control study of quetiapine and risperidone in the treatment of schizophrenia</TI>
<SO>Modern Medicine Health</SO>
<YR>2005</YR>
<VL>21</VL>
<NO>22</NO>
<PG>3089-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2005" MODIFIED="2013-10-23 13:13:14 +0100" MODIFIED_BY="Laila Asmal" NAME="Wu 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-10-23 13:13:14 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu Y, Wang X</AU>
<TI>A control study of quetiapine and risperidone in the treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>2</NO>
<PG>106-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xiang-2005" MODIFIED="2013-10-23 13:13:28 +0100" MODIFIED_BY="[Empty name]" NAME="Xiang 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-10-23 13:13:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xiang DF, Liu XL</AU>
<TI>Treatment of 31 cases of schizophrenia with quetiapine</TI>
<SO>Herald of Medicine</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>1</NO>
<PG>40-2</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:58:41 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2002" MODIFIED="2013-10-23 13:13:46 +0100" MODIFIED_BY="[Empty name]" NAME="Xu 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-10-23 13:13:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu MQ, Peng MY</AU>
<TI>A study of Quetiapine in treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychology Medicine</SO>
<YR>2002</YR>
<VL>12</VL>
<PG>227-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2003" MODIFIED="2009-11-03 20:44:47 +0000" MODIFIED_BY="[Empty name]" NAME="Xu 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-11-03 20:44:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu LZ, Ouyang JL, Gao SZ</AU>
<TI>Effects of domestic quetiapine vs clozapine in treatment of schizophrenia</TI>
<SO>Chinese Journal of New Drugs and Clinical Remedies</SO>
<YR>2003</YR>
<VL>7477</VL>
<NO>9</NO>
<PG>542-5</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:58:48 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2005" MODIFIED="2013-10-23 13:14:02 +0100" MODIFIED_BY="[Empty name]" NAME="Xu 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-10-23 13:14:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu XF, Zhang XB, Zhou CY, Dai XG</AU>
<TI>Comparison of efficacy and safety of seroquel and risperidone in the treatment of schizophrenia</TI>
<SO>Journal of Jiangsu Clinical Medicine</SO>
<YR>2005</YR>
<VL>9</VL>
<NO>1</NO>
<PG>20-2</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:58:54 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2006" MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" NAME="Xu 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu B</AU>
<TI>Comparative observation on the efect of quetiapine fumarate on chronic schizoprenia patients</TI>
<SO>China Tropical Medicine</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>6</NO>
<PG>1032</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamashita-2005" MODIFIED="2009-01-05 15:59:13 +0000" MODIFIED_BY="[Empty name]" NAME="Yamashita 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-05 15:59:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamashita H, Mori K, Nagao M, Okamoto Y, Morinobu S, Yamawaki S</AU>
<TI>Influence of aging on the improvement of subjective sleep quality by atypical antipsychotic drugs in patients with schizophrenia: comparison of middle-aged and older adults</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>5</NO>
<PG>377-84</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2009-01-05 15:59:13 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2004" MODIFIED="2013-10-23 13:14:20 +0100" MODIFIED_BY="[Empty name]" NAME="Yang 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-10-23 13:14:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang FS, Yang YL, Zhang ZH</AU>
<TI>Control study on quetiapine and clozapine in treatment of refractory schizophrenia</TI>
<SO>Medical Journal of Chinese People Health</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>1</NO>
<PG>12-3</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:59:24 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2005" MODIFIED="2009-01-05 16:12:14 +0000" MODIFIED_BY="[Empty name]" NAME="Yang 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-05 16:12:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang Q-P, Huang Y-P, Yang B-X</AU>
<TI>The effect of quetiapine and risperidone on the EEG of first-episode schizophrenic patients</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>3</NO>
<PG>159-60</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:59:18 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2005a" MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" NAME="Yang 2005a" YEAR="2005">
<REFERENCE MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang Q-P, Huang Y-P, Yang B-X</AU>
<TI>The effect of quetiapine and risperidone on the EEG of first-episode schizophrenic patients</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>3</NO>
<PG>159-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2006" MODIFIED="2013-10-23 13:14:32 +0100" MODIFIED_BY="Laila Asmal" NAME="Yang 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 13:14:32 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang Y</AU>
<TI>Control study of quetiapine and clozapine in the treatment of refractory schizophrenia</TI>
<SO>Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease</SO>
<YR>2006</YR>
<VL>14</VL>
<NO>4</NO>
<PG>276-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2006a" MODIFIED="2013-10-23 13:14:40 +0100" MODIFIED_BY="Laila Asmal" NAME="Yang 2006a" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 13:14:40 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang M, Mu X, Zhao A</AU>
<TI>A clinical study of quetiapine associated with clonazepam in the treatment of schizophrenia</TI>
<SO>Journal of Qiqihar Medical College</SO>
<YR>2006</YR>
<VL>27</VL>
<NO>9</NO>
<PG>1034-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2006b" MODIFIED="2013-10-23 13:14:47 +0100" MODIFIED_BY="Laila Asmal" NAME="Yang 2006b" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 13:14:47 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang C, Guo P, Guo H</AU>
<TI>Control study on using quetiapine to treat schizophrenic patients</TI>
<SO>China Practical Medicine</SO>
<YR>2006</YR>
<VL>1</VL>
<NO>1</NO>
<PG>24-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2007" MODIFIED="2013-10-23 13:14:54 +0100" MODIFIED_BY="Laila Asmal" NAME="Yang 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 13:14:54 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang K</AU>
<TI>Comparative study between the effect of risperidone and quetiapine in first-episode schizophrenia</TI>
<SO>Medical Journal of Chinese People's Health</SO>
<YR>2007</YR>
<VL>19</VL>
<NO>3</NO>
<PG>203-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2007a" MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" NAME="Yang 2007a" YEAR="2007">
<REFERENCE MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang X, Wang Z, Lv Y, Shi Y</AU>
<TI>Comparative study of curative effects and influence on cognitive function of quetiapine and clozapine in schizophrenia</TI>
<SO>Journal of Clinical Psychosomatic Disorders</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>1</NO>
<PG>29-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-2003" MODIFIED="2013-10-23 13:15:05 +0100" MODIFIED_BY="[Empty name]" NAME="Yu 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-10-23 13:15:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu G, Liang S, He Z-G</AU>
<TI>Comparison of quetiapine and clozapine in treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychiatry Medicine</SO>
<YR>2003</YR>
<VL>25</VL>
<PG>4-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-2005" MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" NAME="Yu 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu H, Kong H</AU>
<TI>A control study of quetiapine and risperidone in the treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>6</NO>
<PG>362</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-2006" MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" NAME="Yu 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu W, Liu H, Pan S</AU>
<TI>A control study of quetiapine and loxapine in the treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>5</NO>
<PG>298</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yuan-2005" MODIFIED="2009-02-05 16:52:48 +0000" MODIFIED_BY="[Empty name]" NAME="Yuan 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-02-05 16:52:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yuan F-J, Gao M-Z, Liu X</AU>
<TI>A contrast observation of quetiapine and clozapine in affecting electroencephalogram</TI>
<SO>Journal of Practical Medical Techniques</SO>
<YR>2005</YR>
<VL>12</VL>
<NO>2B</NO>
<PG>482-4</PG>
<IDENTIFIERS MODIFIED="2009-01-05 15:59:37 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zeng-2006" MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" NAME="Zeng 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zeng J</AU>
<TI>A control study of quetiapine and aripiprazole in the treatment of children's schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>6</NO>
<PG>367</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2003" MODIFIED="2009-01-05 16:18:01 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-01-05 16:18:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang L, Wu Y, Guo C</AU>
<TI>A comparative study between quetiapine and risperidone in the treatment of schizophrenia</TI>
<SO>Health Psychology Journal</SO>
<YR>2003</YR>
<VL>11</VL>
<NO>4</NO>
<PG>262-3</PG>
<IDENTIFIERS MODIFIED="2009-01-05 16:18:01 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2005" MODIFIED="2009-02-05 16:52:57 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-02-05 16:52:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang M, Zhang H-F, Gu W</AU>
<TI>A comparative study of quetiapine and clozapine in the treatment of schizophrenia</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>2</NO>
<PG>86-8</PG>
<IDENTIFIERS MODIFIED="2009-01-05 16:00:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2005a" MODIFIED="2009-11-03 20:46:27 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 2005a" YEAR="2005">
<REFERENCE MODIFIED="2009-11-03 20:46:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang H, Zhang M, Gu W</AU>
<TI>A comparative study of social function in schizophrenia patients treated with seroquel (quetiapine) or clozapine</TI>
<SO>Sichuan Mental Health</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>2</NO>
<PG>91-3</PG>
<IDENTIFIERS MODIFIED="2009-01-05 16:00:10 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2005b" MODIFIED="2009-01-12 12:14:17 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 2005b" YEAR="2005">
<REFERENCE MODIFIED="2009-01-05 16:18:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang R-X, Cao Y-F</AU>
<TI>A comparative study of EKG changed by quetiapine and clozapine in the treatment of schizophrenia</TI>
<SO>Medical Journal of Chinese People Health</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>6</NO>
<PG>290-1</PG>
<IDENTIFIERS MODIFIED="2009-01-05 16:00:26 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2005c" MODIFIED="2009-11-03 20:47:18 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 2005c" YEAR="2005">
<REFERENCE MODIFIED="2009-11-03 20:47:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang Y, Jiang Y, Zhao S</AU>
<TI>A comparative study of quetiapine combined with clomipramine in treatment of schizophrenia with obsessive-compulsive symptoms</TI>
<SO>Chinese Journal of Health Psychology</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>4</NO>
<PG>260-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2005d" MODIFIED="2013-10-23 13:15:23 +0100" MODIFIED_BY="Laila Asmal" NAME="Zhang 2005d" YEAR="2005">
<REFERENCE MODIFIED="2013-10-23 13:15:23 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang W, Ma J, Ma L</AU>
<TI>A control study of quetiapine and risperidone in the treatment of first-episode schizophrenia</TI>
<SO>Chinese Journal of Current Traditional and Western Medicine</SO>
<YR>2005</YR>
<VL>3</VL>
<NO>12</NO>
<PG>1088-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2006" MODIFIED="2013-10-23 13:15:31 +0100" MODIFIED_BY="Laila Asmal" NAME="Zhang 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 13:15:31 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang w, Ma J, Xu F</AU>
<TI>Comparison study on treatment of primary schizophrenia with quetiapine and chlorpromazine</TI>
<SO>Heilongjiang Medical Journal</SO>
<YR>2006</YR>
<VL>30</VL>
<NO>2</NO>
<PG>81-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2006a" MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" NAME="Zhang 2006a" YEAR="2006">
<REFERENCE MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang Y, Zhou B</AU>
<TI>A control study of quetiapine and clozapine in the treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>5</NO>
<PG>300</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2007" MODIFIED="2013-10-23 13:15:42 +0100" MODIFIED_BY="Laila Asmal" NAME="Zhang 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 13:15:42 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang C</AU>
<TI>A control study of quetiapine and risperidone in the treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2007</YR>
<VL>17</VL>
<NO>3</NO>
<PG>197-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2007a" MODIFIED="2013-10-23 13:15:52 +0100" MODIFIED_BY="Laila Asmal" NAME="Zhang 2007a" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 13:15:52 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang L</AU>
<TI>A comparative study of quetiapine and chlorpromazine in the treatment of schizophrenia</TI>
<SO>Modern Medicine Journal of China</SO>
<YR>2007</YR>
<VL>9</VL>
<NO>2</NO>
<PG>97-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2009b" MODIFIED="2012-04-27 11:21:50 +0100" MODIFIED_BY="Laila Asmal" NAME="Zhang 2009b" YEAR="">
<REFERENCE MODIFIED="2012-04-27 11:21:50 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Zhang B</AU>
<TI>Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (SeroquelIR) in Controlling Agitation and AggressiveSymptoms in the Acute Treatment of Patients With Schizophrenia</TI>
<SO>WHO trial registration</SO>
<YR>2009</YR>
<VL>2</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2004" MODIFIED="2013-10-23 13:16:02 +0100" MODIFIED_BY="[Empty name]" NAME="Zhao 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-10-23 13:16:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao F, Zhang Z, Li H</AU>
<TI>Control studies of quetiapine and risperidone in the treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>1</NO>
<PG>25-6</PG>
<IDENTIFIERS MODIFIED="2009-01-05 16:00:34 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2005" MODIFIED="2009-02-05 14:00:16 +0000" MODIFIED_BY="[Empty name]" NAME="Zhao 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-02-05 14:00:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao L, Li Y, Qi F</AU>
<TI>Control study of quetiapine and risperidone in treatment of schizophrenics</TI>
<SO>Heath Psychology Journal</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>1</NO>
<PG>56, 79-80</PG>
<IDENTIFIERS MODIFIED="2009-01-05 16:00:42 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2005a" MODIFIED="2013-10-23 13:16:20 +0100" MODIFIED_BY="[Empty name]" NAME="Zhao 2005a" YEAR="2005">
<REFERENCE MODIFIED="2013-10-23 13:16:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao YH, Fang JH, Wang SH, An CG, Ma X, Li HX</AU>
<TI>A study of quetiapine and clozapine in treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychology Medicine</SO>
<YR>2005</YR>
<VL>15</VL>
<PG>231-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2007" MODIFIED="2013-10-23 13:16:26 +0100" MODIFIED_BY="Laila Asmal" NAME="Zhao 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 13:16:26 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao L, Gong GQ</AU>
<TI>A study of low-dos equetiapine with sulpiride in the treatment of schizophrenia</TI>
<SO>Journal of Clinical Research</SO>
<YR>2007</YR>
<VL>24</VL>
<NO>7</NO>
<PG>1181-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zheng-2007" MODIFIED="2013-10-23 13:16:38 +0100" MODIFIED_BY="Laila Asmal" NAME="Zheng 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 13:16:38 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zheng J, Wang B, Fu A, Li P</AU>
<TI>A control study of quetiapine and clozapine in the treatment of schizophrenia</TI>
<SO>Medical Recapitulate</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>23</NO>
<PG>1878-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhong-2006a" MODIFIED="2009-01-12 12:15:50 +0000" MODIFIED_BY="[Empty name]" NAME="Zhong 2006a" YEAR="2006">
<REFERENCE MODIFIED="2009-01-05 16:00:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhong Z-Y, Tao J, Wang X-L, Wu X-L, Zhang J-B</AU>
<TI>Effect of antipsychotic plus buflomedil hydrochlorde in ameliorating the negative symptoms of patients with schizophrenia</TI>
<SO>Zhongguo Linchuang Kangfu</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>2</NO>
<PG>30-2</PG>
<CY>China</CY>
<IDENTIFIERS MODIFIED="2009-01-05 16:00:52 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2003" MODIFIED="2009-07-27 11:42:09 +0100" MODIFIED_BY="[Empty name]" NAME="Zhou 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-27 11:42:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou P, Gong F, Fan C</AU>
<TI>A control of treating chronic schizophrenia with seroquel or clozapine</TI>
<SO>Jiangxi Medical Journal</SO>
<YR>2003</YR>
<VL>38</VL>
<NO>6</NO>
<PG>395-6</PG>
<IDENTIFIERS MODIFIED="2009-01-05 16:00:58 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2003a" MODIFIED="2009-01-12 12:16:17 +0000" MODIFIED_BY="[Empty name]" NAME="Zhou 2003a" YEAR="2003">
<REFERENCE MODIFIED="2009-01-05 16:01:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou R, Dai X</AU>
<TI>A comparative study of quetiapine and clozapine in the treatment of patients with schizophrenia</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>4</NO>
<PG>215-7</PG>
<IDENTIFIERS MODIFIED="2009-01-05 16:01:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2006" MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" NAME="Zhou 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou M</AU>
<TI>A study of quetiapine with sulpiride in the treatment of chronic schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>6</NO>
<PG>368</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2007" MODIFIED="2013-10-23 13:16:49 +0100" MODIFIED_BY="Laila Asmal" NAME="Zhou 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-10-23 13:16:49 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou B, Zhang Y</AU>
<TI>A control study of quetiapine and risperidone in the treatment of schizophrenia</TI>
<SO>Journal of Baotou Medical College</SO>
<YR>2007</YR>
<VL>23</VL>
<NO>3</NO>
<PG>261-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2006" MODIFIED="2013-10-23 13:16:57 +0100" MODIFIED_BY="Laila Asmal" NAME="Zhu 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-10-23 13:16:57 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu Q, Zhang S</AU>
<TI>A control study of quetiapine and clozapine in the treatment of female schizophrenia</TI>
<SO>Herald of Medicine</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>8</NO>
<PG>792-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2008" MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" NAME="Zhu 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-08-20 10:13:49 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu M, Pan D, Lu S</AU>
<TI>A control study of quetiapine and aripiprozole in the treatment of schizophrenia</TI>
<SO>Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine</SO>
<YR>2008</YR>
<VL>8</VL>
<NO>1</NO>
<PG>9-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-10-23 13:17:07 +0100" MODIFIED_BY="Laila Asmal">
<STUDY DATA_SOURCE="PUB" ID="STD-Gafoor-2005" MODIFIED="2013-10-23 13:17:07 +0100" MODIFIED_BY="Laila Asmal" NAME="Gafoor 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-10-23 13:17:07 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gafoor R, Landau S, Craig TKH, Elanjithara T, Power P, McGuire P</AU>
<TI>Efficacy and adverse effects of quetiapine versus risperidone in first-episode schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2010</YR>
<VL>30</VL>
<PG>600-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-07-14 08:49:05 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gafoor R, Power P, Craig T, Kerwin R, McGuire P</AU>
<TI>A comparative study of quetiapine and risperidone in patients with first-episode psychosis</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>15(Suppl 3)</VL>
<PG>S509</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2012-04-27 11:32:29 +0100" MODIFIED_BY="Laila Asmal">
<STUDY DATA_SOURCE="PUB" ID="STD-Eli-Lilly-2004b" MODIFIED="2009-01-12 23:20:19 +0000" MODIFIED_BY="[Empty name]" NAME="Eli Lilly 2004b" YEAR="2004">
<REFERENCE MODIFIED="2009-01-12 23:20:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Eli Lilly and Company</AU>
<TI>Comparison of continuing olanzapine to switching to quetiapine in overweight or obese patients with schizophrenia and schizoaffective disorder</TI>
<SO>Eli Lilly and Company Clinical Trial Registry</SO>
<YR>2004</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="8894"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2009b" MODIFIED="2012-04-27 11:32:29 +0100" MODIFIED_BY="Laila Asmal" NAME="Li 2009b" YEAR="">
<REFERENCE MODIFIED="2012-04-27 11:32:29 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Li HF</AU>
<TI>A 6-Week, Multicenter, Rater-Blind, Randomized,Risperidone-Controlled Study to Evaluate the Efficacy and Safety of Seroquel (Quetiapine Fumarate) in the Treatment of Chinese Han Patients With Schizophrenia</TI>
<SO>WHO registration</SO>
<YR>2009</YR>
<VL>1</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ratna-2003" MODIFIED="2011-08-20 10:34:22 +0100" MODIFIED_BY="Laila Asmal" NAME="Ratna 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-08-20 10:34:22 +0100" MODIFIED_BY="Laila Asmal" PRIMARY="NO" TYPE="OTHER">
<AU>Ratna L</AU>
<TI>A multi-centre, double-blind, randomised study to compare the safety tolerability and efficacy of quetiapine and risperidone in the treatment of schizophrenia in subjects with inadequate symptom control improved Response In Schizophrenia - IRIS</TI>
<SO>National Research Register</SO>
<YR>2003</YR>
<VL>1</VL>
<IDENTIFIERS MODIFIED="2009-01-06 14:41:29 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reynolds-2001" MODIFIED="2009-01-06 14:41:40 +0000" MODIFIED_BY="[Empty name]" NAME="Reynolds 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-01-06 14:41:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Reynolds C</AU>
<TI>A six month, rater blind comparison of quetiapine and risperidone in the treatment of tardive dyskinesia in patients with schizophrenia</TI>
<SO>National Research Register</SO>
<YR>2001</YR>
<VL>3</VL>
<IDENTIFIERS MODIFIED="2009-01-06 14:41:40 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-10-23 13:21:21 +0100" MODIFIED_BY="Laila Asmal">
<ADDITIONAL_REFERENCES MODIFIED="2013-10-23 13:21:08 +0100" MODIFIED_BY="Laila Asmal">
<REFERENCE ID="REF-Allebeck-1986" MODIFIED="2013-10-23 13:17:23 +0100" MODIFIED_BY="Laila Asmal" NAME="Allebeck 1986" TYPE="JOURNAL_ARTICLE">
<AU>Allebeck P, Varla A, Wistedt B</AU>
<TI>Suicide and violent death among patients with schizophrenia</TI>
<SO>Acta Psychiatrica Scandinavia</SO>
<YR>1986</YR>
<VL>74</VL>
<NO>1</NO>
<PG>43-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1996" MODIFIED="2009-02-05 16:54:33 +0000" MODIFIED_BY="[Empty name]" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecing skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS MODIFIED="2009-02-05 16:54:33 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Andreasen-1984" MODIFIED="2009-10-29 15:20:08 +0000" MODIFIED_BY="[Empty name]" NAME="Andreasen 1984" TYPE="OTHER">
<AU>Andreasen NC</AU>
<TI>Scale for the assessment of positive symptoms (SAPS)</TI>
<SO>The University of Iowa</SO>
<YR>1984</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andreasen-1989" MODIFIED="2009-10-29 10:34:22 +0000" MODIFIED_BY="[Empty name]" NAME="Andreasen 1989" TYPE="JOURNAL_ARTICLE">
<AU>Andreasen NC</AU>
<TI>Scale for the assessment of negative symptoms (SANS)</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>7</VL>
<PG>53-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andreasen-1991" MODIFIED="2013-10-23 13:17:34 +0100" MODIFIED_BY="Laila Asmal" NAME="Andreasen 1991" TYPE="JOURNAL_ARTICLE">
<AU>Andreasen NC</AU>
<TI>Assessment issues and the cost of schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1991</YR>
<VL>17</VL>
<PG>408-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-2004" MODIFIED="2009-11-03 21:05:50 +0000" MODIFIED_BY="[Empty name]" NAME="APA 2004" TYPE="BOOK_SECTION">
<AU>American Psychiatric Association</AU>
<TI>Practice guidelines for the treatment of patients with schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2004</YR>
<PG>1-114</PG>
<EN>2nd</EN>
<PB>American Journal of Psychiatry</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arnt-1998" NAME="Arnt 1998" TYPE="JOURNAL_ARTICLE">
<AU>Arnt J, Skarsfeldt T</AU>
<TI>Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1998</YR>
<VL>18</VL>
<PG>63-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barnes-1989" MODIFIED="2008-11-03 16:03:46 +0000" MODIFIED_BY="[Empty name]" NAME="Barnes 1989" TYPE="JOURNAL_ARTICLE">
<AU>Barnes TR</AU>
<TI>A rating scale for drug induced akathisia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>154</VL>
<PG>672-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM, Kerry SM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" MODIFIED="2013-10-23 13:17:44 +0100" MODIFIED_BY="Dolores Matthews" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al</AU>
<TI>The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use</TI>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>405-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1984" MODIFIED="2009-02-05 16:55:01 +0000" MODIFIED_BY="[Empty name]" NAME="Carpenter 1984" TYPE="JOURNAL_ARTICLE">
<AU>Heinrichs DW, Hanlon ET, Carpenter WT Jr</AU>
<TI>The quality of life scale: an instrument for rating the schizophrenic deficit syndrom</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1984</YR>
<VL>10</VL>
<PG>388-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1994" NAME="Carpenter 1994" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT Jr, Buchanan RW</AU>
<TI>Schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<PG>681-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chouinard-1980" MODIFIED="2009-11-03 21:09:07 +0000" MODIFIED_BY="[Empty name]" NAME="Chouinard 1980" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Ross-Chouinard A, Annable L, Jones BD</AU>
<TI>The extrapyramidal symptom rating scale</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>1980</YR>
<VL>7</VL>
<PG>233</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" MODIFIED="2013-10-23 13:18:00 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection for meta-analyses of binary data</TI>
<SO>Proceedings of the 8th International Cochrane Colloquium, Cape Town, South Africa, October 25-28, 2000</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazer LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DSM-IV-1994" MODIFIED="2013-10-23 13:18:08 +0100" MODIFIED_BY="[Empty name]" NAME="DSM IV 1994" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders</SO>
<YR>1994</YR>
<EN>4th</EN>
<PB>APA</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duggan-2005" MODIFIED="2009-07-27 12:06:21 +0100" MODIFIED_BY="[Empty name]" NAME="Duggan 2005" TYPE="COCHRANE_REVIEW">
<AU>Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S</AU>
<TI>Olanzapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<PB>Wiley and Sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2009-07-27 12:06:21 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-07-27 12:06:21 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001359.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2009-07-24 14:25:58 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey-Smith G, Schneider M, Minder CSO</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>13</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-El_x002d_Sayeh-2006" MODIFIED="2012-04-27 11:31:43 +0100" MODIFIED_BY="[Empty name]" NAME="El-Sayeh 2006" TYPE="COCHRANE_REVIEW">
<AU>El-Sayeh HG, Morganti C</AU>
<TI>Aripiprazole for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<PB>Wiley and Sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2012-04-27 11:31:43 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-04-27 11:31:43 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004578.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2009-11-03 21:10:36 +0000" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS MODIFIED="2009-11-03 21:10:36 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Furukawa-2006" NAME="Furukawa 2006" TYPE="JOURNAL_ARTICLE">
<AU>Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N</AU>
<TI>Imputing missing standard deviations in meta-analyses can provide accurate results</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2006</YR>
<VL>59</VL>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gaebel-2006" NAME="Gaebel 2006" TYPE="OTHER">
<AU>Gaebel W, Falkai P, Weinmann S, Wobrock T</AU>
<TI>Treatment guidelines for schizophrenia</TI>
<TO>Behandlungsleitlinie Schizophrenie</TO>
<SO>Steinkopf</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldstein-1993" NAME="Goldstein 1993" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein JM, Litwin LC, Sutton EM, Malick JB</AU>
<TI>Seroquel: electrophysiological profile of a potential atypical antipsychotic</TI>
<SO>Psychopharmacology</SO>
<YR>1993</YR>
<VL>112</VL>
<PG>293-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldstein-1995" NAME="Goldstein 1995" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein JM</AU>
<TI>Preclinical tests that predict clozapine-like atypical antipsychotic actions</TI>
<SO>Critical issues in the treatment of schizophrenia. International Academy of biochemical Drug Research</SO>
<YR>1995</YR>
<VL>10</VL>
<PG>95-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC, Ukoumunne OC, Chinn S</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" MODIFIED="2013-10-23 13:18:35 +0100" MODIFIED_BY="[Empty name]" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy U</AU>
<SO>ECDEU Assessment Manual for Psychopharmacology</SO>
<YR>1976</YR>
<PB>National Institute of Mental Health</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heres-2006" MODIFIED="2009-02-09 18:34:44 +0000" MODIFIED_BY="[Empty name]" NAME="Heres 2006" TYPE="JOURNAL_ARTICLE">
<AU>Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S</AU>
<TI>Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<PG>185-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2013-10-23 13:18:54 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008] The Cochrane Collaboration, 2008</TI>
<SO>www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-10-23 13:19:00 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011</TI>
<SO>www.cochrane-handbook.org.</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hutton-2009" MODIFIED="2013-10-23 13:19:14 +0100" MODIFIED_BY="[Empty name]" NAME="Hutton 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hutton JL</AU>
<TI>Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials</TI>
<SO>British Journal of Haematology</SO>
<YR>2009</YR>
<VL>146</VL>
<NO>1</NO>
<PG>27-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-2006" MODIFIED="2013-10-23 13:19:27 +0100" MODIFIED_BY="[Empty name]" NAME="Jones 2006" TYPE="JOURNAL_ARTICLE">
<AU>Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al</AU>
<TI>Randomized controlled trial of the effect on quality of life</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2006</YR>
<VL>63</VL>
<PG>1079-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kane-1988" MODIFIED="2009-02-05 14:01:33 +0000" MODIFIED_BY="[Empty name]" NAME="Kane 1988" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM, Honigfeld G, Singer J, Meltzer H, Clozaril Collaborative Study Group</AU>
<TI>Clozapine for the treatment of treatment-resistant schizophrenia: a double-blind comparison with chlorpromazine</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1988</YR>
<VL>45</VL>
<PG>789-96</PG>
<IDENTIFIERS MODIFIED="2009-02-05 14:01:33 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Kane-1993" NAME="Kane 1993" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM</AU>
<TI>Treatment programme and long term outcome in chronic schizophrenia</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1993</YR>
<VL>46</VL>
<PG>585-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1986" MODIFIED="2013-10-23 13:20:26 +0100" MODIFIED_BY="Dolores Matthews" NAME="Kay 1986" TYPE="BOOK">
<AU>Kay SR, Opler LA, Fiszbein A</AU>
<SO>Positive and Negative Syndrome Scale (PANSS) Manual</SO>
<YR>1986</YR>
<PB>Multi-Health Systems</PB>
<CY>North Tonawanda (NY)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005" MODIFIED="2013-07-24 10:37:52 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>What does the PANSS mean?</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>79</VL>
<PG>231-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005a" MODIFIED="2013-07-24 10:38:00 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>Clinical implications of Brief Psychiatric Rating Scale Scores (BPRSS)</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>187</VL>
<PG>366-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liebermann-2005" MODIFIED="2009-02-09 18:00:18 +0000" MODIFIED_BY="[Empty name]" NAME="Liebermann 2005" TYPE="JOURNAL_ARTICLE">
<AU>Liebermann JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM</AU>
<TI>Effectiveness of antipsychotic drugs in patients with chronic schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<PG>1209-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marvaha-2004" MODIFIED="2009-07-14 12:09:46 +0100" MODIFIED_BY="[Empty name]" NAME="Marvaha 2004" TYPE="JOURNAL_ARTICLE">
<AU>Marvaha S, Johnson S</AU>
<TI>Schizophrenia and employment - a review</TI>
<SO>Social Psychiatry and Psychiatric Epidemiology</SO>
<YR>2004</YR>
<VL>39</VL>
<PG>337-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Migler-1993" NAME="Migler 1993" TYPE="JOURNAL_ARTICLE">
<AU>Migler BM, Warawa EJ, Malick JB</AU>
<TI>Seroquel: behavioral profile of a potential atypical antipsychotic</TI>
<SO>Psychopharmacology</SO>
<YR>1993</YR>
<VL>112</VL>
<PG>299-307</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" MODIFIED="2009-11-03 21:15:30 +0000" MODIFIED_BY="[Empty name]" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman D</AU>
<TI>The CONSORT statement: Revised recommendations for improving the quality of reports of parallel group randomized trials</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<PG>1987-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moller-2000" MODIFIED="2013-10-23 13:20:41 +0100" MODIFIED_BY="Laila Asmal" NAME="Moller 2000" TYPE="JOURNAL_ARTICLE">
<AU>Moller HJ</AU>
<TI>New assessment of atypical antipsychotics</TI>
<TO>Aktuelle Bewertung neuer/atypischer Neuroleptika</TO>
<SO>Nervenarzt</SO>
<YR>2000</YR>
<VL>71</VL>
<PG>329-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mueser-and-McGurk-2004" MODIFIED="2013-10-23 13:20:50 +0100" MODIFIED_BY="Laila Asmal" NAME="Mueser and McGurk 2004" TYPE="JOURNAL_ARTICLE">
<AU>Mueser KT, McGurk SR</AU>
<TI>Schizophrenia</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>363</VL>
<NO>9426</NO>
<PG>2063-72</PG>
<IDENTIFIERS MODIFIED="2010-10-05 14:31:45 +0100" MODIFIED_BY="Laila Asmal"/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rust-1989" MODIFIED="2009-07-24 14:25:58 +0100" MODIFIED_BY="[Empty name]" NAME="Rust 1989" TYPE="BOOK">
<AU>Rust J, Golombok S</AU>
<SO>Modern Psychometrics</SO>
<YR>1989</YR>
<PB>Routledge</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saller-1993" MODIFIED="2009-11-03 21:16:02 +0000" MODIFIED_BY="[Empty name]" NAME="Saller 1993" TYPE="JOURNAL_ARTICLE">
<AU>Saller CF, Salama AI</AU>
<TI>Seroquel: biochemical profile of a potential atypical antipsychotic</TI>
<SO>Psychopharmacology</SO>
<YR>1993</YR>
<VL>112</VL>
<PG>285-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2008" MODIFIED="2013-02-26 12:38:45 +0000" MODIFIED_BY="[Empty name]" NAME="Schünemann 2008" TYPE="BOOK_SECTION">
<AU>Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al</AU>
<TI>Chapter 12: Interpreting results and drawing conclusions</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<PG>359-83</PG>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1970" MODIFIED="2008-11-03 15:12:33 +0000" MODIFIED_BY="[Empty name]" NAME="Simpson 1970" TYPE="JOURNAL_ARTICLE">
<AU>Simpson EN, Angus JWF</AU>
<TI>A rating scale for extrapyramidal side-effects</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1970</YR>
<VL>212</VL>
<PG>11-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Srisurasapont-2004" MODIFIED="2013-07-25 17:41:14 +0100" MODIFIED_BY="[Empty name]" NAME="Srisurasapont 2004" TYPE="COCHRANE_REVIEW">
<AU>Srisurapanont M, Maneeton B, Maneeton N</AU>
<TI>Quetiapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-07-25 17:41:14 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-25 17:41:14 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="CD000967"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thorpe-2009" MODIFIED="2013-10-23 13:21:02 +0100" MODIFIED_BY="[Empty name]" NAME="Thorpe 2009" TYPE="JOURNAL_ARTICLE">
<AU>Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, et al</AU>
<TI>A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2009</YR>
<VL>62</VL>
<NO>5</NO>
<PG>464-75</PG>
<IDENTIFIERS MODIFIED="2013-06-25 10:53:13 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="19348971"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" MODIFIED="2009-02-05 14:03:38 +0000" MODIFIED_BY="[Empty name]" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>3-92</PG>
<IDENTIFIERS MODIFIED="2009-02-05 14:03:38 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Xia-2007" MODIFIED="2013-10-23 13:21:08 +0100" MODIFIED_BY="[Empty name]" NAME="Xia 2007" TYPE="CONFERENCE_PROC">
<AU>Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H</AU>
<TI>The Leeds Outcomes Stakeholders Survey (LOSS) study</TI>
<SO>Proceedings of the 15th Cochrane Colloquium, Sao Paulo, October 23-27, 2007</SO>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-10-23 13:21:21 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Komossa-2009" MODIFIED="2013-07-25 17:36:01 +0100" MODIFIED_BY="[Empty name]" NAME="Komossa 2009" TYPE="COCHRANE_REVIEW">
<AU>Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, Srisurapanont M, Kissling W, Leucht S</AU>
<TI>Quetiapine versus other atypical antipsychotics for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-07-25 17:36:01 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-07-25 17:36:01 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="DOI:10.1002/14651858.CD006625.pub2."/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2008" MODIFIED="2013-10-23 13:21:21 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2008" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al</AU>
<TI>A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2009</YR>
<VL>166</VL>
<PG>152-63</PG>
<IDENTIFIERS MODIFIED="2009-11-03 21:20:01 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-11-03 21:20:01 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1176/appi.ajp.2008.08030368"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Srisurapanont-2004" MODIFIED="2013-06-25 10:08:17 +0100" MODIFIED_BY="[Empty name]" NAME="Srisurapanont 2004" TYPE="COCHRANE_REVIEW">
<AU>Srisurapanont M, Maneeton B, Maneeton N</AU>
<TI>Quetiapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>Issue 2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD000967.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-11-04 17:23:47 +0000" MODIFIED_BY="Laila Asmal">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-11-04 17:22:46 +0000" MODIFIED_BY="Laila Asmal" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-10-23 11:41:58 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Astrazeneca-1998">
<CHAR_METHODS MODIFIED="2013-10-23 08:54:37 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: random.</P>
<P>Blindness: double-blind.</P>
<P>Duration: 10 weeks.</P>
<P>Design: parallel.</P>
<P>Location: multi-centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:41:58 +0100" MODIFIED_BY="Laila Asmal">
<P>Diagnosis: schizophrenia <I>(DSM IV).</I>
</P>
<P>N = 408.</P>
<P>Gender: quetiapine: 129 M, 71 F. risperidone: 127 M, 80 F.</P>
<P>Age: 18 - 65 years, quetiapine 35 years, risperidone 37 years.</P>
<P>History:  duration ill not reported, age at onset not reported.</P>
<P>Setting: not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 08:56:59 +0100" MODIFIED_BY="Laila Asmal">
<P>1. Quetiapine: flexible dose 300mg/day up to week 4, then increased to 600mg if poor response. Mean dose not reported. N = 200.</P>
<P>2. Risperidone: flexible dose 6mg/day up to week 4, then increased to 10mg/day if poor response. Mean dose not reported. N = 208.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-16 14:36:59 +0100" MODIFIED_BY="Laila Asmal">
<P>Mental state: PANSS total score.<BR/>Leaving the study early: any reason, inefficacy.<BR/>Adverse effects: total numbers.</P>
<P>Data not available:</P>
<P>Global state: Global State: CGI.</P>
<P>Mental State: PANSS general subscore, positive subscore, negative subscore, BPRS total score, BPRS positive subscore, BPRS negative subscore.</P>
<P>Adverse effects: Barnes Global Akathisia scale, Simpson Scale and Abnormal Involuntary Movement Scale (AIMS). Prolactin increase, white cell count.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 14:36:40 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:42:39 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Atmaca-2003">
<CHAR_METHODS MODIFIED="2013-10-23 09:34:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: single, rater-blinded.<BR/>Duration: 6 weeks.<BR/>Design: parallel.<BR/>Location: single centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:42:39 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia <I>(DSM IV)</I>.<BR/>N = 56.<BR/>Gender: 24 M, 29 F.<BR/>Age: 19 - 46 years (mean clozapine 31.3 years, mean olanzapine 29.6 years, mean quetiapine 30.1 years, mean risperidone 27.9 years, mean control group 32.1 years).<BR/>History: duration ill: mean clozapine 6.6 years, mean olanzapine 6.3 years, mean quetiapine 5.9 years, mean risperidone 5.6. Age at onset not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 09:28:40 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: not reported. Mean dose: 207.1 mg/day. N = 14.</P>
<P>2. Olanzapine: flexible dose. Allowed dose range: not reported. Mean dose: 15.7 mg/day. N = 14.</P>
<P>3. Quetiapine: flexible dose. Allowed dose range: not reported. Mean dose: 535.7 mg/day. N = 14.</P>
<P>4. Risperidone: flexible dose. Allowed dose range: not reported. Mean dose: 6.7 mg/day. N = 14.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-16 14:37:43 +0100" MODIFIED_BY="Laila Asmal">
<P>Leaving the study early: any reason.<BR/>Mental state: PANSS total score.<BR/>Adverse effects: EPS (use of antiparkinson medication), weight gain (BMI), laboratory (serum leptin, triglyceride levels).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 14:37:43 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:42:55 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Byerly-2008">
<CHAR_METHODS MODIFIED="2013-10-16 14:38:52 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: random, no further details.<BR/>Blindness: double.<BR/>Duration: 6 weeks.<BR/>Design: parallel.<BR/>Location: multi-centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:42:55 +0100" MODIFIED_BY="Laila Asmal">
<P>Diagnosis: schizophrenia (<I>DSM IV</I> ), (N = 28) or schizoaffective disorder (N = 14), moderate sexual dysfunction (ASEX score 15 or more), on risperidone 4mg or less as only antipsychotic treatment.</P>
<P>N = 42.</P>
<P>Gender: 22 M, 20 F.</P>
<P>Age:18 years or older (mean risperidone 41.2 years, mean quetiapine 43.5 years).</P>
<P>History: duration ill not reported, age at onset not reported.</P>
<P>Setting: outpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 09:28:45 +0100" MODIFIED_BY="Laila Asmal">
<P>1. Quetiapine: flexible dose.  Allowed dose range up to 800mg/day. N = 20.</P>
<P>2. Risperidone: flexible dose. Maintained on pre-trial dose of 4mg or less. N = 22.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-16 14:38:53 +0100" MODIFIED_BY="Laila Asmal">
<P>Mental State: PANSS total score.</P>
<P>Adverse events: prolactin, sexual dysfunction.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 14:38:53 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:43:07 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Canuso-2008">
<CHAR_METHODS MODIFIED="2013-10-23 09:44:24 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.</P>
<P>Blindness: double-blinded.</P>
<P>Duration: 2 weeks.</P>
<P>Design: parallel.</P>
<P>Location: multisite, in-patient,</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:43:07 +0100" MODIFIED_BY="Laila Asmal">
<P>Diagnosis: schizophrenia <I>(DSM-IV)</I> , acute exacerbation.<BR/>N = 399 (placebo arm not included in review).<BR/>Gender: quetiapine 105 M 52 F, paliperidone 107 M 50 F.<BR/>Age: mean quetiapine 36.9 years, mean paliperidone 35.7 years.<BR/>History: duration ill not reported. Age at onset: quetiapine 25.2, paliperidone 23.2.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 11:23:15 +0100" MODIFIED_BY="Laila Asmal">
<P>1. Quetiapine: flexible dose, mean dose 690.9. N = 159.</P>
<P>2. Paliperidone: flexible dose, mean dose 10.4. N = 160.</P>
<P>3. Placebo N = 80.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-23 09:52:28 +0100" MODIFIED_BY="Laila Asmal">
<P>Mental state: PANSS total score, PANSS positive subscore, PANSS negative subscore.</P>
<P>Adverse effects: weight gain, gastrointestinal disorders, insomnia, sedation, headache, Simpson-Angus Rating Scale, the Barnes Rating Scale for Drug-Induced Akathisia, and the Abnormal Involuntary Movement Scale.<BR/>Data not available:<BR/>Treatment satisfaction: Medication satisfaction questionnaire.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 14:40:11 +0100" MODIFIED_BY="Laila Asmal"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-04 17:22:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Conley-2005">
<CHAR_METHODS MODIFIED="2013-10-16 14:41:27 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 12 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-04 17:22:07 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia <I>(DSM-IV)</I>, treatment resistance, persistent positive psychotic symptoms, BPRS total score of 35 or more plus CGI score of 4 or more.<BR/>N = 38.<BR/>Gender: 30 M, 8 F.<BR/>Age: 18 - 65 years (mean fluphenazine 44.2 years, mean quetiapine = 43.7 years, mean risperidone 46.3 years).<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 09:34:58 +0100" MODIFIED_BY="[Empty name]">
<P>1. Fluphenazine: flexible dose. Allowed dose range: 10 - 15 mg/day. Mean dose: 13.2 mg/day. N = 13.</P>
<P>2. Quetiapine: flexible dose. Allowed dose range: 300 - 500 mg/day, Mean dose: 463.6 mg/day. N = 12.</P>
<P>3. Risperidone: flexible dose. Allowed dose range: 3 - 5 mg/day. Mean dose: 4.31 mg/day. N = 13.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-23 09:35:00 +0100" MODIFIED_BY="[Empty name]">
<P>Global State: CGI.</P>
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental State: BPRS total score, BPRS positive subscore, BPRS negative subscore.<BR/>Cognitive functioning: Neuropsychological testing.<BR/>Quality of life: QLS.<BR/>Adverse effects: open interviews, EPS (use of antiparkinson medication, SAS), prolactin increase, sexual dysfunction, sedation, weight gain, laboratory (thyroidal hormones).</P>
<P>Unable to use -<BR/>Prolactin increase: no useable data.<BR/>Sexual dysfunction: no useable data.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 14:41:28 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:37:11 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Deberdt-2008">
<CHAR_METHODS MODIFIED="2013-10-16 14:41:58 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.</P>
<P>Blindness: double-blind.</P>
<P>Duration: 24 weeks.</P>
<P>Design: parallel.</P>
<P>Location: multi-site.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:37:11 +0100" MODIFIED_BY="Laila Asmal">
<P>Diagnosis: schizophrenia <I>(DSM-IV) </I>or schizoaffective (DSM IV).</P>
<P>N = 133.</P>
<P>Gender: not reported.</P>
<P>Age: 18 - 75 years, quetiapine mean 42.5 years, olanzapine mean 45.4 years.</P>
<P>History: duration ill not reported, age at onset not reported.</P>
<P>Setting: not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 09:35:14 +0100" MODIFIED_BY="Laila Asmal">
<P>1. Quetiapine: flexible dose between 300 - 800 mg/day, mean modal<B> </B>dose: 439.7 mg/day. N = 65.</P>
<P>2. Olanzapine: flexible dose between 7.5 - 20mg/day, mean modal<B> </B>dose: 16.9 mg/day. N = 68.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-23 09:35:25 +0100" MODIFIED_BY="Laila Asmal">
<P>Leaving the study early.<BR/>Relapse.<BR/>Service use: number of patients re-hospitalised.<BR/>Adverse effects: laboratory (prolactin, lipids, glucose), weight gain.</P>
<P>Unable to use -<BR/>Global state: CGI (no usable data).<BR/>Mental state: PANSS score (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 14:41:58 +0100" MODIFIED_BY="Laila Asmal"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:43:45 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Eerdekens-2007">
<CHAR_METHODS MODIFIED="2013-10-16 14:42:48 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 12 days.<BR/>Design: parallel.<BR/>Location: multi-site.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:43:45 +0100" MODIFIED_BY="Laila Asmal">
<P>Diagnosis: schizophrenia <I>(DSM IV)</I> or schizoaffective (DSM IV), normal ECG.</P>
<P>N = 110*.</P>
<P>Gender: 67 M, 20 F.</P>
<P>Age: quetiapine mean 35 years, paliperidone mean 37 years</P>
<P>History:duration ill not reported. Age at onset: quetiapine 24 years, paliperidone 23 years.</P>
<P>Setting: not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 10:39:23 +0100" MODIFIED_BY="Laila Asmal">
<P>1. Quetiapine: fixed dose of 400mg bd from Day 5 after initial titration. N = 43.</P>
<P>2. Paliperidone: fixed dose of 12mg/d D2 - 6, 15mg/d on D7 and 18mg/d D8 - 11. N = 44.</P>
<P>3. Placebo: N = 22.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-16 14:44:59 +0100" MODIFIED_BY="Laila Asmal">
<P>Leaving study early</P>
<P>Adverse effect: various side effects, QTc interval</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 14:42:31 +0100" MODIFIED_BY="Laila Asmal">
<P> * Assigned 2:2:1 to quetiapine, paliperidone and placebo. Placebo arm not included in review. One participant discontinued prior to double-blind treatment.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:31:47 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Hatta-2009">
<CHAR_METHODS MODIFIED="2013-10-16 14:45:28 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: random, no further details.<BR/>Blindness: single, rater-blinded.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: multi-centre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:31:47 +0100" MODIFIED_BY="Laila Asmal">
<P>Diagnosis: schizophrenia <I>(ICD-10) </I>and schizoaffective disorder.<BR/>N = 80.<BR/>Gender: 33 M, 47 F.<BR/>Age: mean age olanzapine 39.8 years, mean risperidone 41.1 years, mean aripiprazole 42.1 years, mean quetiapine 39.8 years.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: in-patient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 10:49:18 +0100" MODIFIED_BY="Laila Asmal">
<P>1. Risperidone: flexible dose. Initial dose 3mg/day. Allowed dose range: 3 - 12mg/day. Mean dose: 7.2mg/day. N = 20.</P>
<P>2. Olanzapine: flexible dose. Initial dose 10mg/day. Allowed dose range: 10 - 20mg/day. Mean dose: 17.4mg/day. N = 17.</P>
<P>4. Aripiprazole: Flexible dose. Inital dose 12mg/day. Allowed dose range: 12 - 30mg/day. Mean 23.6mg/day.N = 21.</P>
<P>2. Quetiapine: flexible dose. Initial dose 300mg/day. Allowed dose range: 300 - 750mg/day. Mean dose: 570.mg/day. N = 20.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-23 10:43:59 +0100" MODIFIED_BY="Laila Asmal">
<P>Leaving the study early: any reason, adverse events, inefficacy, non-adherence.<BR/>Mental state: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>General functioning: GAF<BR/>
</P>
<P>Service use: admission<BR/>Adverse effects: extrapyramidal side-effects, sedation, weight gain, cholesterol change, fasting glucose change, sexual side-effects.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 14:46:05 +0100" MODIFIED_BY="Laila Asmal">
<P>Intramuscular haloperidol allowed. The significance of this additive antipsychotic is not explored in the results.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:37:33 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Hu-2008">
<CHAR_METHODS MODIFIED="2013-10-16 14:46:24 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: random, no further details.<BR/>Blindness: single, rater-blinded.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: single centre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:37:33 +0100" MODIFIED_BY="Laila Asmal">
<P>Diagnosis: schizophrenia <I>(CCMD-3),</I> first episode, PANSS &#8805; 60.<BR/>N = 68.<BR/>Gender: 38 M, 30 F.<BR/>Age: mean age risperidone 30.25 years, mean quetiapine 28.96 years.<BR/>History: duration ill: mean risperidone 1.08 years, mean quetiapine 0.96 years.<BR/>Setting: not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 10:49:19 +0100" MODIFIED_BY="Laila Asmal">
<P>1. Risperidone: flexible dose. Allowed dose range: 3 - 6mg/day. Mean dose: 4.8mg/day. N = 33.</P>
<P>2. Quetiapine: flexible dose. Allowed dose range: 400 - 800mg/day. Mean dose: 672.5mg/day. N = 35.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-23 10:45:54 +0100" MODIFIED_BY="Laila Asmal">
<P>Global state.<BR/>Mental state: PANSS total, Postive, Negative, General subscore</P>
<P>Extrapyramidal side effects. ECG changes.</P>
<P>Adverse effects (at least one).<BR/>
</P>
<P>Unable to use -<BR/>Leaving the study early: due to specific reasons (not reported).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 14:46:25 +0100" MODIFIED_BY="Laila Asmal"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:44:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kinon-2006b">
<CHAR_METHODS MODIFIED="2013-10-16 14:56:18 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, computer-generated randomisation.<BR/>Blindness: double, identical capsules.<BR/>Duration: 26 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:44:10 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis:<I>)</I> schizophrenia <I>(DSM-IV), </I>(n = 230), schizoaffective disorder (n = 116), prominent negative symptoms.<BR/>N = 346.<BR/>Gender: 228 M, 118 F.<BR/>Age: mean olanzapine 41.67 years, mean quetiapine 40.45 years.<BR/>History: duration ill: mean olanzapine 17.57 years, quetiapine 17.78 years. Age at onset: mean olanzapine 24.16 years, quetiapine 22.59 years.<BR/>Setting: outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 09:36:22 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine flexible dose. Allowed dose range: 10 - 20 mg/day. Mean dose: 15.6 mg/day. N = 171.</P>
<P>2. Quetiapine flexible dose. Allowed dose range: 300 - 700 mg/day. Mean dose: 455.8 mg/day. N = 175.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-23 09:36:25 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental state: PANSS total score, PANSS positive subscore, PANSS negative subscore, SANS total score.<BR/>General functioning: GAF.<BR/>Quality of life: QLS total score.<BR/>Adverse effects: Sedation, weight gain.<BR/>
</P>
<P>Unable to use -<BR/>Adverse effect: Leukopenia (no useable data), use of antiparkinson medication (no data).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 14:56:18 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:44:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li--2005">
<CHAR_METHODS MODIFIED="2013-10-16 14:56:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 12 weeks.<BR/>Design: parallel.<BR/>Location: single centre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:44:21 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia <I>(CCMD-3)</I> .<BR/>N = 67.<BR/>Gender: not reported.<BR/>Age: mean 26.18 years.<BR/>History: duration ill: mean clozapine 0.49 years, mean quetiapine 0.5 years. Age at onset not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 09:36:34 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 100 - 550 mg/day. Mean dose: 255.96 mg/day. N = 34.</P>
<P>2. Quetiapine: flexible dose. Allowed dose range: 150 - 650 mg/day. Mean dose: 362.09 mg/day. N = 33.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-23 10:51:45 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason.<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Unable to use - <BR/>Extrapyramidal symptoms: no data.<BR/>Sedation: no data.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 14:56:58 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:44:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2002">
<CHAR_METHODS MODIFIED="2013-10-16 14:57:34 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: single centre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:44:31 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia, <I>(CCMD-3).</I>
<BR/>N = 63.<BR/>Gender: not reported.<BR/>Age: mean clozapine 30 years, mean quetiapine 28 years.<BR/>History: duration ill: mean clozapine 0.63 years, mean quetiapine 0.65 years. Age at onset not reported.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 09:36:43 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: 25 - 750 mg/day. Mean dose: 270.5 mg/day. N = 31.</P>
<P>2. Quetiapine: flexible dose. Allowed dose range: 25 - 750 mg/day. Mean dose: 478.5 mg/day. N = 32.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-16 14:57:34 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason.<BR/>Global State: CGI.<BR/>Mental State: PANSS total score.<BR/>Adverse effects: cardiac effects (palpitation), EPS (akathisia, rigor, tremor), sedation, weight gain, laboratory (white blood cell count).<BR/>
</P>
<P>Unable to use -<BR/>Leaving the study early: due to adverse events (not fully reported).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 14:57:35 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:44:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2003">
<CHAR_METHODS MODIFIED="2013-10-16 14:58:14 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: single, rater-blinded.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: single centre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:44:41 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia, <I>(CCMD-2)</I>.<BR/>N = 76.<BR/>Gender: not reported.<BR/>Age: mean clozapine 36.2 years, mean quetiapine 34.7 years.<BR/>History: duration ill: mean clozapine 6.12 years, mean quetiapine 5.71 years. Age at onset not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 09:29:49 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: fixed/flexible dose: not reported.</P>
<P>Allowed dose range: start with 25 mg, after two weeks the target should be reached, but which dose this was was not reported. Mean dose: 325 mg/day. N = 38.</P>
<P>2. Quetiapine: fixed/flexible dose: not reported. Allowed dose range: start with 25 mg, after two weeks the target should be reached, but which dose this was was not reported. Mean dose: 375 mg/day. N = 38.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-16 14:59:29 +0100" MODIFIED_BY="[Empty name]">
<P>Global state.<BR/>Leaving the study early.<BR/>Mental state: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>
</P>
<P>Unable to use -<BR/>Leaving the study early: not fully reported.</P>
<P>Adverse events - treatment emergent symptom scale: not fully reported.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 14:58:14 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:37:59 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Lieberman-2005">
<CHAR_METHODS MODIFIED="2013-10-16 14:59:59 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, identical capsules.<BR/>Duration: 78 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:37:59 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia <I>(DSM-IV)</I>, previously more than one schizophrenic episode, responder. N = 1493.<BR/>Gender: 1080 M, 380 F.<BR/>Age: 18 - 65 years (mean = 40.6 years).<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 10:54:42 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 7.5 - 30 mg/day, mean dose 20.1 mg/day. N = 336.</P>
<P>2. Perphenazine: flexible dose. Allowed dose range: 8 - 32 mg/day, mean dose 20.8 mg/day. N = 261.</P>
<P>3. Quetiapine: flexible dose. Allowed dose range: 200 - 800 mg/day, mean dose 543.4 mg/day. N = 337.</P>
<P>4. Risperidone: flexible dose. Allowed dose range: 1.5 - 6.0 mg/day, mean dose 3.9 mg/day. N = 341.</P>
<P>5. Ziprasidone: flexible dose. Allowed dose range: 40 - 160 mg/day, mean dose 112.8 mg/day. N = 185.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-16 15:00:21 +0100" MODIFIED_BY="Laila Asmal">
<P>Global state: CGI-S.</P>
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental state: PANSS total score.<BR/>Service use: number of patients re-hospitalised.<BR/>Adverse effects: Death (suicide attempt), EPS (use of antiparkinson medication, akathisia), cardiac effects (ECG), prolactin-associated side-effects, sedation, weight gain, laboratory (prolactin, lipids, glucose).</P>
<P>Unable to use -<BR/>Leaving the study early: specific reason - data on patients leaving the study early specifically due to extrapyramidal effects were not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 14:59:59 +0100" MODIFIED_BY="[Empty name]">
<P>33 participants were excluded from the analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:44:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2004">
<CHAR_METHODS MODIFIED="2013-10-16 15:00:39 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: single, rater-blinded.<BR/>Duration: 12 weeks.<BR/>Design: parallel.<BR/>Location: single centre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:44:53 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia, <I>(CCMD-3)</I>.<BR/>N = 72.<BR/>Gender: not reported.<BR/>Age: mean clozapine 37.44 years, mean quetiapine 36.86 years.<BR/>History: duration ill: mean clozapine 9.36 years, mean quetiapine 8.64 years. Age at onset not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 09:37:32 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine: flexible dose. Allowed dose range: initial dose: 50 mg/day, after 10 days: 400 - 600 mg/day. Mean dose: not reported N = 36.</P>
<P>2. Quetiapine: flexible dose. Allowed dose range: initial dose: 100 mg/day, after 10 days: 400 - 700 mg/day. Mean dose: not reported, N = 36.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-16 15:00:54 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: adverse events, inefficacy.<BR/>Global state.<BR/>Mental state: BPRS total, SANS total.<BR/>Adverse effects: open interviews, cardiac effects (ECG) EPS (akathisia, tremor), sedation, dry mouth, hypersalivation, hypotonia, liver function, dizziness, hyperemesis, maldigestion, weight gain.</P>
<P>Unable to use -<BR/>Leaving the study early: due to any reason (not fully reported).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 15:00:40 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:38:26 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Lu-2006">
<CHAR_METHODS MODIFIED="2013-10-16 15:01:26 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: random, no further details.<BR/>Blindness: single, rater-blinded.<BR/>Duration: 6 months.<BR/>Design: parallel.<BR/>Location: single centre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:38:26 +0100" MODIFIED_BY="Laila Asmal">
<P>Diagnosis: schizophrenia <I>(CCMD-3)</I> .<BR/>N = 96.<BR/>Gender: 53 M, 43 F.<BR/>Age: mean overall 30.2 years, mean risperidone and mean quetiapine age not reported.<BR/>History: duration ill: overall mean 12.6 months. Mean risperidone and mean quetiapine duration ill not reported. Age at onset: 27.8 years.<BR/>Setting: not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 09:37:42 +0100" MODIFIED_BY="Laila Asmal">
<P>1. Risperidone: flexible dose. Allowed dose range: 2 - 6mg/day. Mean dose: not reported N = 33.</P>
<P>2. Quetiapine: flexible dose. Allowed dose range: 50 - 100mg/day. Mean dose: not reported, N = 31.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-16 15:01:14 +0100" MODIFIED_BY="Laila Asmal">
<P>Leaving the study early: any reason.<BR/>Global State.<BR/>Mental State: PANSS Total, Postive, Negative, General subscore</P>
<P>Quality of Life Scale.<BR/>
</P>
<P>Unable to use -<BR/>Leaving the study early: due to specific reasons (not reported).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 15:01:15 +0100" MODIFIED_BY="Laila Asmal"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:45:11 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Luo-Xin-2008">
<CHAR_METHODS MODIFIED="2013-10-16 15:02:02 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: random, no further details.<BR/>Blindness: single, rater-blinded.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: single centre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:45:11 +0100" MODIFIED_BY="Laila Asmal">
<P>Diagnosis: schizophrenia <I>(CCMD-3)</I>, first episode, PANSS of 60 or more.<BR/>N = 70.<BR/>Gender: 37 M, 33 F.<BR/>Age: mean aripiprazole 28.5 years, mean quetiapine 27.1 years.<BR/>History: duration ill: mean aripiprazole 1.2 years, mean quetiapine 1.2 years. Age at onset not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 09:37:50 +0100" MODIFIED_BY="Laila Asmal">
<P>1. Aripiprazole: flexible dose. Allowed dose range: initial dose: 5 mg/day, after 1 week: 10 - 25 mg/day. Mean dose: not reported N = 35.</P>
<P>2. Quetiapine: flexible dose. Allowed dose range: initial dose: 200 mg/day, after 1 week: 400 - 800 mg/day. Mean dose: not reported, N = 35.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-16 15:02:09 +0100" MODIFIED_BY="Laila Asmal">
<P>Leaving the study early: any reason.<BR/>Mental state: PANSS total score, positive subscore, negative subscore<BR/>Adverse effects: leaving the study early (any reason), number of participants with at least one adverse event, akathisia, tremor, weight gain.</P>
<P>Unable to use -<BR/>ECG changes, all other EPSE data besides akathisia and tremor, reasons for leaving study early.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 15:01:45 +0100" MODIFIED_BY="Laila Asmal"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:39:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McEvoy-2006">
<CHAR_METHODS MODIFIED="2013-10-16 15:02:28 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, identical capsules.<BR/>Duration: 52 weeks (26 weeks observed, because of small group sizes).<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:39:12 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia <I>(DSM-IV)</I> , inadequate efficacy in previous study, clozapine treatment (n = 49) was open-label.<BR/>N = 99 (observed N = 50).<BR/>Gender: 80 M, 19 F.<BR/>Age: 18 - 65 years (mean 39.7 years).<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 09:38:05 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 7.5 - 30 mg/day. Mean dose: 23.4 mg/day. N = 19.</P>
<P>2. Quetiapine: flexible dose. Allowed dose range: 200 - 800 mg/day. Mean dose: 642.9 mg/day. N = 15.</P>
<P>3. Risperidone: flexible dose. Allowed dose range: 1.5 - 6 mg/day. Mean dose: 4.8 mg/day. N = 16.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-23 10:59:28 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental state: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Adverse effects: open interviews, amenorrhoea, galactorrhoea, sexual dysfunction, sedation, laboratory (lipids, glucose, prolactin), weight gain.</P>
<P>Unable to use -<BR/>Global state: CGI (no data).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 15:02:29 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:45:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McEvoy-2007">
<CHAR_METHODS MODIFIED="2013-10-16 15:03:20 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 52 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:45:35 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia <I>(DSM-IV)</I> (n = 231), schizophreniform disorder (n = 115) or schizoaffective disorder (n = 54), first episode, psychotic symptoms for 1 month to 5 years, PANSS psychosis and CGI-S score of 4 or more. N = 400.<BR/>Gender: 292 M, 108 F.<BR/>Age: 16 - 40 years (mean 24.5 years).<BR/>History: duration ill: mean 1.08 years. Age at onset 23.5 years.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 09:38:19 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 2.5 - 20 mg/day. Mean dose: 11.7 mg/day. N = 133.</P>
<P>2. Quetiapine: flexible dose. Allowed dose range: 100 - 800 mg/day. Mean dose: 506 mg/day. N = 134.</P>
<P>3. Risperidone: flexible dose. Allowed dose range: 0.5 - 4 mg/day. Mean dose: 2.4 mg/day. N = 133.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-16 15:03:10 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global State: CGI.<BR/>Mental State: PANSS total, PANSS positive subscore, PANSS negative subscore, depression Calgary depression scale.<BR/>Adverse effects: open interviews, death (suicide attempt, suicide, EPS (akathisia, akinesia, use of antiparkinson medication, laboratory (cholesterol, fasting glucose, prolactin), prolactin associated side effects (amenorrhoea, galactorrhoea, gynaecomastia, sexual dysfunction), sedation, weight gain.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 15:03:10 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:45:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mori-2004">
<CHAR_METHODS MODIFIED="2013-10-16 15:03:45 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks (last 4 weeks observed).<BR/>Design: parallel.<BR/>Location: single centre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:45:46 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia disorganised <I>(DSM-IV, </I>(n = 23), paranoid (n = 10), undifferentiated (n = 34). N = 77.<BR/>Gender: 39 M, 38 F.<BR/>Age: 28 - 84 years (mean = 59.9 years).<BR/>History: duration ill: mean 34.51 years. Age at onset: not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 09:38:31 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 2.5 - 20 mg/day. Mean dose: 16.5 mg/day. N = 20.</P>
<P>2. Perospirone: flexible dose. Allowed dose range: 4 - 48 mg/day. Mean dose: 37.3 mg/day. N = 18.</P>
<P>3. Quetiapine: flexible dose. Allowed dose range: 50 - 750 mg/day. Mean dose: 432.5 mg/day. N = 20.</P>
<P>4. Risperidone: flexible dose. Allowed dose range: 1 - 12 mg/day. Mean dose: 7.37 mg/day. N = 19.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-16 15:04:07 +0100" MODIFIED_BY="[Empty name]">
<P>Mental state: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Unable to use -<BR/>Cognitive functioning: composite data unavailable.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 15:03:45 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:39:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ozguven-2004">
<CHAR_METHODS MODIFIED="2013-10-16 15:04:17 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: single, no further details.<BR/>Duration: 6 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:39:39 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia <I>(DSM-IV)</I>.<BR/>N = 30.<BR/>Gender: 8 M, 22 F.<BR/>Age: mean = 35.3 years.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 09:30:39 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: mean dose: 23.0 mg/day. N = 15.</P>
<P>2. Quetiapine: flexible dose. Allowed dose range: mean dose: 826.67 mg/day. N = 15.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-16 15:04:29 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global state: CGI.<BR/>Mental state: SAPS total score, SANS total score.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 15:04:18 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:45:59 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Peng-2007">
<CHAR_METHODS MODIFIED="2013-10-16 15:04:47 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: random, no further details.<BR/>Blindness: single, rater blinded.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: single centre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:45:59 +0100" MODIFIED_BY="Laila Asmal">
<P>Diagnosis: first episode schizophrenia <I>(CCMD-3)</I>, treatment naive. Duration of untreated psychosis &lt;3 months.<BR/>N = 85.<BR/>Gender: 45 M, 40 F.<BR/>Age: aripiprazole 31.7 years, quetiapine 29.5 years.<BR/>History: duration ill: mean aripiprazole 0.23 years, mean quetiapine 0.23 years. Age at onset not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 09:38:40 +0100" MODIFIED_BY="Laila Asmal">
<P>1. Aripiprazole: flexible dose. Allowed dose range: 5 - 25 mg/day. Mean dose: not reported. N = 41.</P>
<P>2. Quetiapine: flexible dose. Allowed dose range: 100 - 600 mg/day. Mean dose: not reported. N = 44.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-23 11:03:00 +0100" MODIFIED_BY="Laila Asmal">
<P>Leaving the study early: any reason.<BR/>Mental state: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Adverse effects: akathisia, dystonia, parkinsonism, weight gain, cardiac effects (ECG changes).<BR/>Unable to use -<BR/>Adveres effects: extrapyramidal symptoms limited data on specific side effects.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 15:04:47 +0100" MODIFIED_BY="Laila Asmal"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:39:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Potkin-2006">
<CHAR_METHODS MODIFIED="2013-10-16 15:05:56 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation:random, no further details.<BR/>Blindness: double, identical capsules.<BR/>Duration: 6 weeks (2 weeks observed).<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:39:58 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia <I>(DSM-IV),</I> (n = 341) disorganised, paranoid or undifferentiated or schizoaffective disorder (n = 30) plus (n = 11), CGI-S of 5 or more, recent exacerbation.<BR/>N = 382.<BR/>Gender: 251 M, 131 F.<BR/>Age: 18 - 65 years (mean 34.8 years).<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 09:38:53 +0100" MODIFIED_BY="[Empty name]">
<P>1. Quetiapine: flexible dose. Allowed dose range: 50 - 800 mg/day. Mean dose: 523.8 mg/day (after 2 weeks), 579.5 mg/day (after 6 weeks). N = 156.</P>
<P>2. Risperidone: flexible dose. Allowed dose range: 1 - 6 mg/day. Mean dose: 4.32 mg/day (after 2 weeks), 4.7 mg/day (after 6 weeks). N = 153.</P>
<P>3. Placebo: N = 73*.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-23 09:39:20 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason.<BR/>Global state: CGI.<BR/>Mental state: PANSS total score, PANSS positive subscore, PANSS negative subscore, Depression Hamilton Rating Scale for Depression, Readiness for Discharge Questionnaire.<BR/>Satisfaction of treatment: Study Medication Satisfaction.<BR/>Adverse effects: open interviews, death (natural cause), cardiac effects (ECG), EPS (akathisia, rigor, AIMS, SAS),<BR/>prolactin associated side effects (amenorrhoea, decreased libido), sedation, laboratory (prolactin).</P>
<P>Unable to use -<BR/>BAS: no data.<BR/>Cardiac effects: QTc-prolongation: no data.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 15:06:29 +0100" MODIFIED_BY="[Empty name]">
<P>* data not analysed from placebo group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:46:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Riedel-2005">
<CHAR_METHODS MODIFIED="2013-10-16 15:06:38 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, identical capsules.<BR/>Duration: 12 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:46:20 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (<I>DSM-IV</I> or <I>ICD-10</I>), predominant negative symptoms, CGI of 4 or more, PANSS negative subscore of 21 or more.<BR/>N = 44.<BR/>Gender: 27 M, 17 F.<BR/>Age: mean quetiapine 30.6 years, mean risperidone 39.3 years.<BR/>History: duration ill: mean quetiapine 5.4 years, mean risperidone 2.5 years. Age at onset mean quetiapine 25.3 years, mean risperidone 36.9 years.<BR/>Setting: partially in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 09:39:33 +0100" MODIFIED_BY="[Empty name]">
<P>1. Quetiapine: flexible dose. Allowed dose range: 50 - 800 mg/day, Mean dose: 589.7 mg/day. N = 22.</P>
<P>2. Risperidone: flexible dose. Allowed dose range: 2 - 8 mg/day. Mean dose: 4.9 mg/day. N = 22.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-23 11:05:36 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental state: PANSS total score, PANSS positive subscore, PANSS negative subscore, SANS total score.<BR/>Adverse effects: open interviews, cardiac effects (ECG), EPS (akathisia, parkinsonism, use of antiparkinson medication, SAS), sedation, headache, nausea, insomnia, dizziness, weight gain, laboratory (prolactin).</P>
<P>Unable to use -<BR/>Adverse effects: SANS total score, prolactin change from baseline in ng/ml, cardiac effects (no data).</P>
<P>Cognitive functioning: composite data not available.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 15:06:39 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:46:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Riedel-2007">
<CHAR_METHODS MODIFIED="2013-10-16 15:07:33 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: single centre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:46:32 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia <I>(DSM-IV)</I>, acute episode, CGI of more than 4, PANSS total score of more than 60.<BR/>N = 52.<BR/>Gender: 21 M, 12 F (of completers, here defined as those who completed cognitive assessments at two or more time points out of three (baseline, week 4, weeks 8)).<BR/>Age: 18 - 65 years (mean olanzapine 34.47 years, mean quetiapine 36.69 years, of completers).<BR/>History: duration ill: mean olanzapine 4.71 years, mean quetiapine 8.44 years (of completers). Age at onset mean olanzapine 29.76 years, mean quetiapine 28.25 years (of completers).<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 09:39:43 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 10 - 20 mg/day. Mean dose: 15.82 mg/day. N = 26.</P>
<P>2. Quetiapine: flexible dose. Allowed dose range: 400 - 800 mg/day. Mean dose: 586.86 mg/day. N = 26.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-16 15:08:04 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events.<BR/>Mental state: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Adverse effects: open interviews, UKU EPS (akathisia, use of antiparkinson medication, ESRS), sedation, headache, dizziness, obstipation, weight gain.</P>
<P>Unable to use -<BR/>Global state: no data.<BR/>BAS: no data.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 15:07:34 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:46:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sacchetti-2004">
<CHAR_METHODS MODIFIED="2013-10-16 15:08:58 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: single (rater-blinded).<BR/>Duration: 16 weeks (8 weeks observed).<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:46:42 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia <I>(DSM-IV)</I>, PANSS total score &#8805; 70, PANSS positive subscore &#8805; 4 on at least 2 items.<BR/>N = 75.<BR/>Gender: not reported.<BR/>Age: 18 - 65 years.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 09:39:55 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 10 - 20 mg/day. Mean dose: 14.6 mg/day. N = 25.</P>
<P>2. Quetiapine: flexible dose. Allowed dose range: 400 - 800 mg/day. Mean dose: 602.4 mg/day. N = 25.</P>
<P>3. Risperidone: flexible dose. Allowed dose range: 4 - 8 mg/day. Mean dose: 4.3 mg/day. N = 25.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-16 15:08:58 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason.<BR/>Mental State: BPRS hostility cluster score.<BR/>Adverse effects: EPS (BAS, SAS), weight gain.</P>
<P>Unable to use -<BR/>Mental State: PANSS total score, PANSS positive subscore, PANSS negative subscore (no usable data).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 15:08:58 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-04 17:22:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sirota-2006">
<CHAR_METHODS MODIFIED="2013-10-16 15:09:30 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: single, rater-blinded.<BR/>Duration: 12 weeks.<BR/>Design: parallel.<BR/>Location: single centre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:46:55 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia <I>(DSM-IV)</I>, PANSS negative subscore &gt; 15, SANS total score &gt; 60.<BR/>N = 40.<BR/>Gender: 32 M, 8 F.<BR/>Age: 21 - 64 years (mean olanzapine 36.2 years, mean quetiapine 38.3 years).<BR/>History: duration ill: mean olanzapine 13.3 years, mean quetiapine 15.9 years. Age at onset not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-04 17:22:16 +0000" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 5 - 20 mg/day. Mean dose: 16.0 mg/day. N = 21.</P>
<P>2. Quetiapine: flexible dose. Allowed dose range: 200 - 800 mg/day. Mean dose: 637.2 mg/day. N = 19.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-16 15:09:30 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Adverse effects: open interviews, cardiac effects (ECG), EPS (akathisia, parkinsonism, use of antiparkinson medication, SAS, AIMS, BAS), sedation, seizures, weight gain.</P>
<P>Unable to use -<BR/>Mental State: PANSS total score, negative symptoms SANS (median change).<BR/>EPS scales: no data.<BR/>Cardiac effects: no data.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 15:09:30 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:47:04 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Song-2008">
<CHAR_METHODS MODIFIED="2013-10-16 15:09:47 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: random, no further details.<BR/>Blindness: single, rater-blinded.<BR/>Duration: 12 weeks.<BR/>Design: parallel.<BR/>Location: single centre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:47:04 +0100" MODIFIED_BY="Laila Asmal">
<P>Diagnosis: schizophrenia <I>(CCMD-3rd)</I> , PANSS of 60 or more.<BR/>N = 66.<BR/>Gender: 31 M, 35 F.<BR/>Age: mean quetiapine 35.9 years, mean risperidone 36.7 years).<BR/>History: duration ill: mean quetiapine 9.4 years, mean risperidone 8.8 years. Age at onset not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 09:40:18 +0100" MODIFIED_BY="Laila Asmal">
<P>1. Risperidone: flexible dose. Initial dose 1mg/day titrated after 2 weeks to allowed dose range: 4 - 6 mg/day. Mean dose: not reported. N = 32.</P>
<P>2. Quetiapine: flexible dose. Initial dose 100mg/day titrated after 2 weeks to allowed dose range: 200 - 800 mg/day. Mean dose: not reported mg/day. N = 32.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-16 15:10:06 +0100" MODIFIED_BY="Laila Asmal">
<P>Mental state: PANSS total score, positive subscore, negative subscore.</P>
<P>WHO Quality of Life Scale<BR/>Adverse effects: EPS (TESS).</P>
<P>Unable to use -<BR/>Mental State:<BR/>EPS scales: no data except regarding tremor.<BR/>Cardiac effects and weight gain: no data.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 15:09:48 +0100" MODIFIED_BY="Laila Asmal"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:11:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stroup-2006">
<CHAR_METHODS MODIFIED="2013-10-16 15:10:26 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, 2 steps of randomisation before and after availability of ziprasidone, subjects received other medication than in previous phase 1 treatment. Re-randomised.<BR/>Blindness: double, identical capsules.<BR/>Duration: 26 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:10:54 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: chronic schizophrenia, <I>(DSM-IV)</I>.<BR/>N = 444.<BR/>Gender: 308 M, 136 F.<BR/>Age: 18 - 65 years (mean olanzapine 40.0 years, mean quetiapine 40.1 years, mean risperidone 41.8 years, mean ziprasidone 41.3 years).<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: in- and outpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 10:49:28 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 7.5 - 30 mg/day, mean dose = 20.5 mg/day. N = 108.</P>
<P>2. Quetiapine: flexible dose. Allowed dose range: 200 - 800 mg/day, mean dose = 565.2 mg/day. N = 95.</P>
<P>3. Risperidone: flexible dose. Allowed dose range: 1.5 - 6.0 mg/day, mean dose = 4.1 mg/day. N = 104.</P>
<P>4. Ziprasidone: flexible dose. Allowed dose range: 40 - 160 mg/day, mean dose = 115.9 mg/day. N = 137.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-23 11:11:42 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Global state: CGI.<BR/>Mental state: PANSS total score.<BR/>Adverse effects: death (suicide), EPS (akathisia), cardiac effects (ECG), prolactin-associated side effects, weight gain, laboratory results (prolactin, glucose, cholesterol).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 15:10:27 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:47:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Svestka-2003b">
<CHAR_METHODS MODIFIED="2013-10-16 15:11:14 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 6 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:47:21 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: acute schizophrenia, <I>(ICD-10),</I> (n = 32), schizoaffective disorder (n = 10).<BR/>N = 42.<BR/>Gender: 42 F.<BR/>Age: mean 35.78 years.<BR/>History: duration ill: mean 7.05 years. Age at onset not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 09:40:56 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 10 - 20 mg/day. Mean dose: 19.5 mg/day. N = 20.</P>
<P>2. Quetiapine: flexible dose. Allowed dose range: 50 - 700 mg/day. Mean dose: 677.3 mg/day. N = 22.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-16 15:11:54 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: inefficacy.<BR/>Global state: CGI.<BR/>Mental state: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Adverse effects: Cardiac effects (QTc), EPS (akathisia, dystonia, extrapyramidal symptoms, tremor), weight gain, laboratory (prolactin)<BR/>
</P>
<P>Unable to use -<BR/>Cholesterol: no data.<BR/>Glucose: no data.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 15:11:14 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:40:41 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Voruganti-2007">
<CHAR_METHODS MODIFIED="2013-10-16 15:12:13 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: single, rater-blinded.<BR/>Duration: 52 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:40:41 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>N = 86.<BR/>Gender: not reported.<BR/>Age: not reported.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 10:49:29 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: fixed/flexible dose: not reported Allowed dose range: not reported. Mean dose: 17.2 mg/day. N = 42.</P>
<P>2. Quetiapine: fixed/flexible dose. Allowed dose range: not reported. Mean dose: 612.8 mg/day. N = 43.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-23 11:13:41 +0100" MODIFIED_BY="Laila Asmal">
<P>Mental state: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>General functioning: GAF.<BR/>Adverse effects: EPS (SAS, AIMS, BAS), weight gain, number of dysglycaemic individuals.</P>
<P>Unable to use</P>
<P>Cognitive functioning: composite score not available.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 15:12:13 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:47:35 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Wang-2006">
<CHAR_METHODS MODIFIED="2013-10-16 15:12:47 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: random, no further details.<BR/>Blindness: single, rater-blinded.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: single site.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:47:35 +0100" MODIFIED_BY="Laila Asmal">
<P>Diagnosis: schizophrenia <I>(CCMD- 3rd)</I>, PANSS of 60 or more.<BR/>N = 60.<BR/>Gender: 27 M, 33 F.<BR/>Age: mean quetiapine 31.8 years, mean risperidone 32.1 years<BR/>History: duration ill not reported. Age at onset not reported.<BR/>Setting: not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 09:41:10 +0100" MODIFIED_BY="Laila Asmal">
<P>1. Risperidone: Flexible dose: 0.5 - 1mg/day, titrated up to allowed dose range of 4 - 6mg after one week. Mean dose: not reported. N = 30.</P>
<P>2. Quetiapine: Flexible dose: 50 - 100mg/day, titrated up to allowed dose range of 400 - 600mg/day. Mean dose: not reported. N = 30.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-16 15:12:55 +0100" MODIFIED_BY="Laila Asmal">
<P>Mental state: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Adverse effects: EPS, tachycardia, weight gain.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 15:12:47 +0100" MODIFIED_BY="Laila Asmal"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:47:44 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Wei-2006a">
<CHAR_METHODS MODIFIED="2013-10-16 15:13:09 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: random, no further details.<BR/>Blindness: single, rater blinded.<BR/>Duration: 6 months.<BR/>Design: parallel.<BR/>Location: single centre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:47:44 +0100" MODIFIED_BY="Laila Asmal">
<P>Diagnosis: schizophrenia <I>(CCMD-3rd)</I>, first-episode, treatment naive, PANSS of 60 or more.<BR/>N = 58.<BR/>Gender: 23 M, 35 F.<BR/>Age: 18 - 60 years.<BR/>History: duration ill: mean quetiapine 37.44 months, mean risperidone = 37.8 months. Age at onset: (mean quetiapine 28.32 years, mean risperidone 29.04 years).<BR/>Setting: in- and outpatient, initially inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 09:41:26 +0100" MODIFIED_BY="Laila Asmal">
<P>1. Quetiapine:flexible dose. Allowed dose range: 200 - 800 mg/day. Mean dose: 525 mg/day. N = 338.</P>
<P>2. Risperidone: flexible dose. Allowed dose range: 2 - 8 mg/day. Mean dose: 5.2 mg/day. N = 335.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-23 11:15:20 +0100" MODIFIED_BY="Laila Asmal">
<P>Leaving the study early: any reason, adverse events, inefficacy<BR/>Global state: CGI.<BR/>Mental state: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Adverse effects: cardiac effects (QTc), death (natural causes, suicide), EPS (akathisia, dystonia, parkinsonism, use of antiparkinson medication, AIMS, BAS, SAS), sedation, prolactin-associated side effects (dysmenorrhoea, galactorrhoea, sexual dysfunction) weight gain, laboratory results (cholesterol, glucose, prolactin, white blood cell count).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 15:13:09 +0100" MODIFIED_BY="Laila Asmal"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:47:53 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Wei-2006b">
<CHAR_METHODS MODIFIED="2013-10-16 15:14:04 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: single centre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:47:53 +0100" MODIFIED_BY="Laila Asmal">
<P>Diagnosis: schizophrenia <I>(CCMD-3),</I> PANSS &#8805; 60. CGI &#8805; 4.<BR/>N = 108.<BR/>Gender: all female.<BR/>Age: 18 - 60 years.<BR/>History: duration ill: mean aripiprazole 15.33 months, mean quetiapine 14.16 months. Age at onset not reported.<BR/>Setting: inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 11:16:35 +0100" MODIFIED_BY="Laila Asmal">
<P>1. Aripiprazole: flexible dose. Allowed dose range: 5 - 20 mg/day. Mean dose: not reported. N = 50.</P>
<P>2. Quetiapine: flexible dose. Allowed dose range: 100 - 400 mg/day. Mean dose: Not reported. N = 51.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-23 11:16:49 +0100" MODIFIED_BY="Laila Asmal">
<P>Leaving the study early: any reason.<BR/>Mental state: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>
</P>
<P>Adverse effects: at least one adverse events (any reason).<BR/>
</P>
<P>Unable to use<BR/>Adverse effects: extrapyramidal symptoms: no data.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 15:14:04 +0100" MODIFIED_BY="Laila Asmal"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-23 11:48:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhong-2006">
<CHAR_METHODS MODIFIED="2013-10-16 15:14:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 8 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:48:01 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia <I>(DSM-IV)</I>, PANSS &#8805; 60, CGI-S &#8805; 4<BR/>N = 673.<BR/>Gender: 510 M, 163 F.<BR/>Age: 18 - 65 years (mean quetiapine 40.2 years, mean risperidone 39.6 years).<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: in- and outpatient, initially inpatient.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 09:41:51 +0100" MODIFIED_BY="[Empty name]">
<P>1. Quetiapine:flexible dose. Allowed dose range: 200 - 800 mg/day. Mean dose: 525 mg/day. N = 338.</P>
<P>2. Risperidone: flexible dose. Allowed dose range: 2 - 8 mg/day. Mean dose: 5.2 mg/day. N = 335.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-23 11:18:14 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: CGI.</P>
<P>Leaving the study early: any reason, adverse events, inefficacy<BR/>Mental state: PANSS total score, PANSS positive subscore, PANSS negative subscore.<BR/>Adverse effects: cardiac effects (QTc), death (natural causes, suicide), EPS (akathisia, dystonia, parkinsonism, use of antiparkinson medication, AIMS, BAS, SAS), sedation, prolactin-associated side effects (dysmenorrhoea, galactorrhoea, sexual dysfunction), weight gain, laboratory results (cholesterol, glucose, prolactin, white blood cell count).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-10-16 15:14:55 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Diagnostic tools:<BR/>
<I>DSM III-R</I> and <I>DSM-IV</I> <I>Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised,</I> and <I>Fourth Edition</I>
<BR/>
<I>ICD 10</I> <I>International Classification of Diseases, Tenth Revision</I>
<BR/>BMI body mass index</P>
<P>Rating scales:</P>
<P>Global rating scales:<BR/>CGI Clinical Global Impressions<BR/>CGI-S Clinical Global ImpressionsSeverity<BR/>CGI-I Clinical Global ImpressionsImprovement<BR/>
</P>
<P>Mental state:<BR/>BPRS Brief Psychiatric Rating Scale<BR/>MADRS Montgomery-Asberg Depression Rating Scale<BR/>MMSE Mini Mental State Examination<BR/>PANSS Positive and Negative Syndrome Scale<BR/>SANS Scale for the Assessment of Negative Symptoms</P>
<P>Side effects:<BR/>AIMS Abnormal Involuntary Movement Scale<BR/>BAS Barnes Akathisia Scale<BR/>BMI body mass index<BR/>EPS extrapyramidal symptoms<BR/>ESRS Extrapyramidal Syndrome Rating Scale<BR/>HAS Hillside Akathisia Scale<BR/>SAS Simpson-Angus Index for neurological side effects<BR/>UKU Udvalg for kliniske undersøgelser Side Effect Rating Scale for side effect rating</P>
<P>Quality of life:<BR/>QoL Quality of Life Scale<BR/>SWN Subjective Well-being List</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-07-08 09:11:55 +0100" MODIFIED_BY="Laila Asmal" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-An-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:04 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:00:04 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-An-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:00:04 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:00:03 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-An-2006a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:00:03 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:55:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Antonova-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:55:56 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: single-blind (rater-blind).<BR/>Participants: people with schizophrenia.<BR/>Interventions: olanzapine, risperidone and quetiapine versus conventional antipsychotics.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:00:16 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Arango-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:00:16 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-24 09:45:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ascher_x002d_Svanum-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-24 09:45:20 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-24 09:45:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baloescu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-24 09:45:16 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, controlled clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-20 11:57:37 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Ban-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-20 11:57:37 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.</P>
<P>Blindness: not reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 12:11:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beuzen-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 12:11:48 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 12:12:57 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Boter-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 12:12:57 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:16:21 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Brecher-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:16:21 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-02 15:25:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Byerly-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-02 15:25:11 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not reported.<BR/>Blindness: not reported.<BR/>Participants: people with schizophrenia.<BR/>Interventions: clozapine versus quetiapine.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Byerly-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:10 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double-blind.<BR/>Participants: people with schizophrenia.<BR/>Interventions: quetiapine versus risperidone.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:00:49 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Cai-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:00:49 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-24 09:45:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Canas-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-24 09:45:09 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, controlled clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cao-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:10 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cao-2005-a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:11 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:01:10 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Cao-2006a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:01:10 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-20 11:58:44 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Cao-2006d">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-20 11:58:44 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: double-blind.<BR/>Participants: people with schizophrenia.<BR/>Interventions: quetiapine versus chlorpramazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:01:20 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Chang-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:01:20 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-20 12:00:29 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Chang-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-20 12:00:29 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.</P>
<P>Blindness: not reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chaudhry-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:11 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 12:14:36 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Chen-2006a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 12:14:36 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-20 12:02:41 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Chen-2006k">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-20 12:02:41 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: double-blind.<BR/>Participants: people with schizophrenia.<BR/>Interventions: quetiapine versus perphenazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:01:36 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Chen-2007a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:01:36 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:01:45 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Chen-2007b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:01:45 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-20 12:14:06 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Chen-2007c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-20 12:14:06 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.</P>
<P>Blindness: not reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:01:54 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Chen-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:01:54 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.</P>
<P>Blindness: not reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:01:58 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Chu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:01:58 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:02:04 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Cortese-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:02:04 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dai-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:11 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dai-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:11 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:02:10 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Dai-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:02:10 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-20 14:46:24 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Davies-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-20 14:46:24 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: single-blind (rater-blind).<BR/>Participants: people with schizophrenia.<BR/>Interventions: clozapine versus second generation antipsychotics.<BR/>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ding-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:11 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:02:23 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Dong-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:02:23 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-24 09:45:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dossenbach-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-24 09:45:00 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Du-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:11 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:02:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Emsley-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:02:33 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: investigator-blind.<BR/>Participants: people with schizophrenia.<BR/>Interventions: quetiapine versus haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fan-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:12 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:02:53 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Fan-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:02:53 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fleischhacker-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:13 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fu-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:13 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:03:06 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Fu-2005a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:03:06 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gao-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:14 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-24 09:46:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garc_x00ed_a-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-24 09:46:52 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, case series. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:03:15 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Guo-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:03:15 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: double-blind.<BR/>Participants: people with schizophrenia.<BR/>Interventions: quetiapine versus chlorpramazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:03:55 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Hao-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:03:55 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: double-blind.<BR/>Participants: people with schizophrenia.<BR/>Interventions: Imported quetiapine vs domestic quetiapine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harrigan-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:14 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-He-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:14 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 12:24:02 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Horacek-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 12:24:02 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:14 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:04:12 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Huang-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:04:12 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 12:36:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huber-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 12:36:36 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.<BR/>Blindness: open label.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-20 12:21:23 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Jiang-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-20 12:21:23 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.</P>
<P>Blindness: not reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-24 10:04:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karow-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-24 10:04:09 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Keks-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:15 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-24 09:47:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kelemen-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-24 09:47:48 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, controlled clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-24 09:48:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-24 09:48:06 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, controlled clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Knegtering-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:15 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 12:42:58 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Kolotkin-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 12:42:58 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 12:43:24 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Koponen-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 12:43:24 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:04:38 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Kuang-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:04:38 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: non-randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 12:44:46 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-L_x0027_Italien-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 12:44:46 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:04:47 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Lan-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:04:47 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: non-randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:15 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 15:17:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2002a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 15:17:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2003a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:15 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2003b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:16 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:20:31 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Li-2005a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:20:31 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2005b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:16 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:20:33 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Li-2007a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:20:33 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:20:37 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Li-2007h">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:20:37 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:20:43 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Li-2008a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:20:43 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:20:55 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Li-2008b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:20:55 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:20:57 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Li-2008c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:20:57 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:20:58 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Li-2008d">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:20:58 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:20:59 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Liang-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:20:59 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:21:02 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Lin-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:21:02 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-20 14:13:45 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Lin-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-20 14:13:45 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.</P>
<P>Blindness: not reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:21:10 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Liu-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:21:10 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:21:15 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Liu-2003a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:21:15 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2004a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:16 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:21:23 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Liu-2004b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:21:23 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:16 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-20 14:14:03 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Liu-2005a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-20 14:14:03 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-20 14:14:05 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Liu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-20 14:14:05 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:21:34 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Liu-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:21:34 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:21:37 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Liu-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:21:37 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lu-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:17 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Luo-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:17 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-20 12:32:30 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Lv-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-20 12:32:30 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:21:48 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Mei-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:21:48 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mintzer-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:17 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mullen-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:17 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-24 09:48:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Musil-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-24 09:48:27 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-20 12:33:07 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Nai-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-20 12:33:07 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: double-blind.<BR/>Participants: people with schizophrenia.<BR/>Interventions: quetiapine versus chlorpramazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pan-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:17 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pan-2004a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:17 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pan-2004b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:18 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:06:22 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Pan-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:06:22 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: double-blind.<BR/>Participants: people with schizophrenia.<BR/>Interventions: ziprasidone versus chlorpromazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pang-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:18 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 12:47:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peng-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 12:47:55 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: not mentioned.<BR/>Participants: people with schizophrenia.<BR/>Interventions: quetiapine versus chlorpramazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 12:48:53 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Petty-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 12:48:53 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 12:49:40 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Pfizer-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 12:49:40 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Qi-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:18 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Qian-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:18 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-02 15:25:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reznik-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-02 15:25:58 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 12:50:55 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Riera-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 12:50:55 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:23:23 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Ruan-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:23:23 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-24 09:49:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ryu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-24 09:49:02 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, controlled clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-11-02 15:25:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sajatovic-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-11-02 15:25:59 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:07:04 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Sarma-2008a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:07:04 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: double-blind.<BR/>Participants: people with schizophrenia.<BR/>Interventions: lurasidone versus quetiapine.</P>
<P>Outcomes: no usable data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:07:11 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Sheng-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:07:11 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:23:43 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Song-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:23:43 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-20 12:34:22 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Song-2008a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-20 12:34:22 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised, controlled clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-20 12:34:35 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Song-2008b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-20 12:34:35 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised, controlled clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:23:56 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Sun-2006a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:23:56 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-20 15:56:57 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Sun-2006e">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-20 15:56:57 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: double-blind.<BR/>Participants: people with schizophrenia.<BR/>Interventions: quetiapine versus chlorpromazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:24:05 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Sun-2007a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:24:05 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: double-blind.<BR/>Participants: people with schizophrenia.<BR/>Interventions: ziprasidone versus risperidone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-20 12:47:42 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Sun-2007b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-20 12:47:42 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: double-blind.<BR/>Participants: people with schizophrenia.<BR/>Interventions: quetiapine versus perphenazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:24:12 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Sun-2007c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:24:12 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:24:15 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Sun-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:24:15 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:07:45 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Swadi-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:07:45 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: outcome assessors blinded.<BR/>Participants: first episode mood and psychotic disorder.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Swanson-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tang-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:25:01 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Tao-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:25:01 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: non-randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:25:03 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Tian-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:25:03 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:25:06 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Tian-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:25:06 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:25:10 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Tian-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:25:10 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:20 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 15:22:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2004a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 15:22:41 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:20 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2005a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:20 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2005b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:20 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2005c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2005d">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:08:28 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Wang-2006a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:08:28 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:25:39 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Wang-2006b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:25:39 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:25:44 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Wang-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:25:44 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:25:46 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Wang-2007a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:25:46 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:25:52 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Wang-2007b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:25:52 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:25:55 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Wang-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:25:55 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:25:58 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Wang-2008a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:25:58 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:26:00 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Wang-2008b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:26:00 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:26:03 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Wang-2008c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:26:03 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:26:09 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Wei-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:26:09 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:08:55 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Wei-2006c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:08:55 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised (sequential allocation).<BR/>Blindness: double-blind.<BR/>Participants: people with schizophrenia.<BR/>Interventions: quetiapine versus clozapine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:08:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weickert-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:08:59 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Interventions: Within-subject comparison of placebo versus atypical antipsychotics.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:09:03 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Wen-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:09:03 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:09:08 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Wu-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:09:08 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xiang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xu-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xu-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:22 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-26 16:19:27 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Xu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-26 16:19:27 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: double-blind.<BR/>Participants: people with schizophrenia.<BR/>Interventions: quetiapine versus chlorpromazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-24 09:49:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yamashita-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-24 09:49:23 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:22 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:22 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-20 13:23:49 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Yang-2005a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-20 13:23:49 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:26:58 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Yang-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:26:58 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:27:03 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Yang-2006a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:27:03 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: double-blind.<BR/>Participants: people with schizophrenia.<BR/>Interventions: quetiapine versus haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:27:06 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Yang-2006b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:27:06 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: double-blind.<BR/>Participants: people with schizophrenia.<BR/>Interventions: quetiapine versus haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:27:12 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Yang-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:27:12 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:27:17 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Yang-2007a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:27:17 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yu-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:22 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:28:08 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Yu-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:28:08 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:28:11 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Yu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:28:11 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yuan-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:22 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:28:16 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Zeng-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:28:16 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:23 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:23 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2005a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:23 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2005b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:23 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2005c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:23 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:28:35 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Zhang-2005d">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:28:35 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-20 13:27:23 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Zhang-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-20 13:27:23 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: double-blind.<BR/>Participants: people with schizophrenia.<BR/>Interventions: quetiapine versus chlorpromazine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:28:45 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Zhang-2006a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:28:45 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-02 10:28:50 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Zhang-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-02 10:28:50 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-08-20 13:28:19 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Zhang-2007a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-08-20 13:28:19 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: double-blind.<BR/>Participants: people with schizophrenia.<BR/>Interventions: quetiapine versus chlorpromazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:11:11 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Zhang-2009b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:11:11 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.</P>
<P>Blinding: participant blinded.</P>
<P>Intervention: quetiapine versus haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhao-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:23 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhao-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:23 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhao-2005a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:23 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:11:28 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Zhao-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:11:28 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: double-blind.<BR/>Participants: people with schizophrenia.<BR/>Interventions: quetiapine versus sulpiride.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:11:32 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Zheng-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:11:32 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: double-blind.<BR/>Participants: people with schizophrenia.<BR/>Interventions: quetiapine + clozapine vs quetiapine alone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhong-2006a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhou-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-23 14:56:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhou-2003a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-23 14:56:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:11:47 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Zhou-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:11:47 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.<BR/>Blindness: double-blind.<BR/>Participants: people with schizophrenia.<BR/>Interventions: quetiapine versus sulpiride.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:11:50 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Zhou-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:11:50 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:11:52 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Zhu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:11:52 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-08 09:11:55 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Zhu-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-08 09:11:55 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-11-04 17:23:47 +0000" MODIFIED_BY="Laila Asmal" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2013-11-04 17:23:47 +0000" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Gafoor-2005">
<CHAR_METHODS MODIFIED="2013-11-04 17:22:55 +0000" MODIFIED_BY="Laila Asmal">
<P>Allocation: randomised.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-04 17:23:02 +0000" MODIFIED_BY="Laila Asmal">
<P>Diagnosis: schizophrenia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-16 15:15:10 +0100" MODIFIED_BY="Laila Asmal">
<P>1. Quetiapine.</P>
<P>2. Risperidone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-04 17:23:42 +0000" MODIFIED_BY="Laila Asmal">
<P>Leaving the study early: any reason, adverse events, inefficacy.<BR/>Mental state: PANSS total score, PANSS positive subscore, PANSS negative subscore, SANS total score, depression (Calgary Depression Scale).<BR/>General functioning: GAF.<BR/>Quality of life: QLS total score.<BR/>Adverse effects: sedation, libidinal dysfunction, BMI change, weight gain.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-04 17:23:47 +0000" MODIFIED_BY="Laila Asmal">
<P>Not all participants accounted for in intention-to-treat analysis.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-10-23 11:51:43 +0100" MODIFIED_BY="Laila Asmal" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2013-10-23 11:50:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eli-Lilly-2004b">
<CHAR_STUDY_NAME MODIFIED="2013-10-23 11:48:16 +0100" MODIFIED_BY="[Empty name]">
<P>Trial 8894<BR/>F1D-US-HGLR.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-10-23 11:48:30 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 26 weeks.<BR/>Design: parallel.<BR/>Location: not reported.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:49:09 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia or schizoaffective disorder.<BR/>N = not reported.<BR/>Gender: not reported.<BR/>Age: 18 - 75 years.<BR/>History: duration ill not reported, age at onset not reported.<BR/>Setting: not reported.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 11:49:31 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: flexible dose. Allowed dose range: 7.5-20 mg/day, mean dose: not reported. N = not reported.</P>
<P>2. Quetiapine: flexible dose. Allowed dose range: 300-800 mg/day, mean dose: not reported, N = not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-23 11:50:18 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: CGI, PG-I, response to treatment.</P>
<P>Leaving the study early: any reason, lack of efficacy or worsening of psychiatric syndromes.<BR/>Mental state: PANSS, depression, MADRS.<BR/>General functioning: DAI-10, GAF.<BR/>Quality of life: SF-36.<BR/>Adverse effects: EPS (SAS, BAS, AIMS), vital signs, weight (waist circumference, BMI, appetite, metabolic syndrome), laboratory results (fasting glucose, haemoglobin A1c, lipids, insulin).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-10-23 11:50:20 +0100" MODIFIED_BY="[Empty name]">
<P>July 2004.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-10-23 11:50:26 +0100" MODIFIED_BY="[Empty name]">
<P>Eli Lilly and Company.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-01-12 23:20:19 +0000" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-10-23 11:50:55 +0100" MODIFIED_BY="Laila Asmal" STUDY_ID="STD-Li-2009b">
<CHAR_STUDY_NAME MODIFIED="2013-10-23 11:50:38 +0100" MODIFIED_BY="Laila Asmal">
<P>Study NCT00817648: A Study to Evaluate the Efficacy and Safety of Seroquel in Chinese Han Patients With Schizophrenia.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-10-23 11:50:39 +0100" MODIFIED_BY="Laila Asmal">
<P>Allocation: random, no further details.<BR/>Blindness: Single, rater-blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:50:40 +0100" MODIFIED_BY="Laila Asmal">
<P>Outpatients or inpatients with schizophrenia from the Chinese Han race.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-23 11:50:41 +0100" MODIFIED_BY="Laila Asmal">
<P>Quetiapine 600 to 750 mg/d, risperidone 3 to 6 mg/d.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-23 11:50:44 +0100" MODIFIED_BY="Laila Asmal">
<P>Global state: CGI.</P>
<P>Mental state: change in PANSS total score, depression (CDSS).<BR/>Adverse effects: EPSE (AIMS, SAS).</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-10-23 11:50:46 +0100" MODIFIED_BY="Laila Asmal">
<P>December 2008.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-10-23 11:50:55 +0100" MODIFIED_BY="Laila Asmal">
<P>Huafang LI, MD, PhD, 86-21-64387250 ext 3128, lhlh5@yahoo.com.cn</P>
<P>Yan LI, MD, 86-21-64387250 ext 3122, liyan7721@yeah.net</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-10-23 11:50:55 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-10-23 11:51:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ratna-2003">
<CHAR_STUDY_NAME MODIFIED="2013-10-23 11:51:09 +0100" MODIFIED_BY="[Empty name]">
<P>Improved Response in Schizophrenia IRIS.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-10-23 11:51:11 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: double, no further details.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:51:12 +0100" MODIFIED_BY="Dolores Matthews">
<P>Diagnosis: schizophrenia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-16 15:15:48 +0100" MODIFIED_BY="[Empty name]">
<P>1. Quetiapine: dose: not reported.</P>
<P>2. Risperidone: dose: not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-23 11:51:19 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: CGI-S.<BR/>Mental state: PANSS, GAS, HAM-D scores.<BR/>Quality of life SQLS and care-giving inventory scores.<BR/>Health economics.<BR/>Adverse effects: EPS (AIMS, SAS, BAS).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-10-23 11:51:08 +0100" MODIFIED_BY="Dolores Matthews">
<P>1 October 2002</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-01-12 23:34:10 +0000" MODIFIED_BY="[Empty name]">
<P>Dr Lawrence Ratna<BR/>Barnet Hospital<BR/>Wellhouse Lane<BR/>Barnet<BR/>EN5 3DJ<BR/>UK<BR/>Telephone: 020 8216 4617<BR/>Fax: 020 8216 4595<BR/>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-10-23 11:51:08 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-10-23 11:51:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reynolds-2001">
<CHAR_STUDY_NAME MODIFIED="2013-10-23 11:51:32 +0100" MODIFIED_BY="[Empty name]">
<P>A Six-Month, Rater-Blind Comparison of Quetiapine and Risperidone in the Treatment of Tardive Dyskinesia in People With Schizophrenia.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-10-23 11:51:33 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blindness: single, rater-blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-10-23 11:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>N = 30.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-16 15:15:58 +0100" MODIFIED_BY="[Empty name]">
<P>1. Quetiapine: dose: not reported.</P>
<P>2. Risperidone: dose not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-10-23 11:51:36 +0100" MODIFIED_BY="Dolores Matthews">
<P>Not known.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-10-23 11:51:37 +0100" MODIFIED_BY="Dolores Matthews">
<P>Not known.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-10-23 11:51:43 +0100" MODIFIED_BY="[Empty name]">
<P>Not known.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-10-23 11:51:30 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-11-04 17:22:23 +0000" MODIFIED_BY="Laila Asmal">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-10-23 11:18:19 +0100" MODIFIED_BY="Laila Asmal" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 08:57:25 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Astrazeneca-1998">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 09:25:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Atmaca-2003">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 09:43:51 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Byerly-2008">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 09:52:44 +0100" MODIFIED_BY="Laila Asmal" RESULT="YES" STUDY_ID="STD-Canuso-2008">
<DESCRIPTION>
<P>Stratified according to site but method unclear, likely adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 09:53:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Conley-2005">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:38:02 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Deberdt-2008">
<DESCRIPTION>
<P>Randomisation method not reported, statistically significant baseline differences in mean PANSS total and BMI between groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:39:32 +0100" MODIFIED_BY="Laila Asmal" RESULT="YES" STUDY_ID="STD-Eerdekens-2007">
<DESCRIPTION>
<P>Computer randomisation with block permutation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:44:05 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Hatta-2009">
<DESCRIPTION>
<P>Implied but not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:46:00 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2008">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:50:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinon-2006b">
<DESCRIPTION>
<P>Random, computer-generated randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:51:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li--2005">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:52:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2002">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:53:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2003">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:54:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:56:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2004">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:57:17 +0100" MODIFIED_BY="Laila Asmal" RESULT="YES" STUDY_ID="STD-Lu-2006">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:58:16 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Luo-Xin-2008">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:59:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McEvoy-2006">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:00:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McEvoy-2007">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:01:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mori-2004">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:01:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ozguven-2004">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:03:06 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Peng-2007">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:04:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Potkin-2006">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:05:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Riedel-2005">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:07:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Riedel-2007">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:08:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sacchetti-2004">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:09:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sirota-2006">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:10:08 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Song-2008">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:11:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>Random; two steps of randomisation before and after availability of ziprasidone; subjects received other medication than in previous phase 1 treatment. Re-randomised.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:13:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-2003b">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:13:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Voruganti-2007">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:14:18 +0100" MODIFIED_BY="Laila Asmal" RESULT="YES" STUDY_ID="STD-Wang-2006">
<DESCRIPTION>
<P>Random number table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:15:24 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Wei-2006a">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:16:54 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Wei-2006b">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:18:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhong-2006">
<DESCRIPTION>
<P>Random, no further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-10-23 11:18:21 +0100" MODIFIED_BY="Laila Asmal" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 08:57:26 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Astrazeneca-1998">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 09:25:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Atmaca-2003">
<DESCRIPTION>
<P>No further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 09:43:52 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Byerly-2008">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 09:52:45 +0100" MODIFIED_BY="Laila Asmal" RESULT="YES" STUDY_ID="STD-Canuso-2008">
<DESCRIPTION>
<P>Voice response system.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 09:53:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Conley-2005">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:38:02 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Deberdt-2008">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:39:33 +0100" MODIFIED_BY="Laila Asmal" RESULT="YES" STUDY_ID="STD-Eerdekens-2007">
<DESCRIPTION>
<P>Central call centre.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:44:06 +0100" MODIFIED_BY="Laila Asmal" RESULT="YES" STUDY_ID="STD-Hatta-2009">
<DESCRIPTION>
<P>Sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:46:01 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2008">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:50:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kinon-2006b">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:51:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li--2005">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:52:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2002">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:53:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2003">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:54:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>No further details.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:56:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2004">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:57:18 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Lu-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:58:17 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Luo-Xin-2008">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:59:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McEvoy-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:00:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McEvoy-2007">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:01:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mori-2004">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:01:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ozguven-2004">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:03:12 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Peng-2007">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:04:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Potkin-2006">
<DESCRIPTION>
<P>Participants were assigned using a centralised interactive voice response system. Probably a correct method.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:05:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Riedel-2005">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:07:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Riedel-2007">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:08:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sacchetti-2004">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:09:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sirota-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:10:09 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Song-2008">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:11:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:13:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-2003b">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:13:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Voruganti-2007">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:14:19 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:15:27 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Wei-2006a">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:17:17 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Wei-2006b">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:18:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhong-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-10-23 11:18:42 +0100" MODIFIED_BY="Laila Asmal" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Subjective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 08:57:29 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Astrazeneca-1998">
<DESCRIPTION>
<P>Double-blind. Whether blinding was successful has not been examined, but the compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 08:57:35 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Astrazeneca-1998">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 09:25:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Atmaca-2003">
<DESCRIPTION>
<P>Single, rater-blind. Whether blinding was successful has not been examined, but the compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 09:25:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Atmaca-2003">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 09:43:55 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Byerly-2008">
<DESCRIPTION>
<P>Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 09:43:56 +0100" MODIFIED_BY="Laila Asmal" RESULT="YES" STUDY_ID="STD-Byerly-2008">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 09:52:46 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Canuso-2008">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 09:52:47 +0100" MODIFIED_BY="Laila Asmal" RESULT="YES" STUDY_ID="STD-Canuso-2008">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 09:53:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Conley-2005">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 09:53:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Conley-2005">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 10:38:05 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Deberdt-2008">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 10:38:06 +0100" MODIFIED_BY="Laila Asmal" RESULT="YES" STUDY_ID="STD-Deberdt-2008">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 10:39:34 +0100" MODIFIED_BY="Laila Asmal" RESULT="YES" STUDY_ID="STD-Eerdekens-2007">
<DESCRIPTION>
<P>Unlikely that ECG interpretation could have been unblinded. No other subjective outcomes. All medication was identical over encapsulated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 10:39:37 +0100" MODIFIED_BY="Laila Asmal" RESULT="YES" STUDY_ID="STD-Eerdekens-2007">
<DESCRIPTION>
<P>Unlikely that ECG interpretation could have been unblinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 10:44:07 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Hatta-2009">
<DESCRIPTION>
<P>Single, rater blinded. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 10:44:10 +0100" MODIFIED_BY="Laila Asmal" RESULT="YES" STUDY_ID="STD-Hatta-2009">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 10:46:01 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2008">
<DESCRIPTION>
<P>Single, rater blinded. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 10:46:02 +0100" MODIFIED_BY="Laila Asmal" RESULT="YES" STUDY_ID="STD-Hu-2008">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 10:50:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kinon-2006b">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 10:50:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinon-2006b">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 10:51:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li--2005">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 10:51:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li--2005">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 10:52:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2002">
<DESCRIPTION>
<P>Double, probably identical capsules. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 10:52:57 +0100" MODIFIED_BY="Laila Asmal" RESULT="YES" STUDY_ID="STD-Li-2002">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 10:53:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2003">
<DESCRIPTION>
<P>Single, rater-blind. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 10:53:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-2003">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 10:54:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but the examined compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 10:55:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 10:56:18 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2004">
<DESCRIPTION>
<P>Single, rater-blind. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 10:56:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-2004">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 10:57:21 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Lu-2006">
<DESCRIPTION>
<P>Single, rater-blind. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 10:57:22 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Lu-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 10:58:18 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Luo-Xin-2008">
<DESCRIPTION>
<P>Single, rater-blind. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 10:58:18 +0100" MODIFIED_BY="Laila Asmal" RESULT="YES" STUDY_ID="STD-Luo-Xin-2008">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 10:59:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McEvoy-2006">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but the compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 10:59:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McEvoy-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 11:00:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McEvoy-2007">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 11:00:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McEvoy-2007">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 11:01:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mori-2004">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but the compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 11:01:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mori-2004">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 11:01:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ozguven-2004">
<DESCRIPTION>
<P>Single, rater blind. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 11:01:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ozguven-2004">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 11:03:13 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Peng-2007">
<DESCRIPTION>
<P>Single, rater blinded. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 11:03:14 +0100" MODIFIED_BY="Laila Asmal" RESULT="YES" STUDY_ID="STD-Peng-2007">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 11:04:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Potkin-2006">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differsubstantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 11:04:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Potkin-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 11:05:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Riedel-2005">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 11:05:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Riedel-2005">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 11:07:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Riedel-2007">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 11:07:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Riedel-2007">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 11:08:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sacchetti-2004">
<DESCRIPTION>
<P>Single, rater-blind. Whether blinding was successful has not been examined, but the compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 11:08:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sacchetti-2004">
<DESCRIPTION>
<P>Single, rater-blind. Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 11:09:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sirota-2006">
<DESCRIPTION>
<P>Single, rater-blind. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 11:09:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sirota-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 11:10:13 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Song-2008">
<DESCRIPTION>
<P>Single, rater-blind. Whether blinding was successful has not been examined, but the compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 11:10:14 +0100" MODIFIED_BY="Laila Asmal" RESULT="YES" STUDY_ID="STD-Song-2008">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 11:11:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>Double, identical capsules. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 11:11:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 11:13:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-2003b">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 11:13:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Svestka-2003b">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 11:13:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Voruganti-2007">
<DESCRIPTION>
<P>Single, rater-blind. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 11:13:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Voruganti-2007">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 11:14:22 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2006">
<DESCRIPTION>
<P>Single, rater-blind. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 11:14:23 +0100" MODIFIED_BY="Laila Asmal" RESULT="YES" STUDY_ID="STD-Wang-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 11:15:30 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Wei-2006a">
<DESCRIPTION>
<P>Single, rater blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 11:15:33 +0100" MODIFIED_BY="Laila Asmal" RESULT="YES" STUDY_ID="STD-Wei-2006a">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 11:17:19 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Wei-2006b">
<DESCRIPTION>
<P>No further details. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 11:17:22 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Wei-2006b">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-10-23 11:18:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhong-2006">
<DESCRIPTION>
<P>Double, no further details. Whether blinding was successful has not been examined, but both compounds differ substantially in terms of side effects. This can be a problem for blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-10-23 11:18:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zhong-2006">
<DESCRIPTION>
<P>Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-10-23 11:18:53 +0100" MODIFIED_BY="Laila Asmal" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 08:57:51 +0100" MODIFIED_BY="Laila Asmal" RESULT="NO" STUDY_ID="STD-Astrazeneca-1998">
<DESCRIPTION>
<P>36% attrition, early leavers not adequately accounted for.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 09:25:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Atmaca-2003">
<DESCRIPTION>
<P>Overall attrition was low (5.4%). Reasons for leaving early were not assessed; only completer data were presented. Because of the very low rate of attrition, we do not think that a risk of bias was present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 09:44:00 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Byerly-2008">
<DESCRIPTION>
<P>No discussion of participants leaving the study early or of missing data. 100% retention with no missing data is unusual for this type of study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 09:52:51 +0100" MODIFIED_BY="Laila Asmal" RESULT="YES" STUDY_ID="STD-Canuso-2008">
<DESCRIPTION>
<P>Relatively low attrition (15%) for monotherapy phase of study. Difference of 5 participants between randomly assigned and ITT population that are unaccounted for Unlikely to affect final data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 09:53:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Conley-2005">
<DESCRIPTION>
<P>Overall attrition was moderate at 36%. The analysis was based on mixed-effect models. It is unclear whether this statistical method can account for such a relatively high attrition rate.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 10:38:10 +0100" MODIFIED_BY="Laila Asmal" RESULT="NO" STUDY_ID="STD-Deberdt-2008">
<DESCRIPTION>
<P>Overall attrition was very high (57%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change in his condition if he had remained in the study. This assumption obviously can be wrong.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 10:39:41 +0100" MODIFIED_BY="Laila Asmal" RESULT="NO" STUDY_ID="STD-Eerdekens-2007">
<DESCRIPTION>
<P>17.2% attrition in treatment groups. Only completer data were assessed for cardiac effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 10:44:11 +0100" MODIFIED_BY="Laila Asmal" RESULT="NO" STUDY_ID="STD-Hatta-2009">
<DESCRIPTION>
<P>How attrition was accounted for is not described. Half of the participants in the aripiprazole and quetiapine groups dropped out of the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 10:46:05 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2008">
<DESCRIPTION>
<P>No attrition reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 10:51:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kinon-2006b">
<DESCRIPTION>
<P>Overall attrition was very high (54.9%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change in his condition if he had remained in the study. This assumption obviously can be wrong.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 10:51:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Li--2005">
<DESCRIPTION>
<P>Overall attrition was 9.1%. Numbers leaving early were reported only for any reason. Only completer data were assessed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 10:53:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2002">
<DESCRIPTION>
<P>Two participants left the study early as the result of adverse events in the clozapine group. Some doubt continues about whether all data on leaving the study early have been presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 10:53:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2003">
<DESCRIPTION>
<P>One participant in the quetiapine group left the study early because of inefficacy. This participant was not included in the analysis. Some doubt continues about whether all data on leaving the study early have been presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 10:55:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>The attrition rate was very high (75%). Continuous outcomes were evaluated on the basis of a mixed-effects model. It is unclear whether any statistical method can account for such a high attrition rate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 10:56:22 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2004">
<DESCRIPTION>
<P>Five participants left the study early: three because of adverse events in the clozapine group and two for unclear reasons in the quetiapine group. These five participants were not included in the analysis. Some doubt continues about whether all data on leaving the study early have been presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 10:57:25 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Lu-2006">
<DESCRIPTION>
<P>96 participants were recruited, but data are available on only 64 participants. How these missing data were addressed statistically is not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 10:58:29 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Luo-Xin-2008">
<DESCRIPTION>
<P>No leaving early reported. This is unusual for this type of study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 10:59:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McEvoy-2006">
<DESCRIPTION>
<P>Overall attrition was extremely high (74%). We doubt that the validity of the findings was not affected by this high number.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 11:00:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McEvoy-2007">
<DESCRIPTION>
<P>Overall attrition was high (70.3%). The primary analysis was based on a mixed-effects model; secondary outcomes used the last-observation-carried forward approach and included only study completers. Nevertheless, it is unclear whether any statistical method can account for such high attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 11:01:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mori-2004">
<DESCRIPTION>
<P>Data on leaving the study early have not been presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 11:01:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ozguven-2004">
<DESCRIPTION>
<P>The overall attrition rate was 13%. The method used to address incomplete outcomes has not been presented. Nevertheless, because of the low attrition rate, we consider the risk to be low.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 11:03:15 +0100" MODIFIED_BY="Laila Asmal" RESULT="NO" STUDY_ID="STD-Peng-2007">
<DESCRIPTION>
<P>Dropouts not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 11:04:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Potkin-2006">
<DESCRIPTION>
<P>Overall attrition was 12%. The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change in his condition if he had remained in the study. This assumption obviously can be wrong. Nevertheless, because of the overall low attrition, it is unlikely that the results have been affected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 11:05:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Riedel-2005">
<DESCRIPTION>
<P>Overall attrition was considerable (45.2%). The data were analysed using last-observation-carried-forward and a completer analysis. Nevertheless, it is questionable whether any statistical method can account for such high attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 11:07:09 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Riedel-2007">
<DESCRIPTION>
<P>Overall attrition was very high at 61.5%.The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change in his condition if he had remained in the study. This assumptionobviously can be wrong.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 11:08:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sacchetti-2004">
<DESCRIPTION>
<P>The attrition rate was 18.6%. The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change in his condition if he had remained in the study. This assumption obviously can be wrong.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 11:09:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sirota-2006">
<DESCRIPTION>
<P>Overall attrition was low (12%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change in his condition if he had remained in the study. This assumption obviously can be wrong. Nevertheless, because of the low attrition, we do not think that this led to bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 11:10:14 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Song-2008">
<DESCRIPTION>
<P>No dropouts were reported. This is unusual for this type of study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 11:11:55 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>The attrition rate was very high (72.5%). Continuous data were analysed on the basis of mixed-effects models. It is unclear whether any statistical method can account for such high rates of leaving the study early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 11:13:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Svestka-2003b">
<DESCRIPTION>
<P>Data on the overall attrition rate were not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 11:13:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Voruganti-2007">
<DESCRIPTION>
<P>A discrepancy has been noted between the abstract and the text. According to the abstract, fewer participants left the study early; however, this finding was no longer mentioned in the text, according to which the overall attrition was only 1.2%.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 11:14:23 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2006">
<DESCRIPTION>
<P>No dropouts reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 11:15:37 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Wei-2006a">
<DESCRIPTION>
<P>12.1% attrition. How this attrition was accounted for statistically is unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 11:17:28 +0100" MODIFIED_BY="Laila Asmal" RESULT="NO" STUDY_ID="STD-Wei-2006b">
<DESCRIPTION>
<P>Seven participants left the study early s the result of adverse events (4 in quetiapine group and 3 in aripiprazole group). Intention-to-treat analysis not done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 11:18:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhong-2006">
<DESCRIPTION>
<P>Overall attrition was high (52.1%). The last-observation-carried-forward method was used to account for people leaving the study early. It assumes that a participant who discontinued the study would not have had a change in his condition if he had remained in the study. This assumption obviously can be wrong. Data on study completers were also available. Nevertheless, it is unclear whether any statistical method can account for such a degree of attrition.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-11-04 17:22:23 +0000" MODIFIED_BY="Laila Asmal" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 08:57:59 +0100" MODIFIED_BY="Laila Asmal" RESULT="NO" STUDY_ID="STD-Astrazeneca-1998">
<DESCRIPTION>
<P>Not all pre-defined outcomes were described, including CGI scores, PANSS subscales and adverse event rating scales.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 09:25:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Atmaca-2003">
<DESCRIPTION>
<P>Probably free of bias. The study focused on serum leptin and triglyceride levels, which were adequately described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 09:44:01 +0100" MODIFIED_BY="Laila Asmal" RESULT="YES" STUDY_ID="STD-Byerly-2008">
<DESCRIPTION>
<P>We did not find evidence for selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 09:52:52 +0100" MODIFIED_BY="Laila Asmal" RESULT="NO" STUDY_ID="STD-Canuso-2008">
<DESCRIPTION>
<P>Not all pre-defined adverse effects were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 09:53:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Conley-2005">
<DESCRIPTION>
<P>Not all pre-defined adverse effects were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:38:11 +0100" MODIFIED_BY="Laila Asmal" RESULT="NO" STUDY_ID="STD-Deberdt-2008">
<DESCRIPTION>
<P>Not all pre-defined outcomes were described, including PANSS scores.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:39:43 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Eerdekens-2007">
<DESCRIPTION>
<P>Details for concomitant medication prescription in each treatment arm not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:44:15 +0100" MODIFIED_BY="Laila Asmal" RESULT="YES" STUDY_ID="STD-Hatta-2009">
<DESCRIPTION>
<P>Pre-stipulated outcomes are reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:46:09 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2008">
<DESCRIPTION>
<P>Not all pre-defined adverse effects were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:51:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kinon-2006b">
<DESCRIPTION>
<P>The numbers of participants who received antiparkinson medication or who had leukopaenia were not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:51:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Li--2005">
<DESCRIPTION>
<P>No reporting of adverse effects was provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:53:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-2002">
<DESCRIPTION>
<P>We did not find evidence of selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:53:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Li-2003">
<DESCRIPTION>
<P>The study duration was eight weeks, but only outcomes at four weeks were available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:55:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>No evidence of selective reporting was found.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:56:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Liu-2004">
<DESCRIPTION>
<P>Mean doses of the medications used were not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:57:26 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Lu-2006">
<DESCRIPTION>
<P>Mean doses of the medications used were not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:58:32 +0100" MODIFIED_BY="Laila Asmal" RESULT="NO" STUDY_ID="STD-Luo-Xin-2008">
<DESCRIPTION>
<P>PANSS scores and akathisia were the only outcomes reported. No other adverse events mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:59:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McEvoy-2006">
<DESCRIPTION>
<P>Because of small numbers and the very high attrition, only data on 26 weeks of treatment (rather than the full duration of 52 weeks) were presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:00:36 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McEvoy-2007">
<DESCRIPTION>
<P>Adverse events were presented only in cases of moderate or worse severity.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:01:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mori-2004">
<DESCRIPTION>
<P>Adverse events were not reported. Numbers on use of antiparkinson medication have not been presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:01:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ozguven-2004">
<DESCRIPTION>
<P>The study has been published only as an abstract. Efficacy data have been presented only as percentage change from baseline.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:03:18 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Peng-2007">
<DESCRIPTION>
<P>Number on parkinsonian medication not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:04:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Potkin-2006">
<DESCRIPTION>
<P>Data on some adverse effects were not available. Side effects had to occur in at least 10% to be reported. Important side effects may have been missed by this procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:05:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Riedel-2005">
<DESCRIPTION>
<P>Data on negative symptoms (SANS) and some adverse effects were not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:07:10 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Riedel-2007">
<DESCRIPTION>
<P>Data on global state have not been presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:08:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sacchetti-2004">
<DESCRIPTION>
<P>Efficacy data (PANSS) were presented only as percentage change, without indications of standard deviations, standard errors, P values or ranges. Only interim data after half of the participants had been recruited have been presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:09:23 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sirota-2006">
<DESCRIPTION>
<P>Efficacy data (PANSS, SANS) have been presented only as median change. No data on extrapyramidal side effects and cardiac effects were provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:10:16 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Song-2008">
<DESCRIPTION>
<P>Not all stipulated outcome measures were reported, including adverse events, weight and ECG changes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:11:59 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>Use of antiparkinson medication was permitted, but data on this outcome have not been presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:13:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Svestka-2003b">
<DESCRIPTION>
<P>For some metabolic parameters, no data were available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:13:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Voruganti-2007">
<DESCRIPTION>
<P>Use of antiparkinson medication was permitted, but the numbers have not been presented.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:14:33 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2006">
<DESCRIPTION>
<P>ECG changes not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-04 17:22:23 +0000" MODIFIED_BY="Laila Asmal" RESULT="NO" STUDY_ID="STD-Wei-2006a">
<DESCRIPTION>
<P>Use of antiparkinson medication was permitted, but numbers have not been presented. Adverse events not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-28 10:00:38 +0100" MODIFIED_BY="Laila Asmal" RESULT="NO" STUDY_ID="STD-Wei-2006b">
<DESCRIPTION>
<P>PANSS positive and negative scores only reported. Details on adverse events not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:19:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhong-2006">
<DESCRIPTION>
<P>Adverse events were presented only with an incidence of at least 5% among participants; therefore, important side effects may have been missed by this procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-10-23 11:19:03 +0100" MODIFIED_BY="Laila Asmal" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 08:58:00 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Astrazeneca-1998">
<DESCRIPTION>
<P>Study sponsored by manufacturer of quetiapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 09:25:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Atmaca-2003">
<DESCRIPTION>
<P>Data on the allowed dose range have not been presented. Furthermore, the pre-study treatment was heterogeneous, as 19 participants had never taken any psychotropic drugs, but most other participants had a long history of previous treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 09:44:03 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Byerly-2008">
<DESCRIPTION>
<P>No washout period was provided, and a one-week overlap of risperidone in the quetiapine group was described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 09:52:53 +0100" MODIFIED_BY="Laila Asmal" RESULT="NO" STUDY_ID="STD-Canuso-2008">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of paliperidone.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 09:54:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Conley-2005">
<DESCRIPTION>
<P>A slight baseline imbalance was noted in terms of mean age and mean number of previous hospitalisations (14 in the risperidone group and 9.7 in the quetiapine group).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:38:14 +0100" MODIFIED_BY="Laila Asmal" RESULT="NO" STUDY_ID="STD-Deberdt-2008">
<DESCRIPTION>
<P>The study was sponsored by the manufacturers of olanzapine. Mean modal dose rather than mean dose reported. Study inadequately powered for primary outcome because of recruitment difficulties.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:39:45 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Eerdekens-2007">
<DESCRIPTION>
<P>Study sponsored by the manufacturer of paliperidone.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:44:16 +0100" MODIFIED_BY="Laila Asmal" RESULT="NO" STUDY_ID="STD-Hatta-2009">
<DESCRIPTION>
<P>Study was powered for discontinuation of treatment only. Not powered for any other outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:46:10 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Hu-2008">
<DESCRIPTION>
<P>No dropouts were reported. Funding source was not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:51:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kinon-2006b">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of olanzapine.<B>
<BR/>
</B>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:52:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li--2005">
<DESCRIPTION>
<P>Baseline characteristics have not been presented for both groups separately. Therefore, baseline imbalance cannot be excluded. Furthermore, no washout period was provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:53:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2002">
<DESCRIPTION>
<P>No data on pre-study medication were provided; therefore baseline imbalance cannot be excluded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:53:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2003">
<DESCRIPTION>
<P>The allowed dose range was not indicated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:55:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lieberman-2005">
<DESCRIPTION>
<P>Dose ranges were very different; the upper dose range of olanzapine was 30 mg, whereas risperidone could be titrated only up to 6 mg/d. No washout period was provided. An overlap in the administration of formerly given antipsychotics was permitted for the first four weeks after randomisation.<BR/>Allocation to ziprasidone treatment was not possible from the start of the study because of later availability of ziprasidone.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:56:26 +0100" MODIFIED_BY="Laila Asmal" RESULT="NO" STUDY_ID="STD-Liu-2004">
<DESCRIPTION>
<P>Clozapine was titrated to 400 mg/d within 10 days. Such a fast dose increase can be accompanied by a higher rate of adverse effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:57:26 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Lu-2006">
<DESCRIPTION>
<P>Quetiapine dose range was below therapeutic range.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:58:36 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Luo-Xin-2008">
<DESCRIPTION>
<P>Funding source is unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 10:59:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McEvoy-2006">
<DESCRIPTION>
<P>The dose ranges were very different, and the upper dose range of olanzapine was 30 mg/d, whereas risperidone could be given only in a maximum dose of 6 mg/d. Participants had a history of former inefficacy of one of the medications. It was excluded that the same medication could be given again, but still this might implicate a risk of bias due to baseline imbalance in terms of former treatment. No washout phase was provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:00:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-McEvoy-2007">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of quetiapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:01:23 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mori-2004">
<DESCRIPTION>
<P>No washout period was provided. The previous antipsychotic treatment was gradually tapered over four weeks. Thus, during a period of 4 weeks, participants were taking two drugs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:01:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ozguven-2004">
<DESCRIPTION>
<P>Only female participants could be included, so a possible gender bias cannot be excluded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:03:19 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Peng-2007">
<DESCRIPTION>
<P>Funding source unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:04:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Potkin-2006">
<DESCRIPTION>
<P>This study was sponsored by the manufacturer of risperidone.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:05:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Riedel-2005">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of quetiapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:07:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Riedel-2007">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of olanzapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:08:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sacchetti-2004">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of quetiapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:09:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sirota-2006">
<DESCRIPTION>
<P>This study was sponsored by the manufacturer of quetiapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:10:20 +0100" MODIFIED_BY="Laila Asmal" RESULT="NO" STUDY_ID="STD-Song-2008">
<DESCRIPTION>
<P>Whether informed consent was obtained is unclear, and the funding source was not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:12:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stroup-2006">
<DESCRIPTION>
<P>Participants had a history of former intolerance to atypical antipsychotic treatment, but baseline data on this were not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:13:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Svestka-2003b">
<DESCRIPTION>
<P>A slight baseline imbalance in mean age was described as non-significant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:13:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Voruganti-2007">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of quetiapine.No washout period was provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:14:34 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2006">
<DESCRIPTION>
<P>Funding source is unclear. Ethics approval and informed consent not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:15:47 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Wei-2006a">
<DESCRIPTION>
<P>Ethics approval unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:17:36 +0100" MODIFIED_BY="Laila Asmal" RESULT="UNKNOWN" STUDY_ID="STD-Wei-2006b">
<DESCRIPTION>
<P>No data on pre-study medication; therefore, baseline imbalance cannot be excluded. Funding source unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 11:19:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhong-2006">
<DESCRIPTION>
<P>The study was sponsored by the manufacturer of quetiapine.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-11-04 17:25:00 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-10-23 12:16:21 +0100" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2013-06-25 14:29:26 +0100" MODIFIED_BY="Grade Profiler">QUETIAPINE versus ARIPIPRAZOLE for schizophrenia</TITLE>
<TABLE COLS="7" ROWS="24">
<TR>
<TD COLSPAN="7">
<P>
<B>QUETIAPINE versus ARIPIPRAZOLE for schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> participants with schizophrenia<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> QUETIAPINE versus ARIPIPRAZOLE<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>QUETIAPINE versus ARIPIPRAZOLE</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: 1. General - average endpoint score </B>
<BR/>PANSS total</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean mental state: 1. General - average endpoint score in the intervention groups was<BR/>
<B>1.62 higher</B>
<BR/>(0.89 lower to 4.14 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>297<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: 2. Positive symptoms average endpoint score</B>
<BR/>PANSS positive subscore</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean mental state: 2. Positive symptoms - average endpoint score in the intervention groups was<BR/>
<B>0.62 higher</B>
<BR/>(1.13 lower to 2.38 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>297<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: 3. Negative symptoms - average endpoint score (PANSS negative subscore, high = poor)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean mental state: 3. Negative symptoms - average endpoint score (PANSS negative subscore, high = poor) in the intervention groups was<BR/>
<B>1 higher</B>
<BR/>(0.25 lower to 2.25 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>297<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Quality of life: substantial improvement</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported this outcome in any form</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse effects: 1. Sedation</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported this outcome in any form</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Adverse effects: 2. Extrapyramidal effects - use of antiparkinson medication</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>4</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 0.67 </B>
<BR/>(0.12 to 3.57)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>40<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>5,6,7</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>50 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>34 per 1000</B>
<BR/>(6 to 178)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>4</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>150 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>101 per 1000</B>
<BR/>(18 to 535)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>4</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>250 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>168 per 1000</B>
<BR/>(30 to 892)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Adverse effects: 3. Metabolic - weight gain </B>&#8805;<B> 7% of total body weight</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>4</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 0.52 </B>
<BR/>(0.1 to 2.74)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>155<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>8,9</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>10 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>5 per 1000</B>
<BR/>(1 to 27)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>4</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>50 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>26 per 1000</B>
<BR/>(5 to 137)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>4</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>52 per 1000</B>
<BR/>(10 to 274)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence:<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Risk of bias: rated serious - only one study adequately described appropriate allocation concealment methods (but not sequence generation). All other studies did not adequately describe sequence generation and allocation concealment.<BR/>
<SUP>2</SUP> Inconsistency: rated 'no' the P value for heterogeneity not statistically significant and I<SUP>2</SUP> &lt; 50%.<BR/>
<SUP>3</SUP> Imprecise data: rated serious - only a few studies contributed to this outcome and confidence interval was wide.<BR/>
<SUP>4</SUP> Moderate risk equates to that found within study.<BR/>
<SUP>5</SUP> Risk of bias: rated serious - the one study that contributed to this outcome adequately described appropriate allocation concealment methods but not sequence generation.<BR/>
<SUP>6</SUP> Imprecise data: rated serious - only one study with a wide confidence interval reported this outcome.<BR/>
<SUP>7</SUP> Publication bias: rated no - only one study reported this outcome making publication bias difficult to assess<BR/>
<SUP>8</SUP> Risk of bias: rated serious - neither of the two studies reporting this outcome adequately described appropriate allocation concealment and sequence generation methods.<BR/>
<SUP>9</SUP> Imprecise data: rated serious - only two studies reported this outcome, both with wide confidence intervals crossing the line of no effect.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2013-11-04 17:24:00 +0000" MODIFIED_BY="Grade Profiler" NO="2" READONLY="YES">
<TITLE MODIFIED="2013-06-25 15:28:31 +0100" MODIFIED_BY="Grade Profiler">QUETIAPINE versus CLOZAPINE - all data short term for schizophrenia</TITLE>
<TABLE COLS="7" ROWS="25">
<TR>
<TD COLSPAN="7">
<P>
<B>QUETIAPINE versus CLOZAPINE all data short term for schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> participants with schizophrenia<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> QUETIAPINE versus CLOZAPINE all data short term<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>QUETIAPINE versus CLOZAPINE all data short term</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: 1. General - average endpoint score short term (PANSS total, high = poor)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mental state: 1. General - average endpoint score short term (PANSS total, high = poor) in the intervention groups was<BR/>
<B>0.5 lower</B>
<BR/>(2.85 lower to 1.86 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>232<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: 2. Positive symptoms - average endpoint score</B>
<BR/>PANSS positive subscore</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean mental state: 2. Positive symptoms - average endpoint score in the intervention groups was<BR/>
<B>0.7 lower</B>
<BR/>(2.07 lower to 0.68 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>142<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: 3. Negative symptoms - average endpoint score short term </B>
<BR/>PANSS negative subscore</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mental state: 3. Negative symptoms - average endpoint score short term in the intervention groups was<BR/>
<B>2.23 lower</B>
<BR/>(3.48 to 0.99 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>142<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Quality of life: substantial improvement</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No study reported this outcome in any form</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Adverse effects: 1. Sedation</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>5</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 0.22 </B>
<BR/>(0.11 to 0.47)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>135<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>44 per 1000</B>
<BR/>(22 to 94)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>5</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>500 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>110 per 1000</B>
<BR/>(55 to 235)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>5</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>800 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>176 per 1000</B>
<BR/>(88 to 376)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Adverse effects: 2. Extrapyramidal effects - use of antiparkinson medication</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>28<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Risks were calculated from pooled risk differences. No events in either group (RD 0.0 CI -0.13 to 0.13)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Adverse effects: 3. Metabolic - weight gain</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>5</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 0.53 </B>
<BR/>(0.25 to 1.11)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>135<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>53 per 1000</B>
<BR/>(25 to 111)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>5</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>250 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>132 per 1000</B>
<BR/>(62 to 278)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>5</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>400 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>212 per 1000</B>
<BR/>(100 to 444)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence:<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Risk of bias: rated serious none of the studies adequately described sequence generation and allocation concealment.<BR/>
<SUP>2</SUP>Inconsistency: rated 'no' the P value for heterogeneity not statistically significant and I<SUP>2</SUP> &lt; 50%.<BR/>
<SUP>3</SUP>Imprecise data: rated serious wide confidence intervals for all individual studies, all crossing the line of no effect.<BR/>
<SUP>4</SUP>Imprecise data: rated serious only two studies, both with wide confidence intervals.<BR/>
<SUP>5</SUP>Moderate risk equates to that within trials.<BR/>
<SUP>6</SUP>Imprecise data: rated serious one small study. No events.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2013-11-04 17:24:12 +0000" MODIFIED_BY="Grade Profiler" NO="3" READONLY="YES">
<TITLE MODIFIED="2013-06-26 08:14:58 +0100" MODIFIED_BY="Grade Profiler">QUETIAPINE versus OLANZAPINE for schizophrenia</TITLE>
<TABLE COLS="7" ROWS="29">
<TR>
<TD COLSPAN="7">
<P>
<B>QUETIAPINE versus OLANZAPINE for schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> participants with schizophrenia<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> QUETIAPINE versus OLANZAPINE<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>QUETIAPINE versus OLANZAPINE</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: 1. General - average endpoint score (PANSS total, high = poor)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mental state: 1. General - average endpoint score (PANSS total, high = poor) in the intervention groups was<BR/>
<B>3.67 higher</B>
<BR/>(1.95 to 5.39 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1486<BR/>(11 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: 2. Positive symptoms - average endpoint score </B>
<BR/>PANSS positive subscore</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mental state: 2. Positive symptoms - average endpoint score in the intervention groups was<BR/>
<B>1.02 higher</B>
<BR/>(0.81 lower to 2.85 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>801<BR/>(9 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>3,4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: 3. Negative symptoms - endpoint score</B>
<BR/>PANSS negative subscore</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mental state: 3. Negative symptoms - average endpoint score in the intervention groups was<BR/>
<B>0.86 higher</B>
<BR/>(0.32 lower to 2.03 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>801<BR/>(9 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Quality of life: general - average change in endpoint score medium term</B>
<BR/>QLS total score</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean quality of life: general - average change in endpoint score medium term in the intervention groups was<BR/>
<B>1.8 higher</B>
<BR/>(2.42 lower to 6.02 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>286<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>4,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Adverse effects: 1. Sedation</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>7</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 0.98 </B>
<BR/>(0.84 to 1.13)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>1615<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>98 per 1000</B>
<BR/>(84 to 113)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>7</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>300 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>294 per 1000</B>
<BR/>(252 to 339)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>7</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>500 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>490 per 1000</B>
<BR/>(420 to 565)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Adverse effects: 2. Extrapyramidal effects - use of antiparkinson medication</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>7</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>1127<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>Risks were calculated from pooled risk differences</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>50 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>28 per 1000</B>
<BR/>(10 to 44)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>7</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>55 per 1000</B>
<BR/>(21 to 89)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>7</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>150 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>82 per 1000</B>
<BR/>(31 to 133)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Adverse effects: 3. Metabolic - weight significant gain</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>7</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 0.69 </B>
<BR/>(0.51 to 0.95)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>1321<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>138 per 1000</B>
<BR/>(102 to 190)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>7</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>400 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>276 per 1000</B>
<BR/>(204 to 380)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>7</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>600 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>414 per 1000</B>
<BR/>(306 to 570)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence:<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Risk of bias: rated serious no studies adequately described sequence generation and allocation concealment.<BR/>
<SUP>2</SUP>Imprecision: rated &#8217;very serious&#8217; only few studies contribute data to this event and the CI was quite wide.<BR/>
<SUP>3</SUP>Risk of bias: rated serious one study adequately described appropriate allocation concealment methods but not sequence generation, and another study adequately described sequence generation but not allocation concealment. All other studies did not adequately describe sequence generation and allocation concealment.<BR/>
<SUP>4</SUP>Inconsistency: rated &#8217;no&#8217; although the P value for heterogeneity was statistically significant and the I<SUP>2</SUP> &gt; 50%, the direction of the effect of almost all studies was the same. Exclusion of one outlier (<LINK REF="STD-Voruganti-2007" TYPE="STUDY">Voruganti 2007</LINK>) rendered the heterogeneity not statistically significant and I<SUP>2</SUP> &lt; 50%. Therefore, this inconsistency does not challenge the overall results.<BR/>
<SUP>5</SUP>Imprecision: rated 'no' exclusion of potentially skewed data (<LINK REF="STD-Mori-2004" TYPE="STUDY">Mori 2004</LINK>; <LINK REF="STD-Voruganti-2007" TYPE="STUDY">Voruganti 2007</LINK>) revealed an overall significant difference in favour of olanzapine.<BR/>
<SUP>6</SUP>Risk of bias: rated serious no studies adequately described sequence generation and allocation concealment.<BR/>
<SUP>7</SUP>Moderate risk equates to that of studies.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2013-11-04 17:25:00 +0000" MODIFIED_BY="Grade Profiler" NO="4" READONLY="YES">
<TITLE MODIFIED="2013-06-25 16:36:10 +0100" MODIFIED_BY="Grade Profiler">QUETIAPINE versus PALIPERIDONE for schizophrenia</TITLE>
<TABLE COLS="7" ROWS="22">
<TR>
<TD COLSPAN="7">
<P>
<B>QUETIAPINE versus PALIPERIDONE for schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> participants with schizophrenia<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> QUETIAPINE versus PALIPERIDONE<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>QUETIAPINE versus PALIPERIDONE</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: 1. General - average endpoint score </B>
<BR/>PANSS total</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mental state: 1. General - average endpoint score in the intervention groups was<BR/>
<B>6.3 higher</B>
<BR/>(2.77 to 9.83 higher)<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>319<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: 2. Positive symptoms - average endpoint score</B>
<BR/>PANSS positive subscore</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mental state: 2. Positive symptoms average endpoint score in the intervention groups was<BR/>
<B>1.60 higher</B>
<BR/>(0.42 to 2.78 higher)<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>319<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: 3. Negative symptoms - average endpoint score</B>
<BR/>PANSS negative subscore</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mental state: 3. Negative symptoms - average endpoint score in the intervention groups was<BR/>
<B>1.3 higher</B>
<BR/>(0.52 to 2.08 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>319<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Quality of life: substantial improvement</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No trial reported this outcome in any form</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse effects: 1. Sedation</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No trial reported this outcome in any form</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Adverse effects: 2. Extrapyramidal effects use of antiparkinson medication</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>3</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 0.64 </B>
<BR/>(0.45 to 0.91)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>319<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>128 per 1000</B>
<BR/>(90 to 182)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>3</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>400 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>256 per 1000</B>
<BR/>(180 to 364)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>3</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>600 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>384 per 1000</B>
<BR/>(270 to 546)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse effects: 3. Metabolic weight gain </B>&#8805;<B> 7% of total body weight</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>3</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 2.52 </B>
<BR/>(0.5 to 12.78)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>319<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>10 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>25 per 1000</B>
<BR/>(5 to 128)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>3</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>252 per 1000</B>
<BR/>(50 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence:<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Calculated using generic inverse variance.<BR/>
<SUP>2</SUP>Imprecision: rated &#8217;serious&#8217; only one study contributes data to outcome and the CI was quite wide.<BR/>
<SUP>3</SUP>Moderate risk equates to that within the trial.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-05" MODIFIED="2013-10-23 12:27:20 +0100" MODIFIED_BY="Grade Profiler" NO="5" READONLY="YES">
<TITLE MODIFIED="2013-06-25 17:21:19 +0100" MODIFIED_BY="Grade Profiler">QUETIAPINE versus RISPERIDONE for schizophrenia</TITLE>
<TABLE COLS="7" ROWS="27">
<TR>
<TD COLSPAN="7">
<P>
<B>QUETIAPINE versus RISPERIDONE for schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> participants with schizophrenia<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> QUETIAPINE versus RISPERIDONE<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>QUETIAPINE versus RISPERIDONE</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: 1. General - average endpoint score</B>
<BR/>PANSS total score</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mental state: 1. General - average endpoint score in the intervention groups was<BR/>
<B>1.74 higher</B>
<BR/>(0.19 to 3.29 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>2155<BR/>(13 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: 2. Positive symptoms - average endpoint score </B>
<BR/>PANSS positive subscore</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mental state: 2. Positive symptoms - average endpoint score in the intervention groups was<BR/>
<B>1.38 higher</B>
<BR/>(0.51 to 2.24 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1492<BR/>(11 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: 3. Negative symptoms - average endpoint score</B>
<BR/>PANSS negative subscore</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean mental state: 3. Negative symptoms - average endpoint score in the intervention groups was<BR/>
<B>0.69 higher</B>
<BR/>(0.02 lower to 1.41 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1367<BR/>(10 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Quality of life: general average endpoint score</B>
<BR/>QLS total score</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mean quality of life: general average endpoint score in the intervention groups was<BR/>
<B>3.44 lower</B>
<BR/>(4.46 to 2.43 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>152<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse effects: 1. Sedation</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.21 </B>
<BR/>(1.06 to 1.38)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>2226<BR/>(8)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>246 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>298 per 1000</B>
<BR/>(261 to 340)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>239 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>289 per 1000</B>
<BR/>(253 to 330)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Adverse effects: 2. Extrapyramidal effects - use of antiparkinson medication</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>6</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 0.5 </B>
<BR/>(0.36 to 0.69)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>2163<BR/>(8 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>50 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>25 per 1000</B>
<BR/>(18 to 34)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>6</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>150 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>75 per 1000</B>
<BR/>(54 to 103)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>6</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>250 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>125 per 1000</B>
<BR/>(90 to 172)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Adverse effects: 3. Metabolic weight gain </B>&#8805;<B> 7% of total body weight</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>6</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 0.96 </B>
<BR/>(0.82 to 1.14)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>2070<BR/>(9 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>96 per 1000</B>
<BR/>(82 to 114)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>6</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>192 per 1000</B>
<BR/>(164 to 228)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>6</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>300 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>288 per 1000</B>
<BR/>(246 to 342)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence:<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Risk of bias: rated serious overall inadequate description of sequence generation and allocation concealment. Only two studies adequately described sequence generation.<BR/>
<SUP>2</SUP>Inconsistency: rated &#8217;no&#8217; although the P value for heterogeneity was statistically significant and the I<SUP>2</SUP> &gt; 50%, the direction of the effect of almost all studies was the same. Therefore, this inconsistency does not challenge the overall results.<BR/>
<SUP>3</SUP>Risk of bias: rated serious overall inadequate description of sequence generation and allocation concealment. One study adequately described sequence generation and one study sequence generation.<BR/>
<SUP>4</SUP>Imprecision: rated serious most studies comprised small samples sizes with wide confidence intervals.<BR/>
<SUP>5</SUP>Risk of bias: rated serious overall inadequate description of sequence generation and allocation concealment. One study adequately described sequence generation and two studies sequence generation.<BR/>
<SUP>6</SUP>Moderate risk equates to that within trials.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-06" MODIFIED="2013-10-23 12:30:38 +0100" MODIFIED_BY="Grade Profiler" NO="6" READONLY="YES">
<TITLE MODIFIED="2013-06-25 18:23:09 +0100" MODIFIED_BY="Grade Profiler">QUETIAPINE versus ZIPRASIDONE for schizophrenia</TITLE>
<TABLE COLS="7" ROWS="29">
<TR>
<TD COLSPAN="7">
<P>
<B>QUETIAPINE versus ZIPRASIDONE for schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> participants with schizophrenia<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> QUETIAPINE versus ZIPRASIDONE<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>QUETIAPINE versus ZIPRASIDONE</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: 1. General - average endpoint score</B>
<BR/>PANSS total score</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mental state: 1. General - average endpoint score in the intervention groups was<BR/>
<B>3.7 higher</B>
<BR/>(2.97 lower to 10.37 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>198<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: 2. Positive symptoms - average endpoint score medium term </B>
<BR/>PANSS positive subscore</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mental state: 2. Positive symptoms - average endpoint score medium term in the intervention groups was<BR/>
<B>0 higher</B>
<BR/>(2.18 lower to 2.18 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>198<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mental state: 3. Negative symptoms - average endpoint score medium term</B>
<BR/>PANSS negative subscore</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>Mental state: 3. Negative symptoms - average endpoint score medium term in the intervention groups was<BR/>
<B>1.6 higher</B>
<BR/>(0.34 lower to 3.54 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>198<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Quality of life: substantial improvement</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>No trial reported this outcome in any form</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Adverse effects: 1. Sedation</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>3</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 1.36 </B>
<BR/>(1.03 to 1.81)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>754<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>136 per 1000</B>
<BR/>(103 to 181)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>3</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>200 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>272 per 1000</B>
<BR/>(206 to 362)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>3</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>300 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>408 per 1000</B>
<BR/>(309 to 543)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Adverse effects: 2. Extrapyramidal effects - use of antiparkinson medication</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>3</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 0.43 </B>
<BR/>(0.2 to 0.93)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>522<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>50 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>22 per 1000</B>
<BR/>(10 to 47)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>3</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>43 per 1000</B>
<BR/>(20 to 93)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>3</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>150 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>65 per 1000</B>
<BR/>(30 to 140)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Adverse effects: 3. Metabolic weight gain </B>&#8805;<B> 7% of total body weight</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low<SUP>3</SUP>
</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 2.22 </B>
<BR/>(1.35 to 3.63)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>754<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>10 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>22 per 1000</B>
<BR/>(14 to 36)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate<SUP>3</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>50 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>111 per 1000</B>
<BR/>(68 to 182)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>High<SUP>3</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>222 per 1000</B>
<BR/>(135 to 363)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence:<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Risk of bias: rated serious - inadequately described sequence generation and allocation concealment.<BR/>
<SUP>2</SUP>Imprecision: rated serious - only one study contributed to this important outcome and the confidence interval was large.<BR/>
<SUP>3</SUP>Moderate risk equates to that within trials.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-11-04 17:25:08 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-07-24 10:44:01 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-06-26 14:14:53 +0100" MODIFIED_BY="[Empty name]">Studies possible to include but not fully blinded</TITLE>
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P>Study tag</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-An-2003" TYPE="STUDY">An 2003</LINK>;<LINK REF="STD-An-2006" TYPE="STUDY">An 2006</LINK>;<LINK REF="STD-Arango-2009" TYPE="STUDY">Arango 2009</LINK>; <LINK REF="STD-Ban-2008" TYPE="STUDY">Ban 2008</LINK>; <LINK REF="STD-Beuzen-2005" TYPE="STUDY">Beuzen 2005</LINK>; <LINK REF="STD-Boter-2005" TYPE="STUDY">Boter 2005</LINK>; <LINK REF="STD-Brecher-2007" TYPE="STUDY">Brecher 2007</LINK>; <LINK REF="STD-Cai-2005" TYPE="STUDY">Cai 2005</LINK>; <LINK REF="STD-Cao-2005" TYPE="STUDY">Cao 2005</LINK>; <LINK REF="STD-Cao-2005" TYPE="STUDY">Cao 2005</LINK>a; <LINK REF="STD-Cao-2006a" TYPE="STUDY">Cao 2006a</LINK>;<LINK REF="STD-Chang-2007" TYPE="STUDY">Chang 2007</LINK>; <LINK REF="STD-Chang-2008" TYPE="STUDY">Chang 2008</LINK>; <LINK REF="STD-Chaudhry-2006" TYPE="STUDY">Chaudhry 2006</LINK>; <LINK REF="STD-Chen-2006a" TYPE="STUDY">Chen 2006a</LINK>; <LINK REF="STD-Chen-2007a" TYPE="STUDY">Chen 2007a</LINK>; <LINK REF="STD-Chen-2007b" TYPE="STUDY">Chen 2007b</LINK>; <LINK REF="STD-Chen-2007c" TYPE="STUDY">Chen 2007c</LINK>; <LINK REF="STD-Chen-2008" TYPE="STUDY">Chen 2008</LINK>; <LINK REF="STD-Cortese-2008" TYPE="STUDY">Cortese 2008</LINK>; <LINK REF="STD-Dai-2004" TYPE="STUDY">Dai 2004</LINK>; <LINK REF="STD-Dai-2005" TYPE="STUDY">Dai 2005</LINK>; <LINK REF="STD-Ding-2004" TYPE="STUDY">Ding 2004</LINK>; <LINK REF="STD-Du-2003" TYPE="STUDY">Du 2003</LINK>; <LINK REF="STD-Fan-2005" TYPE="STUDY">Fan 2005</LINK>; <LINK REF="STD-Fleischhacker-2005" TYPE="STUDY">Fleischhacker 2005</LINK>; <LINK REF="STD-Fu-2005" TYPE="STUDY">Fu 2005</LINK>; <LINK REF="STD-Fu-2005a" TYPE="STUDY">Fu 2005a</LINK>; <LINK REF="STD-Gao-2003" TYPE="STUDY">Gao 2003</LINK>; <LINK REF="STD-Harrigan-2004" TYPE="STUDY">Harrigan 2004</LINK>; <LINK REF="STD-He-2003" TYPE="STUDY">He 2003</LINK>; <LINK REF="STD-Horacek-2004" TYPE="STUDY">Horacek 2004</LINK>; <LINK REF="STD-Huang-2003" TYPE="STUDY">Huang 2003</LINK>; <LINK REF="STD-Jiang-2006" TYPE="STUDY">Jiang 2006</LINK>; <LINK REF="STD-Keks-2006" TYPE="STUDY">Keks 2006</LINK>; <LINK REF="STD-Knegtering-2004" TYPE="STUDY">Knegtering 2004</LINK>; <LINK REF="STD-Kolotkin-2008" TYPE="STUDY">Kolotkin 2008</LINK>; <LINK REF="STD-Koponen-2008" TYPE="STUDY">Koponen 2008</LINK>; <LINK REF="STD-Li-2001" TYPE="STUDY">Li 2001</LINK>; <LINK REF="STD-Li-2003a" TYPE="STUDY">Li 2003a</LINK>; <LINK REF="STD-Li-2003b" TYPE="STUDY">Li 2003b</LINK>; <LINK REF="STD-Li-2005a" TYPE="STUDY">Li 2005a</LINK>; <LINK REF="STD-Li-2005b" TYPE="STUDY">Li 2005b</LINK>; <LINK REF="STD-Li-2007a" TYPE="STUDY">Li 2007a</LINK>; <LINK REF="STD-Li-2007h" TYPE="STUDY">Li 2007h</LINK>; <LINK REF="STD-Li-2008a" TYPE="STUDY">Li 2008a</LINK>; <LINK REF="STD-Li-2008c" TYPE="STUDY">Li 2008c</LINK>; <LINK REF="STD-Li-2008d" TYPE="STUDY">Li 2008d</LINK>; <LINK REF="STD-Lin-2005" TYPE="STUDY">Lin 2005</LINK>; <LINK REF="STD-Lin-2007" TYPE="STUDY">Lin 2007</LINK>; <LINK REF="STD-L_x0027_Italien-2007" TYPE="STUDY">L'Italien 2007</LINK>; <LINK REF="STD-Liu-2003" TYPE="STUDY">Liu 2003</LINK>; <LINK REF="STD-Liu-2003a" TYPE="STUDY">Liu 2003a</LINK>; <LINK REF="STD-Liu-2004a" TYPE="STUDY">Liu 2004a</LINK>; <LINK REF="STD-Liu-2004b" TYPE="STUDY">Liu 2004b</LINK>; <LINK REF="STD-Liu-2005" TYPE="STUDY">Liu 2005</LINK>; <LINK REF="STD-Liu-2005a" TYPE="STUDY">Liu 2005a</LINK>; <LINK REF="STD-Liu-2006" TYPE="STUDY">Liu 2006</LINK>; <LINK REF="STD-Lu-2005" TYPE="STUDY">Lu 2005</LINK>; <LINK REF="STD-Luo-2005" TYPE="STUDY">Luo 2005</LINK>; <LINK REF="STD-Lv-2008" TYPE="STUDY">Lv 2008</LINK>; <LINK REF="STD-Mintzer-2004" TYPE="STUDY">Mintzer 2004</LINK>; <LINK REF="STD-Mullen-2001" TYPE="STUDY">Mullen 2001</LINK>; <LINK REF="STD-Pan-2004" TYPE="STUDY">Pan 2004</LINK>; <LINK REF="STD-Pan-2004a" TYPE="STUDY">Pan 2004a</LINK>; <LINK REF="STD-Pan-2004b" TYPE="STUDY">Pan 2004b</LINK>; <LINK REF="STD-Pang-2002" TYPE="STUDY">Pang 2002</LINK>; <LINK REF="STD-Petty-2005" TYPE="STUDY">Petty 2005</LINK>; <LINK REF="STD-Pfizer-2005" TYPE="STUDY">Pfizer 2005</LINK>; <LINK REF="STD-Qi-2004" TYPE="STUDY">Qi 2004</LINK>; <LINK REF="STD-Qian-2004" TYPE="STUDY">Qian 2004</LINK>; <LINK REF="STD-Reznik-2004" TYPE="STUDY">Reznik 2004</LINK>; <LINK REF="STD-Riera-2004" TYPE="STUDY">Riera 2004</LINK>; <LINK REF="STD-Ruan-2005" TYPE="STUDY">Ruan 2005</LINK>; <LINK REF="STD-Sajatovic-2002" TYPE="STUDY">Sajatovic 2002</LINK>; <LINK REF="STD-Song-2006" TYPE="STUDY">Song 2006</LINK>; <LINK REF="STD-Swanson-2006" TYPE="STUDY">Swanson 2006</LINK>; <LINK REF="STD-Tang-2003" TYPE="STUDY">Tang 2003</LINK>; <LINK REF="STD-Tang-2005" TYPE="STUDY">Tang 2005</LINK>; <LINK REF="STD-Tian-2006" TYPE="STUDY">Tian 2006</LINK>; <LINK REF="STD-Wang-2000" TYPE="STUDY">Wang 2000</LINK>; <LINK REF="STD-Wang-2004" TYPE="STUDY">Wang 2004</LINK>; <LINK REF="STD-Wang-2005" TYPE="STUDY">Wang 2005</LINK>; <LINK REF="STD-Wang-2005a" TYPE="STUDY">Wang 2005a</LINK>; <LINK REF="STD-Wang-2005b" TYPE="STUDY">Wang 2005b</LINK>; <LINK REF="STD-Wang-2005c" TYPE="STUDY">Wang 2005c</LINK>; <LINK REF="STD-Wang-2005d" TYPE="STUDY">Wang 2005d</LINK>; <LINK REF="STD-Wang-2006b" TYPE="STUDY">Wang 2006b</LINK>; <LINK REF="STD-Wei-2006" TYPE="STUDY">Wei 2006</LINK>; <LINK REF="STD-Wen-2005" TYPE="STUDY">Wen 2005</LINK>; <LINK REF="STD-Wu-2005" TYPE="STUDY">Wu 2005</LINK>; <LINK REF="STD-Xiang-2005" TYPE="STUDY">Xiang 2005</LINK>; <LINK REF="STD-Xu-2002" TYPE="STUDY">Xu 2002</LINK>; <LINK REF="STD-Xu-2003" TYPE="STUDY">Xu 2003</LINK>; <LINK REF="STD-Xu-2005" TYPE="STUDY">Xu 2005</LINK>; <LINK REF="STD-Yang-2004" TYPE="STUDY">Yang 2004</LINK>; <LINK REF="STD-Yang-2005" TYPE="STUDY">Yang 2005</LINK>; <LINK REF="STD-Yang-2005a" TYPE="STUDY">Yang 2005a</LINK>; <LINK REF="STD-Yang-2006" TYPE="STUDY">Yang 2006</LINK>; <LINK REF="STD-Yu-2003" TYPE="STUDY">Yu 2003</LINK>; <LINK REF="STD-Yu-2005" TYPE="STUDY">Yu 2005</LINK>; <LINK REF="STD-Yu-2006" TYPE="STUDY">Yu 2006</LINK>; <LINK REF="STD-Yuan-2005" TYPE="STUDY">Yuan 2005</LINK>; <LINK REF="STD-Zhang-2003" TYPE="STUDY">Zhang 2003</LINK>; <LINK REF="STD-Zhang-2005" TYPE="STUDY">Zhang 2005</LINK>; <LINK REF="STD-Zhang-2005a" TYPE="STUDY">Zhang 2005a</LINK>; <LINK REF="STD-Zhang-2005b" TYPE="STUDY">Zhang 2005b</LINK>; <LINK REF="STD-Zhang-2005c" TYPE="STUDY">Zhang 2005c</LINK>; <LINK REF="STD-Zhang-2005d" TYPE="STUDY">Zhang 2005d</LINK>; <LINK REF="STD-Zhang-2006a" TYPE="STUDY">Zhang 2006a</LINK>; <LINK REF="STD-Zhao-2004" TYPE="STUDY">Zhao 2004</LINK>; <LINK REF="STD-Zhao-2005" TYPE="STUDY">Zhao 2005</LINK>; <LINK REF="STD-Zhao-2005a" TYPE="STUDY">Zhao 2005a</LINK>; <LINK REF="STD-Zhong-2006a" TYPE="STUDY">Zhong 2006a</LINK>; <LINK REF="STD-Zhou-2003" TYPE="STUDY">Zhou 2003</LINK>; <LINK REF="STD-Zhou-2003a" TYPE="STUDY">Zhou 2003a</LINK>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2013-11-04 17:25:08 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2013-06-26 14:04:45 +0100" MODIFIED_BY="[Empty name]">Excluded studies relevant to other quetiapine comparisons</TITLE>
<TABLE COLS="2" ROWS="7">
<TR>
<TH>
<P>Excluded study</P>
</TH>
<TH>
<P>Comparison</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Zheng-2007" TYPE="STUDY">Zheng 2007</LINK>
</P>
</TD>
<TD>
<P>quetiapine versus quetiapine + clozapine</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Cao-2006d" TYPE="STUDY">Cao 2006d</LINK>; <LINK REF="STD-Guo-2008" TYPE="STUDY">Guo 2008</LINK>; <LINK REF="STD-Nai-2007" TYPE="STUDY">Nai 2007</LINK>; <LINK REF="STD-Zhang-2006" TYPE="STUDY">Zhang 2006</LINK>; <LINK REF="STD-Sun-2006e" TYPE="STUDY">Sun 2006e</LINK>; <LINK REF="STD-Xu-2006" TYPE="STUDY">Xu 2006</LINK>; <LINK REF="STD-Zhang-2007a" TYPE="STUDY">Zhang 2007a</LINK>
</P>
</TD>
<TD>
<P>quetiapine versus chlorpramazine</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Yang-2006a" TYPE="STUDY">Yang 2006a</LINK>; <LINK REF="STD-Yang-2006b" TYPE="STUDY">Yang 2006b</LINK>
</P>
</TD>
<TD>
<P>quetiapine versus haloperidol</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Chen-2006k" TYPE="STUDY">Chen 2006k</LINK>; <LINK REF="STD-Sun-2007b" TYPE="STUDY">Sun 2007b</LINK>
</P>
</TD>
<TD>
<P>quetiapine versus perphenazine</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Zhao-2007" TYPE="STUDY">Zhao 2007</LINK>; <LINK REF="STD-Zhou-2006" TYPE="STUDY">Zhou 2006</LINK>
</P>
</TD>
<TD>
<P>quetiapine versus sulpiride</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hao-2007" TYPE="STUDY">Hao 2007</LINK>
</P>
</TD>
<TD>
<P>quetiapine from non-domestic source vs domestic quetiapine</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2013-10-23 12:31:33 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2008-12-19 06:29:34 +0000" MODIFIED_BY="[Empty name]">Suggested design of future study</TITLE>
<TABLE COLS="2" ROWS="4">
<TR>
<TH>
<P>Methods</P>
</TH>
<TD>
<P>Allocation: randomised - clearly described generation of sequence and concealment of allocation.<BR/>Blindness: double - described and tested.<BR/>Duration: 6 months minimum.</P>
</TD>
</TR>
<TR>
<TH>
<P>Participants</P>
</TH>
<TD>
<P>Diagnosis: schizophrenia (operational criteria).<BR/>N = 3000*.<BR/>Age: any.<BR/>Gender: both.<BR/>History: any.</P>
</TD>
</TR>
<TR>
<TH>
<P>Interventions</P>
</TH>
<TD>
<P>1. Quetiapine: dose ~300-800 mg/day. N=300.</P>
<P>2. Amisulpride: dose ~ 400-800 mg/day. N=300.</P>
<P>3. Aripiprazole: dose ~ 10-30 mg/day. N=300.</P>
<P>4. Clozapine: dose ~ 300-800 mg/day. N=300.</P>
<P>5. Olanzapine: dose ~ 10-20 mg/day. N=300.</P>
<P>6. Ziprasidone: dose ~ 120-160 mg/day. N=300.</P>
<P>7. Risperidone: dose ~ 4-8 mg/day. N=300.</P>
<P>8. Sertindole: dose ~ 12-24 mg/day. N=300.</P>
<P>9. Zotepine: dose ~ 100-300 mg/day. N=300.</P>
<P>10. Paliperidone: dose~ 6-12 mg/day. N=300.</P>
<P/>
</TD>
</TR>
<TR>
<TH>
<P>Outcomes</P>
</TH>
<TD>
<P>Global state: CGI**, relapse.</P>
<P>Leaving study early (any reason, adverse events, inefficacy).<BR/>Mental state: PANSS.<BR/>Service outcomes: hospitalised, time in hospital, attending out patient clinics.<BR/>Adverse events: UKU.<BR/>Employment, family satisfaction, patient satisfaction.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*Power calculation suggested 300/group would allow good chance of showing a 10% difference between groups for primary outcome.<BR/>
<BR/>**Primary outcome.<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-10-23 08:48:18 +0100" MODIFIED_BY="Laila Asmal">
<COMPARISON ID="CMP-001" MODIFIED="2013-10-22 15:12:28 +0100" MODIFIED_BY="Laila Asmal" NO="1">
<NAME>QUETIAPINE versus ARIPIPRAZOLE</NAME>
<DICH_OUTCOME CHI2="0.19714864466053392" CI_END="1.704454913235505" CI_START="0.5912401502810897" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.003863625722489" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.23158551762592186" LOG_CI_START="-0.2282360812887243" LOG_EFFECT_SIZE="0.001674718168598808" METHOD="MH" MODIFIED="2011-08-26 11:50:20 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.6570322984392463" P_Q="1.0" P_Z="0.9886091597914345" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="75" WEIGHT="100.0" Z="0.014276786051182294">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.19714864466053392" CI_END="1.704454913235505" CI_START="0.5912401502810897" DF="1" EFFECT_SIZE="1.003863625722489" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.23158551762592186" LOG_CI_START="-0.2282360812887243" LOG_EFFECT_SIZE="0.001674718168598808" MODIFIED="2011-08-26 11:50:20 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.6570322984392463" P_Z="0.9886091597914345" STUDIES="2" TAU2="0.0" TOTAL_1="74" TOTAL_2="75" WEIGHT="100.0" Z="0.014276786051182294">
<NAME>any reason</NAME>
<DICH_DATA CI_END="1.854313636091135" CI_START="0.5945596141567795" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.26818319200040547" LOG_CI_START="-0.2258045938605293" LOG_EFFECT_SIZE="0.021189299069938092" MODIFIED="2011-08-26 11:50:20 +0100" MODIFIED_BY="Laila Asmal" ORDER="546" O_E="0.0" SE="0.2901708706936901" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="21" VAR="0.08419913419913422" WEIGHT="86.64555996338113"/>
<DICH_DATA CI_END="3.1930090641636517" CI_START="0.17616611437566843" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5042001513959027" LOG_CI_START="-0.7540776246125026" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2011-07-28 10:12:15 +0100" MODIFIED_BY="Laila Asmal" ORDER="458" O_E="0.0" SE="0.7391185942027817" STUDY_ID="STD-Wei-2006b" TOTAL_1="54" TOTAL_2="54" VAR="0.5462962962962963" WEIGHT="13.354440036618861"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.4343977623389075" CI_END="4.142732078162537" CI_START="-0.8943204609032129" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="1.6242058086296622" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2013-10-22 15:12:01 +0100" MODIFIED_BY="Laila Asmal" NO="2" P_CHI2="0.9330485707074361" P_Q="1.0" P_Z="0.20623465750296477" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="147" TOTAL_2="150" UNITS="" WEIGHT="100.0" Z="1.2639871685695514">
<NAME>Mental state: 1. General - average endpoint score (PANSS total, high=poor)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.4343977623389075" CI_END="4.142732078162537" CI_START="-0.8943204609032129" DF="3" EFFECT_SIZE="1.6242058086296622" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" MODIFIED="2012-07-05 13:08:30 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.9330485707074361" P_Z="0.20623465750296477" STUDIES="4" TAU2="0.0" TOTAL_1="147" TOTAL_2="150" WEIGHT="100.0" Z="1.2639871685695514">
<NAME>short term</NAME>
<CONT_DATA CI_END="19.870405057104634" CI_START="-10.870405057104636" EFFECT_SIZE="4.5" ESTIMABLE="YES" MEAN_1="-28.9" MEAN_2="-33.4" MODIFIED="2012-07-05 13:08:23 +0100" MODIFIED_BY="Laila Asmal" ORDER="547" SD_1="28.6" SD_2="20.8" SE="7.842187498517538" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="21" WEIGHT="2.6848643295089136"/>
<CONT_DATA CI_END="8.406308295397494" CI_START="-5.606308295397482" EFFECT_SIZE="1.4000000000000057" ESTIMABLE="YES" MEAN_1="51.2" MEAN_2="49.8" MODIFIED="2012-07-05 13:08:29 +0100" MODIFIED_BY="Laila Asmal" ORDER="499" SD_1="15.3" SD_2="14.6" SE="3.5747127756746315" STUDY_ID="STD-Luo-Xin-2008" TOTAL_1="35" TOTAL_2="35" WEIGHT="12.921546159240185"/>
<CONT_DATA CI_END="8.030425185150374" CI_START="-2.4304251851503658" EFFECT_SIZE="2.8000000000000043" ESTIMABLE="YES" MEAN_1="43.27" MEAN_2="40.47" MODIFIED="2012-07-05 13:08:30 +0100" MODIFIED_BY="Laila Asmal" ORDER="498" SD_1="10.28" SD_2="14.14" SE="2.668633314901343" STUDY_ID="STD-Peng-2007" TOTAL_1="41" TOTAL_2="44" WEIGHT="23.185634291096488"/>
<CONT_DATA CI_END="4.319159902288724" CI_START="-2.119159902288735" EFFECT_SIZE="1.0999999999999943" ESTIMABLE="YES" MEAN_1="51.3" MEAN_2="50.2" MODIFIED="2011-07-28 11:10:24 +0100" MODIFIED_BY="Laila Asmal" ORDER="460" SD_1="8.1" SD_2="8.4" SE="1.6424587021399637" STUDY_ID="STD-Wei-2006b" TOTAL_1="51" TOTAL_2="50" WEIGHT="61.207955220154425"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.768012418183117" CI_END="2.377868192316387" CI_START="-1.132046345236099" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.6229109235401442" ESTIMABLE="YES" I2="47.98901627633842" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2013-10-22 15:12:15 +0100" MODIFIED_BY="Laila Asmal" NO="3" P_CHI2="0.12345906263532769" P_Q="1.0" P_Z="0.4866312915968104" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="1.4638959966649248" TOTALS="YES" TOTAL_1="147" TOTAL_2="150" UNITS="" WEIGHT="100.0" Z="0.695676753751734">
<NAME>Mental state: 2. Positive symptoms - average endpoint score (PANSS positive subscore, high=poor)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.768012418183117" CI_END="2.377868192316387" CI_START="-1.132046345236099" DF="3" EFFECT_SIZE="0.6229109235401442" ESTIMABLE="YES" I2="47.98901627633842" ID="CMP-001.03.01" MODIFIED="2011-08-26 12:02:32 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.12345906263532769" P_Z="0.4866312915968104" STUDIES="4" TAU2="1.4638959966649248" TOTAL_1="147" TOTAL_2="150" WEIGHT="100.0" Z="0.695676753751734">
<NAME>short term</NAME>
<CONT_DATA CI_END="2.5179209421324495" CI_START="-8.31792094213245" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" MEAN_1="-9.4" MEAN_2="-6.5" MODIFIED="2011-08-26 12:02:32 +0100" MODIFIED_BY="Laila Asmal" ORDER="548" SD_1="8.6" SD_2="9.1" SE="2.764296173229875" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="21" WEIGHT="8.805337809703095"/>
<CONT_DATA CI_END="2.3817690663018274" CI_START="-1.9817690663018288" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" MEAN_1="11.7" MEAN_2="11.5" MODIFIED="2011-08-04 08:16:49 +0100" MODIFIED_BY="Laila Asmal" ORDER="4205" SD_1="4.4" SD_2="4.9" SE="1.1131679375291301" STUDY_ID="STD-Luo-Xin-2008" TOTAL_1="35" TOTAL_2="35" WEIGHT="29.660920327692995"/>
<CONT_DATA CI_END="3.8563190791659276" CI_START="0.7036809208340746" EFFECT_SIZE="2.280000000000001" ESTIMABLE="YES" MEAN_1="14.71" MEAN_2="12.43" MODIFIED="2011-07-28 11:00:23 +0100" MODIFIED_BY="Laila Asmal" ORDER="461" SD_1="2.72" SD_2="4.53" SE="0.8042592065975346" STUDY_ID="STD-Peng-2007" TOTAL_1="41" TOTAL_2="44" WEIGHT="37.98432915690952"/>
<CONT_DATA CI_END="2.530358127388086" CI_START="-2.930358127388088" EFFECT_SIZE="-0.20000000000000107" ESTIMABLE="YES" MEAN_1="12.6" MEAN_2="12.8" MODIFIED="2011-07-28 11:11:00 +0100" MODIFIED_BY="Laila Asmal" ORDER="455" SD_1="7.1" SD_2="6.9" SE="1.3930654588170004" STUDY_ID="STD-Wei-2006b" TOTAL_1="51" TOTAL_2="50" WEIGHT="23.549412705694404"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.255076389816635" CI_END="2.246311315457863" CI_START="-0.2505064656661725" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.9979024248958451" ESTIMABLE="YES" I2="7.836264322847545" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2013-10-22 15:12:28 +0100" MODIFIED_BY="Laila Asmal" NO="4" P_CHI2="0.3539443326237215" P_Q="1.0" P_Z="0.11719033735807506" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.14150327103330942" TOTALS="YES" TOTAL_1="147" TOTAL_2="150" UNITS="" WEIGHT="100.00000000000001" Z="1.5666764532576687">
<NAME>Mental state: 3. Negative symptoms - average endpoint score (PANSS negative subscore, high=poor)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.255076389816635" CI_END="2.246311315457863" CI_START="-0.2505064656661725" DF="3" EFFECT_SIZE="0.9979024248958451" ESTIMABLE="YES" I2="7.836264322847545" ID="CMP-001.04.01" MODIFIED="2011-09-01 14:51:43 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.3539443326237215" P_Z="0.11719033735807506" STUDIES="4" TAU2="0.14150327103330942" TOTAL_1="147" TOTAL_2="150" WEIGHT="100.00000000000001" Z="1.5666764532576687">
<NAME>short term</NAME>
<CONT_DATA CI_END="4.1247143442723715" CI_START="-5.524714344272372" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="-6.3" MEAN_2="-5.6" MODIFIED="2011-09-01 14:51:43 +0100" MODIFIED_BY="Laila Asmal" ORDER="549" SD_1="9.5" SD_2="5.7" SE="2.4616341842651717" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="21" WEIGHT="6.542527520736376"/>
<CONT_DATA CI_END="2.428555019586903" CI_START="-2.028555019586901" EFFECT_SIZE="0.20000000000000107" ESTIMABLE="YES" MEAN_1="12.8" MEAN_2="12.6" MODIFIED="2011-08-04 08:17:52 +0100" MODIFIED_BY="Laila Asmal" ORDER="4206" SD_1="4.5" SD_2="5.0" SE="1.137038760490223" STUDY_ID="STD-Luo-Xin-2008" TOTAL_1="35" TOTAL_2="35" WEIGHT="28.28519862288877"/>
<CONT_DATA CI_END="3.762140605854957" CI_START="0.4578593941450422" EFFECT_SIZE="2.1099999999999994" ESTIMABLE="YES" MEAN_1="12.32" MEAN_2="10.21" MODIFIED="2011-07-28 11:01:26 +0100" MODIFIED_BY="Laila Asmal" ORDER="462" SD_1="3.67" SD_2="4.1" SE="0.8429443698388498" STUDY_ID="STD-Peng-2007" TOTAL_1="41" TOTAL_2="44" WEIGHT="47.615474848488546"/>
<CONT_DATA CI_END="2.7867741384695663" CI_START="-2.9867741384695656" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="11.8" MEAN_2="11.9" MODIFIED="2011-07-28 11:12:00 +0100" MODIFIED_BY="Laila Asmal" ORDER="457" SD_1="7.6" SD_2="7.2" SE="1.4728710125492468" STUDY_ID="STD-Wei-2006b" TOTAL_1="51" TOTAL_2="50" WEIGHT="17.55679900788631"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="12.025884795203346" CI_START="-14.425884795203338" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1999999999999957" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2013-10-22 13:21:09 +0100" MODIFIED_BY="Laila Asmal" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.8588566236007733" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="21" UNITS="" WEIGHT="100.0" Z="0.17782982521525106">
<NAME>General functioning: General - average endpoint score - medium term (GAF total score, high=poor</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="12.025884795203346" CI_START="-14.425884795203338" EFFECT_SIZE="-1.1999999999999957" ESTIMABLE="YES" MEAN_1="46.6" MEAN_2="47.8" MODIFIED="2011-08-26 13:02:21 +0100" MODIFIED_BY="Laila Asmal" ORDER="561" SD_1="21.5" SD_2="21.7" SE="6.748024402247915" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.808682695550036" CI_END="1.1695075615988468" CI_START="0.7117064911156515" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.912330051570558" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="57" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.06800303414007317" LOG_CI_START="-0.14769907317426437" LOG_EFFECT_SIZE="-0.03984801951709557" METHOD="MH" MODIFIED="2011-08-26 13:03:07 +0100" MODIFIED_BY="Laila Asmal" NO="6" P_CHI2="0.4048084697259787" P_Q="1.0" P_Z="0.4689717064631629" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="109" TOTAL_2="106" WEIGHT="100.00000000000001" Z="0.7241531766302332">
<NAME>Adverse effects: 1. General - at least one adverse effect</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.321488051190618" CI_START="0.21356724508081854" EFFECT_SIZE="0.53125" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.12106324062290091" LOG_CI_START="-0.6704653545061651" LOG_EFFECT_SIZE="-0.27470105694163205" MODIFIED="2011-08-26 12:07:41 +0100" MODIFIED_BY="Laila Asmal" ORDER="550" O_E="0.0" SE="0.46494781490855003" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="17" VAR="0.2161764705882353" WEIGHT="15.00234411626817"/>
<DICH_DATA CI_END="1.732087260175115" CI_START="0.4919330714498847" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.23856976739145294" LOG_CI_START="-0.3080939799098768" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2011-08-04 08:18:36 +0100" MODIFIED_BY="Laila Asmal" ORDER="4207" O_E="0.0" SE="0.3211129911939925" STUDY_ID="STD-Luo-Xin-2008" TOTAL_1="35" TOTAL_2="35" VAR="0.1031135531135531" WEIGHT="22.550398499765592"/>
<DICH_DATA CI_END="1.3056713009265382" CI_START="0.7658895460828267" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="36" LOG_CI_END="0.115833858285889" LOG_CI_START="-0.11583385828588898" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-07-28 10:11:40 +0100" MODIFIED_BY="Laila Asmal" ORDER="459" O_E="0.0" SE="0.13608276348795434" STUDY_ID="STD-Wei-2006b" TOTAL_1="54" TOTAL_2="54" VAR="0.018518518518518517" WEIGHT="62.44725738396625"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="76.74347748032802" CI_START="0.13462554724223408" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.2142857142857144" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="1.8850414745117614" LOG_CI_START="-0.8708725183175499" LOG_EFFECT_SIZE="0.5070844780971057" METHOD="MH" MODIFIED="2011-08-26 13:03:02 +0100" MODIFIED_BY="Laila Asmal" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.47074865216936024" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="44" WEIGHT="99.99999999999999" Z="0.7212614884031853">
<NAME>Adverse effects: 2a. Cardiac effects - QTc prolongation</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="76.74347748032802" CI_START="0.13462554724223408" EFFECT_SIZE="3.2142857142857144" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8850414745117614" LOG_CI_START="-0.8708725183175499" LOG_EFFECT_SIZE="0.5070844780971057" MODIFIED="2011-07-28 11:27:08 +0100" MODIFIED_BY="Laila Asmal" ORDER="463" O_E="0.0" SE="1.6188375213822173" STUDY_ID="STD-Peng-2007" TOTAL_1="41" TOTAL_2="44" VAR="2.6206349206349207" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="140.90707567731394" CI_START="0.3991992575931107" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="7.499999999999999" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="2.1489328018422027" LOG_CI_START="-0.3988102750588027" LOG_EFFECT_SIZE="0.8750612633917" METHOD="MH" MODIFIED="2011-08-26 13:03:00 +0100" MODIFIED_BY="Laila Asmal" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.17818672881129005" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="44" WEIGHT="100.0" Z="1.346359117654854">
<NAME>Adverse effects: 2b. Cardiac effects - Tachycardia</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="140.90707567731394" CI_START="0.3991992575931107" EFFECT_SIZE="7.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1489328018422027" LOG_CI_START="-0.3988102750588027" LOG_EFFECT_SIZE="0.8750612633917001" MODIFIED="2011-07-28 11:27:38 +0100" MODIFIED_BY="Laila Asmal" ORDER="464" O_E="0.0" SE="1.4965568949032775" STUDY_ID="STD-Peng-2007" TOTAL_1="41" TOTAL_2="44" VAR="2.2396825396825397" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.881770430830285" CI_END="1.8206911883844288" CI_START="0.44960118380178415" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9047568256913657" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="26" I2="17.29287015189039" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.26023629035629336" LOG_CI_START="-0.3471725539383154" LOG_EFFECT_SIZE="-0.04346813179101105" METHOD="MH" MODIFIED="2013-04-05 11:46:52 +0100" MODIFIED_BY="Laila Asmal" NO="9" P_CHI2="0.28390030732824345" P_Q="0.9348983474976806" P_Z="0.7790765421643631" Q="1.300323969940318" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.21329426810766702" TOTALS="YES" TOTAL_1="293" TOTAL_2="306" WEIGHT="100.00000000000001" Z="0.2805226614194639">
<NAME>Adverse effects: 3a. Extrapyramidal effects</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.325910835672826" CI_END="4.023526444274799" CI_START="0.0797269428503397" DF="2" EFFECT_SIZE="0.5663774915014961" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" I2="68.3839995226983" ID="CMP-001.09.01" LOG_CI_END="0.6046068600347598" LOG_CI_START="-1.0983948887184207" LOG_EFFECT_SIZE="-0.2468940143418305" MODIFIED="2013-04-05 11:46:04 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.042300586076889024" P_Z="0.5698349260489017" STUDIES="3" TAU2="2.0024663959188627" TOTAL_1="96" TOTAL_2="100" WEIGHT="34.99743627246489" Z="0.5682946320669181">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="2.556675830226646" CI_START="0.107806002130339" EFFECT_SIZE="0.525" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4076756658172201" LOG_CI_START="-0.9673570590053063" LOG_EFFECT_SIZE="-0.2798406965940431" MODIFIED="2011-08-26 12:26:46 +0100" MODIFIED_BY="Laila Asmal" ORDER="554" O_E="0.0" SE="0.8077010290825141" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="21" VAR="0.6523809523809523" WEIGHT="14.705589555570738"/>
<DICH_DATA CI_END="0.9814657798759212" CI_START="0.003525550949819354" EFFECT_SIZE="0.058823529411764705" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.008124838061060551" LOG_CI_START="-2.452773004695487" LOG_EFFECT_SIZE="-1.2304489213782739" MODIFIED="2011-08-04 08:20:14 +0100" MODIFIED_BY="Laila Asmal" ORDER="4209" O_E="0.0" SE="1.4359984342846528" STUDY_ID="STD-Luo-Xin-2008" TOTAL_1="35" TOTAL_2="35" VAR="2.062091503267974" WEIGHT="5.5947719464016155"/>
<DICH_DATA CI_END="13.073425943519133" CI_START="0.5505899067547718" EFFECT_SIZE="2.682926829268293" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.1163894110998798" LOG_CI_START="-0.2591717542229007" LOG_EFFECT_SIZE="0.4286088284384896" MODIFIED="2011-07-28 11:28:15 +0100" MODIFIED_BY="Laila Asmal" ORDER="465" O_E="0.0" SE="0.808011437648186" STUDY_ID="STD-Peng-2007" TOTAL_1="41" TOTAL_2="44" VAR="0.6528824833702882" WEIGHT="14.697074770492534"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="72.92191868001707" CI_START="0.13545380043757582" DF="0" EFFECT_SIZE="3.1428571428571432" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="1.8628580870424774" LOG_CI_START="-0.8682088054265785" LOG_EFFECT_SIZE="0.49732464080794947" MODIFIED="2013-04-05 11:46:52 +0100" MODIFIED_BY="Laila Asmal" NO="2" P_CHI2="1.0" P_Z="0.47534153044019734" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="4.567914996221196" Z="0.7138150935048501">
<NAME>dyskinesia</NAME>
<DICH_DATA CI_END="72.92191868001707" CI_START="0.13545380043757582" EFFECT_SIZE="3.142857142857143" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8628580870424774" LOG_CI_START="-0.8682088054265785" LOG_EFFECT_SIZE="0.4973246408079494" MODIFIED="2011-08-26 12:28:47 +0100" MODIFIED_BY="Laila Asmal" ORDER="555" O_E="0.0" SE="1.6042422116354729" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="21" VAR="2.5735930735930737" WEIGHT="4.567914996221196"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5196524509994618" CI_END="20.774655110758182" CI_START="0.09755779860614233" DF="1" EFFECT_SIZE="1.4236325436738975" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="34.1954800689915" ID="CMP-001.09.03" LOG_CI_END="1.3175338226011357" LOG_CI_START="-1.0107380081122173" LOG_EFFECT_SIZE="0.15339790724445915" MODIFIED="2013-04-05 11:46:52 +0100" MODIFIED_BY="Laila Asmal" NO="3" P_CHI2="0.21767250779475888" P_Z="0.7962031843621791" STUDIES="2" TAU2="1.2803096606587032" TOTAL_1="61" TOTAL_2="65" WEIGHT="9.526607132871087" Z="0.25826397891936803">
<NAME>dystonia</NAME>
<DICH_DATA CI_END="8.102435408890784" CI_START="0.015050422270841747" EFFECT_SIZE="0.3492063492063492" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9086155776031525" LOG_CI_START="-1.8224513148659038" LOG_EFFECT_SIZE="-0.4569178686313755" MODIFIED="2011-08-26 12:33:13 +0100" MODIFIED_BY="Laila Asmal" ORDER="556" O_E="0.0" SE="1.6042422116354729" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="21" VAR="2.5735930735930737" WEIGHT="4.567914996221196"/>
<DICH_DATA CI_END="108.36816797551899" CI_START="0.2648285020221066" EFFECT_SIZE="5.357142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.034901731438726" LOG_CI_START="-0.5770352760118023" LOG_EFFECT_SIZE="0.728933227713462" MODIFIED="2011-07-28 11:29:27 +0100" MODIFIED_BY="Laila Asmal" ORDER="467" O_E="0.0" SE="1.5342647274731482" STUDY_ID="STD-Peng-2007" TOTAL_1="41" TOTAL_2="44" VAR="2.353968253968254" WEIGHT="4.958692136649891"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9796536120234727" CI_START="0.2841406176230241" DF="0" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" ID="CMP-001.09.04" LOG_CI_END="0.29658920665188887" LOG_CI_START="-0.5464666798684887" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2013-04-05 11:46:46 +0100" MODIFIED_BY="Laila Asmal" NO="4" P_CHI2="1.0" P_Z="0.5612921186934026" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="27.76306646720684" Z="0.5809233478859885">
<NAME>parkinsonism</NAME>
<DICH_DATA CI_END="1.9796536120234727" CI_START="0.2841406176230241" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.29658920665188887" LOG_CI_START="-0.5464666798684887" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2011-08-26 12:35:05 +0100" MODIFIED_BY="Laila Asmal" ORDER="557" O_E="0.0" SE="0.4952152009360125" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="21" VAR="0.24523809523809526" WEIGHT="27.76306646720684"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.018150018527648" CI_END="35.91689647764774" CI_START="0.07833293456410989" DF="1" EFFECT_SIZE="1.6773419155108154" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="50.44966970643961" ID="CMP-001.09.05" LOG_CI_END="1.555298802915566" LOG_CI_START="-1.1060556033038509" LOG_EFFECT_SIZE="0.2246215998058577" MODIFIED="2013-04-05 11:46:46 +0100" MODIFIED_BY="Laila Asmal" NO="5" P_CHI2="0.15542879149553446" P_Z="0.740760236566861" STUDIES="2" TAU2="2.4694178227146777" TOTAL_1="76" TOTAL_2="79" WEIGHT="9.69695770436693" Z="0.3308467633926645">
<NAME>tremor</NAME>
<DICH_DATA CI_END="7.9127893408891605" CI_START="0.014041965016931132" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8983296038284552" LOG_CI_START="-1.85257211326778" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-08-04 08:19:31 +0100" MODIFIED_BY="Laila Asmal" ORDER="4208" O_E="0.0" SE="1.6158932858054431" STUDY_ID="STD-Luo-Xin-2008" TOTAL_1="35" TOTAL_2="35" VAR="2.611111111111111" WEIGHT="4.507237018665851"/>
<DICH_DATA CI_END="140.90707567731394" CI_START="0.3991992575931107" EFFECT_SIZE="7.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1489328018422027" LOG_CI_START="-0.3988102750588027" LOG_EFFECT_SIZE="0.8750612633917001" MODIFIED="2011-07-28 11:28:47 +0100" MODIFIED_BY="Laila Asmal" ORDER="466" O_E="0.0" SE="1.4965568949032775" STUDY_ID="STD-Peng-2007" TOTAL_1="41" TOTAL_2="44" VAR="2.2396825396825397" WEIGHT="5.189720685701079"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.5713646359076354" CI_START="0.12444667228203433" DF="0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-001.09.06" LOG_CI_END="0.5528341938718855" LOG_CI_START="-0.905016711983248" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2013-04-05 11:46:46 +0100" MODIFIED_BY="Laila Asmal" NO="6" P_CHI2="1.0" P_Z="0.6358698851622282" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="13.448017426869066" Z="0.4734812378348157">
<NAME>use of antiparkinson medication</NAME>
<DICH_DATA CI_END="3.5713646359076354" CI_START="0.12444667228203433" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5528341938718855" LOG_CI_START="-0.905016711983248" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2011-08-26 12:24:06 +0100" MODIFIED_BY="Laila Asmal" ORDER="553" O_E="0.0" SE="0.8563488385776752" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="20" VAR="0.7333333333333332" WEIGHT="13.448017426869066"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="76.74347748032802" CI_START="0.13462554724223408" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.2142857142857144" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="1.8850414745117614" LOG_CI_START="-0.8708725183175499" LOG_EFFECT_SIZE="0.5070844780971057" METHOD="MH" MODIFIED="2013-04-05 11:47:09 +0100" MODIFIED_BY="Laila Asmal" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.47074865216936024" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="44" WEIGHT="99.99999999999999" Z="0.7212614884031853">
<NAME>Adverse effects: 4a. Prolactin associated side effects</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="76.74347748032802" CI_START="0.13462554724223408" DF="0" EFFECT_SIZE="3.2142857142857144" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="1.8850414745117614" LOG_CI_START="-0.8708725183175499" LOG_EFFECT_SIZE="0.5070844780971057" MODIFIED="2013-04-05 11:47:09 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="1.0" P_Z="0.47074865216936024" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="44" WEIGHT="99.99999999999999" Z="0.7212614884031853">
<NAME>galactorrhea</NAME>
<DICH_DATA CI_END="76.74347748032802" CI_START="0.13462554724223408" EFFECT_SIZE="3.2142857142857144" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8850414745117614" LOG_CI_START="-0.8708725183175499" LOG_EFFECT_SIZE="0.5070844780971057" MODIFIED="2011-07-28 11:30:26 +0100" MODIFIED_BY="Laila Asmal" ORDER="468" O_E="0.0" SE="1.6188375213822173" STUDY_ID="STD-Peng-2007" TOTAL_1="41" TOTAL_2="44" VAR="2.6206349206349207" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0017221473411833852" CI_END="2.744646439521502" CI_START="0.0977273770209359" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5179064562102766" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.4384864073455335" LOG_CI_START="-1.0099837574316979" LOG_EFFECT_SIZE="-0.28574867504308216" METHOD="MH" MODIFIED="2011-08-26 13:02:51 +0100" MODIFIED_BY="Laila Asmal" NO="11" P_CHI2="0.9668982854295897" P_Q="1.0" P_Z="0.4393398604258525" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="76" TOTAL_2="79" WEIGHT="100.0" Z="0.7733084537514309">
<NAME>Adverse effects: 5a. Metabolic - weight gain of 7% or more of total body weight</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.26531901349033" CI_START="0.047480503908589836" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7214246892159656" LOG_CI_START="-1.323484680543928" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2011-08-04 08:21:24 +0100" MODIFIED_BY="Laila Asmal" ORDER="4210" O_E="0.0" SE="1.2011898862615948" STUDY_ID="STD-Luo-Xin-2008" TOTAL_1="35" TOTAL_2="35" VAR="1.442857142857143" WEIGHT="50.173105006098325"/>
<DICH_DATA CI_END="5.696911834792333" CI_START="0.05054033890605228" EFFECT_SIZE="0.5365853658536586" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7556394983825236" LOG_CI_START="-1.296361850177582" LOG_EFFECT_SIZE="-0.2703611758975292" MODIFIED="2011-07-28 11:31:06 +0100" MODIFIED_BY="Laila Asmal" ORDER="469" O_E="0.0" SE="1.2053557497147007" STUDY_ID="STD-Peng-2007" TOTAL_1="41" TOTAL_2="44" VAR="1.4528824833702882" WEIGHT="49.826894993901675"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.544172319114422" CI_START="-0.1441723191144222" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.7" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.12" MODIFIED="2011-08-26 13:02:48 +0100" MODIFIED_BY="Laila Asmal" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.07080292269562329" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="21" UNITS="" WEIGHT="100.0" Z="1.8067393915326202">
<NAME>Adverse effects. 5b. Metabolic - weight gain - change from baseline in kg</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.544172319114422" CI_START="-0.1441723191144222" EFFECT_SIZE="1.7" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="-0.5" MODIFIED="2011-08-26 12:39:45 +0100" MODIFIED_BY="Laila Asmal" ORDER="558" SD_1="3.2" SD_2="2.8" SE="0.9409215341001254" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="28.638296948566794" CI_START="-12.238296948566795" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="8.2" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.13" MODIFIED="2013-10-22 14:37:48 +0100" MODIFIED_BY="Laila Asmal" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.43166104524324267" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="21" UNITS="" WEIGHT="100.0" Z="0.7863524399157654">
<NAME>Adverse effects: 5c. Metabolic - cholesterol - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="28.638296948566794" CI_START="-12.238296948566795" EFFECT_SIZE="8.2" ESTIMABLE="YES" MEAN_1="8.6" MEAN_2="0.4" MODIFIED="2011-08-26 12:53:15 +0100" MODIFIED_BY="Laila Asmal" ORDER="559" SD_1="30.1" SD_2="36.5" SE="10.42789413978087" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.8950424021956831" CI_START="-17.90495759780432" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.4" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.14" MODIFIED="2013-10-22 14:38:00 +0100" MODIFIED_BY="Laila Asmal" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.030293910682363978" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="21" UNITS="" WEIGHT="100.0" Z="2.166226138438698">
<NAME>Adverse effects: 5d. Metabolic - glucose - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.8950424021956831" CI_START="-17.90495759780432" EFFECT_SIZE="-9.4" ESTIMABLE="YES" MEAN_1="-5.2" MEAN_2="4.2" MODIFIED="2011-08-26 12:56:44 +0100" MODIFIED_BY="Laila Asmal" ORDER="560" SD_1="14.6" SD_2="13.1" SE="4.339343816973341" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="21" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-10-22 14:37:38 +0100" MODIFIED_BY="Laila Asmal" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="40" TOTAL_2="34" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 6. Death  </NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.15.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-26 12:13:59 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>natural causes</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-26 12:13:59 +0100" MODIFIED_BY="Laila Asmal" ORDER="551" O_E="0.0" SE="0.0" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.15.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-26 12:22:57 +0100" MODIFIED_BY="Laila Asmal" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>suicide</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-26 12:22:57 +0100" MODIFIED_BY="Laila Asmal" ORDER="552" O_E="0.0" SE="0.0" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-10-23 08:43:36 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>QUETIAPINE versus CLOZAPINE - all data short term</NAME>
<DICH_OUTCOME CHI2="1.1795672256393308" CI_END="1.6957715734407666" CI_START="0.1596866178997282" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.52037681279363" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.22936735082429735" LOG_CI_START="-0.7967314771978812" LOG_EFFECT_SIZE="-0.28368206318679184" METHOD="MH" MODIFIED="2013-10-22 15:05:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5544474623632993" P_Q="0.3442843932708687" P_Z="0.27848490501456746" Q="0.8944127911575631" RANDOM="YES" SCALE="631.7692394662271" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="119" TOTAL_2="120" WEIGHT="200.0" Z="1.0837291920074397">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.23286882130654565" CI_END="2.433298675595832" CI_START="0.18397823344599884" DF="1" EFFECT_SIZE="0.6690844429387144" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.3861954197413375" LOG_CI_START="-0.7352335555419351" LOG_EFFECT_SIZE="-0.17451906790029886" MODIFIED="2009-08-05 15:08:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6294047746716755" P_Z="0.5418437943683427" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="48" WEIGHT="99.99999999999999" Z="0.6100271978681199">
<NAME>any reason</NAME>
<DICH_DATA CI_END="7.545522164113119" CI_START="0.014725436980300866" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8776892991343043" LOG_CI_START="-1.8319318085736291" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1114" O_E="0.0" SE="1.5916448515084427" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="14" VAR="2.5333333333333328" WEIGHT="17.128779264701592"/>
<DICH_DATA CI_END="3.191305412946192" CI_START="0.18710444810272275" EFFECT_SIZE="0.7727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5039683688472687" LOG_CI_START="-0.7279158877351333" LOG_EFFECT_SIZE="-0.11197375944393231" ORDER="1115" O_E="0.0" SE="0.723614910241919" STUDY_ID="STD-Li--2005" TOTAL_1="33" TOTAL_2="34" VAR="0.5236185383244206" WEIGHT="82.8712207352984"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6698693805367633" CI_START="0.00764388078835646" DF="0" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.4264900146605525" LOG_CI_START="-2.116686094689066" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2009-08-05 15:08:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.19271374269536645" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="100.0" Z="1.3025930180328127">
<NAME>due to adverse events</NAME>
<DICH_DATA CI_END="2.6698693805367633" CI_START="0.00764388078835646" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4264900146605525" LOG_CI_START="-2.116686094689066" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="1116" O_E="0.0" SE="1.493874235556739" STUDY_ID="STD-Liu-2004" TOTAL_1="36" TOTAL_2="36" VAR="2.231660231660231" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-08-05 15:09:01 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>due to inefficacy</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1117" O_E="0.0" SE="0.0" STUDY_ID="STD-Liu-2004" TOTAL_1="36" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.129400216141008" CI_START="0.7782061995729836" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.05284786651475986" LOG_CI_START="-0.1089053137152469" LOG_EFFECT_SIZE="-0.028028723600243537" METHOD="MH" MODIFIED="2013-10-22 15:05:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.49698053368977635" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="36" WEIGHT="100.0" Z="0.6792483302150764">
<NAME>Global state: 1a. No clinically significant response (as defined by original studies)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.129400216141008" CI_START="0.7782061995729836" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="32" LOG_CI_END="0.05284786651475986" LOG_CI_START="-0.1089053137152469" LOG_EFFECT_SIZE="-0.028028723600243537" ORDER="1118" O_E="0.0" SE="0.09501461875826148" STUDY_ID="STD-Liu-2004" TOTAL_1="36" TOTAL_2="36" VAR="0.009027777777777773" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1807121023453642" CI_START="0.7411883651420479" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9354838709677419" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.07214401479802988" LOG_CI_START="-0.1300714066686631" LOG_EFFECT_SIZE="-0.028963695935316617" METHOD="MH" MODIFIED="2013-10-22 15:05:35 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.5744848997376282" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="38" WEIGHT="100.0" Z="0.561458670962343">
<NAME>Global state: 1b. No clinically important change - short term (as measured by CGI)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1807121023453642" CI_START="0.7411883651420479" EFFECT_SIZE="0.9354838709677419" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="31" LOG_CI_END="0.07214401479802988" LOG_CI_START="-0.1300714066686631" LOG_EFFECT_SIZE="-0.028963695935316617" ORDER="422" O_E="0.0" SE="0.11878233955201534" STUDY_ID="STD-Li-2003" TOTAL_1="38" TOTAL_2="38" VAR="0.014109244189450268" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.1449943572867953" CI_START="0.5293984279107226" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.065625" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.3314261540487472" LOG_CI_START="-0.2762173527035637" LOG_EFFECT_SIZE="0.02760440067259176" METHOD="MH" MODIFIED="2013-02-21 10:34:47 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.8586625958383602" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="0.17807688400148397">
<NAME>Mental state: 1a. General - no clinically important change - short term (less than 50% PANSS total score reduction)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1449943572867953" CI_START="0.5293984279107226" EFFECT_SIZE="1.065625" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.3314261540487472" LOG_CI_START="-0.2762173527035637" LOG_EFFECT_SIZE="0.02760440067259176" ORDER="414" O_E="0.0" SE="0.35693280375017633" STUDY_ID="STD-Li-2002" TOTAL_1="32" TOTAL_2="31" VAR="0.12740102639296189" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.6053044630016642" CI_END="1.8552113499212544" CI_START="-2.8502806984962215" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.49753467428748366" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2013-04-18 17:26:41 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6581877202751667" P_Q="1.0" P_Z="0.6785276319881489" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="116" TOTAL_2="116" UNITS="" WEIGHT="100.0" Z="0.41447314441485095">
<NAME>Mental state: 1b. General - average endpoint score - short term (PANSS total, high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.467328570728938" CI_START="-4.107328570728953" EFFECT_SIZE="0.1799999999999926" ESTIMABLE="YES" MEAN_1="77.24" MEAN_2="77.06" ORDER="418" SD_1="6.08" SD_2="5.28" SE="2.1874527310434506" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="13" WEIGHT="30.11456264084489"/>
<CONT_DATA CI_END="1.4702478122095108" CI_START="-6.750247812209512" EFFECT_SIZE="-2.6400000000000006" ESTIMABLE="YES" MEAN_1="44.12" MEAN_2="46.76" ORDER="416" SD_1="8.91" SD_2="8.23" SE="2.0971037450844103" STUDY_ID="STD-Li--2005" TOTAL_1="33" TOTAL_2="34" WEIGHT="32.7652950189018"/>
<CONT_DATA CI_END="7.992334547774867" CI_START="-6.592334547774861" EFFECT_SIZE="0.7000000000000028" ESTIMABLE="YES" MEAN_1="49.1" MEAN_2="48.4" ORDER="417" SD_1="14.3" SD_2="15.2" SE="3.720647218671296" STUDY_ID="STD-Li-2002" TOTAL_1="32" TOTAL_2="31" WEIGHT="10.409189802137051"/>
<CONT_DATA CI_END="5.4522946091451" CI_START="-3.6522946091451027" EFFECT_SIZE="0.8999999999999986" ESTIMABLE="YES" MEAN_1="44.6" MEAN_2="43.7" ORDER="415" SD_1="10.3" SD_2="9.8" SE="2.3226419694713885" STUDY_ID="STD-Li-2003" TOTAL_1="37" TOTAL_2="38" WEIGHT="26.710952538116253"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.4164069085617936" CI_START="-3.1964069085617948" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8900000000000006" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2009-10-29 01:11:08 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.44946093338417936" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="33" UNITS="" WEIGHT="100.0" Z="0.7563140483863642">
<NAME>Mental state: 1c. General - average endpoint score - short term (BPRS total, high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.4164069085617936" CI_START="-3.1964069085617948" EFFECT_SIZE="-0.8900000000000006" ESTIMABLE="YES" MEAN_1="30.53" MEAN_2="31.42" ORDER="419" SD_1="4.55" SD_2="5.06" SE="1.1767598418922172" STUDY_ID="STD-Liu-2004" TOTAL_1="34" TOTAL_2="33" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.01640593408646232" CI_END="0.6771378459997974" CI_START="-2.0700845440147653" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6964733490074839" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.07" MODIFIED="2009-10-29 01:11:08 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.8980811953327662" P_Q="1.0" P_Z="0.3203316478061565" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="70" TOTAL_2="72" UNITS="" WEIGHT="100.0" Z="0.9937766124856227">
<NAME>Mental state: 2. Positive symptoms - average endpoint score (PANSS positive subscore, high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0962745886289003" CI_START="-2.656274588628899" EFFECT_SIZE="-0.7799999999999994" ESTIMABLE="YES" MEAN_1="14.55" MEAN_2="15.33" ORDER="421" SD_1="4.26" SD_2="3.53" SE="0.9573005440042338" STUDY_ID="STD-Li--2005" TOTAL_1="33" TOTAL_2="34" WEIGHT="53.596305004158026"/>
<CONT_DATA CI_END="1.4164503817163578" CI_START="-2.616450381716357" EFFECT_SIZE="-0.5999999999999996" ESTIMABLE="YES" MEAN_1="13.5" MEAN_2="14.1" ORDER="420" SD_1="4.6" SD_2="4.3" SE="1.0288201199725406" STUDY_ID="STD-Li-2003" TOTAL_1="37" TOTAL_2="38" WEIGHT="46.40369499584197"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.11360539867081106" CI_END="-0.9852662054396053" CI_START="-3.4781486645428306" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.231707434991218" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.08" MODIFIED="2013-10-23 08:43:28 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.7360762386686961" P_Q="1.0" P_Z="4.493827188292388E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="70" TOTAL_2="72" UNITS="" WEIGHT="100.0" Z="3.5092438318865247">
<NAME>Mental state: 3a. Negative symptoms - average endpoint score - short term (PANSS negative subscore, high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.7320063996589001" CI_START="-4.1279936003410995" EFFECT_SIZE="-2.4299999999999997" ESTIMABLE="YES" MEAN_1="9.86" MEAN_2="12.29" ORDER="423" SD_1="3.81" SD_2="3.25" SE="0.8663391846659716" STUDY_ID="STD-Li--2005" TOTAL_1="33" TOTAL_2="34" WEIGHT="53.88544999795768"/>
<CONT_DATA CI_END="-0.16450663660628018" CI_START="-3.83549336339372" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="12.9" MEAN_2="14.9" ORDER="424" SD_1="4.2" SD_2="3.9" SE="0.9364934140993698" STUDY_ID="STD-Li-2003" TOTAL_1="37" TOTAL_2="38" WEIGHT="46.114550002042314"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.129400216141008" CI_START="0.7782061995729836" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.05284786651475986" LOG_CI_START="-0.1089053137152469" LOG_EFFECT_SIZE="-0.028028723600243537" METHOD="MH" MODIFIED="2013-10-23 08:43:36 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.49698053368977635" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="36" WEIGHT="100.0" Z="0.6792483302150764">
<NAME>Mental state: 3b. Negative symptoms - no clinically important change - short term (less than 50% SANS total score reduction)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.129400216141008" CI_START="0.7782061995729836" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="32" LOG_CI_END="0.05284786651475986" LOG_CI_START="-0.1089053137152469" LOG_EFFECT_SIZE="-0.028028723600243537" ORDER="425" O_E="0.0" SE="0.09501461875826148" STUDY_ID="STD-Liu-2004" TOTAL_1="36" TOTAL_2="36" VAR="0.009027777777777773" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.892509971483759" CI_START="-8.172509971483759" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.6400000000000006" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.10" MODIFIED="2009-10-29 01:11:08 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.6226818995411101" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="33" UNITS="" WEIGHT="99.99999999999999" Z="0.49205297024837175">
<NAME>Mental state: 3c. Negative symptoms - average endpoint score - short term (SANS total, high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.892509971483759" CI_START="-8.172509971483759" EFFECT_SIZE="-1.6400000000000006" ESTIMABLE="YES" MEAN_1="47.0" MEAN_2="48.64" ORDER="426" SD_1="13.99" SD_2="13.29" SE="3.332974494945501" STUDY_ID="STD-Liu-2004" TOTAL_1="34" TOTAL_2="33" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6589252702076317" CI_START="0.2615975649547535" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.41517857142857145" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="-0.18116383666056088" LOG_CI_START="-0.5823663028998943" LOG_EFFECT_SIZE="-0.3817650697802277" METHOD="MH" MODIFIED="2009-10-29 01:11:08 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="1.9146769420719747E-4" Q="0.0" RANDOM="YES" SCALE="11.782234384894473" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="3.7300158911700607">
<NAME>Adverse effects: 1. General - at least one adverse effect</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6589252702076317" CI_START="0.2615975649547535" EFFECT_SIZE="0.41517857142857145" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="28" LOG_CI_END="-0.18116383666056088" LOG_CI_START="-0.5823663028998943" LOG_EFFECT_SIZE="-0.3817650697802277" ORDER="1132" O_E="0.0" SE="0.2356683146532219" STUDY_ID="STD-Li-2002" TOTAL_1="32" TOTAL_2="31" VAR="0.05553955453149001" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9487922447574559" CI_START="0.016468304928013294" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.12500000000000003" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="-0.022828873803598024" LOG_CI_START="-1.7833511001802889" LOG_EFFECT_SIZE="-0.9030899869919435" METHOD="MH" MODIFIED="2009-10-29 01:11:08 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.04434721001788308" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="36" WEIGHT="100.0" Z="2.0107940959607418">
<NAME>Adverse effects: 2. Cardiac effects: ECG abnormalities</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9487922447574559" CI_START="0.016468304928013294" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.022828873803598024" LOG_CI_START="-1.7833511001802889" LOG_EFFECT_SIZE="-0.9030899869919435" ORDER="1133" O_E="0.0" SE="1.0341394704992382" STUDY_ID="STD-Liu-2004" TOTAL_1="36" TOTAL_2="36" VAR="1.0694444444444446" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8324068254313612" CI_END="0.47441371415306627" CI_START="0.10535458041539056" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.2235657795770706" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="-0.32384276505923787" LOG_CI_START="-0.9773465781775152" LOG_EFFECT_SIZE="-0.6505946716183766" METHOD="MH" MODIFIED="2009-10-29 01:11:08 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.36157756135467944" P_Q="1.0" P_Z="9.521289689914962E-5" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="68" TOTAL_2="67" WEIGHT="100.0" Z="3.902477994186987">
<NAME>Adverse effects: 3. Central nervous system - sedation</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.46551811209336685" CI_START="0.050259961971384486" EFFECT_SIZE="0.15296052631578946" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="19" LOG_CI_END="-0.332063417090414" LOG_CI_START="-1.2987778443471858" LOG_EFFECT_SIZE="-0.8154206307187999" ORDER="1140" O_E="0.0" SE="0.5678528398842192" STUDY_ID="STD-Li-2002" TOTAL_1="32" TOTAL_2="31" VAR="0.32245684776457273" WEIGHT="45.69827973953636"/>
<DICH_DATA CI_END="0.8541469901611164" CI_START="0.11084105815927472" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.06846738513922028" LOG_CI_START="-0.9552993368185284" LOG_EFFECT_SIZE="-0.5118833609788743" ORDER="1141" O_E="0.0" SE="0.5209294783053857" STUDY_ID="STD-Liu-2004" TOTAL_1="36" TOTAL_2="36" VAR="0.27136752136752135" WEIGHT="54.30172026046364"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8242168243150239" CI_END="2.0156127192473914" CI_START="0.3342559195735859" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8208108691874474" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="0.30440709024809265" LOG_CI_START="-0.4759208927709023" LOG_EFFECT_SIZE="-0.08575690126140484" METHOD="MH" MODIFIED="2013-06-25 15:12:58 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.7680489309971361" P_Q="0.5019886344467415" P_Z="0.6666179190603485" Q="1.3783558076973716" RANDOM="YES" SCALE="102.47165672224641" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="182" TOTAL_2="179" WEIGHT="300.0" Z="0.4307943366270888">
<NAME>Adverse effects: 4. Extrapyramidal effects</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0515479112373929" CI_END="1.9918848471741946" CI_START="0.07930594347389247" DF="1" EFFECT_SIZE="0.3974522702117823" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-002.14.01" LOG_CI_END="0.29926422782143214" LOG_CI_START="-1.1006942638653783" LOG_EFFECT_SIZE="-0.40071501802197307" MODIFIED="2009-08-05 15:14:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8203913563327557" P_Z="0.26185620811248445" STUDIES="2" TAU2="0.0" TOTAL_1="68" TOTAL_2="67" WEIGHT="100.0" Z="1.1220146997945244">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="5.074328946620748" CI_START="0.04623648626115275" EFFECT_SIZE="0.484375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7053786172159535" LOG_CI_START="-1.3350151775151826" LOG_EFFECT_SIZE="-0.3148182801496145" ORDER="1134" O_E="0.0" SE="1.1985374151372459" STUDY_ID="STD-Li-2002" TOTAL_1="32" TOTAL_2="31" VAR="1.436491935483871" WEIGHT="47.07630091197954"/>
<DICH_DATA CI_END="3.055392699887198" CI_START="0.036365574583984976" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4850670366517737" LOG_CI_START="-1.4393095460910985" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1135" O_E="0.0" SE="1.1303883305208782" STUDY_ID="STD-Liu-2004" TOTAL_1="36" TOTAL_2="36" VAR="1.277777777777778" WEIGHT="52.92369908802047"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.297315786482997" CI_START="0.18494594504461104" DF="0" EFFECT_SIZE="1.9375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-002.14.02" LOG_CI_END="1.307438608543916" LOG_CI_START="-0.7329551861872201" LOG_EFFECT_SIZE="0.2872417111783479" MODIFIED="2009-08-05 15:14:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5810593566322131" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="0.551837993451066">
<NAME>rigor</NAME>
<DICH_DATA CI_END="20.297315786482997" CI_START="0.18494594504461104" EFFECT_SIZE="1.9375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.307438608543916" LOG_CI_START="-0.7329551861872201" LOG_EFFECT_SIZE="0.2872417111783479" ORDER="1136" O_E="0.0" SE="1.1985374151372459" STUDY_ID="STD-Li-2002" TOTAL_1="32" TOTAL_2="31" VAR="1.436491935483871" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.3923100703010208" CI_END="3.33754501686483" CI_START="0.29142275199513223" DF="1" EFFECT_SIZE="0.9862233792211522" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" ID="CMP-002.14.03" LOG_CI_END="0.5234271321836095" LOG_CI_START="-0.5354765449469132" LOG_EFFECT_SIZE="-0.006024706381651918" MODIFIED="2009-08-05 15:14:23 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5310880019720654" P_Z="0.9822064921072425" STUDIES="2" TAU2="0.0" TOTAL_1="68" TOTAL_2="67" WEIGHT="100.0" Z="0.022302703787874134">
<NAME>tremor</NAME>
<DICH_DATA CI_END="8.112310125903376" CI_START="0.26029234987978933" EFFECT_SIZE="1.453125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9091445449717608" LOG_CI_START="-0.584538595831665" LOG_EFFECT_SIZE="0.16230297457004794" ORDER="1137" O_E="0.0" SE="0.8773968707587259" STUDY_ID="STD-Li-2002" TOTAL_1="32" TOTAL_2="31" VAR="0.7698252688172043" WEIGHT="50.25692986900196"/>
<DICH_DATA CI_END="3.754896240474159" CI_START="0.11836397492259897" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.574597940591288" LOG_CI_START="-0.9267804587026505" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="1138" O_E="0.0" SE="0.8819171036881968" STUDY_ID="STD-Liu-2004" TOTAL_1="36" TOTAL_2="36" VAR="0.7777777777777777" WEIGHT="49.74307013099805"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.14.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-08-05 15:14:31 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>use of antiparkinson medication</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1139" O_E="0.0" SE="0.0" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.8843813103531986" CI_START="0.009683006254130959" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.19393939393939397" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.15" LOG_CI_END="0.5893218558533486" LOG_CI_START="-2.013989787641349" LOG_EFFECT_SIZE="-0.7123339658940002" METHOD="MH" MODIFIED="2009-10-29 01:11:08 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.2834530949717221" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="1.0725945328947455">
<NAME>Adverse effects: 5. Haematological: Important decline in white blood cells</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.8843813103531986" CI_START="0.009683006254130959" EFFECT_SIZE="0.19393939393939394" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5893218558533486" LOG_CI_START="-2.013989787641349" LOG_EFFECT_SIZE="-0.7123339658940003" ORDER="1145" O_E="0.0" SE="1.5291981459892532" STUDY_ID="STD-Li-2002" TOTAL_1="32" TOTAL_2="31" VAR="2.3384469696969696" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5253560101986005" CI_END="1.1129617161729544" CI_START="0.2523047200329292" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5299108360907386" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-002.16" LOG_CI_END="0.04648022566373936" LOG_CI_START="-0.59807462476946" LOG_EFFECT_SIZE="-0.27579719955286036" METHOD="MH" MODIFIED="2009-10-29 01:11:08 +0000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.4685659315648466" P_Q="1.0" P_Z="0.09348586251182062" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="68" TOTAL_2="67" WEIGHT="100.00000000000001" Z="1.6772896140563127">
<NAME>Adverse effects: 6a. Metabolic - weight - gain</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9497249636605185" CI_START="0.24558057245424472" EFFECT_SIZE="0.6919642857142857" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.2899733522912395" LOG_CI_START="-0.6098059926189822" LOG_EFFECT_SIZE="-0.15991632016387133" ORDER="1142" O_E="0.0" SE="0.5285348411798544" STUDY_ID="STD-Li-2002" TOTAL_1="32" TOTAL_2="31" VAR="0.27934907834101386" WEIGHT="51.315400532072125"/>
<DICH_DATA CI_END="1.158631233670453" CI_START="0.13809398137242734" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.06394523176522411" LOG_CI_START="-0.8598252491092992" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="1143" O_E="0.0" SE="0.5426273532033234" STUDY_ID="STD-Liu-2004" TOTAL_1="36" TOTAL_2="36" VAR="0.2944444444444444" WEIGHT="48.68459946792789"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.07545521664486454" CI_START="-4.295455216644863" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.1099999999999994" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.17" MODIFIED="2009-10-29 01:11:08 +0000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.05845180690887502" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="1.8922940977616634">
<NAME>Adverse effects: 6b. Metabolic - weight - change from baseline (kg)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.07545521664486454" CI_START="-4.295455216644863" EFFECT_SIZE="-2.1099999999999994" ESTIMABLE="YES" MEAN_1="4.41" MEAN_2="6.52" ORDER="1144" SD_1="2.21" SD_2="3.41" SE="1.1150486610383945" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-10-23 08:48:18 +0100" MODIFIED_BY="Laila Asmal" NO="3">
<NAME>QUETIAPINE versus OLANZAPINE</NAME>
<DICH_OUTCOME CHI2="53.26962327454229" CI_END="1.407204037909532" CI_START="1.1545552831763888" CI_STUDY="95" CI_TOTAL="95" DF="27" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2746351856416007" ESTIMABLE="YES" EVENTS_1="919" EVENTS_2="699" I2="49.314452890258416" I2_Q="86.05830315637915" ID="CMP-003.01" LOG_CI_END="0.1483570726399337" LOG_CI_START="0.06241473292545752" LOG_EFFECT_SIZE="0.10538590278269566" METHOD="MH" MODIFIED="2013-10-22 15:06:45 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.0018670451036855162" P_Q="7.672298741863148E-4" P_Z="1.5338750113736668E-6" Q="14.345456097871757" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.034337960476017046" TOTALS="SUB" TOTAL_1="2512" TOTAL_2="2519" WEIGHT="300.0" Z="4.806771019233286">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="17.81413182690468" CI_END="1.4164668998275016" CI_START="1.1206289164199907" DF="11" EFFECT_SIZE="1.259894347593669" ESTIMABLE="YES" EVENTS_1="622" EVENTS_2="492" I2="38.2512709185934" ID="CMP-003.01.01" LOG_CI_END="0.1512064303282345" LOG_CI_START="0.04946182469911352" LOG_EFFECT_SIZE="0.10033412751367403" MODIFIED="2011-08-25 08:29:58 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.08599486655844402" P_Z="1.1082265687726713E-4" STUDIES="12" TAU2="0.011552051098003994" TOTAL_1="908" TOTAL_2="913" WEIGHT="99.99999999999997" Z="3.8655862909112395">
<NAME>any reason</NAME>
<DICH_DATA CI_END="7.545522164113119" CI_START="0.014725436980300866" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8776892991343043" LOG_CI_START="-1.8319318085736291" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1146" O_E="0.0" SE="1.5916448515084427" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="14" VAR="2.5333333333333328" WEIGHT="0.14035560547611062"/>
<DICH_DATA CI_END="2.959230108372246" CI_START="1.265773012673159" EFFECT_SIZE="1.9353846153846155" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="20" LOG_CI_END="0.4711787370128681" LOG_CI_START="0.10235583191992112" LOG_EFFECT_SIZE="0.28676728446639455" MODIFIED="2011-07-07 11:08:36 +0100" MODIFIED_BY="Laila Asmal" ORDER="8344" O_E="0.0" SE="0.2166484001544218" STUDY_ID="STD-Deberdt-2008" TOTAL_1="65" TOTAL_2="68" VAR="0.046936529289470466" WEIGHT="6.106985784795319"/>
<DICH_DATA CI_END="18.230186804941106" CI_START="1.1988700518458901" EFFECT_SIZE="4.675" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.2607911188985008" LOG_CI_START="0.07877211151857248" LOG_EFFECT_SIZE="0.6697816152085365" MODIFIED="2011-08-25 08:29:58 +0100" MODIFIED_BY="Laila Asmal" ORDER="513" O_E="0.0" SE="0.6943238160234215" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="17" VAR="0.4820855614973262" WEIGHT="0.7235853182281269"/>
<DICH_DATA CI_END="1.598967722608476" CI_START="1.0813328197266263" EFFECT_SIZE="1.3149206349206348" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="81" LOG_CI_END="0.20383969699544452" LOG_CI_START="0.03395938454022198" LOG_EFFECT_SIZE="0.11889954076783325" ORDER="1147" O_E="0.0" SE="0.09978853645730656" STUDY_ID="STD-Kinon-2006b" TOTAL_1="175" TOTAL_2="171" VAR="0.009957752008291201" WEIGHT="16.60586697302811"/>
<DICH_DATA CI_END="1.4045064784460195" CI_START="1.1639840844250289" EFFECT_SIZE="1.2786020441806791" ESTIMABLE="YES" EVENTS_1="277" EVENTS_2="216" LOG_CI_END="0.14752374677495442" LOG_CI_START="0.06594704208909175" LOG_EFFECT_SIZE="0.10673539443202305" ORDER="1148" O_E="0.0" SE="0.04791856014367654" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="336" VAR="0.002296188406243146" WEIGHT="25.79309296966"/>
<DICH_DATA CI_END="2.040288907676097" CI_START="0.9229054866083827" EFFECT_SIZE="1.3722222222222222" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.3096916684678872" LOG_CI_START="-0.03484277215516793" LOG_EFFECT_SIZE="0.13742444815635965" ORDER="1150" O_E="0.0" SE="0.20238123589496917" STUDY_ID="STD-McEvoy-2006" TOTAL_1="15" TOTAL_2="19" VAR="0.04095816464237516" WEIGHT="6.802275023305508"/>
<DICH_DATA CI_END="1.2140415259284965" CI_START="0.8843507922773101" EFFECT_SIZE="1.0361653272101032" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="91" LOG_CI_END="0.08423354190659163" LOG_CI_START="-0.05337543076652705" LOG_EFFECT_SIZE="0.015429055570032291" ORDER="1149" O_E="0.0" SE="0.08083219172359049" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.006533843218839291" WEIGHT="19.749586210205646"/>
<DICH_DATA CI_END="153.7923213075611" CI_START="0.5266842928914012" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.1869346521298794" LOG_CI_START="-0.27844963325122957" LOG_EFFECT_SIZE="0.9542425094393249" ORDER="1151" O_E="0.0" SE="1.4481789330818973" STUDY_ID="STD-Ozguven-2004" TOTAL_1="15" TOTAL_2="15" VAR="2.0972222222222223" WEIGHT="0.16938224897668985"/>
<DICH_DATA CI_END="1.7456011663319289" CI_START="0.735817819796418" EFFECT_SIZE="1.1333333333333333" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.2419450234203388" LOG_CI_START="-0.13322969877515348" LOG_EFFECT_SIZE="0.054357662322592676" ORDER="1152" O_E="0.0" SE="0.22037948896245868" STUDY_ID="STD-Riedel-2007" TOTAL_1="26" TOTAL_2="26" VAR="0.04856711915535444" WEIGHT="5.941348283648529"/>
<DICH_DATA CI_END="2.635455407617342" CI_START="0.24284227999084612" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.42085567227187837" LOG_CI_START="-0.6146756982879912" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="1153" O_E="0.0" SE="0.608276253029822" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" VAR="0.37000000000000005" WEIGHT="0.9361473171780136"/>
<DICH_DATA CI_END="3.9461656961121516" CI_START="0.13758578070443298" EFFECT_SIZE="0.7368421052631579" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5961753169517453" LOG_CI_START="-0.8614264475009272" LOG_EFFECT_SIZE="-0.13262556527459096" ORDER="1154" O_E="0.0" SE="0.8562024916845998" STUDY_ID="STD-Sirota-2006" TOTAL_1="19" TOTAL_2="21" VAR="0.7330827067669172" WEIGHT="0.47968339541834804"/>
<DICH_DATA CI_END="1.5133044409129486" CI_START="1.0219896457805973" EFFECT_SIZE="1.243616287094548" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="46" LOG_CI_END="0.1799263065481082" LOG_CI_START="0.009446495795630947" LOG_EFFECT_SIZE="0.09468640117186959" ORDER="1155" O_E="0.0" SE="0.10014068472467842" STUDY_ID="STD-Stroup-2006" TOTAL_1="63" TOTAL_2="68" VAR="0.010028156737127442" WEIGHT="16.55169087007958"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.3478309477552575" CI_END="1.1775678743052904" CI_START="0.6865338339188387" DF="6" EFFECT_SIZE="0.8991330198844152" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="97" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.0709859489955864" LOG_CI_START="-0.16333805489893305" LOG_EFFECT_SIZE="-0.04617605295167333" MODIFIED="2011-08-25 08:30:53 +0100" MODIFIED_BY="Laila Asmal" NO="2" P_CHI2="0.5000358787034047" P_Z="0.4398398086011942" STUDIES="9" TAU2="0.0" TOTAL_1="804" TOTAL_2="806" WEIGHT="100.00000000000001" Z="0.7724637615379272">
<NAME>due to adverse events</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-25 08:30:53 +0100" MODIFIED_BY="Laila Asmal" ORDER="514" O_E="0.0" SE="0.0" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.057154093354637" CI_START="0.7629443529056205" EFFECT_SIZE="2.149714285714286" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.782268622209177" LOG_CI_START="-0.11750713715304556" LOG_EFFECT_SIZE="0.33238074252806565" ORDER="1156" O_E="0.0" SE="0.5285327350112109" STUDY_ID="STD-Kinon-2006b" TOTAL_1="175" TOTAL_2="171" VAR="0.2793468519784309" WEIGHT="6.782112375868417"/>
<DICH_DATA CI_END="1.1101911590045197" CI_START="0.559280618740133" EFFECT_SIZE="0.7879774097827127" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="62" LOG_CI_END="0.045397764510127656" LOG_CI_START="-0.25237023041259726" LOG_EFFECT_SIZE="-0.10348623295123482" ORDER="1157" O_E="0.0" SE="0.17491039419295543" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="336" VAR="0.030593645996735055" WEIGHT="61.92664130862291"/>
<DICH_DATA CI_END="32.935571950891074" CI_START="0.43843173640739885" EFFECT_SIZE="3.8" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.517665209692186" LOG_CI_START="-0.35809801645856604" LOG_EFFECT_SIZE="0.5797835966168101" ORDER="1159" O_E="0.0" SE="1.1018326042186708" STUDY_ID="STD-McEvoy-2006" TOTAL_1="15" TOTAL_2="19" VAR="1.2140350877192982" WEIGHT="1.5605494117323633"/>
<DICH_DATA CI_END="1.8854713726850547" CI_START="0.45050993788920757" EFFECT_SIZE="0.9216417910447762" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.2754199428517979" LOG_CI_START="-0.346295624390044" LOG_EFFECT_SIZE="-0.03543784076912307" ORDER="1158" O_E="0.0" SE="0.36519880173954977" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.13337016479200298" WEIGHT="14.205289053346052"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1160" O_E="0.0" SE="0.0" STUDY_ID="STD-Ozguven-2004" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="15.149704352020958" CI_START="0.06600788878540728" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.180404157621246" LOG_CI_START="-1.180404157621246" LOG_EFFECT_SIZE="0.0" ORDER="1161" O_E="0.0" SE="1.3867504905630728" STUDY_ID="STD-Riedel-2007" TOTAL_1="26" TOTAL_2="26" VAR="1.923076923076923" WEIGHT="0.9851721058206555"/>
<DICH_DATA CI_END="8.495189495944357" CI_START="0.01582595002838123" EFFECT_SIZE="0.36666666666666664" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9291730708007208" LOG_CI_START="-1.8006302099235953" LOG_EFFECT_SIZE="-0.4357285695614374" ORDER="1162" O_E="0.0" SE="1.6034999598416337" STUDY_ID="STD-Sirota-2006" TOTAL_1="19" TOTAL_2="21" VAR="2.5712121212121213" WEIGHT="0.7368360339984956"/>
<DICH_DATA CI_END="1.887853813486009" CI_START="0.44184203520994175" EFFECT_SIZE="0.9133089133089133" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.27596836154340754" LOG_CI_START="-0.35473296933532183" LOG_EFFECT_SIZE="-0.03938230389595713" ORDER="1163" O_E="0.0" SE="0.3704770837801048" STUDY_ID="STD-Stroup-2006" TOTAL_1="63" TOTAL_2="68" VAR="0.1372532696062108" WEIGHT="13.803399710611112"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.363168405720902" CI_END="2.3630244016347355" CI_START="1.4223959153873813" DF="8" EFFECT_SIZE="1.8333456457651292" ESTIMABLE="YES" EVENTS_1="209" EVENTS_2="110" I2="14.55883678101961" ID="CMP-003.01.03" LOG_CI_END="0.37346820637235956" LOG_CI_START="0.15302049648942023" LOG_EFFECT_SIZE="0.26324435143088987" MODIFIED="2011-08-25 08:31:29 +0100" MODIFIED_BY="Laila Asmal" NO="3" P_CHI2="0.31259168740515453" P_Z="2.8558531039890735E-6" STUDIES="9" TAU2="0.02157935805024875" TOTAL_1="800" TOTAL_2="800" WEIGHT="100.0" Z="4.680923636830931">
<NAME>due to inefficacy</NAME>
<DICH_DATA CI_END="18.230186804941106" CI_START="1.1988700518458901" EFFECT_SIZE="4.675" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.2607911188985008" LOG_CI_START="0.07877211151857248" LOG_EFFECT_SIZE="0.6697816152085365" MODIFIED="2011-08-25 08:31:29 +0100" MODIFIED_BY="Laila Asmal" ORDER="515" O_E="0.0" SE="0.6943238160234215" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="17" VAR="0.4820855614973262" WEIGHT="3.3292367804319616"/>
<DICH_DATA CI_END="3.8847138694914007" CI_START="1.5925305769417377" EFFECT_SIZE="2.4872727272727273" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="22" LOG_CI_END="0.5893590361414961" LOG_CI_START="0.20208777963821106" LOG_EFFECT_SIZE="0.3957234078898536" ORDER="1164" O_E="0.0" SE="0.22748505309366665" STUDY_ID="STD-Kinon-2006b" TOTAL_1="175" TOTAL_2="171" VAR="0.05174944938102834" WEIGHT="22.86713549436335"/>
<DICH_DATA CI_END="2.6174079972121898" CI_START="1.3952129800157291" EFFECT_SIZE="1.910979228486647" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="48" LOG_CI_END="0.4178714250193436" LOG_CI_START="0.1446405079576034" LOG_EFFECT_SIZE="0.2812559664884735" ORDER="1165" O_E="0.0" SE="0.16049719319691874" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="336" VAR="0.02575934902408906" WEIGHT="35.42174847610258"/>
<DICH_DATA CI_END="3.1366177556099983" CI_START="0.5115205515797437" EFFECT_SIZE="1.2666666666666666" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4964615965606342" LOG_CI_START="-0.29113691276633885" LOG_EFFECT_SIZE="0.1026623418971477" ORDER="1167" O_E="0.0" SE="0.46263926305416214" STUDY_ID="STD-McEvoy-2006" TOTAL_1="15" TOTAL_2="19" VAR="0.21403508771929824" WEIGHT="7.116795278381098"/>
<DICH_DATA CI_END="2.158083098168947" CI_START="0.5863282863376501" EFFECT_SIZE="1.1248756218905474" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.3340681634151988" LOG_CI_START="-0.23185915356545705" LOG_EFFECT_SIZE="0.05110450492487088" ORDER="1166" O_E="0.0" SE="0.3324285073798365" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.110508712518786" WEIGHT="12.694710188038634"/>
<DICH_DATA CI_END="153.7923213075611" CI_START="0.5266842928914012" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.1869346521298794" LOG_CI_START="-0.27844963325122957" LOG_EFFECT_SIZE="0.9542425094393249" ORDER="1168" O_E="0.0" SE="1.4481789330818973" STUDY_ID="STD-Ozguven-2004" TOTAL_1="15" TOTAL_2="15" VAR="2.0972222222222223" WEIGHT="0.791400096537335"/>
<DICH_DATA CI_END="16.46981283829314" CI_START="0.0741724669365489" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.216688663908166" LOG_CI_START="-1.129757276345985" LOG_EFFECT_SIZE="0.043465693781090345" ORDER="1169" O_E="0.0" SE="1.3783139604000185" STUDY_ID="STD-Sirota-2006" TOTAL_1="19" TOTAL_2="21" VAR="1.899749373433584" WEIGHT="0.8727396554758704"/>
<DICH_DATA CI_END="2.7705476202195713" CI_START="0.9045528593831798" EFFECT_SIZE="1.583068783068783" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="15" LOG_CI_END="0.4425656192210089" LOG_CI_START="-0.04356604918264977" LOG_EFFECT_SIZE="0.19949978501917962" ORDER="1170" O_E="0.0" SE="0.28555614841087745" STUDY_ID="STD-Stroup-2006" TOTAL_1="63" TOTAL_2="68" VAR="0.08154231389525507" WEIGHT="16.2605953097544"/>
<DICH_DATA CI_END="7.070137371487788" CI_START="0.013101244626080647" EFFECT_SIZE="0.30434782608695654" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8494278521419525" LOG_CI_START="-1.8826874441486245" LOG_EFFECT_SIZE="-0.516629796003336" ORDER="1171" O_E="0.0" SE="1.6048580492299167" STUDY_ID="STD-Svestka-2003b" TOTAL_1="22" TOTAL_2="20" VAR="2.5755693581780537" WEIGHT="0.6456387209147751"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9742566738466436" CI_END="1.4313789048744927" CI_START="0.8620175524015685" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1107986946963648" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="64" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.15575461245588076" LOG_CI_START="-0.06448389098092992" LOG_EFFECT_SIZE="0.045635360737475435" METHOD="MH" MODIFIED="2013-10-22 15:06:45 +0100" MODIFIED_BY="Laila Asmal" NO="2" P_CHI2="0.6143882302580354" P_Q="1.0" P_Z="0.41665184225506446" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="171" TOTAL_2="168" WEIGHT="100.0" Z="0.8122436546850907">
<NAME>Global state: 1a. No clinically significant response (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5658829761347657" CI_START="0.856303978595806" EFFECT_SIZE="1.157960199004975" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="48" LOG_CI_END="0.19475930260190052" LOG_CI_START="-0.06737203813611788" LOG_EFFECT_SIZE="0.06369363223289133" ORDER="1172" O_E="0.0" SE="0.15397724712057562" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.02370899263083081" WEIGHT="70.5908801605452"/>
<DICH_DATA CI_END="4.2577276665705055" CI_START="0.5284508959240973" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6291778795804434" LOG_CI_START="-0.27699536146908094" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="1173" O_E="0.0" SE="0.5322906474223771" STUDY_ID="STD-Ozguven-2004" TOTAL_1="15" TOTAL_2="15" VAR="0.2833333333333333" WEIGHT="5.906959967753742"/>
<DICH_DATA CI_END="1.5337534344846417" CI_START="0.538839074397529" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.185755548237788" LOG_CI_START="-0.2685409185542381" LOG_EFFECT_SIZE="-0.04139268515822506" ORDER="1174" O_E="0.0" SE="0.266855993397415" STUDY_ID="STD-Svestka-2003b" TOTAL_1="22" TOTAL_2="20" VAR="0.0712121212121212" WEIGHT="23.502159871701064"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.12984385883719007" CI_END="1.5673233139314262" CI_START="0.8883218485332656" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.179952347970395" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="54" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.19515859377095823" LOG_CI_START="-0.051429656161053786" LOG_EFFECT_SIZE="0.07186446880495223" METHOD="MH" MODIFIED="2013-10-22 15:06:42 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7185940683547353" P_Q="0.7187020108147262" P_Z="0.25328591573609716" Q="0.12973984501230693" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="156" TOTAL_2="153" WEIGHT="100.0" Z="1.1424045603522752">
<NAME>Global state: 1b. No clinically important change (as measured by CGI)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.1488783578372503" CI_START="0.5905290458754243" DF="0" EFFECT_SIZE="1.3636363636363635" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.4981558840279612" LOG_CI_START="-0.2287587362330489" LOG_EFFECT_SIZE="0.13469857389745618" MODIFIED="2009-08-10 13:31:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.46761220651938573" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="20" WEIGHT="11.507419597161054" Z="0.7263696347533256">
<NAME>short term</NAME>
<DICH_DATA CI_END="3.1488783578372503" CI_START="0.5905290458754243" EFFECT_SIZE="1.3636363636363635" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.4981558840279612" LOG_CI_START="-0.2287587362330489" LOG_EFFECT_SIZE="0.13469857389745618" ORDER="1175" O_E="0.0" SE="0.42699324622672" STUDY_ID="STD-Svestka-2003b" TOTAL_1="22" TOTAL_2="20" VAR="0.18232323232323233" WEIGHT="11.507419597161054"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5658829761347657" CI_START="0.856303978595806" DF="0" EFFECT_SIZE="1.157960199004975" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="48" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="0.19475930260190052" LOG_CI_START="-0.06737203813611788" LOG_EFFECT_SIZE="0.06369363223289133" MODIFIED="2009-08-10 13:31:46 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3408544068979211" STUDIES="1" TAU2="0.0" TOTAL_1="134" TOTAL_2="133" WEIGHT="88.49258040283894" Z="0.9524784397739943">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.5658829761347657" CI_START="0.856303978595806" EFFECT_SIZE="1.157960199004975" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="48" LOG_CI_END="0.19475930260190052" LOG_CI_START="-0.06737203813611788" LOG_EFFECT_SIZE="0.06369363223289133" ORDER="1176" O_E="0.0" SE="0.15397724712057562" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.02370899263083081" WEIGHT="88.49258040283894"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.190642868658333E-31" CI_END="1.5337534344846417" CI_START="0.538839074397529" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" I2="100.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.185755548237788" LOG_CI_START="-0.2685409185542381" LOG_EFFECT_SIZE="-0.04139268515822506" METHOD="MH" MODIFIED="2013-10-22 13:21:25 +0100" MODIFIED_BY="Laila Asmal" NO="4" P_CHI2="0.0" P_Q="1.0" P_Z="0.7209723292906793" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="20" WEIGHT="100.0" Z="0.35715959979352724">
<NAME>Mental state: 1a. General - no clinically important change - short term (less than 50% PANSS total score reduction)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5337534344846417" CI_START="0.538839074397529" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.185755548237788" LOG_CI_START="-0.2685409185542381" LOG_EFFECT_SIZE="-0.04139268515822506" MODIFIED="2009-08-07 15:54:39 +0100" MODIFIED_BY="[Empty name]" ORDER="414" O_E="0.0" SE="0.266855993397415" STUDY_ID="STD-Svestka-2003b" TOTAL_1="22" TOTAL_2="20" VAR="0.0712121212121212" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="6.5271399309174125" CI_END="5.388623224869514" CI_START="1.94643457171213" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="MD" EFFECT_SIZE="3.667528898290822" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.05" MODIFIED="2013-10-22 15:18:26 +0100" MODIFIED_BY="Laila Asmal" NO="5" P_CHI2="0.7692037728833115" P_Q="0.42952629912031537" P_Z="2.959727449536991E-5" Q="1.6901459372867982" RANDOM="YES" SCALE="54.151550027552" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="748" TOTAL_2="738" UNITS="" WEIGHT="99.99999999999999" Z="4.176543052814028">
<NAME>Mental state: 1b. General - average endpoint score (PANSS total, high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.7589278783323908" CI_END="5.870535069181257" CI_START="-1.2953766891306695" DF="4" EFFECT_SIZE="2.2875791900252938" ESTIMABLE="YES" I2="0.0" ID="CMP-003.05.01" MODIFIED="2011-08-25 09:18:05 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.9438679960804224" P_Z="0.21080266364930011" STUDIES="5" TAU2="0.0" TOTAL_1="92" TOTAL_2="87" WEIGHT="23.074187930623708" Z="1.2513614388377787">
<NAME>short term</NAME>
<CONT_DATA CI_END="7.100657875744535" CI_START="-2.3406578757445438" EFFECT_SIZE="2.3799999999999955" ESTIMABLE="YES" MEAN_1="77.24" MEAN_2="74.86" ORDER="1178" SD_1="6.08" SD_2="6.41" SE="2.4085431737422147" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="13" WEIGHT="13.292427273006643"/>
<CONT_DATA CI_END="20.46467507197546" CI_START="-11.46467507197546" EFFECT_SIZE="4.5" ESTIMABLE="YES" MEAN_1="-28.9" MEAN_2="-33.4" MODIFIED="2011-08-25 09:18:05 +0100" MODIFIED_BY="Laila Asmal" ORDER="519" SD_1="28.6" SD_2="20.8" SE="8.145392057151447" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="17" WEIGHT="1.1622222310611001"/>
<CONT_DATA CI_END="11.636211595553027" CI_START="-4.636211595553027" EFFECT_SIZE="3.5" ESTIMABLE="YES" MEAN_1="72.9" MEAN_2="69.4" ORDER="1179" SD_1="15.1" SD_2="10.8" SE="4.151204644437564" STUDY_ID="STD-Mori-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="4.474709817281647"/>
<CONT_DATA CI_END="11.48862861624942" CI_START="-18.728628616249424" EFFECT_SIZE="-3.620000000000001" ESTIMABLE="YES" MEAN_1="-21.5" MEAN_2="-17.88" ORDER="1180" SD_1="23.39" SD_2="20.71" SE="7.708625635687367" STUDY_ID="STD-Riedel-2007" TOTAL_1="16" TOTAL_2="17" WEIGHT="1.297655028605632"/>
<CONT_DATA CI_END="11.939941957500938" CI_START="-8.459941957500934" EFFECT_SIZE="1.740000000000002" ESTIMABLE="YES" MEAN_1="-43.91" MEAN_2="-45.65" ORDER="1181" SD_1="20.94" SD_2="11.96" SE="5.204147646567374" STUDY_ID="STD-Svestka-2003b" TOTAL_1="22" TOTAL_2="20" WEIGHT="2.8471735806686853"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.8626019212952212" CI_END="9.170788884691813" CI_START="1.9717868947764199" DF="2" EFFECT_SIZE="5.5712878897341165" ESTIMABLE="YES" I2="0.0" ID="CMP-003.05.02" MODIFIED="2009-08-10 13:32:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.39404080345024217" P_Z="0.0024163738621403694" STUDIES="3" TAU2="0.0" TOTAL_1="240" TOTAL_2="242" WEIGHT="22.86255430712595" Z="3.0336215010579157">
<NAME>medium term</NAME>
<CONT_DATA CI_END="8.338608670479879" CI_START="-0.13860867047987746" EFFECT_SIZE="4.1000000000000005" ESTIMABLE="YES" MEAN_1="-7.2" MEAN_2="-11.3" ORDER="1182" SD_1="21.2" SD_2="18.3" SE="2.1625951823163496" STUDY_ID="STD-Kinon-2006b" TOTAL_1="169" TOTAL_2="166" WEIGHT="16.48779965412943"/>
<CONT_DATA CI_END="21.044500510629547" CI_START="-8.244500510629546" EFFECT_SIZE="6.4" ESTIMABLE="YES" MEAN_1="-1.3" MEAN_2="-7.7" ORDER="1183" SD_1="19.23" SD_2="9.8" SE="7.47182123046316" STUDY_ID="STD-McEvoy-2006" TOTAL_1="8" TOTAL_2="10" WEIGHT="1.381211606004161"/>
<CONT_DATA CI_END="17.90194253453346" CI_START="2.4980574654665384" EFFECT_SIZE="10.2" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="-8.2" ORDER="1184" SD_1="22.31" SD_2="22.31" SE="3.929634725579348" STUDY_ID="STD-Stroup-2006" TOTAL_1="63" TOTAL_2="66" WEIGHT="4.993543046992362"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.228471056638939" CI_END="5.882219388780285" CI_START="0.9085561358636469" DF="2" EFFECT_SIZE="3.395387762321966" ESTIMABLE="YES" I2="10.252368140851132" ID="CMP-003.05.03" MODIFIED="2009-08-10 13:32:53 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.328166353198023" P_Z="0.007449982507964473" STUDIES="3" TAU2="0.5112091552200567" TOTAL_1="416" TOTAL_2="409" WEIGHT="54.06325776225033" Z="2.6760306797194575">
<NAME>long term</NAME>
<CONT_DATA CI_END="8.59671223050518" CI_START="1.783287769494819" EFFECT_SIZE="5.1899999999999995" ESTIMABLE="YES" MEAN_1="-6.08" MEAN_2="-11.27" ORDER="1185" SD_1="22.31" SD_2="22.31" SE="1.7381504238735466" STUDY_ID="STD-Lieberman-2005" TOTAL_1="329" TOTAL_2="330" WEIGHT="25.523395290772804"/>
<CONT_DATA CI_END="7.248321366050968" CI_START="-1.6483213660509701" EFFECT_SIZE="2.799999999999999" ESTIMABLE="YES" MEAN_1="-15.6" MEAN_2="-18.4" ORDER="1186" SD_1="10.68" SD_2="9.73" SE="2.2695934216846636" STUDY_ID="STD-McEvoy-2007" TOTAL_1="44" TOTAL_2="37" WEIGHT="14.969835773228807"/>
<CONT_DATA CI_END="5.5721235840620285" CI_START="-3.7721235840620313" EFFECT_SIZE="0.8999999999999986" ESTIMABLE="YES" MEAN_1="49.4" MEAN_2="48.5" ORDER="1187" SD_1="12.0" SD_2="9.9" SE="2.383780325003492" STUDY_ID="STD-Voruganti-2007" TOTAL_1="43" TOTAL_2="42" WEIGHT="13.57002669824872"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="241.1999955397852" CI_START="0.9328358381453072" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="2.38237729543724" LOG_CI_START="-0.030194777325877897" LOG_EFFECT_SIZE="1.1760912590556813" METHOD="MH" MODIFIED="2013-10-22 13:21:45 +0100" MODIFIED_BY="Laila Asmal" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.05601695110440141" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.9109037498237105">
<NAME>Mental state: 2a. Positive symptoms - no clinically important change - short term (less than 20% SAPS total score reduction)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="241.1999955397852" CI_START="0.9328358381453072" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.38237729543724" LOG_CI_START="-0.030194777325877897" LOG_EFFECT_SIZE="1.1760912590556813" MODIFIED="2009-08-07 15:55:26 +0100" MODIFIED_BY="[Empty name]" ORDER="415" O_E="0.0" SE="1.4171567779654208" STUDY_ID="STD-Ozguven-2004" TOTAL_1="15" TOTAL_2="15" VAR="2.0083333333333333" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="39.59700358275315" CI_END="2.8484485963538804" CI_START="-0.8106647518955545" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="1.018891922229163" ESTIMABLE="YES" I2="79.79645105397704" I2_Q="0.0" ID="CMP-003.07" MODIFIED="2013-10-22 15:18:43 +0100" MODIFIED_BY="Laila Asmal" NO="7" P_CHI2="3.8077175495976334E-6" P_Q="0.41446777105266175" P_Z="0.2750456506544485" Q="1.761522048527395" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="5.391582126837481" TOTALS="YES" TOTAL_1="405" TOTAL_2="396" UNITS="" WEIGHT="99.99999999999999" Z="1.0915165952229005">
<NAME>Mental state: 2b. Positive symptoms - average endpoint score (PANSS positive subscore, high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.472163734249972" CI_END="2.959193959212814" CI_START="-0.47695399151187456" DF="3" EFFECT_SIZE="1.2411199838504696" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.01" MODIFIED="2012-07-05 10:22:10 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.6887096902253652" P_Z="0.1568167965900277" STUDIES="4" TAU2="0.0" TOTAL_1="78" TOTAL_2="74" WEIGHT="36.56054974173635" Z="1.415858981466049">
<NAME>short term</NAME>
<CONT_DATA CI_END="9.009449318965011" CI_START="-2.609449318965013" EFFECT_SIZE="3.1999999999999993" ESTIMABLE="YES" MEAN_1="-9.4" MEAN_2="-12.6" MODIFIED="2011-08-25 09:22:50 +0100" MODIFIED_BY="Laila Asmal" ORDER="520" SD_1="8.6" SD_2="9.3" SE="2.9640592198577154" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="17" WEIGHT="6.146164674651526"/>
<CONT_DATA CI_END="4.023198149765804" CI_START="-0.6231981497658015" EFFECT_SIZE="1.700000000000001" ESTIMABLE="YES" MEAN_1="13.3" MEAN_2="11.6" MODIFIED="2012-07-05 10:22:10 +0100" MODIFIED_BY="Laila Asmal" ORDER="1188" SD_1="4.3" SD_2="3.1" SE="1.1853269591129698" STUDY_ID="STD-Mori-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="12.820500595627083"/>
<CONT_DATA CI_END="4.023603349657839" CI_START="-5.943603349657839" EFFECT_SIZE="-0.96" ESTIMABLE="YES" MEAN_1="-7.78" MEAN_2="-6.82" ORDER="1189" SD_1="7.3" SD_2="7.3" SE="2.542701492970211" STUDY_ID="STD-Riedel-2007" TOTAL_1="16" TOTAL_2="17" WEIGHT="7.348926751660282"/>
<CONT_DATA CI_END="4.048453250956895" CI_START="-2.8684532509568945" EFFECT_SIZE="0.5899999999999999" ESTIMABLE="YES" MEAN_1="-12.96" MEAN_2="-13.55" ORDER="1190" SD_1="6.28" SD_2="5.14" SE="1.7645493887830246" STUDY_ID="STD-Svestka-2003b" TOTAL_1="22" TOTAL_2="20" WEIGHT="10.244957719797467"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.2603398558686836" CI_END="3.521068793183203" CI_START="0.9030691428647897" DF="2" EFFECT_SIZE="2.2120689680239964" ESTIMABLE="YES" I2="11.517730627663996" ID="CMP-003.07.02" MODIFIED="2009-08-10 13:33:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3229787055903428" P_Z="9.258903688393774E-4" STUDIES="3" TAU2="0.21368085879104903" TOTAL_1="240" TOTAL_2="243" WEIGHT="34.91303339291737" Z="3.3121284092749246">
<NAME>medium term</NAME>
<CONT_DATA CI_END="2.888759794804241" CI_START="0.3112402051957588" EFFECT_SIZE="1.5999999999999999" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-2.3" ORDER="1191" SD_1="6.6" SD_2="5.4" SE="0.6575425900525794" STUDY_ID="STD-Kinon-2006b" TOTAL_1="169" TOTAL_2="167" WEIGHT="14.96161011361955"/>
<CONT_DATA CI_END="8.340619042047734" CI_START="-1.3406190420477353" EFFECT_SIZE="3.5" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="-2.9" ORDER="1192" SD_1="5.94" SD_2="4.11" SE="2.4697489750984816" STUDY_ID="STD-McEvoy-2006" TOTAL_1="8" TOTAL_2="10" WEIGHT="7.5827821086325855"/>
<CONT_DATA CI_END="6.120133594894409" CI_START="1.0798664051055908" EFFECT_SIZE="3.6" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="-3.4" ORDER="1193" SD_1="7.3" SD_2="7.3" SE="1.2858060733630319" STUDY_ID="STD-Stroup-2006" TOTAL_1="63" TOTAL_2="66" WEIGHT="12.368641170665233"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="26.190814604313676" CI_END="4.789620899163944" CI_START="-7.283052244786848" DF="1" EFFECT_SIZE="-1.2467156728114517" ESTIMABLE="YES" I2="96.18186751688397" ID="CMP-003.07.03" MODIFIED="2013-04-24 16:06:56 +0100" MODIFIED_BY="Laila Asmal" NO="3" P_CHI2="3.092985493280409E-7" P_Z="0.6856234613640315" STUDIES="2" TAU2="18.248393360243355" TOTAL_1="87" TOTAL_2="79" WEIGHT="28.526416865346267" Z="0.4048014534206836">
<NAME>long term</NAME>
<CONT_DATA CI_END="3.2125007550028224" CI_START="0.38749924499717747" EFFECT_SIZE="1.7999999999999998" ESTIMABLE="YES" MEAN_1="-5.3" MEAN_2="-7.1" MODIFIED="2012-07-05 09:20:47 +0100" MODIFIED_BY="Laila Asmal" ORDER="1194" SD_1="3.38" SD_2="3.1" SE="0.7206768931186737" STUDY_ID="STD-McEvoy-2007" TOTAL_1="44" TOTAL_2="37" WEIGHT="14.741366012157192"/>
<CONT_DATA CI_END="-2.4704502734139195" CI_START="-6.249549726586079" EFFECT_SIZE="-4.359999999999999" ESTIMABLE="YES" MEAN_1="11.14" MEAN_2="15.5" MODIFIED="2013-04-24 16:06:56 +0100" MODIFIED_BY="Laila Asmal" ORDER="452" SD_1="4.3" SD_2="4.58" SE="0.9640736980325183" STUDY_ID="STD-Voruganti-2007" TOTAL_1="43" TOTAL_2="42" WEIGHT="13.785050853189075"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="57.705570755444924" CI_START="23.974429244555072" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="40.839999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.08" MODIFIED="2013-10-22 13:21:59 +0100" MODIFIED_BY="Laila Asmal" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="2.0742216785789077E-6" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="4.7460551610904655">
<NAME>Mental state: 2c. Positive symptoms - SAPS total score - percent change - short term (high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="57.705570755444924" CI_START="23.974429244555072" EFFECT_SIZE="40.839999999999996" ESTIMABLE="YES" MEAN_1="-18.03" MEAN_2="-58.87" MODIFIED="2009-08-07 15:56:03 +0100" MODIFIED_BY="[Empty name]" ORDER="416" SD_1="27.29" SD_2="19.13" SE="8.605041158142901" STUDY_ID="STD-Ozguven-2004" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.2577276665705055" CI_START="0.5284508959240973" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="0.6291778795804434" LOG_CI_START="-0.27699536146908094" LOG_EFFECT_SIZE="0.17609125905568124" METHOD="MH" MODIFIED="2013-10-22 13:22:06 +0100" MODIFIED_BY="Laila Asmal" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.44621741204055676" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.7617362996543962">
<NAME>Mental state: 3a. Negative symptoms - no clinically important change - short term (less than 20% SANS total score reduction)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.2577276665705055" CI_START="0.5284508959240973" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6291778795804434" LOG_CI_START="-0.27699536146908094" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2009-08-07 15:56:46 +0100" MODIFIED_BY="[Empty name]" ORDER="417" O_E="0.0" SE="0.5322906474223771" STUDY_ID="STD-Ozguven-2004" TOTAL_1="15" TOTAL_2="15" VAR="0.2833333333333333" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="17.120426125224572" CI_END="2.0310984402071375" CI_START="-0.31558144343452565" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="0.8577584983863058" ESTIMABLE="YES" I2="53.27219111554058" I2_Q="0.0" ID="CMP-003.10" MODIFIED="2013-10-22 15:18:54 +0100" MODIFIED_BY="Laila Asmal" NO="10" P_CHI2="0.02887927040700977" P_Q="0.45840943600790174" P_Z="0.15191151853382845" Q="1.5599856966441772" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="1.4918245998143644" TOTALS="YES" TOTAL_1="405" TOTAL_2="396" UNITS="" WEIGHT="100.0" Z="1.4328121837064611">
<NAME>Mental state: 3b. Negative symptoms - average endpoint score (PANSS negative subscore, high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.2812162801697737" CI_END="1.560964333788202" CI_START="-1.697421826626999" DF="3" EFFECT_SIZE="-0.0682287464193984" ESTIMABLE="YES" I2="0.0" ID="CMP-003.10.01" MODIFIED="2013-04-24 16:16:01 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.733598323285919" P_Z="0.9345822587562347" STUDIES="4" TAU2="0.0" TOTAL_1="78" TOTAL_2="74" WEIGHT="31.468601276368133" Z="0.08208105430652639">
<NAME>short term</NAME>
<CONT_DATA CI_END="4.267523390908843" CI_START="-5.667523390908843" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="-6.3" MEAN_2="-5.6" MODIFIED="2011-08-25 09:33:02 +0100" MODIFIED_BY="Laila Asmal" ORDER="521" SD_1="9.5" SD_2="5.7" SE="2.5344972816296796" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="17" WEIGHT="4.527652797073091"/>
<CONT_DATA CI_END="3.4811162326989713" CI_START="-1.4811162326989713" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="23.8" MEAN_2="22.8" MODIFIED="2013-04-24 16:16:01 +0100" MODIFIED_BY="Laila Asmal" ORDER="1197" SD_1="4.6" SD_2="3.3" SE="1.2658988901172161" STUDY_ID="STD-Mori-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="11.582055923865717"/>
<CONT_DATA CI_END="3.7938013295592885" CI_START="-5.053801329559288" EFFECT_SIZE="-0.6299999999999999" ESTIMABLE="YES" MEAN_1="-3.98" MEAN_2="-3.35" ORDER="1199" SD_1="6.48" SD_2="6.48" SE="2.2570829691023246" STUDY_ID="STD-Riedel-2007" TOTAL_1="16" TOTAL_2="17" WEIGHT="5.441434919922206"/>
<CONT_DATA CI_END="1.815007442595907" CI_START="-3.8950074425959054" EFFECT_SIZE="-1.0399999999999991" ESTIMABLE="YES" MEAN_1="-9.59" MEAN_2="-8.55" ORDER="1198" SD_1="4.91" SD_2="4.53" SE="1.4566632168324727" STUDY_ID="STD-Svestka-2003b" TOTAL_1="22" TOTAL_2="20" WEIGHT="9.91745763550712"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.15090149395794006" CI_END="1.4689115547914637" CI_START="-0.66696781739775" DF="2" EFFECT_SIZE="0.4009718686968568" ESTIMABLE="YES" I2="0.0" ID="CMP-003.10.02" MODIFIED="2009-08-10 13:33:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9273254221229614" P_Z="0.46179520663723483" STUDIES="3" TAU2="0.0" TOTAL_1="240" TOTAL_2="243" WEIGHT="36.882548569044616" Z="0.7358940132036091">
<NAME>medium term</NAME>
<CONT_DATA CI_END="1.6617889458647217" CI_START="-0.8617889458647219" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="-3.6" MEAN_2="-4.0" ORDER="1200" SD_1="6.0" SD_2="5.8" SE="0.6437816999789547" STUDY_ID="STD-Kinon-2006b" TOTAL_1="169" TOTAL_2="167" WEIGHT="18.80030761137487"/>
<CONT_DATA CI_END="4.122576017319448" CI_START="-4.922576017319448" EFFECT_SIZE="-0.40000000000000013" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.7" ORDER="1201" SD_1="6.22" SD_2="2.21" SE="2.307479144001089" STUDY_ID="STD-McEvoy-2006" TOTAL_1="8" TOTAL_2="10" WEIGHT="5.257796976760537"/>
<CONT_DATA CI_END="2.8370500951939412" CI_START="-1.637050095193941" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="-0.4" ORDER="1202" SD_1="6.48" SD_2="6.48" SE="1.141373062382527" STUDY_ID="STD-Stroup-2006" TOTAL_1="63" TOTAL_2="66" WEIGHT="12.824443980909207"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.974670084875388" CI_END="6.563635475423848" CI_START="-1.29119438620073" DF="1" EFFECT_SIZE="2.636220544611559" ESTIMABLE="YES" I2="89.97460576148477" ID="CMP-003.10.03" MODIFIED="2013-04-24 16:23:34 +0100" MODIFIED_BY="Laila Asmal" NO="3" P_CHI2="0.0015870924193738256" P_Z="0.1883091681337564" STUDIES="2" TAU2="7.234003290526256" TOTAL_1="87" TOTAL_2="79" WEIGHT="31.648850154587244" Z="1.3155975148453636">
<NAME>long term</NAME>
<CONT_DATA CI_END="2.1271998196488386" CI_START="-0.7271998196488385" EFFECT_SIZE="0.7000000000000002" ESTIMABLE="YES" MEAN_1="-2.8" MEAN_2="-3.5" ORDER="1203" SD_1="3.45" SD_2="3.1" SE="0.7281765537052766" STUDY_ID="STD-McEvoy-2007" TOTAL_1="44" TOTAL_2="37" WEIGHT="17.72377657289346"/>
<CONT_DATA CI_END="6.7486002940236" CI_START="2.671399705976402" EFFECT_SIZE="4.710000000000001" ESTIMABLE="YES" MEAN_1="14.8" MEAN_2="10.09" MODIFIED="2013-04-24 16:23:34 +0100" MODIFIED_BY="Laila Asmal" ORDER="453" SD_1="6.03" SD_2="3.15" SE="1.0401213033013963" STUDY_ID="STD-Voruganti-2007" TOTAL_1="43" TOTAL_2="42" WEIGHT="13.925073581693782"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="7.877280204528899" CI_START="-0.47728020452890085" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.6999999999999993" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.11" MODIFIED="2013-10-23 08:48:18 +0100" MODIFIED_BY="Laila Asmal" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.08255925018496671" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="169" TOTAL_2="166" UNITS="" WEIGHT="100.0" Z="1.7360259278120511">
<NAME>Mental state: 3c. Negative symptoms - average endpoint score - medium term (SANS, high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.877280204528899" CI_START="-0.47728020452890085" EFFECT_SIZE="3.6999999999999993" ESTIMABLE="YES" MEAN_1="-8.3" MEAN_2="-12.0" MODIFIED="2009-08-07 15:57:24 +0100" MODIFIED_BY="[Empty name]" ORDER="418" SD_1="20.1" SD_2="18.9" SE="2.1313045736956155" STUDY_ID="STD-Kinon-2006b" TOTAL_1="169" TOTAL_2="166" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="36.82138665554241" CI_START="-31.90138665554241" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.460000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.12" MODIFIED="2013-10-22 13:22:42 +0100" MODIFIED_BY="Laila Asmal" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.8884089650119402" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="0.140317719139278">
<NAME>Mental state: 3d. Negative symptoms - average change in endpoint score - short term (SANS, high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="36.82138665554241" CI_START="-31.90138665554241" EFFECT_SIZE="2.460000000000001" ESTIMABLE="YES" MEAN_1="-25.68" MEAN_2="-28.14" MODIFIED="2009-08-07 15:58:10 +0100" MODIFIED_BY="[Empty name]" ORDER="419" SD_1="53.09" SD_2="42.33" SE="17.531641870248965" STUDY_ID="STD-Ozguven-2004" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.7199538433493844" CI_END="4.759177492947724" CI_START="0.33297997485187913" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="2.5460787338998014" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.13" MODIFIED="2013-10-22 13:22:47 +0100" MODIFIED_BY="Laila Asmal" NO="13" P_CHI2="0.4231721762839642" P_Q="1.0" P_Z="0.024142266622787067" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="203" TOTAL_2="197" UNITS="" WEIGHT="100.0" Z="2.2548576288541913">
<NAME>General functioning: General - average endpoint score - medium term (GAF total score, low=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.630949576553201" CI_START="-13.830949576553204" EFFECT_SIZE="-2.1000000000000014" ESTIMABLE="YES" MEAN_1="46.6" MEAN_2="48.7" MODIFIED="2011-08-25 09:37:09 +0100" MODIFIED_BY="Laila Asmal" ORDER="522" SD_1="21.5" SD_2="14.7" SE="5.985288336462014" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="17" WEIGHT="3.559059538077541"/>
<CONT_DATA CI_END="6.831270769685814" CI_START="0.7687292303141868" EFFECT_SIZE="3.8000000000000003" ESTIMABLE="YES" MEAN_1="-2.4" MEAN_2="-6.2" MODIFIED="2009-08-07 15:58:46 +0100" MODIFIED_BY="[Empty name]" ORDER="420" SD_1="14.0" SD_2="11.7" SE="1.5465951382760552" STUDY_ID="STD-Kinon-2006b" TOTAL_1="140" TOTAL_2="138" WEIGHT="53.3030580919381"/>
<CONT_DATA CI_END="4.749545954406125" CI_START="-1.9895459544061347" EFFECT_SIZE="1.3799999999999955" ESTIMABLE="YES" MEAN_1="66.1" MEAN_2="64.72" MODIFIED="2011-07-14 11:45:39 +0100" MODIFIED_BY="Laila Asmal" ORDER="5839" SD_1="8.05" SD_2="7.8" SE="1.719187689664034" STUDY_ID="STD-Voruganti-2007" TOTAL_1="43" TOTAL_2="42" WEIGHT="43.13788236998436"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.019154707805795" CI_START="-2.419154707805794" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.8000000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.14" MODIFIED="2013-10-22 13:23:00 +0100" MODIFIED_BY="Laila Asmal" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.4030586704722481" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="143" TOTAL_2="143" UNITS="" WEIGHT="100.0" Z="0.8361710855601288">
<NAME>Quality of life: General - average change in endpoint score - medium term (QLS total score, low=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.019154707805795" CI_START="-2.419154707805794" EFFECT_SIZE="1.8000000000000003" ESTIMABLE="YES" MEAN_1="-2.4" MEAN_2="-4.2" MODIFIED="2009-08-07 15:59:14 +0100" MODIFIED_BY="[Empty name]" ORDER="421" SD_1="18.5" SD_2="17.9" SE="2.152669508769522" STUDY_ID="STD-Kinon-2006b" TOTAL_1="143" TOTAL_2="143" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.9694815310960566" CI_END="2.5174354295346557" CI_START="1.3325478745929713" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8315575969789892" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="51" I2="0.0" I2_Q="0.0" ID="CMP-003.15" LOG_CI_END="0.4009583400175418" LOG_CI_START="0.12468282092416635" LOG_EFFECT_SIZE="0.2628205804708541" METHOD="MH" MODIFIED="2013-10-22 15:19:55 +0100" MODIFIED_BY="Laila Asmal" NO="15" P_CHI2="0.6158568765770815" P_Q="0.7791649479833535" P_Z="1.9222366582178282E-4" Q="0.07862832539755407" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="497" TOTAL_2="512" WEIGHT="100.0" Z="3.729022924718028">
<NAME>Service use: 1. Number of participants re-hospitalised</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9045697286577583" CI_END="3.7483688555277523" CI_START="1.0481084138632197" DF="1" EFFECT_SIZE="1.9820940784285401" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="13" I2="0.0" ID="CMP-003.15.01" LOG_CI_END="0.5738423207531683" LOG_CI_START="0.020406207368479663" LOG_EFFECT_SIZE="0.29712426406082393" MODIFIED="2011-07-07 11:12:47 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.3415594715532645" P_Z="0.03533494713728273" STUDIES="2" TAU2="0.0" TOTAL_1="160" TOTAL_2="176" WEIGHT="24.92010211709205" Z="2.1044989382085926">
<NAME>medium term</NAME>
<DICH_DATA CI_END="43.575782511273545" CI_START="0.6278934116325632" EFFECT_SIZE="5.230769230769231" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6392451946868334" LOG_CI_START="-0.20211407388803426" LOG_EFFECT_SIZE="0.7185655603993996" MODIFIED="2011-07-07 11:12:47 +0100" MODIFIED_BY="Laila Asmal" ORDER="8345" O_E="0.0" SE="1.0816235492362596" STUDY_ID="STD-Deberdt-2008" TOTAL_1="65" TOTAL_2="68" VAR="1.1699095022624435" WEIGHT="2.251167150206279"/>
<DICH_DATA CI_END="3.5107937673448344" CI_START="0.9228682214650187" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="12" LOG_CI_END="0.545405318689296" LOG_CI_START="-0.03486030848268384" LOG_EFFECT_SIZE="0.25527250510330607" ORDER="1209" O_E="0.0" SE="0.34085090176200034" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="108" VAR="0.11617933723196879" WEIGHT="22.66893496688577"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5754762155749633" CI_START="1.235981133817126" DF="0" EFFECT_SIZE="1.784163673278151" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="38" I2="0.0" ID="CMP-003.15.02" LOG_CI_END="0.41085754354207066" LOG_CI_START="0.0920118416737925" LOG_EFFECT_SIZE="0.2514346926079316" MODIFIED="2009-08-10 13:34:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.001993702634786959" STUDIES="1" TAU2="0.0" TOTAL_1="337" TOTAL_2="336" WEIGHT="75.07989788290794" Z="3.09116879473591">
<NAME>long term</NAME>
<DICH_DATA CI_END="2.5754762155749633" CI_START="1.235981133817126" EFFECT_SIZE="1.784163673278151" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="38" LOG_CI_END="0.41085754354207066" LOG_CI_START="0.0920118416737925" LOG_EFFECT_SIZE="0.2514346926079316" ORDER="1210" O_E="0.0" SE="0.18729154358910552" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="336" VAR="0.035078122299989814" WEIGHT="75.07989788290794"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.263806434947238" CI_END="1.048791302242991" CI_START="0.8791612499292603" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9602378206438676" ESTIMABLE="YES" EVENTS_1="361" EVENTS_2="377" I2="0.0" I2_Q="0.0" ID="CMP-003.16" LOG_CI_END="0.020689077038685923" LOG_CI_START="-0.05593146220509352" LOG_EFFECT_SIZE="-0.017621192583203826" METHOD="MH" MODIFIED="2012-04-27 12:45:59 +0100" MODIFIED_BY="Laila Asmal" NO="16" P_CHI2="0.5104503826024047" P_Q="1.0" P_Z="0.3673198420860263" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="646" TOTAL_2="660" WEIGHT="100.00000000000001" Z="0.901505083848069">
<NAME>Adverse effects: 1. General - at least one adverse effect</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.321488051190618" CI_START="0.21356724508081854" EFFECT_SIZE="0.53125" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.12106324062290091" LOG_CI_START="-0.6704653545061651" LOG_EFFECT_SIZE="-0.27470105694163205" MODIFIED="2011-08-26 08:05:00 +0100" MODIFIED_BY="Laila Asmal" ORDER="536" O_E="0.0" SE="0.46494781490855003" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="17" VAR="0.2161764705882353" WEIGHT="0.9370379718974485"/>
<DICH_DATA CI_END="1.0364860916815881" CI_START="0.8405526299834704" EFFECT_SIZE="0.9333922596123493" ESTIMABLE="YES" EVENTS_1="220" EVENTS_2="235" LOG_CI_END="0.015563478792190074" LOG_CI_START="-0.07543508865423927" LOG_EFFECT_SIZE="-0.0299358049310246" ORDER="1211" O_E="0.0" SE="0.053453008968206234" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="336" VAR="0.0028572241677551364" WEIGHT="70.89592894319529"/>
<DICH_DATA CI_END="1.4154065731756211" CI_START="0.5783455579634506" EFFECT_SIZE="0.9047619047619048" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.15088120814593275" LOG_CI_START="-0.2378125957081133" LOG_EFFECT_SIZE="-0.0434656937810903" ORDER="1213" O_E="0.0" SE="0.22832066444922663" STUDY_ID="STD-McEvoy-2006" TOTAL_1="15" TOTAL_2="19" VAR="0.052130325814536346" WEIGHT="3.8857528397695877"/>
<DICH_DATA CI_END="1.3352814969129834" CI_START="0.8677319871471941" EFFECT_SIZE="1.076413706117301" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="71" LOG_CI_END="0.12557283099554564" LOG_CI_START="-0.06161439288417609" LOG_EFFECT_SIZE="0.031979219055684786" ORDER="1212" O_E="0.0" SE="0.10995470189865063" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.012090036469621125" WEIGHT="16.754751905086387"/>
<DICH_DATA CI_END="1.4296515851502825" CI_START="0.4138882385592997" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.1552302101340821" LOG_CI_START="-0.38311691474775555" LOG_EFFECT_SIZE="-0.11394335230683675" ORDER="1214" O_E="0.0" SE="0.31622776601683794" STUDY_ID="STD-Riedel-2007" TOTAL_1="26" TOTAL_2="26" VAR="0.1" WEIGHT="2.0256556157194843"/>
<DICH_DATA CI_END="2.570631501907507" CI_START="0.4752165556568365" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.4100398253172352" LOG_CI_START="-0.32310843775505455" LOG_EFFECT_SIZE="0.043465693781090345" ORDER="1215" O_E="0.0" SE="0.4306549188710953" STUDY_ID="STD-Sirota-2006" TOTAL_1="19" TOTAL_2="21" VAR="0.18546365914786966" WEIGHT="1.0922116090163165"/>
<DICH_DATA CI_END="1.909456131969601" CI_START="0.8241278221155752" EFFECT_SIZE="1.2544464609800363" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="29" LOG_CI_END="0.28090968530039206" LOG_CI_START="-0.08400542406228839" LOG_EFFECT_SIZE="0.09845213061905184" ORDER="1216" O_E="0.0" SE="0.2143529415985624" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="108" VAR="0.045947183571956714" WEIGHT="4.4086611153154935"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.359209958964361" CI_END="4.23455690645132" CI_START="0.12955799948360508" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7406893556001168" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="15.225858029272054" I2_Q="53.05211055239337" ID="CMP-003.17" LOG_CI_END="0.6268079735449622" LOG_CI_START="-0.8875357665891449" LOG_EFFECT_SIZE="-0.13036389652209138" METHOD="MH" MODIFIED="2012-04-27 12:45:59 +0100" MODIFIED_BY="Laila Asmal" NO="17" P_CHI2="0.3074001964902694" P_Q="0.144438819683272" P_Z="0.7357768082237821" Q="2.1300212038626145" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.3674457270630753" TOTALS="YES" TOTAL_1="720" TOTAL_2="730" WEIGHT="100.0" Z="0.3374511813876262">
<NAME>Adverse effects: 2. Death</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.22158517354916424" CI_END="2.2882375905010512" CI_START="0.05343598986825389" DF="1" EFFECT_SIZE="0.34967733798771095" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-003.17.01" LOG_CI_END="0.3595011157881635" LOG_CI_START="-1.2721661411656737" LOG_EFFECT_SIZE="-0.45633251268875513" MODIFIED="2009-08-10 13:34:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6378347586231357" P_Z="0.27294919805736817" STUDIES="2" TAU2="0.0" TOTAL_1="471" TOTAL_2="469" WEIGHT="71.25350654397556" Z="1.0962961793011348">
<NAME>suicide attempt</NAME>
<DICH_DATA CI_END="5.471629250813521" CI_START="0.04541947386927967" EFFECT_SIZE="0.49851632047477745" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.738116662582532" LOG_CI_START="-1.3427579008734836" LOG_EFFECT_SIZE="-0.30232061914547576" ORDER="1226" O_E="0.0" SE="1.2223160190692768" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="336" VAR="1.4940564504733644" WEIGHT="42.50701308795113"/>
<DICH_DATA CI_END="4.096238782411578" CI_START="0.009620924044761317" EFFECT_SIZE="0.1985185185185185" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6123852650725384" LOG_CI_START="-2.016783214004973" LOG_EFFECT_SIZE="-0.7021989744662173" ORDER="1227" O_E="0.0" SE="1.5443865792039984" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="2.385129906025428" WEIGHT="28.74649345602443"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="102.40596956028946" CI_START="0.24052310111903297" DF="0" EFFECT_SIZE="4.962962962962963" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-003.17.02" LOG_CI_END="2.0103252737445763" LOG_CI_START="-0.6188432053329354" LOG_EFFECT_SIZE="0.6957410342058203" MODIFIED="2011-08-26 08:06:55 +0100" MODIFIED_BY="Laila Asmal" NO="2" P_CHI2="1.0" P_Z="0.2995928420490723" STUDIES="3" TAU2="0.0" TOTAL_1="249" TOTAL_2="261" WEIGHT="28.74649345602443" Z="1.0373069511988897">
<NAME>suicide</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-26 08:06:55 +0100" MODIFIED_BY="Laila Asmal" ORDER="537" O_E="0.0" SE="0.0" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="102.40596956028946" CI_START="0.24052310111903297" EFFECT_SIZE="4.962962962962963" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0103252737445763" LOG_CI_START="-0.6188432053329354" LOG_EFFECT_SIZE="0.6957410342058203" ORDER="1228" O_E="0.0" SE="1.5443865792039984" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="2.385129906025428" WEIGHT="28.74649345602443"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1229" O_E="0.0" SE="0.0" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="108" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="229.17075608140954" CI_START="0.7330842824913523" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="12.961538461538463" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.18" LOG_CI_END="2.3601591975764316" LOG_CI_START="-0.13484609177539011" LOG_EFFECT_SIZE="1.1126565529005208" METHOD="MH" MODIFIED="2012-04-27 12:45:59 +0100" MODIFIED_BY="Laila Asmal" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.08044568635342961" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="337" TOTAL_2="336" WEIGHT="100.0" Z="1.748105929999089">
<NAME>Adverse effects: 3a. Cardiac effects - QTc prolongation</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="229.17075608140954" CI_START="0.7330842824913523" EFFECT_SIZE="12.961538461538462" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3601591975764316" LOG_CI_START="-0.13484609177539011" LOG_EFFECT_SIZE="1.1126565529005206" ORDER="1217" O_E="0.0" SE="1.4655784574406283" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="336" VAR="2.1479202149140515" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.7688481542032892" CI_END="9.284771679799718" CI_START="0.34307718609699567" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="4.813924432948356" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.19" MODIFIED="2012-04-27 12:45:59 +0100" MODIFIED_BY="Laila Asmal" NO="19" P_CHI2="0.6808428121952017" P_Q="1.0" P_Z="0.034826948732827046" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="309" TOTAL_2="334" UNITS="" WEIGHT="100.00000000000001" Z="2.110364768002521">
<NAME>Adverse effects: 3b. Cardiac effects - QTc abnormalities - change from baseline in ms</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.834000295045392" CI_START="-0.4340002950453927" EFFECT_SIZE="4.7" ESTIMABLE="YES" MEAN_1="5.9" MEAN_2="1.2" ORDER="1218" SD_1="27.8" SD_2="27.4" SE="2.619436038387303" STUDY_ID="STD-Lieberman-2005" TOTAL_1="214" TOTAL_2="231" WEIGHT="75.83468462898554"/>
<CONT_DATA CI_END="16.979653738255713" CI_START="-2.979653738255715" EFFECT_SIZE="7.0" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="-5.1" ORDER="1220" SD_1="33.3" SD_2="33.0" SE="5.091753632706493" STUDY_ID="STD-Stroup-2006" TOTAL_1="81" TOTAL_2="89" WEIGHT="20.07006216818799"/>
<CONT_DATA CI_END="18.302733433654378" CI_START="-25.882733433654376" EFFECT_SIZE="-3.7899999999999996" ESTIMABLE="YES" MEAN_1="0.64" MEAN_2="4.43" ORDER="1219" SD_1="27.18" SD_2="32.25" SE="11.272009898099679" STUDY_ID="STD-Svestka-2003b" TOTAL_1="14" TOTAL_2="14" WEIGHT="4.095253202826479"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.7172692990569016" CI_END="1.202470819806923" CI_START="0.7811063413863726" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9691530233576418" ESTIMABLE="YES" EVENTS_1="257" EVENTS_2="265" I2="0.0" I2_Q="0.0" ID="CMP-003.20" LOG_CI_END="0.08007454620961366" LOG_CI_START="-0.1072898363744267" LOG_EFFECT_SIZE="-0.01360764508240651" METHOD="MH" MODIFIED="2012-04-27 12:45:59 +0100" MODIFIED_BY="Laila Asmal" NO="20" P_CHI2="0.8867169869174371" P_Q="1.0" P_Z="0.775880743187011" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="801" TOTAL_2="814" WEIGHT="99.99999999999999" Z="0.28469118738677623">
<NAME>Adverse effects: 4a. Central nervous system - sedation</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5454226457574842" CI_START="0.5711157866217916" EFFECT_SIZE="0.9394760614272809" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="41" LOG_CI_END="0.1890472718636209" LOG_CI_START="-0.24327583502350586" LOG_EFFECT_SIZE="-0.027114281579942466" ORDER="1274" O_E="0.0" SE="0.25394873301939136" STUDY_ID="STD-Kinon-2006b" TOTAL_1="175" TOTAL_2="171" VAR="0.06448995900215412" WEIGHT="19.074203908956548"/>
<DICH_DATA CI_END="1.3623070734699168" CI_START="0.707745332905046" EFFECT_SIZE="0.9819197896120972" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="104" LOG_CI_END="0.13427501160189423" LOG_CI_START="-0.15012298582759692" LOG_EFFECT_SIZE="-0.00792398711285134" ORDER="1275" O_E="0.0" SE="0.16705679148287497" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="336" VAR="0.02790797158055277" WEIGHT="43.1160559802781"/>
<DICH_DATA CI_END="4.595582494435764" CI_START="0.2553780967988487" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.6623405664481713" LOG_CI_START="-0.5928163539297474" LOG_EFFECT_SIZE="0.03476210625921191" ORDER="1277" O_E="0.0" SE="0.7372853881569494" STUDY_ID="STD-McEvoy-2006" TOTAL_1="15" TOTAL_2="19" VAR="0.5435897435897437" WEIGHT="2.104152575322482"/>
<DICH_DATA CI_END="1.9122276325957526" CI_START="0.7277108176518241" EFFECT_SIZE="1.1796392389424264" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="71" LOG_CI_END="0.2815395896638546" LOG_CI_START="-0.13804116910551653" LOG_EFFECT_SIZE="0.07174921027916903" ORDER="1276" O_E="0.0" SE="0.24646381465938125" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.06074441193645383" WEIGHT="18.07285805613127"/>
<DICH_DATA CI_END="1.8820684439237267" CI_START="0.20755090031987733" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.27463541307524264" LOG_CI_START="-0.6828753783870921" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="1278" O_E="0.0" SE="0.5624465786598349" STUDY_ID="STD-Riedel-2007" TOTAL_1="26" TOTAL_2="26" VAR="0.31634615384615383" WEIGHT="4.769412504064293"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1279" O_E="0.0" SE="0.0" STUDY_ID="STD-Sirota-2006" TOTAL_1="19" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4801200811484017" CI_START="0.41481016135799254" EFFECT_SIZE="0.7835616438356164" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="30" LOG_CI_END="0.17029695084401378" LOG_CI_START="-0.38215061349887713" LOG_EFFECT_SIZE="-0.1059268313274317" ORDER="1280" O_E="0.0" SE="0.32451043395456164" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="108" VAR="0.10530702174537791" WEIGHT="12.863316975247296"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="76.45670546349922" CI_START="0.142433550255431" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.3" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.21" LOG_CI_END="1.8834155802400456" LOG_CI_START="-0.8463877004842706" LOG_EFFECT_SIZE="0.5185139398778874" METHOD="MH" MODIFIED="2012-04-27 12:45:59 +0100" MODIFIED_BY="Laila Asmal" NO="21" P_CHI2="1.0" P_Q="1.0" P_Z="0.4565300169923171" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="21" WEIGHT="99.99999999999999" Z="0.7445728084647721">
<NAME>Adverse effects: 4b. Central nervous system - seizures</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="76.45670546349922" CI_START="0.142433550255431" EFFECT_SIZE="3.3" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8834155802400456" LOG_CI_START="-0.8463877004842706" LOG_EFFECT_SIZE="0.5185139398778874" ORDER="1281" O_E="0.0" SE="1.6034999598416337" STUDY_ID="STD-Sirota-2006" TOTAL_1="19" TOTAL_2="21" VAR="2.5712121212121213" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.912495854468208" CI_END="1.0612860218753921" CI_START="0.6948000604363841" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8587092593767184" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="163" I2="0.0" I2_Q="34.48148016434589" ID="CMP-003.22" LOG_CI_END="0.02583244420486065" LOG_CI_START="-0.15814015244833135" LOG_EFFECT_SIZE="-0.06615385412173531" METHOD="MH" MODIFIED="2013-04-05 11:44:44 +0100" MODIFIED_BY="Laila Asmal" NO="22" P_CHI2="0.7220379135300274" P_Q="0.15300907005273012" P_Z="0.1586729700366904" Q="10.684002046381265" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1929" TOTAL_2="1932" WEIGHT="800.0" Z="1.4095487466705627">
<NAME>Adverse effects: 5a. Extrapyramidal effects</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7673534933072249" CI_END="1.3823697196203517" CI_START="0.6813164442779722" DF="5" EFFECT_SIZE="0.9704798926558321" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="54" I2="0.0" ID="CMP-003.22.01" LOG_CI_END="0.14062421215317739" LOG_CI_START="-0.16665112878701385" LOG_EFFECT_SIZE="-0.013013458316918228" MODIFIED="2011-08-26 08:11:28 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.979068742747197" P_Z="0.8681464173264187" STUDIES="7" TAU2="0.0" TOTAL_1="653" TOTAL_2="661" WEIGHT="99.99999999999999" Z="0.16601338420083295">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="5.407187486743322" CI_START="0.13361844799562375" EFFECT_SIZE="0.85" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.732971428396856" LOG_CI_START="-0.8741335769682705" LOG_EFFECT_SIZE="-0.07058107428570728" MODIFIED="2011-08-26 08:11:28 +0100" MODIFIED_BY="Laila Asmal" ORDER="539" O_E="0.0" SE="0.9440214354495533" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="17" VAR="0.8911764705882352" WEIGHT="3.655669379298942"/>
<DICH_DATA CI_END="2.1161022962165323" CI_START="0.5344899477736859" EFFECT_SIZE="1.0635014836795251" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.3255366584522356" LOG_CI_START="-0.27206045821473784" LOG_EFFECT_SIZE="0.02673810011874892" ORDER="1230" O_E="0.0" SE="0.3510315044836162" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="336" VAR="0.12322311714003108" WEIGHT="26.43859862252057"/>
<DICH_DATA CI_END="1.4974953960778306" CI_START="0.5640020445918141" EFFECT_SIZE="0.9190160309563294" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="27" LOG_CI_END="0.17536549586197211" LOG_CI_START="-0.24871932163131527" LOG_EFFECT_SIZE="-0.03667691288467155" ORDER="1231" O_E="0.0" SE="0.2491095210492599" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.06205555347739167" WEIGHT="52.49887161618869"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1232" O_E="0.0" SE="0.0" STUDY_ID="STD-Riedel-2007" TOTAL_1="26" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.8315360368393385" CI_START="0.2528402228369983" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6840852231472558" LOG_CI_START="-0.5971538355850752" LOG_EFFECT_SIZE="0.043465693781090345" ORDER="1233" O_E="0.0" SE="0.7526061653349981" STUDY_ID="STD-Sirota-2006" TOTAL_1="19" TOTAL_2="21" VAR="0.5664160401002505" WEIGHT="5.751684811935246"/>
<DICH_DATA CI_END="3.40669543823065" CI_START="0.3793735001360772" EFFECT_SIZE="1.1368421052631579" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.5323333089690633" LOG_CI_START="-0.4209330085728594" LOG_EFFECT_SIZE="0.05570015019810193" ORDER="1234" O_E="0.0" SE="0.5599533536685002" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="108" VAR="0.3135477582846004" WEIGHT="10.390272132400451"/>
<DICH_DATA CI_END="7.070137371487788" CI_START="0.013101244626080647" EFFECT_SIZE="0.30434782608695654" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8494278521419525" LOG_CI_START="-1.8826874441486245" LOG_EFFECT_SIZE="-0.516629796003336" ORDER="1235" O_E="0.0" SE="1.6048580492299167" STUDY_ID="STD-Svestka-2003b" TOTAL_1="22" TOTAL_2="20" VAR="2.5755693581780537" WEIGHT="1.2649034376560926"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5624418306267314" CI_START="0.6705292857992188" DF="0" EFFECT_SIZE="1.023554104477612" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="32" I2="0.0" ID="CMP-003.22.02" LOG_CI_END="0.1938038576269405" LOG_CI_START="-0.17358224930642116" LOG_EFFECT_SIZE="0.010110804160259678" MODIFIED="2009-08-10 13:34:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.9140908588972603" STUDIES="1" TAU2="0.0" TOTAL_1="134" TOTAL_2="133" WEIGHT="100.0" Z="0.10788002940155376">
<NAME>akinesia</NAME>
<DICH_DATA CI_END="1.5624418306267314" CI_START="0.6705292857992188" EFFECT_SIZE="1.023554104477612" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="32" LOG_CI_END="0.1938038576269405" LOG_CI_START="-0.17358224930642116" LOG_EFFECT_SIZE="0.010110804160259678" ORDER="1236" O_E="0.0" SE="0.2158044178032158" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.04657154674338492" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="59.29601510215695" CI_START="0.11151246650499884" DF="0" EFFECT_SIZE="2.5714285714285716" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.22.03" LOG_CI_END="1.773025508249681" LOG_CI_START="-0.9526765780715827" LOG_EFFECT_SIZE="0.41017446508904926" MODIFIED="2013-04-05 11:44:44 +0100" MODIFIED_BY="Laila Asmal" NO="3" P_CHI2="1.0" P_Z="0.5552668728896603" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="17" WEIGHT="100.0" Z="0.5898863144192963">
<NAME>dyskinesia</NAME>
<DICH_DATA CI_END="59.29601510215695" CI_START="0.11151246650499884" EFFECT_SIZE="2.5714285714285716" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.773025508249681" LOG_CI_START="-0.9526765780715827" LOG_EFFECT_SIZE="0.41017446508904926" MODIFIED="2011-08-26 11:01:21 +0100" MODIFIED_BY="Laila Asmal" ORDER="540" O_E="0.0" SE="1.601090897948041" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="17" VAR="2.5634920634920637" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5974567558534147" CI_END="6.229722279734909" CI_START="0.20670072418815025" DF="2" EFFECT_SIZE="1.134763458484745" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-003.22.04" LOG_CI_END="0.794468686295278" LOG_CI_START="-0.6846580017937733" LOG_EFFECT_SIZE="0.05490534225075227" MODIFIED="2013-04-05 11:44:44 +0100" MODIFIED_BY="Laila Asmal" NO="4" P_CHI2="0.44990088234726255" P_Z="0.8843096821756148" STUDIES="3" TAU2="0.0" TOTAL_1="379" TOTAL_2="373" WEIGHT="100.0" Z="0.1455081491489402">
<NAME>dystonia</NAME>
<DICH_DATA CI_END="6.588446122461885" CI_START="0.01239027405611098" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8187829988103563" LOG_CI_START="-1.9069190875109077" LOG_EFFECT_SIZE="-0.5440680443502757" MODIFIED="2011-08-26 11:02:04 +0100" MODIFIED_BY="Laila Asmal" ORDER="541" O_E="0.0" SE="1.601090897948041" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="17" VAR="2.5634920634920637" WEIGHT="29.447875827855484"/>
<DICH_DATA CI_END="15.874502724736235" CI_START="0.06262080169414323" EFFECT_SIZE="0.9970326409495549" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2007001297255513" LOG_CI_START="-1.2032813766885404" LOG_EFFECT_SIZE="-0.0012906234814945737" MODIFIED="2011-07-14 09:44:44 +0100" MODIFIED_BY="Laila Asmal" ORDER="2229" O_E="0.0" SE="1.4121106367680134" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="336" VAR="1.9940564504733644" WEIGHT="37.85720106042488"/>
<DICH_DATA CI_END="89.71570901160766" CI_START="0.23230279356284392" EFFECT_SIZE="4.565217391304348" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9528684936542908" LOG_CI_START="-0.6339455675496006" LOG_EFFECT_SIZE="0.6594614630523452" ORDER="1237" O_E="0.0" SE="1.5195073844872842" STUDY_ID="STD-Svestka-2003b" TOTAL_1="22" TOTAL_2="20" VAR="2.308902691511387" WEIGHT="32.69492311171963"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.20811252378151146" CI_END="3.666295875021043" CI_START="0.7193766551117727" DF="1" EFFECT_SIZE="1.6240220636502225" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" I2="0.0" ID="CMP-003.22.05" LOG_CI_END="0.5642275101908177" LOG_CI_START="-0.14304365981837217" LOG_EFFECT_SIZE="0.21059192518622274" MODIFIED="2013-04-05 11:44:43 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6482508403498205" P_Z="0.2431420371679126" STUDIES="2" TAU2="0.0" TOTAL_1="117" TOTAL_2="128" WEIGHT="100.0" Z="1.1671692734049577">
<NAME>extrapyramidal symptoms</NAME>
<DICH_DATA CI_END="6.586407049046076" CI_START="0.6009354585425223" EFFECT_SIZE="1.9894736842105263" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.818648567203685" LOG_CI_START="-0.22117216943489224" LOG_EFFECT_SIZE="0.29873819888439634" ORDER="1238" O_E="0.0" SE="0.6107958478971595" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="108" VAR="0.37307156780840994" WEIGHT="46.26525529719342"/>
<DICH_DATA CI_END="4.141159650049582" CI_START="0.4490298103356485" EFFECT_SIZE="1.3636363636363635" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6171219737525706" LOG_CI_START="-0.34772482595765836" LOG_EFFECT_SIZE="0.13469857389745618" ORDER="1239" O_E="0.0" SE="0.5667557862184746" STUDY_ID="STD-Svestka-2003b" TOTAL_1="22" TOTAL_2="20" VAR="0.32121212121212117" WEIGHT="53.73474470280658"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.08550734116010036" CI_END="1.7428470989552736" CI_START="0.3395459401708437" DF="1" EFFECT_SIZE="0.7692702105169522" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" I2="0.0" ID="CMP-003.22.06" LOG_CI_END="0.24125928785999198" LOG_CI_START="-0.46910145786971624" LOG_EFFECT_SIZE="-0.11392108500486209" MODIFIED="2013-04-05 11:44:40 +0100" MODIFIED_BY="Laila Asmal" NO="6" P_CHI2="0.7699682961397368" P_Z="0.5295836015361959" STUDIES="2" TAU2="0.0" TOTAL_1="39" TOTAL_2="38" WEIGHT="100.0" Z="0.6286417852661418">
<NAME>parkinsonism</NAME>
<DICH_DATA CI_END="2.447562740291757" CI_START="0.29519161576788666" EFFECT_SIZE="0.85" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.38873383322829835" LOG_CI_START="-0.5298959817997129" LOG_EFFECT_SIZE="-0.07058107428570728" MODIFIED="2011-08-26 11:04:40 +0100" MODIFIED_BY="Laila Asmal" ORDER="542" O_E="0.0" SE="0.539607700638376" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="17" VAR="0.2911764705882353" WEIGHT="59.79664743061281"/>
<DICH_DATA CI_END="2.4087089981711984" CI_START="0.18257846576141007" EFFECT_SIZE="0.6631578947368421" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.38178433502435927" LOG_CI_START="-0.7385504466948914" LOG_EFFECT_SIZE="-0.1783830558352661" ORDER="1240" O_E="0.0" SE="0.6580901965284981" STUDY_ID="STD-Sirota-2006" TOTAL_1="19" TOTAL_2="21" VAR="0.4330827067669173" WEIGHT="40.20335256938719"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3057326177027204" CI_START="0.11625370587695581" DF="0" EFFECT_SIZE="0.38961038961038963" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" I2="0.0" ID="CMP-003.22.07" LOG_CI_END="0.1158542530914256" LOG_CI_START="-0.9345931939970643" LOG_EFFECT_SIZE="-0.4093694704528194" MODIFIED="2013-04-05 11:44:39 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.12660352942341185" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="20" WEIGHT="100.00000000000001" Z="1.5276336206663557">
<NAME>tremor</NAME>
<DICH_DATA CI_END="1.3057326177027204" CI_START="0.11625370587695581" EFFECT_SIZE="0.38961038961038963" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.1158542530914256" LOG_CI_START="-0.9345931939970643" LOG_EFFECT_SIZE="-0.4093694704528194" ORDER="1241" O_E="0.0" SE="0.6170380302185033" STUDY_ID="STD-Svestka-2003b" TOTAL_1="22" TOTAL_2="20" VAR="0.3807359307359307" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.571489146597325" CI_END="0.8071071437310972" CI_START="0.31691150771704296" DF="4" EFFECT_SIZE="0.505748496595905" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="50" I2="0.0" ID="CMP-003.22.08" LOG_CI_END="-0.0930688087197078" LOG_CI_START="-0.4990619903859986" LOG_EFFECT_SIZE="-0.2960653995528531" MODIFIED="2013-04-05 11:44:39 +0100" MODIFIED_BY="Laila Asmal" NO="8" P_CHI2="0.6318820356399711" P_Z="0.004255713582278467" STUDIES="7" TAU2="0.0" TOTAL_1="565" TOTAL_2="562" WEIGHT="100.0" Z="2.858557958094069">
<NAME>use of antiparkinson medication</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1242" O_E="0.0" SE="0.0" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.407187486743322" CI_START="0.13361844799562375" EFFECT_SIZE="0.85" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.732971428396856" LOG_CI_START="-0.8741335769682705" LOG_EFFECT_SIZE="-0.07058107428570728" MODIFIED="2011-08-26 08:09:35 +0100" MODIFIED_BY="Laila Asmal" ORDER="538" O_E="0.0" SE="0.9440214354495533" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="17" VAR="0.8911764705882352" WEIGHT="6.381884978489205"/>
<DICH_DATA CI_END="0.877133627340854" CI_START="0.21941097373002788" EFFECT_SIZE="0.43869436201780415" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="25" LOG_CI_END="-0.0569342387936399" LOG_CI_START="-0.6587416551969745" LOG_EFFECT_SIZE="-0.35783794699530713" ORDER="1243" O_E="0.0" SE="0.35350465539007453" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="336" VAR="0.12496554138245534" WEIGHT="45.51163199000529"/>
<DICH_DATA CI_END="0.8844196451842211" CI_START="0.12376356052250792" EFFECT_SIZE="0.3308457711442786" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" LOG_CI_END="-0.05334161921369209" LOG_CI_START="-0.9074072050210766" LOG_EFFECT_SIZE="-0.4803744121173843" ORDER="1244" O_E="0.0" SE="0.5016823527960907" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.25168518310702126" WEIGHT="22.597221102251787"/>
<DICH_DATA CI_END="4.943824870337866" CI_START="0.05056813430021737" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6940630779397805" LOG_CI_START="-1.296123069267743" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="1247" O_E="0.0" SE="1.1690451944500122" STUDY_ID="STD-Ozguven-2004" TOTAL_1="15" TOTAL_2="15" VAR="1.3666666666666667" WEIGHT="4.161501754265916"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1245" O_E="0.0" SE="0.0" STUDY_ID="STD-Riedel-2007" TOTAL_1="26" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.5330072131060106" CI_START="0.3349133574310906" EFFECT_SIZE="0.9210526315789473" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.4036364265089362" LOG_CI_START="-0.4750675310420054" LOG_EFFECT_SIZE="-0.035715552266534535" ORDER="1246" O_E="0.0" SE="0.5161550543201633" STUDY_ID="STD-Sirota-2006" TOTAL_1="19" TOTAL_2="21" VAR="0.26641604010025066" WEIGHT="21.347760174987805"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.332124915330344" CI_END="0.2039200122037784" CI_START="-0.0905309473135775" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="0.05669453244510044" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.23" MODIFIED="2013-06-25 09:59:06 +0100" MODIFIED_BY="Laila Asmal" NO="23" P_CHI2="0.9315916029483748" P_Q="0.9429743867907565" P_Z="0.4503957004855136" Q="0.3867081892004579" RANDOM="YES" SCALE="3.8235121273282187" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="195" TOTAL_2="193" UNITS="" WEIGHT="400.0" Z="0.7547555076395308">
<NAME>Adverse effects: 5b. Extrapyramidal effects - scale measured</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.48544195141518703" CI_END="0.22018576587951671" CI_START="-0.10104543942025235" DF="1" EFFECT_SIZE="0.059570163229632184" ESTIMABLE="YES" I2="0.0" ID="CMP-003.23.01" MODIFIED="2011-07-14 11:47:22 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.4859676653270951" P_Z="0.46727237404755273" STUDIES="2" TAU2="0.0" TOTAL_1="68" TOTAL_2="67" WEIGHT="100.0" Z="0.7269242374774681">
<NAME>akathisia: Barnes Akathisia Scale (high=poor)</NAME>
<CONT_DATA CI_END="0.3767509155762892" CI_START="-0.5767509155762891" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.3" MEAN_2="-0.2" ORDER="1248" SD_1="0.86" SD_2="0.86" SE="0.24324473272817232" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" WEIGHT="11.349909316871019"/>
<CONT_DATA CI_END="0.2505878672304799" CI_START="-0.09058786723047986" EFFECT_SIZE="0.08" ESTIMABLE="YES" MEAN_1="0.13" MEAN_2="0.05" MODIFIED="2011-07-14 11:47:22 +0100" MODIFIED_BY="Laila Asmal" ORDER="5841" SD_1="0.47" SD_2="0.32" SE="0.08703622544906701" STUDY_ID="STD-Voruganti-2007" TOTAL_1="43" TOTAL_2="42" WEIGHT="88.65009068312898"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.6761267302272236" CI_START="-2.6761267302272236" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.23.02" MODIFIED="2009-08-10 13:35:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="17" WEIGHT="100.0" Z="0.0">
<NAME>extrapyramidal symptoms: ESRS total score (high=poor)</NAME>
<CONT_DATA CI_END="2.6761267302272236" CI_START="-2.6761267302272236" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.0" ORDER="1249" SD_1="3.92" SD_2="3.92" SE="1.3653958701977025" STUDY_ID="STD-Riedel-2007" TOTAL_1="16" TOTAL_2="17" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.4599747747146992" CI_END="0.4395303827652799" CI_START="-0.5680308227998649" DF="1" EFFECT_SIZE="-0.0642502200172925" ESTIMABLE="YES" I2="0.0" ID="CMP-003.23.03" MODIFIED="2011-07-14 11:48:34 +0100" MODIFIED_BY="Laila Asmal" NO="3" P_CHI2="0.4976357935644694" P_Z="0.8026134964619134" STUDIES="2" TAU2="0.0" TOTAL_1="68" TOTAL_2="67" WEIGHT="100.00000000000001" Z="0.2499661887280271">
<NAME>extrapyramidal symptoms: Simpson-Angus Scale (high=poor)</NAME>
<CONT_DATA CI_END="2.5846142764687388" CI_START="-1.384614276468739" EFFECT_SIZE="0.6" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-1.0" ORDER="1250" SD_1="3.58" SD_2="3.58" SE="1.012576910659136" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" WEIGHT="6.44363098347993"/>
<CONT_DATA CI_END="0.4108405185382399" CI_START="-0.6308405185382399" EFFECT_SIZE="-0.10999999999999999" ESTIMABLE="YES" MEAN_1="0.26" MEAN_2="0.37" MODIFIED="2011-07-14 11:48:34 +0100" MODIFIED_BY="Laila Asmal" ORDER="5842" SD_1="1.24" SD_2="1.21" SE="0.26573984146982466" STUDY_ID="STD-Voruganti-2007" TOTAL_1="43" TOTAL_2="42" WEIGHT="93.55636901652008"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7211576326090429" CI_START="-0.3811576326090428" DF="0" EFFECT_SIZE="0.17000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-003.23.04" MODIFIED="2013-06-25 09:59:06 +0100" MODIFIED_BY="Laila Asmal" NO="4" P_CHI2="1.0" P_Z="0.5454882537581005" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="42" WEIGHT="100.0" Z="0.6045346333943568">
<NAME>extrapyramidal symptoms: Abnormal Involuntary Movement Scale (AIMS, high=poor)</NAME>
<CONT_DATA CI_END="0.7211576326090429" CI_START="-0.3811576326090428" EFFECT_SIZE="0.17000000000000004" ESTIMABLE="YES" MEAN_1="0.92" MEAN_2="0.75" MODIFIED="2011-07-21 09:18:45 +0100" MODIFIED_BY="Laila Asmal" ORDER="1360" SD_1="1.5" SD_2="1.06" SE="0.2812080410438681" STUDY_ID="STD-Voruganti-2007" TOTAL_1="43" TOTAL_2="42" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.321287424832945" CI_END="0.9157519239700678" CI_START="0.6210098690545394" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7541160271411119" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="193" I2="0.0" I2_Q="0.0" ID="CMP-003.24" LOG_CI_END="-0.038222160221478056" LOG_CI_START="-0.2069014979846584" LOG_EFFECT_SIZE="-0.12256182910306825" METHOD="MH" MODIFIED="2012-04-27 12:45:59 +0100" MODIFIED_BY="Laila Asmal" NO="24" P_CHI2="0.6948051150109711" P_Q="0.4061059944117943" P_Z="0.004396642259516472" Q="3.999261622273682" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1371" TOTAL_2="1392" WEIGHT="500.0" Z="2.848206236837643">
<NAME>Adverse effects: 6a. Prolactin associated side effects</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7736368507091274" CI_START="0.0058027411120967105" DF="0" EFFECT_SIZE="0.10144927536231882" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-003.24.01" LOG_CI_END="0.2488647035014304" LOG_CI_START="-2.2363668049474277" LOG_EFFECT_SIZE="-0.9937510507229986" MODIFIED="2009-08-10 13:35:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.1170136415398662" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="20" WEIGHT="100.0" Z="1.5674324604322831">
<NAME>abnormally high prolactin value</NAME>
<DICH_DATA CI_END="1.7736368507091274" CI_START="0.0058027411120967105" EFFECT_SIZE="0.10144927536231885" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2488647035014304" LOG_CI_START="-2.2363668049474277" LOG_EFFECT_SIZE="-0.9937510507229984" ORDER="1256" O_E="0.0" SE="1.4598372901572316" STUDY_ID="STD-Svestka-2003b" TOTAL_1="22" TOTAL_2="20" VAR="2.1311249137336095" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.40053706739649175" CI_END="1.2070393272317714" CI_START="0.3627788197673577" DF="1" EFFECT_SIZE="0.6617312917989653" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" I2="0.0" ID="CMP-003.24.02" LOG_CI_END="0.08172142032229021" LOG_CI_START="-0.44035807642637187" LOG_EFFECT_SIZE="-0.1793183280520409" MODIFIED="2009-08-10 13:36:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.526812446080214" P_Z="0.17818151847141325" STUDIES="3" TAU2="0.0" TOTAL_1="127" TOTAL_2="125" WEIGHT="100.0" Z="1.3463752816906203">
<NAME>amenorrhea</NAME>
<DICH_DATA CI_END="1.406304835035261" CI_START="0.18493670618513974" EFFECT_SIZE="0.5099778270509978" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.14807946991867743" LOG_CI_START="-0.7329768816394127" LOG_EFFECT_SIZE="-0.29244870586036764" ORDER="1257" O_E="0.0" SE="0.5175368622045005" STUDY_ID="STD-Lieberman-2005" TOTAL_1="82" TOTAL_2="92" VAR="0.2678444037404801" WEIGHT="35.11283558029534"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1259" O_E="0.0" SE="0.0" STUDY_ID="STD-McEvoy-2006" TOTAL_1="3" TOTAL_2="1" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.606800815228754" CI_START="0.3612761835265241" EFFECT_SIZE="0.7619047619047619" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.20596204340395766" LOG_CI_START="-0.4421606675599467" LOG_EFFECT_SIZE="-0.11809931207799451" ORDER="1258" O_E="0.0" SE="0.3807104886793588" STUDY_ID="STD-McEvoy-2007" TOTAL_1="42" TOTAL_2="32" VAR="0.1449404761904762" WEIGHT="64.88716441970466"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3884683885805278" CI_END="1.72963741858873" CI_START="0.25109701417705904" DF="2" EFFECT_SIZE="0.6590195683107947" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" I2="0.0" ID="CMP-003.24.03" LOG_CI_END="0.23795507214046946" LOG_CI_START="-0.6001584515010837" LOG_EFFECT_SIZE="-0.1811016896803071" MODIFIED="2009-08-10 13:36:04 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4994568438036693" P_Z="0.3969795519229341" STUDIES="4" TAU2="0.0" TOTAL_1="507" TOTAL_2="518" WEIGHT="100.0" Z="0.8470279486017657">
<NAME>galactorrhea</NAME>
<DICH_DATA CI_END="2.5162779795868735" CI_START="0.2902462095059318" EFFECT_SIZE="0.8545994065281899" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.4007586170323797" LOG_CI_START="-0.5372334432565953" LOG_EFFECT_SIZE="-0.06823741311210779" ORDER="1260" O_E="0.0" SE="0.5509811793493259" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="336" VAR="0.303580259997174" WEIGHT="79.83758145611738"/>
<DICH_DATA CI_END="9.553415640689916" CI_START="0.018172674323062684" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9801586730175321" LOG_CI_START="-1.7405811564407443" LOG_EFFECT_SIZE="-0.38021124171160603" ORDER="1262" O_E="0.0" SE="1.5981760437031542" STUDY_ID="STD-McEvoy-2006" TOTAL_1="15" TOTAL_2="19" VAR="2.5541666666666667" WEIGHT="9.48924518211824"/>
<DICH_DATA CI_END="2.7187913096059764" CI_START="0.007395543683054397" EFFECT_SIZE="0.14179894179894179" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4343758730656566" LOG_CI_START="-2.1310298933545675" LOG_EFFECT_SIZE="-0.8483270101444553" ORDER="1261" O_E="0.0" SE="1.5069320461585896" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="2.2708441917397137" WEIGHT="10.673173361764377"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1263" O_E="0.0" SE="0.0" STUDY_ID="STD-Stroup-2006" TOTAL_1="21" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1952179336551494" CI_START="0.0915807244870491" DF="0" EFFECT_SIZE="0.3308457711442786" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" I2="0.0" ID="CMP-003.24.04" LOG_CI_END="0.07744710089455" LOG_CI_START="-1.0381959251293187" LOG_EFFECT_SIZE="-0.4803744121173843" MODIFIED="2009-08-10 13:36:09 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.09144088516044684" STUDIES="1" TAU2="0.0" TOTAL_1="134" TOTAL_2="133" WEIGHT="100.00000000000001" Z="1.6878455292285066">
<NAME>gynecomastia</NAME>
<DICH_DATA CI_END="1.1952179336551494" CI_START="0.0915807244870491" EFFECT_SIZE="0.3308457711442786" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.07744710089455" LOG_CI_START="-1.0381959251293187" LOG_EFFECT_SIZE="-0.4803744121173843" ORDER="1264" O_E="0.0" SE="0.6553342360084654" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.429462960884799" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4481816689842566" CI_END="0.9883267446583618" CI_START="0.6448921460670864" DF="3" EFFECT_SIZE="0.7983508973992753" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="148" I2="0.0" ID="CMP-003.24.05" LOG_CI_END="-0.005099452231577666" LOG_CI_START="-0.19051291216251204" LOG_EFFECT_SIZE="-0.09780618219704486" MODIFIED="2009-08-10 13:36:14 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6942805707237405" P_Z="0.038661250505670326" STUDIES="4" TAU2="0.0" TOTAL_1="581" TOTAL_2="596" WEIGHT="99.99999999999997" Z="2.0677743098368007">
<NAME>sexual dysfunction</NAME>
<DICH_DATA CI_END="0.9942539298785475" CI_START="0.574826569281688" EFFECT_SIZE="0.7559917826980141" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="91" LOG_CI_END="-0.0025026837503856103" LOG_CI_START="-0.24046316638028012" LOG_EFFECT_SIZE="-0.12148292506533287" ORDER="1265" O_E="0.0" SE="0.13977916542018634" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="336" VAR="0.019538215085563814" WEIGHT="60.711761564566096"/>
<DICH_DATA CI_END="7.970370050009344" CI_START="0.20130112333273198" EFFECT_SIZE="1.2666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9014784853793337" LOG_CI_START="-0.6961538015850384" LOG_EFFECT_SIZE="0.1026623418971477" ORDER="1267" O_E="0.0" SE="0.9384571137702378" STUDY_ID="STD-McEvoy-2006" TOTAL_1="15" TOTAL_2="19" VAR="0.880701754385965" WEIGHT="1.3468798600259289"/>
<DICH_DATA CI_END="1.393674540170364" CI_START="0.6325064511747416" EFFECT_SIZE="0.9388866478418717" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="37" LOG_CI_END="0.14416136636546892" LOG_CI_START="-0.19893504059435133" LOG_EFFECT_SIZE="-0.027386837114441207" ORDER="1266" O_E="0.0" SE="0.20153652780280357" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.04061697203881021" WEIGHT="29.204526977996405"/>
<DICH_DATA CI_END="1.3003782366564502" CI_START="0.3067507249157284" EFFECT_SIZE="0.631578947368421" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" LOG_CI_END="0.11406969246119797" LOG_CI_START="-0.5132144022716063" LOG_EFFECT_SIZE="-0.19957235490520417" ORDER="1268" O_E="0.0" SE="0.3684697823523967" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="108" VAR="0.1357699805068226" WEIGHT="8.736831597411555"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="9.842237474749158" CI_END="-0.1567595773034185" CI_START="-11.61783921964609" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.887299398474754" ESTIMABLE="YES" I2="59.35883471352692" I2_Q="0.0" ID="CMP-003.25" MODIFIED="2012-04-27 12:45:59 +0100" MODIFIED_BY="Laila Asmal" NO="25" P_CHI2="0.0431707592803936" P_Q="1.0" P_Z="0.0440537504080997" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="22.395969826513966" TOTALS="YES" TOTAL_1="509" TOTAL_2="512" UNITS="" WEIGHT="100.0" Z="2.01357902524029">
<NAME>Adverse effects: 6b. Prolactin - change from baseline in ng/ml</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.41420078120144854" CI_START="-6.814200781201451" EFFECT_SIZE="-3.200000000000001" ESTIMABLE="YES" MEAN_1="-9.3" MEAN_2="-6.1" ORDER="1269" SD_1="25.7" SD_2="22.0" SE="1.8440138745965762" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="336" WEIGHT="33.13877947251473"/>
<CONT_DATA CI_END="1.6830963440236832" CI_START="-19.883096344023684" EFFECT_SIZE="-9.1" ESTIMABLE="YES" MEAN_1="-13.2" MEAN_2="-4.1" ORDER="1270" SD_1="18.02" SD_2="9.2" SE="5.50168086203592" STUDY_ID="STD-McEvoy-2006" TOTAL_1="13" TOTAL_2="16" WEIGHT="16.23219436882294"/>
<CONT_DATA CI_END="4.434380975829147" CI_START="-10.034380975829144" EFFECT_SIZE="-2.799999999999999" ESTIMABLE="YES" MEAN_1="-18.7" MEAN_2="-15.9" ORDER="1271" SD_1="17.64" SD_2="15.57" SE="3.6910785263877397" STUDY_ID="STD-McEvoy-2007" TOTAL_1="44" TOTAL_2="37" WEIGHT="23.732900097028693"/>
<CONT_DATA CI_END="4.774455695202791" CI_START="-11.174455695202793" EFFECT_SIZE="-3.200000000000001" ESTIMABLE="YES" MEAN_1="-8.3" MEAN_2="-5.1" ORDER="1272" SD_1="18.5" SD_2="37.4" SE="4.068674607341911" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="108" WEIGHT="21.94757295313807"/>
<CONT_DATA CI_END="-16.03717515655097" CI_START="-64.10282484344903" EFFECT_SIZE="-40.07" ESTIMABLE="YES" MEAN_1="-14.74" MEAN_2="25.33" ORDER="1273" SD_1="26.07" SD_2="41.78" SE="12.261870643040835" STUDY_ID="STD-Svestka-2003b" TOTAL_1="20" TOTAL_2="15" WEIGHT="4.948553108495566"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6792238283470766" CI_START="0.5866581345062095" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9925373134328358" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-003.26" LOG_CI_END="0.22510858829839397" LOG_CI_START="-0.23161490309383764" LOG_EFFECT_SIZE="-0.0032531573977218464" METHOD="MH" MODIFIED="2012-04-27 12:45:59 +0100" MODIFIED_BY="Laila Asmal" NO="26" P_CHI2="1.0" P_Q="1.0" P_Z="0.9777252186470544" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="134" TOTAL_2="133" WEIGHT="100.0" Z="0.027920925705567135">
<NAME>Adverse effects: 7a. Metabolic - cholesterol - significant cholesterol increase</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6792238283470766" CI_START="0.5866581345062095" EFFECT_SIZE="0.9925373134328358" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="23" LOG_CI_END="0.22510858829839397" LOG_CI_START="-0.23161490309383764" LOG_EFFECT_SIZE="-0.0032531573977218464" ORDER="1221" O_E="0.0" SE="0.2682816396615412" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.07197503817948506" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="13.075315889292934" CI_END="2.589960318727508" CI_START="-8.049398226925762" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.729718954099127" ESTIMABLE="YES" I2="61.76000608830888" I2_Q="0.0" ID="CMP-003.27" MODIFIED="2012-04-27 12:45:59 +0100" MODIFIED_BY="Laila Asmal" NO="27" P_CHI2="0.022683166805562816" P_Q="1.0" P_Z="0.31454640386154287" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="20.641255798311583" TOTALS="YES" TOTAL_1="574" TOTAL_2="582" UNITS="" WEIGHT="100.0" Z="1.0057280831345699">
<NAME>Adverse effects: 7b. Metabolic - cholesterol - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.36602085742474927" CI_START="-0.18602085742474922" EFFECT_SIZE="0.09000000000000001" ESTIMABLE="YES" MEAN_1="-0.11" MEAN_2="-0.2" MODIFIED="2011-07-07 11:14:00 +0100" MODIFIED_BY="Laila Asmal" ORDER="8346" SD_1="0.68" SD_2="0.93" SE="0.14082955584998832" STUDY_ID="STD-Deberdt-2008" TOTAL_1="65" TOTAL_2="68" WEIGHT="35.65508801222008"/>
<CONT_DATA CI_END="21.820405103546626" CI_START="-21.62040510354663" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="8.6" MEAN_2="8.5" MODIFIED="2011-08-26 11:15:51 +0100" MODIFIED_BY="Laila Asmal" ORDER="544" SD_1="30.1" SD_2="36.3" SE="11.08204297368442" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="17" WEIGHT="5.1352936924323895"/>
<CONT_DATA CI_END="1.4249867887375807" CI_START="-10.22498678873758" EFFECT_SIZE="-4.3999999999999995" ESTIMABLE="YES" MEAN_1="5.3" MEAN_2="9.7" ORDER="1222" SD_1="38.6" SD_2="38.5" SE="2.9719866460222395" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="336" WEIGHT="24.994026173706654"/>
<CONT_DATA CI_END="7.223452661689272" CI_START="-33.62345266168927" EFFECT_SIZE="-13.2" ESTIMABLE="YES" MEAN_1="-13.0" MEAN_2="0.2" ORDER="1223" SD_1="24.5" SD_2="31.6" SE="10.420320384857508" STUDY_ID="STD-McEvoy-2006" TOTAL_1="13" TOTAL_2="16" WEIGHT="5.700729287801398"/>
<CONT_DATA CI_END="21.642550986618247" CI_START="-2.6425509866182466" EFFECT_SIZE="9.5" ESTIMABLE="YES" MEAN_1="25.2" MEAN_2="15.7" MODIFIED="2011-07-26 09:01:13 +0100" MODIFIED_BY="Laila Asmal" ORDER="1224" SD_1="29.58" SD_2="26.16" SE="6.1952929147663625" STUDY_ID="STD-McEvoy-2007" TOTAL_1="44" TOTAL_2="37" WEIGHT="12.481135494970317"/>
<CONT_DATA CI_END="-3.2407865152761524" CI_START="-22.959213484723843" EFFECT_SIZE="-13.099999999999998" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="17.9" ORDER="1225" SD_1="37.0" SD_2="34.3" SE="5.030303394599117" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="108" WEIGHT="16.033727338869166"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="4.149081848445695" CI_END="1.0188811888998486" CI_START="0.2134420722538583" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4663390529853344" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="53" I2="51.79656432303864" I2_Q="0.0" ID="CMP-003.28" LOG_CI_END="0.008123544150163788" LOG_CI_START="-0.6707199712903115" LOG_EFFECT_SIZE="-0.3312982135700739" METHOD="MH" MODIFIED="2012-04-27 12:45:59 +0100" MODIFIED_BY="Laila Asmal" NO="28" P_CHI2="0.1256141262977134" P_Q="1.0" P_Z="0.05574098310315097" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.23594151100206462" TOTALS="YES" TOTAL_1="514" TOTAL_2="511" WEIGHT="100.0" Z="1.9130552239818543">
<NAME>Adverse effects: 7c. Metabolic - glucose - abnormally high fasting glucose value</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9683234117892254" CI_START="0.276011300810141" EFFECT_SIZE="0.5169798878997692" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="27" LOG_CI_END="-0.01397956779771826" LOG_CI_START="-0.5590731361267695" LOG_EFFECT_SIZE="-0.28652635196224385" MODIFIED="2011-07-14 09:36:49 +0100" MODIFIED_BY="Laila Asmal" ORDER="2226" O_E="0.0" SE="0.32019066029316484" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="336" VAR="0.10252205893897287" WEIGHT="46.97887589509674"/>
<DICH_DATA CI_END="1.5392100717049053" CI_START="0.32654250300666454" EFFECT_SIZE="0.7089552238805971" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.18729789647619158" LOG_CI_START="-0.48606028262811135" LOG_EFFECT_SIZE="-0.14938119307595984" ORDER="1251" O_E="0.0" SE="0.39553392758261086" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.15644708786892605" WEIGHT="40.52268106928153"/>
<DICH_DATA CI_END="0.5985484980720833" CI_START="0.011068781951121216" EFFECT_SIZE="0.08139534883720931" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.22290065462806105" LOG_CI_START="-1.9559001678305608" LOG_EFFECT_SIZE="-1.0894004112293108" MODIFIED="2011-07-14 11:49:25 +0100" MODIFIED_BY="Laila Asmal" ORDER="5843" O_E="0.0" SE="1.0179724925410907" STUDY_ID="STD-Voruganti-2007" TOTAL_1="43" TOTAL_2="42" VAR="1.0362679955703211" WEIGHT="12.498443035621733"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="18.07232387548965" CI_END="0.07188031175856313" CI_START="-9.406279483886859" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.6671995860641475" ESTIMABLE="YES" I2="72.33338648395305" I2_Q="0.0" ID="CMP-003.29" MODIFIED="2012-04-27 12:45:59 +0100" MODIFIED_BY="Laila Asmal" NO="29" P_CHI2="0.0028571197909044166" P_Q="1.0" P_Z="0.05357759054347754" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="19.139394241655385" TOTALS="YES" TOTAL_1="574" TOTAL_2="582" UNITS="" WEIGHT="100.0" Z="1.930236099532456">
<NAME>Adverse effects: 7d. Metabolic - glucose - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3985261652965071" CI_START="-0.49852616529650706" EFFECT_SIZE="-0.049999999999999996" ESTIMABLE="YES" MEAN_1="-0.06" MEAN_2="-0.01" MODIFIED="2011-07-07 11:14:57 +0100" MODIFIED_BY="Laila Asmal" ORDER="8347" SD_1="1.08" SD_2="1.53" SE="0.2288440853170896" STUDY_ID="STD-Deberdt-2008" TOTAL_1="65" TOTAL_2="68" WEIGHT="30.463302852764045"/>
<CONT_DATA CI_END="6.354408609691612" CI_START="-10.354408609691612" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="-5.2" MEAN_2="-3.2" MODIFIED="2011-08-26 11:20:34 +0100" MODIFIED_BY="Laila Asmal" ORDER="545" SD_1="14.6" SD_2="11.3" SE="4.262531697311849" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="17" WEIGHT="15.670514937841793"/>
<CONT_DATA CI_END="-0.8444997255057158" CI_START="-15.555500274494282" EFFECT_SIZE="-8.2" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="15.0" ORDER="1252" SD_1="45.9" SD_2="51.3" SE="3.752875222459969" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="336" WEIGHT="17.59733625450696"/>
<CONT_DATA CI_END="-8.695124481497984" CI_START="-85.10487551850203" EFFECT_SIZE="-46.900000000000006" ESTIMABLE="YES" MEAN_1="-23.3" MEAN_2="23.6" ORDER="1253" SD_1="44.0" SD_2="60.8" SE="19.492641609670994" STUDY_ID="STD-McEvoy-2006" TOTAL_1="13" TOTAL_2="16" WEIGHT="1.4648982577069145"/>
<CONT_DATA CI_END="2.1195821883300097" CI_START="-6.919582188330009" EFFECT_SIZE="-2.3999999999999995" ESTIMABLE="YES" MEAN_1="6.2" MEAN_2="8.6" MODIFIED="2011-07-26 09:03:53 +0100" MODIFIED_BY="Laila Asmal" ORDER="1254" SD_1="11.08" SD_2="9.67" SE="2.305951652162946" STUDY_ID="STD-McEvoy-2007" TOTAL_1="44" TOTAL_2="37" WEIGHT="23.905185511351004"/>
<CONT_DATA CI_END="-3.4871827382132228" CI_START="-26.51281726178678" EFFECT_SIZE="-15.0" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="14.8" ORDER="1255" SD_1="41.9" SD_2="41.6" SE="5.873994294078059" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="108" WEIGHT="10.898762185829275"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="12.06032952673625" CI_END="0.9159418679036748" CI_START="0.50543276167227" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6804021074525063" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="243" I2="41.958468178818244" I2_Q="0.0" ID="CMP-003.30" LOG_CI_END="-0.0381320888319279" LOG_CI_START="-0.29633661094727703" LOG_EFFECT_SIZE="-0.16723434988960245" METHOD="MH" MODIFIED="2012-04-27 12:45:59 +0100" MODIFIED_BY="Laila Asmal" NO="30" P_CHI2="0.09859232780487104" P_Q="0.7759934207457635" P_Z="0.01112125044527964" Q="0.08096536887896194" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.056226609464071924" TOTALS="YES" TOTAL_1="829" TOTAL_2="838" WEIGHT="100.0" Z="2.538865702864514">
<NAME>Adverse effects: 7e. Metabolic - weight - gain</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="12.020877656148642" CI_END="0.9518316462699391" CI_START="0.5051945547389094" DF="6" EFFECT_SIZE="0.6934408155882843" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="241" I2="50.086839150791796" ID="CMP-003.30.01" LOG_CI_END="-0.02143985997860451" LOG_CI_START="-0.29654133915310615" LOG_EFFECT_SIZE="-0.15899059956585537" MODIFIED="2009-08-10 13:36:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06150477056659609" P_Z="0.023484398900683694" STUDIES="7" TAU2="0.0676376122358841" TOTAL_1="654" TOTAL_2="667" WEIGHT="98.51074604176475" Z="2.2654610943174363">
<NAME>significant weight gain (as defined by the original studies)</NAME>
<DICH_DATA CI_END="0.7254390767605592" CI_START="0.3887176966676368" EFFECT_SIZE="0.5310282544187847" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="92" LOG_CI_END="-0.13939905426372462" LOG_CI_START="-0.4103656873333477" LOG_EFFECT_SIZE="-0.2748823707985362" ORDER="1282" O_E="0.0" SE="0.1591671415715626" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="336" VAR="0.02533417895606185" WEIGHT="28.204699494959407"/>
<DICH_DATA CI_END="7.970370050009344" CI_START="0.20130112333273198" EFFECT_SIZE="1.2666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9014784853793337" LOG_CI_START="-0.6961538015850384" LOG_EFFECT_SIZE="0.1026623418971477" ORDER="1284" O_E="0.0" SE="0.9384571137702378" STUDY_ID="STD-McEvoy-2006" TOTAL_1="15" TOTAL_2="19" VAR="0.880701754385965" WEIGHT="2.455254442835969"/>
<DICH_DATA CI_END="0.7584824730817795" CI_START="0.5189027955862359" EFFECT_SIZE="0.6273584905660378" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="106" LOG_CI_END="-0.12005445038392706" LOG_CI_START="-0.2849139895394042" LOG_EFFECT_SIZE="-0.20248421996166563" ORDER="1283" O_E="0.0" SE="0.09683930936780745" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.009377851838833919" WEIGHT="35.06465082215294"/>
<DICH_DATA CI_END="2.2600666525183493" CI_START="0.4424648268163769" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.35412124728637384" LOG_CI_START="-0.3541212472863738" LOG_EFFECT_SIZE="0.0" ORDER="1285" O_E="0.0" SE="0.41602514716892186" STUDY_ID="STD-Riedel-2007" TOTAL_1="26" TOTAL_2="26" VAR="0.17307692307692307" WEIGHT="10.032106799534683"/>
<DICH_DATA CI_END="6.360464465990765" CI_START="0.7959324396935245" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.8034888306879787" LOG_CI_START="-0.0991237944652537" LOG_EFFECT_SIZE="0.3521825181113625" ORDER="1288" O_E="0.0" SE="0.5301991240195623" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" VAR="0.28111111111111114" WEIGHT="6.8192715716449035"/>
<DICH_DATA CI_END="0.8689466548386929" CI_START="0.25466759150870183" EFFECT_SIZE="0.4704174228675136" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="29" LOG_CI_END="-0.06100688433420011" LOG_CI_START="-0.5940263189722584" LOG_EFFECT_SIZE="-0.3275166016532293" ORDER="1286" O_E="0.0" SE="0.31309825439514993" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="108" VAR="0.09803051690529004" WEIGHT="14.91274719103503"/>
<DICH_DATA CI_END="116.5681402396685" CI_START="0.35042826609873" EFFECT_SIZE="6.391304347826087" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.066579867671753" LOG_CI_START="-0.45540087021058673" LOG_EFFECT_SIZE="0.8055894987305832" ORDER="1287" O_E="0.0" SE="1.4814239694380784" STUDY_ID="STD-Svestka-2003b" TOTAL_1="22" TOTAL_2="20" VAR="2.1946169772256727" WEIGHT="1.02201571960181"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.338350953479457" CI_START="0.04471456502138438" DF="0" EFFECT_SIZE="0.48857142857142855" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-003.30.02" LOG_CI_END="0.7274071217462292" LOG_CI_START="-1.3495509896624729" LOG_EFFECT_SIZE="-0.3110719339581218" MODIFIED="2009-08-10 13:36:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5571373695445696" STUDIES="1" TAU2="0.0" TOTAL_1="175" TOTAL_2="171" WEIGHT="1.4892539582352458" Z="0.5870987804810539">
<NAME>as "weight gain" reported adverse events</NAME>
<DICH_DATA CI_END="5.338350953479457" CI_START="0.04471456502138438" EFFECT_SIZE="0.48857142857142855" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7274071217462292" LOG_CI_START="-1.3495509896624729" LOG_EFFECT_SIZE="-0.3110719339581218" ORDER="1289" O_E="0.0" SE="1.2200154757499349" STUDY_ID="STD-Kinon-2006b" TOTAL_1="175" TOTAL_2="171" VAR="1.48843776106934" WEIGHT="1.4892539582352458"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="45.637484362727506" CI_END="-1.2573881201529131" CI_START="-3.8231265265473784" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.5402573233501458" ESTIMABLE="YES" I2="80.27936875646377" I2_Q="0.0" ID="CMP-003.31" MODIFIED="2012-04-27 12:45:59 +0100" MODIFIED_BY="Laila Asmal" NO="31" P_CHI2="7.030692450449294E-7" P_Q="1.0" P_Z="1.0402867877722535E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="2.903343032376731" TOTALS="YES" TOTAL_1="716" TOTAL_2="712" UNITS="" WEIGHT="100.0" Z="3.8809980415945375">
<NAME>Adverse effects: 7f. Metabolic - weight - change from baseline in kg</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.4520639697646995" CI_START="-6.5679360302353" EFFECT_SIZE="-4.51" ESTIMABLE="YES" MEAN_1="4.41" MEAN_2="8.92" ORDER="1290" SD_1="2.21" SD_2="3.13" SE="1.0499866561161517" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="13" WEIGHT="10.694923621638775"/>
<CONT_DATA CI_END="0.08040266347111835" CI_START="-3.7004026634711185" EFFECT_SIZE="-1.81" ESTIMABLE="YES" MEAN_1="-0.82" MEAN_2="0.99" MODIFIED="2011-07-07 11:15:49 +0100" MODIFIED_BY="Laila Asmal" ORDER="8348" SD_1="5.3" SD_2="5.82" SE="0.9645088779091725" STUDY_ID="STD-Deberdt-2008" TOTAL_1="65" TOTAL_2="68" WEIGHT="11.175307156094595"/>
<CONT_DATA CI_END="2.386877179064536" CI_START="-2.1868771790645356" EFFECT_SIZE="0.09999999999999987" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="1.1" MODIFIED="2011-09-01 17:48:33 +0100" MODIFIED_BY="Laila Asmal" ORDER="543" SD_1="3.2" SD_2="3.8" SE="1.1667955110926176" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="17" WEIGHT="10.045568295728314"/>
<CONT_DATA CI_END="0.4752126971657028" CI_START="-1.7552126971657027" EFFECT_SIZE="-0.64" ESTIMABLE="YES" MEAN_1="0.39" MEAN_2="1.03" MODIFIED="2011-09-01 17:49:05 +0100" MODIFIED_BY="Laila Asmal" ORDER="1291" SD_1="4.74" SD_2="5.78" SE="0.5689965254271804" STUDY_ID="STD-Kinon-2006b" TOTAL_1="175" TOTAL_2="171" WEIGHT="13.275660667104544"/>
<CONT_DATA CI_END="-2.6908182003877945" CI_START="-4.909181799612205" EFFECT_SIZE="-3.8" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="4.3" ORDER="1292" SD_1="7.0" SD_2="7.0" SE="0.5659194803380518" STUDY_ID="STD-Lieberman-2005" TOTAL_1="305" TOTAL_2="307" WEIGHT="13.290042409784775"/>
<CONT_DATA CI_END="5.5828400313345385" CI_START="-10.182840031334539" EFFECT_SIZE="-2.3" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="2.8" MODIFIED="2011-09-01 17:48:59 +0100" MODIFIED_BY="Laila Asmal" ORDER="1293" SD_1="8.91" SD_2="14.38" SE="4.021931062771242" STUDY_ID="STD-McEvoy-2006" TOTAL_1="15" TOTAL_2="19" WEIGHT="2.2454674603037765"/>
<CONT_DATA CI_END="-0.3592298665985654" CI_START="-10.000770133401431" EFFECT_SIZE="-5.179999999999999" ESTIMABLE="YES" MEAN_1="5.69" MEAN_2="10.87" MODIFIED="2011-09-01 17:49:00 +0100" MODIFIED_BY="Laila Asmal" ORDER="1294" SD_1="11.47" SD_2="10.64" SE="2.4596217948018704" STUDY_ID="STD-McEvoy-2007" TOTAL_1="44" TOTAL_2="37" WEIGHT="4.785154836805449"/>
<CONT_DATA CI_END="1.556291570911831" CI_START="-2.516291570911831" EFFECT_SIZE="-0.48" ESTIMABLE="YES" MEAN_1="3.28" MEAN_2="3.76" ORDER="1295" SD_1="3.17" SD_2="2.77" SE="1.0389433617014594" STUDY_ID="STD-Riedel-2007" TOTAL_1="16" TOTAL_2="17" WEIGHT="10.756870236862058"/>
<CONT_DATA CI_END="-0.8852693054884733" CI_START="-5.514730694511526" EFFECT_SIZE="-3.1999999999999997" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="2.3" ORDER="1296" SD_1="3.73" SD_2="3.73" SE="1.181006749496331" STUDY_ID="STD-Sirota-2006" TOTAL_1="19" TOTAL_2="21" WEIGHT="9.967587184741967"/>
<CONT_DATA CI_END="-3.503130980542993" CI_START="-5.296869019457008" EFFECT_SIZE="-4.4" ESTIMABLE="YES" MEAN_1="2.84" MEAN_2="7.24" MODIFIED="2011-07-14 11:50:13 +0100" MODIFIED_BY="Laila Asmal" ORDER="5844" SD_1="1.72" SD_2="2.43" SE="0.4575946428257844" STUDY_ID="STD-Voruganti-2007" TOTAL_1="43" TOTAL_2="42" WEIGHT="13.763418130935753"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2013-06-25 16:11:46 +0100" MODIFIED_BY="Laila Asmal" NO="4">
<NAME>QUETIAPINE versus PALIPERIDONE</NAME>
<DICH_OUTCOME CHI2="3.276148379994664" CI_END="1.62156019681829" CI_START="0.7034246098311838" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0680099946932535" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="39" I2="0.0" I2_Q="7.345685011178124" ID="CMP-004.01" LOG_CI_END="0.2099330755256443" LOG_CI_START="-0.1527824416390375" LOG_EFFECT_SIZE="0.02857531694330342" METHOD="MH" MODIFIED="2011-09-01 15:48:23 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.51272036749118" P_Q="0.3398401581858761" P_Z="0.757459759259018" Q="2.1585610991147974" RANDOM="YES" SCALE="6.446693200286809" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="566" TOTAL_2="565" WEIGHT="100.0" Z="0.308818285434772">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0840858726389577" CI_END="1.7304725622539188" CI_START="0.6073924050726764" DF="1" EFFECT_SIZE="1.0252199234796817" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="28" I2="7.756384873300673" ID="CMP-004.01.01" LOG_CI_END="0.2381647176687557" LOG_CI_START="-0.2165306428682789" LOG_EFFECT_SIZE="0.010817037400238382" MODIFIED="2011-09-01 15:47:54 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.2977857610365995" P_Z="0.9257020440030675" STUDIES="2" TAU2="0.015057436812885752" TOTAL_1="203" TOTAL_2="203" WEIGHT="73.6390685008697" Z="0.0932536619632528">
<NAME>any reason</NAME>
<DICH_DATA CI_END="2.0696545103810267" CI_START="0.6870983745679355" EFFECT_SIZE="1.1925" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="20" LOG_CI_END="0.3158978542695266" LOG_CI_START="-0.16298107884522356" LOG_EFFECT_SIZE="0.0764583877121515" MODIFIED="2011-07-28 15:01:16 +0100" MODIFIED_BY="Laila Asmal" ORDER="1806" O_E="0.0" SE="0.28129585580055394" STUDY_ID="STD-Canuso-2008" TOTAL_1="160" TOTAL_2="159" VAR="0.07912735849056604" WEIGHT="57.369465911011545"/>
<DICH_DATA CI_END="1.8008865579736557" CI_START="0.22711306588692237" EFFECT_SIZE="0.6395348837209303" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2554863564632014" LOG_CI_START="-0.6437578799618492" LOG_EFFECT_SIZE="-0.19413576174932387" MODIFIED="2011-09-01 15:47:54 +0100" MODIFIED_BY="Laila Asmal" ORDER="3308" O_E="0.0" SE="0.5282205158068352" STUDY_ID="STD-Eerdekens-2007" TOTAL_1="43" TOTAL_2="44" VAR="0.27901691331923895" WEIGHT="16.269602589858156"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.021913500280728585" CI_END="2.1688224900234405" CI_START="0.37342096639185124" DF="1" EFFECT_SIZE="0.8999354366602831" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.3362240080962377" LOG_CI_START="-0.42780130145749" LOG_EFFECT_SIZE="-0.045788646680626134" MODIFIED="2011-09-01 15:48:23 +0100" MODIFIED_BY="Laila Asmal" NO="2" P_CHI2="0.8823174531811306" P_Z="0.8142674016994061" STUDIES="2" TAU2="0.0" TOTAL_1="203" TOTAL_2="203" WEIGHT="22.53807291795031" Z="0.23492441224827199">
<NAME>due to adverse events</NAME>
<DICH_DATA CI_END="2.3409314514003765" CI_START="0.3229845086981349" EFFECT_SIZE="0.86953125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3693886966037451" LOG_CI_START="-0.49081830723006525" LOG_EFFECT_SIZE="-0.060714805313160064" MODIFIED="2011-07-28 15:02:28 +0100" MODIFIED_BY="Laila Asmal" ORDER="1807" O_E="0.0" SE="0.5052898521453228" STUDY_ID="STD-Canuso-2008" TOTAL_1="160" TOTAL_2="159" VAR="0.25531783468104224" WEIGHT="17.779777512307028"/>
<DICH_DATA CI_END="6.94040834790185" CI_START="0.15086323574983163" EFFECT_SIZE="1.0232558139534884" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8413850234841429" LOG_CI_START="-0.821416581670941" LOG_EFFECT_SIZE="0.009984220906600923" MODIFIED="2011-09-01 15:48:23 +0100" MODIFIED_BY="Laila Asmal" ORDER="3309" O_E="0.0" SE="0.9767378938687896" STUDY_ID="STD-Eerdekens-2007" TOTAL_1="43" TOTAL_2="44" VAR="0.9540169133192389" WEIGHT="4.75829540564328"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="42.053986467256415" CI_START="0.5870662602158455" DF="0" EFFECT_SIZE="4.96875" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="1.6238071706136137" LOG_CI_START="-0.23131287861252275" LOG_EFFECT_SIZE="0.6962471460005455" MODIFIED="2011-07-28 15:02:26 +0100" MODIFIED_BY="Laila Asmal" NO="3" P_CHI2="1.0" P_Z="0.14123907102042355" STUDIES="1" TAU2="0.0" TOTAL_1="160" TOTAL_2="159" WEIGHT="3.8228585811799882" Z="1.4711924773484295">
<NAME>due to inefficacy</NAME>
<DICH_DATA CI_END="42.053986467256415" CI_START="0.5870662602158455" EFFECT_SIZE="4.96875" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6238071706136137" LOG_CI_START="-0.23131287861252275" LOG_EFFECT_SIZE="0.6962471460005455" MODIFIED="2011-07-28 15:02:26 +0100" MODIFIED_BY="Laila Asmal" ORDER="1808" O_E="0.0" SE="1.0897066999077776" STUDY_ID="STD-Canuso-2008" TOTAL_1="160" TOTAL_2="159" VAR="1.1874606918238992" WEIGHT="3.8228585811799882"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="9.827935172172097" CI_START="2.772064827827902" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="6.3" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.9924622830887934" LOG_CI_START="0.4428033825193934" LOG_DATA="NO" LOG_EFFECT_SIZE="0.7993405494535817" MODIFIED="2013-06-25 15:59:18 +0100" MODIFIED_BY="Laila Asmal" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="4.6525815808819886E-4" Q="0.0" RANDOM="YES" SCALE="49.75079649579115" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="3.5">
<NAME>Mental state: 1. General - average endpoint score (PANSS total, high=poor)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="9.827935172172097" CI_START="2.772064827827902" DF="0" EFFECT_SIZE="6.3" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="0.9924622830887934" LOG_CI_START="0.4428033825193934" LOG_EFFECT_SIZE="0.7993405494535817" MODIFIED="2011-07-07 09:42:22 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="1.0" P_Z="4.6525815808819886E-4" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="3.5">
<NAME>short term</NAME>
<IV_DATA CI_END="9.827935172172097" CI_START="2.772064827827902" EFFECT_SIZE="6.3" ESTIMABLE="YES" ESTIMATE="6.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-07-07 09:42:22 +0100" MODIFIED_BY="Laila Asmal" ORDER="5238" SE="1.8" STUDY_ID="STD-Canuso-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="2.7759783907240325" CI_START="0.42402160927596766" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="1.6" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.44341608108186703" LOG_CI_START="-0.3726120100342258" LOG_DATA="NO" LOG_EFFECT_SIZE="0.2041199826559248" MODIFIED="2013-06-25 16:11:46 +0100" MODIFIED_BY="Laila Asmal" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.007660761134882526" Q="0.0" RANDOM="YES" SCALE="9.99256158241071" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="2.666666666666667">
<NAME>Mental state: 2. Positive symptoms - average endpoint score (PANSS positive subscore, high=poor)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="2.7759783907240325" CI_START="0.42402160927596766" DF="0" EFFECT_SIZE="1.6" ESTIMABLE="YES" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="0.44341608108186703" LOG_CI_START="-0.3726120100342258" LOG_EFFECT_SIZE="0.2041199826559248" MODIFIED="2011-07-07 09:45:00 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="1.0" P_Z="0.007660761134882526" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="2.666666666666667">
<NAME>short term</NAME>
<IV_DATA CI_END="2.7759783907240325" CI_START="0.42402160927596766" EFFECT_SIZE="1.6" ESTIMABLE="YES" ESTIMATE="1.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-07-07 09:45:00 +0100" MODIFIED_BY="Laila Asmal" ORDER="5239" SE="0.6" STUDY_ID="STD-Canuso-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="3.081487911019577E-31" CI_END="2.083985593816022" CI_START="0.5160144061839785" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="1.3000000000000003" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.3188947124452258" LOG_CI_START="-0.28733817349125584" LOG_DATA="NO" LOG_EFFECT_SIZE="0.11394335230683686" MODIFIED="2013-04-05 11:41:18 +0100" MODIFIED_BY="Laila Asmal" NO="4" P_CHI2="0.0" P_Q="1.0" P_Z="0.0011540500848101628" Q="0.0" RANDOM="YES" SCALE="6.057734995689283" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.00000000000001" Z="3.2500000000000004">
<NAME>Mental state: 3. Negative symptoms - average endpoint score (PANSS negative subscore, high=poor)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="3.081487911019577E-31" CI_END="2.083985593816022" CI_START="0.5160144061839785" DF="0" EFFECT_SIZE="1.3000000000000003" ESTIMABLE="YES" I2="100.0" ID="CMP-004.04.01" LOG_CI_END="0.3188947124452258" LOG_CI_START="-0.28733817349125584" LOG_EFFECT_SIZE="0.11394335230683686" MODIFIED="2011-07-07 09:47:05 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.0" P_Z="0.0011540500848101628" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.00000000000001" Z="3.2500000000000004">
<NAME>short term</NAME>
<IV_DATA CI_END="2.083985593816022" CI_START="0.5160144061839783" EFFECT_SIZE="1.3" ESTIMABLE="YES" ESTIMATE="1.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-07-07 09:47:05 +0100" MODIFIED_BY="Laila Asmal" ORDER="5240" SE="0.4" STUDY_ID="STD-Canuso-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.00000000000001"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5264950609012988" CI_START="1.058797414347277" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2713178294573644" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="0.18369540344189864" LOG_CI_START="0.024812872054999227" LOG_EFFECT_SIZE="0.10425413774844894" METHOD="MH" MODIFIED="2011-07-28 15:12:53 +0100" MODIFIED_BY="Laila Asmal" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.010107091530841033" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="44" WEIGHT="100.0" Z="2.572143752275159">
<NAME>Adverse effects: 1. General - at least one adverse effect</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5264950609012988" CI_START="1.058797414347277" EFFECT_SIZE="1.2713178294573644" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="33" LOG_CI_END="0.18369540344189864" LOG_CI_START="0.024812872054999227" LOG_EFFECT_SIZE="0.10425413774844894" MODIFIED="2011-07-11 11:07:15 +0100" MODIFIED_BY="Laila Asmal" ORDER="1329" O_E="0.0" SE="0.09332838541787931" STUDY_ID="STD-Eerdekens-2007" TOTAL_1="43" TOTAL_2="44" VAR="0.00871018752470823" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.01219275450676442" CI_START="-0.01219275450676442" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="-1.9138981703494944" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-04-05 11:42:00 +0100" MODIFIED_BY="Laila Asmal" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="0.06346" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="159" TOTAL_2="160" WEIGHT="100.0" Z="0.0">
<NAME>Adverse effects: 2a. Cardiac effects - QTc prolongation</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.01219275450676442" CI_START="-0.01219275450676442" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-07-07 09:51:33 +0100" MODIFIED_BY="Laila Asmal" ORDER="5241" O_E="0.0" SE="0.006220907426329928" STUDY_ID="STD-Canuso-2008" TOTAL_1="159" TOTAL_2="160" VAR="3.869968920696685E-5" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="7.104933314082718" CI_START="-2.5049333140827184" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.3" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.07" MODIFIED="2011-07-28 14:57:16 +0100" MODIFIED_BY="Laila Asmal" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.3481492709615134" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="44" UNITS="" WEIGHT="100.0" Z="0.9381851671551669">
<NAME>Adverse effects: 2b. Cardiac effects - QTc abnormalities - change from baseline in ms</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Paliperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.104933314082718" CI_START="-2.5049333140827184" EFFECT_SIZE="2.3" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="3.7" MODIFIED="2011-07-11 11:10:01 +0100" MODIFIED_BY="Laila Asmal" ORDER="1330" SD_1="10.86" SD_2="11.99" SE="2.4515416364705773" STUDY_ID="STD-Eerdekens-2007" TOTAL_1="43" TOTAL_2="44" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.114024422878635" CI_END="0.8913170242313583" CI_START="0.41697986054231534" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.609640261517383" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="105" I2="15.659552971113552" I2_Q="36.83734209187975" ID="CMP-004.08" LOG_CI_END="-0.0499677983357237" LOG_CI_START="-0.3798849202458047" LOG_EFFECT_SIZE="-0.21492635929076426" METHOD="MH" MODIFIED="2013-04-05 11:43:07 +0100" MODIFIED_BY="Laila Asmal" NO="8" P_CHI2="0.31043120319356865" P_Q="0.1756314721571327" P_Z="0.010659757836500942" Q="6.332855729121805" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.04437850551518738" TOTALS="YES" TOTAL_1="765" TOTAL_2="772" WEIGHT="100.0" Z="2.553659058974361">
<NAME>Adverse effects: 3a. Extrapyramidal effects</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6279597194979368" CI_END="3.3433894268469126" CI_START="0.5474965946677305" DF="1" EFFECT_SIZE="1.3529576216004624" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" ID="CMP-004.08.01" LOG_CI_END="0.5241869647112417" LOG_CI_START="-0.26161857771453445" LOG_EFFECT_SIZE="0.13128419349835369" MODIFIED="2013-04-05 11:42:28 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.4281049099351054" P_Z="0.512531708189393" STUDIES="2" TAU2="0.0" TOTAL_1="202" TOTAL_2="204" WEIGHT="15.351642064110676" Z="0.6549006773401967">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="3.0961237244186584" CI_START="0.42718038556908045" EFFECT_SIZE="1.1500449236298294" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.49081830723006525" LOG_CI_START="-0.3693886966037451" LOG_EFFECT_SIZE="0.06071480531316008" MODIFIED="2011-07-07 09:53:57 +0100" MODIFIED_BY="Laila Asmal" ORDER="5242" O_E="0.0" SE="0.5052898521453228" STUDY_ID="STD-Canuso-2008" TOTAL_1="159" TOTAL_2="160" VAR="0.25531783468104224" WEIGHT="12.531512004722105"/>
<DICH_DATA CI_END="28.37207881712911" CI_START="0.3321389387025563" EFFECT_SIZE="3.0697674418604652" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4528911576404968" LOG_CI_START="-0.47868020638797026" LOG_EFFECT_SIZE="0.4871054756262634" MODIFIED="2011-09-01 16:00:06 +0100" MODIFIED_BY="Laila Asmal" ORDER="3310" O_E="0.0" SE="1.1346145806627783" STUDY_ID="STD-Eerdekens-2007" TOTAL_1="43" TOTAL_2="44" VAR="1.2873502466525721" WEIGHT="2.820130059388571"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.94040834790185" CI_START="0.15086323574983163" DF="0" EFFECT_SIZE="1.0232558139534884" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-004.08.02" LOG_CI_END="0.8413850234841429" LOG_CI_START="-0.821416581670941" LOG_EFFECT_SIZE="0.009984220906600923" MODIFIED="2013-04-05 11:42:50 +0100" MODIFIED_BY="Laila Asmal" NO="2" P_CHI2="1.0" P_Z="0.981221893545311" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="44" WEIGHT="3.761684212578671" Z="0.023537039331646">
<NAME>dystonia</NAME>
<DICH_DATA CI_END="6.94040834790185" CI_START="0.15086323574983163" EFFECT_SIZE="1.0232558139534884" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8413850234841429" LOG_CI_START="-0.821416581670941" LOG_EFFECT_SIZE="0.009984220906600923" MODIFIED="2011-09-01 16:01:47 +0100" MODIFIED_BY="Laila Asmal" ORDER="3312" O_E="0.0" SE="0.9767378938687896" STUDY_ID="STD-Eerdekens-2007" TOTAL_1="43" TOTAL_2="44" VAR="0.9540169133192389" WEIGHT="3.761684212578671"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.142794593058714" CI_END="0.9170337740413168" CI_START="0.12498155352630756" DF="1" EFFECT_SIZE="0.3385443925333525" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" I2="0.0" ID="CMP-004.08.03" LOG_CI_END="-0.03761466911769359" LOG_CI_START="-0.9031540813351999" LOG_EFFECT_SIZE="-0.4703843752264468" MODIFIED="2013-04-05 11:42:50 +0100" MODIFIED_BY="Laila Asmal" NO="3" P_CHI2="0.705518589040899" P_Z="0.03314549438349767" STUDIES="2" TAU2="0.0" TOTAL_1="202" TOTAL_2="204" WEIGHT="12.974794578415667" Z="2.130316473913569">
<NAME>rigidity</NAME>
<DICH_DATA CI_END="0.9291966923278727" CI_START="0.10317425450950338" EFFECT_SIZE="0.3096274794388002" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.0318923448321009" LOG_CI_START="-0.9864286604547012" LOG_EFFECT_SIZE="-0.5091605026434011" MODIFIED="2011-07-07 09:55:34 +0100" MODIFIED_BY="Laila Asmal" ORDER="5243" O_E="0.0" SE="0.560699356827682" STUDY_ID="STD-Canuso-2008" TOTAL_1="159" TOTAL_2="160" VAR="0.3143837687469763" WEIGHT="10.468347856987634"/>
<DICH_DATA CI_END="5.436950497499366" CI_START="0.04814520847997375" EFFECT_SIZE="0.5116279069767442" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.735355378843032" LOG_CI_START="-1.3174469283577928" LOG_EFFECT_SIZE="-0.29104577475738025" MODIFIED="2011-09-01 16:00:30 +0100" MODIFIED_BY="Laila Asmal" ORDER="3311" O_E="0.0" SE="1.205826236785068" STUDY_ID="STD-Eerdekens-2007" TOTAL_1="43" TOTAL_2="44" VAR="1.4540169133192389" WEIGHT="2.5064467214280324"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7973432410646095" CI_START="0.16793259996578888" DF="0" EFFECT_SIZE="0.3659233847913093" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="22" I2="0.0" ID="CMP-004.08.04" LOG_CI_END="-0.09835468285694172" LOG_CI_START="-0.7748649881326369" LOG_EFFECT_SIZE="-0.4366098354947894" MODIFIED="2013-04-05 11:42:49 +0100" MODIFIED_BY="Laila Asmal" NO="4" P_CHI2="1.0" P_Z="0.011410672772240952" STUDIES="1" TAU2="0.0" TOTAL_1="159" TOTAL_2="160" WEIGHT="18.565321067649705" Z="2.529864057331719">
<NAME>tremor</NAME>
<DICH_DATA CI_END="0.7973432410646095" CI_START="0.16793259996578888" EFFECT_SIZE="0.3659233847913093" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="22" LOG_CI_END="-0.09835468285694172" LOG_CI_START="-0.7748649881326369" LOG_EFFECT_SIZE="-0.4366098354947894" MODIFIED="2011-07-07 09:56:32 +0100" MODIFIED_BY="Laila Asmal" ORDER="5244" O_E="0.0" SE="0.3973855020989629" STUDY_ID="STD-Canuso-2008" TOTAL_1="159" TOTAL_2="160" VAR="0.15791523727844484" WEIGHT="18.565321067649705"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9101610698993121" CI_START="0.45276716303011033" DF="0" EFFECT_SIZE="0.6419431793537194" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="58" I2="0.0" ID="CMP-004.08.05" LOG_CI_END="-0.04088174440585724" LOG_CI_START="-0.34412507791508073" LOG_EFFECT_SIZE="-0.19250341116046898" MODIFIED="2013-04-05 11:43:07 +0100" MODIFIED_BY="Laila Asmal" NO="5" P_CHI2="1.0" P_Z="0.012830885343765289" STUDIES="1" TAU2="0.0" TOTAL_1="159" TOTAL_2="160" WEIGHT="49.346558077245284" Z="2.488429001286844">
<NAME>use of antiparkinson medication</NAME>
<DICH_DATA CI_END="0.9101610698993121" CI_START="0.45276716303011033" EFFECT_SIZE="0.6419431793537194" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="58" LOG_CI_END="-0.04088174440585724" LOG_CI_START="-0.34412507791508073" LOG_EFFECT_SIZE="-0.19250341116046898" MODIFIED="2011-07-07 09:57:25 +0100" MODIFIED_BY="Laila Asmal" ORDER="5245" O_E="0.0" SE="0.17812663518202781" STUDY_ID="STD-Canuso-2008" TOTAL_1="159" TOTAL_2="160" VAR="0.03172909816127123" WEIGHT="49.346558077245284"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="10.125" CI_END="1.3319837930430245" CI_START="-0.43198379304302437" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.45000000000000007" ESTIMABLE="YES" I2="90.12345679012346" I2_Q="90.12345679012346" ID="CMP-004.09" LOG_CI_END="0.12449894057391898" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.34678748622465627" MODIFIED="2013-04-05 11:43:23 +0100" MODIFIED_BY="Laila Asmal" NO="9" P_CHI2="0.0014627271650524687" P_Q="0.0014627271650524687" P_Z="0.31731052126128756" Q="10.125" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.365" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="1.0000000000000002">
<NAME>Adverse effects: 3b. Extrapyramidal effects - scale measured</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.39199279690801087" CI_START="-0.39199279690801087" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-004.09.01" LOG_CI_END="-0.4067219133158824" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-04-05 11:43:23 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="50.0" Z="0.0">
<NAME>abnormal involuntary movement: AIMS (high=poor)</NAME>
<IV_DATA CI_END="0.39199279690801087" CI_START="-0.39199279690801087" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-07-07 10:04:01 +0100" MODIFIED_BY="Laila Asmal" ORDER="5247" SE="0.2" STUDY_ID="STD-Canuso-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="50.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="1.291992796908011" CI_START="0.5080072030919891" DF="0" EFFECT_SIZE="0.9" ESTIMABLE="YES" I2="0.0" ID="CMP-004.09.02" LOG_CI_END="0.11126009239604377" LOG_CI_START="-0.29413012976150316" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2013-04-05 11:43:23 +0100" MODIFIED_BY="Laila Asmal" NO="2" P_CHI2="1.0" P_Z="6.79534624929015E-6" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="50.0" Z="4.5">
<NAME>extrapyramidal symptoms: Simpson-Angus Scale (high=poor)</NAME>
<IV_DATA CI_END="1.291992796908011" CI_START="0.5080072030919891" EFFECT_SIZE="0.9" ESTIMABLE="YES" ESTIMATE="0.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-07-07 10:03:41 +0100" MODIFIED_BY="Laila Asmal" ORDER="5246" SE="0.2" STUDY_ID="STD-Canuso-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="50.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.15890741920539" CI_START="0.00973927110830477" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.20125786163522014" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-004.10" LOG_CI_END="0.6189792527102689" LOG_CI_START="-2.01147354471136" LOG_EFFECT_SIZE="-0.6962471460005455" METHOD="MH" MODIFIED="2013-04-05 11:43:36 +0100" MODIFIED_BY="Laila Asmal" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.299477432242641" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="158" TOTAL_2="159" WEIGHT="100.0" Z="1.0375546992042364">
<NAME>Adverse effects: 4a. Prolactin associated effects</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.15890741920539" CI_START="0.00973927110830477" DF="0" EFFECT_SIZE="0.20125786163522014" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-004.10.01" LOG_CI_END="0.6189792527102689" LOG_CI_START="-2.01147354471136" LOG_EFFECT_SIZE="-0.6962471460005455" MODIFIED="2013-04-05 11:43:36 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="1.0" P_Z="0.299477432242641" STUDIES="1" TAU2="0.0" TOTAL_1="158" TOTAL_2="159" WEIGHT="100.0" Z="1.0375546992042364">
<NAME>sexual dysfunction</NAME>
<DICH_DATA CI_END="4.15890741920539" CI_START="0.00973927110830477" EFFECT_SIZE="0.20125786163522014" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6189792527102689" LOG_CI_START="-2.01147354471136" LOG_EFFECT_SIZE="-0.6962471460005455" MODIFIED="2011-09-01 16:26:03 +0100" MODIFIED_BY="Laila Asmal" ORDER="3877" O_E="0.0" SE="1.5451409941568113" STUDY_ID="STD-Canuso-2008" TOTAL_1="158" TOTAL_2="159" VAR="2.387460691823899" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-40.803044720221095" CI_START="-57.7969552797789" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-49.3" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.11" MODIFIED="2011-09-01 16:25:04 +0100" MODIFIED_BY="Laila Asmal" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="5.774079733622321E-30" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="158" TOTAL_2="159" UNITS="" WEIGHT="100.0" Z="11.371864539263404">
<NAME>Adverse effects: 4b. Prolactin - change from baseline in ng/ml</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-40.803044720221095" CI_START="-57.7969552797789" EFFECT_SIZE="-49.3" ESTIMABLE="YES" MEAN_1="-10.9" MEAN_2="38.4" MODIFIED="2011-07-07 10:36:24 +0100" MODIFIED_BY="Laila Asmal" ORDER="6137" SD_1="33.9" SD_2="42.8" SE="4.335260926630184" STUDY_ID="STD-Canuso-2008" TOTAL_1="158" TOTAL_2="159" WEIGHT="100.0"/>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="3.081487911019577E-31" CI_END="0.5959963984540055" CI_START="0.20400360154599465" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.4000000000000001" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-004.12" LOG_CI_END="-0.22475636464949117" LOG_CI_START="-0.6903621653302539" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.39794000867203755" MODIFIED="2011-09-01 16:24:59 +0100" MODIFIED_BY="Laila Asmal" NO="12" P_CHI2="0.0" P_Q="1.0" P_Z="6.334248366713427E-5" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.00000000000001" Z="4.000000000000001">
<NAME>Adverse effects: 5a. Metabolic - weight gain - change from baseline in kg</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="0.5959963984540054" CI_START="0.2040036015459946" EFFECT_SIZE="0.4" ESTIMABLE="YES" ESTIMATE="0.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-07-07 10:10:12 +0100" MODIFIED_BY="Laila Asmal" ORDER="5249" SE="0.1" STUDY_ID="STD-Canuso-2008" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.00000000000001"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="12.776789066315406" CI_START="0.4953406948010079" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.5157232704402515" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-004.13" LOG_CI_END="1.1064217250280954" LOG_CI_START="-0.30509599101307366" LOG_EFFECT_SIZE="0.4006628670075109" METHOD="MH" MODIFIED="2011-09-01 16:24:56 +0100" MODIFIED_BY="Laila Asmal" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.2658452831813133" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="159" TOTAL_2="160" WEIGHT="100.0" Z="1.1126814496947892">
<NAME>Adverse effects: 5b. Metabolic - weight gain of 7% or more of total body weight</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="12.776789066315406" CI_START="0.4953406948010079" EFFECT_SIZE="2.5157232704402515" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.1064217250280954" LOG_CI_START="-0.30509599101307366" LOG_EFFECT_SIZE="0.4006628670075109" MODIFIED="2011-07-07 10:27:21 +0100" MODIFIED_BY="Laila Asmal" ORDER="5250" O_E="0.0" SE="0.829132493527964" STUDY_ID="STD-Canuso-2008" TOTAL_1="159" TOTAL_2="160" VAR="0.6874606918238994" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2013-10-22 15:21:10 +0100" MODIFIED_BY="Laila Asmal" NO="5">
<NAME>QUETIAPINE versus RISPERIDONE</NAME>
<DICH_OUTCOME CHI2="41.819776330115765" CI_END="1.2044012025081554" CI_START="1.0275996116079842" CI_STUDY="95" CI_TOTAL="95" DF="28" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1124936889338157" ESTIMABLE="YES" EVENTS_1="1113" EVENTS_2="975" I2="33.046031191141736" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.08077118045280708" LOG_CI_START="0.011823931448199996" LOG_EFFECT_SIZE="0.04629755595050353" METHOD="MH" MODIFIED="2013-10-22 15:07:00 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.04508328578636123" P_Q="0.3815142648105334" P_Z="0.008483341594947033" Q="1.927214491796225" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.013895049531121292" TOTALS="SUB" TOTAL_1="3486" TOTAL_2="3488" WEIGHT="300.0" Z="2.63220196730842">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="15.420948140346397" CI_END="1.188883432079342" CI_START="1.0007812881893434" DF="12" EFFECT_SIZE="1.0907851725538498" ESTIMABLE="YES" EVENTS_1="758" EVENTS_2="683" I2="22.183773067727554" ID="CMP-005.01.01" LOG_CI_END="0.07513927489920971" LOG_CI_START="3.391766692914892E-4" LOG_EFFECT_SIZE="0.03773922578425063" MODIFIED="2011-08-25 08:51:07 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.21921922237145697" P_Z="0.04795819557776269" STUDIES="13" TAU2="0.004516890829509899" TOTAL_1="1404" TOTAL_2="1380" WEIGHT="100.0" Z="1.9777386685829597">
<NAME>any reason</NAME>
<DICH_DATA CI_END="1.5844909709257873" CI_START="0.9447982026547019" EFFECT_SIZE="1.223529411764706" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="68" LOG_CI_END="0.19988976874671704" LOG_CI_START="-0.024660941577741756" LOG_EFFECT_SIZE="0.08761441358448765" MODIFIED="2011-07-07 08:40:59 +0100" MODIFIED_BY="Laila Asmal" ORDER="4296" O_E="0.0" SE="0.13190219878852993" STUDY_ID="STD-Astrazeneca-1998" TOTAL_1="200" TOTAL_2="208" VAR="0.017398190045248868" WEIGHT="8.809199849903466"/>
<DICH_DATA CI_END="7.545522164113119" CI_START="0.014725436980300866" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8776892991343043" LOG_CI_START="-1.8319318085736291" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="1297" O_E="0.0" SE="1.5916448515084427" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="14" VAR="2.5333333333333328" WEIGHT="0.07607002387866678"/>
<DICH_DATA CI_END="3.889157108764376" CI_START="0.4715076582991829" EFFECT_SIZE="1.3541666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5898554875267985" LOG_CI_START="-0.32651124899226175" LOG_EFFECT_SIZE="0.13167211926726838" ORDER="1298" O_E="0.0" SE="0.5382783571197989" STUDY_ID="STD-Conley-2005" TOTAL_1="12" TOTAL_2="13" VAR="0.28974358974358977" WEIGHT="0.6560661043459047"/>
<DICH_DATA CI_END="5.1801150354072085" CI_START="0.9343421848583578" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.714339404279566" LOG_CI_START="-0.029494042635153428" LOG_EFFECT_SIZE="0.3424226808222063" MODIFIED="2011-08-25 08:51:07 +0100" MODIFIED_BY="Laila Asmal" ORDER="516" O_E="0.0" SE="0.4369314487526515" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="20" VAR="0.19090909090909092" WEIGHT="0.9878641797525887"/>
<DICH_DATA CI_END="1.0805016937608911" CI_START="0.907651440715238" EFFECT_SIZE="0.9903125360396725" ESTIMABLE="YES" EVENTS_1="277" EVENTS_2="253" LOG_CI_END="0.03362545200633291" LOG_CI_START="-0.04208089865566188" LOG_EFFECT_SIZE="-0.0042277233246644855" ORDER="1299" O_E="0.0" SE="0.044470285131335434" STUDY_ID="STD-Lieberman-2005" TOTAL_1="377" TOTAL_2="341" VAR="0.0019776062596622733" WEIGHT="29.725831654372975"/>
<DICH_DATA CI_END="1.6325898894569715" CI_START="0.8179081902923311" EFFECT_SIZE="1.1555555555555554" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.2128771026089221" LOG_CI_START="-0.08729544289001123" LOG_EFFECT_SIZE="0.06279082985945544" ORDER="1301" O_E="0.0" SE="0.17632283910413754" STUDY_ID="STD-McEvoy-2006" TOTAL_1="15" TOTAL_2="16" VAR="0.031089743589743576" WEIGHT="5.421863939158416"/>
<DICH_DATA CI_END="1.1562996657274889" CI_START="0.8519680042773983" EFFECT_SIZE="0.9925373134328358" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="95" LOG_CI_END="0.06307040009359766" LOG_CI_START="-0.0695767148890413" LOG_EFFECT_SIZE="-0.0032531573977218464" ORDER="1300" O_E="0.0" SE="0.07791757195461102" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.0060711480193019855" WEIGHT="18.23324696000813"/>
<DICH_DATA CI_END="3.12625289052724" CI_START="0.9042238766789102" EFFECT_SIZE="1.6813186813186813" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="14" LOG_CI_END="0.4950241062865637" LOG_CI_START="-0.04372402929355322" LOG_EFFECT_SIZE="0.2256500384965052" ORDER="1302" O_E="0.0" SE="0.3164633216860421" STUDY_ID="STD-Potkin-2006" TOTAL_1="156" TOTAL_2="153" VAR="0.10014903397256336" WEIGHT="1.8444811672721513"/>
<DICH_DATA CI_END="1.7756422569866896" CI_START="0.4561729688583729" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.24935547187809134" LOG_CI_START="-0.3408704529994415" LOG_EFFECT_SIZE="-0.045757490560675115" ORDER="1306" O_E="0.0" SE="0.346701629938511" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" VAR="0.12020202020202021" WEIGHT="1.5479154328387403"/>
<DICH_DATA CI_END="2.635455407617342" CI_START="0.24284227999084612" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.42085567227187837" LOG_CI_START="-0.6146756982879912" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="1303" O_E="0.0" SE="0.608276253029822" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" VAR="0.37000000000000005" WEIGHT="0.5154756217401973"/>
<DICH_DATA CI_END="1.6062638100715363" CI_START="1.06616597398371" EFFECT_SIZE="1.308641975308642" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="45" LOG_CI_END="0.2058168745972873" LOG_CI_START="0.027824818174953685" LOG_EFFECT_SIZE="0.1168208463861205" ORDER="1304" O_E="0.0" SE="0.10455341501736781" STUDY_ID="STD-Stroup-2006" TOTAL_1="63" TOTAL_2="70" VAR="0.010931416591793952" WEIGHT="12.496794754765007"/>
<DICH_DATA CI_END="3.2768212309952007" CI_START="0.197058977373695" EFFECT_SIZE="0.8035714285714286" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5154527488251325" LOG_CI_START="-0.705403775286846" LOG_EFFECT_SIZE="-0.09497551323085672" MODIFIED="2011-08-04 08:05:50 +0100" MODIFIED_BY="Laila Asmal" ORDER="3269" O_E="0.0" SE="0.7171371656006361" STUDY_ID="STD-Wei-2006a" TOTAL_1="28" TOTAL_2="30" VAR="0.5142857142857142" WEIGHT="0.3721151845597819"/>
<DICH_DATA CI_END="1.262514860779994" CI_START="0.9445444889775968" EFFECT_SIZE="1.0920171491336852" ESTIMABLE="YES" EVENTS_1="184" EVENTS_2="167" LOG_CI_END="0.10123649880397743" LOG_CI_START="-0.024777581561690118" LOG_EFFECT_SIZE="0.03822945862114365" ORDER="1305" O_E="0.0" SE="0.07402129458655114" STUDY_ID="STD-Zhong-2006" TOTAL_1="338" TOTAL_2="335" VAR="0.005479152052268985" WEIGHT="19.31307512740397"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.685065188832137" CI_END="1.566180939845081" CI_START="0.8027888645855603" DF="7" EFFECT_SIZE="1.1212995221767368" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="107" I2="27.72376991254834" ID="CMP-005.01.02" LOG_CI_END="0.19484193437383054" LOG_CI_START="-0.09539866020371612" LOG_EFFECT_SIZE="0.04972163708505719" MODIFIED="2011-08-25 08:52:59 +0100" MODIFIED_BY="Laila Asmal" NO="2" P_CHI2="0.20713408715862103" P_Z="0.5018830261794063" STUDIES="9" TAU2="0.058123266920825985" TOTAL_1="1141" TOTAL_2="1158" WEIGHT="100.00000000000001" Z="0.671529894575418">
<NAME>due to adverse events</NAME>
<DICH_DATA CI_END="1.569026411597452" CI_START="0.5338285154468717" EFFECT_SIZE="0.9152" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="25" LOG_CI_END="0.19563025417615892" LOG_CI_START="-0.27259823127826094" LOG_EFFECT_SIZE="-0.038483988551051014" MODIFIED="2011-07-07 08:41:42 +0100" MODIFIED_BY="Laila Asmal" ORDER="4297" O_E="0.0" SE="0.27503973012430977" STUDY_ID="STD-Astrazeneca-1998" TOTAL_1="200" TOTAL_2="208" VAR="0.07564685314685314" WEIGHT="21.728632629622126"/>
<DICH_DATA CI_END="101.95877526540367" CI_START="0.2843706465163365" EFFECT_SIZE="5.384615384615385" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.008424610058592" LOG_CI_START="-0.5461152346437514" LOG_EFFECT_SIZE="0.7311546877074201" ORDER="1307" O_E="0.0" SE="1.5005493499543263" STUDY_ID="STD-Conley-2005" TOTAL_1="12" TOTAL_2="13" VAR="2.251648351648351" WEIGHT="1.258410906257306"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-25 08:52:59 +0100" MODIFIED_BY="Laila Asmal" ORDER="517" O_E="0.0" SE="0.0" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.1990182176158704" CI_START="0.9670623042133912" EFFECT_SIZE="1.4582824227613895" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="34" LOG_CI_END="0.3422288272585955" LOG_CI_START="-0.014545545043760119" LOG_EFFECT_SIZE="0.16384164110741767" ORDER="1308" O_E="0.0" SE="0.20957103235202923" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="341" VAR="0.04392001760109528" WEIGHT="28.484400608906586"/>
<DICH_DATA CI_END="132.95463996948232" CI_START="0.41605472560188184" EFFECT_SIZE="7.4375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.123703498327829" LOG_CI_START="-0.3808495408546176" LOG_EFFECT_SIZE="0.871426978736606" ORDER="1310" O_E="0.0" SE="1.4711868529532615" STUDY_ID="STD-McEvoy-2006" TOTAL_1="15" TOTAL_2="16" VAR="2.164390756302521" WEIGHT="1.3078170780472709"/>
<DICH_DATA CI_END="2.060360755549452" CI_START="0.4781348683249207" EFFECT_SIZE="0.9925373134328358" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.31394326912028875" LOG_CI_START="-0.3204495839157324" LOG_EFFECT_SIZE="-0.0032531573977218464" ORDER="1309" O_E="0.0" SE="0.3726455021686274" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.13886467028650848" WEIGHT="14.755430393241456"/>
<DICH_DATA CI_END="2.612650889751295" CI_START="0.007811285979830553" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.41708138187280075" LOG_CI_START="-2.107277461901315" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="1313" O_E="0.0" SE="1.4828208806107213" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" VAR="2.1987577639751548" WEIGHT="1.2879020896449767"/>
<DICH_DATA CI_END="4.228037748391886" CI_START="0.7210500566865087" EFFECT_SIZE="1.746031746031746" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.6261388560821988" LOG_CI_START="-0.14203458467291208" LOG_EFFECT_SIZE="0.24205213570464335" ORDER="1311" O_E="0.0" SE="0.4512288816194101" STUDY_ID="STD-Stroup-2006" TOTAL_1="63" TOTAL_2="70" VAR="0.2036075036075036" WEIGHT="11.105464557735022"/>
<DICH_DATA CI_END="1.3414033255144364" CI_START="0.4229840774794441" EFFECT_SIZE="0.7532544378698225" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="25" LOG_CI_END="0.12755937867883801" LOG_CI_START="-0.37367598059887425" LOG_EFFECT_SIZE="-0.12305830096001814" ORDER="1312" O_E="0.0" SE="0.2944281311947721" STUDY_ID="STD-Zhong-2006" TOTAL_1="338" TOTAL_2="335" VAR="0.08668792443884595" WEIGHT="20.071941736545266"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.955912527264102" CI_END="1.7144409545806432" CI_START="1.0213370957057593" DF="7" EFFECT_SIZE="1.3232619337494764" ESTIMABLE="YES" EVENTS_1="236" EVENTS_2="185" I2="36.10755852075033" ID="CMP-005.01.03" LOG_CI_END="0.23412253258810034" LOG_CI_START="0.00916910608546052" LOG_EFFECT_SIZE="0.12164581933678045" MODIFIED="2011-08-25 08:54:46 +0100" MODIFIED_BY="Laila Asmal" NO="3" P_CHI2="0.14055386526101732" P_Z="0.034027950241589076" STUDIES="8" TAU2="0.04281711696477075" TOTAL_1="941" TOTAL_2="950" WEIGHT="100.0" Z="2.119740325601646">
<NAME>due to inefficacy</NAME>
<DICH_DATA CI_END="4.370171431963174" CI_START="0.2685503599532479" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6404984736970393" LOG_CI_START="-0.5709742611786154" LOG_EFFECT_SIZE="0.03476210625921191" ORDER="1314" O_E="0.0" SE="0.7116250813527137" STUDY_ID="STD-Conley-2005" TOTAL_1="12" TOTAL_2="13" VAR="0.5064102564102564" WEIGHT="3.1791297655073656"/>
<DICH_DATA CI_END="7.196537843202885" CI_START="1.0508525300318912" EFFECT_SIZE="2.75" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.8571236134848499" LOG_CI_START="0.021541774175675394" LOG_EFFECT_SIZE="0.43933269383026263" MODIFIED="2011-08-25 08:54:46 +0100" MODIFIED_BY="Laila Asmal" ORDER="518" O_E="0.0" SE="0.49082490860702144" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="20" VAR="0.24090909090909096" WEIGHT="6.154049369680497"/>
<DICH_DATA CI_END="1.3103918169871267" CI_START="0.7986208675712259" EFFECT_SIZE="1.0229888805556462" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="91" LOG_CI_END="0.11740117238304615" LOG_CI_START="-0.09765934609180457" LOG_EFFECT_SIZE="0.009870913145620785" ORDER="1315" O_E="0.0" SE="0.1263276131188629" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="341" VAR="0.0159586658363091" WEIGHT="29.707219666258478"/>
<DICH_DATA CI_END="2.58608316478295" CI_START="0.4399617898109134" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.412642487066249" LOG_CI_START="-0.3565850398657619" LOG_EFFECT_SIZE="0.028028723600243534" ORDER="1317" O_E="0.0" SE="0.45184805705753195" STUDY_ID="STD-McEvoy-2006" TOTAL_1="15" TOTAL_2="16" VAR="0.20416666666666666" WEIGHT="7.069553575766535"/>
<DICH_DATA CI_END="2.828571062683449" CI_START="0.6989754812824222" EFFECT_SIZE="1.4060945273631842" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="12" LOG_CI_END="0.4515670940693962" LOG_CI_START="-0.1555380582035417" LOG_EFFECT_SIZE="0.1480145179329273" ORDER="1316" O_E="0.0" SE="0.35661657166409505" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.12717537918545266" WEIGHT="10.27142450561446"/>
<DICH_DATA CI_END="2.2096718225256033" CI_START="0.16292012068494785" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.34432777764458977" LOG_CI_START="-0.7880252768773026" LOG_EFFECT_SIZE="-0.2218487496163564" ORDER="1320" O_E="0.0" SE="0.6651497894641796" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" VAR="0.4424242424242424" WEIGHT="3.598343498432444"/>
<DICH_DATA CI_END="2.2881253835699598" CI_START="0.8060008754680514" EFFECT_SIZE="1.3580246913580247" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" LOG_CI_END="0.35947981902857945" LOG_CI_START="-0.09366448646942879" LOG_EFFECT_SIZE="0.13290766627957531" ORDER="1318" O_E="0.0" SE="0.26617920815001844" STUDY_ID="STD-Stroup-2006" TOTAL_1="63" TOTAL_2="70" VAR="0.07085137085137085" WEIGHT="15.361030346002588"/>
<DICH_DATA CI_END="2.4524122272090603" CI_START="1.272842834877101" EFFECT_SIZE="1.766786724980705" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="46" LOG_CI_END="0.3895934727610954" LOG_CI_START="0.10477478216157089" LOG_EFFECT_SIZE="0.24718412746133314" ORDER="1319" O_E="0.0" SE="0.16730390873341736" STUDY_ID="STD-Zhong-2006" TOTAL_1="338" TOTAL_2="335" VAR="0.02799059787747964" WEIGHT="24.659249272737632"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.909662807452186" CI_END="1.2172110046681768" CI_START="0.947922795612267" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0741610951785" ESTIMABLE="YES" EVENTS_1="416" EVENTS_2="384" I2="56.58254123827214" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.08536587011158124" LOG_CI_START="-0.023227032709350538" LOG_EFFECT_SIZE="0.03106941870111535" METHOD="MH" MODIFIED="2013-10-22 15:07:00 +0100" MODIFIED_BY="Laila Asmal" NO="2" P_CHI2="0.07483361777350983" P_Q="1.0" P_Z="0.2620635811216847" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.008679213620011152" TOTALS="YES" TOTAL_1="640" TOTAL_2="634" WEIGHT="100.0" Z="1.1215270997073585">
<NAME>Global state: 1a. No clinically significant response (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1598200223752566" CI_START="0.8622027389663848" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.064390601853161" LOG_CI_START="-0.06439060185316105" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-12-11 04:25:40 +0000" MODIFIED_BY="[Empty name]" ORDER="1321" O_E="0.0" SE="0.07564671653433303" STUDY_ID="STD-Conley-2005" TOTAL_1="12" TOTAL_2="13" VAR="0.0057224257224257336" WEIGHT="28.25310335948447"/>
<DICH_DATA CI_END="1.6036965973705413" CI_START="0.8720709417175673" EFFECT_SIZE="1.182597650047634" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="47" LOG_CI_END="0.20512220774405118" LOG_CI_START="-0.05944818439852908" LOG_EFFECT_SIZE="0.07283701167276108" MODIFIED="2012-12-11 04:25:39 +0000" MODIFIED_BY="[Empty name]" ORDER="1322" O_E="0.0" SE="0.15540995798911444" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.02415225504217832" WEIGHT="12.393323280005607"/>
<DICH_DATA CI_END="1.5501358760811952" CI_START="1.0466041367173928" EFFECT_SIZE="1.2737262737262738" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="77" LOG_CI_END="0.19036976761929775" LOG_CI_START="0.019782446962013003" LOG_EFFECT_SIZE="0.10507610729065535" MODIFIED="2013-02-21 13:37:24 +0000" MODIFIED_BY="[Empty name]" ORDER="1323" O_E="0.0" SE="0.10020383657494496" STUDY_ID="STD-Potkin-2006" TOTAL_1="156" TOTAL_2="153" VAR="0.010040808864338276" WEIGHT="21.73560449663252"/>
<DICH_DATA CI_END="1.089516066925826" CI_START="0.9089333311176175" EFFECT_SIZE="0.9951369091823778" ESTIMABLE="YES" EVENTS_1="248" EVENTS_2="247" LOG_CI_END="0.0372336391034098" LOG_CI_START="-0.04146797045192777" LOG_EFFECT_SIZE="-0.0021171656742589753" MODIFIED="2012-12-11 04:25:43 +0000" MODIFIED_BY="[Empty name]" ORDER="1324" O_E="0.0" SE="0.04622971503205563" STUDY_ID="STD-Zhong-2006" TOTAL_1="338" TOTAL_2="335" VAR="0.00213718655194507" WEIGHT="37.6179688638774"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.985659612052478" CI_END="1.2450308126413014" CI_START="0.9794440870222834" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1042816975763345" ESTIMABLE="YES" EVENTS_1="391" EVENTS_2="345" I2="42.73983815216631" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.09518009970042944" LOG_CI_START="-0.009020351288216077" LOG_EFFECT_SIZE="0.043079874206106705" METHOD="MH" MODIFIED="2013-10-22 15:06:57 +0100" MODIFIED_BY="Laila Asmal" NO="3" P_CHI2="0.13664817397336504" P_Q="0.6527874822651603" P_Z="0.10509778262934896" Q="0.20240386581237205" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.007256953719743156" TOTALS="YES" TOTAL_1="675" TOTAL_2="667" WEIGHT="100.0" Z="1.620626419585955">
<NAME>Global state: 1b. No clinically important change (as measured by CGI)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.592723135924856" CI_END="1.2604069716531692" CI_START="0.9511825002173564" DF="3" EFFECT_SIZE="1.0949324429335574" ESTIMABLE="YES" EVENTS_1="335" EVENTS_2="298" I2="54.49528308488345" ID="CMP-005.03.01" LOG_CI_END="0.10051079670929895" LOG_CI_START="-0.021736148432414504" LOG_EFFECT_SIZE="0.0393873241384422" MODIFIED="2011-08-22 11:12:37 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.08607677695589855" P_Z="0.20659631371158804" STUDIES="4" TAU2="0.009999560746859551" TOTAL_1="541" TOTAL_2="534" WEIGHT="88.07228083569703" Z="1.2629802187573882">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.1598200223752566" CI_START="0.8622027389663848" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.064390601853161" LOG_CI_START="-0.06439060185316105" LOG_EFFECT_SIZE="0.0" ORDER="1325" O_E="0.0" SE="0.07564671653433303" STUDY_ID="STD-Conley-2005" TOTAL_1="12" TOTAL_2="13" VAR="0.0057224257224257336" WEIGHT="28.864262960676676"/>
<DICH_DATA CI_END="2.5696713768614976" CI_START="0.22140844307897506" EFFECT_SIZE="0.7542857142857143" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.40987758701178806" LOG_CI_START="-0.6548058219726771" LOG_EFFECT_SIZE="-0.12246411748044454" MODIFIED="2011-08-22 11:12:37 +0100" MODIFIED_BY="Laila Asmal" ORDER="507" O_E="0.0" SE="0.6254003047053471" STUDY_ID="STD-Hu-2008" TOTAL_1="35" TOTAL_2="33" VAR="0.3911255411255411" WEIGHT="0.9404033212620423"/>
<DICH_DATA CI_END="1.5479748613164461" CI_START="1.0982186050835883" EFFECT_SIZE="1.3038461538461539" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="85" LOG_CI_END="0.1897639035818876" LOG_CI_START="0.04068879688264083" LOG_EFFECT_SIZE="0.1152263502322642" ORDER="1326" O_E="0.0" SE="0.08756745560881693" STUDY_ID="STD-Potkin-2006" TOTAL_1="156" TOTAL_2="153" VAR="0.007668059281802124" WEIGHT="25.10150049761263"/>
<DICH_DATA CI_END="1.1859235603230218" CI_START="0.9244102117979786" EFFECT_SIZE="1.0470338340160825" ESTIMABLE="YES" EVENTS_1="206" EVENTS_2="195" LOG_CI_END="0.07405669712287476" LOG_CI_START="-0.034135265591223" LOG_EFFECT_SIZE="0.01996071576582589" ORDER="1327" O_E="0.0" SE="0.06355249445711386" STUDY_ID="STD-Zhong-2006" TOTAL_1="338" TOTAL_2="335" VAR="0.004038919551721488" WEIGHT="33.16611405614568"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6036965973705413" CI_START="0.8720709417175673" DF="0" EFFECT_SIZE="1.182597650047634" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="47" I2="0.0" ID="CMP-005.03.02" LOG_CI_END="0.20512220774405118" LOG_CI_START="-0.05944818439852908" LOG_EFFECT_SIZE="0.07283701167276108" MODIFIED="2009-08-10 13:38:13 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.28051296248375535" STUDIES="1" TAU2="0.0" TOTAL_1="134" TOTAL_2="133" WEIGHT="11.927719164302976" Z="1.0791677667635704">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.6036965973705413" CI_START="0.8720709417175673" EFFECT_SIZE="1.182597650047634" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="47" LOG_CI_END="0.20512220774405118" LOG_CI_START="-0.05944818439852908" LOG_EFFECT_SIZE="0.07283701167276108" ORDER="1328" O_E="0.0" SE="0.15540995798911444" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.02415225504217832" WEIGHT="11.927719164302976"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.26107227957165" CI_END="1.4183148324766273" CI_START="0.8668877813785213" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1088371379160749" ESTIMABLE="YES" EVENTS_1="348" EVENTS_2="324" I2="80.99246794454953" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.15177264469103932" LOG_CI_START="-0.06203711830507204" LOG_EFFECT_SIZE="0.04486776319298363" METHOD="MH" MODIFIED="2009-10-29 01:11:33 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.021807632426423362" P_Q="1.0" P_Z="0.41073952711487616" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.025945659344537797" TOTALS="YES" TOTAL_1="494" TOTAL_2="488" WEIGHT="100.0" Z="0.8225929320797117">
<NAME>Mental state: 1a General - no clinically important change - short term (less than 30% PANSS total score reduction)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5501358760811952" CI_START="1.0466041367173928" EFFECT_SIZE="1.2737262737262738" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="77" LOG_CI_END="0.19036976761929775" LOG_CI_START="0.019782446962013003" LOG_EFFECT_SIZE="0.10507610729065535" MODIFIED="2009-08-10 10:04:15 +0100" MODIFIED_BY="[Empty name]" ORDER="414" O_E="0.0" SE="0.10020383657494496" STUDY_ID="STD-Potkin-2006" TOTAL_1="156" TOTAL_2="153" VAR="0.010040808864338276" WEIGHT="43.831975242160325"/>
<DICH_DATA CI_END="1.089516066925826" CI_START="0.9089333311176175" EFFECT_SIZE="0.9951369091823778" ESTIMABLE="YES" EVENTS_1="248" EVENTS_2="247" LOG_CI_END="0.0372336391034098" LOG_CI_START="-0.04146797045192777" LOG_EFFECT_SIZE="-0.0021171656742589753" MODIFIED="2009-08-10 10:04:15 +0100" MODIFIED_BY="[Empty name]" ORDER="415" O_E="0.0" SE="0.04622971503205563" STUDY_ID="STD-Zhong-2006" TOTAL_1="338" TOTAL_2="335" VAR="0.00213718655194507" WEIGHT="56.168024757839675"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5169070294763494" CI_START="0.6266863964155831" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.975" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="0.18095896389635022" LOG_CI_START="-0.20294973249927653" LOG_EFFECT_SIZE="-0.010995384301463193" METHOD="MH" MODIFIED="2011-08-22 11:35:06 +0100" MODIFIED_BY="Laila Asmal" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.9106099782659796" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0" Z="0.1122691797782909">
<NAME>Mental state: 1b. General - no clinically important change - short term (less than 20% BPRS total score reduction)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5169070294763494" CI_START="0.6266863964155831" EFFECT_SIZE="0.975" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.18095896389635022" LOG_CI_START="-0.20294973249927653" LOG_EFFECT_SIZE="-0.010995384301463193" MODIFIED="2009-08-10 10:04:28 +0100" MODIFIED_BY="[Empty name]" ORDER="416" O_E="0.0" SE="0.22550986864148725" STUDY_ID="STD-Conley-2005" TOTAL_1="12" TOTAL_2="13" VAR="0.05085470085470084" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="17.733627422415942" CI_END="2.9572354786462443" CI_START="0.3895253317702829" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="MD" EFFECT_SIZE="1.6733804052082637" ESTIMABLE="YES" I2="21.053940818089494" I2_Q="0.0" ID="CMP-005.06" MODIFIED="2013-10-22 15:20:36 +0100" MODIFIED_BY="Laila Asmal" NO="6" P_CHI2="0.21918345548059992" P_Q="0.5585132273816005" P_Z="0.010630295285354724" Q="1.164954656401182" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="1.2857414052218865" TOTALS="YES" TOTAL_1="1158" TOTAL_2="1144" UNITS="" WEIGHT="99.99999999999999" Z="2.5546227097584273">
<NAME>Mental state: 1c. General -average endpoint score (PANSS total score, high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.5320505583134" CI_END="3.0117226911660664" CI_START="-0.2808827805126135" DF="7" EFFECT_SIZE="1.3654199553267263" ESTIMABLE="YES" I2="17.956416782136994" ID="CMP-005.06.01" MODIFIED="2012-07-05 10:05:09 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.2880200066569364" P_Z="0.1040419892787307" STUDIES="8" TAU2="0.997767557653849" TOTAL_1="624" TOTAL_2="608" WEIGHT="57.04898029442567" Z="1.6255661112342568">
<NAME>short term</NAME>
<CONT_DATA CI_END="3.0359104983642426" CI_START="-5.075910498364263" EFFECT_SIZE="-1.0200000000000102" ESTIMABLE="YES" MEAN_1="77.24" MEAN_2="78.26" ORDER="1331" SD_1="6.08" SD_2="4.62" SE="2.0693801163474213" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="13" WEIGHT="7.70603022457972"/>
<CONT_DATA CI_END="3.154378787990665" CI_START="-4.354378787990654" EFFECT_SIZE="-0.5999999999999943" ESTIMABLE="YES" MEAN_1="71.5" MEAN_2="72.1" MODIFIED="2011-07-07 09:04:21 +0100" MODIFIED_BY="Laila Asmal" ORDER="1743" SD_1="6.2" SD_2="6.2" SE="1.9155345800253065" STUDY_ID="STD-Byerly-2008" TOTAL_1="20" TOTAL_2="22" WEIGHT="8.65946225906458"/>
<CONT_DATA CI_END="9.93866298113007" CI_START="-7.138662981130059" EFFECT_SIZE="1.4000000000000057" ESTIMABLE="YES" MEAN_1="72.9" MEAN_2="71.5" ORDER="1332" SD_1="15.1" SD_2="12.0" SE="4.356540757116941" STUDY_ID="STD-Mori-2004" TOTAL_1="20" TOTAL_2="19" WEIGHT="2.117313505081921"/>
<CONT_DATA CI_END="12.183551222155742" CI_START="2.2164487778442563" EFFECT_SIZE="7.199999999999999" ESTIMABLE="YES" MEAN_1="-20.5" MEAN_2="-27.7" ORDER="1333" SD_1="22.31" SD_2="22.31" SE="2.5426748968171653" STUDY_ID="STD-Potkin-2006" TOTAL_1="156" TOTAL_2="152" WEIGHT="5.535815563135331"/>
<CONT_DATA CI_END="12.484125205312408" CI_START="-13.884125205312406" EFFECT_SIZE="-0.6999999999999993" ESTIMABLE="YES" MEAN_1="-30.4" MEAN_2="-29.7" ORDER="1335" SD_1="22.31" SD_2="22.31" SE="6.726718097529906" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.9220638101193739"/>
<CONT_DATA CI_END="3.8898855416291163" CI_START="-2.1498855416291214" EFFECT_SIZE="0.8699999999999974" ESTIMABLE="YES" MEAN_1="36.32" MEAN_2="35.45" MODIFIED="2012-07-05 10:05:09 +0100" MODIFIED_BY="Laila Asmal" ORDER="500" SD_1="5.88" SD_2="6.59" SE="1.5407862417113736" STUDY_ID="STD-Song-2008" TOTAL_1="34" TOTAL_2="32" WEIGHT="11.724188226869135"/>
<CONT_DATA CI_END="4.136895561427381" CI_START="-1.7368955614273895" EFFECT_SIZE="1.1999999999999957" ESTIMABLE="YES" MEAN_1="43.3" MEAN_2="42.1" MODIFIED="2011-08-04 12:55:01 +0100" MODIFIED_BY="Laila Asmal" ORDER="488" SD_1="6.0" SD_2="5.6" SE="1.4984436370225385" STUDY_ID="STD-Wang-2006" TOTAL_1="30" TOTAL_2="30" WEIGHT="12.151472582827557"/>
<CONT_DATA CI_END="6.883583336995214" CI_START="-0.8835833369952106" EFFECT_SIZE="3.0000000000000018" ESTIMABLE="YES" MEAN_1="-15.1" MEAN_2="-18.1" ORDER="1334" SD_1="25.36" SD_2="25.0" SE="1.9814564796233105" STUDY_ID="STD-Zhong-2006" TOTAL_1="328" TOTAL_2="318" WEIGHT="8.232634122748053"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.718287490843387" CI_END="5.416513502596924" CI_START="-1.5575411754557826" DF="4" EFFECT_SIZE="1.929486163570571" ESTIMABLE="YES" I2="48.17503228863382" ID="CMP-005.06.02" MODIFIED="2012-07-05 10:05:11 +0100" MODIFIED_BY="Laila Asmal" NO="2" P_CHI2="0.10246028102907068" P_Z="0.2781378156834893" STUDIES="5" TAU2="6.912257972261316" TOTAL_1="161" TOTAL_2="166" WEIGHT="26.388434917369405" Z="1.084512113496251">
<NAME>medium term</NAME>
<CONT_DATA CI_END="10.148770359426397" CI_START="-2.5087703594263973" EFFECT_SIZE="3.8200000000000003" ESTIMABLE="YES" MEAN_1="42.28" MEAN_2="38.46" MODIFIED="2011-08-22 10:17:50 +0100" MODIFIED_BY="Laila Asmal" ORDER="502" SD_1="13.66" SD_2="12.06" SE="3.2290238031652265" STUDY_ID="STD-Lu-2006" TOTAL_1="31" TOTAL_2="33" WEIGHT="3.6634670837282743"/>
<CONT_DATA CI_END="13.411717823063478" CI_START="-15.411717823063478" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-1.3" MEAN_2="-0.3" ORDER="1336" SD_1="19.23" SD_2="6.86" SE="7.353052370727864" STUDY_ID="STD-McEvoy-2006" TOTAL_1="8" TOTAL_2="6" WEIGHT="0.7751642080909115"/>
<CONT_DATA CI_END="3.8898855416291163" CI_START="-2.1498855416291214" EFFECT_SIZE="0.8699999999999974" ESTIMABLE="YES" MEAN_1="36.32" MEAN_2="35.45" MODIFIED="2011-08-04 12:22:56 +0100" MODIFIED_BY="Laila Asmal" ORDER="482" SD_1="5.88" SD_2="6.59" SE="1.5407862417113736" STUDY_ID="STD-Song-2008" TOTAL_1="34" TOTAL_2="32" WEIGHT="11.724188226869135"/>
<CONT_DATA CI_END="17.619733932408348" CI_START="2.380266067591653" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="-8.0" ORDER="1337" SD_1="22.31" SD_2="22.31" SE="3.88769079050015" STUDY_ID="STD-Stroup-2006" TOTAL_1="63" TOTAL_2="69" WEIGHT="2.616345670060297"/>
<CONT_DATA CI_END="2.4893033808681615" CI_START="-5.689303380868164" EFFECT_SIZE="-1.6000000000000014" ESTIMABLE="YES" MEAN_1="34.5" MEAN_2="36.1" MODIFIED="2012-07-05 10:05:11 +0100" MODIFIED_BY="Laila Asmal" ORDER="3266" SD_1="7.3" SD_2="7.6" SE="2.08641761436642" STUDY_ID="STD-Wei-2006a" TOTAL_1="25" TOTAL_2="26" WEIGHT="7.609269728620787"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.013193317092991451" CI_END="5.81969128852787" CI_START="0.39982423087631336" DF="1" EFFECT_SIZE="3.1097577597020916" ESTIMABLE="YES" I2="0.0" ID="CMP-005.06.03" MODIFIED="2009-08-10 13:39:02 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.908554376003934" P_Z="0.02450374730955488" STUDIES="2" TAU2="0.0" TOTAL_1="373" TOTAL_2="370" WEIGHT="16.562584788204912" Z="2.2491375322777936">
<NAME>long term</NAME>
<CONT_DATA CI_END="6.629042464533064" CI_START="-0.16904246453306282" EFFECT_SIZE="3.2300000000000004" ESTIMABLE="YES" MEAN_1="-6.08" MEAN_2="-9.31" ORDER="1338" SD_1="22.31" SD_2="22.31" SE="1.7342372060631095" STUDY_ID="STD-Lieberman-2005" TOTAL_1="329" TOTAL_2="333" WEIGHT="9.994073806019575"/>
<CONT_DATA CI_END="7.389387351577182" CI_START="-1.589387351577181" EFFECT_SIZE="2.9000000000000004" ESTIMABLE="YES" MEAN_1="-15.6" MEAN_2="-18.5" ORDER="1339" SD_1="10.68" SD_2="9.91" SE="2.2905458401220105" STUDY_ID="STD-McEvoy-2007" TOTAL_1="44" TOTAL_2="37" WEIGHT="6.568510982185338"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="11.693441935502356" CI_START="-8.333441935502357" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.6799999999999997" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.07" MODIFIED="2009-10-29 01:11:33 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.7422827235990164" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="13" UNITS="" WEIGHT="99.99999999999999" Z="0.328831935635736">
<NAME>Mental state: 1d. General - average endpoint score - short term (BPRS total score, high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="11.693441935502356" CI_START="-8.333441935502357" EFFECT_SIZE="1.6799999999999997" ESTIMABLE="YES" MEAN_1="53.83" MEAN_2="52.15" MODIFIED="2009-08-10 10:04:34 +0100" MODIFIED_BY="[Empty name]" ORDER="417" SD_1="13.14" SD_2="12.34" SE="5.108992825626955" STUDY_ID="STD-Conley-2005" TOTAL_1="12" TOTAL_2="13" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1155767747824976" CI_START="0.8966384049072353" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0001344809037116" ESTIMABLE="YES" EVENTS_1="222" EVENTS_2="220" I2="0.0" I2_Q="0.0" ID="CMP-005.08" LOG_CI_END="0.04749946410172293" LOG_CI_START="-0.04738266332647714" LOG_EFFECT_SIZE="5.840038762286609E-5" METHOD="MH" MODIFIED="2009-10-29 01:11:33 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.9980749188445334" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="338" TOTAL_2="335" WEIGHT="100.0" Z="0.002412733768234979">
<NAME>Mental state: 2a. Positive symptoms - no clinically important change - short term (less than 40% PANSS positive reduction)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1155767747824976" CI_START="0.8966384049072353" EFFECT_SIZE="1.0001344809037116" ESTIMABLE="YES" EVENTS_1="222" EVENTS_2="220" LOG_CI_END="0.04749946410172293" LOG_CI_START="-0.04738266332647714" LOG_EFFECT_SIZE="5.840038762286609E-5" MODIFIED="2009-08-10 10:04:41 +0100" MODIFIED_BY="[Empty name]" ORDER="418" O_E="0.0" SE="0.05573423132543029" STUDY_ID="STD-Zhong-2006" TOTAL_1="338" TOTAL_2="335" VAR="0.0031063045414365747" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="25.676096711440735" CI_END="1.9355333014255032" CI_START="0.5094218744964677" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="MD" EFFECT_SIZE="1.2224775879609855" ESTIMABLE="YES" I2="53.26392428389222" I2_Q="0.0" ID="CMP-005.09" MODIFIED="2013-10-22 15:20:55 +0100" MODIFIED_BY="Laila Asmal" NO="9" P_CHI2="0.011924746637938188" P_Q="0.995515949678398" P_Z="7.78851833376698E-4" Q="0.008988267693707868" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.8113513011601188" TOTALS="YES" TOTAL_1="830" TOTAL_2="809" UNITS="" WEIGHT="100.0" Z="3.3602031356981126">
<NAME>Mental state: 2b. Positive symptoms - average endpoint score - (PANSS positive subscore, high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="12.720127063618314" CI_END="2.2913009934037425" CI_START="0.2820709740231835" DF="6" EFFECT_SIZE="1.286685983713463" ESTIMABLE="YES" I2="52.83065986690494" ID="CMP-005.09.01" MODIFIED="2011-08-22 11:19:28 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.04770208425819411" P_Z="0.012063777054066317" STUDIES="7" TAU2="0.8696765290504951" TOTAL_1="625" TOTAL_2="606" WEIGHT="52.35909024768656" Z="2.5102732521071545">
<NAME>short term</NAME>
<CONT_DATA CI_END="2.8059742687024336" CI_START="-3.8059742687024336" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="15.7" MEAN_2="16.2" MODIFIED="2011-08-22 11:19:28 +0100" MODIFIED_BY="Laila Asmal" ORDER="508" SD_1="6.9" SD_2="7.0" SE="1.6867525601386233" STUDY_ID="STD-Hu-2008" TOTAL_1="35" TOTAL_2="33" WEIGHT="3.619819294014801"/>
<CONT_DATA CI_END="4.628377261857669" CI_START="0.3716227381423307" EFFECT_SIZE="2.5" ESTIMABLE="YES" MEAN_1="13.3" MEAN_2="10.8" ORDER="1343" SD_1="4.3" SD_2="2.2" SE="1.0859267204122307" STUDY_ID="STD-Mori-2004" TOTAL_1="20" TOTAL_2="19" WEIGHT="6.649199035486347"/>
<CONT_DATA CI_END="4.184853056798829" CI_START="1.415146943201169" EFFECT_SIZE="2.799999999999999" ESTIMABLE="YES" MEAN_1="-5.9" MEAN_2="-8.7" ORDER="1345" SD_1="6.24" SD_2="6.16" SE="0.7065706654420051" STUDY_ID="STD-Potkin-2006" TOTAL_1="156" TOTAL_2="152" WEIGHT="10.09910220620782"/>
<CONT_DATA CI_END="8.113945047009437" CI_START="-0.5139450470094387" EFFECT_SIZE="3.8" ESTIMABLE="YES" MEAN_1="-3.8" MEAN_2="-7.6" ORDER="1346" SD_1="7.3" SD_2="7.3" SE="2.2010328154176744" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" WEIGHT="2.340180051713049"/>
<CONT_DATA CI_END="1.4387312723381007" CI_START="-1.1187312723381004" EFFECT_SIZE="0.16000000000000014" ESTIMABLE="YES" MEAN_1="8.39" MEAN_2="8.23" MODIFIED="2011-08-04 14:01:44 +0100" MODIFIED_BY="Laila Asmal" ORDER="501" SD_1="2.76" SD_2="2.54" SE="0.6524259029372833" STUDY_ID="STD-Song-2008" TOTAL_1="34" TOTAL_2="32" WEIGHT="10.699838772980295"/>
<CONT_DATA CI_END="2.0742847354753495" CI_START="-1.8742847354753505" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="9.2" MEAN_2="9.1" MODIFIED="2011-08-04 12:56:05 +0100" MODIFIED_BY="Laila Asmal" ORDER="489" SD_1="4.0" SD_2="3.8" SE="1.0073066398404542" STUDY_ID="STD-Wang-2006" TOTAL_1="30" TOTAL_2="30" WEIGHT="7.248459213138627"/>
<CONT_DATA CI_END="2.208158543690458" CI_START="-0.008158543690458764" EFFECT_SIZE="1.0999999999999996" ESTIMABLE="YES" MEAN_1="-4.5" MEAN_2="-5.6" ORDER="1344" SD_1="7.24" SD_2="7.13" SE="0.5653974013968989" STUDY_ID="STD-Zhong-2006" TOTAL_1="328" TOTAL_2="318" WEIGHT="11.702491674145618"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="11.904032809549143" CI_END="2.6330318554582774" CI_START="-0.2075654069319559" DF="4" EFFECT_SIZE="1.2127332242631608" ESTIMABLE="YES" I2="66.39794207563598" ID="CMP-005.09.02" MODIFIED="2011-08-22 10:31:15 +0100" MODIFIED_BY="Laila Asmal" NO="2" P_CHI2="0.018079375378941442" P_Z="0.09422285704418099" STUDIES="5" TAU2="1.5655538416184027" TOTAL_1="161" TOTAL_2="166" WEIGHT="37.769901074916184" Z="1.673530756282478">
<NAME>medium term</NAME>
<CONT_DATA CI_END="5.076330146149617" CI_START="1.4036698538503836" EFFECT_SIZE="3.24" ESTIMABLE="YES" MEAN_1="13.26" MEAN_2="10.02" MODIFIED="2011-08-22 10:31:15 +0100" MODIFIED_BY="Laila Asmal" ORDER="504" SD_1="4.18" SD_2="3.22" SE="0.9369203519219508" STUDY_ID="STD-Lu-2006" TOTAL_1="31" TOTAL_2="33" WEIGHT="7.835687679890893"/>
<CONT_DATA CI_END="5.437591153162744" CI_START="-3.2375911531627435" EFFECT_SIZE="1.1" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="-0.5" ORDER="1347" SD_1="5.94" SD_2="1.71" SE="2.213097376980959" STUDY_ID="STD-McEvoy-2006" TOTAL_1="8" TOTAL_2="6" WEIGHT="2.3183510234807003"/>
<CONT_DATA CI_END="1.4387312723381007" CI_START="-1.1187312723381004" EFFECT_SIZE="0.16000000000000014" ESTIMABLE="YES" MEAN_1="8.39" MEAN_2="8.23" MODIFIED="2011-08-04 12:24:38 +0100" MODIFIED_BY="Laila Asmal" ORDER="483" SD_1="2.76" SD_2="2.54" SE="0.6524259029372833" STUDY_ID="STD-Song-2008" TOTAL_1="34" TOTAL_2="32" WEIGHT="10.699838772980295"/>
<CONT_DATA CI_END="4.993234321227295" CI_START="0.00676567877270573" EFFECT_SIZE="2.5" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="-2.3" ORDER="1348" SD_1="7.3" SD_2="7.3" SE="1.2720817019565709" STUDY_ID="STD-Stroup-2006" TOTAL_1="63" TOTAL_2="69" WEIGHT="5.447862377244465"/>
<CONT_DATA CI_END="1.0475160061487052" CI_START="-1.2475160061487045" EFFECT_SIZE="-0.09999999999999964" ESTIMABLE="YES" MEAN_1="8.3" MEAN_2="8.4" MODIFIED="2011-08-04 08:04:09 +0100" MODIFIED_BY="Laila Asmal" ORDER="3267" SD_1="1.6" SD_2="2.5" SE="0.5854781083735031" STUDY_ID="STD-Wei-2006a" TOTAL_1="25" TOTAL_2="26" WEIGHT="11.468161221319825"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.726237841691966" CI_START="-0.12623784169196628" DF="0" EFFECT_SIZE="1.2999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-005.09.03" MODIFIED="2009-08-10 13:39:24 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.07402068788955288" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="37" WEIGHT="9.871008677397262" Z="1.7864854692674523">
<NAME>long term</NAME>
<CONT_DATA CI_END="2.726237841691966" CI_START="-0.12623784169196628" EFFECT_SIZE="1.2999999999999998" ESTIMABLE="YES" MEAN_1="-5.3" MEAN_2="-6.6" ORDER="1349" SD_1="3.38" SD_2="3.16" SE="0.7276857396064152" STUDY_ID="STD-McEvoy-2007" TOTAL_1="44" TOTAL_2="37" WEIGHT="9.871008677397262"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.0166005639148614" CI_START="0.18339943608513887" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.1" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.10" MODIFIED="2013-10-22 14:15:05 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.018666430709810077" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="2.352126398205355">
<NAME>Mental state: 2c. Positive symptoms - average change in endpoint score - short term (BPRS positive subscore, high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.0166005639148614" CI_START="0.18339943608513887" EFFECT_SIZE="1.1" ESTIMABLE="YES" MEAN_1="-0.67" MEAN_2="-1.77" MODIFIED="2009-08-10 10:04:54 +0100" MODIFIED_BY="[Empty name]" ORDER="419" SD_1="1.02" SD_2="1.31" SE="0.46766194233408853" STUDY_ID="STD-Conley-2005" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0426137135685798" CI_START="0.9294456289571976" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.984404773844148" ESTIMABLE="YES" EVENTS_1="293" EVENTS_2="295" I2="0.0" I2_Q="0.0" ID="CMP-005.11" LOG_CI_END="0.01812343293321511" LOG_CI_START="-0.03177601066294122" LOG_EFFECT_SIZE="-0.006826288864863029" METHOD="MH" MODIFIED="2012-07-05 10:10:06 +0100" MODIFIED_BY="Laila Asmal" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.5917860052132573" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="338" TOTAL_2="335" WEIGHT="100.0" Z="0.5362496797150228">
<NAME>Mental state: 3a. Negative symptoms - no clinically important change - short term (less than 40% PANSS negative reduction)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0426137135685798" CI_START="0.9294456289571976" EFFECT_SIZE="0.984404773844148" ESTIMABLE="YES" EVENTS_1="293" EVENTS_2="295" LOG_CI_END="0.01812343293321511" LOG_CI_START="-0.03177601066294122" LOG_EFFECT_SIZE="-0.006826288864863029" MODIFIED="2009-08-10 10:05:01 +0100" MODIFIED_BY="[Empty name]" ORDER="420" O_E="0.0" SE="0.029311180174611706" STUDY_ID="STD-Zhong-2006" TOTAL_1="338" TOTAL_2="335" VAR="8.591452832285504E-4" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="12.818860834146259" CI_END="1.2593559646002168" CI_START="0.133978179197057" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="MD" EFFECT_SIZE="0.696667071898637" ESTIMABLE="YES" I2="14.188942821668409" I2_Q="0.0" ID="CMP-005.12" MODIFIED="2013-10-22 15:21:10 +0100" MODIFIED_BY="Laila Asmal" NO="12" P_CHI2="0.30532948390523085" P_Q="0.8030147974238505" P_Z="0.01523944427780541" Q="0.4387645947119534" RANDOM="YES" SCALE="0.67" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.1357705357726432" TOTALS="YES" TOTAL_1="761" TOTAL_2="753" UNITS="" WEIGHT="100.0" Z="2.4266382149122365">
<NAME>Mental state: 3b. Negative symptoms -average endpoint score - (PANSS negative subscore, high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.947987942714677" CI_END="1.3425856080877336" CI_START="-0.24959237174363424" DF="5" EFFECT_SIZE="0.5464966181720498" ESTIMABLE="YES" I2="15.937960060524485" ID="CMP-005.12.01" MODIFIED="2012-04-26 09:16:25 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.31131312857297455" P_Z="0.1784735695132862" STUDIES="6" TAU2="0.16204456124612088" TOTAL_1="556" TOTAL_2="550" WEIGHT="52.13774452617028" Z="1.3454697940284288">
<NAME>short term</NAME>
<CONT_DATA CI_END="2.3986639068280766" CI_START="-3.798663906828075" EFFECT_SIZE="-0.6999999999999993" ESTIMABLE="YES" MEAN_1="13.5" MEAN_2="14.2" MODIFIED="2012-04-26 09:08:42 +0100" MODIFIED_BY="Laila Asmal" ORDER="566" SD_1="6.2" SD_2="6.8" SE="1.5809800237504064" STUDY_ID="STD-Hu-2008" TOTAL_1="35" TOTAL_2="33" WEIGHT="3.1276320377352387"/>
<CONT_DATA CI_END="1.1533942688869012" CI_START="-4.753394268886902" EFFECT_SIZE="-1.8000000000000007" ESTIMABLE="YES" MEAN_1="23.8" MEAN_2="25.6" MODIFIED="2012-04-26 09:09:28 +0100" MODIFIED_BY="Laila Asmal" ORDER="567" SD_1="4.6" SD_2="4.8" SE="1.506861499590247" STUDY_ID="STD-Mori-2004" TOTAL_1="20" TOTAL_2="19" WEIGHT="3.425092479597866"/>
<CONT_DATA CI_END="2.6089951277876717" CI_START="0.39100487221232827" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="-4.0" MODIFIED="2012-04-26 09:16:03 +0100" MODIFIED_BY="Laila Asmal" ORDER="568" SD_1="5.0" SD_2="4.93" SE="0.5658242378611463" STUDY_ID="STD-Potkin-2006" TOTAL_1="156" TOTAL_2="152" WEIGHT="18.077759966895123"/>
<CONT_DATA CI_END="2.7233670307647624" CI_START="-2.0033670307647635" EFFECT_SIZE="0.35999999999999943" ESTIMABLE="YES" MEAN_1="10.82" MEAN_2="10.46" MODIFIED="2012-04-26 09:16:23 +0100" MODIFIED_BY="Laila Asmal" ORDER="569" SD_1="4.87" SD_2="4.92" SE="1.2058216627482445" STUDY_ID="STD-Song-2008" TOTAL_1="34" TOTAL_2="32" WEIGHT="5.184471031299964"/>
<CONT_DATA CI_END="2.933460396061892" CI_START="-2.333460396061894" EFFECT_SIZE="0.29999999999999893" ESTIMABLE="YES" MEAN_1="12.1" MEAN_2="11.8" MODIFIED="2012-04-26 09:16:25 +0100" MODIFIED_BY="Laila Asmal" ORDER="570" SD_1="5.0" SD_2="5.4" SE="1.3436269323489067" STUDY_ID="STD-Wang-2006" TOTAL_1="30" TOTAL_2="30" WEIGHT="4.246114758306076"/>
<CONT_DATA CI_END="1.5090425542006587" CI_START="-0.7090425542006598" EFFECT_SIZE="0.39999999999999947" ESTIMABLE="YES" MEAN_1="-3.7" MEAN_2="-4.1" MODIFIED="2012-04-26 09:14:22 +0100" MODIFIED_BY="Laila Asmal" ORDER="571" SD_1="6.71" SD_2="6.74" SE="0.5658484354552662" STUDY_ID="STD-Zhong-2006" TOTAL_1="281" TOTAL_2="284" WEIGHT="18.076674252336016"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.789793109898555" CI_END="2.3394468361146115" CI_START="-0.24464310742843898" DF="4" EFFECT_SIZE="1.0474018643430862" ESTIMABLE="YES" I2="41.088042960122486" ID="CMP-005.12.02" MODIFIED="2011-08-22 10:20:52 +0100" MODIFIED_BY="Laila Asmal" NO="2" P_CHI2="0.1474226378386705" P_Z="0.11209351408171071" STUDIES="5" TAU2="0.8479161759313989" TOTAL_1="161" TOTAL_2="166" WEIGHT="35.672665058746745" Z="1.5888533110715668">
<NAME>medium term</NAME>
<CONT_DATA CI_END="5.916216231046889" CI_START="0.9637837689531099" EFFECT_SIZE="3.4399999999999995" ESTIMABLE="YES" MEAN_1="13.26" MEAN_2="9.82" MODIFIED="2011-08-22 10:20:52 +0100" MODIFIED_BY="Laila Asmal" ORDER="503" SD_1="6.08" SD_2="3.65" SE="1.2633988433353711" STUDY_ID="STD-Lu-2006" TOTAL_1="31" TOTAL_2="33" WEIGHT="4.758892138261752"/>
<CONT_DATA CI_END="4.345849663525293" CI_START="-6.545849663525292" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="0.0" ORDER="1356" SD_1="6.22" SD_2="4.16" SE="2.7785457827192026" STUDY_ID="STD-McEvoy-2006" TOTAL_1="8" TOTAL_2="6" WEIGHT="1.0491418404134734"/>
<CONT_DATA CI_END="2.7233670307647624" CI_START="-2.0033670307647635" EFFECT_SIZE="0.35999999999999943" ESTIMABLE="YES" MEAN_1="10.82" MEAN_2="10.46" MODIFIED="2011-08-04 12:25:39 +0100" MODIFIED_BY="Laila Asmal" ORDER="484" SD_1="4.87" SD_2="4.92" SE="1.2058216627482445" STUDY_ID="STD-Song-2008" TOTAL_1="34" TOTAL_2="32" WEIGHT="5.184471031299964"/>
<CONT_DATA CI_END="3.9131723837743655" CI_START="-0.5131723837743658" EFFECT_SIZE="1.7" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="-1.5" ORDER="1357" SD_1="6.48" SD_2="6.48" SE="1.129190332695696" STUDY_ID="STD-Stroup-2006" TOTAL_1="63" TOTAL_2="69" WEIGHT="5.842010390175579"/>
<CONT_DATA CI_END="1.2766498845892627" CI_START="-0.8766498845892605" EFFECT_SIZE="0.20000000000000107" ESTIMABLE="YES" MEAN_1="8.4" MEAN_2="8.2" MODIFIED="2011-08-04 08:04:55 +0100" MODIFIED_BY="Laila Asmal" ORDER="3268" SD_1="1.7" SD_2="2.2" SE="0.5493212595138168" STUDY_ID="STD-Wei-2006a" TOTAL_1="25" TOTAL_2="26" WEIGHT="18.838149658595977"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.240796766860716" CI_START="-0.6407967668607153" DF="0" EFFECT_SIZE="0.8000000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-005.12.03" MODIFIED="2009-08-10 13:39:52 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.2764773898243499" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="37" WEIGHT="12.18959041508297" Z="1.0882667310868712">
<NAME>long term</NAME>
<CONT_DATA CI_END="2.240796766860716" CI_START="-0.6407967668607153" EFFECT_SIZE="0.8000000000000003" ESTIMABLE="YES" MEAN_1="-2.8" MEAN_2="-3.6" ORDER="1358" SD_1="3.45" SD_2="3.16" SE="0.7351138991458703" STUDY_ID="STD-McEvoy-2007" TOTAL_1="44" TOTAL_2="37" WEIGHT="12.18959041508297"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.970152903320298" CI_START="0.16984709667970188" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.57" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.13" MODIFIED="2013-10-22 14:15:23 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.005240255003992167" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="2.791881458107519">
<NAME>Mental state: 3c. Negative symptoms - average change in endpoint score - (BPRS negative subscore, high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.970152903320298" CI_START="0.16984709667970188" EFFECT_SIZE="0.57" ESTIMABLE="YES" MEAN_1="0.42" MEAN_2="-0.15" MODIFIED="2009-08-10 10:05:11 +0100" MODIFIED_BY="[Empty name]" ORDER="421" SD_1="0.51" SD_2="0.51" SE="0.2041633961014861" STUDY_ID="STD-Conley-2005" TOTAL_1="12" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5978747383193891" CI_END="-2.431314802125319" CI_START="-4.457845260549284" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.444580031337302" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.14" MODIFIED="2013-10-22 14:15:30 +0100" MODIFIED_BY="Laila Asmal" NO="14" P_CHI2="0.7416058879824892" P_Q="0.6650509594941927" P_Z="2.685342363264102E-11" Q="0.1874458719092593" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="77" UNITS="" WEIGHT="100.0" Z="6.662868327710621">
<NAME>Quality of life: General - average endpoint score - (QLS total score, low=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="12.86855860365606" CI_START="-13.86855860365606" DF="0" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-005.14.01" MODIFIED="2012-07-05 10:11:33 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="1.0" P_Z="0.9415634246598393" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="12" WEIGHT="0.5744829068899746" Z="0.07330498532594379">
<NAME>short term</NAME>
<CONT_DATA CI_END="12.86855860365606" CI_START="-13.86855860365606" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="27.9" MEAN_2="28.4" ORDER="1360" SD_1="15.93" SD_2="15.93" SE="6.820818499271183" STUDY_ID="STD-Conley-2005" TOTAL_1="10" TOTAL_2="12" WEIGHT="0.5744829068899746"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.4104288664101299" CI_END="-2.445405534318371" CI_START="-4.477782229602959" DF="1" EFFECT_SIZE="-3.461593881960665" ESTIMABLE="YES" I2="0.0" ID="CMP-005.14.02" MODIFIED="2011-08-22 10:36:33 +0100" MODIFIED_BY="Laila Asmal" NO="2" P_CHI2="0.5217519250910393" P_Z="2.4468677563132227E-11" STUDIES="2" TAU2="0.0" TOTAL_1="65" TOTAL_2="65" WEIGHT="99.42551709311003" Z="6.676517550598137">
<NAME>medium term</NAME>
<CONT_DATA CI_END="-2.2369680460524775" CI_START="-4.423031953947523" EFFECT_SIZE="-3.33" ESTIMABLE="YES" MEAN_1="12.88" MEAN_2="16.21" MODIFIED="2011-08-22 10:36:33 +0100" MODIFIED_BY="Laila Asmal" ORDER="505" SD_1="2.41" SD_2="2.02" SE="0.5576796117526747" STUDY_ID="STD-Lu-2006" TOTAL_1="31" TOTAL_2="33" WEIGHT="85.93707404132773"/>
<CONT_DATA CI_END="-1.541060173267499" CI_START="-7.058939826732495" EFFECT_SIZE="-4.299999999999997" ESTIMABLE="YES" MEAN_1="71.5" MEAN_2="75.8" MODIFIED="2011-08-04 12:29:58 +0100" MODIFIED_BY="Laila Asmal" ORDER="485" SD_1="6.07" SD_2="5.36" SE="1.4076482264442935" STUDY_ID="STD-Song-2008" TOTAL_1="34" TOTAL_2="32" WEIGHT="13.488443051782301"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.011164403749645233" CI_END="1.7874584608367192" CI_START="1.0010764501896974" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3376780520125022" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="67" I2="0.0" I2_Q="0.0" ID="CMP-005.15" LOG_CI_END="0.25223595791982334" LOG_CI_START="4.672449395712386E-4" LOG_EFFECT_SIZE="0.12635160142969723" METHOD="MH" MODIFIED="2009-11-02 14:48:17 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.9158507368442274" P_Q="0.9158516686143611" P_Z="0.04915568887459803" Q="0.011164155585859117" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="432" TOTAL_2="445" WEIGHT="100.0" Z="1.9672387824502304">
<NAME>Service use: number of participants re-hospitalised</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3784132275157375" CI_START="0.7105577703859358" DF="0" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" I2="0.0" ID="CMP-005.15.01" LOG_CI_END="0.37628731152698547" LOG_CI_START="-0.14840060691331197" LOG_EFFECT_SIZE="0.11394335230683679" MODIFIED="2009-08-10 13:40:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3946208241045215" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="104" WEIGHT="23.02509290993068" Z="0.8512674256461669">
<NAME>medium term</NAME>
<DICH_DATA CI_END="2.3784132275157375" CI_START="0.7105577703859358" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="0.37628731152698547" LOG_CI_START="-0.14840060691331197" LOG_EFFECT_SIZE="0.11394335230683679" ORDER="1361" O_E="0.0" SE="0.30820428053891485" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="104" VAR="0.09498987854251012" WEIGHT="23.02509290993068"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.76053060173349E-31" CI_END="1.8773495117538506" CI_START="0.9695747466274374" DF="0" EFFECT_SIZE="1.3491592482690407" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="51" I2="100.0" ID="CMP-005.15.02" LOG_CI_END="0.2735451340467522" LOG_CI_START="-0.013418704587834025" LOG_EFFECT_SIZE="0.1300632147294591" MODIFIED="2009-08-10 13:40:11 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.07562347465977243" STUDIES="1" TAU2="0.0" TOTAL_1="337" TOTAL_2="341" WEIGHT="76.97490709006932" Z="1.7766643894657967">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.8773495117538506" CI_START="0.9695747466274374" EFFECT_SIZE="1.3491592482690407" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="51" LOG_CI_END="0.2735451340467522" LOG_CI_START="-0.013418704587834025" LOG_EFFECT_SIZE="0.1300632147294591" ORDER="1362" O_E="0.0" SE="0.16856397930786662" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="341" VAR="0.028413815120102884" WEIGHT="76.97490709006932"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.131765187594976" CI_END="1.1299286150306904" CI_START="0.9111323833326019" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="1.014649965263203" ESTIMABLE="YES" EVENTS_1="711" EVENTS_2="713" I2="33.817806066615525" I2_Q="0.0" ID="CMP-005.16" LOG_CI_END="0.053051007131611" LOG_CI_START="-0.04041851745742619" LOG_EFFECT_SIZE="0.006316244837092435" METHOD="MH" MODIFIED="2011-08-26 07:31:02 +0100" MODIFIED_BY="Laila Asmal" NO="16" P_CHI2="0.11174796613771609" P_Q="1.0" P_Z="0.7910935230061069" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.008857710556575653" TOTALS="YES" TOTAL_1="1428" TOTAL_2="1440" WEIGHT="100.0" Z="0.26489088187124776">
<NAME>Adverse effects: 1. General - at least one adverse effect</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6440839744367703" CI_START="0.5527968513626538" EFFECT_SIZE="0.9533333333333334" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="24" LOG_CI_END="0.2159239961134717" LOG_CI_START="-0.2574344392947106" LOG_EFFECT_SIZE="-0.02075522159061942" MODIFIED="2011-07-07 08:42:42 +0100" MODIFIED_BY="Laila Asmal" ORDER="4298" O_E="0.0" SE="0.2780530881208116" STUDY_ID="STD-Astrazeneca-1998" TOTAL_1="200" TOTAL_2="208" VAR="0.07731351981351982" WEIGHT="3.4982671959601284"/>
<DICH_DATA CI_END="1.7880014673166587" CI_START="0.3348885278248358" EFFECT_SIZE="0.7738095238095238" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.2523678708621732" LOG_CI_START="-0.47509972970022535" LOG_EFFECT_SIZE="-0.11136592941902607" ORDER="1363" O_E="0.0" SE="0.42731806959305224" STUDY_ID="STD-Conley-2005" TOTAL_1="12" TOTAL_2="13" VAR="0.18260073260073262" WEIGHT="1.5744930516934548"/>
<DICH_DATA CI_END="0.8771239306491193" CI_START="0.1686523294072763" EFFECT_SIZE="0.38461538461538464" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="-0.056939039935517785" LOG_CI_START="-0.7730076560061181" LOG_EFFECT_SIZE="-0.4149733479708179" MODIFIED="2011-08-26 07:31:02 +0100" MODIFIED_BY="Laila Asmal" ORDER="524" O_E="0.0" SE="0.4206222496766867" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="20" VAR="0.17692307692307696" WEIGHT="1.6226112103881787"/>
<DICH_DATA CI_END="1.4862555641446134" CI_START="0.5257034780807934" EFFECT_SIZE="0.8839285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.17209349351255374" LOG_CI_START="-0.2792591496578172" LOG_EFFECT_SIZE="-0.05358282807263171" MODIFIED="2011-08-22 11:35:28 +0100" MODIFIED_BY="Laila Asmal" ORDER="510" O_E="0.0" SE="0.2651267768298928" STUDY_ID="STD-Hu-2008" TOTAL_1="35" TOTAL_2="33" VAR="0.07029220779220778" WEIGHT="3.8085950652640386"/>
<DICH_DATA CI_END="1.067425010831842" CI_START="0.8625434341114779" EFFECT_SIZE="0.9595313619154814" ESTIMABLE="YES" EVENTS_1="220" EVENTS_2="232" LOG_CI_END="0.02833737453933301" LOG_CI_START="-0.06421902643440175" LOG_EFFECT_SIZE="-0.017940825947534364" ORDER="1364" O_E="0.0" SE="0.05436808809354578" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="341" VAR="0.0029558890029475543" WEIGHT="25.517200487485848"/>
<DICH_DATA CI_END="2.0770677265836137" CI_START="0.6762725669484307" EFFECT_SIZE="1.1851851851851851" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.3174506577300917" LOG_CI_START="-0.1698782294082543" LOG_EFFECT_SIZE="0.07378621416091864" ORDER="1366" O_E="0.0" SE="0.2862594006219611" STUDY_ID="STD-McEvoy-2006" TOTAL_1="15" TOTAL_2="16" VAR="0.08194444444444443" WEIGHT="3.319855001633404"/>
<DICH_DATA CI_END="1.4498730962512083" CI_START="0.9248201280143754" EFFECT_SIZE="1.157960199004975" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="66" LOG_CI_END="0.16132999119377484" LOG_CI_START="-0.03394272672799222" LOG_EFFECT_SIZE="0.06369363223289133" ORDER="1365" O_E="0.0" SE="0.11470416112278908" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.013157044578882757" WEIGHT="13.693088412039295"/>
<DICH_DATA CI_END="1.235676927531698" CI_START="0.4480000816347595" EFFECT_SIZE="0.7440318302387268" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="29" LOG_CI_END="0.09190493763730402" LOG_CI_START="-0.3487219068645293" LOG_EFFECT_SIZE="-0.12840848461361265" ORDER="1367" O_E="0.0" SE="0.25882638959843407" STUDY_ID="STD-Potkin-2006" TOTAL_1="156" TOTAL_2="153" VAR="0.06699109995256039" WEIGHT="3.9743535385161812"/>
<DICH_DATA CI_END="3.862078352237709" CI_START="1.1692214885758656" EFFECT_SIZE="2.125" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="8" LOG_CI_END="0.5868210803183906" LOG_CI_START="0.06789678845427004" LOG_EFFECT_SIZE="0.32735893438633035" ORDER="1370" O_E="0.0" SE="0.3048186977576569" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" VAR="0.0929144385026738" WEIGHT="2.9620086755142685"/>
<DICH_DATA CI_END="2.237825092114092" CI_START="0.6411899172540039" EFFECT_SIZE="1.1978609625668448" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.3498261391636531" LOG_CI_START="-0.19301331556832546" LOG_EFFECT_SIZE="0.0784064117976638" MODIFIED="2011-08-04 12:32:16 +0100" MODIFIED_BY="Laila Asmal" ORDER="486" O_E="0.0" SE="0.31886658280820207" STUDY_ID="STD-Song-2008" TOTAL_1="34" TOTAL_2="32" VAR="0.10167589763177998" WEIGHT="2.727224718164814"/>
<DICH_DATA CI_END="2.0844923264635438" CI_START="0.8709082969519923" EFFECT_SIZE="1.3473684210526315" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="26" LOG_CI_END="0.3190003007188892" LOG_CI_START="-0.060027572000848" LOG_EFFECT_SIZE="0.12948636435902058" ORDER="1368" O_E="0.0" SE="0.22264284865380285" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="104" VAR="0.049569838056680166" WEIGHT="5.159381072695498"/>
<DICH_DATA CI_END="1.4546761673149986" CI_START="0.5263198897478122" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.16276632363042123" LOG_CI_START="-0.2787502175857947" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2011-08-04 13:37:26 +0100" MODIFIED_BY="Laila Asmal" ORDER="492" O_E="0.0" SE="0.25934900185253223" STUDY_ID="STD-Wang-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.06726190476190477" WEIGHT="3.960214291388329"/>
<DICH_DATA CI_END="1.086440833602869" CI_START="0.9183529274299645" EFFECT_SIZE="0.9988674186390533" ESTIMABLE="YES" EVENTS_1="258" EVENTS_2="256" LOG_CI_END="0.03600608009100832" LOG_CI_START="-0.036990385269866075" LOG_EFFECT_SIZE="-4.921525894288943E-4" ORDER="1369" O_E="0.0" SE="0.04287848509130874" STUDY_ID="STD-Zhong-2006" TOTAL_1="338" TOTAL_2="335" VAR="0.001838564483725586" WEIGHT="28.182707279256572"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.080793290670329" CI_END="3.087804837576029" CI_START="0.1721118387100811" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7290046420792489" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-005.17" LOG_CI_END="0.48964984326917743" LOG_CI_START="-0.7641892557059755" LOG_EFFECT_SIZE="-0.13726970621839904" METHOD="MH" MODIFIED="2011-08-26 07:33:37 +0100" MODIFIED_BY="Laila Asmal" NO="17" P_CHI2="0.5558082230573578" P_Q="0.46937111633811623" P_Z="0.6678127269775808" Q="0.5234562738538309" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1572" TOTAL_2="1574" WEIGHT="100.0" Z="0.4291518434484353">
<NAME>Adverse effects: 2. Death</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.17.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-26 07:33:05 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="3" TAU2="0.0" TOTAL_1="514" TOTAL_2="508" WEIGHT="0.0" Z="0.0">
<NAME>natural causes</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-26 07:33:05 +0100" MODIFIED_BY="Laila Asmal" ORDER="525" O_E="0.0" SE="0.0" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1383" O_E="0.0" SE="0.0" STUDY_ID="STD-Potkin-2006" TOTAL_1="156" TOTAL_2="153" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1384" O_E="0.0" SE="0.0" STUDY_ID="STD-Zhong-2006" TOTAL_1="338" TOTAL_2="335" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.043579919484128184" CI_END="2.949434549006252" CI_START="0.06390129652413902" DF="1" EFFECT_SIZE="0.4341344166206922" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-005.17.02" LOG_CI_END="0.4697387631697511" LOG_CI_START="-1.1944903301425864" LOG_EFFECT_SIZE="-0.36237578348641764" MODIFIED="2011-08-26 07:33:23 +0100" MODIFIED_BY="Laila Asmal" NO="2" P_CHI2="0.8346372574882591" P_Z="0.39335963476315694" STUDIES="2" TAU2="0.0" TOTAL_1="471" TOTAL_2="474" WEIGHT="56.761961819259355" Z="0.8535405219833718">
<NAME>suicide attempt</NAME>
<DICH_DATA CI_END="5.553246593656693" CI_START="0.04609374618303713" EFFECT_SIZE="0.5059347181008902" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7445469588834367" LOG_CI_START="-1.336357993969081" LOG_EFFECT_SIZE="-0.2959055175428221" ORDER="1385" O_E="0.0" SE="1.222333869951212" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="341" VAR="1.4941000896299068" WEIGHT="36.30606068393629"/>
<DICH_DATA CI_END="8.04961521537171" CI_START="0.013599546596798124" EFFECT_SIZE="0.3308641975308642" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9057751208852867" LOG_CI_START="-1.8664755705850085" LOG_EFFECT_SIZE="-0.4803502248498609" ORDER="1386" O_E="0.0" SE="1.6284337790318937" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="2.6517965726920947" WEIGHT="20.45590113532307"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.359765633147023" CI_END="18.31879980520185" CI_START="0.10914277970540248" DF="1" EFFECT_SIZE="1.4139889432405457" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="26.45791483304268" ID="CMP-005.17.03" LOG_CI_END="1.2628970165451134" LOG_CI_START="-0.9620049895729887" LOG_EFFECT_SIZE="0.15044601348606235" MODIFIED="2011-08-26 07:33:37 +0100" MODIFIED_BY="Laila Asmal" NO="3" P_CHI2="0.24357827564887735" P_Z="0.7909615063960059" STUDIES="4" TAU2="0.9051444472313062" TOTAL_1="587" TOTAL_2="592" WEIGHT="43.238038180740645" Z="0.265062251945902">
<NAME>suicide</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-26 07:33:37 +0100" MODIFIED_BY="Laila Asmal" ORDER="527" O_E="0.0" SE="0.0" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="102.40596956028946" CI_START="0.24052310111903297" EFFECT_SIZE="4.962962962962963" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0103252737445763" LOG_CI_START="-0.6188432053329354" LOG_EFFECT_SIZE="0.6957410342058203" ORDER="1387" O_E="0.0" SE="1.5443865792039984" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="2.385129906025428" WEIGHT="22.742949298041186"/>
<DICH_DATA CI_END="8.84293328858401" CI_START="0.015031325308768516" EFFECT_SIZE="0.3645833333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9465963486938471" LOG_CI_START="-1.8230027260724326" LOG_EFFECT_SIZE="-0.4382031886892928" ORDER="1388" O_E="0.0" SE="1.6268762062542406" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="104" VAR="2.6467261904761905" WEIGHT="20.495088882699456"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1389" O_E="0.0" SE="0.0" STUDY_ID="STD-Zhong-2006" TOTAL_1="338" TOTAL_2="335" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4602382216857623" CI_END="5.0352525147823375" CI_START="0.3573652256477252" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3414261631332773" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" I2="31.51802321366738" I2_Q="0.0" ID="CMP-005.18" LOG_CI_END="0.702021255033964" LOG_CI_START="-0.44688770992792803" LOG_EFFECT_SIZE="0.12756677255301796" METHOD="MH" MODIFIED="2011-08-22 11:43:56 +0100" MODIFIED_BY="Laila Asmal" NO="18" P_CHI2="0.22689252271303462" P_Q="1.0" P_Z="0.6633873342413494" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.34397041212995705" TOTALS="YES" TOTAL_1="710" TOTAL_2="709" WEIGHT="100.0" Z="0.43524123747475685">
<NAME>Adverse effects: 3a. Cardiac effects - QTc prolongation</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="32.02551843190373" CI_START="0.444135619525777" EFFECT_SIZE="3.7714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5054961688708264" LOG_CI_START="-0.35248439515967794" LOG_EFFECT_SIZE="0.5765058868555742" MODIFIED="2011-08-22 11:43:56 +0100" MODIFIED_BY="Laila Asmal" ORDER="514" O_E="0.0" SE="1.0913869804636398" STUDY_ID="STD-Hu-2008" TOTAL_1="35" TOTAL_2="33" VAR="1.1911255411255413" WEIGHT="29.669546880047093"/>
<DICH_DATA CI_END="2.553920805611268" CI_START="0.29454248791489246" EFFECT_SIZE="0.867316659601526" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.40720742612266886" LOG_CI_START="-0.5308520491415771" LOG_EFFECT_SIZE="-0.061822311509454116" ORDER="1371" O_E="0.0" SE="0.5510207792395095" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="341" VAR="0.30362389915371635" WEIGHT="70.3304531199529"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1372" O_E="0.0" SE="0.0" STUDY_ID="STD-Zhong-2006" TOTAL_1="338" TOTAL_2="335" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="9.44466404838607" CI_END="9.477035354136714" CI_START="-5.051744185947557" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="2.212645584094578" ESTIMABLE="YES" I2="78.824021799465" I2_Q="0.0" ID="CMP-005.19" MODIFIED="2009-10-29 01:11:33 +0000" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.00889444410303697" P_Q="1.0" P_Z="0.5505197946454657" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="31.07341108788215" TOTALS="YES" TOTAL_1="469" TOTAL_2="471" UNITS="" WEIGHT="100.0" Z="0.5969814110555098">
<NAME>Adverse effects: 3b. Cardiac effects - QTc abnormalities - change from baseline in ms</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="10.832370665113213" CI_START="0.5676293348867878" EFFECT_SIZE="5.7" ESTIMABLE="YES" MEAN_1="5.9" MEAN_2="0.2" ORDER="1373" SD_1="27.8" SD_2="26.6" SE="2.6186045792660972" STUDY_ID="STD-Lieberman-2005" TOTAL_1="214" TOTAL_2="218" WEIGHT="36.21708687576933"/>
<CONT_DATA CI_END="16.013687214400953" CI_START="-3.41368721440095" EFFECT_SIZE="6.300000000000001" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="-4.4" ORDER="1374" SD_1="33.3" SD_2="30.4" SE="4.956053933144321" STUDY_ID="STD-Stroup-2006" TOTAL_1="81" TOTAL_2="85" WEIGHT="24.691479844929592"/>
<CONT_DATA CI_END="0.35315820068501713" CI_START="-7.553158200685017" EFFECT_SIZE="-3.5999999999999996" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="1.3" ORDER="1375" SD_1="19.0" SD_2="18.3" SE="2.016954511341547" STUDY_ID="STD-Zhong-2006" TOTAL_1="174" TOTAL_2="168" WEIGHT="39.09143327930107"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="9.443567144407261" CI_END="1.3842549511131457" CI_START="1.0632624594549192" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2131884947662552" ESTIMABLE="YES" EVENTS_1="331" EVENTS_2="275" I2="25.87546746945521" I2_Q="0.0" ID="CMP-005.20" LOG_CI_END="0.1412160855430268" LOG_CI_START="0.02664048053801477" LOG_EFFECT_SIZE="0.08392828304052079" METHOD="MH" MODIFIED="2009-10-29 01:11:33 +0000" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.22235822275567196" P_Q="1.0" P_Z="0.0040865318295320655" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1109" TOTAL_2="1117" WEIGHT="100.0" Z="2.871403769354022">
<NAME>Adverse effects: 4. Central nervous system - sedation</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.151926612758096" CI_START="0.19633569169837414" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.33282745648428863" LOG_CI_START="-0.7070007431985774" LOG_EFFECT_SIZE="-0.18708664335714442" ORDER="1448" O_E="0.0" SE="0.6108002317263175" STUDY_ID="STD-Conley-2005" TOTAL_1="12" TOTAL_2="13" VAR="0.3730769230769231" WEIGHT="1.7537265323448172"/>
<DICH_DATA CI_END="1.3715569756633248" CI_START="0.8593440737038216" EFFECT_SIZE="1.0856515825914936" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="96" LOG_CI_END="0.13721385328377067" LOG_CI_START="-0.0658329137102448" LOG_EFFECT_SIZE="0.035690469786762914" ORDER="1449" O_E="0.0" SE="0.1192706760299913" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="341" VAR="0.01422549416065114" WEIGHT="34.867601262548874"/>
<DICH_DATA CI_END="4.046481924893648" CI_START="0.43933911253650343" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.607077604796165" LOG_CI_START="-0.3572001315795652" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="1451" O_E="0.0" SE="0.566421515598881" STUDY_ID="STD-McEvoy-2006" TOTAL_1="15" TOTAL_2="16" VAR="0.32083333333333336" WEIGHT="1.4142955906006591"/>
<DICH_DATA CI_END="1.4498730962512083" CI_START="0.9248201280143754" EFFECT_SIZE="1.157960199004975" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="66" LOG_CI_END="0.16132999119377484" LOG_CI_START="-0.03394272672799222" LOG_EFFECT_SIZE="0.06369363223289133" ORDER="1450" O_E="0.0" SE="0.11470416112278908" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.013157044578882757" WEIGHT="24.204053452024915"/>
<DICH_DATA CI_END="3.1724179106782247" CI_START="0.6822221094416135" EFFECT_SIZE="1.4711538461538463" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.5013903931305825" LOG_CI_START="-0.16607421009294557" LOG_EFFECT_SIZE="0.16765809151881847" ORDER="1452" O_E="0.0" SE="0.39207201193657265" STUDY_ID="STD-Potkin-2006" TOTAL_1="156" TOTAL_2="153" VAR="0.15372046254399196" WEIGHT="3.6890687573596486"/>
<DICH_DATA CI_END="7.5906483831072515" CI_START="1.5229265560141627" EFFECT_SIZE="3.4" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="5" LOG_CI_END="0.8802788743380111" LOG_CI_START="0.18267895974649914" LOG_EFFECT_SIZE="0.5314789170422551" ORDER="1455" O_E="0.0" SE="0.4097736430063234" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" VAR="0.1679144385026738" WEIGHT="1.826798471192518"/>
<DICH_DATA CI_END="1.7508874047666985" CI_START="0.6262546146499817" EFFECT_SIZE="1.0471395881006864" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="23" LOG_CI_END="0.24325821857871724" LOG_CI_START="-0.20324906094962542" LOG_EFFECT_SIZE="0.020004578814545912" ORDER="1453" O_E="0.0" SE="0.2622805862416286" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="104" VAR="0.06879110591925236" WEIGHT="8.02322544634302"/>
<DICH_DATA CI_END="1.7688074871724604" CI_START="1.0098753876051862" EFFECT_SIZE="1.3365160480545095" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="66" LOG_CI_END="0.24768056789652965" LOG_CI_START="0.0042677878279395115" LOG_EFFECT_SIZE="0.12597417786223458" ORDER="1454" O_E="0.0" SE="0.14298187192498374" STUDY_ID="STD-Zhong-2006" TOTAL_1="338" TOTAL_2="335" VAR="0.02044381569917245" WEIGHT="24.221230487585554"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="45.159376890527525" CI_END="0.6773612497150043" CI_START="0.47570379649990197" CI_STUDY="95" CI_TOTAL="95" DF="29" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5676471774714869" ESTIMABLE="YES" EVENTS_1="240" EVENTS_2="454" I2="35.78299348483053" I2_Q="39.85885403633773" ID="CMP-005.21" LOG_CI_END="-0.16917965197292362" LOG_CI_START="-0.32266338254608823" LOG_EFFECT_SIZE="-0.24592151725950592" METHOD="MH" MODIFIED="2013-04-05 11:49:06 +0100" MODIFIED_BY="Laila Asmal" NO="21" P_CHI2="0.02839164619397938" P_Q="0.10187130103484232" P_Z="3.3691968009386875E-10" Q="13.302041176324874" RANDOM="YES" SCALE="30.673379120173312" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.10319628142046289" TOTALS="SUB" TOTAL_1="4156" TOTAL_2="4167" WEIGHT="900.0" Z="6.280761029877522">
<NAME>Adverse effects: 5a. Extrapyramidal effects</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="15.363120130596439" CI_END="0.948877435949128" CI_START="0.31538869591494745" DF="7" EFFECT_SIZE="0.547051384338907" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="112" I2="54.436338839405785" ID="CMP-005.21.01" LOG_CI_END="-0.02278988064809689" LOG_CI_START="-0.5011538766055282" LOG_EFFECT_SIZE="-0.2619718786268126" MODIFIED="2011-08-26 07:36:15 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.03161645811376146" P_Z="0.03181602305805955" STUDIES="8" TAU2="0.27337140270905064" TOTAL_1="1132" TOTAL_2="1138" WEIGHT="100.0" Z="2.146714432565876">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="1.8255673991975914" CI_START="0.08764398404042836" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2613978715554003" LOG_CI_START="-1.0572778888994754" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2011-08-26 07:36:15 +0100" MODIFIED_BY="Laila Asmal" ORDER="528" O_E="0.0" SE="0.7745966692414833" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="20" VAR="0.5999999999999999" WEIGHT="9.040515740480894"/>
<DICH_DATA CI_END="1.5350727165108762" CI_START="0.4268742690429511" EFFECT_SIZE="0.8094955489614243" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" LOG_CI_END="0.18612895286299191" LOG_CI_START="-0.3697000226367867" LOG_EFFECT_SIZE="-0.09178553488689735" ORDER="1390" O_E="0.0" SE="0.3264966916063726" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="341" VAR="0.1066000896299068" WEIGHT="20.77979025445831"/>
<DICH_DATA CI_END="1.3279536805257148" CI_START="0.5151672733829815" EFFECT_SIZE="0.8271144278606966" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="30" LOG_CI_END="0.12318292695751512" LOG_CI_START="-0.28805173384820837" LOG_EFFECT_SIZE="-0.08243440344534665" ORDER="1391" O_E="0.0" SE="0.24156127540168346" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.05835184977368796" WEIGHT="23.802153917105663"/>
<DICH_DATA CI_END="0.68223512836376" CI_START="0.011652368676662994" EFFECT_SIZE="0.08916083916083917" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="-0.16606592248100427" LOG_CI_START="-1.9335857829091712" LOG_EFFECT_SIZE="-1.0498258526950879" ORDER="1392" O_E="0.0" SE="1.0382499153799225" STUDY_ID="STD-Potkin-2006" TOTAL_1="156" TOTAL_2="153" VAR="1.0779628867864162" WEIGHT="5.842912427261052"/>
<DICH_DATA CI_END="0.9605784766442864" CI_START="0.00360221230913349" EFFECT_SIZE="0.058823529411764705" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.0174671486770072" LOG_CI_START="-2.4434306940795407" LOG_EFFECT_SIZE="-1.2304489213782739" ORDER="1395" O_E="0.0" SE="1.425022995282672" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" VAR="2.0306905370843986" WEIGHT="3.4268731135695383"/>
<DICH_DATA CI_END="8.511035550580567" CI_START="0.5632446234493069" EFFECT_SIZE="2.1894736842105265" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.9299824045665925" LOG_CI_START="-0.24930294521876495" LOG_EFFECT_SIZE="0.3403397296739138" ORDER="1393" O_E="0.0" SE="0.6927180520205474" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="104" VAR="0.4798582995951417" WEIGHT="10.482496759386093"/>
<DICH_DATA CI_END="1.0912771015330225" CI_START="0.01870117428161628" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.03793504241817489" LOG_CI_START="-1.7281311224466887" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2011-08-04 13:38:10 +0100" MODIFIED_BY="Laila Asmal" ORDER="493" O_E="0.0" SE="1.0373960074101287" STUDY_ID="STD-Wang-2006" TOTAL_1="30" TOTAL_2="30" VAR="1.076190476190476" WEIGHT="5.850586058280975"/>
<DICH_DATA CI_END="0.8728707167644535" CI_START="0.2425922550216811" EFFECT_SIZE="0.46016483516483514" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="28" LOG_CI_END="-0.05905007605804614" LOG_CI_START="-0.6151230684943378" LOG_EFFECT_SIZE="-0.337086572276192" ORDER="1394" O_E="0.0" SE="0.3266400283627837" STUDY_ID="STD-Zhong-2006" TOTAL_1="338" TOTAL_2="335" VAR="0.10669370812884016" WEIGHT="20.774671729457463"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.6195538382223735E-31" CI_END="1.36669287238411" CI_START="0.6056833481937535" DF="0" EFFECT_SIZE="0.9098258706467661" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="36" I2="100.0" ID="CMP-005.21.02" LOG_CI_END="0.13567092948009735" LOG_CI_START="-0.21775436605434065" LOG_EFFECT_SIZE="-0.041041718287121644" MODIFIED="2009-08-10 13:40:58 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.6489625431429489" STUDIES="1" TAU2="0.0" TOTAL_1="134" TOTAL_2="133" WEIGHT="99.99999999999999" Z="0.45520391846745556">
<NAME>akinesia</NAME>
<DICH_DATA CI_END="1.36669287238411" CI_START="0.6056833481937535" EFFECT_SIZE="0.9098258706467661" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="36" LOG_CI_END="0.13567092948009735" LOG_CI_START="-0.21775436605434065" LOG_EFFECT_SIZE="-0.041041718287121644" ORDER="1396" O_E="0.0" SE="0.2076037680803571" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.0430993245211627" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.903914722906753" CI_START="0.06709646549862754" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-005.21.03" LOG_CI_END="1.1733003569528009" LOG_CI_START="-1.1733003569528009" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-05 11:49:06 +0100" MODIFIED_BY="Laila Asmal" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.0">
<NAME>dyskinesia</NAME>
<DICH_DATA CI_END="14.903914722906746" CI_START="0.06709646549862758" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1733003569528007" LOG_CI_START="-1.1733003569528007" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-08-26 07:43:52 +0100" MODIFIED_BY="Laila Asmal" ORDER="530" O_E="0.0" SE="1.378404875209022" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="20" VAR="1.9" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4896816988236492" CI_END="0.43460672291560265" CI_START="0.03845026261372987" DF="3" EFFECT_SIZE="0.1292700376336197" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="27" I2="0.0" ID="CMP-005.21.04" LOG_CI_END="-0.36190355987797507" LOG_CI_START="-1.415100689638772" LOG_EFFECT_SIZE="-0.8885021247583735" MODIFIED="2013-04-05 11:49:06 +0100" MODIFIED_BY="Laila Asmal" NO="4" P_CHI2="0.6846538558309825" P_Z="9.431961753081753E-4" STUDIES="4" TAU2="0.0" TOTAL_1="725" TOTAL_2="726" WEIGHT="100.0" Z="3.306944380126143">
<NAME>dystonia</NAME>
<DICH_DATA CI_END="2.5983769423254333" CI_START="0.007854196568971131" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4147021537028376" LOG_CI_START="-2.1048982337313515" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2011-08-26 07:44:32 +0100" MODIFIED_BY="Laila Asmal" ORDER="531" O_E="0.0" SE="1.4800257398019099" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="20" VAR="2.1904761904761907" WEIGHT="17.47253828775529"/>
<DICH_DATA CI_END="3.2263323096224688" CI_START="0.035261221227914946" EFFECT_SIZE="0.33728981206726016" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5087090973377018" LOG_CI_START="-1.4527026505347085" LOG_EFFECT_SIZE="-0.4719967765985033" MODIFIED="2011-07-14 09:45:58 +0100" MODIFIED_BY="Laila Asmal" ORDER="2230" O_E="0.0" SE="1.1521429698449928" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="341" VAR="1.32743342296324" WEIGHT="28.832466053984138"/>
<DICH_DATA CI_END="2.6515870907376713" CI_START="0.007696584184088997" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4235058959862219" LOG_CI_START="-2.1137019760147355" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2011-08-04 13:38:45 +0100" MODIFIED_BY="Laila Asmal" ORDER="494" O_E="0.0" SE="1.490368463394884" STUDY_ID="STD-Wang-2006" TOTAL_1="30" TOTAL_2="30" VAR="2.2211981566820276" WEIGHT="17.23087109152078"/>
<DICH_DATA CI_END="0.4101251694007491" CI_START="0.007392558680299151" EFFECT_SIZE="0.055062458908612756" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="18" LOG_CI_END="-0.38708357722206077" LOG_CI_START="-2.1312052194661706" LOG_EFFECT_SIZE="-1.2591443983441155" ORDER="1397" O_E="0.0" SE="1.024505686195559" STUDY_ID="STD-Zhong-2006" TOTAL_1="338" TOTAL_2="335" VAR="1.0496119010470333" WEIGHT="36.464124566739805"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0339632742350975" CI_END="0.8149240339574958" CI_START="0.4281751456902002" DF="1" EFFECT_SIZE="0.5907031546946372" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="85" I2="0.0" ID="CMP-005.21.05" LOG_CI_END="-0.08888287367810932" LOG_CI_START="-0.368378545829236" LOG_EFFECT_SIZE="-0.22863070975367264" MODIFIED="2013-04-05 11:49:04 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8537850119747314" P_Z="0.0013433851716902038" STUDIES="2" TAU2="0.0" TOTAL_1="433" TOTAL_2="439" WEIGHT="100.0" Z="3.206546659046166">
<NAME>extrapyramidal symptoms</NAME>
<DICH_DATA CI_END="1.5545654249466037" CI_START="0.26232763965068245" EFFECT_SIZE="0.6385964912280702" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.19160900434342779" LOG_CI_START="-0.5811559483902986" LOG_EFFECT_SIZE="-0.19477347202343542" ORDER="1398" O_E="0.0" SE="0.45392595848399975" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="104" VAR="0.20604877578561787" WEIGHT="13.081433577197682"/>
<DICH_DATA CI_END="0.8244594075229683" CI_START="0.4134072860506608" EFFECT_SIZE="0.5838129204830996" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="73" LOG_CI_END="-0.08383072209679528" LOG_CI_START="-0.38362187346656235" LOG_EFFECT_SIZE="-0.23372629778167886" ORDER="1399" O_E="0.0" SE="0.17609880630473393" STUDY_ID="STD-Zhong-2006" TOTAL_1="338" TOTAL_2="335" VAR="0.031010789581952195" WEIGHT="86.91856642280231"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.1976171243670657" CI_END="0.7806678915304704" CI_START="0.19037376189205155" DF="2" EFFECT_SIZE="0.3855109379758137" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="28" I2="8.99233638907784" ID="CMP-005.21.06" LOG_CI_END="-0.10753368257703236" LOG_CI_START="-0.7203929081086837" LOG_EFFECT_SIZE="-0.4139632953428581" MODIFIED="2013-04-05 11:49:04 +0100" MODIFIED_BY="Laila Asmal" NO="6" P_CHI2="0.3332681767808445" P_Z="0.008102618263784798" STUDIES="4" TAU2="0.041872156847998325" TOTAL_1="415" TOTAL_2="410" WEIGHT="100.0" Z="2.6477635189049353">
<NAME>parkinsonism</NAME>
<DICH_DATA CI_END="0.9643873049425113" CI_START="0.18002218633670253" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="-0.015748515247822607" LOG_CI_START="-0.7446739681753893" LOG_EFFECT_SIZE="-0.38021124171160603" MODIFIED="2011-08-26 07:46:03 +0100" MODIFIED_BY="Laila Asmal" ORDER="532" O_E="0.0" SE="0.42817441928883765" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="20" VAR="0.18333333333333335" WEIGHT="57.54633721796039"/>
<DICH_DATA CI_END="1.4190716695032157" CI_START="0.1566128777956553" EFFECT_SIZE="0.4714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.15200432983644577" LOG_CI_START="-0.8051725301091844" LOG_EFFECT_SIZE="-0.32658410013636935" MODIFIED="2011-08-22 11:36:46 +0100" MODIFIED_BY="Laila Asmal" ORDER="511" O_E="0.0" SE="0.562250425633935" STUDY_ID="STD-Hu-2008" TOTAL_1="35" TOTAL_2="33" VAR="0.31612554112554114" WEIGHT="36.200654793788274"/>
<DICH_DATA CI_END="0.9605784766442864" CI_START="0.00360221230913349" EFFECT_SIZE="0.058823529411764705" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.0174671486770072" LOG_CI_START="-2.4434306940795407" LOG_EFFECT_SIZE="-1.2304489213782739" ORDER="1401" O_E="0.0" SE="1.425022995282672" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" VAR="2.0306905370843986" WEIGHT="6.253007988251333"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1400" O_E="0.0" SE="0.0" STUDY_ID="STD-Zhong-2006" TOTAL_1="338" TOTAL_2="335" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.4343875495686016E-32" CI_END="1.2528994257042252" CI_START="0.1586251672874045" DF="0" EFFECT_SIZE="0.4458041958041957" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" I2="100.0" ID="CMP-005.21.07" LOG_CI_END="0.09791621016833095" LOG_CI_START="-0.799627906886469" LOG_EFFECT_SIZE="-0.35085584835906913" MODIFIED="2013-04-05 11:49:03 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Z="0.12544215484103524" STUDIES="1" TAU2="0.0" TOTAL_1="156" TOTAL_2="153" WEIGHT="100.0" Z="1.5323254054753863">
<NAME>rigor</NAME>
<DICH_DATA CI_END="1.2528994257042252" CI_START="0.1586251672874045" EFFECT_SIZE="0.4458041958041958" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.09791621016833095" LOG_CI_START="-0.799627906886469" LOG_EFFECT_SIZE="-0.3508558483590691" ORDER="1402" O_E="0.0" SE="0.5272218572730234" STUDY_ID="STD-Potkin-2006" TOTAL_1="156" TOTAL_2="153" VAR="0.27796288678641623" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.2069952500788284" CI_END="27.667548753943663" CI_START="0.04363849352227975" DF="1" EFFECT_SIZE="1.0988039620770986" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="68.81816398152071" ID="CMP-005.21.08" LOG_CI_END="1.4419706839044906" LOG_CI_START="-1.360130250435985" LOG_EFFECT_SIZE="0.04092021673425287" MODIFIED="2013-04-05 11:49:03 +0100" MODIFIED_BY="Laila Asmal" NO="8" P_CHI2="0.07332407209972247" P_Z="0.9543505909571618" STUDIES="2" TAU2="3.7631179832242356" TOTAL_1="64" TOTAL_2="62" WEIGHT="100.0" Z="0.057244298416099564">
<NAME>tremor</NAME>
<DICH_DATA CI_END="122.95832189465744" CI_START="0.3542663833467026" EFFECT_SIZE="6.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.089757927386423" LOG_CI_START="-0.45067005630268586" LOG_EFFECT_SIZE="0.8195439355418687" MODIFIED="2011-08-04 12:34:26 +0100" MODIFIED_BY="Laila Asmal" ORDER="487" O_E="0.0" SE="1.492259972940314" STUDY_ID="STD-Song-2008" TOTAL_1="34" TOTAL_2="32" VAR="2.226839826839827" WEIGHT="45.22920877673473"/>
<DICH_DATA CI_END="2.1080777784770572" CI_START="0.029647862445166522" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3238866303262053" LOG_CI_START="-1.52800661298213" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2011-08-04 13:39:18 +0100" MODIFIED_BY="Laila Asmal" ORDER="495" O_E="0.0" SE="1.0878112581387145" STUDY_ID="STD-Wang-2006" TOTAL_1="30" TOTAL_2="30" VAR="1.1833333333333331" WEIGHT="54.77079122326527"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.536427831723056" CI_END="0.6896227134384386" CI_START="0.35630703999292396" DF="7" EFFECT_SIZE="0.49569892852127334" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="150" I2="17.99848674422557" ID="CMP-005.21.09" LOG_CI_END="-0.16138844300913924" LOG_CI_START="-0.4481755966782445" LOG_EFFECT_SIZE="-0.3047820198436919" MODIFIED="2013-04-05 11:49:02 +0100" MODIFIED_BY="Laila Asmal" NO="9" P_CHI2="0.28767267258535956" P_Z="3.101410412122845E-5" STUDIES="8" TAU2="0.03986942499552118" TOTAL_1="1077" TOTAL_2="1086" WEIGHT="99.99999999999999" Z="4.165889401854056">
<NAME>use of antiparkinson medication</NAME>
<DICH_DATA CI_END="0.7307517209376697" CI_START="0.33562804431079335" EFFECT_SIZE="0.49523809523809526" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="63" LOG_CI_END="-0.1362301531954954" LOG_CI_START="-0.4741417576747824" LOG_EFFECT_SIZE="-0.3051859554351389" MODIFIED="2011-07-07 08:40:12 +0100" MODIFIED_BY="Laila Asmal" ORDER="4295" O_E="0.0" SE="0.19849094916055215" STUDY_ID="STD-Astrazeneca-1998" TOTAL_1="200" TOTAL_2="208" VAR="0.0393986568986569" WEIGHT="35.8010893894438"/>
<DICH_DATA CI_END="2.5333740706490695" CI_START="0.00805572438028364" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.40369932118580726" LOG_CI_START="-2.093895401214321" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="1403" O_E="0.0" SE="1.4670995032311038" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="14" VAR="2.152380952380952" WEIGHT="1.29450710325314"/>
<DICH_DATA CI_END="8.113157044444973" CI_START="0.3254744097192127" EFFECT_SIZE="1.625" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9091898825938717" LOG_CI_START="-0.48748315196408537" LOG_EFFECT_SIZE="0.21085336531489318" ORDER="1404" O_E="0.0" SE="0.8204126541423669" STUDY_ID="STD-Conley-2005" TOTAL_1="12" TOTAL_2="13" VAR="0.6730769230769229" WEIGHT="3.9805010479341947"/>
<DICH_DATA CI_END="1.2108417211183848" CI_START="0.06741810398292612" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.08308737672071692" LOG_CI_START="-1.171223465421268" LOG_EFFECT_SIZE="-0.5440680443502757" MODIFIED="2011-08-26 07:39:03 +0100" MODIFIED_BY="Laila Asmal" ORDER="529" O_E="0.0" SE="0.7367883976130072" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="20" VAR="0.5428571428571427" WEIGHT="4.870009095484984"/>
<DICH_DATA CI_END="0.678577846477239" CI_START="0.17829316429797729" EFFECT_SIZE="0.34783011869436203" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="32" LOG_CI_END="-0.16840032286617215" LOG_CI_START="-0.7488653072148715" LOG_EFFECT_SIZE="-0.45863281504052184" ORDER="1405" O_E="0.0" SE="0.34096800515443926" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="341" VAR="0.11625918053899771" WEIGHT="18.176577417747996"/>
<DICH_DATA CI_END="1.2631363079672293" CI_START="0.1611380503687338" EFFECT_SIZE="0.45115332428765265" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.10145021880854249" LOG_CI_START="-0.7928018952483987" LOG_EFFECT_SIZE="-0.3456758382199281" ORDER="1406" O_E="0.0" SE="0.5252881184164034" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.2759276073494455" WEIGHT="8.98641657443825"/>
<DICH_DATA CI_END="0.9135174956377119" CI_START="0.0540577671311149" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.039283130647344365" LOG_CI_START="-1.267141896903343" LOG_EFFECT_SIZE="-0.6532125137753437" ORDER="1408" O_E="0.0" SE="0.7212503172976913" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" VAR="0.5202020202020203" WEIGHT="5.067002986774799"/>
<DICH_DATA CI_END="1.474857251707983" CI_START="0.45452497906007827" EFFECT_SIZE="0.8187548237715462" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.1687499879103856" LOG_CI_START="-0.34244224452153244" LOG_EFFECT_SIZE="-0.08684612830557341" ORDER="1407" O_E="0.0" SE="0.30027684777286967" STUDY_ID="STD-Zhong-2006" TOTAL_1="338" TOTAL_2="335" VAR="0.09016618530841115" WEIGHT="21.823896384922815"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="35.772309247832354" CI_END="-0.11995232389504362" CI_START="-0.773226259884388" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4465892918897158" ESTIMABLE="YES" I2="77.6363333309695" I2_Q="0.0" ID="CMP-005.22" MODIFIED="2012-07-05 10:12:58 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="1.9328021020892372E-5" P_Q="0.7111421499837194" P_Z="0.0073681534306401265" Q="0.6817661006604446" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.24250518083443756" TOTALS="SUB" TOTAL_1="1382" TOTAL_2="1353" UNITS="" WEIGHT="300.0" Z="2.6797301400353613">
<NAME>Adverse effects: 5b. Extrapyramidal effects - scale measured - endpoint/ change to endpoint score</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.10561432959340465" CI_END="0.07840416819915869" CI_START="-0.7577937113013087" DF="1" EFFECT_SIZE="-0.33969477155107497" ESTIMABLE="YES" I2="0.0" ID="CMP-005.22.01" MODIFIED="2009-08-10 13:41:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7451935290251988" P_Z="0.11129014817359716" STUDIES="2" TAU2="0.0" TOTAL_1="485" TOTAL_2="473" WEIGHT="100.0" Z="1.592420967090712">
<NAME>abnormal involuntary movement: AIMS (high=poor)</NAME>
<CONT_DATA CI_END="0.15415106095052644" CI_START="-0.9541510609505265" EFFECT_SIZE="-0.4" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="0.3" ORDER="1409" SD_1="2.5" SD_2="2.47" SE="0.28273532846603266" STUDY_ID="STD-Potkin-2006" TOTAL_1="156" TOTAL_2="153" WEIGHT="56.924836822196404"/>
<CONT_DATA CI_END="0.3770383833296409" CI_START="-0.8970383833296409" EFFECT_SIZE="-0.26" ESTIMABLE="YES" MEAN_1="-0.51" MEAN_2="-0.25" ORDER="1410" SD_1="4.17" SD_2="4.11" SE="0.3250255557523089" STUDY_ID="STD-Zhong-2006" TOTAL_1="329" TOTAL_2="320" WEIGHT="43.07516317780359"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="27.082157121425592" CI_END="0.5447914542988747" CI_START="-2.0017658466911317" DF="1" EFFECT_SIZE="-0.7284871961961285" ESTIMABLE="YES" I2="96.30753194615777" ID="CMP-005.22.02" MODIFIED="2012-07-05 10:12:24 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.9499648507004252E-7" P_Z="0.2621330294119584" STUDIES="2" TAU2="0.8137986449450336" TOTAL_1="354" TOTAL_2="346" WEIGHT="100.0" Z="1.12136386421613">
<NAME>akathisia: Barnes Akathisia Scale (high=poor)</NAME>
<CONT_DATA CI_END="-0.9232490844237109" CI_START="-1.8767509155762894" EFFECT_SIZE="-1.4000000000000001" ESTIMABLE="YES" MEAN_1="-0.3" MEAN_2="1.1" ORDER="1412" SD_1="0.86" SD_2="0.86" SE="0.24324473272817232" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" WEIGHT="48.345168938163724"/>
<CONT_DATA CI_END="0.011471995066894308" CI_START="-0.2114719950668943" EFFECT_SIZE="-0.09999999999999999" ESTIMABLE="YES" MEAN_1="-0.09" MEAN_2="0.01" ORDER="1411" SD_1="0.73" SD_2="0.72" SE="0.05687451195336811" STUDY_ID="STD-Zhong-2006" TOTAL_1="329" TOTAL_2="321" WEIGHT="51.65483106183628"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.710962090067092" CI_END="-0.016787871099452567" CI_START="-1.164738522472772" DF="4" EFFECT_SIZE="-0.5907631967861122" ESTIMABLE="YES" I2="29.959261908653147" ID="CMP-005.22.03" MODIFIED="2009-08-10 13:41:44 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.221798720978448" P_Z="0.04366527596586726" STUDIES="5" TAU2="0.11892570413741407" TOTAL_1="543" TOTAL_2="534" WEIGHT="100.00000000000001" Z="2.0172898333344507">
<NAME>extrapyramidal symptoms: Simpson-Angus Scale (high=poor)</NAME>
<CONT_DATA CI_END="2.131532638154782" CI_START="-2.8115326381547816" EFFECT_SIZE="-0.33999999999999986" ESTIMABLE="YES" MEAN_1="-1.64" MEAN_2="-1.3" ORDER="1413" SD_1="3.15" SD_2="3.15" SE="1.261009211215061" STUDY_ID="STD-Conley-2005" TOTAL_1="12" TOTAL_2="13" WEIGHT="5.017997376302252"/>
<CONT_DATA CI_END="1.6106402353010725" CI_START="-3.4106402353010723" EFFECT_SIZE="-0.9" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="0.8" ORDER="1414" SD_1="2.5" SD_2="15.65" SE="1.2809624335470866" STUDY_ID="STD-Potkin-2006" TOTAL_1="156" TOTAL_2="153" WEIGHT="4.873369098633869"/>
<CONT_DATA CI_END="-0.015410568645230605" CI_START="-1.2445894313547694" EFFECT_SIZE="-0.63" ESTIMABLE="YES" MEAN_1="0.17" MEAN_2="0.8" ORDER="1416" SD_1="1.04" SD_2="1.04" SE="0.3135717983608742" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" WEIGHT="39.475217200913754"/>
<CONT_DATA CI_END="-0.6153857235312612" CI_START="-4.584614276468739" EFFECT_SIZE="-2.6" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="2.2" ORDER="1417" SD_1="3.58" SD_2="3.58" SE="1.012576910659136" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" WEIGHT="7.495040950205115"/>
<CONT_DATA CI_END="0.3539418535517811" CI_START="-0.753941853551781" EFFECT_SIZE="-0.19999999999999998" ESTIMABLE="YES" MEAN_1="-0.41" MEAN_2="-0.21" ORDER="1415" SD_1="3.62" SD_2="3.58" SE="0.28262858803590457" STUDY_ID="STD-Zhong-2006" TOTAL_1="328" TOTAL_2="321" WEIGHT="43.138375373945024"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="72.73137404572043" CI_START="0.12156257065979414" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.9734513274336285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.23" LOG_CI_END="1.8617217923677687" LOG_CI_START="-0.91520012455492" LOG_EFFECT_SIZE="0.47326083390642437" METHOD="MH" MODIFIED="2009-11-02 14:41:53 +0000" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="1.0" P_Q="1.0" P_Z="0.5040957751667378" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="338" TOTAL_2="335" WEIGHT="99.99999999999999" Z="0.6680592522946396">
<NAME>Adverse effects: 6. Haematological: important decline in white blood cells</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="72.73137404572043" CI_START="0.12156257065979414" EFFECT_SIZE="2.9734513274336285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8617217923677687" LOG_CI_START="-0.91520012455492" LOG_EFFECT_SIZE="0.47326083390642437" ORDER="1470" O_E="0.0" SE="1.6311776799855684" STUDY_ID="STD-Zhong-2006" TOTAL_1="338" TOTAL_2="335" VAR="2.6607406236831013" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="19.779342934804564" CI_END="0.7552645170353346" CI_START="0.4339594068344372" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5724981587880886" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="237" I2="24.163304870934976" I2_Q="7.631318640405462" ID="CMP-005.24" LOG_CI_END="-0.12190091834498634" LOG_CI_START="-0.3625508930965214" LOG_EFFECT_SIZE="-0.2422259057207538" METHOD="MH" MODIFIED="2011-08-22 11:39:55 +0100" MODIFIED_BY="Laila Asmal" NO="24" P_CHI2="0.18056187586434402" P_Q="0.3631249770981718" P_Z="7.960100637429616E-5" Q="4.33047212661601" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.05837775429574614" TOTALS="SUB" TOTAL_1="2106" TOTAL_2="2096" WEIGHT="500.0" Z="3.9455981811379264">
<NAME>Adverse effects: 7a. Prolactin associated side effects</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.4759740773711445" CI_END="0.9643184783753683" CI_START="0.3170042211173734" DF="3" EFFECT_SIZE="0.5528951330464705" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="36" I2="13.693257394230065" ID="CMP-005.24.01" LOG_CI_END="-0.0157795111608227" LOG_CI_START="-0.498934954830269" LOG_EFFECT_SIZE="-0.2573572329955458" MODIFIED="2011-08-22 11:39:55 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.32389171540408046" P_Z="0.0367990950692922" STUDIES="5" TAU2="0.04937274195214762" TOTAL_1="218" TOTAL_2="209" WEIGHT="100.00000000000001" Z="2.0879860278558673">
<NAME>amenorrhea</NAME>
<DICH_DATA CI_END="4.01511152634609" CI_START="0.3459506923108985" EFFECT_SIZE="1.1785714285714286" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6036976130279009" LOG_CI_START="-0.46098579595656436" LOG_EFFECT_SIZE="0.07135590853566827" MODIFIED="2011-08-22 11:39:55 +0100" MODIFIED_BY="Laila Asmal" ORDER="512" O_E="0.0" SE="0.6254003047053471" STUDY_ID="STD-Hu-2008" TOTAL_1="35" TOTAL_2="33" VAR="0.3911255411255411" WEIGHT="18.28541149467617"/>
<DICH_DATA CI_END="0.8741780836040656" CI_START="0.12865828817902422" EFFECT_SIZE="0.3353658536585366" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" LOG_CI_END="-0.0584000858458296" LOG_CI_START="-0.8905622312610784" LOG_EFFECT_SIZE="-0.474481158553454" ORDER="1425" O_E="0.0" SE="0.4888161634859716" STUDY_ID="STD-Lieberman-2005" TOTAL_1="82" TOTAL_2="88" VAR="0.23894124168514413" WEIGHT="27.937224088676004"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1427" O_E="0.0" SE="0.0" STUDY_ID="STD-McEvoy-2006" TOTAL_1="3" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9671507062479098" CI_START="0.2646824431163325" EFFECT_SIZE="0.5059523809523809" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="16" LOG_CI_END="-0.014505846711053733" LOG_CI_START="-0.5772748653120866" LOG_EFFECT_SIZE="-0.29589035601157015" ORDER="1426" O_E="0.0" SE="0.33057330727781675" STUDY_ID="STD-McEvoy-2007" TOTAL_1="42" TOTAL_2="34" VAR="0.10927871148459384" WEIGHT="50.76973575905818"/>
<DICH_DATA CI_END="61.87597307266315" CI_START="0.10748872621809767" EFFECT_SIZE="2.5789473684210527" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7915220417883344" LOG_CI_START="-0.968637083636965" LOG_EFFECT_SIZE="0.4114424790756847" ORDER="1428" O_E="0.0" SE="1.621331133282846" STUDY_ID="STD-Potkin-2006" TOTAL_1="56" TOTAL_2="48" VAR="2.6287146437522377" WEIGHT="3.007628657589662"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3764393222800955" CI_START="0.0843330537388706" DF="0" EFFECT_SIZE="0.44767441860465124" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-005.24.02" LOG_CI_END="0.3759267299140302" LOG_CI_START="-1.0740021733841643" LOG_EFFECT_SIZE="-0.349037721735067" MODIFIED="2009-08-10 13:42:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.34535654068299526" STUDIES="1" TAU2="0.0" TOTAL_1="86" TOTAL_2="77" WEIGHT="100.0" Z="0.943634356540517">
<NAME>dysmenorrhea</NAME>
<DICH_DATA CI_END="2.3764393222800955" CI_START="0.0843330537388706" EFFECT_SIZE="0.4476744186046512" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3759267299140302" LOG_CI_START="-1.0740021733841643" LOG_EFFECT_SIZE="-0.34903772173506703" ORDER="1429" O_E="0.0" SE="0.8516954150611842" STUDY_ID="STD-Zhong-2006" TOTAL_1="86" TOTAL_2="77" VAR="0.7253850800362428" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7578780575610274" CI_END="0.8534083280070157" CI_START="0.16174338226011975" DF="3" EFFECT_SIZE="0.371528127361588" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="20" I2="0.0" ID="CMP-005.24.03" LOG_CI_END="-0.06884312338220853" LOG_CI_START="-0.791173479479712" LOG_EFFECT_SIZE="-0.4300083014309603" MODIFIED="2009-08-10 13:42:11 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8595132245114336" P_Z="0.019618748330605437" STUDIES="5" TAU2="0.0" TOTAL_1="593" TOTAL_2="595" WEIGHT="100.0" Z="2.3335604733858384">
<NAME>galactorrhea</NAME>
<DICH_DATA CI_END="1.1150984308865126" CI_START="0.16864838277646793" EFFECT_SIZE="0.433658329800763" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" LOG_CI_END="0.0473132046972747" LOG_CI_START="-0.7730178190441453" LOG_EFFECT_SIZE="-0.3628523071734353" ORDER="1430" O_E="0.0" SE="0.48186650404976783" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="341" VAR="0.2321953277251449" WEIGHT="77.53422685822977"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1432" O_E="0.0" SE="0.0" STUDY_ID="STD-McEvoy-2006" TOTAL_1="15" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.7187913096059764" CI_START="0.007395543683054397" EFFECT_SIZE="0.14179894179894179" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4343758730656566" LOG_CI_START="-2.1310298933545675" LOG_EFFECT_SIZE="-0.8483270101444553" ORDER="1431" O_E="0.0" SE="1.5069320461585896" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="2.2708441917397137" WEIGHT="7.927926222657341"/>
<DICH_DATA CI_END="10.277041064992723" CI_START="0.018786247204341747" EFFECT_SIZE="0.4393939393939394" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.0118680918847456" LOG_CI_START="-1.7261599671705707" LOG_EFFECT_SIZE="-0.3571459376429126" ORDER="1433" O_E="0.0" SE="1.6083312353465724" STUDY_ID="STD-Stroup-2006" TOTAL_1="21" TOTAL_2="28" VAR="2.5867293625914316" WEIGHT="6.959786932339369"/>
<DICH_DATA CI_END="3.67776731445009" CI_START="0.008742314837553923" EFFECT_SIZE="0.1793103448275862" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5655842487609416" LOG_CI_START="-2.0583735572892556" LOG_EFFECT_SIZE="-0.746394654264157" ORDER="1434" O_E="0.0" SE="1.5413258040745064" STUDY_ID="STD-Zhong-2006" TOTAL_1="86" TOTAL_2="77" VAR="2.375685234305924" WEIGHT="7.578059986773518"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7853852883381367" CI_START="0.06679850275048317" DF="0" EFFECT_SIZE="0.22904707233065444" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" I2="0.0" ID="CMP-005.24.04" LOG_CI_END="-0.1049172380966764" LOG_CI_START="-1.175233271873116" LOG_EFFECT_SIZE="-0.6400752549848961" MODIFIED="2009-08-10 13:42:14 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.01906727240922263" STUDIES="1" TAU2="0.0" TOTAL_1="134" TOTAL_2="133" WEIGHT="100.0" Z="2.34421312505111">
<NAME>gynecomastia</NAME>
<DICH_DATA CI_END="0.7853852883381367" CI_START="0.06679850275048317" EFFECT_SIZE="0.2290470723306544" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" LOG_CI_END="-0.1049172380966764" LOG_CI_START="-1.175233271873116" LOG_EFFECT_SIZE="-0.6400752549848961" ORDER="1435" O_E="0.0" SE="0.6287089363900953" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.39527492669676484" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.340642527673117" CI_END="1.0065299800931622" CI_START="0.4808968159984063" DF="5" EFFECT_SIZE="0.6957277216222888" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="164" I2="40.052580081082716" ID="CMP-005.24.05" LOG_CI_END="0.0028267151363656454" LOG_CI_START="-0.31794809836578564" LOG_EFFECT_SIZE="-0.15756069161470998" MODIFIED="2009-08-10 13:42:18 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.13843458058699565" P_Z="0.0541767105983343" STUDIES="6" TAU2="0.0686502500621253" TOTAL_1="1075" TOTAL_2="1082" WEIGHT="100.0" Z="1.9254209990647078">
<NAME>sexual dysfunction</NAME>
<DICH_DATA CI_END="1.009357970004" CI_START="0.5832021770003906" EFFECT_SIZE="0.7672416604167346" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="91" LOG_CI_END="0.004045216609901472" LOG_CI_START="-0.23418086353525994" LOG_EFFECT_SIZE="-0.1150678234626792" ORDER="1436" O_E="0.0" SE="0.13993517871538305" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="341" VAR="0.019581854242106195" WEIGHT="40.239176960266676"/>
<DICH_DATA CI_END="2.4985369127511308" CI_START="0.1138444034958217" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3976857699826114" LOG_CI_START="-0.9436883141100868" LOG_EFFECT_SIZE="-0.27300127206373764" ORDER="1438" O_E="0.0" SE="0.7879297769048542" STUDY_ID="STD-McEvoy-2006" TOTAL_1="15" TOTAL_2="16" VAR="0.6208333333333333" WEIGHT="5.1493427025344065"/>
<DICH_DATA CI_END="1.4376022730613638" CI_START="0.6477180825891321" EFFECT_SIZE="0.9649668325041459" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="36" LOG_CI_END="0.15763875078513198" LOG_CI_START="-0.1886139784145989" LOG_EFFECT_SIZE="-0.015487613814733464" ORDER="1437" O_E="0.0" SE="0.20339056711057413" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.04136772278956096" WEIGHT="32.270975065691374"/>
<DICH_DATA CI_END="71.67903550691616" CI_START="0.1208071095201489" EFFECT_SIZE="2.9426751592356686" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.855392152948122" LOG_CI_START="-0.9179075066543388" LOG_EFFECT_SIZE="0.46874232314689174" ORDER="1439" O_E="0.0" SE="1.6290499481052039" STUDY_ID="STD-Potkin-2006" TOTAL_1="156" TOTAL_2="153" VAR="2.6538037334215674" WEIGHT="1.3041128629588625"/>
<DICH_DATA CI_END="0.7056127539007839" CI_START="0.18871678816859896" EFFECT_SIZE="0.3649122807017544" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="30" LOG_CI_END="-0.15143357796314874" LOG_CI_START="-0.724189463456311" LOG_EFFECT_SIZE="-0.43781152070972984" ORDER="1440" O_E="0.0" SE="0.33643964232604195" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="104" VAR="0.11319163292847503" WEIGHT="19.52458476718591"/>
<DICH_DATA CI_END="2.730662310773064" CI_START="0.007342011868429579" EFFECT_SIZE="0.1415929203539823" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.43626799613545825" LOG_CI_START="-2.134184917790448" LOG_EFFECT_SIZE="-0.8489584608274949" ORDER="1441" O_E="0.0" SE="1.5098967655872106" STUDY_ID="STD-Zhong-2006" TOTAL_1="338" TOTAL_2="335" VAR="2.2797882427307203" WEIGHT="1.5118076413627648"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="50.78029093354624" CI_END="-26.914770582944207" CI_START="-43.58925266884069" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-35.25201162589245" ESTIMABLE="YES" I2="88.18439223230935" I2_Q="0.0" ID="CMP-005.25" MODIFIED="2011-07-07 09:05:29 +0100" MODIFIED_BY="Laila Asmal" NO="25" P_CHI2="3.278542548557084E-9" P_Q="1.0" P_Z="1.159117832085796E-16" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="103.88806095420061" TOTALS="YES" TOTAL_1="874" TOTAL_2="899" UNITS="" WEIGHT="100.00000000000003" Z="8.287234687520048">
<NAME>Adverse effects: 7b. Prolactin - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-19.524904988381124" CI_START="-50.675095011618865" EFFECT_SIZE="-35.099999999999994" ESTIMABLE="YES" MEAN_1="9.7" MEAN_2="44.8" MODIFIED="2011-07-07 09:05:29 +0100" MODIFIED_BY="Laila Asmal" ORDER="1744" SD_1="7.2" SD_2="36.5" SE="7.946623067807997" STUDY_ID="STD-Byerly-2008" TOTAL_1="20" TOTAL_2="22" WEIGHT="10.832686292193179"/>
<CONT_DATA CI_END="-20.6784766224104" CI_START="-28.721523377589605" EFFECT_SIZE="-24.700000000000003" ESTIMABLE="YES" MEAN_1="-9.3" MEAN_2="15.4" ORDER="1442" SD_1="25.7" SD_2="27.7" SE="2.0518353445833006" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="341" WEIGHT="16.739038809148045"/>
<CONT_DATA CI_END="-14.17870957490101" CI_START="-43.021290425099" EFFECT_SIZE="-28.6" ESTIMABLE="YES" MEAN_1="-13.2" MEAN_2="15.4" ORDER="1443" SD_1="18.02" SD_2="17.91" SE="7.357936441104168" STUDY_ID="STD-McEvoy-2006" TOTAL_1="13" TOTAL_2="11" WEIGHT="11.450288840587454"/>
<CONT_DATA CI_END="-23.495994762961104" CI_START="-38.10400523703889" EFFECT_SIZE="-30.799999999999997" ESTIMABLE="YES" MEAN_1="-18.7" MEAN_2="12.1" ORDER="1444" SD_1="17.64" SD_2="15.88" SE="3.7266017613853895" STUDY_ID="STD-McEvoy-2007" TOTAL_1="44" TOTAL_2="37" WEIGHT="15.363604841799706"/>
<CONT_DATA CI_END="-40.55984351936713" CI_START="-60.24015648063287" EFFECT_SIZE="-50.4" ESTIMABLE="YES" MEAN_1="-10.1" MEAN_2="40.3" ORDER="1445" SD_1="44.96" SD_2="43.29" SE="5.0205802546632325" STUDY_ID="STD-Potkin-2006" TOTAL_1="156" TOTAL_2="153" WEIGHT="14.016562252973133"/>
<CONT_DATA CI_END="-23.502781897213772" CI_START="-37.09721810278623" EFFECT_SIZE="-30.3" ESTIMABLE="YES" MEAN_1="-8.3" MEAN_2="22.0" ORDER="1446" SD_1="18.5" SD_2="29.6" SE="3.4680321456933982" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="104" WEIGHT="15.610173871005955"/>
<CONT_DATA CI_END="-41.02597789289964" CI_START="-52.97402210710036" EFFECT_SIZE="-47.0" ESTIMABLE="YES" MEAN_1="-11.5" MEAN_2="35.5" ORDER="1447" SD_1="33.25" SD_2="30.4" SE="3.048026471007981" STUDY_ID="STD-Zhong-2006" TOTAL_1="209" TOTAL_2="231" WEIGHT="15.987645092292546"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.238621422240824" CI_START="0.7184949030956016" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2682421227197347" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-005.26" LOG_CI_END="0.3499806553775081" LOG_CI_START="-0.14357630834437812" LOG_EFFECT_SIZE="0.10320217351656498" METHOD="MH" MODIFIED="2009-10-29 01:11:33 +0000" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="1.0" P_Q="1.0" P_Z="0.41241437367829226" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="472" TOTAL_2="468" WEIGHT="99.99999999999999" Z="0.8196522715165214">
<NAME>Adverse effects: 8a. Metabolic - cholesterol - significant cholesterol increase</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.238621422240824" CI_START="0.7184949030956016" EFFECT_SIZE="1.2682421227197347" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="18" LOG_CI_END="0.3499806553775081" LOG_CI_START="-0.14357630834437812" LOG_EFFECT_SIZE="0.10320217351656498" ORDER="1376" O_E="0.0" SE="0.289917803636609" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.0840523328654754" WEIGHT="99.99999999999999"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1377" O_E="0.0" SE="0.0" STUDY_ID="STD-Zhong-2006" TOTAL_1="338" TOTAL_2="335" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="4.242170751955911" CI_END="12.292471183132713" CI_START="4.852657228337685" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="8.5725642057352" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.27" MODIFIED="2011-08-26 07:54:28 +0100" MODIFIED_BY="Laila Asmal" NO="27" P_CHI2="0.5151020975494142" P_Q="1.0" P_Z="6.2793797428516535E-6" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="727" TOTAL_2="746" UNITS="" WEIGHT="99.99999999999999" Z="4.516757327666565">
<NAME>Adverse effects: 8b. Metabolic - cholesterol - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="33.03220913377189" CI_START="-19.632209133771894" EFFECT_SIZE="6.699999999999999" ESTIMABLE="YES" MEAN_1="8.6" MEAN_2="1.9" MODIFIED="2011-08-26 07:54:28 +0100" MODIFIED_BY="Laila Asmal" ORDER="534" SD_1="30.1" SD_2="52.0" SE="13.435047450604705" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="20" WEIGHT="1.995673857018406"/>
<CONT_DATA CI_END="12.955444822883152" CI_START="1.8445551771168498" EFFECT_SIZE="7.4" ESTIMABLE="YES" MEAN_1="5.3" MEAN_2="-2.1" ORDER="1378" SD_1="38.6" SD_2="35.1" SE="2.8344627078373836" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="341" WEIGHT="44.83596097465776"/>
<CONT_DATA CI_END="11.874422373662128" CI_START="-29.874422373662128" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="-13.0" MEAN_2="-4.0" ORDER="1379" SD_1="24.5" SD_2="27.2" SE="10.650411200571494" STUDY_ID="STD-McEvoy-2006" TOTAL_1="13" TOTAL_2="11" WEIGHT="3.1756689736682495"/>
<CONT_DATA CI_END="26.426324563856266" CI_START="1.173675436143732" EFFECT_SIZE="13.799999999999999" ESTIMABLE="YES" MEAN_1="25.2" MEAN_2="11.4" ORDER="1380" SD_1="29.58" SD_2="28.28" SE="6.442120703977779" STUDY_ID="STD-McEvoy-2007" TOTAL_1="44" TOTAL_2="37" WEIGHT="8.679810863944665"/>
<CONT_DATA CI_END="18.070861901378503" CI_START="-3.2708619013785025" EFFECT_SIZE="7.4" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="-2.6" ORDER="1381" SD_1="37.0" SD_2="39.8" SE="5.444417339067911" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="104" WEIGHT="12.152486871889067"/>
<CONT_DATA CI_END="18.23866955962194" CI_START="4.461330440378063" EFFECT_SIZE="11.350000000000001" ESTIMABLE="YES" MEAN_1="4.9" MEAN_2="-6.45" ORDER="1382" SD_1="38.3" SD_2="36.2" SE="3.5146919096263423" STUDY_ID="STD-Zhong-2006" TOTAL_1="218" TOTAL_2="233" WEIGHT="29.16039845882184"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.4243027400536103" CI_END="1.6919595992338075" CI_START="0.47089923551245016" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8926043254416548" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="29" I2="17.502052571380894" I2_Q="0.0" ID="CMP-005.28" LOG_CI_END="0.22838998870341792" LOG_CI_START="-0.32707201461778695" LOG_EFFECT_SIZE="-0.04934101295718448" METHOD="MH" MODIFIED="2011-07-14 09:37:58 +0100" MODIFIED_BY="Laila Asmal" NO="28" P_CHI2="0.2975565050999134" P_Q="1.0" P_Z="0.7276881671461459" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.06545910260226794" TOTALS="YES" TOTAL_1="809" TOTAL_2="809" WEIGHT="100.0" Z="0.34820242529130696">
<NAME>Adverse effects: 8c. Metabolic - glucose - abnormally high fasting glucose value</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3042342222987546" CI_START="0.34890793502981166" EFFECT_SIZE="0.6745796241345203" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="21" LOG_CI_END="0.11535559163935469" LOG_CI_START="-0.4572891535083988" LOG_EFFECT_SIZE="-0.1709667809345221" MODIFIED="2011-07-14 09:37:58 +0100" MODIFIED_BY="Laila Asmal" ORDER="2227" O_E="0.0" SE="0.3363743579369953" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="341" VAR="0.11314770867752584" WEIGHT="59.60544015538386"/>
<DICH_DATA CI_END="4.422098225921107" CI_START="0.6188178026125397" EFFECT_SIZE="1.654228855721393" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.6456283851223268" LOG_CI_START="-0.20843720068505775" LOG_EFFECT_SIZE="0.21859559221863456" ORDER="1418" O_E="0.0" SE="0.5016823527960907" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.25168518310702126" WEIGHT="33.56812050790126"/>
<DICH_DATA CI_END="5.439204109239727" CI_START="0.04515032345428985" EFFECT_SIZE="0.49556213017751477" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7355353562693536" LOG_CI_START="-1.345339134078935" LOG_EFFECT_SIZE="-0.3049018889047907" ORDER="1419" O_E="0.0" SE="1.222315976125436" STUDY_ID="STD-Zhong-2006" TOTAL_1="338" TOTAL_2="335" VAR="1.4940563454914777" WEIGHT="6.826439336714886"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="4.153418226075309" CI_END="3.051872530580429" CI_START="-2.447141023480767" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="0.30236575354983114" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.29" MODIFIED="2011-08-26 07:56:18 +0100" MODIFIED_BY="Laila Asmal" NO="29" P_CHI2="0.5275458508013136" P_Q="1.0" P_Z="0.8293470960537865" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="729" TOTAL_2="747" UNITS="" WEIGHT="100.0" Z="0.2155390166944797">
<NAME>Adverse effects: 8d. Metabolic - glucose - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="13.39608042465595" CI_START="-5.396080424655951" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="1.2" MODIFIED="2011-08-26 07:56:18 +0100" MODIFIED_BY="Laila Asmal" ORDER="535" SD_1="14.6" SD_2="15.7" SE="4.794006675005782" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="20" WEIGHT="8.56280665890457"/>
<CONT_DATA CI_END="6.373309520309011" CI_START="-6.173309520309012" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="6.7" ORDER="1420" SD_1="45.9" SD_2="36.9" SE="3.200726936715203" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="341" WEIGHT="19.209504266220417"/>
<CONT_DATA CI_END="14.37575562911752" CI_START="-125.37575562911752" EFFECT_SIZE="-55.5" ESTIMABLE="YES" MEAN_1="-23.3" MEAN_2="32.2" ORDER="1421" SD_1="44.0" SD_2="111.1" SE="35.651550834754396" STUDY_ID="STD-McEvoy-2006" TOTAL_1="13" TOTAL_2="11" WEIGHT="0.1548305135494002"/>
<CONT_DATA CI_END="6.071033055432766" CI_START="-3.271033055432765" EFFECT_SIZE="1.4000000000000004" ESTIMABLE="YES" MEAN_1="6.2" MEAN_2="4.8" ORDER="1422" SD_1="11.08" SD_2="10.34" SE="2.3832239226216796" STUDY_ID="STD-McEvoy-2007" TOTAL_1="44" TOTAL_2="37" WEIGHT="34.648441736598045"/>
<CONT_DATA CI_END="6.9237628145371986" CI_START="-16.9237628145372" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="4.8" ORDER="1423" SD_1="41.9" SD_2="43.9" SE="6.083664245154665" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="104" WEIGHT="5.317199214015052"/>
<CONT_DATA CI_END="4.252364968668127" CI_START="-5.452364968668128" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="3.9" MEAN_2="4.5" ORDER="1424" SD_1="26.7" SD_2="26.0" SE="2.4757419049242553" STUDY_ID="STD-Zhong-2006" TOTAL_1="220" TOTAL_2="234" WEIGHT="32.1072176107125"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.885311693429787" CI_END="1.1357579397473907" CI_START="0.8162647535471375" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9628495078552559" ESTIMABLE="YES" EVENTS_1="182" EVENTS_2="183" I2="0.0" I2_Q="0.0" ID="CMP-005.30" LOG_CI_END="0.05528578152137802" LOG_CI_START="-0.08816895600635825" LOG_EFFECT_SIZE="-0.016441587242490105" METHOD="MH" MODIFIED="2011-08-22 11:41:52 +0100" MODIFIED_BY="Laila Asmal" NO="30" P_CHI2="0.8673199064109042" P_Q="1.0" P_Z="0.653237260953736" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1031" TOTAL_2="1039" WEIGHT="100.00000000000001" Z="0.449269496418315">
<NAME>Adverse effects: 8e. Metabolic - weight gain of 7% or more of total body weight</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.3126301577105135" CI_START="0.14082554650392395" EFFECT_SIZE="0.9428571428571428" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8002103457711055" LOG_CI_START="-0.8513185547158818" LOG_EFFECT_SIZE="-0.025554104472388168" MODIFIED="2011-08-22 11:41:52 +0100" MODIFIED_BY="Laila Asmal" ORDER="513" O_E="0.0" SE="0.9701162513459617" STUDY_ID="STD-Hu-2008" TOTAL_1="35" TOTAL_2="33" VAR="0.9411255411255411" WEIGHT="0.7544968562845793"/>
<DICH_DATA CI_END="1.7325802059906377" CI_START="0.804357632278661" EFFECT_SIZE="1.1805143422354105" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="42" LOG_CI_END="0.23869334845722276" LOG_CI_START="-0.09455081295367812" LOG_EFFECT_SIZE="0.0720712677517723" ORDER="1456" O_E="0.0" SE="0.19574926999796635" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="341" VAR="0.03831777670473673" WEIGHT="18.531249023656603"/>
<DICH_DATA CI_END="6.642886317962055" CI_START="0.1712776229063682" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8223568202717129" LOG_CI_START="-0.766299373071226" LOG_EFFECT_SIZE="0.028028723600243534" ORDER="1457" O_E="0.0" SE="0.9331845119446279" STUDY_ID="STD-McEvoy-2006" TOTAL_1="15" TOTAL_2="16" VAR="0.8708333333333333" WEIGHT="0.8153985785435532"/>
<DICH_DATA CI_END="1.0792562195133042" CI_START="0.6910942509382934" EFFECT_SIZE="0.8636363636363636" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="77" LOG_CI_END="0.03312456007792322" LOG_CI_START="-0.1604627198166778" LOG_EFFECT_SIZE="-0.06366907986937727" ORDER="1458" O_E="0.0" SE="0.11371412648257895" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.012930902561695962" WEIGHT="54.91312449076361"/>
<DICH_DATA CI_END="26.662770421418234" CI_START="0.3375493190598938" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.42590527321826" LOG_CI_START="-0.4716627637789349" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1462" O_E="0.0" SE="1.1146408580454255" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" VAR="1.2424242424242424" WEIGHT="0.5715247963633016"/>
<DICH_DATA CI_END="2.9118995703113004" CI_START="0.567691702469352" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.4641763923402582" LOG_CI_START="-0.24588745349012195" LOG_EFFECT_SIZE="0.10914446942506807" ORDER="1459" O_E="0.0" SE="0.4170950179134893" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" VAR="0.17396825396825394" WEIGHT="4.08164274775052"/>
<DICH_DATA CI_END="1.9260791055055384" CI_START="0.45714267872529785" EFFECT_SIZE="0.9383458646616541" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.28467411995312597" LOG_CI_START="-0.33994823119448714" LOG_EFFECT_SIZE="-0.0276370556206806" ORDER="1460" O_E="0.0" SE="0.36690626099461215" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="104" VAR="0.13462020435704647" WEIGHT="5.274663380134562"/>
<DICH_DATA CI_END="2.6921683779126004" CI_START="0.23772658695895926" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4301022187434325" LOG_CI_START="-0.6239222447595453" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2011-08-04 13:46:49 +0100" MODIFIED_BY="Laila Asmal" ORDER="497" O_E="0.0" SE="0.6191391873668903" STUDY_ID="STD-Wang-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.38333333333333336" WEIGHT="1.8523728577782894"/>
<DICH_DATA CI_END="1.608699208406252" CI_START="0.6482034224496807" EFFECT_SIZE="1.0211583288506365" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="33" LOG_CI_END="0.20647484811314815" LOG_CI_START="-0.1882886802660319" LOG_EFFECT_SIZE="0.009093083923558136" ORDER="1461" O_E="0.0" SE="0.23188605068091134" STUDY_ID="STD-Zhong-2006" TOTAL_1="338" TOTAL_2="335" VAR="0.053771140500390176" WEIGHT="13.205527268724975"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="34.26691202510049" CI_END="2.456959577431551" CI_START="-0.5868984687640713" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="0.9350305543337398" ESTIMABLE="YES" I2="79.57213070476702" I2_Q="0.0" ID="CMP-005.31" MODIFIED="2011-09-01 17:16:59 +0100" MODIFIED_BY="Laila Asmal" NO="31" P_CHI2="1.5352341772634226E-5" P_Q="1.0" P_Z="0.22853280305980384" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="3.0451232021620824" TOTALS="YES" TOTAL_1="756" TOTAL_2="730" UNITS="" WEIGHT="100.0" Z="1.2041469629171224">
<NAME>Adverse effects: 8f. Metabolic - weight gain - change from baseline in kg</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.092020190290769" CI_START="2.6479798097092315" EFFECT_SIZE="3.87" ESTIMABLE="YES" MEAN_1="4.41" MEAN_2="0.54" MODIFIED="2011-09-01 17:16:59 +0100" MODIFIED_BY="Laila Asmal" ORDER="1463" SD_1="2.21" SD_2="0.72" SE="0.6234911457199764" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="13" WEIGHT="17.55939196849149"/>
<CONT_DATA CI_END="5.934170825607917" CI_START="-7.034170825607917" EFFECT_SIZE="-0.5499999999999999" ESTIMABLE="YES" MEAN_1="-1.2" MEAN_2="-0.65" ORDER="1464" SD_1="11.22" SD_2="2.43" SE="3.3083112122234026" STUDY_ID="STD-Conley-2005" TOTAL_1="12" TOTAL_2="13" WEIGHT="4.309962237131706"/>
<CONT_DATA CI_END="3.7796861514498303" CI_START="0.2203138485501699" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="-0.8" MODIFIED="2011-08-26 07:48:47 +0100" MODIFIED_BY="Laila Asmal" ORDER="533" SD_1="3.2" SD_2="2.5" SE="0.9080198235721509" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="20" WEIGHT="15.582026468337368"/>
<CONT_DATA CI_END="1.2076063901701892" CI_START="-1.007606390170189" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="0.4" ORDER="1465" SD_1="7.0" SD_2="6.9" SE="0.5651156852405692" STUDY_ID="STD-Lieberman-2005" TOTAL_1="305" TOTAL_2="300" WEIGHT="17.921518379593582"/>
<CONT_DATA CI_END="3.8791060882984016" CI_START="-6.479106088298401" EFFECT_SIZE="-1.3" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="1.8" ORDER="1466" SD_1="8.91" SD_2="5.2" SE="2.642449621090249" STUDY_ID="STD-McEvoy-2006" TOTAL_1="15" TOTAL_2="16" WEIGHT="6.013023168307181"/>
<CONT_DATA CI_END="4.0170403541450375" CI_START="-5.5970403541450375" EFFECT_SIZE="-0.79" ESTIMABLE="YES" MEAN_1="5.69" MEAN_2="6.48" MODIFIED="2008-12-05 11:52:38 +0000" MODIFIED_BY="[Empty name]" ORDER="1467" SD_1="11.47" SD_2="10.58" SE="2.452616676664652" STUDY_ID="STD-McEvoy-2007" TOTAL_1="44" TOTAL_2="37" WEIGHT="6.654918841103597"/>
<CONT_DATA CI_END="3.4565986376359534" CI_START="-1.0365986376359533" EFFECT_SIZE="1.2100000000000002" ESTIMABLE="YES" MEAN_1="2.93" MEAN_2="1.72" ORDER="1469" SD_1="4.02" SD_2="3.57" SE="1.1462448572304578" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" WEIGHT="13.83265991961437"/>
<CONT_DATA CI_END="0.5595370005905751" CI_START="-1.5195370005905755" EFFECT_SIZE="-0.4800000000000002" ESTIMABLE="YES" MEAN_1="1.64" MEAN_2="2.12" ORDER="1468" SD_1="6.66" SD_2="6.68" SE="0.5303857666724034" STUDY_ID="STD-Zhong-2006" TOTAL_1="324" TOTAL_2="309" WEIGHT="18.126499017420713"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2013-10-22 15:22:14 +0100" MODIFIED_BY="Laila Asmal" NO="6">
<NAME>QUETIAPINE versus ZIPRASIDONE</NAME>
<DICH_OUTCOME CHI2="1.307417131844483" CI_END="1.1330042294457383" CI_START="0.9842552192832649" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0560138854683596" ESTIMABLE="YES" EVENTS_1="504" EVENTS_2="386" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.05423153106508945" LOG_CI_START="-0.006892273566016821" LOG_EFFECT_SIZE="0.02366962874953632" METHOD="MH" MODIFIED="2009-10-29 01:11:59 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9341666225779488" P_Q="0.803722355209241" P_Z="0.1290255168603337" Q="0.4370031095602131" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1200" TOTAL_2="966" WEIGHT="300.0" Z="1.5179558980828236">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.3471231876464038" CI_END="1.130792934250825" CI_START="0.9735172616220554" DF="1" EFFECT_SIZE="1.0492122953975673" ESTIMABLE="YES" EVENTS_1="330" EVENTS_2="253" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="0.053383086140912875" LOG_CI_START="-0.011656343516579307" LOG_EFFECT_SIZE="0.020863371312166788" MODIFIED="2009-08-10 13:43:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5557463556280566" P_Z="0.2085958668168324" STUDIES="2" TAU2="0.0" TOTAL_1="400" TOTAL_2="322" WEIGHT="100.0" Z="1.2574358841482418">
<NAME>any reason</NAME>
<DICH_DATA CI_END="1.1301876267564681" CI_START="0.9467994028469218" EFFECT_SIZE="1.0344375138779547" ESTIMABLE="YES" EVENTS_1="277" EVENTS_2="147" LOG_CI_END="0.05315054835136436" LOG_CI_START="-0.023742024655469138" LOG_EFFECT_SIZE="0.014704261847947606" ORDER="1471" O_E="0.0" SE="0.045167078008588976" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="185" VAR="0.002040064935833962" WEIGHT="71.54588515302153"/>
<DICH_DATA CI_END="1.2511636693705848" CI_START="0.9449001523064409" EFFECT_SIZE="1.0873015873015872" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="106" LOG_CI_END="0.09731412508521309" LOG_CI_START="-0.024614081007525466" LOG_EFFECT_SIZE="0.036350022038843834" ORDER="1472" O_E="0.0" SE="0.07162123181322881" STUDY_ID="STD-Stroup-2006" TOTAL_1="63" TOTAL_2="137" VAR="0.005129600846444258" WEIGHT="28.454114846978463"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.43512352495854073" CI_END="1.490464809097047" CI_START="0.7220201341760925" DF="1" EFFECT_SIZE="1.0373743786353091" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="47" I2="0.0" ID="CMP-006.01.02" LOG_CI_END="0.17332172649720515" LOG_CI_START="-0.14145069157211418" LOG_EFFECT_SIZE="0.01593551746254545" MODIFIED="2009-08-10 13:43:49 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5094855840345841" P_Z="0.842694258025631" STUDIES="2" TAU2="0.0" TOTAL_1="400" TOTAL_2="322" WEIGHT="100.0" Z="0.19844839324340108">
<NAME>adverse events</NAME>
<DICH_DATA CI_END="1.4742865179916649" CI_START="0.6260050812985989" EFFECT_SIZE="0.9606824925816023" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="28" LOG_CI_END="0.16858189403224094" LOG_CI_START="-0.20342214159630173" LOG_EFFECT_SIZE="-0.01742012378203041" ORDER="1473" O_E="0.0" SE="0.21851701197788084" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="185" VAR="0.04774968452374132" WEIGHT="71.59752965967938"/>
<DICH_DATA CI_END="2.4850562121407833" CI_START="0.6378256596379096" EFFECT_SIZE="1.2589807852965749" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="0.39533621695122156" LOG_CI_START="-0.19529801313477924" LOG_EFFECT_SIZE="0.10001910190822118" ORDER="1474" O_E="0.0" SE="0.34694147043910845" STUDY_ID="STD-Stroup-2006" TOTAL_1="63" TOTAL_2="137" VAR="0.12036838391045075" WEIGHT="28.402470340320615"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.260688186831745E-4" CI_END="1.4702247242425752" CI_START="0.8912902864766594" DF="1" EFFECT_SIZE="1.1447257381815228" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="86" I2="0.0" ID="CMP-006.01.03" LOG_CI_END="0.16738372184973718" LOG_CI_START="-0.04998082650996635" LOG_EFFECT_SIZE="0.05870144766988538" MODIFIED="2009-08-10 13:43:53 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9770708282792578" P_Z="0.2897750107964706" STUDIES="2" TAU2="0.0" TOTAL_1="400" TOTAL_2="322" WEIGHT="100.0" Z="1.0586153458929675">
<NAME>inefficacy</NAME>
<DICH_DATA CI_END="1.5669876034045966" CI_START="0.8407916616827584" EFFECT_SIZE="1.1478284326949015" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="44" LOG_CI_END="0.19506556073516715" LOG_CI_START="-0.07531160395308115" LOG_EFFECT_SIZE="0.059876978391043015" ORDER="1475" O_E="0.0" SE="0.15882088492642749" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="185" VAR="0.025224073488813524" WEIGHT="64.63048385281105"/>
<DICH_DATA CI_END="1.7349934601184203" CI_START="0.7478404880758421" EFFECT_SIZE="1.1390778533635677" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="42" LOG_CI_END="0.23929784210105082" LOG_CI_START="-0.12619102584678907" LOG_EFFECT_SIZE="0.056553408127130854" ORDER="1476" O_E="0.0" SE="0.21468997023163586" STUDY_ID="STD-Stroup-2006" TOTAL_1="63" TOTAL_2="137" VAR="0.04609178331806069" WEIGHT="35.369516147188946"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.654218121272513" CI_END="6.1446181796429435" CI_START="-6.359612316548716" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.10749706845288608" ESTIMABLE="YES" I2="62.32412129261745" I2_Q="62.32412129261745" ID="CMP-006.02" MODIFIED="2013-10-22 15:21:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.1032755830430685" P_Q="0.1032755830430685" P_Z="0.973117131651759" Q="2.654218121272513" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="13.085073913627628" TOTALS="YES" TOTAL_1="392" TOTAL_2="318" UNITS="" WEIGHT="100.0" Z="0.03369905611952088">
<NAME>Mental state: 1. General - average endpoint score (PANSS total score, high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.7019642341910619E-32" CI_END="10.371801205111927" CI_START="-2.9718012051119262" DF="0" EFFECT_SIZE="3.7000000000000006" ESTIMABLE="YES" I2="100.0" ID="CMP-006.02.01" MODIFIED="2009-08-10 13:44:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.27706207590453114" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="135" WEIGHT="41.24232919054188" Z="1.0869428689274838">
<NAME>medium term</NAME>
<CONT_DATA CI_END="10.371801205111927" CI_START="-2.9718012051119267" EFFECT_SIZE="3.7" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="-1.7" ORDER="1477" SD_1="22.31" SD_2="22.31" SE="3.404042756774228" STUDY_ID="STD-Stroup-2006" TOTAL_1="63" TOTAL_2="135" WEIGHT="41.24232919054188"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.2523586068283707" CI_START="-6.812358606828371" DF="0" EFFECT_SIZE="-2.7800000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-006.02.02" MODIFIED="2009-08-10 13:44:05 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.17661732356095186" STUDIES="1" TAU2="0.0" TOTAL_1="329" TOTAL_2="183" WEIGHT="58.75767080945811" Z="1.3512438769197157">
<NAME>long term</NAME>
<CONT_DATA CI_END="1.2523586068283707" CI_START="-6.812358606828371" EFFECT_SIZE="-2.7800000000000002" ESTIMABLE="YES" MEAN_1="-6.08" MEAN_2="-3.3" ORDER="1478" SD_1="22.31" SD_2="22.31" SE="2.0573636243497844" STUDY_ID="STD-Lieberman-2005" TOTAL_1="329" TOTAL_2="183" WEIGHT="58.75767080945811"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.1830635946802817" CI_START="-2.1830635946802817" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.03" MODIFIED="2013-10-22 15:21:57 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="135" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>Mental state: 2. Positive symptoms - average endpoint score - medium term (PANSS positive subscore, high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.1830635946802817" CI_START="-2.1830635946802817" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="0.2" MODIFIED="2009-08-10 10:31:02 +0100" MODIFIED_BY="[Empty name]" ORDER="422" SD_1="7.3" SD_2="7.3" SE="1.1138284233281879" STUDY_ID="STD-Stroup-2006" TOTAL_1="63" TOTAL_2="135" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.5378427525381126" CI_START="-0.3378427525381129" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.5999999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.04" MODIFIED="2013-10-22 15:22:14 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.10560558084083535" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="135" UNITS="" WEIGHT="100.0" Z="1.61826462500982">
<NAME>Mental state: 3. Negative symptoms - average endpoint score - medium term (PANSS negative subscore, high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.5378427525381126" CI_START="-0.3378427525381129" EFFECT_SIZE="1.5999999999999999" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="-1.4" MODIFIED="2009-08-10 10:31:07 +0100" MODIFIED_BY="[Empty name]" ORDER="423" SD_1="6.48" SD_2="6.48" SE="0.9887134497488571" STUDY_ID="STD-Stroup-2006" TOTAL_1="63" TOTAL_2="135" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.07922643432155077" CI_END="1.5908728277669826" CI_START="0.8543450471881417" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.165827740752859" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="55" I2="0.0" I2_Q="0.0" ID="CMP-006.05" LOG_CI_END="0.2016354641176652" LOG_CI_START="-0.06836669391860677" LOG_EFFECT_SIZE="0.06663438509952925" METHOD="MH" MODIFIED="2009-11-02 14:48:55 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.7783484816078747" P_Q="0.7783667994900626" P_Z="0.3333406018369408" Q="0.07921298859334616" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="432" TOTAL_2="322" WEIGHT="99.99999999999997" Z="0.9674070450170614">
<NAME>Service use: number of participants re-hospitalised</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.170080056785571" CI_START="0.7147925349311942" DF="0" EFFECT_SIZE="1.2454545454545454" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" I2="0.0" ID="CMP-006.05.01" LOG_CI_END="0.3364757557742827" LOG_CI_START="-0.1458199917779193" LOG_EFFECT_SIZE="0.0953278819981817" MODIFIED="2009-08-10 13:44:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4384631425771073" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="137" WEIGHT="31.340621553921228" Z="0.7747910546057529">
<NAME>medium term</NAME>
<DICH_DATA CI_END="2.170080056785571" CI_START="0.7147925349311942" EFFECT_SIZE="1.2454545454545454" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" LOG_CI_END="0.3364757557742827" LOG_CI_START="-0.1458199917779193" LOG_EFFECT_SIZE="0.0953278819981817" ORDER="1481" O_E="0.0" SE="0.2833029095146174" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="137" VAR="0.08026053853944748" WEIGHT="31.340621553921228"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.64612056798823" CI_START="0.7773416884656577" DF="0" EFFECT_SIZE="1.1311932380181637" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="33" I2="0.0" ID="CMP-006.05.02" LOG_CI_END="0.21646164138314136" LOG_CI_START="-0.10938804066309336" LOG_EFFECT_SIZE="0.05353680036002398" MODIFIED="2009-08-10 13:44:23 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5195491578799095" STUDIES="1" TAU2="0.0" TOTAL_1="337" TOTAL_2="185" WEIGHT="68.65937844607875" Z="0.6440405274863487">
<NAME>long term</NAME>
<DICH_DATA CI_END="1.64612056798823" CI_START="0.7773416884656577" EFFECT_SIZE="1.1311932380181637" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="33" LOG_CI_END="0.21646164138314136" LOG_CI_START="-0.10938804066309336" LOG_EFFECT_SIZE="0.05353680036002398" ORDER="1482" O_E="0.0" SE="0.19140571621589825" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="185" VAR="0.036636148200120976" WEIGHT="68.65937844607875"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7749183520141479" CI_END="1.1721767989004253" CI_START="0.9118831279046503" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0338705169597304" ESTIMABLE="YES" EVENTS_1="252" EVENTS_2="157" I2="0.0" I2_Q="0.0" ID="CMP-006.06" LOG_CI_END="0.06899312106433589" LOG_CI_START="-0.0400608197402306" LOG_EFFECT_SIZE="0.014466150662052682" METHOD="MH" MODIFIED="2009-10-29 01:11:59 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.3786998495209667" P_Q="1.0" P_Z="0.6030749576067949" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="432" TOTAL_2="322" WEIGHT="100.0" Z="0.5199836719952113">
<NAME>Adverse effects: 1. General - at least one adverse effect</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.158773000904629" CI_START="0.8888668839463032" EFFECT_SIZE="1.0148866668329053" ESTIMABLE="YES" EVENTS_1="220" EVENTS_2="119" LOG_CI_END="0.06399836770644282" LOG_CI_START="-0.051163273783741525" LOG_EFFECT_SIZE="0.006417546961350663" ORDER="1483" O_E="0.0" SE="0.06764651827065345" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="185" VAR="0.00457605143414185" WEIGHT="89.67410168242317"/>
<DICH_DATA CI_END="1.7949398678697013" CI_START="0.8216309366031888" EFFECT_SIZE="1.214404432132964" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="38" LOG_CI_END="0.2540499038949463" LOG_CI_START="-0.08532321675363672" LOG_EFFECT_SIZE="0.0843633435706548" ORDER="1484" O_E="0.0" SE="0.19934945099301835" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="137" VAR="0.03974020361121783" WEIGHT="10.325898317576826"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.09806521565282314" CI_END="3.1490541272485904" CI_START="0.053099648196905366" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4089176766904471" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-006.07" LOG_CI_END="0.4981801255344025" LOG_CI_START="-1.2749083562565506" LOG_EFFECT_SIZE="-0.388364115361074" METHOD="MH" MODIFIED="2009-10-29 01:11:59 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.7541639453632699" P_Q="0.7571171602486241" P_Z="0.3905657330226957" Q="0.09564712813442758" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="432" TOTAL_2="322" WEIGHT="100.0" Z="0.8585918715422651">
<NAME>Adverse effects: 2. Death</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.725698614167325" CI_START="0.03453690744208156" DF="0" EFFECT_SIZE="0.5489614243323442" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-006.07.01" LOG_CI_END="0.9408002083683691" LOG_CI_START="-1.4617165533050185" LOG_EFFECT_SIZE="-0.26045817246832487" MODIFIED="2009-08-10 13:44:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6708646970299637" STUDIES="1" TAU2="0.0" TOTAL_1="337" TOTAL_2="185" WEIGHT="54.46631138048997" Z="0.424961561692894">
<NAME>suicide attempt</NAME>
<DICH_DATA CI_END="8.725698614167325" CI_START="0.03453690744208156" EFFECT_SIZE="0.5489614243323442" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.9408002083683691" LOG_CI_START="-1.4617165533050185" LOG_EFFECT_SIZE="-0.26045817246832487" ORDER="1490" O_E="0.0" SE="1.4112502384567203" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="185" VAR="1.9916272355441496" WEIGHT="54.46631138048997"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.921778848132172" CI_START="0.01395801027356351" DF="0" EFFECT_SIZE="0.2875" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-006.07.02" LOG_CI_END="0.7724521844059883" LOG_CI_START="-1.85517648635469" LOG_EFFECT_SIZE="-0.5413621509743507" MODIFIED="2009-08-10 13:44:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.41931481868778187" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="137" WEIGHT="45.53368861951003" Z="0.8076105503870127">
<NAME>suicide</NAME>
<DICH_DATA CI_END="5.921778848132172" CI_START="0.01395801027356351" EFFECT_SIZE="0.2875" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.7724521844059883" LOG_CI_START="-1.85517648635469" LOG_EFFECT_SIZE="-0.5413621509743507" ORDER="1491" O_E="0.0" SE="1.5434820881765163" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="137" VAR="2.382336956521739" WEIGHT="45.53368861951003"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8724086008821893E-32" CI_END="8.077707424838367" CI_START="0.3357670272019334" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6468842729970326" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="99.99999999999999" I2_Q="0.0" ID="CMP-006.08" LOG_CI_END="0.9072881189405131" LOG_CI_START="-0.473961954437838" LOG_EFFECT_SIZE="0.2166630822513376" METHOD="MH" MODIFIED="2009-10-29 01:11:59 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="1.0" P_Z="0.5386336735470942" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="337" TOTAL_2="185" WEIGHT="100.0" Z="0.6148804567349924">
<NAME>Adverse effects: 3a. Cardiac effects - QTc prolongation</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.077707424838367" CI_START="0.3357670272019334" EFFECT_SIZE="1.6468842729970326" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="0.9072881189405131" LOG_CI_START="-0.473961954437838" LOG_EFFECT_SIZE="0.2166630822513376" ORDER="1485" O_E="0.0" SE="0.8113531304005772" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="185" VAR="0.6582939022108161" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.5636698059626409" CI_END="8.184207208251438" CI_START="-1.3697634706811965" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="3.4072218687851206" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.09" MODIFIED="2009-10-29 01:11:59 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.4527855008857582" P_Q="1.0" P_Z="0.16212522230665982" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="295" TOTAL_2="254" UNITS="" WEIGHT="99.99999999999999" Z="1.3979595237573332">
<NAME>Adverse effects: 3b. Cardiac effects - QTc abnormalities - change from baseline in ms</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="10.302240559549277" CI_START="-1.1022405595492764" EFFECT_SIZE="4.6000000000000005" ESTIMABLE="YES" MEAN_1="5.9" MEAN_2="1.3" ORDER="1486" SD_1="27.8" SD_2="26.8" SE="2.9093598681036092" STUDY_ID="STD-Lieberman-2005" TOTAL_1="214" TOTAL_2="148" WEIGHT="70.180546719628"/>
<CONT_DATA CI_END="9.347905242271311" CI_START="-8.147905242271312" EFFECT_SIZE="0.5999999999999999" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="1.3" ORDER="1487" SD_1="33.3" SD_2="25.7" SE="4.463298974508548" STUDY_ID="STD-Stroup-2006" TOTAL_1="81" TOTAL_2="106" WEIGHT="29.81945328037199"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.073762590949074" CI_END="1.8091727833414175" CI_START="1.02652752194492" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.362778651892397" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="63" I2="6.869543749319573" I2_Q="0.0" ID="CMP-006.10" LOG_CI_END="0.25748004572569044" LOG_CI_START="0.011370597611704907" LOG_EFFECT_SIZE="0.1344253216686977" METHOD="MH" MODIFIED="2011-07-14 10:31:16 +0100" MODIFIED_BY="Laila Asmal" NO="10" P_CHI2="0.30009752824050706" P_Q="1.0" P_Z="0.03226838628591686" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.003936809455959562" TOTALS="YES" TOTAL_1="432" TOTAL_2="322" WEIGHT="100.0" Z="2.141070089749936">
<NAME>Adverse effects: 4. Central nervous system - sedation</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6975193501660548" CI_START="0.9300757977217962" EFFECT_SIZE="1.2565117045829213" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="45" LOG_CI_END="0.22981473354013532" LOG_CI_START="-0.03148165661712786" LOG_EFFECT_SIZE="0.09916653846150372" ORDER="1505" O_E="0.0" SE="0.15348679301636797" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="185" VAR="0.023558195630449384" WEIGHT="76.0112671896114"/>
<DICH_DATA CI_END="3.102046854868259" CI_START="1.0014883965748667" EFFECT_SIZE="1.7625730994152047" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" LOG_CI_END="0.49164835332834533" LOG_CI_START="6.459218445729517E-4" LOG_EFFECT_SIZE="0.24614713758645917" ORDER="1506" O_E="0.0" SE="0.28841725875480234" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="137" VAR="0.08318451514763461" WEIGHT="23.988732810388598"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.535967892721873" CI_END="1.0903953845548124" CI_START="0.45705847763075413" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7059564111758057" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="43" I2="46.92121759352052" I2_Q="53.46427737639732" ID="CMP-006.11" LOG_CI_END="0.03758400454101668" LOG_CI_START="-0.34002823124826026" LOG_EFFECT_SIZE="-0.15122211335362185" METHOD="MH" MODIFIED="2011-07-14 09:48:35 +0100" MODIFIED_BY="Laila Asmal" NO="11" P_CHI2="0.11013378460375467" P_Q="0.09179012772877271" P_Z="0.11645911840162346" Q="6.446660395208767" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.2230471463447033" TOTALS="SUB" TOTAL_1="1201" TOTAL_2="829" WEIGHT="400.0" Z="1.5698108681230871">
<NAME>Adverse effects: 5. Extrapyramidal effects</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.1025672573372" CI_END="1.448110284094978" CI_START="0.41919957052772716" DF="1" EFFECT_SIZE="0.7791323438090603" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="21" I2="9.302585094437621" ID="CMP-006.11.01" LOG_CI_END="0.1608016377934756" LOG_CI_START="-0.37757917096119464" LOG_EFFECT_SIZE="-0.10838876658385956" MODIFIED="2009-08-10 13:44:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.29370389241925476" P_Z="0.43001029976353067" STUDIES="2" TAU2="0.021398300767514002" TOTAL_1="432" TOTAL_2="322" WEIGHT="100.0" Z="0.7891740395593753">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="1.2564560267845035" CI_START="0.3132710445624332" EFFECT_SIZE="0.6273844849512505" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.0991472938366568" LOG_CI_START="-0.5040797448179328" LOG_EFFECT_SIZE="-0.20246622549063806" ORDER="1492" O_E="0.0" SE="0.35433854852770524" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="185" VAR="0.12555580697272092" WEIGHT="68.05697080615644"/>
<DICH_DATA CI_END="3.562676704129198" CI_START="0.4288682843334494" EFFECT_SIZE="1.2360902255639097" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.5517764139920238" LOG_CI_START="-0.3676760695181322" LOG_EFFECT_SIZE="0.09205017223694577" ORDER="1493" O_E="0.0" SE="0.5400909401770624" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="137" VAR="0.2916982236613432" WEIGHT="31.943029193843557"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.746676794402041" CI_START="0.019170286134906556" DF="0" EFFECT_SIZE="0.1829871414441148" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-006.11.02" LOG_CI_END="0.24221255043591663" LOG_CI_START="-1.7173714048118909" LOG_EFFECT_SIZE="-0.7375794271879871" MODIFIED="2011-07-14 09:48:35 +0100" MODIFIED_BY="Laila Asmal" NO="2" P_CHI2="1.0" P_Z="0.14009296152590783" STUDIES="1" TAU2="0.0" TOTAL_1="337" TOTAL_2="185" WEIGHT="100.0" Z="1.4754449373344916">
<NAME>dystonia</NAME>
<DICH_DATA CI_END="1.7466767944020405" CI_START="0.019170286134906546" EFFECT_SIZE="0.18298714144411474" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.24221255043591652" LOG_CI_START="-1.717371404811891" LOG_EFFECT_SIZE="-0.7375794271879873" MODIFIED="2011-07-14 09:48:35 +0100" MODIFIED_BY="Laila Asmal" ORDER="2231" O_E="0.0" SE="1.1510693154095817" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="185" VAR="1.3249605688774828" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.171746744571235" CI_START="0.660452971444387" DF="0" EFFECT_SIZE="2.018947368421053" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-006.11.03" LOG_CI_END="0.7904080966374099" LOG_CI_START="-0.18015810154581574" LOG_EFFECT_SIZE="0.30512499754579714" MODIFIED="2011-07-14 09:47:22 +0100" MODIFIED_BY="Laila Asmal" NO="3" P_CHI2="1.0" P_Z="0.21782194887367734" STUDIES="1" TAU2="0.0" TOTAL_1="95" TOTAL_2="137" WEIGHT="100.0" Z="1.232340477325662">
<NAME>extrapyramidal symptoms</NAME>
<DICH_DATA CI_END="6.171746744571235" CI_START="0.660452971444387" EFFECT_SIZE="2.0189473684210526" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.7904080966374099" LOG_CI_START="-0.18015810154581574" LOG_EFFECT_SIZE="0.305124997545797" ORDER="1494" O_E="0.0" SE="0.5701153891929918" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="137" VAR="0.3250315569946765" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9306877805803037" CI_START="0.19989822698467916" DF="0" EFFECT_SIZE="0.43132683340398476" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" I2="0.0" ID="CMP-006.11.04" LOG_CI_END="-0.031195988097869075" LOG_CI_START="-0.6991910578788065" LOG_EFFECT_SIZE="-0.3651935229883378" MODIFIED="2011-07-14 09:47:20 +0100" MODIFIED_BY="Laila Asmal" NO="4" P_CHI2="1.0" P_Z="0.0321108300937558" STUDIES="1" TAU2="0.0" TOTAL_1="337" TOTAL_2="185" WEIGHT="100.0" Z="2.1430282492329504">
<NAME>use of antiparkinson medication</NAME>
<DICH_DATA CI_END="0.9306877805803037" CI_START="0.19989822698467916" EFFECT_SIZE="0.43132683340398476" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="-0.031195988097869075" LOG_CI_START="-0.6991910578788065" LOG_EFFECT_SIZE="-0.3651935229883378" ORDER="1495" O_E="0.0" SE="0.39238361061824667" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="185" VAR="0.15396489788181184" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.181984103442873" CI_END="1.178864956521522" CI_START="0.5821506138830368" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8284183472884962" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="70" I2="28.26371583932586" I2_Q="20.58110141541458" ID="CMP-006.12" LOG_CI_END="0.07146405785454257" LOG_CI_START="-0.23496464023664115" LOG_EFFECT_SIZE="-0.08175029119104928" METHOD="MH" MODIFIED="2009-10-29 01:11:59 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.24247195083732342" P_Q="0.28389642943884885" P_Z="0.2956652710485357" Q="2.5182922901781266" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.05420653474299979" TOTALS="SUB" TOTAL_1="872" TOTAL_2="592" WEIGHT="300.0" Z="1.0457742858825831">
<NAME>Adverse effects: 6a. Prolactin associated effects</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.1790290866514766E-32" CI_END="1.237468098020358" CI_START="0.14722256239390338" DF="0" EFFECT_SIZE="0.4268292682926829" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="100.0" ID="CMP-006.12.01" LOG_CI_END="0.09253401161990281" LOG_CI_START="-0.8320256276867849" LOG_EFFECT_SIZE="-0.36974580803344104" MODIFIED="2009-08-10 13:45:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.11696510548735756" STUDIES="1" TAU2="0.0" TOTAL_1="82" TOTAL_2="56" WEIGHT="100.0" Z="1.5676402827266769">
<NAME>amenorrhea</NAME>
<DICH_DATA CI_END="1.237468098020358" CI_START="0.14722256239390338" EFFECT_SIZE="0.4268292682926829" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.09253401161990281" LOG_CI_START="-0.8320256276867849" LOG_EFFECT_SIZE="-0.36974580803344104" ORDER="1498" O_E="0.0" SE="0.5430909087727741" STUDY_ID="STD-Lieberman-2005" TOTAL_1="82" TOTAL_2="56" VAR="0.29494773519163764" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.677922624282878" CI_START="0.17960223018853017" DF="0" EFFECT_SIZE="0.5489614243323442" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" ID="CMP-006.12.02" LOG_CI_END="0.22477192990044587" LOG_CI_START="-0.7456882748370955" LOG_EFFECT_SIZE="-0.26045817246832487" MODIFIED="2009-08-10 13:45:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.29277444320332235" STUDIES="2" TAU2="0.0" TOTAL_1="358" TOTAL_2="214" WEIGHT="100.0" Z="1.052054757165646">
<NAME>galactorrhea</NAME>
<DICH_DATA CI_END="1.677922624282878" CI_START="0.17960223018853017" EFFECT_SIZE="0.5489614243323442" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.22477192990044587" LOG_CI_START="-0.7456882748370955" LOG_EFFECT_SIZE="-0.26045817246832487" ORDER="1499" O_E="0.0" SE="0.5700531281183209" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="185" VAR="0.3249605688774828" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1500" O_E="0.0" SE="0.0" STUDY_ID="STD-Stroup-2006" TOTAL_1="21" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2617170592988105" CI_END="1.4227978275968414" CI_START="0.6434018689255435" DF="1" EFFECT_SIZE="0.956781470022811" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="56" I2="20.742927851372457" ID="CMP-006.12.03" LOG_CI_END="0.15314319341040808" LOG_CI_START="-0.1915176819126443" LOG_EFFECT_SIZE="-0.019187244251118053" MODIFIED="2009-08-10 13:45:20 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.26132641995196904" P_Z="0.8272560772656414" STUDIES="2" TAU2="0.02152424948032081" TOTAL_1="432" TOTAL_2="322" WEIGHT="100.00000000000001" Z="0.21822208662074588">
<NAME>sexual dysfunction</NAME>
<DICH_DATA CI_END="1.5590661530574046" CI_START="0.7512443255434125" EFFECT_SIZE="1.0822382365409071" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="35" LOG_CI_END="0.19286454321851512" LOG_CI_START="-0.1242187953812054" LOG_EFFECT_SIZE="0.034322873918654837" ORDER="1501" O_E="0.0" SE="0.1862563226813159" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="185" VAR="0.03469141773876647" WEIGHT="72.912469484513"/>
<DICH_DATA CI_END="1.3913578819187349" CI_START="0.3389350493612091" EFFECT_SIZE="0.6867167919799498" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="21" LOG_CI_END="0.1434388526028196" LOG_CI_START="-0.4698835183355401" LOG_EFFECT_SIZE="-0.1632223328663603" ORDER="1502" O_E="0.0" SE="0.36026859668389255" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="137" VAR="0.12979346175658124" WEIGHT="27.08753051548702"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="7.455324578487429E-4" CI_END="-1.3716474107929115" CI_START="-8.160825601485232" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.766236506139072" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.13" MODIFIED="2009-10-29 01:11:59 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.9782169161828815" P_Q="1.0" P_Z="0.005924623182205565" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="432" TOTAL_2="322" UNITS="" WEIGHT="100.0" Z="2.7519242039160545">
<NAME>Adverse effects: 6b. Prolactin - change from baseline in ng/ml</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.6290161936014558" CI_START="-8.970983806398547" EFFECT_SIZE="-4.800000000000001" ESTIMABLE="YES" MEAN_1="-9.3" MEAN_2="-4.5" ORDER="1503" SD_1="25.7" SD_2="21.8" SE="2.128092066639353" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="185" WEIGHT="66.23650613907044"/>
<CONT_DATA CI_END="1.142026479850565" CI_START="-10.542026479850566" EFFECT_SIZE="-4.700000000000001" ESTIMABLE="YES" MEAN_1="-8.3" MEAN_2="-3.6" ORDER="1504" SD_1="18.5" SD_2="26.9" SE="2.980680525729924" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="137" WEIGHT="33.763493860929565"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.13489167522883302" CI_END="23.460636369209595" CI_START="8.568655961625055" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="16.014646165417325" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.14" MODIFIED="2009-10-29 01:11:59 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.7134132361710872" P_Q="1.0" P_Z="2.4929095935043033E-5" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="432" TOTAL_2="322" UNITS="" WEIGHT="100.0" Z="4.2154406399009705">
<NAME>Adverse effects: 7a. Metabolic - cholesterol - change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="25.489808566237045" CI_START="3.5101914337629534" EFFECT_SIZE="14.5" ESTIMABLE="YES" MEAN_1="5.3" MEAN_2="-9.2" ORDER="1488" SD_1="38.6" SD_2="70.7" SE="5.607148219519978" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="185" WEIGHT="45.90549409223834"/>
<CONT_DATA CI_END="27.423854184795694" CI_START="7.176145815204306" EFFECT_SIZE="17.3" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="-12.5" ORDER="1489" SD_1="37.0" SD_2="41.0" SE="5.165326641025735" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="137" WEIGHT="54.094505907761665"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.23523705520635957" CI_END="10.19197687271376" CI_START="-3.9933163602680866" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="3.099330256222836" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.15" MODIFIED="2009-10-29 01:11:59 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.6276675540755526" P_Q="1.0" P_Z="0.3917428086188588" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="432" TOTAL_2="322" UNITS="" WEIGHT="100.0" Z="0.8564610655024352">
<NAME>Adverse effects: 7b. Metabolic - glucose- change from baseline in mg/dl</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="13.574325385951404" CI_START="-4.574325385951404" EFFECT_SIZE="4.5" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="2.3" ORDER="1496" SD_1="45.9" SD_2="53.0" SE="4.62984292442541" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="185" WEIGHT="61.092507117301"/>
<CONT_DATA CI_END="12.270817750497486" CI_START="-10.470817750497485" EFFECT_SIZE="0.9000000000000001" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-1.1" ORDER="1497" SD_1="41.9" SD_2="45.6" SE="5.801544232541539" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="137" WEIGHT="38.907492882698996"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.355705709016569" CI_START="0.30256020754510266" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6404549950544016" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-006.16" LOG_CI_END="0.13216542491357164" LOG_CI_START="-0.5191881905889948" LOG_EFFECT_SIZE="-0.1935113828377116" METHOD="MH" MODIFIED="2011-07-14 09:42:15 +0100" MODIFIED_BY="Laila Asmal" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.24419074948006436" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="337" TOTAL_2="185" WEIGHT="100.0" Z="1.164575836944787">
<NAME>Adverse effects: 7c. Metabolic - glucose - abnormally high fasting glucose value</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.355705709016569" CI_START="0.30256020754510266" EFFECT_SIZE="0.6404549950544016" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.13216542491357164" LOG_CI_START="-0.5191881905889948" LOG_EFFECT_SIZE="-0.1935113828377116" MODIFIED="2011-07-14 09:40:02 +0100" MODIFIED_BY="Laila Asmal" ORDER="2228" O_E="0.0" SE="0.38260833799860433" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="185" VAR="0.14638914030605427" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.004469705029441674" CI_END="3.6306378434571616" CI_START="1.3514805898382476" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2151154764852663" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-006.17" LOG_CI_END="0.5599829301488171" LOG_CI_START="0.13080981267871306" LOG_EFFECT_SIZE="0.34539637141376506" METHOD="MH" MODIFIED="2011-07-14 09:41:33 +0100" MODIFIED_BY="Laila Asmal" NO="17" P_CHI2="0.9466964589133807" P_Q="1.0" P_Z="0.0016064209610781475" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="432" TOTAL_2="322" WEIGHT="100.0" Z="3.154738359906508">
<NAME>Adverse effects: 7d. Metabolic - weight gain of 7% or more of total body weight</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.106040804078592" CI_START="1.223742553523333" EFFECT_SIZE="2.2415924826904057" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="12" LOG_CI_END="0.6134232608889617" LOG_CI_START="0.08769006213616634" LOG_EFFECT_SIZE="0.35055666151256404" ORDER="1507" O_E="0.0" SE="0.30881828336869716" STUDY_ID="STD-Lieberman-2005" TOTAL_1="337" TOTAL_2="185" VAR="0.09536873214278893" WEIGHT="66.63988157694057"/>
<DICH_DATA CI_END="5.088781492279518" CI_START="0.9195230891052184" EFFECT_SIZE="2.163157894736842" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.7066138030574921" LOG_CI_START="-0.03643736121101178" LOG_EFFECT_SIZE="0.3350882209232402" ORDER="1508" O_E="0.0" SE="0.436471932053903" STUDY_ID="STD-Stroup-2006" TOTAL_1="95" TOTAL_2="137" VAR="0.19050774747086693" WEIGHT="33.360118423059426"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.450662028678069" CI_START="-0.05066202867806946" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.2" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.18" MODIFIED="2011-07-14 09:41:45 +0100" MODIFIED_BY="Laila Asmal" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.06003051313925749" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="305" TOTAL_2="161" UNITS="" WEIGHT="100.0" Z="1.88056943244215">
<NAME>Adverse effects: 7e. Metabolic - weight gain - change from baseline in kg</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Ziprasidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.450662028678069" CI_START="-0.05066202867806946" EFFECT_SIZE="1.2" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="-0.7" ORDER="1509" SD_1="7.0" SD_2="6.3" SE="0.6381045970962385" STUDY_ID="STD-Lieberman-2005" TOTAL_1="305" TOTAL_2="161" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2012-07-05 13:41:09 +0100" MODIFIED_BY="Laila Asmal" NO="7">
<NAME>QUETIAPINE versus ARIPIPRAZOLE - sensitivity analyses (skewed data excluded)</NAME>
<CONT_OUTCOME CHI2="0.1800691059896052" CI_END="4.3936699395179915" CI_START="-1.9079245682956614" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="1.2428726856111652" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.01" MODIFIED="2012-07-05 13:41:09 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.6713138643921983" P_Q="1.0" P_Z="0.43944361033135604" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="71" TOTAL_2="71" UNITS="" WEIGHT="99.99999999999999" Z="0.773133116751946">
<NAME>Mental state: 1. General - average endpoint score - short term (PANSS total, high=poor)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="19.870405057104634" CI_START="-10.870405057104636" EFFECT_SIZE="4.5" ESTIMABLE="YES" MEAN_1="-28.9" MEAN_2="-33.4" MODIFIED="2012-07-05 13:40:37 +0100" MODIFIED_BY="Laila Asmal" ORDER="565" SD_1="28.6" SD_2="20.8" SE="7.842187498517538" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="21" WEIGHT="4.2021378120932535"/>
<CONT_DATA CI_END="4.319159902288724" CI_START="-2.119159902288735" EFFECT_SIZE="1.0999999999999943" ESTIMABLE="YES" MEAN_1="51.3" MEAN_2="50.2" MODIFIED="2012-07-05 13:41:09 +0100" MODIFIED_BY="Laila Asmal" ORDER="566" SD_1="8.1" SD_2="8.4" SE="1.6424587021399637" STUDY_ID="STD-Wei-2006b" TOTAL_1="51" TOTAL_2="50" WEIGHT="95.79786218790673"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2012-07-05 13:11:34 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>QUETIAPINE versus CLOZAPINE- sensitivity analysis (skewed data excluded)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.467328570728938" CI_START="-4.107328570728953" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.1799999999999926" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.01" MODIFIED="2009-10-29 01:12:21 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.9344181003033182" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="0.0822874924086381">
<NAME>Mental state: 1. General - average endpoint score - short term (PANSS total, high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.467328570728938" CI_START="-4.107328570728953" DF="0" EFFECT_SIZE="0.1799999999999926" ESTIMABLE="YES" I2="0.0" ID="CMP-008.01.01" MODIFIED="2009-08-10 13:45:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9344181003033182" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="100.0" Z="0.0822874924086381">
<NAME>short term</NAME>
<CONT_DATA CI_END="4.467328570728938" CI_START="-4.107328570728953" EFFECT_SIZE="0.1799999999999926" ESTIMABLE="YES" MEAN_1="77.24" MEAN_2="77.06" ORDER="1510" SD_1="6.08" SD_2="5.28" SE="2.1874527310434506" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2013-10-22 15:23:13 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>QUETIAPINE versus OLANZAPINE- sensitivity analysis (skewed data excluded)</NAME>
<CONT_OUTCOME CHI2="4.967632357373925" CI_END="5.9533292097544015" CI_START="2.250766019174118" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="MD" EFFECT_SIZE="4.10204761446426" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.01" MODIFIED="2013-10-22 15:22:47 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.8371206722263766" P_Q="0.4388629738625134" P_Z="1.406367189413502E-5" Q="1.6471371402464348" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="705" TOTAL_2="696" UNITS="" WEIGHT="99.99999999999999" Z="4.342864752543683">
<NAME>Mental state: 1. General - average endpoint score (PANSS total subscore, high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.7589278783323908" CI_END="5.870535069181257" CI_START="-1.2953766891306695" DF="4" EFFECT_SIZE="2.2875791900252938" ESTIMABLE="YES" I2="0.0" ID="CMP-009.01.01" MODIFIED="2012-07-05 14:02:29 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.9438679960804224" P_Z="0.21080266364930011" STUDIES="5" TAU2="0.0" TOTAL_1="92" TOTAL_2="87" WEIGHT="26.69697449756839" Z="1.2513614388377787">
<NAME>short term</NAME>
<CONT_DATA CI_END="7.100657875744535" CI_START="-2.3406578757445438" EFFECT_SIZE="2.3799999999999955" ESTIMABLE="YES" MEAN_1="77.24" MEAN_2="74.86" MODIFIED="2012-07-05 13:59:33 +0100" MODIFIED_BY="Laila Asmal" ORDER="567" SD_1="6.08" SD_2="6.41" SE="2.4085431737422147" STUDY_ID="STD-Atmaca-2003" TOTAL_1="14" TOTAL_2="13" WEIGHT="15.379418464702114"/>
<CONT_DATA CI_END="20.46467507197546" CI_START="-11.46467507197546" EFFECT_SIZE="4.5" ESTIMABLE="YES" MEAN_1="-28.9" MEAN_2="-33.4" MODIFIED="2012-07-05 14:00:05 +0100" MODIFIED_BY="Laila Asmal" ORDER="568" SD_1="28.6" SD_2="20.8" SE="8.145392057151447" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="17" WEIGHT="1.3446981257340627"/>
<CONT_DATA CI_END="11.636211595553027" CI_START="-4.636211595553027" EFFECT_SIZE="3.5" ESTIMABLE="YES" MEAN_1="72.9" MEAN_2="69.4" MODIFIED="2012-07-05 14:00:38 +0100" MODIFIED_BY="Laila Asmal" ORDER="569" SD_1="15.1" SD_2="10.8" SE="4.151204644437564" STUDY_ID="STD-Mori-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="5.177266226450376"/>
<CONT_DATA CI_END="11.48862861624942" CI_START="-18.728628616249424" EFFECT_SIZE="-3.620000000000001" ESTIMABLE="YES" MEAN_1="-21.5" MEAN_2="-17.88" MODIFIED="2012-07-05 14:01:26 +0100" MODIFIED_BY="Laila Asmal" ORDER="570" SD_1="23.39" SD_2="20.71" SE="7.708625635687367" STUDY_ID="STD-Riedel-2007" TOTAL_1="16" TOTAL_2="17" WEIGHT="1.501394688709615"/>
<CONT_DATA CI_END="11.939941957500938" CI_START="-8.459941957500934" EFFECT_SIZE="1.740000000000002" ESTIMABLE="YES" MEAN_1="-43.91" MEAN_2="-45.65" MODIFIED="2012-07-05 14:02:29 +0100" MODIFIED_BY="Laila Asmal" ORDER="571" SD_1="20.94" SD_2="11.96" SE="5.204147646567374" STUDY_ID="STD-Svestka-2003b" TOTAL_1="22" TOTAL_2="20" WEIGHT="3.294196991972222"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.8626019212952212" CI_END="9.170788884691813" CI_START="1.9717868947764199" DF="2" EFFECT_SIZE="5.5712878897341165" ESTIMABLE="YES" I2="0.0" ID="CMP-009.01.02" MODIFIED="2012-07-05 14:05:13 +0100" MODIFIED_BY="Laila Asmal" NO="2" P_CHI2="0.39404080345024217" P_Z="0.0024163738621403694" STUDIES="3" TAU2="0.0" TOTAL_1="240" TOTAL_2="242" WEIGHT="26.452113119723364" Z="3.0336215010579157">
<NAME>medium term</NAME>
<CONT_DATA CI_END="8.338608670479879" CI_START="-0.13860867047987746" EFFECT_SIZE="4.1000000000000005" ESTIMABLE="YES" MEAN_1="-7.2" MEAN_2="-11.3" MODIFIED="2012-07-05 14:03:35 +0100" MODIFIED_BY="Laila Asmal" ORDER="572" SD_1="21.2" SD_2="18.3" SE="2.1625951823163496" STUDY_ID="STD-Kinon-2006b" TOTAL_1="169" TOTAL_2="166" WEIGHT="19.076483567298922"/>
<CONT_DATA CI_END="21.044500510629547" CI_START="-8.244500510629546" EFFECT_SIZE="6.4" ESTIMABLE="YES" MEAN_1="-1.3" MEAN_2="-7.7" MODIFIED="2012-07-05 14:04:03 +0100" MODIFIED_BY="Laila Asmal" ORDER="573" SD_1="19.23" SD_2="9.8" SE="7.47182123046316" STUDY_ID="STD-McEvoy-2006" TOTAL_1="8" TOTAL_2="10" WEIGHT="1.5980701523324135"/>
<CONT_DATA CI_END="17.90194253453346" CI_START="2.4980574654665384" EFFECT_SIZE="10.2" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="-8.2" MODIFIED="2012-07-05 14:04:35 +0100" MODIFIED_BY="Laila Asmal" ORDER="574" SD_1="22.31" SD_2="22.31" SE="3.929634725579348" STUDY_ID="STD-Stroup-2006" TOTAL_1="63" TOTAL_2="66" WEIGHT="5.777559400092029"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.6989654174998787" CI_END="7.011112056012459" CI_START="1.601782353353487" DF="1" EFFECT_SIZE="4.306447204682973" ESTIMABLE="YES" I2="0.0" ID="CMP-009.01.03" MODIFIED="2012-07-05 14:07:14 +0100" MODIFIED_BY="Laila Asmal" NO="3" P_CHI2="0.40313197301172043" P_Z="0.0018041407460735073" STUDIES="2" TAU2="0.0" TOTAL_1="373" TOTAL_2="367" WEIGHT="46.85091238270823" Z="3.1207125046760873">
<NAME>long term</NAME>
<CONT_DATA CI_END="8.59671223050518" CI_START="1.783287769494819" EFFECT_SIZE="5.1899999999999995" ESTIMABLE="YES" MEAN_1="-6.08" MEAN_2="-11.27" MODIFIED="2012-07-05 14:06:26 +0100" MODIFIED_BY="Laila Asmal" ORDER="576" SD_1="22.31" SD_2="22.31" SE="1.7381504238735466" STUDY_ID="STD-Lieberman-2005" TOTAL_1="329" TOTAL_2="330" WEIGHT="29.530722173965586"/>
<CONT_DATA CI_END="7.248321366050968" CI_START="-1.6483213660509701" EFFECT_SIZE="2.799999999999999" ESTIMABLE="YES" MEAN_1="-15.6" MEAN_2="-18.4" MODIFIED="2012-07-05 14:07:14 +0100" MODIFIED_BY="Laila Asmal" ORDER="577" SD_1="10.68" SD_2="9.73" SE="2.2695934216846636" STUDY_ID="STD-McEvoy-2007" TOTAL_1="44" TOTAL_2="37" WEIGHT="17.320190208742645"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.386516078416938" CI_END="2.6729165073112218" CI_START="1.015959641929176" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="1.844438074620199" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.02" MODIFIED="2013-10-22 15:22:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6245222015475269" P_Q="0.5781735070784751" P_Z="1.2802157222690982E-5" Q="1.0957629688472892" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="342" TOTAL_2="334" UNITS="" WEIGHT="100.0" Z="4.3634596331347115">
<NAME>Mental state: 2. Positive symptoms - average endpoint score (PANSS positive subscore, high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.1413893470780176" CI_END="3.2396228409035857" CI_START="-1.865154559962602" DF="2" EFFECT_SIZE="0.6872341404704918" ESTIMABLE="YES" I2="0.0" ID="CMP-009.02.01" MODIFIED="2012-07-05 10:39:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5651328878759869" P_Z="0.5976916251466959" STUDIES="3" TAU2="0.0" TOTAL_1="58" TOTAL_2="54" WEIGHT="10.535830805801346" Z="0.5277229773192268">
<NAME>short term</NAME>
<CONT_DATA CI_END="9.009449318965011" CI_START="-2.609449318965013" EFFECT_SIZE="3.1999999999999993" ESTIMABLE="YES" MEAN_1="-9.4" MEAN_2="-12.6" MODIFIED="2012-07-05 10:39:03 +0100" MODIFIED_BY="Laila Asmal" ORDER="564" SD_1="8.6" SD_2="9.3" SE="2.9640592198577154" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="17" WEIGHT="2.033726181782492"/>
<CONT_DATA CI_END="4.023603349657839" CI_START="-5.943603349657839" EFFECT_SIZE="-0.96" ESTIMABLE="YES" MEAN_1="-7.78" MEAN_2="-6.82" ORDER="1511" SD_1="7.3" SD_2="7.3" SE="2.542701492970211" STUDY_ID="STD-Riedel-2007" TOTAL_1="16" TOTAL_2="17" WEIGHT="2.7636018592952762"/>
<CONT_DATA CI_END="4.048453250956895" CI_START="-2.8684532509568945" EFFECT_SIZE="0.5899999999999999" ESTIMABLE="YES" MEAN_1="-12.96" MEAN_2="-13.55" ORDER="1512" SD_1="6.28" SD_2="5.14" SE="1.7645493887830246" STUDY_ID="STD-Svestka-2003b" TOTAL_1="22" TOTAL_2="20" WEIGHT="5.738502764723579"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.260339855868683" CI_END="3.5210687931832028" CI_START="0.9030691428647901" DF="2" EFFECT_SIZE="2.2120689680239964" ESTIMABLE="YES" I2="11.517730627663978" ID="CMP-009.02.02" MODIFIED="2009-08-10 13:46:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.32297870559034303" P_Z="9.258903688393746E-4" STUDIES="3" TAU2="0.21368085879104873" TOTAL_1="240" TOTAL_2="243" WEIGHT="55.062062608446105" Z="3.3121284092749255">
<NAME>medium term</NAME>
<CONT_DATA CI_END="2.888759794804241" CI_START="0.3112402051957588" EFFECT_SIZE="1.5999999999999999" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="-2.3" ORDER="1513" SD_1="6.6" SD_2="5.4" SE="0.6575425900525794" STUDY_ID="STD-Kinon-2006b" TOTAL_1="169" TOTAL_2="167" WEIGHT="41.325532300419745"/>
<CONT_DATA CI_END="8.340619042047734" CI_START="-1.3406190420477353" EFFECT_SIZE="3.5" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="-2.9" ORDER="1514" SD_1="5.94" SD_2="4.11" SE="2.4697489750984816" STUDY_ID="STD-McEvoy-2006" TOTAL_1="8" TOTAL_2="10" WEIGHT="2.9292780986857876"/>
<CONT_DATA CI_END="6.120133594894409" CI_START="1.0798664051055908" EFFECT_SIZE="3.6" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="-3.4" ORDER="1515" SD_1="7.3" SD_2="7.3" SE="1.2858060733630319" STUDY_ID="STD-Stroup-2006" TOTAL_1="63" TOTAL_2="66" WEIGHT="10.807252209340572"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.2125007550028224" CI_START="0.38749924499717747" DF="0" EFFECT_SIZE="1.7999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-009.02.03" MODIFIED="2009-08-10 13:46:11 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.01250188961929898" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="37" WEIGHT="34.40210658575254" Z="2.4976518842038056">
<NAME>long term</NAME>
<CONT_DATA CI_END="3.2125007550028224" CI_START="0.38749924499717747" EFFECT_SIZE="1.7999999999999998" ESTIMABLE="YES" MEAN_1="-5.3" MEAN_2="-7.1" ORDER="1516" SD_1="3.38" SD_2="3.1" SE="0.7206768931186737" STUDY_ID="STD-McEvoy-2007" TOTAL_1="44" TOTAL_2="37" WEIGHT="34.40210658575254"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.917393003275473" CI_END="1.1409126377394045" CI_START="-0.3733241203460905" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="0.38379425869665706" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.03" MODIFIED="2013-10-22 15:23:13 +0100" MODIFIED_BY="Laila Asmal" NO="3" P_CHI2="0.96427057700387" P_Q="0.7845557817884914" P_Z="0.3204497560495453" Q="0.48527522914775945" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="362" TOTAL_2="354" UNITS="" WEIGHT="100.0" Z="0.9935340963057313">
<NAME>Mental state: 3. Negative symptoms - average endpoint score (PANSS negative subscore, high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Olanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.2812162801697737" CI_END="1.560964333788202" CI_START="-1.697421826626999" DF="3" EFFECT_SIZE="-0.0682287464193984" ESTIMABLE="YES" I2="0.0" ID="CMP-009.03.01" MODIFIED="2012-07-05 14:27:51 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.733598323285919" P_Z="0.9345822587562347" STUDIES="4" TAU2="0.0" TOTAL_1="78" TOTAL_2="74" WEIGHT="21.596454764842818" Z="0.08208105430652639">
<NAME>short term</NAME>
<CONT_DATA CI_END="4.267523390908843" CI_START="-5.667523390908843" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="-6.3" MEAN_2="-5.6" MODIFIED="2012-07-05 14:26:06 +0100" MODIFIED_BY="Laila Asmal" ORDER="578" SD_1="9.5" SD_2="5.7" SE="2.5344972816296796" STUDY_ID="STD-Hatta-2009" TOTAL_1="20" TOTAL_2="17" WEIGHT="2.3229921171090915"/>
<CONT_DATA CI_END="3.4811162326989713" CI_START="-1.4811162326989713" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="23.8" MEAN_2="22.8" MODIFIED="2012-07-05 14:26:29 +0100" MODIFIED_BY="Laila Asmal" ORDER="579" SD_1="4.6" SD_2="3.3" SE="1.2658988901172161" STUDY_ID="STD-Mori-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="9.311793949476208"/>
<CONT_DATA CI_END="3.7938013295592885" CI_START="-5.053801329559288" EFFECT_SIZE="-0.6299999999999999" ESTIMABLE="YES" MEAN_1="-3.98" MEAN_2="-3.35" MODIFIED="2012-07-05 14:27:14 +0100" MODIFIED_BY="Laila Asmal" ORDER="580" SD_1="6.48" SD_2="6.48" SE="2.2570829691023246" STUDY_ID="STD-Riedel-2007" TOTAL_1="16" TOTAL_2="17" WEIGHT="2.929114495071953"/>
<CONT_DATA CI_END="1.815007442595907" CI_START="-3.8950074425959054" EFFECT_SIZE="-1.0399999999999991" ESTIMABLE="YES" MEAN_1="-9.59" MEAN_2="-8.55" MODIFIED="2012-07-05 14:27:51 +0100" MODIFIED_BY="Laila Asmal" ORDER="581" SD_1="4.91" SD_2="4.53" SE="1.4566632168324727" STUDY_ID="STD-Svestka-2003b" TOTAL_1="22" TOTAL_2="20" WEIGHT="7.0325542031855655"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.15090149395794006" CI_END="1.4689115547914637" CI_START="-0.66696781739775" DF="2" EFFECT_SIZE="0.4009718686968568" ESTIMABLE="YES" I2="0.0" ID="CMP-009.03.02" MODIFIED="2012-07-05 14:29:41 +0100" MODIFIED_BY="Laila Asmal" NO="2" P_CHI2="0.9273254221229614" P_Z="0.46179520663723483" STUDIES="3" TAU2="0.0" TOTAL_1="240" TOTAL_2="243" WEIGHT="50.26134729778806" Z="0.7358940132036091">
<NAME>medium term</NAME>
<CONT_DATA CI_END="1.6617889458647217" CI_START="-0.8617889458647219" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="-3.6" MEAN_2="-4.0" MODIFIED="2012-07-05 14:28:31 +0100" MODIFIED_BY="Laila Asmal" ORDER="582" SD_1="6.0" SD_2="5.8" SE="0.6437816999789547" STUDY_ID="STD-Kinon-2006b" TOTAL_1="169" TOTAL_2="167" WEIGHT="36.00428086127721"/>
<CONT_DATA CI_END="4.122576017319448" CI_START="-4.922576017319448" EFFECT_SIZE="-0.40000000000000013" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.7" MODIFIED="2012-07-05 14:29:08 +0100" MODIFIED_BY="Laila Asmal" ORDER="583" SD_1="6.22" SD_2="2.21" SE="2.307479144001089" STUDY_ID="STD-McEvoy-2006" TOTAL_1="8" TOTAL_2="10" WEIGHT="2.8025658572015986"/>
<CONT_DATA CI_END="2.8370500951939412" CI_START="-1.637050095193941" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="-0.4" MODIFIED="2012-07-05 14:29:41 +0100" MODIFIED_BY="Laila Asmal" ORDER="584" SD_1="6.48" SD_2="6.48" SE="1.141373062382527" STUDY_ID="STD-Stroup-2006" TOTAL_1="63" TOTAL_2="66" WEIGHT="11.45450057930925"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.1271998196488386" CI_START="-0.7271998196488385" DF="0" EFFECT_SIZE="0.7000000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-009.03.03" MODIFIED="2012-07-05 14:30:56 +0100" MODIFIED_BY="Laila Asmal" NO="3" P_CHI2="1.0" P_Z="0.3363986823427271" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="37" WEIGHT="28.142197937369115" Z="0.9613053268992225">
<NAME>long term</NAME>
<CONT_DATA CI_END="2.1271998196488386" CI_START="-0.7271998196488385" EFFECT_SIZE="0.7000000000000002" ESTIMABLE="YES" MEAN_1="-2.8" MEAN_2="-3.5" MODIFIED="2012-07-05 14:30:56 +0100" MODIFIED_BY="Laila Asmal" ORDER="585" SD_1="3.45" SD_2="3.1" SE="0.7281765537052766" STUDY_ID="STD-McEvoy-2007" TOTAL_1="44" TOTAL_2="37" WEIGHT="28.142197937369115"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2013-10-22 15:23:42 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>QUETIAPINE versus RISPERIDONE- sensitivity analysis (skewed data excluded)</NAME>
<DICH_OUTCOME CHI2="1.33997166471511" CI_END="1.0851893139291375" CI_START="0.9341472756200434" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.006839928260142" ESTIMABLE="YES" EVENTS_1="316" EVENTS_2="307" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="0.03550550852813327" LOG_CI_START="-0.029584648452065324" LOG_EFFECT_SIZE="0.002960430038033941" METHOD="MH" MODIFIED="2013-02-25 10:23:28 +0000" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.5117158686357783" P_Q="1.0" P_Z="0.8584982672162624" Q="0.0" RANDOM="YES" SCALE="2.56" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="484" TOTAL_2="481" WEIGHT="100.00000000000001" Z="0.17828613487788295">
<NAME>Global state: 1a. No clinically significant response (as defined by the original studies)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experiment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1598200223752566" CI_START="0.8622027389663848" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.064390601853161" LOG_CI_START="-0.06439060185316105" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-02-21 13:35:58 +0000" MODIFIED_BY="Laila Asmal" ORDER="1199" O_E="0.0" SE="0.07564671653433303" STUDY_ID="STD-Conley-2005" TOTAL_1="12" TOTAL_2="13" VAR="0.0057224257224257336" WEIGHT="25.5461629299471"/>
<DICH_DATA CI_END="1.6036965973705413" CI_START="0.8720709417175673" EFFECT_SIZE="1.182597650047634" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="47" LOG_CI_END="0.20512220774405118" LOG_CI_START="-0.05944818439852908" LOG_EFFECT_SIZE="0.07283701167276108" MODIFIED="2013-02-21 13:36:19 +0000" MODIFIED_BY="Laila Asmal" ORDER="1200" O_E="0.0" SE="0.15540995798911444" STUDY_ID="STD-McEvoy-2007" TOTAL_1="134" TOTAL_2="133" VAR="0.02415225504217832" WEIGHT="6.052686161367371"/>
<DICH_DATA CI_END="1.089516066925826" CI_START="0.9089333311176175" EFFECT_SIZE="0.9951369091823778" ESTIMABLE="YES" EVENTS_1="248" EVENTS_2="247" LOG_CI_END="0.0372336391034098" LOG_CI_START="-0.04146797045192777" LOG_EFFECT_SIZE="-0.0021171656742589753" MODIFIED="2013-02-21 13:36:45 +0000" MODIFIED_BY="Laila Asmal" ORDER="1201" O_E="0.0" SE="0.04622971503205563" STUDY_ID="STD-Zhong-2006" TOTAL_1="338" TOTAL_2="335" VAR="0.00213718655194507" WEIGHT="68.40115090868554"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="8.155563986900324" CI_END="4.711600440748637" CI_START="1.4943528727375277" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="3.1029766567430825" ESTIMABLE="YES" I2="1.9074583578792943" I2_Q="0.0" ID="CMP-010.02" MODIFIED="2013-10-22 15:23:24 +0100" MODIFIED_BY="Laila Asmal" NO="2" P_CHI2="0.4184237670408174" P_Q="0.8022061210858586" P_Z="1.5638859560469792E-4" Q="0.44077971921535847" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.1244755976698761" TOTALS="YES" TOTAL_1="1000" TOTAL_2="986" UNITS="" WEIGHT="100.0" Z="3.780699099786496">
<NAME>Mental state: 1. General - average endpoint score - (PANSS total score, high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.500020994753906" CI_END="5.034832859939444" CI_START="0.5027061597537688" DF="4" EFFECT_SIZE="2.7687695098466065" ESTIMABLE="YES" I2="11.111525820364553" ID="CMP-010.02.01" MODIFIED="2012-07-05 14:48:34 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.342545111397342" P_Z="0.016631034198956483" STUDIES="5" TAU2="0.8102729221343393" TOTAL_1="556" TOTAL_2="541" WEIGHT="60.28777966088295" Z="2.394764700894017">
<NAME>short term</NAME>
<CONT_DATA CI_END="9.93866298113007" CI_START="-7.138662981130059" EFFECT_SIZE="1.4000000000000057" ESTIMABLE="YES" MEAN_1="72.9" MEAN_2="71.5" MODIFIED="2012-07-05 14:46:44 +0100" MODIFIED_BY="Laila Asmal" ORDER="586" SD_1="15.1" SD_2="12.0" SE="4.356540757116941" STUDY_ID="STD-Mori-2004" TOTAL_1="20" TOTAL_2="19" WEIGHT="3.5260643264502485"/>
<CONT_DATA CI_END="12.183551222155742" CI_START="2.2164487778442563" EFFECT_SIZE="7.199999999999999" ESTIMABLE="YES" MEAN_1="-20.5" MEAN_2="-27.7" MODIFIED="2012-07-05 14:47:13 +0100" MODIFIED_BY="Laila Asmal" ORDER="587" SD_1="22.31" SD_2="22.31" SE="2.5426748968171653" STUDY_ID="STD-Potkin-2006" TOTAL_1="156" TOTAL_2="152" WEIGHT="10.22230987395759"/>
<CONT_DATA CI_END="12.484125205312408" CI_START="-13.884125205312406" EFFECT_SIZE="-0.6999999999999993" ESTIMABLE="YES" MEAN_1="-30.4" MEAN_2="-29.7" MODIFIED="2012-07-05 14:47:41 +0100" MODIFIED_BY="Laila Asmal" ORDER="588" SD_1="22.31" SD_2="22.31" SE="6.726718097529906" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" WEIGHT="1.484613020639405"/>
<CONT_DATA CI_END="4.136895561427381" CI_START="-1.7368955614273895" EFFECT_SIZE="1.1999999999999957" ESTIMABLE="YES" MEAN_1="43.3" MEAN_2="42.1" MODIFIED="2012-07-05 14:48:06 +0100" MODIFIED_BY="Laila Asmal" ORDER="589" SD_1="6.0" SD_2="5.6" SE="1.4984436370225385" STUDY_ID="STD-Wang-2006" TOTAL_1="30" TOTAL_2="30" WEIGHT="28.42493349768527"/>
<CONT_DATA CI_END="6.883583336995214" CI_START="-0.8835833369952106" EFFECT_SIZE="3.0000000000000018" ESTIMABLE="YES" MEAN_1="-15.1" MEAN_2="-18.1" MODIFIED="2012-07-05 14:48:34 +0100" MODIFIED_BY="Laila Asmal" ORDER="590" SD_1="25.36" SD_2="25.0" SE="1.9814564796233105" STUDY_ID="STD-Zhong-2006" TOTAL_1="328" TOTAL_2="318" WEIGHT="16.629858942150438"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.7490220222505004" CI_END="16.47653330198642" CI_START="-3.93532971252033" DF="1" EFFECT_SIZE="6.270601794733047" ESTIMABLE="YES" I2="42.825191033713764" ID="CMP-010.02.02" MODIFIED="2012-07-05 14:53:35 +0100" MODIFIED_BY="Laila Asmal" NO="2" P_CHI2="0.18599983726260394" P_Z="0.22850583528373547" STUDIES="2" TAU2="25.909240575396815" TOTAL_1="71" TOTAL_2="75" WEIGHT="5.66348004163352" Z="1.2042167508506558">
<NAME>medium term</NAME>
<CONT_DATA CI_END="13.411717823063478" CI_START="-15.411717823063478" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-1.3" MEAN_2="-0.3" MODIFIED="2012-07-05 14:53:03 +0100" MODIFIED_BY="Laila Asmal" ORDER="591" SD_1="19.23" SD_2="6.86" SE="7.353052370727864" STUDY_ID="STD-McEvoy-2006" TOTAL_1="8" TOTAL_2="6" WEIGHT="1.2430218814049026"/>
<CONT_DATA CI_END="17.619733932408348" CI_START="2.380266067591653" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="-8.0" MODIFIED="2012-07-05 14:53:35 +0100" MODIFIED_BY="Laila Asmal" ORDER="592" SD_1="22.31" SD_2="22.31" SE="3.88769079050015" STUDY_ID="STD-Stroup-2006" TOTAL_1="63" TOTAL_2="69" WEIGHT="4.420458160228617"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.013193317092991451" CI_END="5.81969128852787" CI_START="0.39982423087631336" DF="1" EFFECT_SIZE="3.1097577597020916" ESTIMABLE="YES" I2="0.0" ID="CMP-010.02.03" MODIFIED="2012-07-05 14:55:34 +0100" MODIFIED_BY="Laila Asmal" NO="3" P_CHI2="0.908554376003934" P_Z="0.02450374730955488" STUDIES="2" TAU2="0.0" TOTAL_1="373" TOTAL_2="370" WEIGHT="34.04874029748353" Z="2.2491375322777936">
<NAME>long term</NAME>
<CONT_DATA CI_END="6.629042464533064" CI_START="-0.16904246453306282" EFFECT_SIZE="3.2300000000000004" ESTIMABLE="YES" MEAN_1="-6.08" MEAN_2="-9.31" MODIFIED="2012-07-05 14:54:52 +0100" MODIFIED_BY="Laila Asmal" ORDER="593" SD_1="22.31" SD_2="22.31" SE="1.7342372060631095" STUDY_ID="STD-Lieberman-2005" TOTAL_1="329" TOTAL_2="333" WEIGHT="21.507181915071968"/>
<CONT_DATA CI_END="7.389387351577182" CI_START="-1.589387351577181" EFFECT_SIZE="2.9000000000000004" ESTIMABLE="YES" MEAN_1="-15.6" MEAN_2="-18.5" MODIFIED="2012-07-05 14:55:34 +0100" MODIFIED_BY="Laila Asmal" ORDER="594" SD_1="10.68" SD_2="9.91" SE="2.2905458401220105" STUDY_ID="STD-McEvoy-2007" TOTAL_1="44" TOTAL_2="37" WEIGHT="12.54155838241157"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.213682230496568" CI_END="2.479016124507027" CI_START="1.0429389396189848" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="1.760977532063006" ESTIMABLE="YES" I2="4.09848972472218" I2_Q="0.0" ID="CMP-010.03" MODIFIED="2013-10-22 15:23:32 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.39036304447932446" P_Q="0.7024492120903298" P_Z="1.5338168718638488E-6" Q="0.7063646372009018" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.03663426479896104" TOTALS="YES" TOTAL_1="621" TOTAL_2="604" UNITS="" WEIGHT="100.0" Z="4.806778600408999">
<NAME>Mental state: 6. Positive symptoms - average endpoint score - (PANSS positive subscore, high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.351936445517882" CI_END="3.556062782612567" CI_START="0.6035643808667159" DF="2" EFFECT_SIZE="2.0798135817396415" ESTIMABLE="YES" I2="54.04344652000084" ID="CMP-010.03.01" MODIFIED="2009-08-10 13:46:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.11349829000728817" P_Z="0.0057572626181698686" STUDIES="3" TAU2="0.8569088578330966" TOTAL_1="506" TOTAL_2="492" WEIGHT="65.46348259120823" Z="2.761295120333711">
<NAME>short term</NAME>
<CONT_DATA CI_END="4.184853056798829" CI_START="1.415146943201169" EFFECT_SIZE="2.799999999999999" ESTIMABLE="YES" MEAN_1="-5.9" MEAN_2="-8.7" ORDER="1517" SD_1="6.24" SD_2="6.16" SE="0.7065706654420051" STUDY_ID="STD-Potkin-2006" TOTAL_1="156" TOTAL_2="152" WEIGHT="25.045792886482285"/>
<CONT_DATA CI_END="8.113945047009437" CI_START="-0.5139450470094387" EFFECT_SIZE="3.8" ESTIMABLE="YES" MEAN_1="-3.8" MEAN_2="-7.6" ORDER="1518" SD_1="7.3" SD_2="7.3" SE="2.2010328154176744" STUDY_ID="STD-Riedel-2005" TOTAL_1="22" TOTAL_2="22" WEIGHT="2.7496321276894893"/>
<CONT_DATA CI_END="2.208158543690458" CI_START="-0.008158543690458764" EFFECT_SIZE="1.0999999999999996" ESTIMABLE="YES" MEAN_1="-4.5" MEAN_2="-5.6" ORDER="1519" SD_1="7.24" SD_2="7.13" SE="0.5653974013968989" STUDY_ID="STD-Zhong-2006" TOTAL_1="328" TOTAL_2="318" WEIGHT="37.668057577036464"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.3007984115356175" CI_END="4.313911912039684" CI_START="-0.00926839772661614" DF="1" EFFECT_SIZE="2.152321757156534" ESTIMABLE="YES" I2="0.0" ID="CMP-010.03.02" MODIFIED="2009-08-10 13:46:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5833824121997122" P_Z="0.05099045271788573" STUDIES="2" TAU2="0.0" TOTAL_1="71" TOTAL_2="75" WEIGHT="10.830445622739255" Z="1.9515601131134919">
<NAME>medium term</NAME>
<CONT_DATA CI_END="5.437591153162744" CI_START="-3.2375911531627435" EFFECT_SIZE="1.1" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="-0.5" ORDER="1520" SD_1="5.94" SD_2="1.71" SE="2.213097376980959" STUDY_ID="STD-McEvoy-2006" TOTAL_1="8" TOTAL_2="6" WEIGHT="2.7199569103759424"/>
<CONT_DATA CI_END="4.993234321227295" CI_START="0.00676567877270573" EFFECT_SIZE="2.5" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="-2.3" ORDER="1521" SD_1="7.3" SD_2="7.3" SE="1.2720817019565709" STUDY_ID="STD-Stroup-2006" TOTAL_1="63" TOTAL_2="69" WEIGHT="8.110488712363312"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.726237841691966" CI_START="-0.12623784169196628" DF="0" EFFECT_SIZE="1.2999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-010.03.03" MODIFIED="2009-08-10 13:46:35 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.07402068788955288" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="37" WEIGHT="23.706071786052505" Z="1.7864854692674523">
<NAME>long term</NAME>
<CONT_DATA CI_END="2.726237841691966" CI_START="-0.12623784169196628" EFFECT_SIZE="1.2999999999999998" ESTIMABLE="YES" MEAN_1="-5.3" MEAN_2="-6.6" ORDER="1522" SD_1="3.38" SD_2="3.16" SE="0.7276857396064152" STUDY_ID="STD-McEvoy-2007" TOTAL_1="44" TOTAL_2="37" WEIGHT="23.706071786052505"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.103502238035227" CI_END="1.541055037581546" CI_START="0.04209649147956873" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="0.7915757645305573" ESTIMABLE="YES" I2="18.079820322806242" I2_Q="0.0" ID="CMP-010.04" MODIFIED="2013-10-22 15:23:42 +0100" MODIFIED_BY="Laila Asmal" NO="4" P_CHI2="0.29627767782839187" P_Q="0.8239138720006433" P_Z="0.0384476099207398" Q="0.38737870843907163" RANDOM="YES" SCALE="2.442218569992257" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.1590658082056239" TOTALS="YES" TOTAL_1="572" TOTAL_2="567" UNITS="" WEIGHT="100.0" Z="2.0700505608366595">
<NAME>Mental state: 6. Negative symptoms - average endpoint score - (PANSS negative subscore, high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.000891841140653" CI_END="1.8754986510172977" CI_START="-0.8248624772748631" DF="2" EFFECT_SIZE="0.5253180868712174" ESTIMABLE="YES" I2="60.00713345674319" ID="CMP-010.04.01" MODIFIED="2012-07-05 15:12:51 +0100" MODIFIED_BY="Laila Asmal" NO="1" P_CHI2="0.08204847270409865" P_Z="0.44572106422788027" STUDIES="3" TAU2="0.8022841432218832" TOTAL_1="457" TOTAL_2="455" WEIGHT="67.0426029622032" Z="0.7625680283334855">
<NAME>short term</NAME>
<CONT_DATA CI_END="1.1533942688869012" CI_START="-4.753394268886902" EFFECT_SIZE="-1.8000000000000007" ESTIMABLE="YES" MEAN_1="23.8" MEAN_2="25.6" MODIFIED="2012-07-05 15:11:49 +0100" MODIFIED_BY="Laila Asmal" ORDER="595" SD_1="4.6" SD_2="4.8" SE="1.506861499590247" STUDY_ID="STD-Mori-2004" TOTAL_1="20" TOTAL_2="19" WEIGHT="6.01825915365996"/>
<CONT_DATA CI_END="2.6089951277876717" CI_START="0.39100487221232827" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="-4.0" MODIFIED="2012-07-05 15:12:20 +0100" MODIFIED_BY="Laila Asmal" ORDER="596" SD_1="5.0" SD_2="4.93" SE="0.5658242378611463" STUDY_ID="STD-Potkin-2006" TOTAL_1="156" TOTAL_2="152" WEIGHT="30.513043642705846"/>
<CONT_DATA CI_END="1.5090425542006587" CI_START="-0.7090425542006598" EFFECT_SIZE="0.39999999999999947" ESTIMABLE="YES" MEAN_1="-3.7" MEAN_2="-4.1" MODIFIED="2012-07-05 15:12:51 +0100" MODIFIED_BY="Laila Asmal" ORDER="597" SD_1="6.71" SD_2="6.74" SE="0.5658484354552662" STUDY_ID="STD-Zhong-2006" TOTAL_1="281" TOTAL_2="284" WEIGHT="30.51130016583739"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.8715577869831449" CI_END="3.353433626709635" CI_START="-0.7472178347031433" DF="1" EFFECT_SIZE="1.3031078960032458" ESTIMABLE="YES" I2="0.0" ID="CMP-010.04.02" MODIFIED="2012-07-05 15:19:56 +0100" MODIFIED_BY="Laila Asmal" NO="2" P_CHI2="0.3505245037723598" P_Z="0.21288285671352458" STUDIES="2" TAU2="0.0" TOTAL_1="71" TOTAL_2="75" WEIGHT="12.051862676383712" Z="1.2456774579208911">
<NAME>medium term</NAME>
<CONT_DATA CI_END="4.345849663525293" CI_START="-6.545849663525292" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="0.0" MODIFIED="2012-07-05 15:13:58 +0100" MODIFIED_BY="Laila Asmal" ORDER="599" SD_1="6.22" SD_2="4.16" SE="2.7785457827192026" STUDY_ID="STD-McEvoy-2006" TOTAL_1="8" TOTAL_2="6" WEIGHT="1.8557987999045804"/>
<CONT_DATA CI_END="3.9131723837743655" CI_START="-0.5131723837743658" EFFECT_SIZE="1.7" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="-1.5" MODIFIED="2012-07-05 15:19:56 +0100" MODIFIED_BY="Laila Asmal" ORDER="600" SD_1="6.48" SD_2="6.48" SE="1.129190332695696" STUDY_ID="STD-Stroup-2006" TOTAL_1="63" TOTAL_2="69" WEIGHT="10.196063876479132"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.240796766860716" CI_START="-0.6407967668607153" DF="0" EFFECT_SIZE="0.8000000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-010.04.03" MODIFIED="2012-07-05 15:15:31 +0100" MODIFIED_BY="Laila Asmal" NO="3" P_CHI2="1.0" P_Z="0.2764773898243499" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="37" WEIGHT="20.905534361413086" Z="1.0882667310868712">
<NAME>long term</NAME>
<CONT_DATA CI_END="2.240796766860716" CI_START="-0.6407967668607153" EFFECT_SIZE="0.8000000000000003" ESTIMABLE="YES" MEAN_1="-2.8" MEAN_2="-3.6" MODIFIED="2012-07-05 15:15:31 +0100" MODIFIED_BY="Laila Asmal" ORDER="601" SD_1="3.45" SD_2="3.16" SE="0.7351138991458703" STUDY_ID="STD-McEvoy-2007" TOTAL_1="44" TOTAL_2="37" WEIGHT="20.905534361413086"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.375331353592689" CI_END="0.3128565792958342" CI_START="-1.951256502619694" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8191999616619299" ESTIMABLE="YES" I2="44.18948707236622" I2_Q="0.0" ID="CMP-010.05" MODIFIED="2013-02-21 13:34:07 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.14628833748488457" P_Q="1.0" P_Z="0.1561014878426741" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.5971144069148634" TOTALS="YES" TOTAL_1="521" TOTAL_2="512" UNITS="" WEIGHT="100.00000000000001" Z="1.4183058556735808">
<NAME>Adverse effects: 1. Extrapyramidal effects - Simpson-Angus Scale (high=poor)</NAME>
<GROUP_LABEL_1>Quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.131532638154782" CI_START="-2.8115326381547816" EFFECT_SIZE="-0.33999999999999986" ESTIMABLE="YES" MEAN_1="-1.64" MEAN_2="-1.3" ORDER="1523" SD_1="3.15" SD_2="3.15" SE="1.261009211215061" STUDY_ID="STD-Conley-2005" TOTAL_1="12" TOTAL_2="13" WEIGHT="15.252460693067446"/>
<CONT_DATA CI_END="1.6106402353010725" CI_START="-3.4106402353010723" EFFECT_SIZE="-0.9" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="0.8" ORDER="1524" SD_1="2.5" SD_2="15.65" SE="1.2809624335470866" STUDY_ID="STD-Potkin-2006" TOTAL_1="156" TOTAL_2="153" WEIGHT="14.906785973390988"/>
<CONT_DATA CI_END="-0.6153857235312612" CI_START="-4.584614276468739" EFFECT_SIZE="-2.6" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="2.2" ORDER="1525" SD_1="3.58" SD_2="3.58" SE="1.012576910659136" STUDY_ID="STD-Sacchetti-2004" TOTAL_1="25" TOTAL_2="25" WEIGHT="20.562458953245766"/>
<CONT_DATA CI_END="0.3539418535517811" CI_START="-0.753941853551781" EFFECT_SIZE="-0.19999999999999998" ESTIMABLE="YES" MEAN_1="-0.41" MEAN_2="-0.21" ORDER="1526" SD_1="3.62" SD_2="3.58" SE="0.28262858803590457" STUDY_ID="STD-Zhong-2006" TOTAL_1="328" TOTAL_2="321" WEIGHT="49.27829438029581"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-11-04 17:22:24 +0000" MODIFIED_BY="Laila Asmal">
<FIGURE FILENAME="quetiapine.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2013-10-23 13:54:43 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Quetiapine.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-06-25 09:33:46 +0100" MODIFIED_BY="Laila Asmal" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAPKCAYAAAC+wNxJAABX+klEQVR42u2dD2RW7///P2SSZMbM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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-11-04 17:22:24 +0000" MODIFIED_BY="Laila Asmal" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAU0AAAWsCAIAAAAixUanAABGfklEQVR42u3dvY4dx3r18QEMGA4Y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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-11-04 17:22:24 +0000" MODIFIED_BY="Laila Asmal" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAApsAAAEACAMAAADLBU1LAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAetUlEQVR42u1da2wc13U+lDh3ZnZJLmeWTESpdSWR9R/FQCpDliiL
TULJhok8lLoxItRJY+sHHcdyizR/bKNFmhTwQ4DRJnbSWAiitIkDGA5U2HlItaRN4yVbmCpcFLHR
wCApQY65VETOkhTJ2Z1Zcnsf89wHuVyR0u7qfBJ3Z+6ce8+5M9/ex+zcbwEQiNpEE2h4EhC1iPQm
PAeIGgVyE4HcRCCQmwjkJgKB3EQgNxEI5CYCsRqa8RTUENJ4CgLfBSE3668ba+i+Lod9OgLHmwgE
chOB3EQgkJsI5CaiBIwbnhFRi9zspyDqSMlDNyumbWV869FVItxaOmN/aesWEzlY2+1mIpGYJB+r
qRPTS6Mq1Sp+7v1VMu4vndGtacH+ZQ3b2Zrv0/WLSwAdKlE02ri0KyQJYEcJ+5LAjsgRegH7XyIH
9aQsi4ZGl4lCt4yIHDW4ycl+0SjRP7uFRG26FRsg1MQeICe9NF7coEaNRqIkMiJc6V45/e0yjUGi
MfTzfzDi+G53/e5s05lv1fcNXlmdzJ+TkcYeiIGhU+X+aCUfkWVaL5NIA0nQj+1EEtb8eLOHhrJg
WJFFup2fOH8QIE4m2bXX5KxyG30fnPx59lOpmRi3XohYEcqp22azZ+h1jiupx/2S4mlLjrONl8+3
0exfiz3K00hcHJWeZaXued+aPkTflydaFrxy4KcpGoNNY0iIFq7f8b3s+s0d5r5V3zcr61fW9B7K
tv9aaHczxiXrtWYvBobsB5E9fGP+C9kZ6jL2S/vUPQCHbSRhTXOTjTezb9Krq4JxN92/qPcdoFdz
TL/A6DAGo+ybrAu6uveirh7gOZptfZQ2SDkJ+lRqOaoHvorOSmBkRSl9ANbuqxmels6Koxe5raKD
atH3Szrz6JQDu3UvBkFF6tvmVo5fa1ehb1bWXaDSLXtcynoxjMNuxYuBYVqfUvhGpg9YYc0HTZMG
tgu5WQ41sc6yPwHJV77JutYdS7n9CbbP/uQsf2N7xHIT+R+1/IPcQ/92lffiQxY77FqyN5pIznh7
CXcOMsS46NnSzaQdzDIkfPgxFPsGuO8M8730Jd93uCwIZKTx+xnZ6+AJ9mZ3fuOJ3gQrJR+7KuJx
kcbv03Pa2k7GDUDfnbfxyTF5M3Q7hvW+w/Str2h4ujj56hw9RmdR9No2GTDi38EZoolnPMshPiYc
Eobg2TbRBL/JGvYOh2Mo8p0YYb5TAd9+WUOBaQ3dNvKhiDvB+Fe+0ZZvm+M1SL1E30ewfaz5z+DD
QNvN5d+OHvKT5J28UZdU6Hmr0Fw19SZ2zIaTtDeVu4HlG0oa21kXa8O5iGdJ3rYVnqaJNHkHHBoC
ODcCuuoZOeUw0Bj2eJQ+Xuib3EF9665vU/TSTllkpy1TynLGZ3vg7WwoYhNuF7OipanDbORLSzlC
2XsHQRLWfP+g7jUgcrQrENC0zac0iTgxi+7KvKFLCzP0WIw8OscsCcs329+1meVrl57370Kqz7ek
edo+kTadk5lt+uOyOec3h6IchujRLvaJIFv4naQ4yYR8Sx+mvk1pgZaVaCfaNdH7iLLSmZZzdBzZ
wrumrHQ4F67fgCnGxC+1djFqv7GXxKjph/EpxZoeb67XoLVSvHnfYrVejK6Uvp5Rh8vD8WZwvNk4
3AzOKVZC/lBSmpGqdnPy8fn1jDr64sOA3Gx0bjYCcE1GYE1GGkc7NXldEIDPISGQmwgEchOB3EQg
NhY4F8J5eq3OB5GbddSN3QqdHGonIHC8iUAgNxHITQQCuYlAbjYSjJtfNK7pXS9sBrWewtX2z2QA
+i+y/6XwrVy5IxVhpbzfFnc3tGZr5TzfLh2Ck1Z4KK9nAnuZphXDa7oFCLns8TFTZ+2m/dYXVzy+
snDBdaFXtIr70qvbrUE7IbcP29nG6NMN6/3vedfSjpIWm74psg7QoZBBT/HAbpGEcIEiJYUptzEi
RDU8uQQnLUqYOEJKJco50bBpRNY7uFSCc0zY9wu5mO5hCUxClA5PHoFHwv3ZquyFEPYlYuAxeb6S
EitFGu5GEjYEN3uyuuRdyzixmuMA7WrrIsD8WavXUzyIN9uEfeGVn0gc5KbCRpMtlQshcLkEJ23G
+ncN4KhhqZ90+D85k7G4VAI7tt21d4q2CECsxWqZp15mLPlJEckMX9mkya37XLuwL54ycUaINzBf
n6IsbbXOXgMgWSRhQ3DT0uE1b+FudgzGs0zeYCrDBQke9hQPjozD2CPAFA/6hOKBsFE8IQQul8DT
VCGAcFqFtJM9rav7hFQCO+bLKzh98HsA0teT7wk5BuMF4Y9uHWHaCVOnXbuwL4bLet8RvsF87Wdr
SJK7aPjvLSEJyw6v6+hZa2MLZczQpF6ka0B50ZnryyZWEi6AAiEEX1MhaYOx/aETnmBCUFAhIK/A
7SXWd7fbff87VaCdMJwt0k4IiS74MTm+aClNrVNr0k64Jb5Prz3thMq6dCmRSJAeZ2/Ik1agiOVP
/8CzGzYK7uQIG5bcVJgmZA+2bfrxtSJ3wyF5BYceNJe0MPnkfFCOgRlm3RL9EMLTatuNyfFFS1Fp
KUYTNpCN8FGcZjoD0lFn7696YKcC0NzTSV9zU7ue9wiX6YHu4K0Zx4aJMEgFaRkhmrAsjRY/kZXx
BRVYC8oVOJrfpf21qcvLQYkGOcWFGZq7OwZcu7AvhjZ4VxZ3SYQvJamnaH/+Lj4J1hDcfGSMvoy9
6LQ/z2QlexpgZvEa5cVsa9f3adrxLt4vZIkVajiFzeU4yVwuSEvHZCaaEJ1/onjZedoXVGAE5ENX
8g5Aq0YOnudyDJ8WcgwXe0iGhjbzwLVTrt3luBzwxTB37L5pvuH4anmFMO2Zd1DXoyHGm7Uw5H3w
dWk9y7M/83Ll2gm32HgTublGaOs7QMzHgw08cjPITRztrBHp9Z27NIUnbcsrGi/fWqcauVlTjTKe
glusm0AgNxEI5CYCuYlA4FwIwW8C4ClA7YRa78Zu3e4MtRMQON5EIJCbCOQmAoHcRCA3GwTGKvsb
7K46E0SF3GS/xqt08jU0/SGjogQHJ1tKJJokX00g/aG3yoxDW9sKbLaVLqyMn+hJb9OOyKTNXi3D
g6vHuhXptX7tZiIxqYplM0Wr/0vJARiPlkqNtVzPU2TVKx/0Fu+vQcPg/Ue9Vq5VTk1CfLUM2dVj
3Y/0Ws8+XU8vey2lxpf9G0wQQCQIKQI7KreLFqOb3AX9JhcQGImSyAjP03/go2BEZCE6IDMpAkVP
cimCTpUwtQKnXCFd4ORj6IzwPJ6dLhNV/DhpUpUULeDfUyMQW6IMplhA/UYNXsBJT0YhWiCjUMaP
Tna6DWF+TNfnsmKP/Y2ojugBLYuJNYz4EgnKCK2Hm84iaiGOrWPAbb3z4Z8Lp95+HRGrjzcDv40r
lv2/oqbcFdT5ibmDAHEp9YzYt67QlxOThLYxe2asaf4LvhNMO+A2Oav8iO68ngJ4ejKdyaZm2gE+
H7WiC16531UvLQbyAfz+d5Hb+IZjNx+xDPH91b2GHVn0/DeTSbHuBuKnJ9m3CKIM5veV2ewUzWL+
LPaoJ6Pwmk14G8jzruDniu02hMd3vGlDQNFgzwdnxLdn8cv2VVrWJ+RLplM8mYNfy246RbNkvdbs
t7QJ+IRCbb3z8fTk2cwn+blw6r3g1RGxCjfpgPOjx729i3zZ/09HdYcKIBQFsuP6nU679RvWdepj
TJZAApVdzjHepO0dg9HX6ftH6N6durpvt67Skl6cAq4jIMp9fawrkI8ip0/t5RuOnWSbplgsaaoi
o/CvjOkXnG71I/olCJbxVbpFr7i1+6q3yjKzG1h81Kl6YEU/v/FGmF9cGogOdPhnJa33iZ+izsa5
o33jXW7xVz4Lr0tuOnDFhDY5eEb38Vq65+NOvY/JMtztxdzs1RFRjOB6Iba8v3MuG1j9T//Y0v5Q
gpx15QDcLSYJAIUyAwHhAOfP7rSXexMlpQsgKGzg2I18fAnm+boxY8eMur+8f9+3r2YAsJKMQkk/
cqCpNHZYZnFlios3njihZNx0gAJvfi2LzocT88jHlp06Oh8D/D59Be2Eq4WT7E2FOgTgJeQNby8s
M1AsHMAnSfmpwLw+JF3A0OHmcezuWkxFHhMz7qb4m6X80/eRUBnDQs1gqEDDIFylMn58K9kAfXbJ
vwtkuxmc4gMSCfpLMdNLByHnkA/ePyol2hCo911mKtKCDWSF401tc+EtoW7YHkqQd4I2xLckprCx
HbplLjMQGKkeLxIO4J+IKTPQNDV3pwZC+Uy4PRO0U0296Ydi4Pt/o4cC/t92A6JbLN0pgxLguNgi
bzNVBEdG4R3oVsIVKu1HJX4FbSNGwx9KGtxRDFTRT8vTXCLheE+KltjDi9fuTHrprNfvgbdpmUmT
5yS2Y1t8PpyYmW/kYIXjTZL5dYHBBUs+FUqYtskJscUVNjYTa5pLEJh+A9AbJ5niGyyzrQ8EvP3K
3P5WKF9kYPFC0C56v7QwK+49Ht0SyDh9WP6Ws/VZmX2SaBmLc5TsW6C3nSzS+NXn59J8nxFwgMcX
QBk/f9fsztMvpVu25Gbo8f4u/kGdVTpFCdN/RDJRgK8s7qDF/4QX/8bQR7x04KINh+n0LBHjJSdb
HNvi8+HUm/meQRJWMN6sGJrFdfuMrRN6f6IxzoPdOqGvcNhQY9YNiALHm9enndBi55ujV8VwK7tA
rMY4JS1XV9QW1+fP9yE3a56biA3kJp4CQF2PGr8uCMBn5BDITQQCuYlAbiIQGwucC+E8vVbng8hN
7MZqqq6onYDADyoCgdxEIDcRCOQmArnZULhhCgqonXATuMkUFCKpNSgoaKUVFNqqCecmKyjkAw9b
JBWZ/Up6OdOtq0e5Dem13u1mIjFJxG9GVqagsK/UHePY+bnriOpmKSjk9nltXeehluzZa3ZZ0/2r
R9mL9Fr/Pl2fOe+1lOcUwgULBl0FhXYuemCo8jlHQWFYgn5TVulVnY6S6DTP03/g63RvkAsJtCs0
RR7UTWXQZEIIRDnnl6sO6l4+BvsYL8GzSw4SRazH7VBlFoPrPyI7bRzdYivdRBlMr4DGyhQU7GM0
3VFQMKKOmAPPW96PNNztNod/G5mCvgjzYauO2IIjzUBjNp2CVRumVTcdfD/gaieE6kfPgmyavN7G
1/i5Mcl9x5JIwjWNN52lWQxnJma5YMGzroLC8gRTHND+KXW/2Ld+QV+U1HfpZXxmxpKZrsL7XEFB
l04Q9rXTpgmA+1O95paJL8YAnn7DUp/xym2Xv7Po56No/qYq2OPYHey1zs7zhPk3sr2Lvv/vuJIO
mpJia79FGcxvfOaEvJ0WfUfrM66Cgkay39G8vCv4+YXlNoev8991ZSvZ4x9ExMdA+w8uzaDJf6k5
BUs/YOvTnfSAH6elTTj120Esidc5dU7v4vXWnj0xFae9S/TMnfcgCSvnJh1w/om/bPYpLjrwyBiX
KWC4xKUP1AdcSYXcLvaiH1YBXpDAeIHuHeaX/ZFxGGMLFEdZy6E/3HtR76Mlne6DdN4r1x6XMn4+
YEIFU4/wDceOPN6xSyyLzPTBw3f7/g+7/tVR/SkIlnGEbh2hIT0wddqthDoGLD4n7wp+dnlfmeVZ
HXTeIutTYr2GcheodMsaP+DqHZC/gWOymx7w40HULzsG4y/wOvf1jovzKYFKY5T+PnkYtRPKoXhN
BludlrwnU1IwoUhSgbUdttii7wFxgWLZAufP2D744v4SCgqF4gOOnd1ubWqd4pe5M7fUW96/75tt
DWeLFBQku0BBoaQfb/2TnGKiTS3ZQN4S2glbM0XaCZJdoXYCjdHWrCZRO+cTg9+nr6CdINC3XHw/
JHxHxJdU2OQoKNCSejwRAQamGPCl4slr0z8EhBDEKu9APtst1rGTFq6ook9vy58eL+PfDpXBdAmy
IYkDHkq4pmX8+BIHx+nIEz7EVpWn3LyORkJPQDthc/tzQe0E348Rql+R/oQTozQ/+Yt5bCDXRN72
wseT5J0FCgpMUkGM4ptZJ7Ydemj33WaDNuCZZHqg+6WiopeJucffU3baSihfDN6Vg3ZKUncGlktT
u54P+3dCexWeBK+MoRGmS8DGy83dHWKfMU+FnnDfWcbPu17Fv7LYAR2LrG49cLswlUa44IHyNot5
mE/hye42L933M2xyBa7kiFs/FXaGBRxkEaNi6vIyknAt401ijxWkTefkMF3TWfmUyMuVFE7JWToe
faZdyvy33zpniZ0rKj06vyWwEPzJbMvZUL5Z5b7poF3LPaRN3I0639r1/YB/S3EkHS59VWHpThnk
AOTaSYbGP2NeO8X3KS7rciZ8p6uMnwPEnadLrfPyfCtb6zyqmmKsffkThIk0PPlpFnMzv6v7++HD
XrrvZybGy5QPuPXrlOywgMO0iLFVkw+eRxJWPN6sGCcfW+S914OvSw2joPCZl0srKNxo7QQcb17H
+vS2I/+yeVZo/OjTTUENtnpGCynzPaO2GDWQm3XCTcSGcBNPAWon1Pp1QQA+I4dAbiIQyE0EchOB
2FjgXAjn6bU6H0Ru1l83tu593VINnYE89ukIHG8iEMhNBHITgUBuIpCbDQyjqkNrzWIED6Fiwnqh
np5DqvgpUd+Q/7Z1aSiZNZcW/q3zk4/P++nOIWqrZEoG6qQVHgr/rlEa7yHltbWdjPrFvvKH9q+9
tJAYgvHo5UC6cyixmqhC4aHLGrazDdKn98cGCG2h7AFykgk6ECHOcFDWzYMsvd/kKcBWSLItIaVA
Wpw0xx5cZYMRLqUwEhGCBy+Rg3pSlmkxI1ESGRFZhERDh0oOajxLcoDI7fzQTqL76by82IBTbr/v
S8TLi1JZmfRQhyKzQk0iDSRBP7YTSdgo482Xz7cBaF+LPQoQl6zX2Pday6+2Lna9ytKhc5LEuVk8
bclxR0rBctMce6cBS8An1EuM0HJWuY2mDE7+PPup1Axl3p73rWnxy8OawlfSLRjW/5g8y72nrIgg
m30lkM6lFDa/7JTLfBHHF4+Xp3wQEYv45s9mZxYA2n9pn7oH4HAOSdgg3Lyo9/UBWLuvMkmCcdjN
li9e0qf2j/N0SOhjYhiZlcDIFm459h5yY10me4VR1rBe0NW9F3X1bjoU1UEVy4Nyo1yiwVTBEGMA
upUW8gu2GUxnGA2sNcqOCV8iXoZpfUo4z/QBk0/YfNA0mVqDhSQsg82g1k2sOy7Cji/zt499me3T
1+eal0SaSN/xlEihFjt27Lgc3ArYXxS2bjF/SpM3L7G8XvE0yyW+NnfT07CZJhjfkzb9Ic9Ctwav
XuRn7mkIpPuxeUU/d8+om8aCp6PTTctsx44/92ua6cqL9z2mL/KIPGQq+jX1df/J9XwtXWWPj5n6
nAsNGc6rkS+8mzPiWISkFCwI2zvzDyGvwAQPwj/y20SziCFqkxBm2AbEEXzY2kT+0b9Z5KeXiNAI
z3s6weA/xw5ty3xVs774k5fo+0geG8hGGW9yEC5fkO2BtwsWeGpwr9A5UGw4FwFIGiCnQIuKflbY
J01jO2OPDVJPin5Kj6vQ81aolHOeGEKmG5iK3fJvR/cIwuWlUWfISnqC6b6KyJAd8BXAItxOxB2b
6cNs/Kvq+hHKyzsIkrChuKk+zyQJclnpswUzCZ04IgXT7dLzlJHyFpj+Y5IRRHPsE7EuVmupBdKL
OyileuMkE27i0h+XTSGGcMFSWA8aPdrFputkS0D6ofloMF3a4maWWgK+AogMOBIM51u5/zf2khg1
/TA+pVh+7NJIa/tupIaDsXVCX4dSnng2UAreew/ee28sbpIbOenVswvXX0j0xYcBuXkrcLPegWsy
UDuh5q8LAvAZOQRyE4FAbiKQmwjExgLnQjhPr9X5IHKzDruxtXR2S3V2BlA7AYHjTQQCuYlAbiIQ
yE0EcvOWgHEDclxfPkTDcnM6SuR/9nnRX3B4W3HSKiiXQ2+pKl9/6bjy+HhH43PzC9Jk6ontZQ/3
rqhosIYcxuLlqvI5KDyU24ftbMNz8/y4rs9mmWiBFJJPAJsJJAhFA2WE7rnprBFrl137fl1WDXCF
FvpjqqOB0B9TpCRLlzXR5HWz0qrIB7bqCDekVKKcA0hKstIB0nA3krDRuSltP9kJlJvxGVv25BPI
kwDtauuio2hA7oUPyW46w09Tnv10StW45EEz29v8gaOBAPmJxEGAJ6WU075Zk9XlA+2DM+JLuKOG
pX6SsrQ1e/YajSmLJGx0bl6efWxW6QQ4IoFxhKdkJUi/wKQRplxVris5sH/rpjPs1j37nD6qcMmD
cUYWXwbhkt53AOCFcd35rptJJlSTDy7rfY/wjdNCfkG2krtolveWkIRl0EhrMoxuM8MnG8NZtqqN
bQ1Zzvo2tp8wurJKxk0XiQF7kGz+RkQensPdYguRREHsZ2WrycdeZW5vbH/oxP4E2O3Wptap8Bqn
NH6f3og6crIBejovpBJEN+nIJ/grx0HPxMygrAKDa2+DsUlIHpQq/SE/3agyn+1ubdv042tsELJw
Rd1Di2vCBrLR+3R5+4jRvhm4VEKEpyg2F01o7ulUXCUQ7c64l+7mc+zj0CPTYz2w05FMSo4ESm/b
Cdow32ruqS4ftMG7QtZhWcgvKEn9Z3RK9O5mJGGjc/MSfL/rG78DuNhDMmM8Zbp9MEPZM/MX1+gr
eYIljQ+NeukOXPtT8tcv0WPZQUd8AeQDgdKfsgf1L/Gt13LV5YO5Y/cJi+j8E2xU2vIK+dEcwDsy
kvAWGG9eD1ZXXdAzXAPZ2PrmXdXkKwP7My+vWTvhVhlvIjed1m7lWzktdl6KXOWb5om/ripfmUsR
D45TkZvIzVoFrslA7YSavy4IwGfkEMhNBAK5iUBuIhAbC5wL4Ty9VueDyE1sKlbBjb1DitoJCBxv
IhDITQRyE4FAbiKQm4j1Bi7rRW7WGpIqUdhPDD5YRnahjH4CArm50eg8FLXOXrMBVlnWm8BThdy8
wTCjU9AXaRfiCbosmwAjURIZoS2lJhYTdUYiBm83O1Ui68yIqCaeOOTmhsMepS9jOSHUkEvN/BnA
nhlr+hA7NsEtfv+7yG184/NRK7oAMB+xDHxmE7m58bibrfzRnS/dLumqBaBIoLIefkwsCsrpU3v5
xotTYNzNVrabZgZPHHJzw8FXwrvrzQUZ7+7v71/29kCi8yXRxLZH2e9m/2q5vcvGE4fc3HBIbOl6
d+hxjf9MJBIB8nW41I3lp5hU4l2LqchjeOKQmxuO9Oc6oOOBCECPd4PTtEFXA7MluF104bkpk3X1
qqk3/RBPHHJz49vNUwvkz09dBfjJFo+uMXlxzreYGVi8wDdmWx9gZz56v7QwiyeuDHANcE21vPj8
ZiNqdSEaDvjce00hh6cAuVmbwPEVzoUQyE0EArmJQG4iEMhNBHITgUBuIhDITQRyE7G+SN/k/LVV
AHITge0mAoHcRDQG8PnNRhpvNgLwN1xq/cJUye3rbWhqoADs0xE43kQgkJsInAshEDdmYohzoZqb
qWv8Tat8XuHl4e9ryurPP7TqfPvzF63iCMQhP+pyTpGbtUVNcYX4/4qp6V5VzdmrPGvo9kA1vv3s
aag0gnRBTcs6xfFm3UMLtkbVfiDW6UO1rt6w3azlJrSa4UAVWdOFN1bX7lurOAKt4gojN2uyKUyz
/+mK56lul07f15oVvJxV+i4qp6oISuVBbtZsP+2MxtbYtVeRVbtu39cbQek8ON5sgC49fZ098vUP
J7TrH8EW50FuNgqNq39OZL2eMFnvJ1Xw3nuN8Sx4Q6eyaxO4u7jWrGGn11GAtpbgS93fLJEnjdxE
1OrHFPt0RK0CuYlAbiIQyE0EchOBQG4ibkUEvrPERX6IWoBWgpt4pxNRA0hjn47A8SYCgdxEIDcR
COQm4pZG88pTpQaZwWOFGoabha3pcqNVs/5/NrIpvJvHPh2BQG4iEJVzM13h0SK7dNpPraXvRdMl
I0rXbyW9CpWLs84u0nqtAV5N/aYhhuz1UkmtMS7S2vv0dNr5ZHqftDT/5xwJfoKFZbrgk+mY+dY3
vwF1IwpW0X1L118lRQAQqlQdXqQ1t5ulhG/SWvhIcN9VYPIWxodFmmqDnJr/vzhCvwJ1VEnmPBRR
HV6kKvt0Le38K+gEtKIOoqij0Gqv89BKBqSF3+ugkumCa1QcdV1dpHXUnNECOpCrn0EtXbujzxXm
BDVdyQo0FOrpIjWv76lhn8ZVlHDSARHRGiWnFgq0sSpZR/FXe39T44JhWjU3mQKzqJt7ldJFXVt6
lRtMdVXJdMWJNXqRmtdYV618M+8fEaQNW2pp76A4cvP79IIQghGyLSfQ+qxkyeDr7CIFNGf8JqRQ
7WO57h+NKPw+ve4rVPh9ulamY67DqmllLhqiQZCG+n82CbnZmGiEZ+ZKc3O50S5VrtEqlL8FPl/N
jfqhwwrVPfAZOQRyE4FAbiKQmwgEchOB3EQgagfBe0gocoioUW6ixCEC+3QEArmJQG4iEMhNBHIT
gUBuIhDITQQCgVgH/D8ku7WAj3bVlwAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2008-11-10 12:16:23 +0000" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2013-10-23 13:55:18 +0100" MODIFIED_BY="Laila Asmal">
<APPENDIX ID="APP-01" MODIFIED="2010-11-11 09:12:06 +0000" MODIFIED_BY="Laila Asmal" NO="1">
<TITLE MODIFIED="2010-11-11 09:08:29 +0000" MODIFIED_BY="Laila Asmal">Previous search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-11-11 09:12:06 +0000" MODIFIED_BY="Laila Asmal">
<P>1.1. We searched the Cochrane Schizophrenia Group&#8217;s Specialised Reg-<BR/>ister (April 2007) using the phrase:<BR/>[((quetiapin* AND (amisulprid* OR aripiprazol* OR clozapin*<BR/>OR olanzapin* OR risperidon* OR sertindol* OR ziprasidon*<BR/>OR zotepin*)) in title, abstract or index terms of REFERENCE)<BR/>or ((quetiapin* AND (amisulprid* OR aripiprazol* OR clozapin*<BR/>OR olanzapin* OR risperidon* OR sertindol* OR ziprasidon*<BR/>OR zotepin*)) in interventions of STUDY)]<BR/>This register is compiled by systematic searches of major databases,<BR/>hand searches and conference proceedings (see Group Module).<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-10-23 13:55:18 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-06-07 10:48:55 +0100" MODIFIED_BY="[Empty name]">Previous data collection methods</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-23 13:55:18 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Data extraction and management</HEADING>
<P>At least two review authors independently extracted data from selected trials onto standard simple forms. When disputes arose, we attempted to resolve these by discussion. When this was not possible and further information was necessary to resolve the dilemma, we did not enter data and added the trial to the list of those awaiting assessment. Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for quetiapine.</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Rating scales</HEADING>
<P>A wide range of instruments are available to measure outcomes in mental health studies. These instruments vary in quality and many are not validated, or are even ad hoc. It is accepted generally that measuring instruments should have the properties of reliability (the extent to which a test effectively measures anything at all) and validity (the extent to which a test measures that which it is supposed to measure; <LINK REF="REF-Rust-1989" TYPE="REFERENCE">Rust 1989</LINK>). Unpublished scales are known to be subject to bias in trials of treatments for schizophrenia (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>). Therefore continuous data from rating scales were included only if the measuring instrument had been described in a peer-reviewed journal.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of risk of bias in included studies  </HEADING>
<P>Two review authors worked independently and assessed risk of bias using the tool described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). This tool encourages consideration of how the sequence was generated, how allocation was concealed, the integrity of blinding at outcome, the completeness of outcome data, selective reporting and other biases.</P>
<P>The risks of bias in each domain and overall were assessed and categorised into:</P>
<P>A. Low risk of bias: plausible bias unlikely to seriously alter the results;<BR/>B. High risk of bias: plausible bias that seriously weakens confidence in the results; or<BR/>C. Unclear risk of bias: plausible bias that raises some doubt about the results</P>
<P>If the raters disagreed, the final rating was made by consensus with the involvement of another member of the review group. Where inadequate details of randomisation and other characteristics of trials are provided, authors of the studies were contacted to obtain further information. Non-concurrence in quality assessment was reported. Earlier versions of this review used a different, less well-developed means of categorising risk of bias (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Measures of treatment effect  </HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Data types</HEADING>
<P>We assessed outcomes using continuous (e.g. changes on a behaviour scale), categorical (e.g. one of three categories on a behaviour scale, such as 'little change', 'moderate change' or 'much change') or dichotomous (e.g. either 'no important changes or 'important change' in a person's behaviour) measures. Currently Review Manager 5 does not support categorical data, so we were unable to analyse these.</P>
<SUBSECTION>
<HEADING LEVEL="5">1.1 Dichotomous data</HEADING>
<P>We carried out an intention-to-treat analysis. Everyone allocated to the intervention was counted, whether they completed the follow-up or not. It was assumed that those who dropped out had no change in their outcome. This rule is conservative in terms of response to treatment, because it assumes that those discontinuing the studies would not have responded. It is not conservative in terms of adverse effects, but we believed that assuming that all those leaving early would have developed side effects would overestimate risk. Where possible, efforts were made to convert outcome measures to dichotomous data. This can be done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It was generally assumed that if there had been a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or the Positive and Negative Syndrome Scale (PANSS, <LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>), this could be considered as a clinically significant response (<LINK REF="REF-Leucht-2005" TYPE="REFERENCE">Leucht 2005</LINK>; <LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>). If data based on these thresholds were not available, we used the primary cut-off presented by the original authors.</P>
<P>We calculated the risk ratio (RR) and its 95% confidence interval (CI) based on the random-effects model, as this takes into account any differences between studies even if there is no statistically significant heterogeneity. It has been shown that RRs are more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) than odds ratios and that odds ratios tend to be interpreted as RRs by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). This misinterpretation then leads to an overestimation of the impression of the effect. When the overall results were significant, we calculated the number needed to treat for an additional beneficial outcome (NNTB) and the number needed to treat for an additional harmful outcome (NNTH) as the inverse of the risk difference.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2 Continuous data</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">a. Normal distribution of the data</HEADING>
<P>The meta-analytical formulas applied by RevMan Analyses (the statistical programme included in RevMan) require a normal distribution of data. The software is robust towards some skew, but to which degree of skewness meta-analytical calculations can still be reliably carried out is unclear. On the other hand, excluding all studies on the basis of estimates of the normal distribution of the data also leads to a bias because a considerable quantity of data may be lost, leading to a selection bias. Therefore, we included all studies in the primary analysis. In a sensitivity analysis, we excluded potentially skewed data by applying the following rules: (1) When a scale started from the finite number zero, the standard deviation, when multiplied by two, was greater than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution; <LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). (2) If a scale started from a positive value (such as PANSS, which can have values from 30 to 210), the calculation described above was modified to take the scale starting point into account. In these cases, skew is present if 2 SD &gt; (S - Smin), where S is the mean score and Smin is the minimum score. (3) In large studies (as a cut-off, we used 200 participants), skewed data pose less of a problem. In these cases, we entered the data into a synthesis. (4) The rules explained in (1) and (2) do not apply to change data. The reason is that when continuous data are presented on a scale that includes a possibility of negative values, it is difficult to tell whether or not data are non-normally distributed (skewed). This is also the case for change data (endpoint - baseline). In the absence of individual patient data, it is impossible to know whether data are skewed, although this is likely. After consulting the ALLSTAT electronic statistics mailing list, we presented change data in RevMan analyses to summarise available information. In doing this, it was assumed that data were not skewed or that the analysis could cope with the unknown degree of skew. Without individual patient data, it is impossible to test this assumption. Change data were therefore included and a sensitivity analysis was not applied.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">b. The statistic</HEADING>
<P>For continuous outcomes, we estimated a weighted mean difference (MD) between groups. MDs were again based on the random-effects model, as this takes into account any differences between studies even if no statistically significant heterogeneity is noted. We combined both endpoint data and change data in the analysis because there is no principal statistical reason why endpoint and change data should measure different effects (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). When standard errors instead of standard deviations (SDs) were presented, we converted the former to standard deviations. If both were missing, we estimated SDs from P values or used the average SD of the other studies (<LINK REF="REF-Furukawa-2006" TYPE="REFERENCE">Furukawa 2006</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Unit of analysis issues  </HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Cluster trials</HEADING>
<P>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice), but analysis and pooling of clustered data pose problems. First, authors often fail to account for intraclass correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>), whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>; <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>When clustering was not accounted for in primary studies, we presented the data in a table, with an (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review, we will seek to contact first authors of studies to obtain intraclass correlation coefficients of their clustered data and to adjust for this using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). When clustering has been incorporated into the analysis of primary studies, we will also present these data as if from a non-cluster randomised study but adjusted for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intraclass correlation coefficient (ICC) [Design effect = 1 + (m - 1) * ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported, it was assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>If cluster studies had been appropriately analysed by taking into account intraclass correlation coefficients and relevant data documented in the report, we synthesised these with other studies using the generic inverse variance technique.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Cross-over trials</HEADING>
<P>A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological, psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase, participants can differ systematically from their initial state despite a washout phase. For the same reason, cross-over trials are not appropriate if the condition of interest is unstable (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). As both effects are very likely in schizophrenia, we will use only data of the first phase of cross-over studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Studies with multiple treatment groups</HEADING>
<P>When a study involved more than two treatment groups, if relevant, the additional treatment groups were presented in additional relevant comparisons. Data were not double counted. When the additional treatment groups were not relevant, these data were not reproduced.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Dealing with missing data  </HEADING>
<P>At some degree of loss of follow-up, data must lose credibility (<LINK REF="REF-Xia-2007" TYPE="REFERENCE">Xia 2007</LINK>). Although high rates of premature discontinuation are a major problem in this field, we believe that it is unclear which degree of attrition leads to a high degree of bias. We, therefore, did not exclude trials on the basis of the percentage of participants completing them. However, we addressed the attrition problem in all parts of the review, including the abstract. For this purpose, we calculated, presented and commented on frequency statistics (overall rates of leaving the studies early in all studies and comparators pooled).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of heterogeneity  </HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Clinical heterogeneity</HEADING>
<P>We considered all included studies within any comparison to judge for clinical heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Statistical</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Visual inspection</HEADING>
<P>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Employing the I<SUP>2</SUP> statistic</HEADING>
<P>Visual inspection was supplemented, using primarily the I<SUP>2</SUP>statistic. This provides an estimate of the percentage of variability due to heterogeneity rather than chance alone. When the I<SUP>2</SUP> estimate was &#8805; 50%, we interpreted this as indicating the presence of considerable levels of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of reporting biases  </HEADING>
<P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). These are described in Section 10.1 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). We are aware that funnel plots may be useful in investigating small study effects but are of limited power for detecting such effects when there are few studies. We entered data from all identified and selected trials into a funnel graph (trial effect vs trial size) in an attempt to investigate the likelihood of overt publication bias. We did not undertake a formal test for funnel plot asymmetry.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data synthesis  </HEADING>
<P>When possible, for both dichotomous and continuous data, we used the random-effects model for data synthesis, as this takes into account any differences between studies, even if no statistically significant heterogeneity is noted. We understand that there is no closed argument for preference for use of fixed-effect or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This does seem true to us; however, random-effects models do put added weight onto the smaller of the studies-those trials that are most vulnerable to bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis and investigation of heterogeneity  </HEADING>
<P>If data were clearly heterogeneous, we checked that data were correctly extracted and entered and that we had made no unit of analysis errors. If inconsistency was high and clear reasons explaining the heterogeneity were found, we presented the data separately. If not, we commented on the heterogeneity of the data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis  </HEADING>
<P>We planned sensitivity analyses to examine the change in robustness of the sensitivity to include studies with potentially skewed data. A recent report showed that some of the comparisons of atypical antipsychotic drugs may have been biased by the use of inappropriate comparator doses (<LINK REF="REF-Heres-2006" TYPE="REFERENCE">Heres 2006</LINK>). Therefore, we also analysed whether exclusion of studies with inappropriate comparator doses changed the results of the primary outcome and the general mental state.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2008-11-10 12:16:23 +0000" MODIFIED_BY="[Empty name]">
<EXTENSION ID="FLOW_2" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="2">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;&lt;p&gt;n=35&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of studies included in qualitative synthesis&lt;/p&gt;&lt;p&gt;n=14 (in current update)&lt;/p&gt;&lt;p&gt;n=21 (in previous review)&lt;/p&gt;&lt;p&gt;Total n=35&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of full-text articles assessed for eligibility&lt;/p&gt;&lt;p&gt;n=238&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of records screened&lt;/p&gt;&lt;p&gt;n=3723&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of records after duplicates removed&lt;/p&gt;&lt;p&gt;n=3723&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of records identified through database searching&lt;/p&gt;&lt;p&gt;n=4157&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;# of additional records identified through other sources&lt;/p&gt;&lt;p&gt;n=0&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;# of records excluded&lt;/p&gt;&lt;p&gt;n=3485&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;# of full-text articles excluded, with reasons&lt;/p&gt;&lt;p&gt;n=198&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>